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1002-1 The Combination Of Diabetes Mellitus And 
Hypercholesterolemia In Swine Leads To The 
Development Of Complex, Human-like Atherosclerosis
Damir Hamamdzic, Sumeet K. Mainigi, Zachary M. Gertz, Emile R. Mohler, III, Robert L. 
Wilensky, University of Pennsylvania, Division of Cardiovascular Medicine, Philadelphia
Background: Atherosclerotic lesions can be developed in pigs by inducing diabetes mellitus 
(DM) and hypercholesterolemia (HC), although it is unknown whether these lesions 
accurately represent human atherosclerosis in its complexity and phenotypic presentation.
Methods: Swine (n=42) were made diabetic by streptozotocin and fed a high-fat diet to induce 
HC. Whole blood platelet aggregation to collagen was measured by impedance aggregometry 
at 1, 3 and 6 months. Flow-mediated endothelial function was evaluated by quantifying 
changes in femoral artery diameter following a 5-minute occlusion at 1, 3 and 6 months. The 
arteries were stained with Movat’s stain and evaluated for the presence of smooth muscle 
cells, macrophages, and calcifications and the extent of endothelial coverage. The resulting 
lesions were compared to human lesions using the Stary/AHA and Virmani criteria.
Results: Glucose levels increased to >300 mg/dl and cholesterol levels to >700 mg/dl from 
baseline (p<0.0001 for both). Platelet aggregation increased from 12.3 ± 0.81 Ω to 15.5 
± 0.66 Ω at one month (p=0.002) and remained increased thereafter (p<0.001). Flow-
mediated dilatation in femoral arteries decreased by 33% at 6 months (p<0.05). Progressive 
atherosclerotic lesion development was observed in the coronary arteries with intimal area 
increasing from 0.18 ± 0.23 mm2 at 3 months to 0.74± 1.45 mm2 at 6 months to 2.00 ± 2.24 
mm2 at 9 months (p=0.001). Femoral artery intimal area increased from 0.15 ± 0.15 at 3 
months to 2.28 ± 4.38 mm2 (p=0.06) at 9 months while carotid artery lesion area did not 
change significantly. At 9 months 83% of coronary arteries exhibited Stary/AHA grade IV 
compared to 17% at 3 months. Complex disease by the Virmani criteria was seen 89% at 
9 months vs. 6% at 3 months. At 6 and 9 months high-grade, complex lesions consisted of 
smooth muscle cells, extracellular matrix, with lipid pools and necrotic debris.
Conclusions: The DM/HC pig model develops increased platelet aggregation, endothelial 
dysfunction, and complex coronary artery disease that accurately reflect human disease.
11:00 a.m.
1002-2 Comparison of Thrombotic Cardiovascular Event Rates 
Following Long-term Treatment of Arthritis Patients 
at Elevated Cardiovascular Risk with Etoricoxib and 
Diclofenac: Results of the Etoricoxib MEDAL Program
Christopher P. Cannon, Sean P. Curtis, Henry Krum, Erland Erdmann, Robert L. Jesse, 
Amarjot Kaur, Gary S. Swergold, Loren Laine, Merck Research Laboratories, Rahway, NJ
Background: For arthritis patients requiring NSAID therapy, the thrombotic CV safety profile of 
a COX-2 selective vs. traditional NSAID is a factor in selecting an agent. The MEDAL Program 
compared the relative thrombotic CV event rates of the COX-2 selective NSAID etoricoxib and 
the traditional NSAID diclofenac in arthritis patients with a broad range of CV risk. This analysis 
of subgroups focuses on results in patients with elevated baseline CV risk.
Methods: 34,701 patients 40 to 94 yrs of age with OA or RA were randomized to receive 
etoricoxib (60 or 90 mg/day) or diclofenac (150 mg/day) for a mean of 18 months. Patients 
with a range of CV-risk, including established symptomatic atherosclerotic CV disease 
(ASCVD) were enrolled. The primary endpoint was thrombotic CV events as confirmed 
by a blinded adjudication committee.
Results: Patients with established ASCVD experienced the highest rate of thrombotic 
CV events, ~3-fold higher than patients without pre-existing ASCVD (Table). Diabetics 
and aspirin users similarly had higher event rates. Etoricoxib and diclofenac showed no 
overall difference in event rates (HR 0.95, 95% CI 0.81, 1.11).
Conclusion: Arthritis patients with established ASCVD treated long-term with etoricoxib 
or diclofenac in the MEDAL Program had ~3 fold higher rate of thrombotic CV events 
compared to patients without ASCVD. A comparison of rates of thrombotic CV events in 
the etoricoxib and diclofenac treatment groups with and without ASCVD and other CV 
risk factors will be presented.
Thrombotic CV Events in Patient Subgroups (In Aggregate)
Subgroup Patients with Events/PYR Rate per 100 PYs
Patients with OA 413/34695 1.19
Patients with RA 230/15908 1.45
Without Established ASCVD at Baseline 469/45205 1.04
Established ASCVD at Baseline 174/5397 3.22
Not a Baseline Low Dose Aspirin User 339/33438 1.01
Baseline Low Dose Aspirin User 304/17164 1.77
No History of Diabetes Mellitus 545/45537 1.20
History of Diabetes Mellitus 98/5066 1.93
PYRs = Patient-years at risk
PYs = Patient-years
11:00 a.m.
1002-3 Nitric Oxide Production in Freshly Isolated Circulating 
Endothelial Progenitor Cells: A Marker of Cellular 
Functional Status and Clinical Disease?
Marco A. Costa, Sergey Zharikov, Dominick J. Angiolillo, Yuan Hang, Bhaloo Desai, 
K.C. Kurian, Elaine Beem, Larysa Sautina, Cecilia M. Lansang, Luis Guzman, Martin M. 
Zenni, Theodore A. Bass, Mark S. Segal, University of Florida Health Science Center, 
Jacksonville, FL, University of Florida Health Science Center, Gainesville, FL
Background: Circulating endothelial progenitor cells (cEPC) have been suggested to 
play a role in rendothelialization and vascular repair. Diabetes mellitus (DM) is associated 
with endothelial cell (EC) dysfunction, low number and poor migration of CD34+ cEPC.
Nitric oxide(NO) is a key vasculoprotective product of EC. Although cEPC are known 
to express NO synthase gene, NO production by freshly isolated cEPC has not yet 
been demonstrated. The aim of this study was to determine if 1) freshly isolated cEPC 
produces NO, 2) NO represents a marker of cEPC functional status, and 3) NO production 
is associated with DM and coronary artery disease (CAD).
Methods: The study included 50 patients (30 DM and 20 non-DM) scheduled for 
elective cardiac catheterization. NO production inside cEPC was analyzed within 24h 
after harvesting using a fluorescent indicator for NO, DAF-FM diacetate, and direct 
visualization by laser scanning confocal microscope. Other cEPCs functional assays 
included: 1) migration in response to stromal cell derived factor-1 (SDF1), 2) CD26/
dipeptidyl peptidase IV activity, 3) number of colony-forming units. Quantitative analysis 
of all epicardial vessels was performed by an independent core laboratory to assess the 
presence of severe CAD, defined as >50% diameter stenosis.
Results: NO production was detected in 88.5% of samples; this ranged from 5 to 100% 
of cEPC per sample. Mean NO fluorescence intensity per sample was 784.35+/-617.1 
(median= 612.3). Patients were divided into above (High-NO) and below (Low-NO) median 
intensity groups. Migration was not associated with NO, DM or CAD status. However, 
CD26 activity was higher in Low-NO vs. High-NO samples (0.0170+/-0.0137 vs. 0.0070+/-
0.0070, p=0.04). There were >8 colony forming unit in 83.3% of High-NO samples versus 
23.1% of Low-NO (p<0.05). CAD severity was similar between High-No and Low-NO, but 
incidence of DM was 25% in High-NO versus 75% in Low-NO (p<0.05).
Conclusion: Our preliminary results suggest that fresh CD34+ cEPC are able to produce 
NO, confirming their commitment to EC lineage. DM patients have diminished NO 
production. Similar to CFU, NO production may represent a marker of cEPC functional 
status, and of clinical disease.
11:00 a.m.
1002-4 Pregnancy-Associated Plasma Protein-A Levels Are 
Related to Urinary Albumin Excretion Rate: a Novel 
Pathway Linking Atherosclerotic Processes With 
Microalbuminuria in Essential Hypertension
Costas Tsioufis, Kyriakos Dimitriadis, Dimitris Chatzis, Ioannis Skiadas, Elena Vezali, 
Dimitris Tousoulis, Christodoulos Stefanadis, Ioannis Kallikazaros, Department of 
Cardiology, Hippokration Hospital, Athens, Greece
Background: Microalbuminuria is a marker of subclinical atherosclerosis, whereas pregnancy 
associated plasma protein-A (PAPP-A) is related to increased risk of cardiovascular events. 
In this study we examined the relationships of urinary albumin excretion, expressed as the 
albumin to creatinine ratio (ACR), with PAPP-A in essential hypertensives.
Methods: Our population consisted of 80 newly diagnosed untreated non-diabetic 
patients with stage I to II essential hypertension [55 men, mean age=51 years, office 
blood pressure (BP)=144/92 mmHg]. According to the ACR values determined as the 
mean of two non-consecutive morning spot urine samples, the study population was 
divided into microalbuminurics (n=18) (mean ACR=30-300 mg/g) and normoalbuminurics 
(n=62) (mean ACR<30 mg/g). Moreover, all patients underwent ambulatory BP monitoring 
and venous blood sampling for estimation of lipid profile and PAPP-A concentrations.
Results: Microalbuminurics compared to normoalbuminurics had higher 24-h systolic BP 
(138±18 vs 131±11 mmHg, p<0.05), while did not differ regarding age, sex, and metabolic 
profile (p=NS for all). Moreover, microalbuminurics compared to normoalbuminurics 
exhibited higher PAPP-A values (5.1±1.8 vs 2.5±0.7 mIU/L, p<0.0001). In the total 
population, ACR was associated with 24-h systolic BP (r=0.284, p<0.05), body mass 
index (r=0.375, p=0.001) and PAPP-A (r=0.617, p<0.0001), while PAPP-A was correlated 
with body mass index (r=0.308, p<0.005), and 24-h pulse pressure (r=0.225, p<0.05). By 
multiple regression analysis it was revealed that ACR exhibited an independent relationship 
with PAPP-A (p<0.0001). Additionally, analysis of covariance revealed that PAPP-A values 
were significantly different between groups after adjustment for confounders (p<0.05).
Conclusions: The increased levels of PAPP-A that accompany microalbuminuria in 
essential hypertension, further support the role of ACR as a marker of diffuse vascular 
disease burden. Although PAPP-A has been considered until now only to reflect plaque 
instability, our findings suggest an involvement of this metalloproteinase in the early 
stages of the hypertensive atherosclerotic disease.
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1002-5 Efonidipine Simultaneously Improves Endothelial 
Function and Metabolic Parameters In Patients with 
Hypertension
Kwang K. Koh, Michael J. Quon, Wook-Jin Chung, Chan I. Moon, Sang M. Park, Eak K. 
Shin, Gachon Medical School, Gil Medical Center, Incheon, South Korea, Diabetes Unit, 
NIH, Bethesda, MD
Background: Reciprocal relationships between endothelial dysfunction and insulin 
resistance imply that improvement in endothelial dysfunction will have beneficial metabolic 
consequences. We hypothesized that efonidipine therapy in hypertensive subjects will 
simultaneously improve endothelial dysfunction and metabolic parameters.
Methods: Efonidipine (40 - 80 mg daily for 8 weeks) or placebo was given to 38 patients with mild 
to moderate hypertension in a randomized, double-blind, placebo-controlled, crossover study.
Results: When compared with placebo, efonidipine treatment reduced plasma 
malondialdehyde levels from 1.22±0.04 to 1.12±0.05 uM (p=0.011) and improved flow-
mediated dilator response to hyperemia from 5.42±0.26 to 6.20±0.25 % (p<0.001). 
Efonidipine treatment also increased plasma adiponectin levels from 4.2±0.6 to 
4.6±0.6 ug/ml (p=0.013) and decreased plasma leptin and resistin levels from 5.2±0.6 
to 4.7±0.5 ng/ml (p=0.030) and from 7.76 (5.83-10.41) to 8.12 (5.31-9.99) ng/ml 
(p=0.001), respectively. A trend to improve insulin sensitivity assessed by QUICKI did 
not achieve statistical significance (increase of 3±2%, p=0.239). Correlations were 
noted between percent changes in flow-mediated dilation and malondialdehyde levels 
(r=-0.479, p=0.002), leptin (r=-0.424 and p=0.008), insulin (r=-0.354 and p=0.029), 
and QUICKI (r=0.471 and p=0.003). Only changes in malondialdehyde (β=-0.822, 
p=0.017) and QUICKI (β=1.032, p=0.034) were independent predictors of changes in 
flow-mediated dilation (multivariate regression analysis). We also observed correlations 
between percent changes in adiponectin levels and QUICKI (r=0.379, p=0.019) and HDL 
cholesterol (r=0.434, p=0.006) with changes in HDL cholesterol (β=0.459, p=0.006) or 
QUICKI (β=0.467, p=0.067) as independent predictors of changes in adiponectin levels. 
Conclusions: Efonidipine therapy simultaneously improves endothelial function and 
metabolic parameters in patients with hypertension.
11:00 a.m.
1002-6 Effects of Angiotensin-II Receptor Blockers on Coronary 
Atherosclerosis in Patients with Acute Myocardial 
Infarction Taking Angiotensin-Converting-Enzyme 
Inhibitors: Final Results of Captopril Combined with 
Valsartan In Acute Myocardial Infarction Study (CVAS)
Hideto Yano, Kiyoshi Hibi, Hiroyuki Ozaki, Ikuyoshi Kusama, Mitsuaki Endou, Takayuki 
Mitsuhashi, Naohiro Komura, Toshiaki Ebina, Masami Kosuge, Kengo Tsukahara, Jun 
Okuda, Noriaki Iwahashi, Tatsuya Nakachi, Fumiyuki Otsuka, Satoshi Umemura, Kazuo 
Kimura, Division of Cardiology, Yokohama City University Medical Center, Yokohama, 
Japan, Department of Medical Science and Cardiorenal Medicine,Yokohama City 
University Graduate School, Yokohama, Japan
Background:The inhibition of renin-angiotensin-aldosterone system (RAS) by 
angiotensin-converting-enzyme inhibitors (ACE-I) reduce cardiovascular mortality and 
morbidity. Systematic inhibition of RAS using angiotensin-II receptor blockers (ARB) in 
addition to ACE-I is more effective anti hypertensive strategy than ACE-I alone. However, 
whether the combination of ARB with ACE-I improve clinical outcome compared with 
ACE-I alone remain controversial. The aim of this study was to clarify whether systematic 
inhibition of RAS have impact on the non-culprit intermediate coronary atherosclerosis.
Methods:A total of 116 patients (pts) with acute myocardial infarction (AMI) were randomly 
assigned to the valsartan (group V, target dose 80 mg daily, 58 pts) or non-valsartan 
(group NV, 58 pts) groups. All pts received captopril (target dose 75 mg daily) and study 
drug after revascularization. The target plaque were qualified if it had not been influenced 
by any previous intervention, if the diameter of the stenosis was <50% on quantitative 
coronary angiography. The plaque had to be >10 mm apart from acute intervention site. 
IVUS interrogation was performed at acute phase and at 7- month follow-up. The percent 
plaque volume changes (%ΔPV), the percent lumen volume changes (%ΔLV) and the 
percent vessel volume changes (%ΔVV) were calculated.
Results:Patient characteristics were similar between the groups. Plasma aldsterone 
levels were lower (54 vs. 75pg/ml, p=0.02) and blood pressure was lower (114 vs. 
127mmHg, p=0.03) at follow-up in group V. Plaque volume did not increase in both 
groups (-2.4 vs. -3.6%, p=0.6). %ΔLV (8.1 vs. -0.5%, p=0.02) and %ΔVV (2.0 vs. -2.3%, 
p=0.01) were larger in group V. By multivariate analysis, the combination of ARB and 
ACE-I was an independent predictor of larger %ΔVV (p=0.03; OR 2.8; 95%CI 1.1-7.4) 
after adjustment for other factors including blood pressure.
Conclusions: In patients with AMI, systematic inhibition of RAS with ARB and ACE-I is 
an independent predictor of coronary artery enlargement without plaque progression. 
Improved coronary vascular tone may confer additional cardiovascular protection, leading 
to the reduction of relevant cardiovascular events.
11:00 a.m.
1002-7 Combination of Amlodipine and Atorvastatin Reverses 
Age-Dependent Endothelial Dysfunction in Rat Aorta
R. Preston Mason, Ruslan Kubant, Christopher Malinski, Mary F. Walter, Charles A. 
Day, Robert F. Jacob, Tadeusz Malinski, Ohio University, Athens, OH, Brigham and 
Women’s Hospital, Harvard Medical School, Boston, MA
Background: Several previous studies have demonstrated that both HMG-CoA reductase 
inhibitors and certain calcium channel blockers may improve endothelial-dependent 
nitric oxide (NO) release. However, their combined effects are not well understood 
under conditions of cardiovascular risk, such as aging. We assessed the effects of 
co-administered atorvastatin and amlodipine on NO release and nitroxidative stress 
(peroxynitrite [ONOO-]) in intact rat aorta with aging.
Methods: Nanosensors were used to measure simultaneously NO and ONOO- release in 
single aortic endothelial cells of adult (12 week) and aged (75 week) normotensive Wistar 
Kyoto rats. Amlodipine and atorvastatin (doses 2 mg/day of each) were administered 
intragastrically starting 46 days prior to the animals being sacrificed. The in vitro effect 
of amlodipine and atorvastatin on low-density lipoprotein oxidation was determined by 
copper-induced malondialdehyde (MDA) formation.
Results: The results showed evidence for progressive endothelial NO synthase (eNOS) 
uncoupling with aging due to increased nitroxidative stress (70% increase in ONOO- 
release from 303 ± 25 nM to 522 ± 20 nM) from aorta, concomitant with a 18% reduction 
in NO release in the aorta from 570 ± 10 nM to 470 ± 8 nM. The ratio of NO to ONOO-, 
a comprehensive indicator of eNOS coupling efficiency, decreased with aging from 1.8 
to 0.9. Treatment with amlodipine/atorvastatin reversed eNOS uncoupling, as evidenced 
by an increase in the NO/ONOO- ratio by more than 70% to 1.6, independently of blood 
pressure changes. The combination of amlodipine and atorvastatin also reduced copper-
induced MDA formation by >40%, compared with untreated samples.
Conclusions: With biological aging, there was a pronounced loss in endothelial function 
due to enhanced nitroxidative stress and eNOS uncoupling. Co-administration of 
amlodipine/atorvastatin restored eNOS coupling activity in aorta from normotensive rats 
by reducing nitroxidative stress.
11:00 a.m.
1002-8 Phosphorylation Of 5-lipoxygenase By Protein Kinase 
A Determines Whether Cardiomyocytes Will Produce 
15-epi-lipoxin A4 Or Leukotriene B4 When Incubated 
With Atorvastatin And Pioglitazone
Yochai Birnbaum, Yumei Ye, Yu Lin, Shawn P. Nishi, Barry F. Uretsky, Jose R. Perez-
Polo, University Of Texas Medical Branch, Galveston, TX
Background: 15-epi-lipoxin A4 (ELA), a strong antiinflammatory mediator, is produced 
by cyclooxygenase-2 (COX2) and 5-lipoxygenase (5LO). 5LO also produces leukotriene 
B4 (LEU) from arachidonic acid (AA) following stimulation with lipopolysaccharide and 
translocation to the perinuclear membrane. However, phosphorylation by protein kinase 
A (PKA) prevents its translocation. Atorvastatin (AT) and pioglitazone (PI) upregulate 
both COX2 and 5LO. We assessed whether phosphorylation of 5LO (P-5LO) by PKA 
determines whether the cells produce LEU or ELA.
Methods: Rat myocardial cells in tissue culture were incubated with AT+PI, AT+PI+H89 (a 
PKA inhibitor), H89, or vehicle for 8h.
Results: Immunoblotting showed that AT+PI increased P-5LO (2189%) compared 
to control (100%). H-89 attenuated the effect of AT+PI (437%). AT+PI increased the 
production of ELA. H-89 alone had no effect, but with AT+PI it switched the cells from 
producing ELA to LEU (Figure). Immunofluorescence shows that AT+PI increased 
cytosolic expression of 5LO. H-89 alone had no effect, whereas in the AT+PI+H89 5LO 
translocated to the perinuclear membrane.
Conclusions: Phosphorylation of 5LO by PKA determines its location. If located in the 
cytoplasm, it produces ELA from 15-R-HETE (produced by COX2); however, upon 
translocation to the perinuclear membrane, it produces LEU from AA (produced by 
phospholipase A2). Defects in the PKA/5LO axis may result in proinflammatory state 
when exposed to AT+PI.
11:00 a.m.
1002-9 Ottawa Heart Genomics Study - The First Genome-wide 
Scan To Search For CAD Genes Utilizing 500,000 Markers
Alexandre FR Stewart, Ruth McPherson, Kathryn Williams, George Wells, Julie 
Rutberg, Heather Doelle, Gwen Ewart, Yanqing Wang, Lan Vo, Sybill Hebert, Thet 
Naing, Nihan Kavaslar, Marino Labinaz, Miguel Andrade, Robert Roberts, University of 
Ottawa Heart Institute, Ottawa, ON, Canada
Background: Coronary artery disease (CAD) remains the number one killer in the western 
world. Genetics account for over 50% of the risk for CAD. Genetic screening and early 
prevention in individuals identified at increased risk could dramatically reduce CAD, thus, 
the necessity to identify genes predisposing to CAD. Genes identified by the candidate 
gene approach have not been replicated due in part to inadequate sample size. Genome 
wide scan association studies have been limited by the use of thousands of markers 
rather than the hundreds of thousands required and hundreds of individuals rather than 
the thousands required (Science 2005;307:1072). Replication of positive findings in an 
independent population is essential. To detect a Minor Allele Frequency of ≥ 5%, an odds 
ratio for risk of ≥ 1.3, with 90% power, we estimate 14,000 (9,000 affected and 5,000 
control) subjects are required (Nat Rev Genet, 2005;6:95).
Methods: The Affymetrix 500,000 marker set provides a marker every 6,000 base pairs 
as required and is being used to genotype 1,000 cases of premature CAD and 1,000 
normals followed by replication in 8,000 cases and 4,000 controls. The phenotype is 
confirmed or excluded by coronary arteriograms by catheterization or multi-slice CT.
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Results: Phase 1, initiated in 2005, will be completed shortly providing a total of 1 billion 
genotypes. We have completed genotyping of 690 controls and 600 cases for a total of 
600 million genotypes. On average each DNA sample analyzed provided accurate and 
interpretable genotypes for 99% of the 500,000 SNPs. Cases and controls in Hardy-
Weinberg equilibrium exhibited over 9,770 SNPs with a difference in allele frequency 
(P<0.001). We have identified 31 non-synonymous cDNA polymorphisms, 264 gene-
specific clusters and 9 intergenic clusters associated with CAD. Genes containing SNPs 
or near a SNP associated with CAD are being assessed for their function in vitro (cell 
culture) and in vivo (transgenic animals).
Conclusions: This is the first genome wide scan for CAD genes utilizing a marker every 
6,000 base pairs. Several genes associated with CAD have been identified.
11:00 a.m.
1002-10 Associations of Serum Uric Acid with Markers of 
Inflammation, Metabolic Syndrome, and Sub-clinical 
Coronary Atherosclerosis
Thais de A. Coutinho, Stephen T. Turner, Patricia A. Peyser, Lawrence F. Bielak, Patrick F. 
Sheedy, Iftikhar J. Kullo, Mayo Clinic, Rochester, MN, University of Michigan, Ann Arbor, MI
Background: We examined the associations of serum uric acid (UA) with indices of 
coronary heart disease (CHD) risk, including the 10-year probability of CHD (10y-CHDr), 
metabolic syndrome (MetS), inflammation (C-reactive protein (CRP) and fibrinogen), and 
the presence and quantity of coronary artery calcium (CAC).
Methods: Subjects (n = 1107, mean age 58 years, 59% women) belonged to sibships 
with ≥ 2 individuals with hypertension diagnosed before age 60. UA was measured by 
a colorimetric method, CAC by electron beam computed tomography, and CAC score 
calculated using the method of Agatston. The correlation of UA with 10y-CHDr, MetS 
components, log CRP, and fibrinogen was assessed after adjustment for age and sex. 
Multivariable regression was used to identify independent predictors of higher UA and to 
assess whether UA was associated with CAC presence and quantity after 1) adjustment 
for age and sex, and 2) additional adjustment for CHD risk factors.Results: Most subjects 
(71%) had hypertension and 14% had diabetes. Mean (± SD) UA level was 5.97±1.6 
mg/dL, and CAC was detectable in 63% of patients. Independent predictors of higher 
UA were higher age (P <0.0001), male sex (P <0.0001), higher total cholesterol (P 
<0.0001), higher HDL cholesterol (P = 0.0001), higher BMI (P <0.0001), higher number of 
alcoholic drinks per week (P = 0.0015), diuretic use (P <0.0001), log serum creatinine (P 
<0.0001) and log CRP (P= 0.05). After adjustment for age and sex, UA was significantly 
correlated with 10y-CHDr (P <0.0001), number of MetS components (P <0.0001), log 
CRP (P <0.0001), and fibrinogen (P <0.0001). UA was associated with CAC presence(P 
= 0.0005) and quantity (P = 0.0001) after adjustment for age and sex but not after further 
adjustment for systolic BP, diabetes, total and HDL cholesterol, smoking, and BMI (P 
= 0.75 and 0.93, respectively).Conclusion: Serum UA was significantly correlated with 
several indices of CHD risk. UA was associated with presence and quantity of CAC but 
not independently of conventional risk factors.
11:00 a.m.
1002-11 Aortic Augmentation Index is Associated with Ankle 
Brachial Index; A community Based Study
Mahyar Khaleghi, Iftikhar J. Kullo, Mayo Clinic, Rochester, MN, University of Michigan, 
Ann Arbor, MI
Background. We investigated whether aortic augmentation index (AIx), a measure of 
arterial stiffness and wave reflection, was associated with the ankle-brachial index (ABI), 
a measure of peripheral arterial disease (PAD), in a community-based sample of adults 
without prior history of heart attack or stroke (n = 475, mean age 59.3 years, 46.5% men). 
Methods. Radial artery pulse waveforms were obtained by applanation tonometry and an 
ascending aortic pressure waveform derived by a transfer function. AIx is the difference 
between the first and second systolic peak of the ascending aortic pressure waveform 
indexed to the central pulse pressure. ABI was measured using a standard protocol, and 
subjects with non-compressible vessels (ABI > 1.5) were excluded from the analyses. 
Multivariable linear and logistic generalized estimating equations (GEE) analyses were 
used to assess whether AIx was associated with ABI and ABI < 1.00 respectively, 
independent of conventional risk factors. 
Results. Mean (± SD) values were: AIx, 29.3 ± 11.6 %; ABI, 1.12 ± 0.13; 59 (12.4%) 
participants had an ABI < 1.00. Variables associated with a lower ABI (and ABI < 1.00) 
included older age, shorter height, female sex, higher total cholesterol, hypertension 
medication use, history of smoking, and higher AIx. After adjustment for mean arterial 
pressure and the above variables, higher AIx remained associated with a lower ABI (P 
= 0.015) and ABI < 1.00 (P = 0.002). A significant interaction (P = 0.007) was present 
between AIx and age in the prediction of ABI and the effect of AIx on ABI; the relationship 
being stronger in older subjects (> 65 years). 
Conclusion. Greater AIx, a measure of arterial stiffness and wave reflection, was 
independently associated with a lower ABI in asymptomatic subjects from the community, 
and this association was modified by age.
11:00 a.m.
1002-12 Circulating Levels of Endogenous Nitric Oxide 
Synthase (NOS) Inhibitors Independently Predict 
Carotid Intima-Media Thickness (cIMT): A Population-
Based Study
Julio A. Chirinos, Josefina Medina Lezama, Robert David, J. Alexander Bralley, 
Humberto Zea Diaz, Fernando F. Corrales, Zoila Valdivia, Carolina Cuba, Mauricio 
Postigo MacDowall, Edgar Munoz Atahualpa, Juan F. Bolaños, Oscar L. Morey, Julio 
Chirinos Pacheco, Santa Maria Catholic University School of Medicine, Arequipa, Peru
Background: Asymmetric dimethylarginine (ADMA) and L-Monomethylarginine (L-
NMMA) are endogenous NOS inhibitors associated with various cardiovascular risk 
factors (CVRF). We aimed to determine whether circulating levels of ADMA and L-NMMA 
independently correlate with carotid atherosclerosis in the general population.
Methods: We studied 298 subjects (165 males and 122 females) participating 
in a population-based study. cIMT was obtained from high-resolution ultrasound 
(Sonosite Titan) and computer-assisted measurements (SonoCalc; Sonosite; Bothell, 
WA). Circulating ADMA, L-NMMA and L-Arginine levels were measured by liquid 
chromatography-mass spectrometry (Metametrix Clinical Laboratory; Atlanta, GA).
Results: Regression estimates corresponding to 1 standard deviation increase in ADMA, 
L-NMMA and L-Arginine as predictors of cIMT are shown in the table. In univariate 
analysis, increasing ADMA and L-NMMA predicted higher cIMT. After adjustment for age, 
gender, smoking, family history of coronary heart disease, LDL and HDL cholesterol, 
diabetes mellitus, hypertension, creatinine clearance and C-reactive protein, ADMA and 
L-NMMA remained significant predictors of cIMT.
Conclusions: Circulating levels of endogenous NOS inhibitors predict subclinical carotid 
atherosclerosis in the general population independently of established CVRF, supporting 
the role for assymmetric arginine methylation in the pathophysiology of endothelial 
dysfunction and atherosclerosis.
ADMA, L-NMMA and L-Arginine as predictors of Carotid IMT
Estimate (Beta) 95% CI for Estimate P value
Univariate Analysis (Log) ADMA 0.26 0.004 to 0.5 0.02
L-NMMA 0.046 0.024 to 0.068 <0.0001
L-Arginine -0.021 -0.004 to 0.0001 0.053
Multivariate Analysis (Log) ADMA 0.023 0.002 to 0.045 0.03
L-NMMA 0.03 0.01 to 0.05 0.005
L-Arginine 0.001 -0.02 to 0.02 0.91
11:00 a.m.
1002-13 Is Calcific Aortic Stenosis Progression Accompanied 
by a Higher Rate of Atherosclerotic Cardiovascular 
Events?
Charlotte Ng, George Eckert, Masoor Kamalesh, Indiana University Medical Center, 
Indianapolis, IN
Is Calcific Aortic Stenosis Progression Accompanied by a Higher Rate of Atherosclerotic 
Cardiovascular Events?
Charlotte Ng, George Eckert, Masoor Kamalesh
Background Calcific aortic stenosis (CAS) is now considered to be an active disease like 
atherosclerosis (AS). However, therapies such as statins have not shown benefit in CAS 
patients when studied prospectively. We tested the hypothesis that if CAS was indeed 
similar to AS, then subjects with progressive CAS should have a higher AS related event 
rate than those without progression of CAS.
Methods: Two readers independently measured the aortic valve area using continuity 
equation in 166 consecutive subjects with CAS between 1/97- 3/05, referred to our 
laboratory for serial echocardiograms for CAS. Subjects with no progression of CAS 
(group I) were compared to subjects with progression of reduction in valve area (group II) 
with regards to baseline demographics, occurrence of all myocardial infarctions, stroke, 
unstable angina requiring hospitalization and coronary revascularization. Chi-square test 
were use to compare the groups for differences in endpoints.
Results: Study cohort included 164 males (99%) with age 70±9 years. Age, low density 
lipoprotein level, hypertension, or diabetes status were similar among the two groups, 
while Group I had more smokers and fewer patients on statins (p<0.05). CAS progressed 
in 99 subjects-group I (60% of total) during mean follow up of 2.5 years. 28 patients had 
cardiovascular events (9 myocardial infarctions, 1 stroke, 20 coronary revascularizations, 
5 unstable angina requiring hospitalization). Of these, 8 (12%) occurred in group I and 20 
(20%) occurred in group II (p=0.16).
Conclusions: Progressive CAS is not paralleled with increased occurrence of 
atherosclerotic cardiovascular events despite described similarities in risk factors for 
CAS and AS. This mirrors inconsistency seen in benefit from statin therapy between CAS 
progression and AS events.
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1002-14 Impact of HMG-CoA reductase inhibitors on 
progression of Coronary Atherosclerosis in Chronic 
Kidney Disease
Anand M. Pillai, Andrew Yen, Vijay K. Verma, Barry Milcarek, Richard K. Kasama, Elias 
A. Iliadis, Cooper University Hospital, University of Medicine and Dentistry of New 
Jersey, Camden, NJ
Background: Chronic Kidney Disease (CKD) and progression of kidney disease has been 
associated with high cardiovascular morbidity and mortality. Statins have been proven to 
be effective in retarding the progression and even promote regression of atherosclerotic 
Coronary Artery Disease (CAD). Trials investigating the role of statins in CKD suggests 
varying results. We preformed a case controlled Quantitative Coronary Angiographic 
(QCA) trial evaluating the effect of HMG-CoA reductase inhibitors on progression of 
atherosclerotic CAD in patients with CKD .
Methods: 79 patients (pts) with CKD who underwent at least two coronary angiograms 
with a minimum interval of six months were analyzed: 60 subjects with stage 2 and stage 
3 CKD ( mean GFR: 52.4 ml/min/1.73 m2) and 19 patients with End Stage Kidney Disease 
( mean GFR: 10.1 ml/min/1.73 m2). 39 pts received statin therapy (n=25, simvastatin 
(20-80mg/day) or n=14, atorvastatin (20-80mg/day), while 40 pts were untreated with 
statins. Analysis was performed with respect to clinical, demographic and angiographic 
variables. Vessel analysis was performed on non-PCI artery and similar location based 
upon side-branch origin.
Results: Average duration between the angiograms was 23 months. Both groups were 
similar with respect to clinical and demographic variables. Changes in QCA measurements 
between statin and non-statin groups were as follows:
Stage 2 and 3 CKD: mean diameters, -0.04 mm versus -0.06mm (p=0.82); minimum 
diameters, -0.06 mm versus -0.37 mm (p= 0.02); and percent diameter stenosis, 2.25% 
versus 11.50% (p=0.04) .
ESRD: mean diameters, -0.08 mm versus -0.07mm (p=0.91); minimum diameters, -0.12 mm 
versus -0.29 mm ( p= 0.38); and percent diameter stenosis, 4.87% versus 12.24% (p=0.31) . 
The angiographic benefit of retardation of progression of atherosclerosis was demonstrated in 
both groups of CKD but was statistically significant only in mild-moderate CKD.
Conclusion: This study extends the beneficial angiographic effects of HMG-CoA reductase 
inhibitors to subjects with CKD, specifically to those with mild to moderate CKD. With 
worsening renal function, the effect of statins on atherosclerosis appears less marked.
11:00 a.m.
1002-34 Is Vascular Dysfunction the Forerunner of Paroxysmal 
Atrial Fibrillation in Hypertensive Subjects?
Ioannis Skiadas, Costas Tsioufis, Costas Thomopoulos, Maria Selima, Christos Zounis, 
Dimitris Syrogiannidis, Christodoulos Stefanadis, Ioannis Kallikazaros, Department of 
Cardiology, Hippokration Hospital, Athens, Greece
Background: Although the sequels of essential hypertension on rhythm disturbances is 
currently under vigorous investigation, the structural and functional characteristics of the 
vasculature and the heart of the hypertensives with paroxysmal atrial fibrillation (PAF) and 
their prognostic role has not been fully studied yet. 
Methods: We studied 46 consecutive essential hypertensive subjects (aged 64 years, 
22 men, office blood pressure (BP) 144/86mmHg) with a history of paroxysmal atrial 
fibrillation and no other evident comorbidity and 49 consecutive essential hypertensives 
without any evidence of PAF, matched for age, sex and BP. All included subjects were 
on sinus rhythm and underwent a complete conventional and tissue doppler imaging 
(TDI) echocardiographic study. Left Ventricular (LV) diastolic function was estimated by 
TDI, averaging the diastolic mitral annular velocities measurements. Aortic stiffness was 
evaluated, on the basis of carotid -femoral pulse wave velocity (PWV) measurements by 
means of a computerized method (Complior SP).
Results: Hypertensives with PAF compared to those without PAF had increased body 
mass index (28.1vs 26.9kg/m2, p<0.05), were smokers in a higher percentage (45 vs 
31%, p<0.05), had a longer duration of hypertension (5 vs 2 years, p< 0.05), showed 
significantly increased relative wall thickness (0.46 vs 0.44, p<0.05), left atrial volume 
indexed for body surface area (LAV index) (23.7±7 vs 19.7±3 ml/m2 p<0.05) and lower 
Em
 
(7.5±1.6 vs 8.4±1.4cm, p<0.05) and Em/Am
 
values (0.8±0.1 vs 0.9±0.4 p<0.05). 
Hypertensive subjects with PAF compared to those without PAF had increased PWV 
(9.65 vs 8.44 m/sec, p<0.05) and it was positively correlated with age (r=0.54, p<0.001), 
office systolic BP (r=0.35, p<0.05), relative wall thickness (r=0.32, p<0.005) and LA 
volume index (r=0.29, p<0.05).
Conclusions: Hypertensive subjects with PAF have significantly augmented values of aortic 
PWV, higher LAV index, and worse TDI-detected LV diastolic dysfunction. Although the 
underlying pathophysiological mechanisms are largely undetermined, this association could 
at least partially explain the increased vulnerability of such patients for development of PAF.
11:00 a.m.
1002-35 Comparison of Four Commercial Platelet Function 
Assays Abilities to Detect Response to Aspirin at 81 
and 325 mg Doses.
David L. McGlasson, George A. Fritsma, 59th Clinical Research Squadron/MSRL, 
Lackland Air Force Base, TX, University of Alabama, Birmingham, Birmingham, AL
Background: We compared the ability of four commercial platelet function assays to 
detect aspirin (ASA) response in normal subjects taking 81 or 325 mg of aspirin (ASA) 
for seven days.
Methods: We employed the (1) Chronolog 570VS whole blood (WB) aggregometer 
with agonists 1.0µg/mL collagen and 0.5 mM arachidonic acid (AA); (2) Dade-Behring 
PFA-100 with epinephrine/collagen (EPI/COLL) cartridge, (3) Accumetrics Ultegra 
Verify/Now arachidonic acid cartridge, and (4) urine 11-dehydrothromboxane (11-DHT) 
immunoassay normalized to urine creatinine. Forty-five subjects who met the inclusion 
criteria were consented. Blood and urine were collected at baseline; then each was given 
an 81mg enteric-coated ASA regimen daily. At seven days, blood and urine specimens 
were obtained and retested. After a minimum of two ASA-free weeks the process was 
repeated using a seven-day regimen of 325mg enteric-coated ASA.
Results: Based on chosen discrimination indices, the results are: 81 mg seven-day study: 
Collagen and AA WB aggregation showed 28.9% and 15.6% of the subjects resistant to 
ASA respectively. The Verify/Now showed 2.2% subjects resistant. The PFA-100 results 
showed 31.1% resistant, and 11-DHT indicated 22.1% resistance. Using the same 
criteria, at 325mg ASA: Collagen and AA WB aggregation demonstrates 15.6% and 
4.4% resistance respectively. The Verify/Now system showed 4.4% resistance. PFA-100 
indicated 22.2% of subjects resistant to ASA. The 11-DHT showed 13.3% resistance. 
Student’s t-test indicated significance between baseline and 7-day post-ASA results for 
all four platforms at both dosages (<0.001).
Conclusions: The relative sensitivities to ASA resistance ranges at 81 mg dosage ranged 
from 2.2% (Verify/Now) to 31.1% (PFA-100). At 325 mg dosages, the relative sensitivity 
ranged from 4.4% (Verify/Now) to 22.2% (PFA-100). Extension to clinical outcomes 
studies may further elucidate the relative predictive values for each platform.
11:00 a.m.
1002-36 Low-grade Inflammation and Hypoadiponectinemia 
Have an Additive Detrimental Effect on Aortic Stiffness 
in Essential Hypertensive Patients: A “Double-Edged 
Sword” of Vascular Damage
Costas Tsioufis, Kyriakos Dimitriadis, Costas Thomopoulos, Dimitris Chatzis, Carmen 
Vasiliadou, Dimitris Syrogiannidis, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Melissia, Greece
Background: Subclinical inflammation and arterial stiffening are associated with 
atherosclerosis progression, while adiponectin acts as an endogenous antiatherogenic 
factor. In this study we examined whether the combination of increased high-sensitivity 
C-reactive protein (hs-CRP) levels with hypoadiponectinemia exert an unfavorable effect 
on aortic stiffness in essential hypertensive subjects. 
Methods: 267 untreated patients with stage I-II essential hypertension (177 men, 
aged 50 years, office blood pressure (BP) =147/95 mmHg) underwent aortic stiffness 
evaluation on the basis of carotid to femoral pulse wave velocity (PWV) and venous blood 
sampling for estimation of hs-CRP and adiponectin levels. The distributions of hs-CRP 
and adiponectin were split by the median (1.3 mg/L and 7.8 μg/ml, respectively) and 
accordingly subjects were stratified into those with high and low values.
Results: Patients with high (n=134) hs-CRP compared to those with low hs-CRP (n=133) 
values exhibited greater PWV (8.2±1.3 vs 7.4±1.1 m/sec, p<0.0001), whereas patients 
with low (n=134) adiponectin compared to those with high (n=133) adiponectin levels had 
higher PWV (8.3±1.3 vs 7.4±0.9 m/sec, p<0.0001). Multiple stepwise regression analysis 
revealed that age (b=0.04, p<0.0001), 24-h systolic BP (b=0.168, p=0.009), hs-CRP 
(b=0.203, p=0.002) and adiponectin (b=0.172, p=0.008) were independent predictors of 
arterial stiffness. In patients with low hs-CRP, hypoadiponectinemia (n=46) compared to 
high adiponectin (n=87) was accompanied by increased PWV (7.8±1.2 vs 7.1±0.9 m/sec, 
p<0.0001). Similarly in patients with high hs-CRP, hypoadiponectinemia (n=84) compared 
to high adiponectin (n=50) was related to heightened PWV (8.5±1.3 vs 7.8±1.2 m/sec, 
p=0.004). Analysis of covariance revealed that PWV values remained different between 
the abovementioned groups after adjustment for confounding factors (p<0.05 for all).
Conclusion: In hypertensive patients, hypoadiponectinemia in conjunction with 
pronounced low-grade inflammation exerts an additive unfavorable effect on aortic 
stiffness, accelerating the vascular aging process.
11:00 a.m.
1002-37 Exaggerated Exercise Blood Pressure Response 
Is Related to a State of Pronounced Inflammatory 
Activation, Impaired Thrombosis/Fibrinolysis System 
and Arterial Stiffening in Essential Hypertensive 
Subjects
Costas Tsioufis, Kyriakos Dimitriadis, Dimitris Tsiachris, Costas Thomopoulos, Dimitris 
Tousoulis, Dimitris Syrogiannidis, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: There are conflicting data regarding the cardiovascular prognostic value of 
hypertensive response to exercise (HRE), while low-grade inflammation, arterial stiffness 
and impaired fibrinolysis are associated with atherosclerosis progression. In this study 
we examined the correlations between HRE, high-sensitivity C-reactive protein (hs-
CRP), plasminogen-activator inhibitor type 1 (PAI-1) and arterial stiffening, in essential 
hypertensives.
Methods: 84 newly diagnosed untreated non-diabetic subjects with stage I to II essential 
hypertension [58 men, mean age=52 years, office blood pressure (BP)=145/93 mmHg] 
with a negative treadmill exercise test (Bruce protocol) were divided into those with HRE 
(n=24) (peak systolic BP >210mmHg in men and >190 in women) and to those without 
HRE (n=60). Moreover, in all subjects venous blood samples were drawn for estimation of 
hs-CRP and PAI-1 levels, whereas arterial stiffness was evaluated on the basis of carotid to 
femoral pulse wave velocity (PWV), by means of a computerized method (Complior SP).
Results: Patients with HRE compared to those without HRE were older (56±9 vs 50±9 
years, p<0.05) and had greater 24-h systolic BP (138±14 vs 131±12 mmHg, p<0.05). 
Although groups did not differ regarding metabolic profile and left ventricular mass index 
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(p=NS for all), patients with HRE as compared to those without HRE exhibited higher 
levels of PWV (8.7±1.6 vs 7.7±1.3 m/sec, p<0.005), hs-CRP (5.1±1.2 vs 2.1±0.8 mg/l, 
p<0.0001) and PAI-1 (38.6±8.5 vs 18.9±2.6 ng/ml, p<0.05). In the total population, peak 
systolic BP was related to 24-h systolic BP (r=0.238, p<0.05), PWV (r=0.288, p<0.005) and 
hs-CRP (r=0.439, p<0.0001), whereas there was no association with PAI-1 levels (p=NS). 
By analysis of covariance it was revealed that PWV, hs-CRP and PAI-1 values remained 
significantly different between groups after adjustment for confounders (p<0.05).
Conclusion: Hypertensives with an HRE exhibit augmented hs-CRP, PAI-1 and PWV 
values. These findings suggest that impaired thrombosis/fibrinolysis system, arterial 
stiffening and microinflammation may be mechanisms that contribute to exercise 
hypertension and increase risk in this setting.
11:00 a.m.
1002-38 Endothelial Layer Restoration After Vascular Injury 
Is Delayed With Aging Bone Marrow While The 
Inflammatory Response And Intimal Formation Are 
Increased.
Marian Calfa, Roberto Vazquez-Padron, Abdelouahab Aitouche, Sen Li, Si Pham, 
University of Miami, Miller School of Medicine, Miami, FL
Introduction: Bone marrow (BM) plays an important role in vascular remodeling. Herein, 
we tested whether aging as opposed to young bone marrow delays reendothelialization, 
exaggerates inflammation and such intimal formation post vascular injury. 
Method: Two and 22 month old Fisher rats were used (four groups; n=8-12). Lethally 
irradiated, age matched and mismatched animals were reconstituted with syngeneic 
bone marrow. Balloon injury to the iliac artery was inflicted and 30 days after vessels were 
sampled. Intimal thickness (intima/media [I/M] ratio), reendothelialization (von Willebrand 
factor immunostained intima/intima internal perimeter [vWFI] ratio), inflammatory reaction 
(CD 68+ macrophages/unit area [IR] ratio) were estimated.
Results: Less vWFI and more neointima was quantified with aging as opposed to young 
bone marrow indifferent of recipient age. Considerably higher CD 68+ IR ratio was 
measured within the aging as compared to young age matched groups, likewise with 
aging bone marrow within young recipients (see Table; *, ***: p <0.05 compared to Young 
BM - Young Recipient; ** p<0.05 compared to Young BM -Aging Recipient). 
Conclusion: Aging bone marrow delays endothelial layer restoration after vascular 
injury and increases intimal formation while young bone marrow achieves the opposite, 
seemingly protective effect. Aging intensifies inflammation post vascular injury as the 
aging bone marrow compared to the young one exerts a considerable proinflammatory 
influence. 
Aging bone marrow 
- young recipient
Young bone marrow 
- young recipient
Aging bone marrow 
- aging recipient
Young bone 
marrow -aging 
recipient
I/M 
ratio 0.57 ±0.14* 0.42 ±0.13 0.79 ±0.29** 0.58 ±0.14
vWFI 
ratio 0.42 ±0.09* 0.7 ±0.17 0.38 ±0.09** 0.64 ±0.14
IR 239 ±139* 78 ±58 181 ±77*** 154 ±113
11:00 a.m.
1002-39 Role of Nox2-Containing NADPH Oxidase in Cigarette 
Smoke-Induced Impairment of Angiogenesis
Paola Haddad, Sylvie Dussault, Jessika Groleau, Sophie-Elise Michaud, Julie Turgeon, 
Alain Rivard, Notre Dame Hospital- CHUM, Montreal, PQ, Canada
BACKGROUND: We have previously demonstrated that cigarette smoke exposure is 
associated with impaired angiogenesis following tissue ischemia, and that this is at least 
partly due to increased generation of reactive oxygen species (ROS). Because NADPH 
oxidase is a major source of ROS in the vasculature, we investigated its role in the 
modulation of angiogenesis by cigarette smoke.
METHODS AND RESULTS: Mice deficient for the Nox2-containing NADPH oxidase 
(Nox2-/-) and control (Nox2+/+) mice were exposed to cigarette smoke for a total of 4 weeks. 
After two weeks, hindlimb ischemia was surgically induced by femoral artery removal. 
We found that Nox2-/- mice had a significantly faster rate of blood flow recovery when 
compared to Nox2+/+ mice, as assessed by Doppler flow ratios between the ischemic 
and normal hindlimbs at day 14 after surgery (0.89±0.04 vs. 0.61±0.02, p<0.001). At 
the microvascular level, Nox2-/- mice showed a statistically significant higher capillary 
density in ischemic muscles. The improved angiogenic response in Nox2-/- mice was 
associated with reduced oxidative stress in serum (antioxidant levels) and ischemic 
tissues (nitrotyrosine immunostaining), which correlated with an increased expression of 
the angiogenic factor VEGF. Moreover, the number of endothelial progenitor cells (EPCs) 
isolated from the spleen (FACS analysis) was significantly increased in Nox2-/- vs. control 
mice (0.77±0.07% vs. 0.45±0.05%, p<0.05). In vitro, HUVECs exposed to cigarette smoke 
extracts (CSE) showed increased production of superoxide (DHE) and ROS (DCFDA), 
which was associated with impaired migratory (Boyden chamber assay) and angiogenic 
(Matrigel) activities in response to VEGF. Interestingly, oxidative stress was significantly 
reduced and the angiogenic properties of HUVECs (endothelial cells) exposed to CSE 
were rescued following treatment with apocynin, a specific inhibitor of NADPH oxidase.
CONCLUSIONS: NADPH oxidase deficiency protects against cigarette smoke-induced 
impairment of angiogenesis. This beneficial effect is associated with a reduced level of 
oxidative stress together with a preserved expression of VEGF and an increased number 
of endothelial progenitor cells.
11:00 a.m.
1002-40 Hepatocyte Growth Factor Increases mRNA and Protein 
Expression of Stem Cell Markers in Left Ventricular 
Myocardium of Dogs with Heart Failure
Sharad Rastogi, Sanjaya Khanal, Victor G. Sharov, Michael S. Sabbah, Menjung Wang, 
Hani N. Sabbah, Henry Ford Health System, Detroit, MI
Background: Hepatocyte growth factor (HGF) can act to mobilize stem cells (SC) and 
promote their survival and proliferation. Sca1 and c-Kit are markers of SC. We previously 
showed that intramyocardial injections of naked plasmid encoding human HGF improves 
regional LV wall motion in dogs with microembolization-induced heart failure (HF). This 
study examined the effects of HGF on mRNA and protein expression of Sca1 and c-Kit 
in LV tissue of dogs with HF.
Methods: Expression of Sca1 and c-Kit was examined in the LV anterior wall (LVAW) and 
posterior wall (LVPW) of 14 HF dogs randomized to receive 10-15 injections in the LVAW 
of HGF plasmid (total of 4.0 mg, n=7) or saline as control (CON, n=7). LV tissue from 7 
normal (NL) dogs was used for comparison. Tissue was used to extract RNA and to prepare 
homogenate. mRNA expression for Sca1 and c-Kit was measured using RT-PCR and protein 
expression using Western blotting. Bands were quantified in densitometric units (du).
Results: Compared to NL, mRNA and protein expression of Sca1 and c-Kit was elevated 
in the LVAW and LVPW of CON dogs. HGF therapy significantly increased the expression 
of Sca1 and c-Kit in the LVAW but not in the LVPW.
Conclusions: In dogs with HF, injections of HGF into the LVAW promotes upregulation 
of mRNA and protein expression of Sca1 and c-Kit. This upregulation of key SC markers 
suggests that enhanced colonization of the LVAW by SC occurs after administration of HGF. 
This finding represents a pathway by which HGF therapy can benefit the failing myocardium.
LVAW LVPW
NL HF-Control HF + HGF NL HF-Control HF (No HGF)
c-Kit mRNA (du) 67 ± 4 156 ± 12* 216 ± 7† 55 ± 2 137 ± 5* 134 ± 3
Sca1 mRNA (du) 63 ± 4 150 ± 12* 239 ± 6† 73 ± 6 136 ± 10* 137 ± 5
c-Kit Protein (du) 84 ± 5 161 ± 6* 276 ± 12† 180 ± 10 303 ± 15* 312 ± 8
Sca1 Protein (du) 103 ± 6 162 ± 6* 251 ± 9† 76 ± 4 140 ± 4* 144 ± 7
*=p<0.05 vs. NL; †=p<0.05 vs. HF-Control
11:00 a.m.
1002-41 Relationships between Adiponectin and Markers of 
Oxidative Stress in High-risk Patients for Coronary 
Artery Disease
Fumihiko Kamezaki, Hiromi Tasaki, Kazuhito Yamashita, Tetsuo Adachi, Yutaka Otsuji, 
Second Department of Internal Medicine, University of Occupational and Environmental 
Health, Kitakyusyu, Japan, Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical 
University, Gifu, Japan
Background: Adiponectin has been reported to have protective activities against 
atherosclerosis. Limited data are available on the association of adiponectin and oxidative 
stress, which has an important role in the pathogenesis and development of coronary 
artery disease (CAD). 
Methods and Results: Among consecutive 153 patients undergoing cardiac 
catheterization, 117 patients (69±11 years old, 77 males) were enrolled in this study. 
Patients with hemodialysis, severe left ventricular dysfunction (ejection fraction<35%) and 
mutant extracellular superoxide dismutase (ECSOD) were excluded. Serum adiponectin, 
plasma ECSOD and urinary 8-epi-prostaglandin-F2α (8-epi-PGF2α) were measured. 
Study patients had 2.1±1.1 coronary risk factor, and 62 patients (53%) had at least one 
significant organic stenosis (≥75% stenosis of the luminal diameter). Although serum 
adiponectin level, plasma ECSOD and urinary 8-epi-PGF2α did not reflect coronary 
atherosclerosis, heparin-releasable ECSOD was significantly reduced in patients with 
CAD compared with that in patients without CAD (101.1±43.6 ng/mL versus 87.0±33.0 
ng/mL, p<0.05). Total adiponectin (Total-Ad; 5.74±3.68 μg/mL) levels and high-molecular 
adiponectin (HMW-Ad; 2.76±2.43 μg/mL) levels positively correlated with plasma ECSOD 
concentration (63.7±25.0 ng/mL) (r=0.403, p<0.001; r=0.334, p<0.001, respectively). 
However, we did not find correlations between serum adiponectin levels and heparin-
releasable ECSOD (93.6±38.9 ng/mL) and between serum adiponectin levels and urinary 
8-epi-PGF2α (162.7±81.4 pg/mg•cr). Stepwise-multiple regression analysis also showed 
significant influence of Total-Ad (F=21.74), HMW-Ad (F=14.55), triglyceride (r=-0.285, 
F=10.10), high-density lipoprotein cholesterol (r=0.271, F=9.01), age (r=0.50, F=7.59) 
and fasting glucose (r=0.193, F=4.52) on the ECSOD levels.
Conclusions: We suggest that circulating adiponectin plays an important role on the 
regulation of the plasma ECSOD levels in high-risk patients for coronary artery disease. 
Adiponectin may exert protective activities against atherosclerosis, at least in part, 
through upregulation of antioxidant enzyme ECSOD.
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1002-42 Risk Factors for Preclinical Atherosclerosis in Alaskan 
Natives: The GOCADAN Study
Alexis Cutchins, Mary J. Roman, Richard B. Devereux, Sven O. E. Ebbesson, Jianhui 
Zhu, Barbara V. Howard, Weill Medical College of Cornell University, New York, NY, 
MedStar Reasearch Institute, Hyattsville, MD
Background Both traditional and novel risk factors for coronary artery disease have been 
shown to correlate with carotid artery intimal-medial thickness (IMT) and atherosclerotic 
plaque in populations of several ethnicities. In this study, we examine whether similar 
relations exist in a population of Alaskan Natives.
Methods Participants in the population-based Genetics of Coronary Artery Disease in 
Alaskan Natives (GOCADAN) Study underwent evaluation of cardiovascular risk factors, 
inflammatory markers, and carotid ultrasonography. Outcome variables were carotid IMT 
and presence (discrete plaque) and extent (score of 0 to 8 carotid segments containing 
plaque) of atherosclerosis.
Results The population consisted of 508 men and 645 women with a mean age of 42±16 
years (range 17-92); 2.1% of men and 4.9% of women had diabetes (DM) (p=0.005); 25% 
of men and 20% of women had hypertension (HTN) (p=0.053); 63% of men and 57% of 
women were current smokers (p=0.12). Although plaque was comparable in men (35%) 
and women (31%), men had more extensive atherosclerosis (plaque score: 0.86±1.50 
in vs. 0.69±1.30 in women, p=0.04). In multivariate analyses, IMT, presence of plaque 
and plaque score were all associated with older age and presence of HTN (p<0.03 to 
p<0.001). In addition, IMT was related to male gender (p<0.001), DM (p=0.006), higher 
body mass index (BMI) (p=0.02) and low HDL (p=0.04). Presence of plaque was 
additionally related to lower BMI (p<0.001), higher LDL (p=0.04) and smoking (p=0.008), 
whereas higher plaque score was additionally related to male gender (p=0.04), lower BMI 
(p<0.001) and presence of DM (p=0.03). Dietary intake of omega-3 fatty acids was not 
protective against any measure of atherosclerosis. Although C-reactive protein (CRP), 
fibrinogen and homocysteine were related to atherosclerosis in univariate analyses, only 
CRP was related in multivariate analyses (p=0.092 for presence of plaque and p=0.001 
for plaque score).
Conclusions. Alaskan Natives have similar traditional and novel risk factors for carotid 
atherosclerosis, assessed by several parameters, as other ethnic and racial populations. 
Plaque score may better integrate the effects of a wider spectrum of risk factors.
11:00 a.m.
1002-43 Dynamic Responses of Proinflammatory Markers 
and Oxidative Stress Induced by Postchallenge 
Hyperglycemia are Associated with Coronary Artery 
Disease in Patients without Previous Diagnosis of Type 
2 Diabetes Mellitus
Chih-Sheng Chu, Kun-Tai Lee, Kai-Hung Cheng, Tsung-Hsien Lin, Ho-Ming Su, Wen-
Chol Voon, Sheng-Hsiung Sheu, Wen-Ter Lai, Kaohsiung Medical Univeristy Hospital, 
Kaohsiung, Taiwan,ROC
Background- Meta-analysis has shown an exponential relationship between 2-hr 
postchallenge hyperglycemia and the incidence of coronary artery disease (CAD). 
Pulsatile hyperglycemia can acutely increase inflammatory markers by oxidative 
mechanism. We sought to investigate the inflammatory and oxidative responses induced 
by postchallenge hyperglycemia and their associations with CAD in patients (pts) without 
previously known diabetes.
Methods - Serial changes of glucose, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-
6) and nitrotyrosine (NT) levels were analyzed at 0, 1 and 2 hr during 75-g oral glucose 
tolerance test (OGTT) in 120 pts (81M, age 62±11yrs) without known diabetes before 
coronary arteriography. Pts were categorized as with or without CAD (by Gensini score) 
and as normal (NGT), impaired (IGT) and diabetic (DGT) glucose tolerance by OGTT.
Results- The proportions of NGT, IGT and DGT were 42%, 34% and 24%, respectively. 
No significant difference of glucose levels during OGTT can be found in pts with or without 
CAD in either NGT or IGT groups. The levels of TNF-α, IL-6 and NT at 0, 1 and 2 hr of 
OGTT were stepwisely elevated in each group. Significant higher level of TNF-α, IL-6 
and NT at 2 hr of OGTT were demonstrated in IGT and DGT pts with CAD compared with 
those without CAD (p<0.05).
Conclusions- These results highlight the importance of postchallenge hyperglycemia-
induced inflammatory and oxidative responses, rather than hyperglycemia per se, in the 
presence of CAD in pts with IGT and DGT. 
11:00 a.m.
1002-44 Statin Therapy improves Left Ventricular Function 
and Carotid Arterial Stiffness in Patients With 
Hypercholesterolemia
Yukio Mizuguchi, Hideji Tanaka, Yoshifumi Oishi, Hirokazu Miyoshi, Takeo Ishimoto, 
Norio Nagase, Takashi Oki, Higashi Tokushima National Hospital, National Hospital 
Organization, Tokushima, Japan
Background: The widespread use of pulsed and tissue Doppler echocardiography 
has facilitated the noninvasive evaluation of left ventricular (LV) diastolic function. 
Hypercholesterolemia is a well-established risk factor for the development of vascular 
events. We wished to determine whether treatment with pitavastatin affects LV systolic 
and diastolic function and carotid arterial stiffness in patients with hypercholesterolemia.
Methods:A total of 30 patients with hypercholesterolemia (240mg/dl or more for serum 
total cholesterol) were randomized to either administration of pitavastatin 1 or 2 mg/day 
(n=15) or non-statin therapy (n=15) for 12-months. LV systolic and diastolic function 
were determined by measuring transmitral flow velocity, mitral annular motion velocity, 
and myocardial strain and strain rate profiles using pulsed Doppler, tissue velocity, and 
ultrasonic strain imaging. Subclinical atherosclerosis also was determined by measuring 
the intima-media thickness (IMT) and stiffness (β) of the left and right common carotid 
arteries using B- and M-mode ultrasonography.
Results: The mean peak systolic strain of the LV posterior and inferior walls increased 
from 39.2±15.9% to 51.5±17.7% (p< 0.01) and 46.0±12.2% to 57.5±10.3% (p< 0.01), 
respectively, in the pitavastatin group compared to the non-statin group during the follow-
up period. The mean peak early diastolic strain rate of the LV posterior and inferior walls 
also increased from -6.5±2.9s-1 to -9.5±2.8s-1 (p< 0.01) and -6.5±2.5s-1 to -9.1±2.7s-1 (p< 
0.01), respectively, in the pitavastatin group. The stiffness (β) decreased from 5.6±2.5 to 
4.1±0.8 (p< 0.05) in the pitavastatin group, although there was no significant change in 
IMT during the follow-up period.
Conclusions: The use of pitavastatin improved not only carotid arterial stiffness but also 
LV systolic and diastolic function in patients with hypercholesterolemia. Ultrasonic strain 
imaging is a promising tool for detecting earlier cardiovascular involvement.
11:00 a.m.
1002-45 Accelerated Vascular Damage in Hypertensive Subjects 
With Obstructive Sleep Apnea Syndrome: an Adverse 
Nocturnal Stimulus on Arterial Properties
Costas Thomopoulos, Costas Tsioufis, Kyriakos Dimitriadis, Anastasia Amfilochiou, 
Dimitris Tousoulis, Pavlos Toutouzas, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: Although obstructive sleep apnea syndrome (OSAS) is accompanied by 
increased atherosclerotic disease burden, its relation with arterial stiffness is not yet well 
determined. We investigated whether hypertensive subjects with OSAS are characterized 
by increased arterial stiffness.
Methods: Our study population consisted of 46 consecutive subjects with newly 
diagnosed untreated stage I-II hypertension suffering from OSAS (35 men, aged 49±8 
years), and 53 hypertensive subjects without OSAS, matched for age, sex, and smoking 
status. OSAS was confirmed by polysomnography study [apnea hypopnea index (AHI) 
≥5], and the level of minimum oxygen saturation during sleep (minSatO2) was also 
estimated. Metabolic status (biochemical measurements), aortic stiffness as determined 
by carotid - femoral pulse wave velocity (PWV) (Complior SP), left ventricle mass index 
(LVMI), and relative wall thickness (RWT) (echocardiography) were also assessed.
Results: Hypertensives with OSAS compared to those without OSAS demonstrated 
higher levels of body mass index (31.4 vs. 29.3 Kg/m2, p=0.015), office systolic and 
diastolic blood pressure (151/98.8 vs. 145/93.7 mmHg, p<0.05 for both cases), low 
density lipoprotein cholesterol (4.14±0.44 vs. 3.65±0.46 mmol/l, p=0.042), RWT (0.46 vs. 
0.42, p=0.01), PWV (8.56±0.49 vs. 7.85±0.93 m/s, p=0.001) and logAHI (1.48±0.45 vs. 
0.33±0.21 events/h, p=0.0001). Lower minSatO2 was noticed in hypertensives with OSAS 
(77±4.6 vs. 91.5±2 %, p=0.0001). Waist/hip ratio, glucose levels and LVMI were similar in 
the two groups (0.92 vs. 0.91, 4.72 vs. 4.61 mmol/l, and 92 vs. 88 gr/m2 p=NS in all cases). 
The 9% increase of PWV in the OSAS group remained significant after adjustment for 
confounders (p=0.04). PWV was correlated with age (r=0.35, p=0.015), office systolic 
BP (r=0.30, p=0.007), RWT (r=0.30, p=0.03), logAHI (r=0.389, p=0.0001), and minSatO2 
(r=-0.418, p=0.0001).
Conclusions: OSAS has a significant incremental effect on arterial stiffening as 
determined by PWV values in the setting of hypertension. This finding suggests that the 
presence of OSAS in hypertensives accelerates vascular damage.
11:00 a.m.
1002-46 Urotensin II is a Major Risk Biomarker for Stroke in Type 
2 Diabetes
Michel P. Hermans, Sylvie A. Ahn, Damien Gruson, Jean-Marie Ketelslegers, Michel F. 
Rousseau, University of Louvain, Brussels, Belgium
Background: Various cardiovascular conditions upregulate circulating urotensin II, a 
potent endogenous vasoconstrictor peptide, as well as its receptor GPR14, possibly 
resulting in further vascular and myocardial damage. Type 2 diabetes is associated with a 
high prevalence of coronary, peripheral artery disease and stroke that is not adequately 
addressed by conventional risk factors targeting.
Methods: To clarify the potential involvement of urotensin II in the relation between type 
2 diabetes and cardiovascular complications, particularly stroke, we measured plasma 
concentrations of urotensin II in 122 diabetics male patients (mean age: 63±12 years, 
hypertension and metabolic syndrome prevalence 69% and 78%, respectively). Forty-
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one patients in the lower tertile were compared with 41 patients from the upper tertile. 
Urotensin II was determined using a specific radioimmunoassay (Bachem, Torrance, 
Ca) after plasma extraction using Sep-Pack C18 columns. In addition, we analyzed the 
homocysteine levels and the vasoactive peptides, BNP [automated immunoassay system 
(Axsym, Abbott, Chicago IL)] and BigET-1 (home-made radioimmunoassay).
Results: Data were expressed as means (1SD) or as proportions (%). Mean plasma 
levels of urotensin II (pg/mL) were [1.07(0.18)] in the upper tertile vs [0.54(0.08)] in the 
lower tertile. No significant difference was found between tertiles for age, body mass 
index, smoking exposure and diabetes duration. The upper tertile of urotensin II levels 
was associated with significant higher values for homocysteine [18.8(11.1) vs 10.9(3.0) 
μmol/L, p<0.05], BNP [103(178) vs 42(55) pg/mL, p<0.05] and BigET-1 [7.06(2.72) vs 
5.98(1.88) pg/mL, p<0.05]. The prevalence of stroke was dramatically higher in the upper 
urotensin II tertile group (17 vs 2%, p<0.05).
Conclusion: Our data suggest that urotensin II is a major risk biomarker for stroke 
in male patients with type 2 diabetes, in whom homocysteine levels and vasoactive 
markers, BNP and BigET-1, are higher. These results provide further insights into stroke 
pathophysiology as well as into potential diagnostic and therapeutic interventions to 
prevent vascular cerebral complications in type 2 diabetes.
11:00 a.m.
1002-47 Polymorphism in the Cholesteryl Ester Transfer Protein 
Gene and the Risk of Early Onset Myocardial Infarction 
among Smokers
Ilan Goldenberg, Arthur J. Moss, Wojciech Zareba, Daniel Ryan, Shirley Eberly, 
University of Rochester Medical Center, Rochester, NY
Background: Cigarette smoking has been shown to interfere with cholesteryl ester transfer 
protein (CETP) activity, thereby possibly affecting lipoprotein levels and cardiovascular 
risk. We hypothesized that susceptibility to early onset myocardial infarction (MI) among 
smokers may be related to the presence of the common CETP TaqIB polymorphism.
Methods: The age at onset of a first MI among current (n=199), past (n=345) and never 
(n=270) smokers was related to the presence of the CETP B1 and B2 alleles in a cohort 
of 814 first MI patients.
Results: Current and past smokers carrying the B1 allele exhibited a significantly higher 
frequency of early MI cases (Figure). Multivariate regression analysis revealed that current 
and past smoking were independently associated with a respective 8.1 year (p<0.001) 
and 3.1 year (p<0.001) reduction in the age at onset of a first MI as compared with never 
smoking. However, smoking was associated with early onset MI only among B1B1 (curent 
smokers: 9.5 year reduction [p<0.001]; past smokers: 4.9 year reduction [p=0.001]) and 
B1B2 (current smokers: 8.2 year reduction [p<0.001]; past smokers: 2.6 year reduction 
[p=0.01]) genotype carriers, whereas among B2B2 carriers smoking was not associated 
with a significantly earlier MI age (p-value for genotype x smoking category interaction 
= 0.03).
Conclusions: The current findings suggest that genetic factors modify susceptibility to 
coronary athero-thrombotic events among smokers. 
11:00 a.m.
1002-76 Is Elastin Really Useful For Marker Of Acute Aortic 
Dissection?
Koichi Akutsu, Masahiko Katayama, Morimasa Takayama, Naoki Sato, Takeshi 
Yamamoto, Hiroyuki Yamanaka, Kazuo Munakata, Keiji Tanaka, Nippon Medical School, 
Tokyo, Japan, National Cardiovascular Center, Osaka, Japan
Background: Previous studies have suggested that serum elastin levels of patients 
with acute aortic dissection (AAD) is increased. However, whether measuring the serum 
eleatin level is useful for the diagnosis of AAD remains controversial because normal 
range of elastin level has not been determined yet.
Methods: Forty-two patients with AAD who admitted to our hospital constituted the study 
population. In all patients, serum elastin levels were measured within 48 hours after the 
onset of AAD, and were compared with those of healthy volunteers (n = 533). Elastin 
levels were also evaluated according to the status of the false lumen (Group P: patients 
with patent false lumen (n = 28); and Group T: patients with thrombosed false lumen (n = 
14)). All results were shown as mean±SD.
Results: From the data of 533 healthy volunteers (54±17 years), upper limit of elastin 
levels were determined as mean+2SD (Y = 2.0513×Age-4.7785, R2 = 0.7636) or 
mean+3SD (Y = 2.4109×Age-6.6735, R2 = 0.7223). The number of patients with AAD 
whose elastin level was under the upper limit of age matched healthy volunteers was 
21/28 (75%) in group P and 11/14 (79%) in group T (mean+2SD) or 24/28 (86%) in group 
P and 13/14 (93%) in group T(mean+3SD).
Conclusions: Our data support that measuring the serum elastin level may not be useful 
for the diagnosis of AAD because normal range of elastin was higher than previously 
evaluated level.
11:00 a.m.
1002-77 Obstructive Sleep Apnea Syndrome Adversely Affects 
on Cerebral Blood Flow
YUHKI HARA, Akiko Noda, Seiko Miyata, Makoto Minoshima, Mayo Sukegawa, Mari 
Sugiura, Aki Iwami, Yuki Adachi, Tetsuya Iidaka, Norio Ozaki, Yasuo Koike, Nagoya 
University Graduate School of Medicine, Nagoya, Japan
Background : Obstructive sleep apnea syndrome (OSAS) is related to the quality of life 
and health-related variables. Sleep fragmentation and nocturnal oxygen desaturation in 
OSAS may increase the risk of industrial or car accidents secondary to the disturbance 
of cognitive function during daytime. Near-infrared spectroscopy (NIRS) enables the 
noninvasive observation of brain function by measuring hemoglobin concentrations. The 
influence of OSAS on cerebral blood flow during cognitive activation was investigated.
Methods : Fifteen patients with OSAS (11 males, 4 females; age 50.9 ± 11.9 years, 
mean ± SD) and eighteen healthy controls (14 males, 4 females; age 51.9 ± 8.2 years) 
were included in the study. Standard polysomnography was performed in all subjects.
The oxyhemoglobin (oxyHb) level was measured on the mornings following the 
polysomnography. The relative concentrations of oxyHb were measured with frontal 
probes every 0.1 sec during a word fluency task with a 24-channel NIRS recorder (Hitachi 
ETG-100, Hitachi Medical, Tokyo, Japan). We measured the peak oxyHb level, time from 
the start of the task to the peak oxyHb level, and the recovery time from the peak oxyHb 
level to the baseline level.
Results : The percentage of time spent in sleep stage 3/4 or stage REM and lowest 
oxygen saturation were significantly lower, and the number of apnea or hypopnea 
episodes per hour (AHI), time during which nocturnal oxygen saturation was< 90%, and 
arousal index were significantly greater in patients with OSAS than in helthy controls. The 
peak oxyHb level on frontal region was significantly lower in patients with OSAS than in 
healthy controls (0.51 ± 0.18 vs 0.74 ± 0.23 mmol, p<0.05). The time from the start of the 
task to the peak oxyHb level was significantly shorter in patients with OSAS than healthy 
controls (45.4 ± 9.6 vs 62.1 ± 4.5 seconds, p=0.0031).
Conclusion : OSAS might have an adverse effect on the cerebral blood flow during the 
daytime as a result of sleep fragmentation and nocturnal oxygen desaturation. NIRS 
could be a useful tool for understanding the interrelation between OSAS and disturbance 
of daytime cognitive function.
11:00 a.m.
1002-78 An Abbreviated Carotid Intima-Media Thickness 
Scanning Protocol to Facilitate Clinical Screening for 
Subclinical Atherosclerosis
Adam D. Gepner, Rachael A. Wyman, Claudia E. Korcarz, Susan E. Aeschlimann, James 
H. Stein, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background: Carotid intima-media thickness (CIMT) testing can assist with 
cardiovascular risk prediction, but its use is limited by the need for comprehensive, time-
consuming scanning protocols. The purpose of this study was to determine if abbreviated 
protocols that focused on plaque screening and CIMT of the far wall of the common 
carotid artery (CCA) could identify patients with increased CIMT as effectively as a more 
comprehensive protocol.
Methods: Bilateral ultrasound images of the CCA, bulb, and internal carotid artery were 
obtained using a comprehensive scanning protocol and composite CIMT was calculated. 
Three abbreviated models for identifying composite CIMT≥75th percentile for the patient’s 
age, sex, and race were compared.
Results: Of 261 subjects, 77 (29%) had increased composite CIMT. There were 134 
(51%) subjects with increased left or right CCA CIMT (CCA model). Carotid plaque was 
detected in 136 (52%) subjects (plaque model), and plaque or at least one CCA CIMT 
≥75th percentile was detected in 190 (72%) subjects (combination model). The areas 
under the receiver-operator characteristic curves for the CCA and the combination models 
were similar (figure), and higher than for the plaque model (p<0.05). The combination 
model identified all subjects with increased composite CIMT (100% sensitivity).
Conclusions: Combining plaque and far wall CCA CIMT screening identifies all patients with 
increased composite CIMT that would be been found using a comprehensive protocol. 
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1002-79 Microalbuminuria Is Correlated With Endothelin-1, 
Adiponectin, C-Reactive Protein and Arterial Stiffness 
in Essential Hypertension: Reflections Beyond the 
Glomerulus
Costas Tsioufis, Kyriakos Dimitriadis, Carmen Vasiliadou, Efstathios Taxiarchou, Fotini 
Rozi, Maria Selima, Kostas Toutouzas, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: Microalbuminuria is a marker of cardiovascular risk, whereas increased 
levels of endothelin-1 (ET-1), hypoadiponectinemia and low-grade inflammation are 
associated with atherosclerosis progression. In this study we investigated the relationships 
between albumin to creatinine ratio (ACR), ET-1, adiponectin, high-sensitivity C-reactive 
protein (hs-CRP) and arterial stiffness in essential hypertensives.
Methods: 210 newly diagnosed untreated non-diabetic patients with stage I to II essential 
hypertension [130 men, aged 50 years, office blood pressure (BP)=148/95 mmHg], 
according to the ACR values determined as the mean of two non-consecutive morning 
spot urine samples, were divided into microalbuminurics (n=35) (mean ACR=30-300 mg/
g) and normoalbuminurics (n=175) (mean ACR<30 mg/g). Moreover, arterial stiffness 
was evaluated on the basis of carotid to femoral pulse wave velocity (PWV), by means of 
a computerized method (Complior SP)
Results: Microalbuminurics compared to normoalbuminurics were older (52±7 vs 49±7 
years, p<0.05) and had higher 24-h systolic BP (141±15 vs 130±12 mmHg, p<0.0001). 
Although groups did not differ regarding sex, body mass index and metabolic profile (p=NS), 
microalbuminurics as compared to normoalbuminurics exhibited lower concentrations of 
adiponectin (6.1±1.8 vs 9.3±3.5 μg/ml, p<0.0001) and increased levels of ET-1 (1.25±0.37 
vs 0.53±0.17 fmol/ml, p<0.0001), PWV (9±1.8 vs 7.8±1.1 m/sec, p<0.0001) and hs-CRP 
(5.3±1.1 vs 2.1±0.7 mg/l, p<0.0001). In a multivariate linear regression, 24-h systolic BP 
(b=0.31, p<0.0001), ET-1 (b=0.251, p<0.0001), hs-CRP (b=0.431, p<0.0001) and PWV 
(b=0.276, p<0.0001) were independent predictors of the ACR. Moreover, analysis of 
covariance revealed that hs-CRP, ET-1, adiponectin and PWV values remained significantly 
different between groups after adjustment for confounders (p<0.05).
Conclusion: Microalbuminuria in essential hypertension is accompanied by 
diffuse vascular dysfunction, as reflected by augmented hs-CRP, ET-1, PWV and 
hypoadiponectinemia. These findings further support that ACR determination is a useful 
tool to identify subjects at high cardiovascular risk, in this setting.
11:00 a.m.
1002-80 Hospitalizations and Associated Costs in Patients with 
Peripheral Arterial Disease: Results from the REACH 
Registry
Elizabeth M. Mahoney, Kaijun Wang, David J. Cohen, Dogan Fidan, Joseph Jackson, Alan 
T. Hirsch, Ph. Gabriel Steg, Deepak L. Bhatt, Mid-America Heart Institute, Kansas City, MO
Background: The impact of peripheral arterial disease (PAD) on healthcare resource use 
and costs is not well understood.
Methods: Using 1-yr follow-up data on symptomatic (CAD, CVD and/or PAD) US patients 
(pts) from the REACH Registry (n=15,719), we compared 1-yr hospitalization (HOSP) 
rates for vascular reasons and associated acute care costs in pts with PAD to other risk 
groups according to vascular disease site(s), after adjusting for baseline risk factors and 
medication use. To accommodate a high % pts with zero HOSP costs, a 2-part model 
was used to estimate costs conditional on covariates, by which the predicted probability 
of non-zero costs from a logistic regression model is multiplied by estimated costs from a 
linear model fit to data from pts w/ costs>0.
Results: In pts with 1 vascular site involved, the adjusted risk of any HOSP for pts w/ PAD was 
greater than that for CVD (OR=1.55; p<.0001) and CAD (OR=1.33; p<.0001). There was also 
an incremental effect of PAD on the risk of any HOSP in pts with either CAD (p<0001) or CVD 
(p<.01). In pts with PAD only, PAD- and CAD-related HOSPs accounted for 58% and 25% of 
total HOSPs, respectively. Mean adjusted 1-yr HOSP costs for pts with PAD only were higher 
than for CAD only and CVD only, and PAD was associated with significantly higher 1-yr costs 
in pts who also had a history of CVD and/or CAD (all p<.0001; see figure).
Conclusions: PAD confers a significant burden to the US health care system. The economic 
burden is estimated to be greater than, and incremental to that for CAD and CVD. 
11:00 a.m.
1002-81 Peripheral Arterial Disease is Associated with 
Increased Serum Myeloperoxidase Levels 
Independently of the Presence of Severity of Coronary 
Artery Disease
Julio A. Chirinos, Anila Veerani, Leah Corson, Alan Schob, Simon Chakko, Guido O. 
Perez, Armando J. Mendez, University of Miami Miller School of Medicine, Miami, FL
Background: The propensity to acute plaque rupture differs between the coronary 
and lower extremity arterial beds. Inflammation is an important determinant of plaque 
vulnerability and the association between inflammation and atherosclerosis may also 
differ between coronary and lower extremity beds. Increased levels of inflammatory 
markers are associated with the presence of peripheral arterial disease (PAD). However, 
both inflammation and PAD are associated coronary artery disease (CAD), and previous 
studies have not accounted for this common association. We examined the relation 
between 2 inflammatory markers and the presence of PAD among subjects refered for 
coronary angiography.
Methods: We studied 283 males undergoing coronary angiography. Serum 
myeloperoxidase (MPO) and C-reactive protein (CRP) were compared between subjects 
with (n=24) and without (n=260) PAD.
Results: Subjects with PAD had significantly higher MPO (median=403.8 vs. 669.1 µg/L; 
p=0.002) and CRP levels (0.74 vs. 0.43 mg/L; p=0.02). CRP significantly correlated with 
MPO (R=0.36; p<0.0001). However, after adjusting for each other, only MPO remained an 
independent predictor of PAD (adjusted OR per SD increase in MPO=1.76; 95%CI=1.13 
to 2.74; p=0.01). A higher proportion of subjects with PAD had a history of smoking (50 vs. 
21.5%; p=0.001), diabetes mellitus (32.7 vs 54.2%; p=0.03), cerebrovascular disease (5.0 
vs. 20.8 %; p=0.002) and statin use (41.5 vs 66.7%; p=0.01). However, after adjustment 
for age, systolic and diastolic blood pressure, number of vessels involved with significant 
coronary artery disease, presence of left main coronary artery disease, CRP, statin, aspirin, 
angiotensin converting enzyme inhibitor use and smoking, MPO remained significantly 
higher among patients with PAD (adjusted mean=635.8 vs. 402.5 µg/L; ANCOVA p=0.01).
Conclusions: PAD is associated with inflammation independently of coronary artery 
disease. Although CRP and MPO are correlated with each other in subjects with vascular 
disease, only MPO is independently associated with PAD. Further studies are needed to 
evaluate the prognostic role of different inflammatory markers in the progression of PAD.
11:00 a.m.
1002-82 Acute and Chronic Effect of Smoking on Arterial 
Stiffness
Takuro Kubozono, Masaaki Miyata, Kiyo Ueyama, Aya Nagaki, Shuuihi Hamasaki, Ken 
Kusano, Osamu Kubozono, Chuwa Tei, Kagoshima University, Kagoshima, Japan
Background: Cigarette smoking is one of major cardiovascular risk factors. brachial-Ankle 
pulse wave velocity (baPWV) is used to evaluate the atherosclerosis and arterial distensibility. 
The major problem of baPWV is blood pressure dependency. A novel atherosclerotic index, 
Cardio-Ankle Vascular Index (CAVI), has been developed. CAVI is adjusted for blood pressure 
based on the theory of stiffness parameter β and can measure arterial stiffness independent 
of blood pressure during measuremnt. The purpose of this study is elucidated the acute and 
chronic effect of smoking on arterial stiffness measured by baPWV and CAVI.
Methods: We studied 11 male smokers (mean age of 35±6 years) to evaluate the acute effect 
of smoking on arterial stiffness. To elucidate the chronic effect of smoking on arterial stiffness, 
we analyzed 160 male active smokers (mean age of 46±12 years). CAVI and baPWV were 
calculated by measuring pulse volume record, BP, and vascular length from heart to ankle. 
We measured CAVI and baPWV using VaSera VS-1000. CAVI is calculated by the following 
equation: CAVI=2ρ x 1/(SBP-DBP) x In (SBP/DBP) x PWV2 ( ρ: density of blood, SBP: systolic 
blood pressure, DBP: diastolic blood pressure, PWV: pulse wave velocity).
Results: Acute effect: SBP, heart rate (HR), baPWV and CAVI increased just after smoking 
1 cigarette (SBP: 120±8→123±11 mmHg, P=0.09; HR: 64±8→75±9 bpm, P<0.001; baPWV: 
1172±115→1222±112 cm/sec, P<0.01; CAVI: 7.0±0.9→7.3±0.7; P<0.01), and returned to 
baseline 5 minutes after smoking. Chronic effect: Although baPWV or CAVI significantly 
correlated with age (baPWV: r=0.498, p<0.0001; CAVI: r=0.563, p<0.0001) and Brinkman 
index (baPWV: r=0.352, p<0.0001; CAVI: r=0.447, p<0.0001), only baPWV significantly 
correlated with SBP (baPWV: r=0.476, p<0.0001; CAVI: r=0.149, not significant). In 
multiple regression analysis, baPWV independently correlated with age and SBP, and CAVI 
independently correlated with age and Brinkman index, not with SBP.
Conclusions: Smoking causes the significant increase of arterial stiffness measured by 
baPWV and CAVI. Blood pressure independently, CAVI may be a useful index to evaluate 
the degree of the arterial stiffness caused by smoking.
11:00 a.m.
1002-83 Relationship of Mild Troponin-I Elevations to Cardiac 
Function and Pulmonary Congestion In Patients with 
Subarachnoid Hemorrhage: Results From The SAHMII 
Study
Masaki Tanabe, Elizabeth A. Crago, Marilyn Hravnak, Michael B. Horowitz, John 
Gorcsan, III, University of Pittsburgh, Pittsburgh, PA
Background: Elevations of troponin-I occur often with subarachnoid hemorrhage (SAH), 
however their significance is not clear, especially when mildly positive (+). Accordingly, 
we studied the relationship of troponin-I to cardiac function and occurrence of pulmonary 
congestion in SAH patients (pts).
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Methods: Ninety-one SAH pts (53±10 yrs) were prospectively studied with troponin-I, 
chest X-ray and echocardiography (<48 hrs). Maximum troponin-I was used to indicate 
myocardial injury. Systolic function was assessed by ejection fraction (EF) and diastolic 
function was assessed by mitral inflow E and mitral E’ annular velocities.
Results: Forty-two pts (46%) had negative troponin-I (<0.1ng/ml), 27 pts (30%) had 
mildly+ troponin-I (0.1 - 1.0ng/ml) and 22 pts (24%) had highly+ troponin-I (>1.0ng/ml). 
The high+ group showed relatively depressed EF; 51±11%* vs. 63±6% and 60±8% in 
negative or mildly+ groups, respectively (*p<0.05). However, both mildly+ and highly+ 
groups had abnormal diastolic function (E/E’): 16±5* and 16±7*, respectively vs. 12±3 in 
troponin-negative pts (*p<0.05). Pulmonary congestion occurred in 23% of the troponin-
negative pts, 67%* of mildly+ pts, and 81%* of highly+ pts (*p<0.05 vs. troponin neg).
Conclusions: Highly+ troponin-I after SAH was associated with systolic and diastolic 
dysfunction and pulmonary congestion. Even mild elevations of troponin-I were 
associated with diastolic dysfunction and pulmonary congestion, and appear to be of 
clinical significance with SAH. 
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1002-84 Endothelial Dysfunction by Flow Mediated Brachial 
Artery Dilatation is a Marker of Ischemic Response 
during Stress Echocardiography
Ajay Shah, Ramya Suryadevara, Simbo Chiadika, Donna Macmillan-Marotti, Danny 
Pudpud, Bilal Ayub, Eftekhari Hossein, Farooq A. Chaudhry, St.Luke’s Roosevelt 
Hospital Center, Columbia University, New York, NY
Background: The utility of endothelial dysfunction by flow mediated dilatation (FMD) of 
brachial artery(BA) in predicting ischemia on Stress Echocardiography (SE) is not well 
defined. We sought to determine whether FMD could be used to identify patients with flow 
limiting coronary artery disease (CAD).
Methods: We studied 24 consecutive pts.( 65 ± 13yrs; 52% male) referred for Stress 
Echocardiogram with risk factors for CAD. Baseline BA cross sectional (CSD), 
longitudinal diameter (LD) and Brachial artery flow rate (BAFR) were measured . BA 
was occluded for 5 min at 50mm Hg above their baseline systolic BP. Post occlusion 
continuous imaging at the same level and settings was performed. Parameters similar 
to baseline were measured to compare the percent (%) changes post occlusion. SE and 
FMD study readers were blinded to each other. Ischemia was defined by any worsening 
of contractility from baseline to peak of stress.
Results: 13 pts (54%) demonstrated ischemia on SE. 10 (77%) out of these 13 pts demonstrated 
significant ≥ 70 % stenosis in at least one of the major arteries on coronary angiogram. Pts. 
with normal SE demonstrated significantly better reactivity as compared to those developing 
ischemia at peak stress(See Fig). A FMD change (CS) by ≤ 5.3% predicts ischemia on stress 
echo with a high sensitivity of 92%. The AUC on ROC is 0.99 (95% CI = 0.84-1.00).
Conclusion: Endothelial dysfunction by flow mediated brachial artery dilatation is a strong 
marker of ischemia on Stress Echocardiography.
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1002-85 Postchallenge Plasma Glucose Is Associated With 
Arterial Stiffness in Non-Diabetic Healthy Men
Ryotaro Takahashi, Kenji Okumura, Mari Yoshikane, Nobuo Ikeda, Toyoaki Murohara, 
Chunichi Hospital, Nagoya, Japan, Nagoya University Graduate School of Medicine, 
Nagoya, Japan
Background: Arterial stiffness is an important predictor of cardiovascular risk, and aging 
and blood pressure (BP) are known as independent determinants of arterial stiffness. 
Recent studies indicate that postchallenge plasma glucose (PG) levels are predictors 
of cardiovascular death. Although it has been reported that diabetes is associated with 
increased arterial stiffness, the association between postchallenge PG and arterial 
stiffness remains unclear. The aim of this study was to investigate the relationship of 
postchallenge PG and arterial stiffness in non-diabetic healthy men.
Methods: Fasting PG, postchallenge PG during an oral glucose tolerance test (OGTT), 
hemoglobin A1c, fasting insulin levels, and other risk factors were assessed in 102 non-
diabetic Japanese men (54±9 years), who did not have any history of atherosclerotic 
disease and who were not taking any medication. PG spike was defined as the difference 
between the maximal PG level during OGTT and the level of fasting PG. Arterial stiffness 
was assessed by measuring brachial-ankle pulse wave velocity (baPWV) with an 
oscilometric technique (form PWV/ABI®, Colin Co, Japan).
Results: In univariate analysis, age (r=0.335, p<0.001), systolic BP (r=0.395, p<0.0001), 
diastolic BP (r=0.291, p<0.01), total cholesterol (r=0.218, p<0.05), triglycerides (r=0.202, 
p<0.05), 1h-PG (r=0.303, p<0.01), 2h-PG (r=0.285, p<0.01), maximal PG (r=0.318, 
p<0.01), and PG spike (r=0.288, p<0.01) were significantly correlated with baPWV, 
whereas fasting PG, hemoglobin A1c, fasting insulin levels, and other risk factors were not 
correlated with baPWV. In stepwise multiple regression analysis, systolic BP (β=0.407), 
age (β=0.344), and 2h-PG (β=0.178) were identified as independent determinants of 
baPWV (R2=0.303, p<0.0001).
Conclusion: Two hour-post challenge PG during OGTT is an important determinant of 
arterial stiffness as well as systolic BP and age in non-diabetic healthy men.
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1002-86 Gene Transfer of Human Extracellular Superoxide 
Dismutase Ameliorates Monocrotaline-Induced 
Pulmonary Arterial Hypertension in Rats
Fumihiko Kamezaki, Hiromi Tasaki, Kazuhito Yamashita, Shinichiro Koide, Testuo 
Adachi, Yutaka Otsuji, Second Department of Internal Medicine, University of 
Occupational and Environmental Health, Kitakyusyu, Japan, Laboratory of Clinical 
Pharmaceutics, Gifu Pharmaceutical University, Gifu, Japan
Background: Pulmonary arterial hypertension (PAH) is a life-threatening disease 
characterized by vascular remodeling and vasoconstriction, for which available treatments 
has been limited. Recent evidence suggests that oxidant stress may be contributed to 
the pathogenesis or development of PAH. In the present study, we examined whether 
intratracheal gene transfer of human extracellular superoxide dismutase (ECSOD), which 
is the primary antioxidant enzyme in the lung, could ameliorate monocrotaline (MCT)-
induced PAH in rats. 
Methods and Results: Rats were given a single subcutaneous injection of MCT (40 
mg/kg body weight), and concomitantly received an intratracheal administration of an 
adenovirus expressing β-galactosidase (Adβgal group) or human ECSOD (AdECSOD 
group). Control rats (Control group) were given an equal volume of sterile saline solution. 
Three days after ECSOD gene transfer, ECSOD protein was expressed in airway 
epithelial cells, alveolar epithelial cells, and small pulmonary arteries as evidenced by 
immunohistochemical staining. In ECSOD group, ECSOD concentration measured by 
ELISA in lung tissue, bronchoalveolar lavage fluid and plasma increased on day 5, and 
in lung, decreased gradually over a 14- to 21-day duration. Twenty-eight days after the 
MCT injection, the Adβgal group developed severe PAH with right ventricular hypertrophy, 
and pulmonary arterial remodeling. Right ventricular systolic pressure and the weight 
ratio of the right ventricle to the left ventricle plus septum were significantly lower in 
the AdECSOD group (42.50±1.46 mmHg and 0.453±0.029) than in the Adβgal group 
(61.50±2.61 mmHg and 0.653±0.038). Systemic arterial pressure and heart rate were 
similar. Compared to the Adβgal group, medial wall thickening as well as muscularization 
of pulmonary microvessels was markedly suppressed in the AdECSOD group (p<0.01, 
p<0.01, respectively). Furthermore, the ECSOD group inhibited MCT-induced proliferation 
of vascular smooth muscle cells.
Conclusions: Human ECSOD overexpression to the lung ameliorated the MCT-induced 
PAH in rats. We suggest that gene therapy with ECSOD may be a new therapeutic 
strategy for the treatment of PAH.
11:00 a.m.
1002-87 Double Trouble for 1,934 Hospitalized Medical Patients 
Who Developed Deep Venous Thrombosis: Prophylaxis 
Omitted More Often and Pulmonary Embolism More 
Frequent
Gregory Piazza, Ali Seddighzadeh, Victor F. Tapson, Samuel Z. Goldhaber, Beth Israel 
Deaconess Medical Center, Boston, MA, Brigham and Women’s Hospital, Boston, MA
Background: Patients hospitalized with medical illness are susceptible to the development of 
venous thromboembolism including deep venous thrombosis (DVT) and pulmonary embolism.
Methods: We studied hospitalized medical patients in a prospective registry of 5,451 
consecutive ultrasound-confirmed DVT patients at 183 institutions in the United States.
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RESULTS: Of 5,451 patients who participated in the registry, 1,934 were hospitalized 
medical patients, 1,549 were hospitalized nonmedical patients, 549 were treated 
exclusively as outpatients, and 1,419 had uncertain status. The hospitalized medical 
patients received venous thromboembolism prophylaxis far less often than nonmedical 
patients: 564 (32.2%) versus 838 (60.7%) (p < 0.0001). This underutilization of 
prophylaxis encompassed both mechanical and pharmacological modalities (TABLE). 
Hospitalized medical patients demonstrated a significantly higher clot burden, suffering 
pulmonary embolism more often [338 (21.3%) versus 222 (17.9%) (p = 0.02)], compared 
with nonmedical patients.
CONCLUSION: More frequent omission of venous thromboembolism prophylaxis leading 
to DVT with a higher clot burden illustrates the “double trouble” of hospitalized medical 
patients. Further studies should focus on improving implementation of prophylaxis in this 
vulnerable population.
TABLE. Patterns of venous thromboembolism prophylaxis in hospitalized medical patients 
compared with nonmedical patients. 
Type of Prophylaxis Medical Patients(N = 1,934)
Nonmedical 
Patients
(N = 1,549)
p-Value
No prophylaxis whatsoever 1,185 (67.8%) 543 (39.3%) < 0.0001
Pneumatic compression devices 51 (7.9%) 243 (27.6%) < 0.0001
Vascular compression stockings 37 (5.7%) 158 (17.9%) < 0.0001
Subcutaneous unfractionated 
heparin 91 (14.1%) 184 (20.9%) < 0.001
Low molecular weight heparin 82 (12.7%) 178 (20.2%) < 0.001
11:00 a.m.
1002-88 Noninvasive Evaluation of Right Ventricular 
Dysfunction and Disease Severity in Patients with 
Chronic Pulmonary Arterial Hypertension Using Tissue 
Doppler and Strain Rate Imaging
Hiroto Utsunomiya, Satoshi Nakatani, Shingo Kyotani, Norifumi Nakanishi, Division of 
Cardiology, National Cardiovascular Center, Osaka, Japan
Background: The evaluation of right ventricular (RV) function is clinically important in 
patients with pulmonary arterial hypertension (PAH) because the presence of RV failure 
has prognostic implications. However, no method has been clinically established to 
evaluate RV function. It has been reported that peak systolic longitudinal strain (εSYS) 
and peak systolic strain rate at RV free wall derived from tissue Doppler echocardiography 
with strain rate imaging (TDE/SRI) predict pulmonary artery systolic pressure, but it is 
unknown whether they are associated with RV global function and disease severity.
Methods: For 20 consecutive patients with chronic PAH (42±14 years, pulmonary 
systolic pressure 86±28mmHg) and 20 aged-matched healthy subjects, we prospectively 
performed conventional echocardiography and TDE/SRI in apical 4 chamber view. In 
PAH group, we also measured 6-min walked distance, plasma brain natriuretic peptide 
(BNP) level and catheterization-derived pulmonary artery pressure, cardiac index, and 
pulmonary vascular resistance.
Results: Patients with chronic PAH had worse RV performance than healthy subjects (RV 
ejection fraction, 34±11 vs. 63±10%, p<0.001; RV Tei index, 0.62±0.13 vs. 0.29±0.03, 
p<0.001). TDE/SRI showed significant smaller peak systolic velocity (7.3±1.9 vs. 8.8±1.4 
cm/s, p<0.01), εSYS (-18.1±7.3 vs. -28.4±4.3%, p<0.05) and peak systolic strain rate 
(-1.16±0.50 vs. -1.70±0.23, p<0.001) at basal RV free wall. In PAH group, εSYS and 
peak systolic strain rate at basal RV free wall were related to RV ejection fraction (r=-
0.75, -0.66, respectively), RV Tei index (r=0.69, 0.51), 6-min walked distance (r=-0.40, 
-0.45), plasma BNP level (r=0.74, 0.62), pulmonary vascular resistance (r=0.74, 0.74) 
and cardiac index (r=-0.70, -0.82), while peak systolic velocity was not related to any of 
these parameters. Among TDI/SRI parameters, -0.85 of basal RV strain rate showed the 
sensitivity 75% and the specificity 83% to predict severe RV dysfunction defiend as RV 
ejection fraction≤40% and cardiac index≤2.0.
Conclusion: In patients with chronic PAH, εSYS and peak systolic strain rate at basal RV 
free wall may be useful markers for RV dysfunction and disease severity.
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1002-89 Pharmacological Venous Thromboembolism 
Prophylaxis in Hospitalized Medical Patients: a Meta-
Analysis of Randomized Controlled Trials
Lironne Wein, Sara Wein, Steven Haas, James Shaw, Henry Krum, NHMRC Centre of 
Clinical Research Excellence in Therapeutics, Monash University, Melbourne, Australia
Background: Unfractionated heparin (UFH), low-molecular-weight heparin and heparinoid 
(LMWH), and selective factor Xa inhibitors are used for venous thromboembolism 
prophylaxis in hospitalized medical patients, however there is a lack of consensus as to 
which agent is associated with optimal results. The aim of this analysis was to determine 
which pharmacological agent most effectively prevents venous thromboembolism in 
hospitalized medical patients.
Methods: MEDLINE (via PubMed), EMBASE, the Cochrane Central Register of 
Controlled Trials (from inception through June 2006) and reference lists of relevant trials 
were searched. Eligible studies were randomized controlled trials involving at least 30 
medical patients that compared UFH to control, LMWH to control, LMWH to UFH, or 
factor Xa inhibitors to a comparator. Trials were considered appropriate if they reported 
deep venous thrombosis, pulmonary embolism and/or mortality. Data analysis was 
conducted via the use of STATA v8.2 using the Mantel-Haenszel fixed-effects method and 
the Der Simonian and Laird random-effects method.
Results: Thirty six of the 936 potentially relevant studies were deemed eligible for 
inclusion. Compared with control, UFH was associated with a reduced risk of deep venous 
thrombosis (risk ratio (RR), 0.33; 95% confidence interval (CI), 0.26,0.42; P<0.001) and 
pulmonary embolism (RR, 0.64; 95% CI, 0.50,0.82; P=0.001), as was LMWH (RR, 0.56; 
95% CI, 0.45,0.70; P<0.001 and RR, 0.37; 95% CI, 0.21,0.64; P<0.001, respectively). 
Neither UFH nor LMWH significantly reduced mortality (RR, 0.95; 95% CI, 0,88,1.02; 
P=0.14 and RR, 1.02; 95% CI, 0.88, 1.19; P=0.76, respectively). When pooling results 
of trials which evaluated the differences between the two agents, LMWH was associated 
with a lower risk of deep venous thrombosis (RR, 0.68; 95% CI, 0.52,0.88; P=0.004).
Conclusions: UFH and LMWH reduce venous thromboembolic risk in hospitalized 
medical patients, but neither agent reduces mortality. When directly compared, LMWH is 
more effective in preventing deep venous thrombosis.
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1002-118 Is the pH Induced Change in IK
r
 Inhibition by Ibutilide 
Arrhymogenic
Congrong Lin, Xiaogang Ke, Vasant Ranade, John C. Somberg, Department of 
Pharmacology, Rush University, Chicago, IL
Ibutilide (I) a class III antiarrhythmic agent is employed in conversion of atrial fibrillation 
and atrial flutter. I inhibits the cardiac IK
r
 channel and prolongs the QT interval and can 
give rise to ventricular tachycardia. In previous studies we have shown that extracellular 
acidosis significantly attenuates the IK
r
 inhibitory effect of proarrhythmic drugs (quinidine) 
and that extracellular acidosis has little impact on the inhibitory effect of less proarrhythmic 
drugs such as amiodarone. We hypothesized that I would behave more like quinidine than 
amiodarone with extracellular acidosis. Cardiac IK
r
 was studied using human-ether-a-
go-go-related gene (HERG) expressed on Xenopus oocytes, and two electrode voltage 
clamp technique. The recording solution contained 96mM NaCl, 5.0mM KCl, 2.0mM 
CaCl2, 5mM HEPES. The pH of solution was adjusted to 6.2 or 7.4 to represent the acidic 
or normal conditions. At pH 7.4 I, 0.3, 1, 3 and 10µM inhibited current by 22 + 5, 54 + 
5, 80 + 3 and 93 + 1% respectively. When I was applied at pH 6.2, I 0.3, 1, 3 and 10µM 
I decreased HERG current by 10 + 4, 29 + 4, 32 + 8 and 36 + 5% respectively. I 30 µM 
produced only a 48 + 5% current block at pH 6.2. There were significant differences in 
the percentage current inhibition by 1, 3 and 10µM I at normal pH vs. pH 6.2, (p values 
<0.01). The IC50 of I was 0.9 + 0.1µM at pH 7.4 and the IC50 was increased to 31 + 6 
µM at pH 6.2. Our results indicated that I is a potent IK
r
 inhibitor, and that extracellular 
acidosis markedly attenuated IK
r
 inhibition. Diminished IK
r
 inhibition in the ischemic region 
with low extracellular pH and potent IK
r
 inhibition in the normal pH regions could result in 
heterogeneity in action potential duration, which may trigger and sustain arrhythmias and 
contribute to the proarrhythmic toxicity of ibutilide.
11:00 a.m.
1002-119 Inhibition of HERG Channel by Aspirin: pH or Direct 
Effect
Congrong Lin, Xiaogang Ke, Vasant Ranade, John C. Somberg, Department of 
Pharmacology, Rush University, Chicago, IL
Aspirin (ASA) has been widely used for many years for relieving pain and fever, and in 
preventing heart attack and stroke. ASA overdose can result in an anion gap, metabolic 
acidosis, tinnitus, and in severe cases, encephalopathy and cardiovascular collapse. There 
are studies showing the inhibitory effect of ASA on heat-evoked currents in rat dorsal 
root ganglion neurons and the augmented effect of ASA on NMDA type of glutamate 
responses in spiral ganglion neurons. The effect of ASA on cardiac ion channels has 
not been studied. We evaluated the effect of ASA on cardiac IK
r
 channel using HERG 
expressed on xenopus oocytes. Two microelectrodes voltage clamp technique was used 
for recording, and the recording solution contained 96 mM NaCl, 5.0 mM KCl, 2.0 mM, 
CaCl2, and 1.0 mM MgCl2, 5 mM HEPES and the pH of solution was adjusted with NaOH 
to 7.4. ASA was dissolved in the recording solution. At a concentration less than 1 mM, 
ASA has little effect on HERG current. ASA 1 mM and 2 mM inhibited current by 12 + 2 and 
22 + 4% respectively. ASA 3 mM inhibited current by 80 + 6%. Considering the acidifying 
influence of ASA, the pH values of 1, 2 and 3 mM ASA solutions were determined as 7.1, 
6.5 and 4.9. The pH of the recording solutions was adjusted to the corresponding pH, 
and the results showed that pH 7.1, 6.5 and 4.9 reduced HERG current by 6 + 2, 10 + 2 
and 49 + 5%. ASA 1, 2 and 3 mM caused greater inhibition of current than the recording 
solutions with the corresponding pH adjustment. There were significant differences in 
current inhibition between 2 mM ASA and the pH 6.5 recording solution (p < 0.05), and 
between 3 mM ASA and pH 4.9 recording solution (p < 0.01). ASA inhibits HERG current 
not only through acidification, but by a direct effect. The potent inhibition at 3 mM (54 
mg/dl) further suggests that ASA at therapeutic doses and at doses seen with acute and 
chronic salicylism (40-120 mg/dl) may be arrhythmogenic due to potent inhibition of the 
cardiac IK
r
 channel.
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1002-120 Rifalazil Prevents Chlamydia pneumoniae Induced 
Acceleration of Atherosclerosis and Eradicates the 
Organism in a Rabbit Model Better than Azithromycin
Joseph B. Muhlestein, David B. Rothstein, M. Elizabeth Hammond, Jeffrey L. Anderson, 
LDS Hospital, Salt Lake City, UT
Background: Chlamydia pneumoniae (Cpn) vascular infection is associated with 
cardiovascular disease (CVD) and accelerates the development of atherosclerosis in rabbits. 
Azithromycin (AZ) was shown to temporarily prevent this atherosclerotic acceleration in 
the rabbit model but did not eradicate Cpn from vascular tissue. Also, in large randomized 
clinical trials, AZ failed to affect the outcome of patients with CVD. The new antibiotic, 
rifalazil, (R) has greater potency and bactericidal activity against Cpn compared with AZ. 
Therefore we tested R for its effect on atherosclerotic development in the rabbit model.
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Methods: In a randomized study of 45 rabbits fed a mildly atherogenic diet (0.25% 
cholesterol), 15 received saline, and 30 were inoculated intranasally with Cpn, and then 
received either a 7-week course of R (5 mg/kg po q day x 1 week, then 5 mg/kg po twice 
weekly x 6 weeks), AZ (30 mg/kg po q day x 1 week, then 30 mg/kg po twice weekly x 6 
weeks); or placebo. Twelve weeks after completion of therapy rabbits were sacrificed and 
aortas removed and evaluated for extent of atherosclerosis by quantitative microscopy 
and for the presence within the plaque of Cpn by direct immunofluorescence.
Results: All rabbits showed some degree of intimal thickening. Quantitatively, plaque 
area stenosis (cross sectional plaque area / reference vessel area) for each group was: 
infected-placebo=29.0%, uninfected=22.8% (p-value versus infected-placebo = 0.016), 
infected-AZ=30.6% (p = 0.37), infected-R=24.1% (p=0.04). Mean immunofluorescence 
score (ranging 0-3+) for each group was: infected-placebo=2.0, uninfected=0.2 (versus 
infected-placebo, p=0.001), infected-AZ=1.0 (p=0.005), infected-R=0.2 (p<0.0001).
Conclusions: In this rabbit model of Cpn-accelerated atherosclerosis, R was more 
effective than AZ both in preventing the acceleration of atherosclerosis and in eradicating 
the Cpn from the plaque 12 weeks after 7 weeks treatment. The inability of AZ to eradicate 
Cpn may explain the negative results of published clinical trials. Whether R can reduce 
clinical CVD remains to be seen.
11:00 a.m.
1002-121 Association Between the TaqIB Polymorphism of 
the Cholesteryl Ester Transfer Protein Gene and 
Postprandial Triglyceride Levels in Patients with 
Familial Hypercholesterolemia.
Genovefa Kolovou, Katherine Anagnostopoulou, Klelia Salpea, George Hatzigeorgiou, 
Christina Marvaki, Constantinos Mihas, Dimitris Degiannis, Dimitri Mikhailidis, Dennis V. 
Cokkinos, Onassis Cardiac Surgery Center, Athens, Greece
Background: Postprandial hypertriglyceridemia plays an important role in the 
development of premature atherosclerosis. Patients with familial hypercholesterolemia 
(FH) and postprandial dyslipoproteinemia have higher risk for coronary heart disease. 
Cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl ester from 
high-density lipoprotein cholesterol (HDL) to apolipoprotein B-containing lipoproteins 
in exchange for triglycerides (TG). The B2 allele of the TaqIB polymorphism has been 
reported to decrease CETP mass and activity giving rise to an antiatherogenic profile.
The aim was to examine the influence of CETP TaqIB polymorphism on TG response to 
an oral fat tolerance test (OFTT) in heterozygous FH (hFH).
Methods: We selected and genotyped 67 hFH patients who were previously subjected 
to OFTT. A value of greater than 219 mg/dl was taken as an abnormal response to the 
fat load according to previous studies of ours and others. Patients were divided into two 
groups according to their response to the OFTT (abnormal or normal).
Results: B1 carriers showed a trend towards higher fasting TG levels, p=0.069 but 
displayed a significantly higher postprandial TG response at the 6th and 8th hours 
(p=0.05 and p=0.04, respectively) compared with B2 carriers. B2 carriers had higher 
HDL cholesterol levels compared with B1 carriers, p=0.013. Similarly, the subjects 
with the B2B2 genotype had higher HDL cholesterol levels compared with the B1B1 
and B1B2 subjects, p=0.008. B1 allele carriers had higher fasting TG levels (p=0.04), 
and a higher postprandial TG magnitude/curve at the 2th and 6th hours (p=0.05 and 
p=0.006, respectively) compared with B2. Accordingly, the area under the curve of TG 
levels was higher in B1 compared with B2 carriers, p=0.03. Conclusion: In the case 
of an abnormal postprandial response, B2 carriers displayed a lower postprandial TG 
magnitude compared with B1 carriers. On the contrary, there were no differences in TG 
levels between B1 and B2 carriers in patients with a normal response. Therefore, at higher 
TG concentration, the B2 allele may protect against an exaggerated postprandial TG 
rising and a subsequent lowering of HDL cholesterol concentration.
11:00 a.m.
1002-122 Effect Of Co-administration Of Ezetimibe/Simvastatin 
And Fenofibrate On Apolipoproteins (A-III, B, and C-III) 
In Patients With Mixed Hyperlipidemia
Eli Roth, Michel Farnier, Inna Perevozskaya, Michael Davies, Debra Kush, Yale Mitchel, 
Merck Research Laboratories, Rahway, NJ
Background: Apolipoproteins (apo) are major determinants of the structure and function 
of lipoproteins. Since ezetimibe/simvastatin (EZE/SIMVA) and fenofibrate (FENO) affect 
lipid metabolism through separate but complimentary mechanisms, the purpose of this 
post-hoc analysis was to examine the effects of these treatments alone and in combination 
on the apo profile in patients with mixed hyperlipidemia.
Methods: Data were from a multicenter, randomized, double-blind, placebo (PBO)-
controlled, parallel arm trial. Randomized patients had mixed hyperlipidemia (defined 
as LDL-C 130-220 mg/dL and TG 150-500 mg/dL), and no history of CHD, CHD-
equivalent disease (except for type 2 diabetes), or CHD risk >20%. Patients (N=611) 
were randomized (3:3:3:1) to 1of 4 treatments for 12 wks: EZE/SIMVA 10/20 mg+FENO 
160 mg; EZE/SIMVA 10/20 mg; FENO 160 mg; or PBO.
Results: Apo B and the ratio of apo B/apo A-I were significantly improved with co-
administered EZE/SIMVA+FENO relative to the other treatments. Apo A-I was significantly 
increased with co-administration and FENO alone compared with EZE/SIMVA and 
PBO. EZE/SIMVA+FENO significantly reduced apo C-III, especially apo C-III on apo B-
containing lipoproteins compared with other treatments. There were no significant effects 
on apo C-III on non-apo B-containing lipoproteins or Lp(a).
Conclusion: Co-administration of EZE/SIMVA + FENO significantly improved the apo 
profile of patients with mixed hyperlipidemia and thus may decrease atherosclerotic risk. 
Percent change EZE/SIMVA 10/20 mg + FENO 160 mg
FENO
160 mg
EZE/
SIMVA
10/20 mg
Placebo
Apo B* -44.7 -20.1† -39.0† 0.0†
Apo A-I§ 11.1 10.8 6.6† 1.6†
Apo B/apo A-I* -48.3 -28.3† -42.4† -2.8†
Apo C-III§ -28.9 -23.7† -14.7† 0.2†
Apo C-III on apo B* -56.3 -41.1† -26.1† 13.9†
Apo C-III on non-
apo B* -10.3 -9.5 -6.3 -16.2
*Median % change; §LS mean % change; †p<0.05 for EZE/SIMVA+FENO vs. specific group
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1002-123 Impact of HMG-CoA Reductase Inhibitors (statins) 
on New Cardiovascular Events Following Coronary 
Intervention and on the Progression-Regression of 
Coronary Atherosclerotic Plaque: A Three-Dimensional 
Intravascular Ultrasound Study.
Hiroaki Takashima, Kenji Asai, Yoshinori Wakita, Yasuo Kuroda, Takashi Kosaka, Yasushi 
Kuhara, Takayuki Ito, Department of Cardiology, Aichi Medical University School of 
Medicine, Nagakute, Japan
Background: HMG-CoA reductase inhibitor (statin) reduces cardiac events, and 
recent clinical trials have reported that statin retards the progression of coronary 
atherosclerotic plaque. However, it is not fully understood whether the regression of 
coronary atherosclerotic plaque by statin therapy affects new cardiovascular events. We 
investigated the effect of statins on the progression-regression of coronary atherosclerotic 
plaque and new cardiovascular events.
Methods: We examined 403 patients undergoing intravascular ultrasound (IVUS) guided 
percutaneous coronary intervention (PCI) for the treatment of coronary artery disease 
(CAD). All patients were assigned to the statin group (187 patients) or the non-statin 
group (216 patients). The following cardiovascular events were selected as the clinical 
end-points: myocardial infarction, death, coronary artery bypass graft, and PCI for new 
lesion. Of 403 patients, 165 underwent volumetric IVUS analyses at baseline and at 
average 10-month follow-up in the matched left main coronary artery.
Results: Although baseline clinical characteristics were similar between the 2 groups, 
LDL-cholesterol levels in the statin group were significantly lower than those in the non-
statin group (108±25 mg/dl vs. 125±26 mg/dl, p <0.001). In long-term clinical events, the 
incidence of PCI for new lesions was significantly lower in the statin group than that in the 
non-statin group (10.1% vs. 26.4%, p <0.001). In serial volumetric IVUS analyses, there 
were no differences in each volume index at baseline between the 2 groups. However, 
plaque volume index (PVI) was significantly reduced in the statin group (5.4±15.7% 
decrease) compared with the non-statin group (9.5±15.7% increase, p <0.001) at follow-
up. There was a positive correlation between %change in LDL-C level and %change in 
PVI (r =0.288, p <0.001).
Conclusions: Statin therapy significantly induced coronary atherosclerotic plaque 
regression associated with a significant reduction of LDL-C level in the short-term. These 
results suggest that statin therapy prevents the incidence of new cardiovascular events 
including PCI for new lesions in patients with CAD in the long-term.
11:00 a.m.
1002-124 Rimonabant Improves Body Weight and 
Cardiometabolic Risk Factors in Older Adults
Louis J. Aronne, on behalf of the RIO Investigators, Weill Medical College of Cornell 
University, New York, NY
Background:Age is an established cardiovascular disease (CVD) risk factor; accordingly, 
strategies to reduce other CVD risks, including reducing abdominal obesity and its 
cardiometabolic consequences, are important. 
Methods: We evaluated the clinical effects of rimonabant, the first cannabinoid type 
1 receptor blocker, in the subgroup of older adults (>60 years) who participated in the 
Rimonabant in Obesity (RIO) clinical trials (n= 626), 4 double-blind, placebo-controlled 
randomized trials comparing treatment with a lifestyle management program and either 
placebo, rimonabant 5 mg (R5) or 20 mg (R20) for one year. We report here the results of 
a retrospective analysis of rimonabant 20 mg vs. placebo in this subgroup.
Results: At one year R20 produced significantly greater weight loss than placebo (-6.7 
kg vs. -2.1 kg; P<0.001). Waist circumference, a measure of abdominal obesity, was 
also reduced more with R20 than placebo at 1 year (-6.8 vs -2.5 cm; P<0.001). HDL-C 
and TG levels were improved significantly more by R20 (15.2 % vs 8.3% and -10.2% 
vs +6.8%, respectively; both P<0.001). R20 reduced blood pressure -1.6 (systolic) and 
-1.0 (diastolic) mm Hg more than placebo; both P=0.04. These results are comparable to 
the effects of rimonabant in patients < 60 years of age and suggest that the efficacy of 
rimonabant is similar in older and younger adults. The safety profile of rimonabant in the 
older adults was similar to that in patients < 60 years of age. Fewer older adults dropped 
out of the study (30.0% and 31.1% for placebo and R20) compared with patients <60 
years old (45.3% and 43.3%). The most commonly reported adverse events leading to 
discontinuation in older adults were depressed mood, nausea, dizziness, and fatigue and 
in younger patients, depressed mood, anxiety, and nausea.
Conclusions: In summary, rimonabant therapy for one year produced significantly greater 
weight loss and improvement in multiple cardiometabolic benefits than placebo in older 
adults with an efficacy and safety profile comparable to that seen in younger patients.
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1002-125 Pioglitazone Increases Adiponectin Levels in Non-
Diabetic Patients With Coronary Artery Disease
Lynn M. Mailloux, Snehal Patel, John T. Coppola, Cezar S. Staniloae, Saint Vincents 
Catholic Medical Centers, New York, NY
Background:Hypoadiponectinemia is associated with coronary artery disease (CAD). 
Pioglitazone has been shown to increase levels of adiponectin in diabetic patients. We 
sought to assess whether administration of pioglitazone to non-diabetic patients with CAD 
would affect plasma adiponectin levels and endothelial function.
Methods: Seventeen non-diabetic patients with stable coronary artery disease were 
treated with 12 weeks of pioglitazone hydrochloride (Actos) 30 mg daily. Baseline and 
post-therapy adiponectin levels and endothelin-dependent flow mediated dysfunction 
(ED-FMD) measurements were obtained. In addition, after a 3 month washout period, 
adiponectin levels and ED-FMD measurements were repeated.
Results: Treatment with pioglitazone increased adiponectin levels from an average of 10.6 
µg/ml to 21.1 µg/ml (p=0.001) and improved ED-FMD from 4.45% to 8.43% (p=<0.001). 
There was no significant correlation between change in adiponectin levels with change 
in HDL, change in ESR, or baseline body surface area. However, there was a moderate 
correlation between increase in adiponectin levels and decrease in Hgb A1C (p=0.057).
Conclusions: Treatment with pioglitazone increased plasma adiponectin levels and 
improved ED-FMD in non-diabetic patients with coronary artery disease. There was a 
moderate correlation between improvement in adiponectin levels and hemoglobin A1C. 
11:00 a.m.
1002-126 Association of HDL Cholesterol with Coronary Heart 
Disease Risk across Categories of LDL Cholesterol: the 
Atherosclerosis Risk in Communities (ARIC) Study
Brad C. Astor, Fleur Lee, Paul M. Muntner, Johns Hopkins University, Baltimore, MD, 
Pfizer, Inc., New York, NY
Background: National cholesterol treatment guidelines include a low level of high density 
lipoprotein (HDL) cholesterol (<40 mg/dL) as a major risk factor for coronary heart disease 
(CHD) that should be considered when making decisions on treatment of LDL cholesterol. 
However, it remains uncertain whether the association of lower levels of HDL cholesterol 
with higher CHD risk is similar across the range of LDL cholesterol levels.
Methods: We investigated the association of HDL and LDL cholesterol with CHD events 
(fatal or non-fatal CHD or coronary revascularization procedures) over 14 years of follow-
up among 13,473 adults aged 45-64 years in the Atherosclerosis Risk in Communities 
(ARIC) Study.
Results: A total of 945 (7.0%) of participants had a CHD event during follow-up. After 
adjustment for known risk factors, including age, race, sex, diabetes, smoking, systolic 
blood pressure, waist circumference, chronic kidney disease and physical activity, lower 
levels of HDL cholesterol were associated with a higher risk of CHD events overall 
(p<0.001) and within every quintile of LDL cholesterol (all p<0.04).
Conclusions: These data suggest a graded association exists between lower levels of 
HDL cholesterol and coronary heart disease across the range of LDL cholesterol levels 
examined. As interventions specifically targeting HDL levels are being developed, it is 
essential to examine the combinatorial effects of lower HDL levels with various levels of 
LDL cholesterol.
11:00 a.m.
1002-127 Fibrates in the Prevention of Cardiovascular Events in 
Dyslipidemic Patients: A Meta-Analysis of Randomized 
Placebo-Controlled Clinical Trials
Sandeep A. Saha, Lenney Kizhakepunnur, Amol Bahekar, Rohit R. Arora, Internal 
Medicine and Cardiology, The Chicago Medical School, North Chicago, IL
Background: Fibrates are anti-lipidemic agents with peroxisome proliferator-activated 
receptor (PPAR) agonist activity and have been demonstrated to reduce cardiovascular 
events, but the data from clinical trials are conflicting. We therefore conducted a meta-
analysis of randomized clinical trials to evaluate the role of fibrates in the prevention of 
adverse cardiovascular events in dyslipidemic patients.
Methods: A total of 36,489 patients from 10 published randomized placebo-controlled 
clinical trials were analyzed using the Mantel-Haenszel fixed effects model, and odds 
ratios were computed for various adverse cardiovascular outcomes. Results were 
considered statistically significant if p<0.05.
Results: When compared to placebo, the use of fibrates did not significantly reduce the 
odds of all-cause mortality (p=0.53), cardiovascular mortality (p=0.33), fatal myocardial 
infarction (p=0.76) and stroke (p=0.56). However, the use of fibrates significantly reduced 
the odds of developing non-fatal myocardial infarction by 22% (p<0.00001). The odds of 
developing cancer were not significantly higher with the use of fibrates (p=0.86), but the 
odds of cancer-related death tended to be higher among patients randomized to fibrates 
(odds ratio 1.17, p=0.06)
Conclusions: Our meta-analysis revealed that fibrates did not reduce mortality but 
significantly decreased the risk of non-fatal myocardial infarction when used for the 
prevention of cardiovascular events in dyslipidemic patients. 
11:00 a.m.
1002-128 “First In Human” Experience With PRT060128, A New 
Direct-acting, Reversible, P2Y12 Inhibitor For IV And 
Oral Use
Daniel D. Gretler, Pamela B. Conley, Patrick Andre, Marzena Jurek, Anjali Pandey, 
Kevin Romanko, Philip T. Leese, Athiwat Hutchaleelaha, David R. Phillips, Portola 
Pharmaceuticals, Inc, South San Francisco, CA
Background: PRT060128 (PRT128) is an investigational direct-acting, reversible P2Y12 
inhibitor for IV and oral administration designed to overcome the major limitations of 
clopidogrel and prasugrel - delayed onset of action, a requirement for cytochrome P450 
metabolism, and irreversible platelet inhibition.
Methods: Single oral doses of PRT060128 (10, 30 ± aspirin, 100, 200, 400 and 800 mg) 
were administered to 6 groups of 8 healthy subjects (6 active, 2 placebo) in a randomized, 
double-blind, dose escalation study for the determination of tolerability, pharmacokinetic 
and pharmacodynamic parameters. Collagen (4µg/mL)- and ADP (10 µM)-induced 
platelet aggregation were measured, as was platelet deposition on a collagen surface 
under shear using a proprietary perfusion chamber.
Results: All doses were well tolerated with no serious or clinically important adverse events. 
The drug was well absorbed and had a terminal half-life of 12 hours. Drug concentrations 
increased dose-proportionally up to 100 mg (well above expected therapeutic levels) 
and less thereafter. Full inhibition of ADP-induced platelet aggregation was obtained in a 
concentration-dependent manner with IC50s of 980 ng/mL (maximum aggregation) and 
450 ng/mL (at 6 min endpoint). In the perfusion chamber assay, PRT060128 promoted 
thrombus destabilization and inhibited thrombus growth starting at 30 mg. The addition of 
aspirin did not enhance the inhibition of ADP-induced platelet aggregation but there was 
a synergistic effect on collagen-induced platelet aggregation. In the perfusion chamber 
assay with PRT060128 30mg + aspirin, complete thrombus destabilization prevented the 
formation of large platelet aggregates, an effect equivalent to PRT060128 100mg alone.
Conclusions: PRT060128 is a potent, selective, direct-acting, reversible P2Y12 inhibitor 
with excellent pharmacologic and pharmacokinetic properties. It was well tolerated and 
resulted in predictable levels of platelet inhibition. It is the first P2Y12 inhibitor under 
development with IV and oral formulations suitable for both acute and chronic therapies.
11:00 a.m.
1002-129 Effect of Early Versus Late In-hospital Initiation of Statin 
Therapy on the Clinical Outcomes of Patients with 
Acute Coronary Syndrome
Yi-Heng Li, Hui-Ling Wu, Yea-Huei Yang Kao, Hui-Shan Tsai, Ting-Hsing Chao, National 
Cheng Kung University Medical Center, Tainan, Taiwan,ROC
Background: Statins provide effective secondary prevention after acute coronary 
syndrome (ACS). However, it remains uncertain how soon statins should be started after 
an ACS. Recent studies suggest patients (pts) receiving very early statin therapy after 
ACS have lower mortality than the non-statin users. We investigated the influence of early 
versus late in-hospital initiation of statin therapy on the clinical outcomes of ACS pts.
Methods: A consecutive of 210 ACS pts (mean age 62 years, 158 men) with no previous 
statin treatment was recruited in this study. They were divided into early (statin treatment 
within 48 hrs after admission, n=98) and late (statin treatment > 48 hrs after admission 
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and before discharge, n=112) statin group. After discharge, all pts were followed up 
until the occurrence of a component of the composite end point: cardiovascular death, 
recurrent myocardial infarction, angina requiring rehospitalization, revascularization and 
stroke. Cox proportional hazards models were used for data analyses.
Results: Age, gender, severity of coronary artery disease, left ventricular function, 
cardiac risk factors and lipid profile were similar between the 2 groups. At 4 months after 
discharge, the event-free survival was 85% in the early and 79% in the late statin group. 
In multivariate analyses, Killip IV (hazard ratio [HR] 4.79, 95% confidence interval [CI] 
1.92-7.98) and abnormal renal function (HR 2.63, 95% CI 1.29-5.37) were independent 
predictors of the composite end point. Early statin treatment has no significant influence 
(HR 1.11, 95% CI 0.54-2.25). At 12 months after discharge, Killip IV (HR 3.40, 95% CI 
1.45-7.98), smoking (HR 2.81, 95% CI 1.51-5.24) and abnormal renal function (HR 3.26, 
95% CI 1.76-6.05) were predictors of the composite end point. Early statin treatment still 
has no significant influence on the composite end point at 12 months after discharge (HR 
1.53, 95% CI 0.83-2.81). Conclusion: Our data indicated that there was no significant 
difference of the 4 and 12-month clinical outcomes between the early and late statin 
group in ACS. To ensure all eligible ACS pts to start statin therapy during admission is 
more important than to emphasize the very early use of the statin. 
11:00 a.m.
1002-130 Comparison of Statin Treatment of 
Hypercholesterolemic Patients in Ethnically Diverse 
Populations With and Without Diabetes
Prakash Deedwania, Steven Haffner, Keith Ferdinand, Joseph Ycas, Michael Stein, VA 
Central California Health Care System/University of California, San Francisco, Fresno, CA, 
AstraZeneca, Wilmington, DE
Background: Diabetes mellitus (DM) is a CHD risk equivalent, and its prevalence is 
rapidly increasing in the US, especially in minorities such as Hispanics, African Americans 
and South Asians. Although statins are effective in reducing CHD events in DM patients, 
few data are available on comparative efficacy of statins in ethnic minorities. We evaluated 
efficacy of rosuvastatin (RSV) and atorvastatin (ATV) in DM and non-DM patients in 3 
trials in specific ethnic groups in North America: South Asians (IRIS), African Americans 
(ARIES) and Hispanics (STARSHIP).
Methods: ARIES required LDL-C >160 mg/dL; other 2 trials allowed lower LDL-C based 
on ATP III risk. In each trial, after 6-wk dietary lead-in, patients were randomized for 6 wks 
to RSV 10 or 20 mg or ATV 10 or 20 mg. Primary end point was % LDL-C reduction from 
baseline. Secondary end points included % changes from baseline in other lipoproteins. 
Statistical comparisons were not done for exploratory subgroup analyses.
Results: As shown in Table, both RSV and ATV at 10 and 20 mg were effective in 
improving atherogenic lipid profile in all 3 minority groups. There were no consistent 
differences in responses of DM vs non-DM patients; however, responses to RSV were 
greater than to same dose of ATV. At 20 mg dose, RSV showed a trend toward greater 
increase in HDL-C. All treatments were well tolerated. Conclusion: Statins were shown 
to be efficacious in this first study in ethnically diverse, high-risk diabetic patients. 
Least-Squares Mean % Change from Baseline
RSV 10 mg ATV 10 mg RSV 20 mg ATV 20 mg
DM Non-DM DM Non-DM DM Non-DM DM Non-DM
IRIS
n 72 110 86 94 75 96 77 97
Baseline LDL-C (mg/dL) 147 164 142 173 144 160 145 165
LDL-C change (%) -46 -44 -39 -40 -50 -49 -47 -47
Baseline HDL-C (mg/dL) 44 44 43 43 45 45 44 44
HDL-C change (%) +4.8 +8.7 +6.5 +7.5 +5.4 +7.8 +3.4 +5.8
Baseline non-HDL-C 
(mg/dL) 181 202 182 212 180 194 183 202
Non-HDL-C change (%) -41 -39 -35 -37 -44 -45 -42 -42
STARSHIP
n 69 103 70 90 76 91 77 84
Baseline LDL-C (mg/dL) 163 167 158 169 155 163 160 169
LDL-C (%) -47 -42 -36 -34 -51 -48 -41 -42
Baseline HDL-C (mg/dL) 46 46 47 48 45 48 48 47
HDL-C change (%) +3.4 +8.2 +3.9 +4.5 +6.9 +6.0 +3.7 +6.4
Baseline non-HDL-C 
(mg/dL) 204 205 197 202 192 198 198 206
Non-HDL-C change (%) -42 -39 -33 -31 -45 -43 -38 -39
ARIES
n 29 157 28 150 33 155 34 142
Baseline LDL-C (mg/dL) 205 189 184 190 185 191 199 190
LDL-C (%) -37 -39 -35 -33 -49 -46 -41 -39
Baseline HDL-C (mg/dL) 53 51 50 53 53 52 49 50
HDL-C change (%) +5.8 +6.2 +6.2 +4.5 +4.6 +6.0 +1.5 +3.2
Baseline non-HDL-C 
(mg/dL) 233 216 216 217 216 219 230 219
Non-HDL-C change (%) -34 -36 -33 -31 -45 -44 -39 -37
11:00 a.m.
1002-131 Long-Term Rosuvastatin Treatment Improves Renal 
Function In National Cholesterol Education Program 
Adult Treatment Panel III High Risk Patients
Jonathan Sorof, Susan Harris, AstraZeneca, Wilmington, DE
Background: ATP III criteria for identifying high risk patients are also predictors of 
progressive renal dysfunction. To determine whether rosuvastatin (RSV) for LDL-C 
lowering provides renal benefit, the effect of long term treatment on renal function in high 
risk patients was analyzed.
Methods: From 4,259 high risk patients in RSV clinical trials, 681 with ≥ 144 wks treatment 
were identified. To avoid bias, 13 patients with <144 wks treatment due to discontinuation 
from a renal AE were also included using LOCF data. Mean treatment duration was 3.9 
± 1.1 yrs (57 days to 5.6 yrs). Mean age was 58.3 ± 11.6 yrs, 41% hypertensive, 13% 
diabetic, and 26% CHD. Baseline lipid profile was LDL-C 188 ± 29 mg/dl and HDL-C 53 
± 13 mg/dl. Estimated GFR (MDRD) was 65.7 ± 11.3 ml/min at baseline; 30% of patients 
had moderate renal dysfunction (<60 ml/min).
Results: Overall, GFR increased 5% from baseline to last visit (p<0.001). This increase 
was observed consistently for subgroups of interest including elderly, male, hypertensive 
and/or diabetic, and across all RSV doses. Importantly, patients with moderate renal 
dysfunction at baseline showed the greatest increase in GFR (7.4%).
Conclusions: Long term RSV treatment stabilizes or improves renal function in high 
risk patients with expected progressive renal dysfunction. Albeit retrospective and 
uncontrolled, this evidence of statin renoprotection is consistent with previous studies 
and hypothesis-generating for future statin trials with primary renal endpoints.
GFR Changes (%) by Subgroup
N
Mean 
Change 
(%)
SD Lower 95% CI
Upper 
95% CI
p Value 
(Change from 
baseline)
Total 694 5.0 14.2 4.0 6.1 <.001
Age >=65 yrs 229 3.4 15.9 1.3 5.4 <.01
Gender (Male) 338 5.2 12.2 3.9 6.5 <.001
Hypertensive 281 3.7 17.8 1.6 5.7 <.01
Diabetic 91 1.9 18.5 -1.9 5.7 NS
Hypertensive + 
Diabetic 67 1.8 20.1 -3.0 6.6 NS
Baseline GFR 
<60 ml/min 211 7.4 16.8 5.2 9.7 <.01
Dose
5 mg
10 mg
20 mg
40 mg
101
394
118
81
6.2
4.9
5.2
3.9
11.7
14.6
16.5
12.0
3.9
3.5
2.2
1.4
8.5
6.3
8.1
6.6
<.001
<.001
<.001
<.01
11:00 a.m.
1002-160 The Prevalence and Incidence of Coronary Heart 
Disease are Significantly Increased in Periodontitis:  
A Meta-Analysis
Amol Bahekar, Sarabjeet Singh, Sandeep Saha, Janos Molnar, Rohit Arora, The 
Chicago Medical School,Rosalind Franklin University of Medicine and Science, North 
Chicago, IL
Background: Previous studies have shown conflicting results whether periodontitis (PD) 
is associated with increased risk of coronary heart disease (CHD). The aim of this study 
was to evaluate if this association exists.
Methods: A systematic review of the literature revealed 5 prospective cohort studies 
(follow-up >6 years), 5 case control and 5 cross sectional studies that were eligible for 
meta-analysis.The 3 study categories were analyzed separately. Heterogeneity of the 
studies was assessed by Cochran’s Q test. The studies were homogeneous, therefore 
the Mantel-Haenszel fixed-effect model was used to compute common relative risk (RR) 
and odds ratio (OR).
Results: Meta-analysis of the 5 prospective cohort studies (86,092 patients) indicated 
that individuals with PD had a 1.14 times higher risk of developing CHD than the controls 
(RR= 1.14, p<0.001). The case control studies (1,423 patients) showed even a greater 
risk of developing CHD (OR= 2.22, p<0.001). The prevalence of CHD in the cross 
sectional studies (17,724 patients) was significantly greater among individuals with PD 
than in those without PD (OR of 1.59 p<0.001).
Conclusion: This meta-analysis indicates that both the prevalence and incidence of CHD 
are significantly increased in PD. Therefore PD may be a risk factor for CHD. Prospective 
studies are required to prove this assumption and evaluate risk reduction with the 
treatment of PD. 
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1002-161 Impact of Renal Dysfunction on Prognosis after Acute 
Myocardial Infarction
Shinichiro Suna, Hiroshi Sato, Yasuhiko Sakata, Daisaku Nakatani, Hiroya Mizuno, 
Masahiko Shimizu, Masami Nishino, Yoshio Yasumura, Masatsugu Hori, Osaka 
University graduate school of Medicine, Suita, Japan, Osaka Rosai Hospital, Sakai, 
Japan
Background: Renal dysfunction has been reported to have a close relation with future 
cardiac events. Nevertheless, there are few reports concerning the incidence of cardiac 
events after acute myocardial infarction (AMI) in patients with renal dysfunction in the 
percutaneous coronary intervention era.
Methods: To investigate the impact of renal dysfunction after AMI, we studied 2,646 AMI 
patients (mean age 66.1, Male 1,966(74.3%)) registered to the Osaka Acute Coronary 
Insufficiency Study from January 2000 to December 2005 for a mean follow-up period of 
422 days. Out of 2,646 patients, 2,260 patients(85.4%) received emergent PCI.
Results: We classified the patients into 4 groups according to creatinin clearance (Ccr) 
calculated by Cockcroft-Gault equation. Mean value of Ccr was 119.3ml/min (over 91.4) 
in the 1st quartile, 78.2(67.1-91.4) in the 2nd, 57.7 (47.2-67.1) in the 3rd and 31.1 (less 
than 47.2) in the 4th quartile. Renal dysfunction was associated with high age, the 
prevalence of female, hypertension and heart failure (Killip≥2), and high levels of serum 
hsCRP, but neither with the prevalence of diabetes mellitus nor peak CK levels after 
MI. In univariate analysis, Ccr was significantly associated with all cause death, cardiac 
death and non-cardiac death at both 30days and follow-up (p<0.001). In multivariate Cox 
hazard model, Ccr was an independent risk factor of all cause death both at 30days 
(Hazard Ratio(HR) 2.16, 95%C.I. 1.55-3.01, p<0.001) and at follow up (HR 1.75, 95%C.I. 
1.26-2.43, p=0.001), and heart failure at follow up (HR 1.35, 95%C.I. 1.07-1.71, p=0.011). 
In multivariate Cox hazard model, ACE inhibitors, ARBs, Beta blockers nor statins did not 
attenuated these outcomes with statistical significance.
Conclusions: Renal dysfunction was significantly associated with all cause death and 
heart failure after AMI, suggesting that patients with renal dysfunction should be treated 
as high risk patients.
11:00 a.m.
1002-162 Relation of Smoking Status to a Panel of Inflammatory 
Markers: The Framingham Offspring Study
Yamini S. Levitzky, Chao-Yu Guo, Jian Rong, Martin G. Larson, Robert E. Walter, John F. 
Keaney, Jr., Patrice A. Sutherland, Aditi Vasan, Izabella Lipinska, Jane C. Evans, Emelia 
J. Benjamin, National Heart, Lung, and Blood Institute’s Framingham Heart Study, 
Framingham, MA, Boston University, Boston, MA
Background: The precise mechanisms by which smoking promotes atherosclerosis 
are incompletely understood. We hypothesized that smoking is accompanied by an 
inflammatory state.
Methods: We measured inflammatory markers in Framingham Heart Study participants 
(n=2944, mean age 60, 55% women, 12% minorities). The cohort was divided into never 
(n=1149), former (n=1424), and current smokers with last cigarette >6 hours (>6 h, 
n=134) or ≤6 hours (acute exposure, n=237) prior to phlebotomy. Eleven inflammatory 
markers were measured: serum CD40 ligand (sCD40), plasma CD40 ligand (pCD40), 
TNF receptor 2 (TNFr2), MPO, MCP-1, P-selectin, CRP, fibrinogen, IL-6, ICAM-1, and 
isoprostanes. Analysis of covariance was used to compare mean multivariable-adjusted 
values for each log transformed marker across smoking groups.
Results: There were significant between-smoking group differences for every inflammatory 
marker tested except sCD40, TNFr2 and MPO (Figure). In pair-wise comparisons versus 
never smokers: a) former smokers had significantly lower pCD40 and higher CRP levels; 
b) smokers with >6 h exposure had significantly lower pCD40, and higher CRP, IL-6, 
ICAM-1, and isoprostanes levels; and c) smokers with acute exposure had significantly 
higher levels of all markers except pCD40, sCD40, TNFr2 and MPO.
Conclusions: Cigarette smokers have significantly higher levels of most circulating 
inflammatory markers compared with never smokers, which are attenuated but not 
eliminated by smoking cessation.
11:00 a.m.
1002-163 The Predictive Value of Elevated Amino Terminal Pro-B-
type Natriuretic Peptide and B-type Natriuretic Peptide 
for Mortality in the Absence of Cardiovascular Risk 
Factors or Structural Cardiac Abnormalities in the 
General Community
Paul M. McKie, Richard J. Rodeheffer, Alessandro Cataliotti, Fernando L. Martin, 
Margaret M. Redfield, John C. Burnett, Jr., Mayo Clinic, Rochester, MN
Background: Studies report that plasma NT-proBNP and BNP have prognostic value for 
mortality in the general population even in the absence of heart failure (HF). It is unclear 
if NT-proBNP and BNP retain prognostic value in individuals who are free of traditional 
cardiovascular risk factors (CV RFs) or structural cardiac abnormalities (SCA).
Methods: We identified a community-based cohort of 2,006 subjects in Olmsted Co, 
Minnesota. We excluded those with HF. The remaining 1,991 subjects underwent 
echocardiography, NT-proBNP and BNP (Biosite and Shionogi) measurement, and 
identification of age/gender specific 80th percentile NT-proBNP and BNP levels. Subjects 
were divided into a normal group without CV RFs or SCA (n=663) and a non-healthy 
group with 1 or more CV RFs or SCA (n=1,328). Figure 1 defines CV RFs and SCA 
criteria. Median follow up for mortality was 5.6 years.
Results: Ninety three deaths were recorded. Figure 1 shows mortality in the general 
population, non-healthy, and normal subgroups according to NT-proBNP above and 
below the 80th percentile. There was a higher mortality above the 80th percentile in the 
total population and non-healthy subgroup. There was no increase in mortality in the 
normal subgroup. BNP by Shionogi and Biosite assay followed a similar pattern.
Conclusions: These findings suggest that the predictive value of NT-proBNP and BNP 
for future events may be limited to individuals with CV RFs or SCA which may have 
implications for early detection strategies of cardiovascular disease.
11:00 a.m.
1002-164 Predictors of Total Mortality Among Individuals With 
Cardiovascular Disease Aged 75 Years or Over
Timo E. Strandberg, Kaisu H. Pitkala, Reijo S. Tilvis, University of Oulu, Oulu, Finland, 
University of Helsinki, Helsinki, Finland
Background: There is an increasing number of cardiovascular patients aged 75 years 
and over, but there are scarce data of predictors of mortality in this patient group living 
in the community.
Methods: Mailed questionnaires to a random sample of individuals aged 75 and over 
were used to retrieve 400 home-living patients with cardiovascular diseases. At baseline 
in 2000, they underwent clinical examinations and laboratory testing. Mini Mental State 
Examination (MMSE) score below 24 points was considered to indicate cognitive 
impairment. Total mortality up to July 31, 2006 was collected from national registers. 
Hierarchical Cox regression was used to determine independent predictors of mortality 
expressed as a risk ratio (RR) with 95% confidence interval (CI).
Results: Average age at baseline was 80 years and 65.3% (n= 261) were women. Of 
the patients, 80.8% (n= 323), 36.5% (n=146) and 13.8% (n=55) had a history of coronary 
heart disease, cerebrovascular disorders, or peripheral artery disease, respectively. 
Median MMSE score was 27 (interquartile range 25-28) and 60 individuals had a score 
below 24 points. During the 6-year follow up 129 (32.3%) individuals died. When a large 
number of baseline variables including diseases and traditional risk factors were tested 
with multivariate analysis, only the following four predicted total mortality: MMSE score 
below 24 (RR 2.40, 95% CI 1.54-3.74), C-reactive protein (CRP) over 3 mg/L (RR 1.80, 
95% CI 1.18-2.73), a history of congestive heart failure (RR 1.66, 95% 1.12-2.45), and 
serum creatinine (per 10 micromol/L, RR 1.09, 95% 1-03-1.16).
Conclusions: Relatively few clinical variables independently predicted 6-year mortality 
among elderly home-living cardiovascular patients. The strongest predictor was impaired 
cognitive function assessed with MMSE.
11:00 a.m.
1002-165 Cumulative Burden of Atherosclerotic Risk Genotypes 
and the Age at Onset of a First Myocardial Infarction
Ilan Goldenberg, Arthur J. Moss, Scott McNitt, Daniel Ryan, Wojciech Zareba, Shirley W. 
Eberly, University of Rochester Medical Center, Rochester, NY
Background: We hypothesized that several genetic atherosclerotic single nucleotide 
polymorphisms (SNPs) may exert an additive effect on the earlier occurrence of 
myocardial infarction (MI) after adjustment for clinical factors.
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Methods: Eighteen atheroscrlerotic high-risk SNPs were prespecified and incorporated 
into a carriership model. Multivariate regression analysis, with the end point the age at 
onset of a first MI, was used to identify the independent contribution of selected genotypes 
to the earlier development of a first MI in a cohort of 814 white (n=622) and non-white 
(n=192) patients.
Results: Multivariate regression analysis demonstrated that genotypes were independently 
associated with an earlier occurrence of a first MI among white subjects (0.6 year reduction 
per carried genotype; p = 0.027), whereas genotypes were not related to early MI among 
non-white patients (0.7 year increase per carried genotype; p=0.16). There was a significant 
ethnic x genotype interaction effect (p=0.02). The mean age at onset of a first MI per number 
of carried genotypes in white patients is shown in the Figure.
Conclusions: Currently identified atherosclerotic genetic factors confer an independent 
additive contribution to an earlier onset of coronary athero-thrombotic disease among 
white patients. The lack of a significant association between these genotypes and 
outcome in other ethnic groups suggests that cardiovascular genetic risk should be 
studied directly in these populations. 
11:00 a.m.
1002-166 Body Fat related to Risk Factors for Cardiovascular 
Disease in Young Children
Magnus Dencker, Ola Thorsson, Magnus K. Karlsson, Christian Lindén, Per Wollmer, 
Lars B. Andersen, Dept of Clinical Sciences, Malmo University Hospital, Malmö, 
Sweden, Norwegian University of Sport and Physical Education, Oslo, Norway
Background: Obesity is associated with increased risk of cardiovascular disease in adults 
and less favourable cardiovascular risk factor status in children. These relationships have 
not been extensively studied in young subjects with the use of objective methods.
Methods: Cross-sectional study of 171 (92 boys and 79 girls) children aged 8-11 years, 
recruited from a population-based cohort. Total fat mass was measured by Dual-energy 
x-ray absorptiometry and expressed as percentage of total body mass (BF%). Maximal 
oxygen uptake (VO2PEAK) was assessed by indirect calorimetry during maximum ergometer 
test. Blood was sampled and blood pressure (BP) measured. Echocardiography, 2-
dimensional guided M-mode, was performed in accordance with ASE-guidelines. Left 
ventricular mass (LVM) was calculated and adjusted for (height)2.7. Maturity evaluated 
according to Tanner. Variables analysed were BF%, triglycerides (TG) and lipoprotein 
concentrations, systolic and diastolic BP, LVM and VO2PEAK.
Results: Mean BF% was 18.8±8.9% (range 6.2-44.7). Significant univariate correlations 
(p<0.05) between BF% and selected variables; VO2peak (r=-0.66), log TG (r=0.40), LDL/
HDL quotient (r=0.37), systolic BP (r=0.31), log HDL (r=-0.27), log LDL (r=0.16), diastolic 
BP (r=0.16) and log total cholesterol (r=0.15). Multiple regression analysis with the 
inclusion of possible confounders, such as age, gender and Tanner stage, showed that 
the significant independent correlates for BF% were VO2peak, systolic BP, log TG and 
gender, but not LVM. 
Conclusion: Findings from this population-based cohort of young children shows that 
BF% was associated with a less favourable cardiovascular risk factor status. In addition, 
these results imply that blood lipids and blood pressure precedes development of LVM as 
risk factor in combination with body fat.
11:00 a.m.
1002-167 The Predictive Ability of Lipoprotein-Associated 
Phospholipase A2 for Coronary Artery Disease Death 
and All-Cause Mortality as Assayed by Mass Versus 
Activity
Heidi T. May, Benjamin D. Horne, Jeffrey L. Anderson, Robert R. Pearson, Robert L. Wolfert, 
Matthew J. Kolek, John F. Carlquist, Richard B. Lanman, Brianna S. Ronnow, Joseph B. 
Muhlestein, LDS Hospital, Salt Lake City, UT, University of Utah, Salt Lake City, UT
Background: Lipoprotein-associated phospholipase A2 (LpPLA2) has been proposed to 
be a marker of vascular inflammation. LpPLA2 as assayed by mass has been shown to 
independently predict death; however, it is unknown whether LpPLA2 activity has the 
same ability. We sought to evaluate the association of LpPLA2 activity to all-cause death 
and cause-specific coronary artery disease (CAD) death.
Methods: LpPLA2 activity (PLACTM test, diaDexus, Inc.) was measured from samples 
donated by consenting patients (N=3,947) enrolled in the registry of the Intermountain 
Heart Collaborative Study and an available corresponding LpPLA2 mass level where 
possible (n=1155). All patients were evaluated by angiography to determine the presence 
of CAD (≥70% stenosis, n=2633 [67%]). Quartiles (Q) of LpPLA2 activity (nmol/min/ml) (Q1: 
<88.8, Q2: 88.8-113.0, Q3: 113.1-136.2, Q4: >136.2) were evaluated by Cox regression 
analysis with adjustments for standard cardiovascular risk factors, congestive heart failure, 
presenting status, prior myocardial infarction and stroke, and disease severity for the 
prediction of incident death and CAD death (average follow-up: 6.8±2.6 years).
Results: Age averaged 63±12 years and 69% were male. Correlation between LpPLA2 
mass and activity was weak (r=0.20, p<0.0001). LpPLA2 activity was significantly 
increased among males, hyperlipidemics, smokers, and those with CAD severity, but 
not hypertension. LpPLA2 activity also significantly predicted all-cause death (vs Q1: Q2: 
hazard ratio (HR)=1.19, p=0.08; Q3: HR=1.26, p=0.02; Q4: HR=1.33, p=0.003) as well as 
CAD-specific death (vs Q1: Q2: HR=2.13, p=0.09; Q3: HR=3.28, p=0.005; Q4: HR=2.68, 
p=0.02). In a model containing both activity and mass, both maintained their independent 
predictive ability.
Conclusions: LpPLA2 activity was shown to significantly predict all-cause death as well 
as CAD-specific death. As previous studies have also reported, LpPLA2 activity and mass 
were weakly correlated. This study suggests that LpPLA2 activity is a useful marker of 
longitudinal risk, independent of LpPLA2 mass, and thus they may provide complementary 
information with adjunctive assays.
11:00 a.m.
1002-168 Small Dense Low-Density Lipoprotein (LDL)-
Cholesterol Is a Superior Marker than LDL-Cholesterol 
in Determining Severe Coronary Atherosclerosis
Shinji Koba, Yuuya Yokota, Yoshihisa Ban, Fumitoshi Tsunoda, Takatoshi Sato, Makoto 
Shoji, Ryuji Sato, Hiroshi Suzuki, Eiichi Geshi, Takashi Katagiri, Showa University 
School of Medicine, Tokyo, Japan
Background: Recent evidence suggests that small dense low-density lipoprotein (sd-
LDL) particles are more atherogenic than large LDL in spite of their lower cholesterol 
contents. This study aimed to determine whether sd-LDL-cholesterol (sd-LDL-C) is 
superior to LDL-C as a biomarker of the progression of coronary heart disease (CHD).
Methods: We compared the LDL particle size by gradient gel electrophoresis and sd-
LDL-C concentrations quantified by heparin-magnesium precipitation in 386 male and 96 
female consecutive patients with stable CHD who had undergone coronary arteriography, 
and in 226 male and 163 female non-diabetic subjects without CHD who were not 
receiving any lipid-lowering drugs.
Results: The LDL size, large-LDL-C (estimated by subtracting the sd-LDL-C concentration 
from the LDL-C concentration), and HDL-C were significantly lower in the CHD subjects 
than in the healthy subjects, and the sd-LDL-C was significantly higher. All of the aforesaid 
differences applied for subjects of both sexes. The LDL-C was modestly higher and sd-
LDL-C was significantly higher in 258 severe CHD (defined as total or subtotal occlusive 
coronary arteries and/or coronary revascularization therapy) than in the patients with 
mild CHD irrespective of treatment by LDL-lowering drugs. Large-LDL-C, in contrast, was 
similar between the two groups. Multivariate logistic regression analysis revealed that 
sd-LDL-C levels were significantly associated with severe CHD independently of LDL-
C, HDL-C and high-sensitivity CRP (hs-CRP). The reduced LDL particle size, elevated 
sd-LDL-C, and decreased large-LDL-C were strongly associated with atherogenic 
dyslipidemia such as low HDL-C and high triglyceride in spite of similar LDL-C levels 
among 177 male and 100 female subjects with normal LDL-cholesterol who did not take 
any lipid-lowering drugs.
Conclusions: These results suggest that the sd-LDL-C levels are more powerful than 
LDL-C and hs-CRP levels as disease markers for the determination of high risk patients 
among patients with stable CHD.
11:00 a.m.
1002-169 Genetic Variability Of p22-phox Subunit Of NADPH 
Oxidase, And Risk For Myocardial Infarction In Young 
Individuals
Carmen Vasiliadou, Dimitris Tousoulis, Charalambos A. Antoniades, Kyriakoula Marinou, 
Costas Tentolouris, Nikolas Koumallos, Evaggelia Gerodimou, Georgia Triantafyllou, 
Christos Pitsavos, Gregory Vyssoulis, Christodoulos Stefanadis, Athens University, A 
Cardiology Department, Athens, Greece
Background: The p22-phox, a component of the NADH/NADPH oxidase in phagocytes 
and vascular smooth muscle cells, is essential for the production of reactive oxygen 
species. Evidence suggests that C242T and A640G polymorphisms of p22 phox gene 
may affect its enzymatic activity. We examined the role of these polymorphisms on the 
risk for premature myocardial infarction (MI).
Methods: Three hundred and seventy three subjects were recruited for the study. One 
hundred eighty eight patients with first event of premature MI (aged 46.8±1.2 yrs old) and 
185 age- and gender- matched controls. C242T and A640G polymorphisms on p22-phox 
and A290G in its promoter, were detected by PCR.
Results: The prevalence of the 242T allele was higher in MI patients (CC/CT/TT: 63/92/33) 
compared to controls (CC/CT/TT: 80/84/21, p<0.05), but there was no difference in the 
distribution of A640G among cases (AA/AG/GG: 98/63/27) and controls (AA/AG/GG: 
97/63/25, p=NS). The 930AA genotype was more frequent in MI (GG/AG/AA: 40/72/53) 
compared to controls (GG/AG/AA: 42/108/44, p<0.05). The risk for MI after adjustment for 
potential cofounders such as smoking, diabetes mellitus, dyslipidemias and hypertension) 
was higher in 242TT compared to CT+CC (1.797[95%CI:1.031-3.132] p=0.039), or 
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compared to CC (2.620[95%CI:1.124-6.106] p=0.026). Similarly, the risk for MI for the 
930AA was 1.613[95%CI:1.110-2.578], p=0.046 compared to 930GG+AG. Carriers of the 
242T+930A genotype had significantly elevated risk for MI (1.552[95%CI:1.120-2.361, 
p=0.040) compared to the other genotypes.
Conclusions. Genetic polymorphism C242T on p22-phox subunit of NADPH oxidase, 
as well as the A290G on its promoter region, are associated with the development of 
premature MI. In particular, the presence of the 242T+930A allele may have a functional 
effect on NADPH oxidase, leading to a higher risk for myocardial infarction in younger 
individuals.
11:00 a.m.
1002-170 The Impact Of Different Aerobic Exercise Intensity 
On Endothelial Function In Patients Post Myocardial 
Infarction
Magnus Benetti, Henrique Cascaes, Tales Carvalho, João Antônio Carvalho, Santa 
Catarina Heart Institute, Florianópolis, Brazil, Santa Catarina State University, 
Florianópolis, Brazil
Background: In normal individuals, moderate-intensity aerobic exercise augments 
endothelium-dependent vasodilatation. In patients, post myocardial infarction, high-
intensity exercise training improves angina threshold, a finding that could be associated 
with improved endothelial function.
Aim: To test the hypothesis that high-intensity aerobic exercise could result in improved 
endothelial function compared to moderate-intensity exercise in patients post myocardial 
infarction.
Methods: Forty two post-myocardial infarction male patients, with a mean (±SD) age of 59 
± 5 years, were randomly assigned to high-intensity (HI - 80-85% of maximal heart rate - n 
= 25) or moderate-intensity (MI - 65-70 % of maximal heart rate; n = 25). Training sessions 
on cycle ergometers lasted for 45 minutes and were performed 5 times per week. Before 
and after 4 weeks of training, patients underwent maximal exercise testing and studies 
of endothelial dependent (post-occlusion) and endothelial independent (post-sublingual 
nitrate) vasodilatation with high-resolution ultrasound of the brachial artery.
Results: HI training resulted in improvement of the functional capacity assessed by 
maximal tolerance time in exercise test (HI from 7.54 ± 1.51 min to 9.49 ± 1.80 min; MI 
from 7.30 ± 1.47 min to 7.53 ± 1.66 min; ANOVA p<0.01). Only the HI training program 
resulted in improvement in endothelial dependent vasodilatation (before: 1.6 ± 1.5 
mL/min/100mL; after: 7.9 ± 3.6 mL/min/100mL; ANOVA<0.01) as well as endothelial 
independent vasodilatation (before: 3.4 ± 2.1 mL/min/100mL; after: 7.7 ± 3.3 mL/min/
100mL; ANOVA<0.01). There was a significant correlation between the increase in 
exercise time and the improvement in the endothelial dependent vasodilatation (r = 0.44, 
P<0.01) but not with the improvement in endothelial independent vasodilatation.
Conclusion: High-intensity aerobic training compared to moderate-intensity training results 
in greater improvement functional capacity, endothelium dependent as well as endothelial 
independent vasodilatation. High intensity exercise training (80-85 % of maximal heart 
rate) may be considered for selected patients post myocardial infarction.
11:00 a.m.
1002-171 Household Passive Smoking Exposure on the Risk 
of Ischaemic Heart Disease in Female Never-smoker 
Patients
Ding Ding, Cheuk-man Yu, The Chinese University of Hong Kong, Hong Kong, Hong 
Kong
Objective The causative relationship between passive smoking and Ischaemic Heart 
Disease (IHD) is controversial. No evidence data in Hong Kong population has been 
reported. This study investigates whether household passive smoking exposure will 
increase the risk of IHD among female never-smoker by a retrospective case-control 
analysis.
Methods 239 Female patients with a diagnosis of IHD (presented with acute coronary 
syndrome) had percutaneous coronary intervention (PCI) or coronary arterial bypass graft 
(CABG) done were included. 268 Controls were enrolled from those who attended the 
same hospitals during the same period of IHD cases for non-IHD or conditions unrelated 
to cigarette use. We interviewed patients for their demographics, lifestyle, duration and 
intensity of exposure to passive smoking. Medical history was confirmed through reviewing 
medical records and computer records system. We evaluated the dose metrics of passive 
smoking exposure by using “pack-years” and “hour-years”, which indicate the cumulative 
amount and weighted duration of exposure. Odds ratios (ORs) and 95% confidence 
intervals (95% CIs) were computed by unconditional logistic regression, adjusted for age, 
education, history of Hypertension, Diabetes Mellitus, Hypercholesterolaemia, Stroke, 
and Gout, family history, physical activities, alcohol, and estrogen use.
Results Subjects with passive smoking exposure were associated with higher risk of 
IHD (OR=1.62, 95% CI: 1.01-2.59, P<0.05) compared to non-exposed subjects. Subjects 
exposed to an average of more than 1 pack of cigarette per day had an OR for IHD of 3.92 
(95% CI: 1.51-10.21, P<0.05). Cumulative measures also seemed to follow an exposure-
response pattern. Pack-years of exposure displayed an increase with a higher amount 
exposure level (over 10 pack-years), with an OR of 1.80 (95% CI: 1.00-3.23). Similarly, 
the risk of IHD increased by the weight duration, with an OR of 1.61(95%CI: 0.93-2.79) at 
the exposure level over 10 hour-years.
Conclusion Our data suggested an increased risk of IHD from household passive 
smoking exposure in Hong Kong Chinese residents.
11:00 a.m.
1002-172 End-tidal PCO2 (PETCO2) During Exercise Predicts 
Future Cardiovascular Events in Cardiac Patients
Masayo Hoshimoto, Akira Koike, Ayumi Goda, Kaori Yamaguchi, Osamu Nagayama, 
Akihiko Tajima, Tadanori Aizawa, The Cardiovascular Institute, Tokyo, Japan
Background: PETCO2 during exercise, an index of arterial PCO2, is known to decrease 
with progressing severity of heart failure. No studies, however, have established whether 
the measurement of PETCO2 is useful to predict future cardiovascular events. We 
compared the prognostic power of PETCO2 at peak exercise with those of established 
respiratory gas indexes during exercise testing in cardiac patients.
Methods: A total of 347 consecutive patients with coronary artery disease (CAD) (65 
± 9 years) performed a symptom-limited incremental exercise test with respiratory gas 
measurements. PETCO2 at peak exercise, peak VO2, VE/VCO2 slope, and ΔVO2/ΔWR 
were measured.
Results: A total of 56 cardiovascular-related events such as worsening of heart failure, 
worsening of angina pectoris, and cardiovascular death occurred over 757 ± 421 days 
of prospective follow-up. Peak VO2 (p<0.0001), VE/VCO2 slope (p<0.0001), ΔVO2/ΔWR 
(p<0.0001), and PETCO2 at peak exercise (p<0.0001) were significant prognostic indexes 
for total cardiovascular events. Among the cases who died of cardiovascular related 
causes, however, a lower PETCO2 at peak exercise was a stronger index (p=0.003) than 
a lower peak VO2 (p=0.02) in multivariate Cox proportional hazards analysis. Both the 
VE/VCO2 slope and ΔVO2/ΔWR were insignificant prognostic indices in this analysis.
Conclusion:A lower PETCO2 at peak exercise is useful to predict future cardiovascular 
events, especially cardiovascular-related deaths, in CAD patients. 
11:00 a.m.
1002-173 Impact of Subclinical Hypothyroidism on Coronary 
Heart Disease , Cardiovascular and all Cause Mortality: 
A Meta-analysis .
Sarabjeet Singh, Jasleen Duggal, Janos Molnar, Frank Maldonado, Rohit Arora, 
Chicago Medical School, North Chicago, IL
Background: : Previous studies have suggested that sub-clinical hypothyroid state (SH) 
may have detrimental effects on the coronary heart disease (CHD). Whether SH a risk 
factor for the above is controversial.
Methods: A systemic search of the literature using Pubmed, Medline and Ovid online 
tool was performed to identify relevant studies. Amongst the clinical studies, crossectional 
study and studies with follow up period ranging between 4 and 20 years were identified 
(Walsh et al, Rodondi et al, Rotterdam study, Imaizumi et al, Capolla et al)
Results: The pooled estimate of the relative risk of CHD revealed significant difference 
both at baseline [RR with 95% CI: 1.533 (1.312-1.791), P<0.05] and at follow-up [RR with 
95% CI: 1.188 (1.024-1.379), P< 0.05]. The relative risk of all-cause mortality at follow-up 
revealed no significant difference. However, the relative risk of death from cardiovascular 
causes at follow-up was significantly higher [RR with 95% CI: 1.278 (1.023-1.597), 
P<0.05].
Conclusions: The present meta-analysis indicates that sub-clinical hypothyroidism is 
associated with both, a significant risk of CHD at baseline and at follow-up. In addition, 
mortality from cardiovascular causes is significantly higher at follow up. 
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1002-202 Development of New Electrocardiographic Strain 
Pattern During Antihypertensive Therapy is Associated 
With Increased Incidence of Sudden Cardiac Death: The 
LIFE Study
Peter M. Okin, Lasse Oikarinen, Matti Viitasalo, Lauri Toivonen, Sverre E. Kjeldsen, 
Markku S. Nieminen, Jonathan M. Edelman, Björn Dahlöf, Richard B. Devereux, Cornell 
Medical Center, New York, NY
Background: Presence of the ECG strain pattern of lateral ST depression and T-wave 
inversion at baseline predicts increased cardiovascular morbidity and mortality. Although 
persistence or development of ECG left ventricular hypertrophy (LVH) is associated 
with increased risk of sudden cardiac death (SCD), the relationship of regression vs 
persistence vs development of new ECG strain to SCD during antihypertensive therapy 
is unclear.
Methods: ECG strain was evaluated at baseline and after 1 year of losartan- or atenolol-
based treatment in 7407 hypertensive patients. SCD was defined as death due to 
coronary heart disease occurring within 24 hours of symptom onset. Only SCD occurring 
after year-1 was considered for analyses.
Results: During mean follow-up of 3.8±0.9 years after the year-1 ECG, SCD occurred 
in 90 patients (1.2%). Compared with the absence of strain on both ECGs, new ECG 
strain and persistent strain had the highest SCD rates and hazard ratios in univariate 
analyses; regression of strain had an intermediate rate and risk of SCD. In multivariate 
Cox analyses adjusting for in-treatment ECG LVH by Cornell product and Sokolow-Lyon 
voltage, in-treatment systolic and diastolic pressure, treatment effect and Framingham 
risk score, new ECG strain was associated with an increased risk of SCD while the risk 
associated with regression or persistence of strain was attenuated.
Conclusions: Development of new ECG strain is associated with an increased risk of 
SCD in the setting of antihypertensive therapy.
Relation of Sudden Cardiac Death to the Presence or Absence of ECG 
Strain at Baseline and Year 1
No Strain 
Baseline/
No Strain 
Year 1:
Absence of 
Strain
(n=6323)
Strain Baseline/
No Strain Year 1:
Regression of 
Strain
(n=244)
Strain 
Baseline/
Strain Year 1:
Persistent 
Strain
(n=549)
No Strain Baseline/
Strain Year 1:
Development of 
New Strain
(n=291)
p 
value
SCD rate 
(%) 1.1 1.4 2.7 4.1 0.001
Hazard Ratios and 95% Confidence Intervals
Univariate 
Cox Model 1
1.6
(0.6 - 4.4)
2.2
(1.2 - 4.1)
3.2
(1.6 - 6.4) 0.002
Multivariate 
Cox Model 1
1.4
(0.5 - 3.8)
1.5
(0.7 - 2.9)
2.5
(1.2 - 5.2) 0.011
11:00 a.m.
1002-203 Enhanced Sub-clinical Inflammation in Middle Aged 
Hypertensive Subjects With Obstructive Sleep Apnea: 
a Molecular Insight of Atherogenic Load in Restless 
Sleep
Costas Thomopoulos, Costas Tsioufis, Anastasia Amfilochiou, Platonas Missovoulos, 
Maria Selima, Dimitris Tousoulis, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: Although hypertension and obstructive sleep apnea syndrome (OSAS) 
are well correlated, the underlying pathophysiological links are not yet fully clarified. We 
investigated the possible additional effect of OSAS in the state of sub-clinical inflammation 
in middle aged hypertensive subjects.
Methods: We studied 51 subjects (aged 49±8 years, 38 males) with stage I-II 
hypertension and positive polysomnography (PSG) [apnea/hypopnea index (AHI)≥5, and 
63 hypertensives with negative PSG, matched for age, sex and smoking status. From a 
blood sample metabolic profile and inflammatory markers (hsCRP, IL-6, and IL-18) were 
estimated.
Results: Hypertensives with OSAS compared to hypertensives without OSAS had higher 
levels of office systolic/diastolic blood pressure (151/98.8 vs 145/94.2 mmHg, respectively, 
p<0.05, for both cases), body mass index (BMI) (31.2 versus 29.5 Kgr/m2, p<0.05), 
logAHI (1.45±0.35 vs 0.35±0.18 events/h, p<0.05), LDL-cholesterol (161 vs 142 mg/dl, 
p=0.04) and lower minimum oxygen saturation during sleep (minSatO2) (77 vs 91.2%, 
p<0.05). Waist/hip ratio and glucose levels were similar (0.92 vs 0.91 and 84vs 82, p=NS 
for both cases). LoghsCRP, logIL-6 and logIL-18 were greater in OSAS hypertensives 
compared to hypertensives without OSAS by 34% (0.55±0.38 vs 0.37±0.31 mg/l), 48% 
(0.087±0.14 vs -0.28±0.32 pg/ml) and 28% (2.48±0.1 vs 2.34±0.1 pg/ml) respectively 
(p<0.05 in all cases). In OSAS hypertensives logIL-6 and logIL-18 remained statistically 
higher after adjustment for covariates (p<0.05 for both cases) while loghsCRP did not 
reach significance (p=NS). LoghsCRP was correlated with BMI (r=0.47, p<0.05), office 
systolic blood pressure (r=0.19, p<0.05), logAHI (r=0.19, p=0.05), and minSatO2 (r=-0.3, 
p<0.05), while log IL-6 with logAHI (r=0.4, p<0.05), and minSatO2 (r=-0.5, p<0.05), and 
finally log IL-18 with logAHI (r=0.4, p<0.05), and minSatO2 (r=-0.5, p<0.05).
Conclusions: The higher level of sub-clinical inflammation in OSAS hypertensives 
compared with hypertensives without OSAS underscores the importance of OSAS as an 
accelerator of atherogenic effects in a hypertensive substrate.
11:00 a.m.
1002-204 Benefits of Candesartan are Consistent Regardless 
of Pre-treatment Systolic Blood Pressure in the 
Candesartan in Heart failure: Assessment of Reduction 
in Mortality and morbidity (CHARM) Program.
P. A. Meredith, J. Ostergren, J. J.V. McMurray, C. B. Granger, K. Swedberg, S. Yusuf, 
E. L. Michelson, B. Olofsson, M. Puu, S. D. Solomon, M. A. Pfeffer, for the CHARM 
Investigators, University of Glasgow, Glasgow, United Kingdom
Background: Although candesartan has been shown to reduce the incidence of 
cardiovascular (CV) death or heart failure (HF) hospitalisation in the CHARM Program, 
physicians may be concerned about the addition of an angiotensin receptor blocker (ARB) 
in patients with low systolic blood pressure (SBP), who are at higher risk of mortality 
and morbidity. We therefore examined the effect of candesartan in the CHARM Program, 
according to baseline SBP.
Methods: The effect of candesartan compared to placebo was examined in the 7599 
patients according to baseline SBP quartile. A Cox regression model was fitted to each 
category separately with treatment as the only explanatory variable.
Results: The effect of candesartan was consistent across SBP quartiles. In the CHARM 
Program overall, the candesartan:placebo hazard ratio (HR) for the primary outcome 
of CV death or HF hospitalization was 0.84 (95%CI 0.77-0.91). The HRs for the SBP 
quartiles <119, 119-130, 131-142 and >142mmHg were 0.86 (0.75-1.00), 0.91 (0.79-
1.04), 0.76 (0.63-0.93) and 0.77 (0.65-0.91), respectively (no statistically significant 
heterogeneity). Similar findings were observed in each of the component trials e.g. in 
CHARM-Added (all patients taking an ACE-I), the HR for all patients was 0.85 (0.75-
0.96) and the HRs for the SBP quartiles <111, 111-122, 123-140 and >140mmHg were 
0.91 (0.73-1.14), 0.86 (0.66-1.12), 0.79 (0.64-0.99) and 0.84 (0.62-1.14), respectively 
(no heterogeneity). Dose reduction or discontinuation of study drug (placebo or active) 
due to hypotension was more frequent in patients in the lowest SBP quartile, and more 
frequent in patients on candesartan, compared to placebo, across all quartiles. However, 
the relative difference between candesartan and placebo was similar across all quartiles 
of SBP (drug discontinuation 4.1% vs 2.0%, respectively, overall).
Conclusions: Dose reduction and discontinuation of treatment for hypotension were 
more common in patients with a low baseline SBP and with candesartan than placebo. 
This underlines the importance of careful monitoring, especially of patients with a low 
SBP. However, the benefits of candesartan in the CHARM program were consistent 
irrespective of baseline SBP.
11:00 a.m.
1002-205 Protective Effects of a Novel Long-Acting Calcium 
Channel Blocker Azelnidipine Against Cardiac 
Hypertrophy and Failure in Dahl Salt-Sensitive Rats
Kohzo Nagata, Koji Obata, Hirotaka Kimata, Masako Saka, Xian Wu Cheng, Ayako 
Fukata, Takao Nishizawa, Katsunori Hashimoto, Sahoko Ichihara, Akiko Noda, Hideo 
Izawa, Toyoaki Murohara, Yasuo Koike, Mitsuhiro Yokota, Nagoya University School of 
Health Sciences, Nagoya, Japan
Background: The clinical trial ACTION has demonstrated that the long-acting calcium 
channel blocker (CCB) nifedipine GITS reduced the incidence of new overt heart failure 
in patients with stable angina. However, the molecular mechanisms responsible for such 
effects of CCBs are largely unknown. We investigated whether long-term administration 
of a new CCB, azelnidipine, attenuates cardiac hypertrophy and failure in Dahl salt-
sensitive (DS) rats. Methods and Results: DS rats fed a high-salt diet from 7 weeks 
of age were randomized at 12 weeks (hypertrophy stage) to receive a subdepressor (2 
mg/kg per day, Azel-L, n=10) or a depressor dose (6 mg/kg per day, Azel-H, n=10) of 
azelnidipine, hydralazine (8 mg/kg per day, Hyd, n=8), or not (HF, n=10) until 19 weeks 
(heart failure stage). Systolic blood pressure did not differ between Azel-H and Hyd rats 
at 12 weeks and thereafter. LV (and cardiomyocyte) hypertrophy and fibrosis and systolic 
and diastolic dysfunction were apparent in HF rats compared with controls (n=8). The 
amounts of mRNAs for atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), 
collagen types I and III, and the ratio of collagen type I to type III were increased in HF 
rat hearts. Treatment of HF rats with both Azel-L and Azel-H inhibited these changes in 
gene expression, as well as improved LV remodeling and dysfunction and heart failure. 
The protective effects of Azel-H were greater than those of Hyd. Hemodynamic overload 
resulted in a decrease in the ratio of reduced to oxidized glutathione and an increase 
in NADPH oxidase activity in HF rat hearts. These effects were also attenuated to a 
greater extent by treatment with Azel-H than Hyd. The survival rate was higher in Azel-H 
compared with Hyd rats.
Conclusions: The present results first demonstrate that long-term administration of 
azelnidipine, in a manner independent of its antihypertensive effect, ameliorated cardiac 
hypertrophy and failure in DS rats. The beneficial cardiac effects of azelnidipine are likely 
attributable, at least in part, to attenuation of myocardial oxidative stress.
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1002-206 Diastolic Function in Primary Aldosteronism. A Tissue 
Doppler Imaging Approach
Dimitris Tsiachris, Costas Tsioufis, Efstathios Taxiarchou, Platonas Missovoulos, 
Apostolis Kakkavas, Ioannis Vlasseros, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: Primary Aldosteronism (PA) has been experimentally linked to myocardial 
fibrosis, while it has been further associated with left ventricular structural and functional 
abnormalities. The aim of our study was to assess the diastolic function by means of both 
conventional and Tissue Doppler Imaging (TDI) methods in hypertensives patients with PA.
Methods: We studied 16 subjects with an established recent diagnosis of PA (9 males, aged 
56±10 years, body mass index=30.3±3.9 kg/m2, office BP=136±11/86±8 mmHg) and 30 
subjects with essential hypertension (EH) selected from our database and matched for age, 
sex, left ventricular mass index (LVMI), office BP and known duration of hypertension. Apart 
from the standard 2-D echocardiographic study, left ventricular diastolic function was estimated 
by means of both transmitral inflow Doppler [ estimating early and late transmitral filling peak 
velocities (E, A, E/A ratio)], and tissue Doppler imaging, [measuring early and late diastolic mitral 
annular peak velocities (Em, Am, Em/Am ratio) from four separate sites (septal, lateral, anterior 
and inferior walls), and their obtained average values (Em
av
, Am
av
, Em
av
/Am
av
 ratio)].
Results: Subjects with PA compared with controls had by selection similar LVMI (117.2 vs. 
114.7 g/m2, p=0.78) while they exhibited significantly increased myocardial relative wall 
thickness (0.49 vs. 0.41, p<0.001) indicating altered LV geometry. Although E/A ratio was 
similar in both groups (0.93 vs. 0.98, p=0.54), subjects with PA compared with controls 
are characterized by significantly decreased values of Em
av 
(by 1.1 cm/s, p<0.05) and 
Em
av
/Am
av
 ratio (by 0.14, p<0.05), indicating an abnormal relaxation of the left ventricle. 
Assessing the four walls separately, we exhibited significantly decreased Em/Am ratio 
only regarding the septal (by 0.13, p=0.01) and the lateral wall (by 0.24, p=<0.05).
Conclusions: The altered left ventricular geometry in hypertensive subjects with PA is 
accompanied by impaired diastolic function, as it is indicated using the more accurate 
TDI derived indices. The clicinal implications of these findings remain to be elucidated in 
future properly designed studies.
11:00 a.m.
1002-207 Prevalence and Correlates of Mitral Annular 
Calcification in Hypertensive Adults with Left 
Ventricular Hypertrophy: The LIFE Study
Zhibin Li, Sverre E. Kjeldsen, Stevo Julius, Michael H. Olsen, Kristian Wachtell, Hans 
Ibsen, Eva Gerdts, Markku S. Nieminen, Sverker Jern, Peter M. Okin, Björn Dahlöf, 
Richard B. Devereux, Weill Cornell Medical College, New York City, NY
Background: The prevalence and correlates of MAC in hypertensive patients with 
electrocardiographic defined left ventricular hypertrophy (LVH) has not been well documented.
Methods: Hypertensive patients with LVH by Cornell voltage-duration product or 
Sokolow-Lyon voltage criteria on a screening electrocardiograms were randomized to 
losartan- or atenolol-based treatment and followed a mean of 4.8 years in the Losartan 
Intervention For Endpoint reduction in hypertension (LIFE) study. In the echo substudy 
of LIFE, statistical analyses were performed using echocardiographic parameters and 
clinical parameters from the 960 participants (mean age: 66±7 years, 42% female, 84% 
Caucasian and 11% with history of diabetes).
Results: The presence of MAC in 460 (48%) of participants was associated with older age, female 
gender, higher systolic and pulse pressures (all p<0.001) and fasting glucose level (p<0.05) but 
not cholesterol level (p>0.05). Using logistic regression adjusting for significant confounders, 
MAC was associated with aortic valve sclerosis [odd ratio (OR)=3.63], LVH (OR=1.54), mitral 
regurgitation (OR=2.99) (all p<0.05) but not associated with aortic regurgitation or concentric left 
ventricular (LV) geometry (both p>0.05). Using analysis of covariance adjusting for significant 
covariates, MAC was associated with larger left atrial size, higher body mass index and LV 
mass index (all p<0.05), but not with albuminuria, serum albumin/creatinine ratio or creatinine 
(all p>0.05). This analysis also showed that MAC was not associated with significantly lower 
LV systolic and diastolic functional indices including ejection fraction, mid-wall shortening, 
isovolumic relaxation time and deceleration time (all p>0.05).
Conclusions: Among hypertensive patients at high risk because of electrocardiographic 
LVH, MAC is prevalent and independently associated with female gender, older 
age, higher blood pressures and glucose level, larger left atrial size and LVH, mitral 
regurgitation and aortic valve sclerosis.
11:00 a.m.
1002-208 Gender Difference in the Association between 
Leptinemia and Blood Pressure in the US Population: 
The Third National Health and Nutrition Examination 
Survey (NHANES III)
Julio A. Chirinos, Leonardo J. Tamariz, Ana Palacio, Ronald Goldberg, Eduardo De 
Marchena, University of Miami Miller School of Medicine, Miami, FL
Background: Mechanisms linking obesity and hypertension are incompletely understood. 
Leptin-induced renal sympathetic activation leading to sodium retention has been proposed. We 
examined the relation between leptinemia and blood pressure (BP) in the US general population.
Methods: We examined the relation between serum leptin and systolic blood pressure (SBP), 
diastolic blood pressure (DBP), pulse pressure (PP) and mean arterial pressure (MAP) among 
5127 subjects free of antihypertensive medication use enrolled in NHANES III.
Results: In univariate analysis, leptin correlated positively with SBP and DBP in both 
men and women. After adjustment for age, ethnicity, physical activity, body mass index, 
homeostatic model assessment insulin resistance score, triglycerides, HDL cholesterol, 
C-reactive protein and creatinine clearance, leptin remained a positive predictor of MAP 
and DBP in men but not in women. Furthermore, in adjusted analyses, leptin was a 
negative predictor of PP among women (Table).
Conclusions: Important gender differences exist in the relationship between serum leptin 
and BP in the US population. An independent positive correlation between leptin and MAP 
exists only in men. These findings are in agreement with animal studies suggesting that 
androgens are necessary for the obesity-mediated increase in renal adrenergic receptors. 
The direct nitric-oxide releasing effects of leptin in the vasculature may be responsible for 
its inverse relation with PP in women.
Serum Leptin as a predictor of blood pressure in men and women
Men (n=2463) Women (n=2664)
Beta (95%CI) P value Beta (95%CI) P value
Univariate SBP 10.2 (7.9 to12.6 <0.001 11.3 (8.4 to 14.2) <0.001
DBP 8.9 (7.0 to 10.7) <0.001 8.0 (6.6 to 9.5) <0.001
MAP 9.3 (7.6 to 11.0) <0.001 9.1 (7.4 to 10.9) <0.001
PP 1.3 (-1.0 to 3.7) NS 3.3 (1.0 to 5.5) 0.006
Adjusted SBP 1.4 (-2.0 to 4.8) NS -4.0 (-6.5 to -1.5) <0.001
DBP 3.5 (0.5 to 6.4) 0.02 1.1 (-0.7 to 2.8) NS
MAP 2.8 (0.3 to 5.2 0.02 -0.6 (-2.4 to 1.2) NS
PP -2.1 (-6.0 to 1.9) NS -5.1 (-7.2 to -3.0) <0.001
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1206-274 Time Course of Endothelial Dysfunction and 
Endothelial Microparticle Generation After Acute 
Secondhand Smoke Exposure in Healthy Nonsmokers
Nicolas Amabile, Christian Heiss, Andrew C. Lee, Wendy May Real, David Lao, Suzaynn 
Schick, Sarah Jahn, Franca S. Angeli, Petros Minasi, Matthew L. Springer, Katherine 
Hammond, John Balmes, Yerem Yeghiazarians, UCSF, San Francisco, CA
Background: Active smoking is a well-known cardiovascular risk factor with impaired 
endothelial function in chronic smokers. However, data about the effect of second hand smoke 
(SHS) exposure on the cardiovascular system are more limited. We sought to evaluate the 
impact of SHS on the endothelium by assessing the endothelial function and the level of 
endothelial microparticles (EMPs) formation, which is a specific marker of endothelial injury.
Methods: Eight healthy young non-smokers volunteers (6M/2F, mean age: 31 y) were 
exposed to controlled levels of second hand smoke in a controlled human exposure 
chamber for 30 min. Endothelial function was assessed as flow mediated dilation (FMD) 
using ultrasound and blood was drawn before (baseline), then immediately, 1 h, 1.5h, and 
24 h after exposure. In parallel,concentrations of circulating EMPs were determined in 
platelet poor plasma. PECAM+ (CD31+/CD41-), VE-cadherin+ (CD144+), and E-selectin+ 
(CD62e+) EMPs were measured using flow cytometry. After a wash-out period of > 1 week, 
5 of the volunteers were subjected to the same protocol with 30 min control air exposure.
Results: Baseline values of FMD and EMPs number did not significantly differ between 
study days. SHS transiently blunted FMD immediately and 1h after (4.0±0.5% and 5.1±0.6 
%, p<0.01 versus a baseline of 6.9±0.3%, repeated measurements ANOVA). FMD 
returned to baseline at 1.5h and was significantly greater than baseline at 24h (8.1±0.7%, 
p=0.023). Moreover, the number of circulating EMPs after SHS significantly increased by 
3-fold, suggesting endothelial activation and apoptosis. Peak increase was observed 1h 
after exposure and remained significantly elevated throughout the study: CD31+/CD41- 
(1218±349 versus 445±75 events/µl, p=0.021 1h versus baseline), CD62e+ (205±60 
versus 71±19 events/µl, p=0.006) and CD144+ (587±178 versus 186±48 events/µl, 
p=0.004). FMD and EMPs remained unaffected by control air exposure.
Conclusions: Our results suggest that a short-term exposure to SHS induces acute 
endothelial injury, as indicated by reversible endothelial dysfunction with concomitant 
increase in circulating endothelial microparticles.
Noon
1206-275 Lipid Levels in Patients Hospitalized With Coronary 
Artery Disease: An Analysis of 136,905 Hospitalizations 
in Get With The Guidelines-Coronary Artery Disease
Gregg C. Fonarow, Christopher P. Cannon, Prakash C. Deedwania, Kenneth A. LaBresh, 
Sidney C. Smith, David Dai, GWTG Steering Committee and Investigators, UCLA 
Medical Center, Los Angeles, CA
Background: While LDL levels have decreased in the general US population, lipid levels 
among contemporary patients hospitalized with CAD have not been well studied.
Methods: The GWTG database was analyzed for CAD hospitalizations from 1/00 to 4/06 
with documented lipid levels in the first 24 hours of admission. Pts were divided into 
LDL, HDL, and TG categories. Clinical presentation, comorbidies, and prior use of lipid 
medications (LRx) were assessed.
Results: Of 270,655 hospitalizations from 541 hospitals, lipid levels were documented in 
136,905 (50.6%) CAD hospitalizations, 79% with ACS. Pts were mean age 65 + 14, 63% 
male, 80% white, 32% diabetes, and 59.3% prior CHD or risk equivalent. Mean for LDL 
104.9 + 39.8, HDL 39.7 + 13.2, and TG 161 + 128 mg/dL. LDL < 70 was observed in 10.8% 
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and ideal levels (LDL <70 with HDL >60 mg/dL) in only 1.4% (Table). Prior to admission, 
only 21.1% of pts were receiving LRx (LDL 94.3 + 36.4, HDL 39.6 + 12.6 mg/dL). Predictors 
for higher LDL included younger age, no diabetes, higher BMI, Hx hyperlipidemia and no 
prior LRx. Lower HDL was associated with younger age, prior MI, male, higher BMI, and 
diabetes. Both LDL and HDL levels declined over time (P<0.0001).
Conclusions: In a large cohort of hospitalized CAD patients, almost half have admission 
LDL levels < 100 mg/dL and less than 10% have HDL levels above 60 mg/dL. These 
findings provide further support for recent guideline revisions with even lower LDL goals 
and for developing effective treatments to raise HDL.
Distribution of LDL and HDL Levels in Patients Hospitalized with CAD
HDL (mg/dL)
LDL (mg/dL)
Total
(n=103,632)<70(n=18,191)
70-100
(n=33,111)
100-130
(n=28,429)
130-160
(n=15,385)
>160
(n=8,516)
<40
(n=56,587) 10.8% 17.8% 14.7% 7.6% 3.8% 54.6%
40-60
(n=38,883) 5.3% 11.7% 10.6% 6.2% 3.7% 37.5%
>60
(n=8,162) 1.4% 2.5% 2.1% 1.1% 0.7% 7.8%
Total
(n=103,632) 17.6% 32.0% 27.4% 14.9% 8.2%
Noon
1206-276 The Effect of External Counterpulsation Therapy on 
Circulating Endothelial Progenitor Cells in Patients 
With Angina Pectoris
Alon Barsheshet, Hanoch Hod, Michael Shechter, Orna Sharabani-Yosef, Eti Rosenthal, 
Israel M. Barbash, Shlomi Matetzky, Reshef Tal, Ariel G. Bentancur, Ben-Ami Sela, 
Arnon Nagler, Jonathan Leor, Neufeld Cardiac Research Institute, Heart Institute, 
Sheba Medical Center, Ramat Gan, Israel, The Division of Hematology and Bone 
Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel
Background: External counter pulsation therapy (ECPT) offers symptomatic relief and 
improves ischemia in patients with refractory angina pectoris. Its mechanism of action, 
however, remains unclear. Our objective was to test the hypothesis that ECPT improves 
the number and function of circulating endothelial progenitor cells (EPCs).
Methods: We prospectively studied 25 consecutive patients with angina pectoris treated 
with ECPT (n=15) or standard care (n=10). The number of EPCs positive for CD34 and 
kinase insert domain receptor (KDR) was determined by flow cytometry and function 
was assessed by the number of colony forming units (CFUs) in a 7-day culture, prior to 
intervention and after 2 months.
Results: Anginal score was improved by ECPT from 3.0 to 2.0 ( p<0.001). The number and 
function of circulating EPCs were significantly improved in patients treated by ECPT: EPC 
numbers increased from 10.2 to 17.8/ 105 mononuclear cells (p<0.05), and CFUs from 3.5 
to 11.0 (p=0.01). Flow mediated dilatation (FMD) was improved by ECPT (from 7.4 to 12.2, 
p<0.001) and was correlated with an increase in EPC-CFUs (r= 0.461, p=0.027). The levels 
of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase 
were reduced by ECPT (from 0.70 to 0.60 µmol/L, p<0.01). Conversely, these variables 
remained unchanged in the control group, before and after 2- month follow-up.
Conclusions: Our preliminary findings show, for the first time, that ECPT increases the 
number and function of circulating EPCs and proposes a new mechanism whereby ECPT 
relieves symptoms in patients with angina
Noon
1206-277 Higher Resting Heart Rate Is Associated With Metabolic 
Syndrome and Lower Ejection Fraction in Patients 
With Diabetes and Known Coronary Artery Disease in 
Bypass Angioplasty Revascularization Investigation 2 
Diabetes (BARI 2D) Trial
Jamal S. Rana, Regina M. Hardison, Rodica Pop-Busui, Maria M. Brooks, Teresa Jones, 
Richard W. Nesto, Martial G. Bourassa, University of Pittsburgh, Pittsburgh, PA
Background: Neuroadrenergic status affects key regulatory mechanisms of cardiovascular 
as well as metabolic function. Both Metabolic Syndrome (Met S) and the presence of a 
high resting heart rate have been shown to be associated with increased cardiovascular 
events. However, the relation between Met S and resting heart rate is unknown.
Methods: We evaluated 2252 patients in Bypass Angioplasty Revascularization Investigation 
2 Diabetes (BARI 2D) trial. All patients had Type 2 Diabetes and coronary artery disease 
(CAD) and were randomized to early revascularization and aggressive medical therapy versus 
aggressive medical therapy alone for CAD and to insulin-sensitizing versus insulin-providing 
treatments for diabetes. The ATP III definition of Met S was used. Linear regression model 
adjusted for age, sex, use of beta blockers, exercise and LDL levels was used to evaluate the 
relation of Met S and its risk factors (RF) to resting heart rate as measured on the 12 lead ECG. 
The relationship between heart rate and ventricular function was also evaluated.
Results: In BARI 2D, 90.8% of the participants had the Met S. The mean heart rate was 
68.3±12.5 beats per minute. The heart rate was higher (p < 0.001 for trend) with increasing 
number of risk factors for Met S. Multiple linear regression analyses demonstrated that 
as compared to individuals without Met S, the heart rate was significantly higher in 
participants with Met S (regression coefficient: 2.0, p=0.001). Participants with 2 RFs had 
adjusted regression coefficient of 1.5 (p=0.13), presence of 3 RF regression coefficient 
of 3.0 (p=0.002) and participants with all 4 RF had a regression coefficient of 4.1 (p 50% 
, the heart rate was significantly higher in participants with EF 60% participants with EF < 
35% had adjusted regression coefficient of 5.5 (<0.001).
Conclusion: Higher heart rate is associated with Metabolic Syndrome and ventricular 
dysfunction. Autonomic dysfunction manifests as sympathetic overactivity and 
consequently may be one way by which Met S imparts higher risk for cardiovascular 
disease. Higher resting heart rate in diabetic patients with CAD identifies a subgroup 
in whom additional secondary preventive strategies may be necessary.
Noon
1206-278 Statin-Like, Dose-Dependent Reductions in LDL-C 
and Apolipoprotein B With ISIS 301012, an Antisense 
Inhibitor of Apolipoprotein B, in Subjects With 
Polygenic Hypercholesterolemia
Evan Stein, JoAnn Bradley, Emil Chuang, Mark Wedel, John Su, Richard Geary, Rosie 
Yu, John Kastelein, Metabolic & Atheroscelrosis Research Center, Cincinnati, OH, Isis 
Pharmaceuticals, Inc., Carlsbad, CA
Background: ISIS 301012 selectively inhibits apoB protein synthesis in the liver. Previously, 
we have shown an LDL-C reduction up to 70% in healthy volunteers in Phase I dose ranging 
studies with short term dosing. The safety and efficacy profile allowed for longer treatment 
duration (13 weeks), less frequent dosing (every other week), and a target population of 
polygenic hypercholesterolemics failing to meet target with diet and exercise alone.
Methods: Subjects (n=10 per group) with elevated LDL-C > 130mg/dL were enrolled into 1 
of 5 groups. The first 2 groups received four 200 mg doses of ISIS 301012 in the first 11 days 
(Days 1, 4, 8, and 11; “Load”) followed by 100 mg qow (avg 50 mg/week), or 200 mg qow (avg 
100 mg/week). The last 3 groups received 200, 300, or 400 mg every week without a load. 
Treatment to placebo was 4:1 in each cohort. Study drug was administered subcutaneously.
Results: The study is ongoing. A 12, 22, and 42% median reduction in LDL-C and a 
22, 23, and 47% median reduction in apoB were observed in the 50, 100, and 200 mg/
week dose groups, respectively, with negligible changes in the pooled placebo group. 
Preliminary results in the 300 mg/wk cohort showed a 42 and 41% reduction in LDL-
C and apoB, respectively following the first 7 weeks of 13 weeks treatment. The most 
common adverse event has been mild, painless erythema at injection sites. No serious 
adverse events occurred. The drug was well tolerated. One subject displayed an isolated 
ALT >3x ULN 45 days after last dose.
Conclusions: The initial results show that ISIS 301012 achieves statin-like LDL-C reductions 
via a complementary mechanism. Furthermore, achieving such LDL-C reductions with a 
dosing interval of every other week is feasible. Dose escalation to the 400 mg/wk dose 
group is underway. Final data from the study will be presented at the meeting.
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1008-1 Rapid True Aneurysm Formation after Healing of 
Thrombosed Aortic Dissection
Rieko Ishimura, Akiko Maehara, Tomotaka Dohi, Jun Masuda, Hajime Fujimoto, 
Yo Fujimoto, Haruo Mitani, Sugao Ishiwata, Minoru Ohno, Cardiovascular center, 
Toranomon Hospital, Tokyo, Japan
Background: Aortic dissection (AD) of DeBakey IIIb type with thrombosed false lumen has a 
good short-term prognosis. However, the long-term prognosis has not been well evaluated.
Methods and Results: From 1996 to 2006, 96 consecutive patients (age 65 ± 13 y.o., 
70 males) were admitted to our institution for acute AD. AD was evaluated with computed 
tomography (CT). CT scans were performed every year. There were 20 patients with type 
IIIb AD with thrombosed false lumen. Among these, 8 patients (38%) showed rapid aortic 
dilatation as a true aneurysm in the follow-up period. During the acute phase, the first 
measured maximum dissected segment diameter in the dilated group (N = 8) tended to be 
larger than that of non-dilated group (N = 12) (max dissected segment; 44.7±7.0mm vs. 
37.0±8.5mm, p=0.06), although the adjacent reference diameter between two groups were 
similar. The expanded diameter per year tended to be larger than that of the true thoracic 
aortic aneurysm (TAA) group (N = 14) as control (5.6±6.5 vs. 2.0 ± 3.2mm, p = 0.12), although 
the first measured maximum dilated segment diameter in each group was similar.
Conclusions: One third of thrombosed aortic dissections of DeBakey IIIb type with the 
larger maximum dissected diameter may undergo rapid dilatation that may develop into a 
true thoracic aneurysm in the healed dissected segment. 
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1008-2 Effect Of 3-hydroxy-3-methylglutaryl-coa Reductase 
Inhibitiors On Fasting Blood Sugar
Rishi Sukhija, Zoran Bursac, Rajesh Sachdeva, Anjan Sinha, Jawahar L Mehta, 
University of Arkansas for Medical Sciences, Little Rock, AR, Central Arkansas Veterans 
Healthcare System, Little Rock, AR
Background: 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) reduce serum 
cholesterol, and cardiovascular morbidity and mortality. But, the effect of statins on 
glucose metabolism is unclear. Some studies have suggested that statins may cause 
hyperglycemia by increasing calcium concentration in the islet cells leading to a decrease 
in insulin release, or by decreasing GLUT 4-mediated peripheral glucose uptake.
Methods: We analyzed data in 345,417 patients (mean age 61±15 years, 94% males, 
6% diabetics, 20% statin users), from the Veterans Affairs VISN 16 database. We studied 
change in fasting blood sugar (FBS) in this population over a mean time of 2 years between 
the first available measurement and the last measurement form the most recent recorded 
visit. Data was limited to patients who had two FBS measurements. In the diabetic group, 
diagnosis of diabetes had to be present before the first FPG measurement.
Results: Among non-diabetics, FBS increased with statin use from 97.8 mg/dl to 105.2 
mg/dl, and among non-statin users FPG increased from 96.6 mg/dl to 101.6 mg/dl over 
the period of observation (increase in FBS with statin use p<0.0001). Among diabetics, 
FBS increased with statin use from 101.7 mg/dl to 140.8 mg/dl and among non-statin 
users FBS increased from 100.4 mg/dl to 129.9 mg/dl (increase in FBS with statin 
use; p<0.0001). After adjustment for age, use of aspirin, beta blockers and angiotensin 
converting enzyme inhibitors, the change in FBS in non-diabetic statin users was +6.4 
mg/dl (vs. +5.2 mg/dl in non-statin users, p<0.0001) and for diabetic statin users it was 
+38.9 mg/dl (vs. +29.8 in non-statin users, p<0.0001).
Conclusion: Statin use increases FBS in diabetic as well as non-diabetic patients. This 
relationship between statin use and rise in FBS is independent of age, and use of aspirin, 
beta blockers and angiotensin converting enzyme inhibitors.
3:30 p.m.
1008-3 Low Endothelial Shear Stress (ESS) Predicts the 
Development of High-Risk Coronary Atherosclerotic 
Plaques: A Correlative IVUS and Histopathology 
Natural History Study
Yiannis S. Chatzizisis, Michael Jonas, Ahmet Umit Coskun, Benjamin V. Stone, Philip 
Seifert, Ross Gerrity, William Daley, Elazer Edelman, Charles L. Feldman, Peter 
H. Stone, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 
Massachusetts Institute of Technology, Cambridge, MA
Background: The role of low ESS in the development of high-risk plaques remains 
unclear. We investigated the effect of low ESS in the development of lipid-rich and 
inflamed plaques in swine coronary arteries.
Methods: In 11 diabetic hyperlipidemic swine, IVUS-based 3D reconstruction of the 
coronary arteries was performed at baseline (wk 23) and followup (wk 30). Baseline 
ESS was calculated using computational fluid dynamics, and plaque-free subsegments 
(plaque area<3 mm2) of 4-mm length with low (<1.6 Pa) or higher (≥1.6 Pa) ESS were 
identified. Atherosclerotic subsegments at followup were classified by IVUS into early 
(plaque area<4 mm2) and advanced plaques (plaque area≥4 mm2). The coronary arteries 
were harvested at followup, stained histologically, and intima/media ratio (IM), maximum 
plaque thickness (maxPT), lipid content (oil red O), and inflammation (CD45) quantified.
Results: In the early plaques (n=52), IM, maxPT, lipids and inflammation were significantly 
increased in subsegments with baseline low ESS (Fig A). Advanced plaques (n=6) were 
only found in baseline low ESS subsegments and were associated with large lipid core, 
diffuse inflammation, and thin fibrous cap (14±3.1 μm, Fig B).
Conclusion: Low ESS determines the progression of atherosclerosis and predicts 
the development of lipid-rich and inflamed high-risk plaques. These findings provide a 
rationale for preemptive diagnostic and therapeutic strategies for the prevention of acute 
coronary syndromes.
3:30 p.m.
1008-4 Identification of 5-, 12/15-Lipoxygenase and NADPH 
Oxidase as Key Mediators of Oxidized LDL-induced 
Apoptosis of Human Aortic Smooth Muscle Cells: 
Implications for Atherosclerotic Plaque Destabilization
Laura Semprun-Prieto, Sergiy Sukhanov, Yusuke Higashi, Jane Titterington, Patrick 
Delafontaine, Tulane University School of Medicine, New Orleans, LA
Apoptosis of smooth muscle cells (SMC) is a prominent feature of advanced atherosclerotic 
plaque. We have previously shown that the pro-atherogenic molecule oxidized low density 
lipoprotein (OxLDL) is associated with apoptotic SMC in advanced plaques of human 
aorta and that OxLDL produces marked SMC apoptosis in vitro. In human aortic smooth 
muscle cells (HASMC) the antioxidant Tiron (1 mM) suppressed superoxide production 
(by 18±2%, DHE assay) and peroxide generation (by 88±4%, CDC assay) induced by 
OxLDL (80 ug/ml, 16h) and completely blunted HASMC apoptosis (by 89±2.6%, Cell 
Death ELISA), indicating that OxLDL induced apoptosis was mediated by a redox-
sensitive mechanism. The lipoxygenase (LOX) inhibitors AA-861, 5 uM and NDGA, 10 
uM decreased OxLDL-induced superoxides (by 15±2% and 25±4%, respectively) and 
peroxides (by 48±3% and 62±6%, respectively) and NDGA completely blocked HASMC 
apoptosis (flow cytometry with annexin V staining). AA-861, 10 uM, another LOX 
inhibitor Baicalein, 10uM and the NADPH oxidase specific blocker Apocynin, 100uM 
suppressed OxLDL-induced HASMC apoptosis (by 93.0±7%, 94±0.4% and 83±3%, 
respectively, as determined by Cell Death ELISA). To identify the oxidases involved in 
OxLDL-induced apoptosis we studied the effect of OxLDL on SMC isolated from the 
aorta of 5-LOX- and 12/15-LOX-deficient and wild-type (WT) mice. 12/15-LOX deficiency 
markedly reduced OxLDL-induced superoxides and peroxides (by 31±3% and 62±7%, 
respectively compared to WT). OxLDL-induced apoptosis was completely inhibited 
in 5-LOX- or 12/15-LOX-deficient SMC (by 82.6±0.5% and 94.1±0.7% respectively), 
however OxLDL produced 90.8±4.4% apoptosis of WT SMC compared to control (0.5 
uM staurosporine). In summary, we have identified 5-, 12/15-lipoxygenase and NADPH 
oxidase as key mediators of OxLDL-induced oxidative stress and SMC apoptosis. These 
data establish a novel functional relationship between different oxidases and together 
with our previous findings have major implication for understanding mechanism of SMC 
depletion in advanced atherosclerotic plaque contributing to plaque destabilization and 
acute coronary events.
3:30 p.m.
1008-5 Uric Acid as a Mediator of Coronary Microvascular 
Dysfunction and Inflammation: a Gender-Specific Study
So Kuwahata, Shuichi Hamasaki, Sanemasa Ishida, Tetsuro Kataoka, Akiko Yoshikawa, 
Masakazu Ogawa, Keishi Saihara, Hideki Okui, Tsuyoshi Fukudome, Naoya Oketani, 
Koji Orihara, Takuro Shinsato, Takahiro Shirasawa, Takuro Kubozono, Etsuko Mizoguchi, 
Hitoshi Ichiki, Shoji Fujita, Chuwa Tei, Graduate School of Medicine, Kagoshima 
University, Kagoshima, Japan
Background: Recent experimental and human studies have shown that hyperuricemia 
is associated with systemic inflammation and cardiovascular disease mediated by 
endothelial dysfunction. Additionally, a recent evidence suggests that c-reactive protein 
(CRP) may participate directly in the development of atherosclerosis. Therefore, the goal 
of this study was to investigate the relation of uric acid (UA) and inflammatory reaction to 
coronary vasodilating function.
Methods: The study population consisted of 186 consecutive patients, 112 men and 
74 women, with normal coronary arteries underwent Doppler flow study of the left 
anterior descending coronary artery. Vascular reactivity was examined by intra-coronary 
administration of papaverine, acetylcholine (Ach), and nitroglycerin using a Doppler 
guidewire. Plasma level of uric acid (UA), white blood cell (WBC), CRP, body mass index, 
LDL-cholesterol, HDL-cholesterol, triglycerides (TG), and insulin resistance (HOMA-R) 
were measured. Vascular responses were compared between men and women.
Results: In a monovariate analysis, when only subjects of women were considered, 
plasma level of UA and CRP had inverse correlations with the percent change in coronary 
blood flow (CBF) induced by papaverine (r=-0.31, p<0.01; r=-0.28, p<0.02, respectively). 
Ach-induced percent change in CBF inversely correlated with plasma level of UA, CRP, 
and TG (r=-0.35, p<0.01; r=-0.23, p<0.05; r=-0.24, p<0.05, respectively). A multivariate 
analysis showed that plasma level of UA was highly correlated with the percent change in 
CBF induced by Ach (p<0.05). Additionally, serum level of UA had a positive correlation 
with C-reactive protein (r=0.46, p<0.0001), whereas, these significant correlations among 
UA, CRP, and coronary vasodilating function were not found in men.
Conclusions: Our findings that elevated uric acid is highly associated with coronary 
endothelial microvascular dysfunction, which may be mediated by the expression of C-
reactive protein, calls for reconsideration of the role of uric acid in coronary artery disease 
in women.
3:30 p.m.
1008-6 Pre-Existing True Aortic Aneurysms in Patients 
Presenting with Acute Aortic Dissection
Yuiichi Tamori, Koichi Akutsu, Naoyuki Yokoyama, Hiroaki Sasaki, Kenji Minatoya, 
Hitoshi Matuda, Hitoshi Ogino, Hiroshi Nonogi, Satoshi Takeshita, National 
Cardiovascular Center, Osaka, Japan
Background: Previous studies have documented an incidence of acute aortic dissection 
(AAD) associated with true aortic aneurysms in the range of 5% to 7%. The purpose of 
this study was to elucidate clinical characteristics of pre-existing true aortic aneurysms 
in patients with AAD. 
Methods: Between January 2003 and May 2006, 93 patients (59 men; average age 
69 ± 13 yrs) with AAD were admitted to our hospital. Incidence, location of true aortic 
aneurysms and clinical profiles of the patients with true aortic aneurysms were evaluated. 
Patients with Marfan syndrome and those with prior aortic surgery were excluded from 
the study. 
Results: True aortic aneurysms were found to be associated with AAD in 31 (33%) of 93 
patients: 16 patients (17%) had thoracic aortic aneurysms (TAA), 10 (11%) had abdominal 
aortic aneurysms (AAA), and 5 (5%) had both types. Seven patients had ≥ 2 aneurysms. 
Patients with true aortic aneurysms had COPD more frequently than those without 
(16% vs. 5%, p=0.025). Other clinical characteristics, including Stanford classification, 
false lumen patency, and atherosclerotic risk factors (hypertension, diabetes mellitus, 
hyperlipidemia), were not different between patients with true aortic aneurysms and those 
without. Among the 31 patients with true aortic aneurysms, 14 had aneurysms at the 
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proximal end of the dissected segment, 9 at the distal end of the dissected segment, 8 
within the dissected segment, and 7 apart from the dissected segment.
Conclusions: Approximately one-third of our patients had AAD associated with true aortic 
aneurysms, an incidence 5-6 times higher than those previously reported (5% to 7%). 
In addition, TAA was observed 1.5 times more frequently than AAA in our patients with 
AAD. This incidence is in contrast with that observed in the general population, where the 
incidence of TAA is lower than that of AAA, suggesting that pre-existing TAA may play an 
important role in the pathogenesis of AAD.
3:30 p.m.
1008-7 Interleukin-17 Stimulates C-reactive Protein Expression 
In Hepatocytes And Smooth Muscle Cells Via P38 
MAPK And ERK1/2-dependent NF-κB And C/EBPβ 
Activation.
Devang N. Patel, Carter A. King, David B. Schuchman, Hinh D. Nguyen, Nikhil S. 
Joshi, John K. Gresham, Alok Agrawal, Srinivas Mummidi, Anthony J. Valente, Bysani 
Chandrasekar, University of Texas Health Science Center, San Antonio, TX, South Texas 
Veterans Health Care System, San Antonio, TX
Background: Elevated serum C-reactive protein (CRP) is a risk factor for cardiovascular 
disease. Purpose of this study was to investigate whether interleukin (IL)-17, a modulator 
of inflammatory and immune responses, stimulates CRP expression in a human hepatic 
and coronary artery smooth muscle cells (CASMC).
Methods: Human primary hepatocytes, Hep3B hepatoma cells and CASMC were 
treated with recombinant human IL-17. (1) CRP expression was analyzed by real time 
PCR, Western blotting, ELISA, and promoter-reporter assays; (2) NF-κB and C/EBP 
activation by gel shift, supersfift, ELISA and reporter gene assays; and (3) p38MAPK and 
ERK1/2 activation by immunoblotting using activation-specific antibodies and immune 
complex kinase assays. Pharmacological inhibitors, siRNA interference, and adenoviral 
transduction of dominant negative expression vectors targeted activation of NF-κB, C/
EBP, p38MAPK and ERK1/2.
Results: IL-17 potently induced CRP expression in Hep3B cells independently of IL-6. 
IL-17-induced CRP promoter-driven reporter gene activity was attenuated by mutation 
in NF-κB or C/EBP binding sites. IL-17 stimulated NF-κB DNA-binding (p50, p65) and 
reporter gene activities. IL-17 stimulated C/EBP (β) phosphorylation, DNA-binding and 
transactivation activity. While targeting NF-κB and C/EBPβ activation by pharmacological 
inhibitors, siRNA interference and adenoviral transduction of dominant negative 
expression vectors blocked IL-17-mediated CRP induction, wild type p50, p65 and C/
EBPβ stimulated CRP transcription. In addition, IL-17 stimulated p38 MAPK and ERK1/2 
activation, and treatment with SB203580 and PD98059 blocked IL-17-mediated NF-κB 
and C/EBP activation and CRP transcription. These results were confirmed in primary 
human hepatocytes. Similar to hepatic cells, IL-17 stimulated CRP expression in CASMC 
via p38 MAPK, ERK1/2, NF-κB and C/EBPβ.
Conclusions: These results demonstrate for the first time that IL-17 potently induces 
CRP in hepatic and vascular cells through p38 MAPK and ERK1/2-dependent NF-κB and 
C/EBPβ activation, and suggest that IL-17 may be a marker of chronic inflammation and 
play a role in atherosclerosis.
3:30 p.m.
1008-8 Combination Therapy of Calcium Channel Blocker and 
Angiotensin Converting Enzyme Inhibitor Improves 
Endothelial Function and Arterial Stiffness in Patients 
with Angina Pectoris
Kye Hun Kim, Myung Ho Jeong, Jae Youn Moon, Young Joon Hong, Young Keun Ahn, 
Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang, Chonnam National University 
Hospital, Gwangju, South Korea
Background: Both endothelial dysfunction and arterial stiffness are involved in the 
pathogenesis of atherosclerosis and are well known as risk factors of cardiovascular 
morbidity and mortality. The aim of this study was to evaluate the effects of calcium channel 
blocker (CCB: Cilnidipine) and angiotensin converting enzyme inhibitor (ACEI: captopril) 
on endothelial function measured by flow mediated vasodilation (FMD) of brachial artery 
and arterial stiffness pulse wave velocity (PWV) in patients with angina pectoris.
Methods: Eighty patients with angina pectoris (57.8±9.9 years old, 50 males) were 
divided into CCB group (group I: n=41, 58.1±9.7 years old, 21 males) and CCB plus ACEI 
group (group II: n=39, 57.5±10.4 years old, 29 males). FMD and PWV were measured at 
baseline and 6 months after medical therapy. 
Results: Baseline FMD and PWV were not different between the groups at baseline. After 
6 months of medical treatment, FMD were significantly improved in group II (7.5±3.8 % to 
8.7±4.1%, p=0.04), but not in group I (8.1±4.2 % to 8.0±3.7 %, p=0.92). Brachial-ankle PWV 
were significantly improved in both groups (1797.7±357.3 to 1534.9±321.9 cm/s in group 
I, p=0.004, 1620.1±288.2 to 1456.1±191.5 cm/s in group II, p=0.006). However, heart-
femoral PWV was significantly improved only in group II (1060.9±250.4 to 971.3±210.7 
cm/s, p=0.04), but not in group I (1050.3±239.6 to 996.8±220.5 cm/s, p=0.09).
Conclusions: Combination therapy of CCB and ACEI improves more effectively endothelial 
function and arterial stiffness than CCB mono-therapy in patients with angina pectoris.
3:30 p.m.
1008-9 Low Endothelial Shear Stress (ESS) Leads to Expansive 
Remodeling of Atherosclerotic Coronary Subsegments: 
An In-Vivo Followup IVUS Study
Yiannis S. Chatzizisis, Michael Jonas, Ahmet Umit Coskun, Benjamin V. Stone, Ross 
Gerrity, William Daley, Elazer Edelman, Charles L. Feldman, Peter H. Stone, Brigham 
and Women’s Hospital, Harvard Medical School, Boston, MA, Massachusetts Institute of 
Technology, Cambridge, MA
Background: Expansive arterial remodeling is closely associated with the development 
of high risk plaques. We investigated the hypothesis that low ESS leads to the expansive 
remodeling of coronary atherosclerotic subsegments.
Methods: In 11 diabetic hyperlipidemic swine, IVUS based 3D reconstruction of the 
coronary arteries was performed at baseline (wk 23) and followup (wk 30). Local ESS was 
calculated using computational fluid dynamics, and subsegments with low (<1.6 Pa) or 
higher (≥1.6 Pa) ESS were identified and classified into non-atherosclerotic (followup wall 
area<2.5 mm2) and atherosclerotic (followup wall area≥2.5 mm2). The association of the 
remodeling index of each subsegment (ΔEEM/ΔWall) with baseline ESS was investigated.
Results: In atherosclerotic subsegments (n=20) expansive remodeling occurred 
associated with plaque growth (increased ΔWall area, Fig A). These lesions all developed 
in subsegments with low baseline ESS (p<0.001, Fig B), and ESS remained low at 
followup (Fig A). Expansive remodeling occurred in non-atherosclerotic subsegments 
(n=20); however the vast majority of these had higher baseline ESS (Fig B), which 
decreased at followup (Fig A).
Conclusion: Low ESS is associated with expansive remodeling of atherosclerotic 
subsegments, which leads to continued low ESS, and a vicious cycle of continued plaque 
progression, vessel expansion and development of high risk plaque. In non diseased 
subsegments higher ESS leads to expansive remodeling in order to normalize ESS.
3:30 p.m.
1008-10 Circulating Endothelium- and Platelet-Derived 
Microparticles in Healthy Subjects and Patients with 
Coronary Artery Disease
Michael Shechter, Ibrahim Marai, Yaniv Sherer, Micha S. Feinberg, Yehuda Shoenfeld, Aida 
Inbal, The Heart Institute, Sheba Medical Center, Tel Hashomer, Israel, Department of Medicine 
B and Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer
Background: Circulating microparticles are markers of cell activation associated with 
various prothrombotic states, however, the association of circulating endothelium-derived 
microparticles (EMP) and platelet-derived microparticles (PMP) in healthy human subjects 
and patients with coronary artery disease (CAD) has not yet been determined.
Methods: We prospectively assessed flow-mediated dilation (FMD) in 110 consecutive 
subjects [46 (42%) CAD patients and 64 (58%) healthy controls], 68 (62%) men, mean age 
57±11 (range 17-81) years. After an overnight fast and discontinuation of all medications 
for ≥ 12 hours, percent improvement in endothelium-dependent brachial artery FMD 
(%FMD) and endothelium-independent nitroglycerin (%NTG)-mediated vasodilatation 
were assessed using high resolution (15 MHz) linear array ultrasound. EMP and PMP 
were measured using flow-cytometry technique.
Results: 
%FMD %NTG EMP/ml plasma PMP/ml plasma
Patients (n=46) 8.5 12.5 25,000 250,000
Controls (n=64) 12.8 15.4 19,000 180,000
p-value 0.01 0.09 <0.05 0.01
Values are expressed as median; %FMD, %NTG=% change from baseline in brachial 
artery diameter caused by FMD and NTG, respectively.
%FMD was significantly associated with EMP (r=-0.44, p<0.01) and PMP (r=-0.58, p<0.01).
Conclusions: CAD patients have significantly higher circulating EMP and PMP and lower 
brachial artery FMD compared to healthy controls. Circulating EMP and PMP may be 
useful markers in detecting endothelial dysfunction in humans. The clinical and practical 
value of these results, however, needs further exploration. 
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1008-11 Genetic Polymorphism G894T on eNOS Gene Increases 
The Smoking-Associated Risk For Premature 
Myocardial Infarction: A Gene-Environment Interaction
Charalambos A. Antoniades, Dimitris Tousoulis, Carmen Vasiliadou, Christos Pitsavos, 
Kyriakoula Marinou, Elli Stefanadi, Nikolas koumallos, Kostantinos Toutouzas, 
Gerasimos Siasos, Christina Chrysochoou, Christodoulos Stefanadis, Athens University, 
A Cardiology Department, Athens, Greece
Introduction. Genetic polymorphism G894T on endothelial nitric oxide synthase (eNOS) 
has been associated with increased cardiovascular risk. Moreover, the 894T allele has 
been associated with endothelial dysfunction in high-risk patients and especially in 
smokers, but not in healthy, low-risk individuals. We examined the impact of 894T allele 
on the smoking-associated risk for premature myocardial infarction (MI).
Methods. Two hundred twenty eight patients with first event of premature MI (aged <49 
yrs) and 519 age- and gender- matched controls were recruited. Smokers were defined 
as those smoking at least 10 cigarettes/day for at >1 year. “Heavy” smokers were defined 
as those with ≥20 pack-years and “light” smokers those with <20 pack-years.
Results. The prevalence of smoking was higher in patients (200, 87.7%) compared to 
controls (301, 57.9%, p<0.001). The frequencies of GG, GT and TT were 97 (42.5%), 
99(43.5%) and 32 (14%) in MI and 255(49.1%), 217(41.8%) and 47 (9.1%) in controls. 
The risk for MI in smokers was 4.62(95%CI:2.94-7.28) p<0.001 compared to non smokers 
(1.98(95%CI: 1.11-3.74) p=0.034 for “light” and 5.96(95%CI: 3.76-9.46) p<0.001 for 
“heavy” smokers). Among 894TT, the smoking-associated risk for MI was 13.25(95%CI: 
2.66-66.10) p=0.002 (6.75(95%CI: 0.55-83.23) p=0.13 for “light” and 17.83(95%CI: 
3.65-87.22) p=0.001 for “heavy” smokers). Among 894GT, the smoking-associated risk 
for MI was 4.08(95%CI: 2.05-8.13) p=0.001 (1.79(95%CI:0.68-4.76) p=0.240 for “light” 
and 5.18(95%CI:2.57-10.43) p<0.001 for “heavy” smokers). In 894GG, the smoking-
associated risk was 4.77(95%CI2.37-9.61) p<0.001 (2.00(95%CI: 0.73-5.49) p=0.178 
for “light” and 6.35(95%CI: 3.10-12.99) p=0.0001 for “heavy” smokers). The unadjusted 
risk for MI of 894TT homozygotes in the overall population was 1.64(95%CI: 1.02-2.65) 
p=0.043 compared to 894GT+GG, and it was elevated to 2.51(95%CI: 1.36-4.61) p=0.003 
after exclusion of non-smokers.
Conclusions. The G894T polymorphism on eNOS gene increases the smoking-
associated risk for premature MI. 894T homozygotes are more vulnerable to the 
deleterious effects of cigarette smoking, and are at higher risk for MI compared to carriers 
of the 894G allele.
3:30 p.m.
1008-12 Regression Of Coronary Atherosclerosis During 
Treatment With Statins: Does Age Make A Difference?
Ilke Sipahi, E. Murat Tuzcu, Stephen J. Nicholls, Keon-Woong Moon, Paul Schoenhagen, 
Katherine E. Wolski, Adam Grasso, William Magyar, Timothy D. Crowe, Samir Kapadia, 
Steven E. Nissen, Cleveland Clinic, Cleveland, OH
Background: Animal models and clinical studies have shown that atherosclerosis is a 
potentially reversible disease. It is not known whether age is a determinant of the response to 
antiatherosclerotic interventions that can induce regression, such as treatment with statins.
Methods: 1515 patients completing the four major intravascular ultrasound (IVUS) 
trials reported to date (REVERSAL, CAMELOT, ACTIVATE and ASTEROID trials) were 
included in a pooled analysis. All patients had angiographically documented coronary 
artery disease. Overall, 95% of the patients received a statin either as the study drug 
(REVERSAL and ASTEROID trials) or according to the discretion of the treating physician 
(CAMELOT and ACTIVATE trials) .The progression-regression rate of disease (annualized 
change in total atheroma volume) as assessed by serial volumetric IVUS was compared 
in younger and older patients, before and after adjusting for possible confounders.
Results: The mean (median) age was 57.8 (57) ± 9.7 years. Older patients (i.e. age>median) 
were more likely to be female and hypertensive, less likely to have a history of smoking and 
they had lower LDL-cholesterol and higher HDL-cholesterol levels as compared to younger 
patients (i.e. age ≤mean). Older patients had greater atheroma burden at baseline (203.3 
± 83.6 vs. 194.2 ± 85.0 mm3, p=0.017). Overall, there was a net regression of disease 
in both older and younger patients (p<0.001 for both groups). The regression rates were 
not different in younger and older patients (-1.2 ± 17.3 vs. -1.7 ± 15.7 mm3/year, p=0.83). 
Multivariable analysis with adjustments for gender, lipid levels, and histories of hypertension 
and smoking did not change the results. Similarly, age was not a determinant of the 
regression rate when analyzed as a continuous variable (p=0.94).
Conclusion: Although older patients present with more advanced coronary 
atherosclerosis, the response to statins in terms of regression of coronary disease is 
similar in older and younger patients. These findings highlight the importance of statin 
treatment to reverse atherosclerosis in older patients with coronary artery disease.
3:30 p.m.
1008-13 Active Atorvastatin Metabolite Preferentially Inhibits 
Oxidation of Small Dense Low Density Lipoproteins:  
A Comparative Analysis
Mary F. Walter, Robert F. Jacob, Jungsoo Byun, Charles A. Day, Ngoc-Anh Le, R 
Preston Mason, Atlanta VA Medical Center, Decautur, GA, Brigham and Women’s 
Hospital, Harvard Medical School, Boston, MA
Background: Elevated levels of small dense low-density lipoprotein (sdLDL) are 
associated with increased cardiovascular risk. As compared with large low-density 
lipoprotein (LDL), sdLDL has greater susceptibility to oxidation and reduced turnover 
rates. Atorvastatin hydoxy metabolite is the primary form of the drug in circulation and 
accounts for most (70%) of the HMG-CoA reductase inhibition. This metabolite also has 
antioxidant properties that may lead to benefits beyond LDL reduction.
Methods: The comparative effects of statins on in vitro oxidation were determined in 
various LDL subfractions (sdLDL, large buoyant LDL) isolated from plasma by sequential 
ultracentrifugation. Measurements of oxidation included conjugated diene, lipid 
hydroperoxide (LOOH), and malondialdehyde (MDA) formation as a function of treatment 
with statins in their active form (atorvastatin metabolite, pravastatin, simvastatin, 
rosuvastatin). The molecular lipid interactions of statins were determined by small angle 
x-ray diffraction approaches.
Results: Over a broad pharmacologic range (100 nM to 1.0 µM), only the atorvastatin 
metabolite significantly inhibited sdLDL oxidation by up to 44% (P < 0.05). As a positive 
control, probucol inhibited sdLDL oxidation (6%), but only at 10.0 µM. The atorvastatin 
metabolite (1.0 µM) alone slowed the rate of conjugated diene formation in sdLDL, resulting 
in an increased lag phase (>2-fold, P < 0.01). Interestingly, the antioxidant activity of 
the atorvastatin metabolite was >4-fold greater in sdLDL than large LDL particles when 
normalized for apolipoprotein B-100. This is consistent with its ability to reduce LOOH 
formation in small lipid vesicles enriched with polyunsaturated fatty acids at low levels (100 
nM, P < 0.001). X-ray diffraction analysis showed that active atorvastatin metabolite is co-
localized with lipids, with its phenoxy group in proximity to polyunsaturated fatty acids.
Conclusions: Active atorvastatin metabolite preferentially inhibited sdLDL oxidation, 
independent of HMG-CoA activity. The phenoxy group unique to the atorvastatin 
metabolite is an antioxidant due to direct proton-donation mechanisms with sdLDL.
3:30 p.m.
1008-14 Endothelial Microparticle Binding To Leukocytes As 
Predictors of Neutrophil and Monocyte Activation in 
Subjects With The Metabolic Syndrome
Julio A. Chirinos, Roque Arteaga, Wenche Jy, Joaquin J. Jimenez, Lawrence Horstman, 
Alexandre Ferreira, Eduardo De Marchena, Yeon S. Ahn, University of Miami Miller 
School of Medicine, Miami, FL
Background: The metabolic syndrome (MS) is associated with subclinical inflammation. 
Endothelial-leukocyte interactions are key components of the inflammatory response. 
Both endothelial microparticles (EMP) and leukocyte (LK) activation are elevated in the 
MS. EMP have been shown to mediate transcellular effects in vitro, including the induction 
of LK activation, but whether EMP binding to LK correlates with LK activation in vivo is 
unknown. Furthermore, it has become clear that EMP are heterogeneous, and different 
phenotypic species appear to exert different biologic actions. We examined the relation 
between the binding of different species of EMP to LK and levels of LK activation in 
patients with MS.
Methods: We obtained a peripheral venous blood sample from 37 patients with MS. Using 
flow cytometry, we measured neutrophil expression of activation marker CD11b. We also 
measured LK levels of nitric oxide (NO) after loading LK with the membrane permeable 
NO-selective fluorescent indicator DAF-DA. EMP62E-LK and EMP54-LK conjugates were 
measured as markers of EMP binding to LK based on the detection of E-selectin (CD62E) 
or CD54, respectively, co-expressed with CD45 in neutrophils or monocytes.
Results: EMP62E-neutrophil conjugates strongly correlated with CD11b expression 
(R=0.70; p<0.0001), and predicted CD11b expression independently of free EMP62E 
levels (R2 increase=0.47; p<0.0001), whereas EMP54-neutrophil conjugates did not 
correlate with neutrophil activation. In contrast, EMP54-monocyte conjugates correlated 
with monocyte NO levels (R=0.49; p=0.002) and predicted monocyte NO independently of 
free EMP54 levels (R2 increase=0.21; p=0.004), whereas EMP62E-monocyte conjugates 
did not correlate with monocyte NO levels.
Conclusions: The binding of EMP62E to neutrophils predicts circulating neutrophil 
activation in the MS. In contrast, the binding of EMP54 to monocytes predict monocyte 
NO levels. Our findings support in vitro studies showing that EMP binding to LK can 
influence LK activation and are in line with the concept that different species of EMP exert 
different transcellular effects.
3:30 p.m.
1008-34 Differential Effects of Inhibition of Cholesterol 
Absorption by Plant Sterols Compared to Ezetimibe on 
Atherogenesis
Oliver Weingärtner, Dieter Lütjohann, Nicole Weisshoff, Franka List, Michael Böhm, 
Ulrich Laufs, Universitätsklinikum des Saarlandes, Homburg, Germany, Klinische 
Pharmakologie, Bonn, Germany
Background: “Functional foods” supplemented with plant sterols and ezetimibe, an 
intestinal inhibitor of NPC1L1, are therapeutic options for the inhibition of intestinal 
cholesterol absorption with the aim to prevent atherosclerotic disease progression. Their 
differential effect on atherosclerotic lesion formation is unknown.
Methods and Results: Male apoE -/- mice were randomised to 8 treatment groups (n=10 
per group): Mice received either Western-type diet (WTD; 40 kcal% butterfat, 0.15% 
cholesterol) or cholesterol-free normal chow (NC; 14 kcal% vegetable oil) supplemented 
with 2 % plant sterols (PSE), ezetimibe (EZE, 0.005% ezetimibe) or the combination (PSE 
+ EZE). After 6 months plasma concentrations of cholesterol, sitosterol and campesterol 
were determined by gas-chromatography/mass spectrometry. PSE and EZE similarly 
lowered plasma cholesterol levels, but plant sterol concentrations were significantly 
higher in PSE treated mice. EZE inhibited plant sterol absorption. Atherosclerotic lesion 
formation was most pronounced in mice on WTD and reduced by cholesterol lowering. 
However, mice treated with EZE showed less plaque formation compared to PSE 
treatment despite equal cholesterol lowering (plaque area 10.0% vs 20.4%; p<0.05).
Conclusions: Inhibition of cholesterol absorption by plant sterols was associated with 
increased plasma plant sterol concentrations and increased plaque formation compared 
to ezetimibe despite equal lowering of plasma cholesterol concentrations.
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1008-35 Oxidized Low-Density Lipoprotein Downregulates 
Insulin-Like Growth Factor-1 Receptor via Enhanced 
Generation of Nitric Oxide and Reactive Oxygen 
Species in Human Aortic Smooth Muscle Cells.
Yusuke Higashi, Sergiy Sukhanov, Sampath Parthasarathy, Patrick Delafontaine, Tulane 
University School of Medicine, New Orleans, LA, The Ohio State University College of 
Medicine, Columbus, OH
Increased apoptosis and depletion of smooth muscle cells (SMC) plays an important 
role in atherosclerotic plaque vulnerability to rupture, a major cause of acute coronary 
events. We previously reported that the ability of oxidized low-density lipoprotein (oxLDL) 
to downregulate insulin-like growth factor-1 receptor (IGF-1R) expression is a critical 
mediator of oxLDL induced SMC apoptosis. OxLDL induced IGF-1R downregulation was 
dependent on the generation of reactive oxygen species (ROS), namely peroxide and 
superoxide as measured by H2DCFDA and dihydroethidium fluorescence. However, an 
oxidative stress-inducing agent, paraquat (0-800 μM, up to 24 hours), did not stimulate 
IGF-1R downregulation, suggesting that another downstream event was critical for 
receptor downregulation. To explore mechanisms, we assessed the ability of oxLDL 
to induce nitric oxide (NO) generation in human aortic SMC culture using DAF-FM 
fluorescence. OxLDL (60 μg/ml, 4 hours) enhanced NO generation by 2.4 fold vs. native 
LDL (nLDL) control (n=8, P<0.01). As an enzymatic source, we detected NO synthase 2 
by western blot analysis. To evaluate the significance of oxLDL induced NO generation 
in mediating IGF-1R downregulation we incubated SMC with 60μg/ml oxLDL plus NO-
scavenger, carboxy-PTIO (40 μM). Carboxy-PTIO completely prevented OxLDL induced 
IGF-1R downregulation. Consistent with this observation, the NO-donor, S-nitroso-N-
acetylpenisillamine (SNAP), in combination with paraquat, decreased IGF-1R protein 
level by 60% (400 μM paraquat and 1mM SNAP, n=4, P<0.01), while SNAP or paraquat 
alone did not downregulate IGF-IR. RNase protection assay, real-time PCR, and pulse-
chase labeling experiments indicated that oxLDL decreased IGF-1R mRNA expression 
by 40% and reduced IGF-1R protein half-life from 20 hours (nLDL) to 12 hours (oxLDL). 
In summary, oxLDL enhanced NO and ROS generation in human SMC, and these 
radicals acted coordinately to downregulate IGF-1R via a decrease in gene expression 
and in protein stability. These findings provide novel insights into oxLDL-triggered oxidant 
signaling and mechanisms of SMC depletion that contribute to plaque destabilization and 
acute coronary events.
3:30 p.m.
1008-36 Interleukin-18 Suppresses Adiponectin Expression 
In 3T3L1 Adipocytes Via A Novel Signal Transduction 
Pathway Involving ERK1/2 Dependent NFATc4 
Activation
Nikhil S. Joshi, David B. Schuchman, Devang N. Patel, Steven R. Bailey, Bysani 
Chandrasekar, Univeristy of Texas Health Science Center, San Antonio, TX
Background: Interleukin-18 is a proinflammatory and pro-atherogenic cytokine while 
adiponectin is an anti-inflammatory and anti-atherogenic adipokine. An inverse correlation 
exists between serum IL-18 and adiponectin levels, with increased IL-18 and decreased 
adiponectin in patients with obesity, DM 2, CAD, and metabolic syndrome. Whether this 
inverse correlation is coincident or causally related is not known.
Methods: Fully differentiated 3T3L1 adipocytes were treated with recombinant mouse 
IL-18. Adiponectin expression was quantified by real time PCR, Western blotting, ELISA, 
nuclear run on, and promoter reporter assays; NFATc4 activation by gel shift, supershift, 
immunoblotting and reporter gene assays; and ERK1/2 activation by immunoblotting 
using activation-specific antibodies and immunecomplex kinase assays. Pharmacological 
inhibitors, dominant negative (dn) expression vectors and siRNA interference targeted 
ERK1/2 and NFATc4 activation.
Results: IL-18 suppressed adiponectin transcription, mRNA expression and secretion 
from adiposities, effects that were blocked by IL-18BP/Fc chimera, anti-IL-18 or IL-18Rá 
neutralizing antibodies. IL-18 stimulated adiponectin promoter-reporter activity while 
deletion constructs lacking NFATc4 binding element or mutation in NFATc4 reversed 
IL-18-mediated suppression of adiponectin expression. IL-18 stimulated NFATc4 
phosphorylation, nuclear translocation, DNA binding, and reporter gene activities. IL-18 
induced ERK1/2 phosphorylation and enzyme activity. These effects were blocked by 
PD98059 or overexpression of dnERK1/2. Furthermore, inhibition of ERK1/2 attenuated 
IL-18-mediated NFATc4 activation. Finally, inhibition of ERK1/2 and NFATc4 knockdown 
attenuated IL-18-mediated adiponectin transcription.
Conclusions: These data show for the first time that IL-18 is causally related to 
adiponectin expression. IL-18 suppresses adiponectin via ERK1/2-dependent-NF-ATc4 
activation. Inhibiting IL-18 or enhancing adiponectin expression may be a therapeutic 
strategy to attenuate onset or progression of atherosclerosis.
3:30 p.m.
1008-37 Atorvastatin Exhibits Differential Effects on Circulating 
OxLDL Markers in Patients With Acute Coronary 
Syndromes in the MIRACL Trial According to the 
Severity of Underlying Cardiovascular Risk Factors
Alexander E. Fraley, Jason P. Brown, Gregory G. Schwartz, Anders G. Olsson, Michael 
Szarek, Fady Ntanios, Joseph L. Witztum, Sotirios Tsimikas, University of California San 
Diego, La Jolla, CA, VA Medical Center and University of Colorado Health Sciences 
Center, Denver, CO
Background: The MIRACL trial showed that atorvastatin (AT), compared to placebo 
(PL), reduced cardiovascular events during 16 weeks’ treatment following acute coronary 
syndromes (ACS) and that OxLDL markers reflected the benefits of AT. We had previously 
shown that most oxidized phospholipids (OxPL) are carried on Lp(a) particles in plasma 
and that statins and diet raise the OxPL/apoB ratio and postulated this reflects plaque 
stabilization.
Methods: The content of OxPL per apoB-100 particle (OxPL/apoB), IgG and IgM apoB-
100-immune complexes per apoB (IC/apoB), total levels of IC on all apoB-100 particles 
(i.e. IC/apoB X plasma apoB), IgG and IgM MDA-LDL autoantibodies (AB), and Lp(a) 
levels were measured in 2342 patients at baseline and after 16 wks treatment with AT 
80 mg/d or PL.
Results: The cohort consisted of 1549 males, 793 females (F), 1114 <65yo, 1228 >65yo, 
713 with HTN, 526 with DM, 890 with metabolic syndrome (MS) and 666 current smokers, 
1061 with unstable angina (UA) and 1281 with nonQ-MI. At presentation, compared to 
other demographics/risk factors, Total IgG apoB-IC levels were higher in patients with 
HTN, DM and MS, Total IgM apoB-IC were higher in F, age<65 and UA, OxPL/apoB and 
Lp(a) were higher in age<65 and those without DM/MS, and IgM MDA-LDL AB were 
higher in F, age<65 and non-DM. At 16 wks, in the overall cohort, smokers, nonQ-MI and 
LDL-C<122 mg/dl (median level) had significantly higher levels of all OxLDL markers than 
those without these parameters (P=0.0149-0.0001). Following AT therapy, F, age <65, 
LDL-C<122, non-smokers and the absence of DM/MS had significantly higher increases 
in OxPL/apoB (P<0.0001 for all). The PL group had either modest or non-significant 
differences in OxLDL markers in the various subgroups.
Conclusions: In patients with ACS, baseline levels of IgG OxLDL markers tended to 
segregate in higher risk subsets, whereas IgM markers in lower risk subsets. AT resulted 
in higher OxPL/apoB in lower risk subsets, suggesting a differential effect on OxLDL 
markers reflecting the severity of underlying risk factors. These baseline differences in 
OxLDL markers and their response to statin therapy may allow improved risk stratification 
and event prediction in ACS patients.
3:30 p.m.
1008-38 Insulin-like Growth Factor I Prevents Atherosclerosis 
Progression in Aged Apolipoprotein E Deficient Mice
Yusuke Higashi, Sergiy Sukhanov, Shaw-Yung Shai, Jane Titterington, Patrick 
Delafontaine, Tulane University School of Medicine, New Orleans, LA
Insulin-like growth factor I (IGF-1) is an important endocrine and autocrine/paracrine 
factor which produces a wide range of biological effects via activation of IGF-1 receptor 
(IGF-1R). Recently, we reported that continuous IGF-1 infusion suppresses development 
of atherosclerotic plaques in relatively young (3-months old) apolipoprotein E-deficient 
mice (apoe null mice) fed a cholesterol-rich diet, presumably by decreasing inflammatory 
responses. To examine whether IGF-1 administration prevents pre-existing atherosclerotic 
plaque progression, we infused 7-month old apoe null mice with 1.5 mg/kg/day IGF-1 or 
saline for 8 weeks using osmotic mini-pumps and evaluated changes in atherosclerotic 
burden. In saline-infused control animals, atherosclerotic lesion size in the aortic sinus 
root was increased by 30% (base-line; 439 ± 59 x 1000 µm2 vs. saline-infusion; 573 ± 
41 x 1000 µm2, n=6, p<0.05), showing time-dependent progression of atherosclerosis. 
In marked contrast, there was no increase in lesion size in IGF-1 infused apoe null 
mice (base-line; 439 ± 59 x 1000 µm2 vs. IGF-infusion; 419 ± 37 x 1000 µm2, n=6, 
p=0.38), indicating IGF-1 prevented progression of pre-existing atherosclerotic lesions. 
To determine mechanisms we overexpressed IGF-1R using recombinant adenovirus in 
cultured macrophages (Mε) exposed to 100 µg/ml native LDL (nLDL) or oxidized LDL 
(oxLDL) for 24h. IGF-1R upregulation markedly inhibited Mε lipid accumulation and 
foam cell formation (85 ± 11 % inhibition vs. Mε infected with GFP adenovirus, n=4, 
P<0.05). Furthermore, flow cytometry analysis indicated that IGF-1 infusion increased 
levels of circulating Sca-1/Flk-1 positive endothelial progenitor cells (EPC) which are 
thought to contribute to endothelial repair (3.46 ± 2.1 % in IGF-1 infused mice vs. 0.96 
± 0.28 % in saline-infused mice, n=6). In conclusion, our data demonstrates that IGF-1 
markedly suppresses atherosclerotic plaque progression in apoe null mice, potentially via 
prevention of foam cell formation and lipid accumulation in lesions, and via promotion of 
endothelial repair by increasing circulating EPCs. Our findings establish a new paradigm 
for IGF-1 effects on the cardiovascular system.
3:30 p.m.
1008-39 Plasma Levels Of Arginine/(ornithine + Citrulline), A 
Global Index Of Functional Arginine Bioavailability, 
Predicts Future Risk For Major Adverse Cardiac Events
Leslie Cho, zeneng wang, stanley hazen, cleveland clinic foundation, cleveland, OH
Background: Arginine (ARG), the substrate of nitric oxide synthase (NOS), serves as the 
direct nitrogen source for nitric oxide (NO) synthesis. Despite the links between ARG, NO 
and vascular functions, ARG have not proven useful in cardiovascular risk assessments 
and therapeutic monitoring. We hypothesized that a better global index of functional ARG 
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bioavailability would be the ratio of ARG divided by the sum of ornithine (ORN) + citrulline 
(CIT) [ie. ARG/(ORN+CIT)], since ORN and CIT, the respective products of arginases and 
NOSs, are the two major catabolites of ARG metabolism. 
Method: Plasma levels of free ARG, ORN, and CIT were quantified simultaneously using 
HPLC with on-line tandem mass spectrometry, and then examined for their relationship 
to both prevalent and incident cardiovascular disease. An initial hypothesis-generating 
case:control study was comprised of subjects (n=150) with established CAD and age and 
gender matched subjects (n=300) without CAD. A subsequent validation study examined 
1,000 consecutive subjects for whom 3 yr outcomes for major adverse cardiac events 
(MACE = MI, stroke and death) were monitored.
Result: In the case:control study, there was no significant association between CAD and 
ARG levels (p=0.08). However, CAD subjects demonstrated significantly higher plasma 
levels of CIT (p<0.01), ORN (p<0.001), and ARG/(ORN+CIT) (<0.001). Only ARG/
(ORN+CIT) remained significantly associated (P < 0.001) with prevalent CAD following 
adjustments for traditional cardiac risk factors. In the validation study using 1,000 
consecutive subjects undergoing cardiac catheterization, the ratio ARG/(ORN+CIT) in a 
step wise manner predicted MACE (p=0.04), whereas ARG, ORN, and CIT individually 
did not. In a multivariable logistic regression modeling adjusting traditional cardiac risk 
factors, ARG/(ORN+CIT) remained a strong independent predictor of MACE (OR 0.62, 
95% CI 0.41 to 0.94, p=0.02). 
Conclusion: The ratio ARG/(CIT+ORN) is associated with CAD prevalence and predicts 
future risk of death, MI, and stroke. The ratio ARG/(CIT+ORN) may be a better gauge 
of ARG metabolism equilibrium state, and thus a better surrogate of functional ARG 
bioavailability, and CD risk.
3:30 p.m.
1008-40 Long-term Outcome of Autologous Transplantation 
of Bone Marrow Mononuclear Cells in Patients with 
Thromboangiitis Obliterans
Satoshi Takeshita, Koji Miyamoto, Kazuhiro Nishigami, Masaaki Chiku, Koichi Akutsu, 
Naoyuki Yokoyama, Yuichi Tamori, Masahiro Higashi, Noritoshi Nagaya, Hiroshi Nonogi, 
National Cardiovascular Center, Osaka, Japan
Background: The short-term clinical benefits of bone marrow mononuclear cell (BM-
MNC) transplantation have been shown in patients with critical limb ischemia. The purpose 
of this study was to assess the long-term safety and efficacy of BM-MNC transplantation 
in patients with thromboangiitis obliterans.
Methods: Eleven limbs (3 with rest pain and 8 with an ischemic ulcer) of 8 patients were 
treated with BM-MNC transplantation. Patients were followed-up for clinical events for a 
mean of 684±549 days (range 103-1466).
Results: At 4 weeks, improvement in pain was observed in all 11 limbs, with complete 
relief in 4 (36%). Pain scale (visual analog scale) decreased from 5.1±0.7 to 1.5±1.3 
(P<0.005). Improvement in skin ulcers was observed in all 8 limbs, with complete healing 
in 7 (88%). During the follow-up, however, clinical events occurred in 4 of the 8 patients. 
The first patient suffered sudden death at 20 months after transplantation at 30 years of 
age. The second patient with incomplete healing of a skin ulcer showed worsening of the 
lesion at 4 months. The third patient had worsening of rest pain at 8 months. The last 
patient developed an arteriovenous shunt in the foot at 7 months, which spontaneously 
regressed by 1 year.
Conclusions: BM-MNC transplantation is associated with excellent short-term benefits. 
However, long-term adverse events were observed in half of the patients, and included 
death and unfavorable angiogenesis. Given the current incomplete knowledge on the 
safety and efficacy of this strategy, careful long-term monitoring is required in future 
patients receiving this treatment.
3:30 p.m.
1008-41 Macrophage Scavenger Receptor 1 Sequence Variations are 
Associated with Atherosclerosis Susceptibility in Humans
Ronen Durst, Yehuda Neumark, Vardiella Meiner, Yechiel Friedlander, Arthur Polak, 
Morris Mosseri, Ronen Beeri, Haim Dannenberg, Thea Pugatch, Shoshi Spitzen, 
Liat Ben Avi, Eran Leitersdorf, Chaim Lotan, Cardiology Department, Hadassah 
Hebrew University Medical Center, Jerusalem, Israel, Braun School of Public Health & 
Community Medicine, Hebrew University Medical School, Jerusalem, Israel
Background: Macrophage scavenger receptor 1 mediates uptake of modified LDL-
cholesterol, therefore, polymorphisms in its encoding gene, MSR1, may modulate genetic 
susceptibility to atherosclerosis. We investigated possible association between common 
MSR1 polymorphisms and coronary atherosclerosis.
Methods & results: DNA samples from 136 non-diabetic Ashkenazi males under age 
55 (mean = 47.3(4.8 years), undergoing coronary angiography, were genotyped for 
MSR1 coding and non-coding SNPs. Information on classic risk factors were collected 
from patients’ files. The angiographic extent of coronary artery disease were assessed 
by the number of coronary segments with stenosis greater than 20% (CAGE>20%), 
segments with stenosis greater than 50% (CAGE>50%) and the total number of diseased 
vessels. Associations between atherosclerotic burden and MSR1 SNPs and haplotypes 
were examined through linear regression modeling accounting for covariates. Three 
polymorphic sites were analyzed including a 3-bp “TTA” insertion-deletion in intron 7 
(rs3036811, Indel 7), an intron 5 SNP (rs33959637, IVS5-59), and a missense coding 
SNP in exon 6 (rs3747531, P275A). All three were within Hardy-Weinberg equilibrium 
boundaries. A significant association was noted between IVS5-59 and the number of 
diseased vessels (p=0.009) and CAGE>20% (p=0.017). These relationships remained 
significant upon controlling for age, cholesterol level, hypertension, smoking, and the 
effects of INDEL7 and P275A. Gene-environment interaction effects on CAGE>20% were 
noted, including INDEL7 and smoking (p=0.022), P275A and smoking (p=0.034) and 
INDEL7 and age (p=0.024).
Conclusion: We demonstrate an association between MSR1 polymorphisms and 
atherosclerosis in this sample of men. Our data also suggest that atherosclerotic risk 
associated with classic risk factors may be modified by MSR1 polymorphisms. These 
findings point to a significant role of MSR1 in human atherosclerosis. 
3:30 p.m.
1008-42 Inflammatory Markers, Angiographic Severity of 
Coronary Artery Disease and Patient Outcome
Rishi Sukhija, Ibrahim Fahdi, Luis Garza, Louis Fink, Margaret Scott, Wady Aude, April Grant, 
Mehta Jawahar, Division of Cardiovascular Medicine, Central Arkansas Veterans Healthcare 
System, Little Rock, AR, University of Arkansas for Medical Sciences, Little Rock, AR
Background: Serum levels of high sensitive-C reactive protein (hs-CRP), interleukin-6 
(IL-6) and tumor necrosis factor-α (TNF-α) have been shown to be predictors of adverse 
outcome in coronary artery disease (CAD) patients. We hypothesized that measurement 
of these inflammatory markers could be useful in predicting atherosclerotic burden and 
major adverse cardiac events (MACE).
Methods: We prospectively measured hs-CRP, IL-6 and TNF-α in 249 patients (mean age 
60 ± 10 years, 89% males) admitted with acute coronary syndrome, who also underwent 
coronary angiography. We analyzed relationship between serum levels of inflammatory 
markers and angiographic severity of CAD (segments with luminal narrowing). Over a 6 
month follow up period, occurrence of MACE, defined as myocardial infarction, any cause 
death, or coronary revascularization, was correlated with inflammatory markers.
Results: In the unadjusted model, hs-CRP correlated with the number of coronary 
segments with ≥50% stenosis (β=0.199, SE=0.884, p<0.0001), number of coronary 
segments with ≥70% stenosis (β=0.138, SE=0.063, p=0.0296), and coronary segments 
with any stenosis (obstructive+non-obstructive) (β=0.286, SE=0.124, p<0.001). However, 
after adjustment for age, sex, diabetes, hypertension, smoking, and hypercholesterolemia; 
there was no association between hs-CRP with number of coronary arteries or segments 
with ≥50%, ≥70% or any stenosis (obstructive + non-obstructive) (all p>0.05). Similarly, 
serum IL-6 and TNF-α levels were not associated with angiographic severity of CAD 
after adjustment for conventional risk factors. However, there was a significant positive 
correlation between age, male gender, diabetes mellitus and hypercholesterolemia with 
angiographic atherosclerotic burden. Further, there was no association between MACE 
and hs-CRP or TNF-α levels in the unadjusted and adjusted models.
Conclusion: In patients with non-ST elevation acute coronary syndrome, we did not find any 
positive association of serum levels of hs-CRP, IL-6 and TNF-α, with coronary atherosclerotic 
burden, or MACE at 6 months, after adjustment for traditional CAD risk factors.
3:30 p.m.
1008-43 Relationship of Acute Cardiac Dysfunction with Clinical 
Severity of Subarachnoid Hemorrhage: Results from 
the SAHMII Study
Masaki Tanabe, Elizabeth A. Crago, Marilyn Hravnak, Michael B. Horowitz, John 
Gorcsan, III, University of Pittsburgh, Pittsburgh, PA
Background: Acute cardiac dysfunction manifest by troponin-I elevations and left 
ventricular (LV) wall motion abnormalities have been reported after aneurysmal 
subarachnoid hemorrhage (SAH), however their relationship with severity of SAH is not 
clearly understood.
Methods: Ninety-one SAH patients (pts) (aged 53±10 yrs, 70% women) were prospectively 
studied. Clinical severity of SAH (Hunt and Hess grade) was determined on admission. 
Troponin-I was measured daily as a marker of myocardial injury and echocardiography 
was performed < 48 hrs after SAH. LV wall motion scores (WMS) were derived using a 
standard 16-segment model and ejection fraction using biplane Simpson’s rule.
Results: Troponin-I levels > 1.0 ng/ml occurred in 22 pts (24%) and abnormal WMS in 16 
pts (18%). Troponin-I elevations were associated with abnormal WMS, levels > 1.32ng/
ml predicting WMS abnormalities with 81% sensitivity and 92% specificity. Markers of 
cardiac injury were significantly associated with clinical severity of SAH. Pts with troponin-
I > 1.32ng/ml showed significantly higher Hunt and Hess grade 3.4±1.2 (> 3 indicating 
confusion or focal neurological deficit), vs. 2.6±0.9 compared with pts with lower troponin, 
p<0.05. Troponin-I elevated pts also had higher WMS and lower ejection fractions (1.3±0.3 
vs 1.0±0.1, 50±11% vs 62±7% in the other pts, p<0.05).
Conclusions: Evidence of cardiac injury or dysfunction, detected by troponin-I and 
abnormal LV regional function are associated with clinical severity of SAH. 
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1008-44 Short-term Statin Therapy is Associated with Marked 
Reduction of c-Jun N-terminal Kinase of Aortic Wall in 
Patients with Abdominal Aortic Aneurysm
Kan Kajimoto, Katsumi Miyauchi, Takatoshi Kasai, Yuko Kojima, Kazunori Shimada, 
Akie Shimada, Hiroshi Niinami, Atsushi Amano, Hiroyuki Daida, Department of 
Cardiovascular Surgery, Juntendo University, Tokyo, Japan, Department of Cardiology, 
Juntendo University, Tokyo, Japan
Background: We have reported that atorvastatin has inhibitory effect on inflammatory 
cells infiltration and MMPs levels in human abdominal aortic aneurysms (AAA). Recent 
study indicated that expression of c-jun N-terminal kinase (JNK) played an important role 
in expansion of AAA. The aim of this study was to investigate the effect of atrovastatin on 
expression of JNK in human tissue of AAA.
Methods: Patients with AAA were randomized to atorvastatin (20 mg/day, 10 patients) or 
control (10 patients). After an average treatment of 4 weeks, patients underwent abdominal 
aorta replacement, tissue specimens were obtained, and the tissue composition was 
determined by immunohistochemistry.
Results: In atorvastatin pre-operatively group, serum LDL-C level was significantly 
decreased by 40% whereas there was no significant difference in control group. The % 
positive area for expression of JNK in the aortic wall were 1.7 ± 1.0 % in atorovastatin 
group versus 4.3 ± 3.0 % in control group (p=0.020).
Conclusions: Short-term atorvastatin treatment reduced the expression of JNK in 
human abdominal aortic aneurysm wall. The result of this study indicated the possible 
use of statin for prevention of AAA expansion. 
3:30 p.m.
1008-45 Differences in Clinical Profiles of Patients with Non-
Ascending vs. Ascending Thoracic Aortic Aneurysms
Makoto Amaki, Koichi Akutsu, Satoshi Kasai, Yuiichi Tamori, Naoyuki Yokoyama, Hiroshi 
Nonogi, Satoshi Takeshita, National Cardiovascular Center, Suita, Japan
Background: Previous studies have indicated that atherosclerosis is less commonly 
involved in the pathogenesis of ascending thoracic aortic aneurysms (TAA). However, the 
role of atherosclerosis in the pathogenesis of non-ascending TAA still remains unknown. 
In this study, we investigated the differences in atherosclerotic profiles of patients between 
those with non-ascending vs. ascending TAA.
Methods: We reviewed clinical records of 288 consecutive patients with TAA (non-
ascending 229 and ascending 59), who were admitted to our hospital for elective surgical 
repair between 2001 and 2004. Atherosclerotic risk factors, including male sex, older age, 
diabetes mellitus (DM), hypertension (HTN), hyperlipidemia (HL), and history of tobacco 
use were evaluated by using logistic regression model to determine the association with 
the location of thoracic aortic aneurysms.
Results: Atherosclerotic risk factors, including male sex (75% vs 59%, P<0.05), age >70 
(67% vs 49%, P<0.05), DM (24% vs 12%, P<0.05), HTN (91% vs 79%, P<0.05) and HL 
(67% vs 49%, P<0.05), were more frequently observed in patients with non-ascending 
TAA than in those with ascending TAA. By multivariate analysis, age >70 (RR, 2.25; 
95% CI, 1.2 to 4.2; P = 0.011), male sex (RR, 2.1; 95% CI, 1.0 to 4.2; P = 0.044) and 
hyperlipidemia (RR, 1.85; 95% CI, 1.0 to 3.4; P = 0.048) were found to be independently 
associated with non-ascending TAA.
Conclusions: Atherosclerotic risk factors including older age, male sex, and 
hyperlipidemia, are independently associated with non-ascending TAA. Hyperlipidemia 
may have an important contribution to the pathogenesis of non-ascending TAA, which 
should be reflected in the treatment strategies to prevent the expansion and the rupture 
of aortic aneurysms.
3:30 p.m.
1008-46 Lipoprotein-Associated Phospholipase A2 Is Especially 
Predictive of Coronary Artery Disease Among Patients 
with the Metabolic Syndrome
Farangis Lavasani, Heidi T. May, Benjamin D. Horne, Jeffrey L. Anderson, John F. 
Carlquist, Robert L. Wolfert, Robert R. Pearson, Richard B. Lanman, Joseph B. 
Muhlestein, LDS Hospital, Salt Lake City, UT, University of Utah, Salt Lake City, UT
Background: Inflammation plays a role in the development and progression of 
atherosclerosis, and circulating markers of vascular inflammation are useful in risk 
assessment. Lipoprotein-associated phospholipase A2 (LpPLA2) is an enzyme that 
circulates with LDL cholesterol and has been proposed to be a more vascular-specific 
biomarker than C-reactive protein. We evaluated whether the predictive ability of Lp-PLA2 
for angiographically-confirmed (>70% stenosis) coronary artery disease (CAD) differs in 
patients with the metabolic syndrome (MS).
Methods: LpPLA2 (PLACTM test, diaDexus, Inc.) was measured from samples donated 
by consenting patients (N=1,493) enrolled in the registry of the Intermountain Heart 
Collaborative Study. All patients underwent coronary angiography (1996-1998) to evaluate 
for the presence of CAD. MS was defined using ATP III criteria with BMI >27 kg/m2 used 
as a surrogate for waist circumference. Patients were also followed for 7.5±2.4 (max: 10.1 
years) to determine CAD death incidence.
Results: Average age was 63±12 years; 70% were male; 67% had CAD; and 42% had 
MS. LpPLA2 divided at the median (350.2 ng/mL) was more predictive of the presence of 
CAD in MS subjects [univariate (non-MS Odds Ratio [OR]=1.65, p=0.003; MS OR=2.31, 
p<0.0001) and multivariate analysis (non-MS Odds Ratio [OR]=1.64, p=0.009; MS 
OR=2.14, p=0.001; p-interaction=0.20)]. Further, in multivariable Cox regression, LpPLA2 
was a clinically important predictor of CAD death risk in both non-MS (adjusted hazard ratio 
[HR]=1.56, p=0.08) and MS pts (adjusted HR=1.51, p=0.13), with p-interaction=0.88.
Conclusions: Predictive ability of LpPLA2 for CAD was enhanced in patients with MS and 
remained predictive of future CAD death as well. These findings emphasize the important 
role that vascular inflammation plays in atherosclerotic risk associated with the metabolic 
syndrome.
3:30 p.m.
1008-47 Impact of Low Density Lipoprotein Cholesterol and 
C-Reactive Protein on the Tissue Characteristics 
of Coronary Plaques determined by Integrated 
Backscatter Intravascular Ultrasound
Hiroyuki Ozaki, Kiyoshi Hibi, Ikuyoshi Kusama, Hideto Yano, Jun Okuda, Kengo 
Tsukahara, Yoshio Tahara, Masami Kosuge, Toshiaki Ebina, Shinichi Sumita, Kazuaki 
Uchino, Satoshi Umemura, Kazuo Kimura, Division of Cardiology, Yokohama City 
University Medical Center, Yokohama, Japan, Department of Medical Science and 
Cardiorenal Medicine, Yokohama City University Graduate School, Yokohama, Japan
Background: Although PROVE IT-TIMI22 trial have demonstrated that patients with high 
C-reactive protein (CRP) and low density lipoprotein cholesterol (LDL-C) levels had worse 
clinical outcomes than those with low CRP and LDL-C levels, its precise mechanisms 
were unknown. Integrated backscatter (IB) IVUS system allows the analysis of tissue 
characterization of coronary plaques and enables the quantification of plaque components 
in vivo. The aim of this study was to investigate the characteristics of coronary plaques 
stratified by LDL-C and CRP levels using IB-IVUS.
Methods: A total of 32 de novo culprit lesions in 32 patients with angina pectoris who 
underwent PCI to native coronary artery were enrolled. IVUS interrogation was performed 
before any interventions and radiofrequency data was acquired. Patients were divided 
into 3 groups on the basis of LDL-C and CRP levels on admission above and below the 
respective values of 100mg/dl and 2mg/l; 7 patients with LDL-C >100mg/dl and CRP 
>2mg/l (group H), 4 patients with LDL-C <100mg/dl and CRP <2mg/l (group L), and the 
other 21 patients (group M). Measurements of IB-IVUS were made every 1 mm for the 
entire segment within 5 mm proximal and distal to the slice of the minimal lumen area. We 
compared each plaque component (lipid, calcification, and fibrosis) of the average of the 
entire segment among 3 groups.
Results: There was a stepwise increase in percent area of lipid among 3 groups (28 vs. 
44 vs. 52% in group L, M, and H, respectively, p = 0.025), whereas a stepwise decrease in 
percent area of calcification was observed (4.3 vs. 1.3 vs. 1.1%, p = 0.0005).
Conclusions: Higher LDL cholesterol and CRP levels were associated with lipid-rich 
plaque with less calcification. Therapies designed to reduce both serum LDL cholesterol 
levels and inflammation may affect plaque component, leading to the stabilization of 
vulnerable plaque.
3:30 p.m.
1008-76 Genetic Polymorphism C242T On The p22-phox Subunit 
Of NADPH Oxidase, As A Risk Factor For Myocardial 
Infarction: Effects On Platelets Activation And Oxidized 
LDL levels
Carmen Vasiliadou, Dimitris Tousoulis, Charalambos A. Antoniades, Kyriakoula 
Marinou, Costas Tentolouris, Nikolaos Koumallos, G. Triantafyllou, E. Gerodemou, 
Nikos Papageorgiou, Gregory Vyssoulis, Christodoulos Stefanadis, Athens University, A 
Cardiology Department, Athens, Greece
Background: Enzymatic production of free radicals plays a key role in atherogenesis. 
The p22 phox, a component of the NADH/NADPH oxidase in phagocytes and vascular 
smooth muscle cells, is essential for the production of reactive oxygen species. Evidence 
suggests that C/T polymorphism at position 242 of the p22 phox gene may affect its 
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enzymatic activity. However, its role in the development of premature myocardial infarction 
(MI) as well as its ability to modify overall oxidative stress status and endothelial injury is 
unknown. We examined the effect of C242T polymorphism on p22 phox gene on the risk 
for MI, and on the variations of ox-LDL and sP-selectin.
Methods. The study population consisted of 197 patients with first event of premature MI 
(aged 46.90±1.1 yrs old) and 204 age- and sex- matched controls. C242T polymorphism 
was detected by PCR, and levels of ox-LDL and P-selectin were determined by ELISA.
Results. The prevalence of the T allele was higher in MI patients (CC/CT/TT: 65/98/34) 
compared to controls (CC/CT/TT: 88/95/21, p<0.05). The risk for MI was higher in 
TT compared to CT+CC (1.818[95%CI:1.014-3.258] p=0.036), or compared to CC 
(2.192[95%CI:1.166-4.121] p=0.01). Carriers of the T allele (CT+TT) also had higher risk 
for premature MI (1.541[95%CI:1.026-2.312] p=0.023) compared to CC. Homozygosity 
for the T allele in the overall population was associated with higher levels of P-selectin 
(39.9±1.6ng/ml) compared to CT+CC (32.08±2.8ng/ml p<0.05). However, homozygosity 
for the T allele was associated with slightly but not significantly higher levels of ox-LDL 
(83.9±7.09IU/L) compared to CT+CC (79.4±2.31 IU/L, p=NS)
Conclusions. Genetic polymorphism C242T on p22 phox, is associated with the 
development of premature MI, since the presence of 242T allele increases the risk for MI in 
young individuals. Furthermore, our findings suggest that although C242T polymorphism 
is associated with higher levels of P-selectin, it fails to predict plasma levels of ox-LDL, 
suggesting that it may exert its effect at a local level inside the vessel wall and not by 
modifying the overall oxidative stress status.
3:30 p.m.
1008-77 Bleeding is Common Among Patients Treated with 
Heparin Experiencing Thrombocytopenia and Confers a 
High Mortality Risk: Report from the CATCH Registry
Marc E. Jolicoeur, Magnus E. Ohman, Emily F. Honeycutt, Francisco J.N. Mazon, 
Richard C. Beckerd, Eric M. Crespo, Gustavo B.F. Oliveira, David J. Moliterno, Kevin 
J. Anstrom, Christopher B. Granger, Duke Clinical Research Institute, Durham, NC, 
University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: Thrombocytopenia developing under heparin therapy is paradoxically 
associated with thrombosis, but little is known about risk of bleeding related to this 
syndrome. We sought to assess the incidence, risk factors and outcome of bleeding in 
patients developing thrombocytopenia who were treated with heparin.
Methods: The CATCH registry enrolled 3510 patients at risk for HIT (thrombocytopenia 
and/or >96 hours of heparin) from March 2003 to April 2004 at 48 US hospitals. 
Thrombocytopenia was defined as platelets drop <150,000/mm3 or >50% drop from 
baseline. Moderate or severe bleeding was identified using the GUSTO classification. 
Thromboembolic complications were defined as myocardial infarction, stroke, systemic 
embolization, venous thromboembolic disease.
Results: Of the 1955 patients who developed thrombocytopenia in the registry, 218 
(11.2%) experienced a bleeding complication. Bleeding was more frequent among 
patients with prior congestive heart failure, or coagulation disorder (p<0.001), and among 
patients experiencing in-hospital renal dysfunction (p<0.005). Patients who bled had a 
more severe nadir platelet count (84 vs 107 x 109/L, p<0.001) and a lower nadir hematocrit 
(22.8% vs 35.2%, p<0.001). Thromboembolic complications were more frequent among 
bleeders than non-bleeders (31.7% vs 17.8%, p<0.001). The overall use of non-heparin 
anticoagulation was low (5.0%), yet was significantly higher among bleeders (9.6%) 
than non-bleeders (4.4%) (p<0.001). In hospital mortality was 11.9% with and 6.6% 
without bleeding (OR: 1.9 [1.2-3.0], p<0.01), which was comparable to the mortality risk 
associated with the development of a new thromboembolic complication (OR: 2.2 [1.5-
3.1]). These observations were consistent after excluding patients undergoing coronary 
artery bypass surgery.
Conclusion: Bleeding is common among patients treated with heparin experiencing 
thrombocytopenia and confers a mortality risk similar to that of thromboembolic 
complications.
3:30 p.m.
1008-78 Successful Revascularization of at Least a Branch of 
the Tibial Artery to the Pedal Arch Contributes Limb 
Salvage in Critical Limb Ischemia
Osamu Iida, Shinsuke Nanto, Masaaki Uematsu, Takakazu Morozumi, Tetsuya 
Watanabe, Masaki Awata, Toshinari Onishi, Fusako Sera, Hitoshi Minamiguchi, 
Hirokuni Akahori, Masamichi Yano, Hiroki Yasui, Seiki Nagata, Kansai Rosai Hospital, 
Amagasaki, Japan
Background: Recently, developments in endovascular techniques have emerged to 
improve the poor limb salvage rate in critical limb ischemia (CLI). We retrospectively 
analyzed the factors influencing the limb salvage in CLI in this new era of advanced 
techniques.
Methods: Consecutive 80 patients with CLI who underwent skin perfusion pressure (SPP) 
measurement (Rutherford V = 50, VI = 30 patients) were enrolled between July, 2005 and 
July, 2006. All were followed up for 8±3 month. Multivariate analysis was performed to 
explore the independent determinants of limb salvage.
Results: Major amputation occurred in 18 patients during the follow up. The palpable 
tibial or dorsalis pedis artery, SPP >40mmHg after percutaneous peripheral intervention 
(PPI), improvement in SPP by PPI ([[Unsupported Character - &#8895;]]SPP) >20mmHg, 
complete revascularization to the pedal arch, successful revascularization of at least a 
branch of the tibial artery to the pedal arch, were chosen as the independent variables 
related to limb salvage by single regression analysis. Among these, the complete 
revascularization and at least one intact tibial artery branch were chosen as the 
independent factors by multivariate analysis (Table). Patient characteristics and lower 
limb status were not different in patients with and without these factors.
Conclusion: Complete revascularization to the pedal arch and at least one intact tibial 
artery branch revascularization contribute the limb salvage in patients presenting CLI.
3:30 p.m.
1008-79 Magnitude of the Improvement in Skin Perfusion 
Pressure is as Important as Skin Perfusion Pressure 
Immediately Following Intervention for Predicting Limb 
Salvage in Critical Limb Ischemia
Hirokuni Akahori, Masaaki Uematsu, Takakazu Morozumi, Tetsuya Watanabe, Masaaki 
Awata, Toshinari Onishi, Osamu Iida, Fusako Sera, Hitoshi Minamiguchi, Masamichi 
Yano, Hiroki Yasui, Shinsuke Nanto, Seiki Nagata, Kansai Rosai Hospital, Amagasaki, 
Japan
Background: Skin perfusion pressure (SPP) using a laser Doppler technique has recently 
been introduced to be used in identifying patients with critical limb ischemia (CLI) who 
need percutaneous peripheral intervention (PPI), and those who are destined to major 
amputation after PPI. However, the magnitude of the improvement in SPP by PPI (d-SPP) 
may also play a role in predicting the fate of CLI. We sought to analyze the relationship 
between d-SPP and the outcome of CLI.
Methods: We analyzed consecutive 80 limbs presenting non-healing foot ulcer from 
67patients (age ranged 29-88 years; including 42 men) whose SPP was measured in the 
foot before and after PPI performed between July, 2005 and September, 2006. Patients 
were followed up 7.8±3.4 months later. Lesions were located above the knee in 2 (2%), 
below the knee in 36 (45%), and both above and below the knee in 42 limbs (53%). 
SPP was measured using a cuff type laser Doppler scanner designed for this purpose. 
Predictive power of d-SPP as well as that of SPP following PPI was compared regarding 
limb salvage using ROC analysis.
Results: d-SPP >20 mmHg and SPP > 45 mmHg best predicted limb salvage in CLI. Area 
under the curve was similar between d-SPP and SPP (Figure).
Conclusions: Magnitude of the improvement in SPP is as important as SPP immediately 
following PPI for predicting limb salvage in CLI. 
3:30 p.m.
1008-80 Increase in Arterial Stiffness in Patients with 
Obstructive Sleep Apnea
Shang Qing, David SC Hui, Fanny Ko, Kin-wang To, Gabriel WK Yip, Alex PW Lee, 
Cheuk-man Yu, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background: Obstructive sleep apnea (OSA) has recently been suggested to play a role 
in the pathogenesis of cardiovascular disease including atherosclerosis. Nowadays, 
early increase in arterial stiffness due to atherosclerosis can be detected by applenation 
tonometry. The aim of this study was to evaluate whether artery stiffness is increased in 
patients with OSA.
Methods: Twenty-three patients with OSA and 24 normal controls matched for age, 
gender and body mass index were studied non-invasively by tonometry that measured 
brachial-femoral pulse wave velocity (baPWV) and ankle brachial index (ABI), as well as 
B-mode ultrasound to measure carotid intimo-medial thickness (IMT).
Results: In patients with OSA, there was a significant increase in baPWV (1558 ± 268 
vs. 1366 ± 193 cm/s, P=0.007) and ABI (1.15 ± 0.06 vs. 1.18 ± 0.05mm, P=0.032) when 
compared with the controls, although there was no difference in carotid IMT (0.073 ± 0.17 
vs. 0.069 ± 0.16 mm, P=NS). Stepwise liner regression analysis showed that OSA was 
independently associated with increased baPWV (Beta=0.315, P=0.017) and reduced 
ABI (Beta=0.313, P=0.032) after adjusted for age, sex, body mass index and blood 
pressure. Conclusion: OSA is possibly a risk factor for the increase in artery stiffness, 
as reflected by the changes of BaPWV and ABI. This may precede clinically apparent 
atherosclerosis such as increase in carotid IMT.
Key words: Obstructive sleep apnea; Atherosclerosis
JACC  March 6, 2007    ABSTRACTS - Vascular Disease, Hypertension and Prevention    341A 
Vascular D
isease, H
ypertension and P
revention
3:30 p.m.
1008-81 Impact of Stent Fractures after Femoropopliteal 
Stenting
Yoshimitsu Soga, Kenji Ando, Masashi Iwabuchi, Hiroyoshi Yokoi, Hitoshi Yasumoto, 
Hideyuki Nosaka, Masakiyo Nobuyoshi, Kokura Memorial Hospital, Kitakyushu, Japan
Background:It has recently been reported that stent fractures of nitinol stent were 
associated with poor outcomes after femoropopliteal stenting. But a little is known 
about the frequency and the clinical impact of stent fractures after stent implantation of 
superficial femoral artery .
Objectives: In this study, we investigated its period of occurrence and the impact of stent 
fractures after femoropopliteal stenting.
Method: From Jan. 2004 to Des. 2005, we prospectively enrolled 40 patients (32 male 
gender, aged 71 ± 8 years) who were treated in our hospital by implantation of self-
expandable nitinol stents. We evaluated clinical and angiographic follow-up information 
at 3, 6 and 12 months after stenting. Stent fracture was defined as more than single strut 
fracture by using a systematic X-ray screening .
Results: All procedures were considered to be technically successful and all patients 
were treated with antiplatelet drug after stenting. Of all patients, 7 patient dropped out of 
this study. A total of 33 patients (39 legs and 53 stents) constituted the study population 
for this trials. In a stent bases analysis, the rate of stent fractures was 1.9% (3 months), 
3.8% (6 months) and 18.9% (12 months). The mean period up to fracture after stenting 
was 182 ± 24 days . The classification of fractures was mild in 4 stents, moderate in 
4 stents (44%) and severe in 1 stent (12%). There was a total stent reocclusion in a 
severe fracture case. Overall, 14 of all stents (36%) showed restenosis of more than 50% 
diameter reduction. Resenosis at the stent fracture site was 6 in 9 stents (67%). Kaplan-
Meyer survival curve showed that the restenosis rate at 12 months was significant higher 
for patients with stent fractures (18% vs. 67%, p = 0.0034). Using univariate analysis of 
various factors that may have affected in-stent restenosis, stent fracture (Hazard ratio 4.6, 
95% confidence interval 1.5 to 16, p=0.003) was identified as only predictors.
Conclusions: Stent fractures after femoropopliteal stenting were considered to be 
associated with in-stent renstenosis.
3:30 p.m.
1008-82 Hepatocyte Growth Factor Generated in the Distal 
Segment of the Occlusive Lesions Enhances the 
Collateral Development in Peripheral Artery Disease
Daizo Kawasaki, Takeshi Tsujino, Kenichi Fujii, Motomaru Masutani, Masaaki Lee, 
Tsuyoshi Sakoda, Mitsumasa Ohyanagi, Tohru Masuyama, Hyogo College of Medicine, 
Nishinomiya, Japan
Background: Angiogenic growth factors such as hepatocyte growth factor (HGF), 
vascular endothelial growth factor (VEGF), and basic-fibroblast growth factor (b-FGF) 
have been suggested to play important roles in the development of collateral circulation.
We aimed to determine the association with regionally secreted angiogenic factors and 
collateral function in patients with peripheral artery disease.
Methods: The study population consisted of 27 consecutive patients (34 lesions) who 
underwent percutaneous peripheral intervention from February to August 2006. The 
participants were divided into 2 groups: the occlusive lesion (OL) group (n=12), all with 
collateral formation to the distal vessel segments, and the stenotic lesion (SL) group 
(n=22), all without collateral formation to the distal vessel segments. Blood samplings, 
obtained proximal and distal to the lesion, respectively, prior to percutaneous peripheral 
intervention were provided for the concentrations of HGF, VEGF and b-FGF.
Results: The levels of all factors were not different between the distal and proximal 
segments in the SL group. In the OL group, however, HGF levels were significantly higher 
(6.6±3.2 vs. 2.3±4.1 ng/ml, p<0.0005) and VEGF levels were significant lower (6.1±7.9 
vs. 49.5±47.7 pg/ml, p<0.01) in the distal segments than in the proximal segments. There 
were no significant difference in b-FGF levels between the distal and proximal segments 
in the OL groups (distal 5.6±4.5 vs. proximal 3.8±6.3 pg/ml, p=n.s.). The difference in HGF 
concentration between the distal and proximal segments positive correlated with ankle 
brachial index before percutaneous peripheral intervention in the OL groups (r=0.65, 
p<0.05).
Conclusions: These data map for the first time the regionally different levels of 
endogenous angiogenic factors in patients with peripheral artery disease. Locally 
generated HGF appears to play important roles in the collateral development in the 
peripheral artery disease patients with occlusive lesions.
3:30 p.m.
1008-83 The Effectiveness on Improvement of Activities of 
Daily Living in Intermediate Term With Percutaneous 
Peripheral Intervention of Lower Limbs in Hemodialysis 
Patients
Yutaka Koyama, Hidenori Watanabe, Takayoshi Sato, Takako Kobori, Yasuyuki 
Maruyama, Takaaki Isshiki, Iwatsuki-minami hospotal, Saitama, Japan
Background: Hemodialysis patients are high risk subset for cardiovascular complications. 
Although the prevalence of peripheral artery disease (PAD) of lower limbs is high in this 
patient group the clinical results of percutaneous peripheral intervention (PPI) of lower 
limbs has not been well unknown. The purpose of this study is to evaluate the efficacy in 
intermediate-term clinical outcomes after PPI to lower limbs in hemodialysis patients.
Methods: Single center registration database of PPI in our hospital was analyzed and 
mid-term clinical results were investigated.
Results: Between 10/2004 and 8/2006, we performed PPI to lower limbs for 151 lesions 
in 66 patients (mean age; 67.5 years old). All the patients had had ischemic symptoms of 
lower limbs.Eighteen lesions (11.9%) were located in iliac artery (IA), 6(4.0%) in common 
femoral artery (CFA), 51(33.8%) in superficial femoral artery (SFA), 9(6.0%) in popliteal 
artery (PA) and 67(44.4%) in below-the-knee arteries (BTK). Stent was implanted in IA in 
88.9%, CFA in 16.7% and SFA in 47.1%. No stent was implanted in PA and BTK. Lesion 
success rate was 100% in IA, CFA and PA, 90.2% in SFA and 76.1% in BTK. Before 
and after PPI, ankle-brachial index (ABI), Fontaine grade and Rutherford category was 
significantly improved (0.64 ±0.19 vs 0.82±0.19, 2.3±1.3 vs 1.7±1.5, 2.9±1.9 vs 2.0±2.1, 
p<0.05). In more than 3-months clinical follow-up period (mean; 8.3±4.4 months) ABI 
demonstrated approximately same level of after PPI (0.80±0.19), however Fontaine 
grade and Rutherford category demonstrated further significant improvement (1.0±1.9, 
1.1±1.8, p<0.05 vs before and after PPI). Mortality rate was 10.6% and target lesion 
revascularization (TLR) rate was 9.3%. TLR in SFA was 11.8%, PA was 11.1%, BTK was 
10.4%, IA and CFA was 0% respectively.
Conclusions: Clinical improvement in Fontaine grade and Rutherford category after PPI 
to lower limbs in hemodialysis patients was demonstrated. Further investigation will be 
required to assess outcomes including mortality and TLR.
3:30 p.m.
1008-84 Predictive Value of High-Sensitivity C-Reactive Protein 
in the Diagnosis and Prognosis of Acute Aortic 
Syndromes
Soufian Almahameed, Gian M. Novaro, Craig R. Asher, Ryan Zurek, Deepak L. Bhatt, 
Gary S. Francis, Eric J. Topol, Cleveland Clinic Florida, Weston, FL, Cleveland Clinic, 
Cleveland, OH
Background: Acute aortic syndromes (AAS) represent aortic dissection (AD), intramural 
hematoma (IMH), penetrating aortic ulcer (PAU), and symptomatic aortic aneurysm 
(SAA). High sensitivity C-reactive protein (hsCRP), a marker of inflammation, is elevated 
in AD patients (pts). Whether hsCRP differs among AAS and predicts AAS is not known.
Methods: Pts presenting with AAS between 2001-03 were identified. Demographic, 
imaging and lab data including hsCRP were obtained at time of presentation. For 
comparison, a group of acute myocardial infarction (MI) pts (n=84; age 61±13 years, 72% 
male, median hsCRP 7 mg/l) was used.
Results: A total of 131 AAS pts were identified (age 70±13 years, 55% male; median 
hsCRP 21 mg/l). Hospital mortality was 7%. HsCRP differed among AAS; median hsCRP 
was higher in the AD group (40 mg/l) than in those with PAU (19 mg/l), SAA (12 mg/l), and 
IMH (9 mg/l; p=0.014). In multivariable analysis, AD pts had higher median hsCRP levels 
compared to IMH (p=0.02) and SAA (p=0.03) pts, after adjusting for age and gender. 
Versus acute MI pts, a hsCRP value >40 mg/L yielded a specificity of 95% and 80% 
overall accuracy for AAS pts. In multivariable Cox regression, elevated hsCRP (>20 mg/L) 
at presentation was independently related to 3-year mortality (p=0.04; Kaplan Meier).
Conclusions: Among pts with AAS, AD pts have the highest hsCRP levels at presentation. 
HsCRP levels >40 mg/L help predict AAS pts from acute MI pts. Elevated hsCRP at 
presentation of AAS is independently related to long-term mortality. 
3:30 p.m.
1008-85 Vascular Disease Burden and In-Hospital Outcomes 
Among Patients With Coronary Artery Disease 
Undergoing Percutaneous Coronary Intervention
Jeffrey S. Berger, John L. Petersen, David L. Brown, Stony Brook University Medical 
Center, Stony Brook, NY, Duke University Medical Center, Durham, NC
Background: Recent data suggest that atherosclerosis in other vascular beds in patients 
with coronary artery disease (CAD) is associated with increased cardiovascular events. 
However, there is little data on the impact of vascular disease burden on in-hospital 
cardiovascular outcomes among patients with CAD undergoing percutaneous coronary 
intervention (PCI).
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Methods: We analyzed 69,045 consecutive patients from the New York State Coronary 
Angioplasty Reporting System database who underwent PCI from 1998-9. Vascular 
disease burden was assessed by history and/or imaging evidence of aortoiliac, femoral-
popliteal and carotid disease.
Results: Any history of vascular disease was present in 5,915 (8.6%) of the population, 
of whom 4,840 had CAD and 1 other disease location and 1,075 had CAD and 2 or 3 
other disease locations. Vascular disease burden was associated with higher in-hospital 
adverse events (Table 1). In unadjusted analysis, in-hospital mortality was approximately 
3-fold higher (OR 2.89, 95% CI 2.31-3.60, P<0.001) and 4-fold higher (OR 3.78, 95% CI 
2.57-5.56, P<0.001) in patients with CAD and additional vascular disease at 1 site and 2+ 
sites, respectively. After multivariable adjustment, each additional vascular bed affected 
was associated with an increase in in-hospital mortality (OR 1.50, 95% CI 1.27-1.78, 
P<0.001).
Conclusions: Among patients with CAD undergoing PCI, vascular disease burden 
markedly increases the risk for in-hospital mortality, myocardial infarction and MACE.
In-Hospital Outcomes
CAD 
Alone(n=63,133)
CAD and 1 
site(n=4,840)
CAD and 2+ 
sites(n=1,075) P value
All-Cause 
Mortality (%) 0.7 2.0 2.6 <0.001
MI (%) 1.9 2.7 2.9 <0.001
Death/MI (%) 2.5 4.4 5.3 <0.001
MACE (%) 3.0 6.2 7.3 <0.001
Length of Stay 
(days) ± SD 3.4+ 6.1 5.2+10.2 6.2+9.7 <0.001
3:30 p.m.
1008-86 Right Ventricular Myocardial Strain Distinguishes 
Compensated from Decompensated Function in 
Pulmonary Hypertension
Marc A. Simon, Navin Rajagopalan, Angel Lopez-Candales, Matthew S. Suffoletto, 
Kathy Edelman, Michael A. Mathier, University of Pittsburgh, Pittsburgh, PA
Background: Right ventricular (RV) dysfunction confers a dismal prognosis in pulmonary 
hypertension (PH). The mechanisms of RV failure in the setting of chronic pressure 
overload are unknown.
Objective: To evaluate RV myocardial strain in PH.
Methods: Nineteen patients (age 53±12, 6 males) underwent right heart catheterization 
and 2D echo with tissue Doppler imaging of the RV. Peak longitudinal systolic strain was 
measured at the mid and basal segments of the RV free wall (RVFW) from the apical 
4-chamber view. RV fractional area change (FAC) was calculated from the same view. 
Patients were divided into 3 groups: normal (n=5), PH (MPAP > 25 mmHg, n=4), PH + RV 
Failure (PH-RVF, RA pressure > 10 mmHg or RV FAC < 0.35, n=10).
Results: Hemodynamics differed as expected (RA pressure: 7 ± 2, 7 ± 5, 12 ± 6 mmHg 
for normal, PH, PH-RVF, respectively, p=0.13; mean PA pressure: 20 ± 3, 39 ± 26, 61 ± 15 
mmHg, p=0.001; PVR: 1.3 ± 0.5, 4.4 ± 2.9, 15.6 ± 6.6 Wood units, p<0.001; cardiac index: 
3.3 ± 1.0, 2.9 ± 0.6, 1.9 ± 0.6 L/min/m2, p=0.005). RV FAC for the 3 groups was: 0.53 ± 
0.13, 0.39 ± 0.07, 0.20 ± 0.05, p<0.001. RVFW strain was significantly different between 
the 3 groups overall and by post-hoc analysis with Bonferroni correction (figure).
Conclusions: RVFW strain decreases with PH and further deteriorates in PH-RVF. 
RVFW strain appears to be useful in identifying abnormal RV deformation in PH and 
RV failure and should be further assessed as a potential mechanism of RV failure in the 
setting of chronic pressure overload. 
3:30 p.m.
1008-87 The French Registry of Pulmonary Arterial 
Hypertension in Children: Characteristics at Diagnosis
Alain Fraisse, Xavier Jais, Jean-Marc Schleich, Maurice Beghetti, Virginie Gressin, 
Michel Voisin, Claire Dauphin, Pierre Clerson, François Gaudart, Damien Bonnet, 
French Scientific Committee for Pediatric Pulmonary Hypertension, Paris, France
Background: Epidemiology and clinical data relative to pulmonary artery hypertension 
(PAH) in the pediatric population remain scarce.
Methods: This national prospective non-interventional registry was set up in the 21 
referral pediatric cardiology hospital centres in France with the objectives to describe the 
clinical, epidemiological and outcome characteristics of PAH in children. It consists of a 
transversal phase (enrolment from May 2005 to June 2006) followed by a 2-year survey. 
Patients < 18 years with PAH were included except persistent pulmonary hypertension of 
the newborn. Patients with congenital heart disease (CHD) were included only when PAH 
was not caused by left to right shunting or left heart disease.
Results: Fifty five patients have been enrolled. Preliminary results of the transversal 
phase showed that the low estimates of prevalence for pediatric PAH in France is 4.2 
cases/million of children (< 18 years) inhabitants/year. Mean age at diagnosis was 4.23 
+ 4.5 years and female/male ratio was 1/1. A history of prematurity (median: 35 weeks, 
range 29 to 36) was present in 15% of the cases. Mean delay from onset of symptoms to 
diagnosis was 5 ± 12 months. At diagnosis, 45% of patients were in NYHA III-IV functional 
class. PAH was idiopathic in 72%, familial in 11%, associated with CHD in 13%, with 
connective tissue diseases in 2% and with portal hypertension in 2% of the cases. Down 
syndrome was present in 4% whereas 6% of the patients had other genetic syndromes. 
Right heart catheterization at diagnosis revealed a mean value for pulmonary artery 
pressure, pulmonary vascular resistance and cardiac index of 58 ± 17 mmHg, 20.0 ± 
10.9 wood units and 3.3 ± 0.9 L/min/m2, respectively. 13% of the patients responded 
acutely to inhaled nitric oxide.
Conclusions: Despite rapid diagnosis after presentation, pediatric PAH is already at an 
advanced stage at this time. Prematurity, genetic syndromes and non left-to-right shunting 
CHD are frequently associated whereas connective tissue diseases and HIV infection 
are rare in children with PAH. Only few patients are acute responders to vasoreactivity 
testing.
3:30 p.m.
1008-88 Nebulized Delivery of Nano-Scale All-trans Retinoic 
Acid Particles Inhibited Monocrotaline-induced 
Pulmonary Hypertension in Rats.
Toru Takahashi, Hisae Kobayashi, Seiji Ayabe, Yoko Yamaguchi, Rie Igarashi, Minoru 
Ohno, Department of Cardiovascular Medicine,Graduate School of Medicine, The 
University of Tokyo, Tokyo, Japan, Department of Cardiology, Okinaka Memorial Institute 
for Medical Research, Toranomon Hospital
Background: Retinoic acid including all-trans retinoic acid (atRA) may have therapeutic 
potential for pulmonary hypertension/pulmonary vascular remodeling, since it has 
antimitogenic effects on smooth muscle cells. However, systemic administration of retinoid 
causes many of side effects including liver dysfunction. We postulated that treatment with 
retinoid by inhalation would be a more efficient means of targeting lung.
Methods: We prepared inorganic-coated atRA nanoparticles, in turn an egg-like structure 
in nano-scale (Nano-atRA), using boundary-organized reaction droplets. The interfacial 
properties of organic architectures, in atRA micelles, were used to template the nucleation 
of inorganic minerals. As a result, irritation and inflammation associated with atRA 
therapy were substantially reduced due to the complete encapsulation of the carboxylic 
function. Both irritative symptoms and physicochemical instability of the atRA micelle 
were improved. We have already reported that this Nano-atRA improved the permeability 
to skin and the remarkable pharmacological effects were resulted in comparison with 
um-modified atRA. In addition, nebulized delivery of atRA became possible, as it is 
dissolved in water. Male SD rats were given MCT(60 mg/kg, subcutaneously), and they 
were assigned to receive repeated inhalation of Nano-atRA (0.12%; n = 12), un-modified 
atRA(0.06%;n=5), or saline (n = 8). They were inhaled as an aerosol using an ultrasonic 
nebulizer for 60 min once a day in closed chamber.
Results: Nano-atRA significantly attenuated the elevation of peak right ventricular 
pressure (mmHg) in rats of 4-wk after MCT injection (Nano-atRA+MCT 43±1.8, un-
modified atRA+MCT 62±1.9, saline+MCT 62±3.9 and normal control 30±1.7;n=7). Right 
ventricular hypertrophy and medial wall thickness in pulmonary arteries corresponding 
to the respiratory and terminal bronchioles were also less severe in Nano-atRA -treated 
rats. Nano-atRA also phosphorylated Akt and eNOS of lung. It suggested that activation 
of eNOS may play a protective role of Nano-atRA.
Conclusions: Nebulized delivery of nano-scale atRA particles has therapeutic potential 
for pulmonary hypertension.
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1008-89 Effects of Acute Hyperglycemia On Endothelial 
Function And Inflammatory Process In Newly 
Diagnosed Diabetes Mellitus Type 2. The Impact of Diet 
and Metformine Treatment
Dimitris Tousoulis, Katerina Koniari, Charalambos Antoniades, Aggeliki Nikolopoulou, 
Vasilis Karamanos, Carmen Vasiliadou, Gerasimos Siasos, Christos Partheniou, Costas 
Tentolouris, Costas Tsioufis, Christodoulos Stefanadis, Athens University, A Cardiology 
Department, Athens, Greece
Background: The role of glucose alterations in the pathogenesis of endothelial 
dysfunction and inflammatory process in diabetic patients remains unclear. We examined 
the effect of diet or metformin on endothelial function and inflammatory process during 
glucose loading, in patients with newly diagnosed diabetes mellitus.
Methods: Twenty patients with newly diagnosed diabetes mellitus type 2 underwent 
glucose loading (75gr glucose) by admission to the protocol and 3 months after dietary 
instructions (n=12, group A) or after daily metformine administration for (n=8, group B). 
Blood samples were taken and gauge-strain plethysmography was performed at baseline 
and 3 hours after loading, while the protocol was performed after 3 months treatment. 
Endothelium dependent dilation (EDD) and endothelium-independent dilation (EID) were 
expressed as the % change of flow from baseline to the maximum flow during reactive 
hyperemia or after sublingual nitroglycerin administration respectively. SICAM-1 levels 
were determined by ELISA.
Results: In group B, EDD was significantly decreased at 1h (from 67±27% to 54±5%, 
p<0.05) and recovered at 3h after loading (66±6%, p=ns). Similarly, sICAM was slightly 
increased at 3h (from 258±22 to 372±18 ng/ml, p=ns). After dietary treatment, EDD was 
also decreased at 2h after loading (from 78±10% to 52±5%, p<0.05) and recovered at 
3h (70±9%, p=ns), while the increase of sICAM-1 at 3h was prevented (from 350±13 to 
245±11 ng/ml p<0.05). In group A, EDD was significantly decreased at 2h after loading 
(from 75±9% to 48±8%, p<0.05) and recovered at 3h (73±11%, p=ns). Metformin 
treatment significantly improved basal EDD (83±9%, p<0.05) but it had no effect on EDD 
at 2h (50±9%, p<0.05) and 3h after loading (72±4%, p=ns). Furthermore, metformin 
treatment decreased both basal sICAM-1 levels (from 422±36 to 382±35 ng/ml, p<0.05) 
and 3h after loading (from 421±34 to 377±35 ng/ml, p<0.05).
Conclusions: Acute hyperglycemia leads to endothelial dysfunction and increased 
inflammatory response, in subjects with newly diagnosed diabetes mellitus. Both diet 
and metformin improve endothelial function and decrease sICAM-1 levels in patients with 
newly-diagnosed diabetes mellitus.
3:30 p.m.
1008-118 Des-Serine-Proline B-Type Natriuretic Peptide (BNP 
3-32), Which is Produced From Mature BNP 1-32 by 
Dipeptidyl Peptidase IV, has Reduced Bioactivity
Guido Boerrigter, Lisa C. Costello-Boerrigter, Gail J. Harty, Horng H. Chen, Harald Lapp, 
John C. Burnett, Jr., Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN, 
Helios-Klinikum, Erfurt, Germany
Background: 32-amino acid B-type natriuretic peptide (BNP 1-32) plays an important 
compensatory role in cardiovascular (CV) diseases. Recently, it has been reported 
that dipeptidyl peptidase IV (DPP4) cleaves BNP 1-32 in vitro to BNP 3-32. As DPP4 
also cleaves peptides involved in glucose homeostasis, DPP4 inhibitors are in clinical 
development for diabetes mellitus. Importantly, there is evidence that DPP4 inhibitors have 
beneficial actions in CV disease models. To date, the bioactivity of BNP 3-32 in cardiorenal 
regulation as compared to BNP 1-32 is unknown. We hypothesized that BNP 3-32 has 
reduced vasodilating and natriuretic bioactivity as compared to BNP 1-32 in vivo.
Methods: We investigated the cardiorenal actions of synthetic BNP 3-32 and BNP 1-32 in 
a crossover study in eight anesthetized normal canines. After a baseline clearance, BNP 
1-32 was infused at 30 ng/kg/min. After a 15’ lead-in period a 30’ clearance was performed. 
This was followed by a 60’ washout and a 30’ post-infusion clearance. Subsequently, an 
equimolar dose of BNP 3-32 was infused with a 30’ clearance after a 15’ lead-in. In half 
the studies the peptide sequence was reversed. Peptides were compared by analyzing 
the respective changes from the preinfusion to infusion clearance with paired t-test. 
*p<0.05 between peptides. 
Results: Mean arterial pressure decreased with BNP 1-32 but not with BNP 3-32 (-
7±2 vs 0±1* mmHg). Renal blood flow increased with BNP 1-32 but not with BNP 3-32 
(+51±10 vs +11±10* mL/min). Changes in heart rate and cardiac output were similar. 
Urinary sodium excretion increased more with BNP 1-32 than with BNP 3-32 (+338±40 vs 
+128±18* uEq/min) as did urine flow (+2.8±0.4 vs +1.1±0.2* mL/min) and plasma levels 
of the second messenger cGMP (+30±1 vs +9±2* pmol/mL).
Conclusions: BNP 3-32 has markedly reduced renal vasodilating, natriuretic, and 
diuretic actions as compared to BNP 1-32, suggesting that DPP4 may have an important 
role in the regulation of BNP 1-32 bioactivity. Thus, DPP4 inhibition could be a potential 
strategy to increase the bioactivity of BNP in cardiovascular disease states. Conversely, 
BNP augmentation may be a mechanism by which DPP4 inhibition exerts beneficial 
actions in CV disease models.
3:30 p.m.
1008-119 The Primary In Vivo Metabolic Activation of Clopidogrel 
is by Hepatic and not Enterocytic Cytochrome P450 
3A4 Isoenzyme
Wei C. Lau, Lucille R. Hallock, David G. Carville, Kirk E. Guyer, University of Michigan, 
Ann Arbor, MI
Background: Clopidogrel response variability has been shown to correlate with 
cytochrome P450 (CYP)3A4 metabolic activity. To determine whether the in vivo 
metabolic activation of clopidogrel is by intestinal epithelial (enterocytic) or hepatic 
CYP3A4 isoenzyme, platelet responsiveness was determined after the co-administration 
of grapefruit juice (GFJ), a known enterocytic CYP3A4 inhibitor or erythromycin (ERM), 
a known hepatic CYP3A4 inhibitor, with clopidogrel in pre-defined clopidogrel responsive 
volunteers.
Methods: At baseline, 10 clopidogrel responsive healthy volunteers (relative platelet 
aggregation > 30% 2 hours after clopidogrel 450mg) were included in this study. After a 14 
day washout period, subjects were randomized to receive oral ERM 1gm (n=5) or GFJ 12 
ounce (n=5) 1 hour or 0.5 hours before a repeated oral dose of clopidogrel 450mg. Platelet 
aggregation (Plateletworks™, Beaumont, TX) using 20µmol/L ADP-induced aggregation 
were measured at 0 and 2 hours after clopidogrel 450mg on baseline and 14 days. In vivo 
metabolic activity of hepatic CYP3A4 was also measured using the erythromycin breath 
test (ERMBT) at 0 and 2 hours after clopidogrel 450mg at 14 days.
Results: Platelet aggregation at 2 hours after clopidogrel 450mg was increased after 
ERM as compare to baseline (74±26% vs. 19±14% p=0.003). Platelet aggregation at 
2 hours after clopidogrel 450mg increased after GFJ as compare to baseline (25±13 
vs. 54±34 p=0.1), not statistically significant. Hepatic CYP3A4 metabolic activity was 
decreased from 0 to 2 hours after clopidogrel 450mg in the group that received ERM 
(1.8± 0.3% vs. 0.8± 0.3% 14CO2 exhaled/hour, p = 0.003).
Conclusions: Data suggest that the in vivo metabolic activation of clopidogrel is primarily 
by hepatic CYP3A4 and may in part by intestinal epithelial cell CYP3A4 isoenzyme.
3:30 p.m.
1008-120 A Novel Next Generation Natriuretic Peptide: CD-NP
Ondrej Lisy, Brenda K. Huntley, Daniel J. McCormick, John C. Burnett, Jr., Mayo Clinic 
and Mayo Clinic College of Medicine, Rochester, MN
Background: C-type natriuretic peptide (CNP) is a potent anti-proliferative, venodilating 
and minimally hypotensive member of the natriuretic peptide family that functions via 
the NPR-B receptor and cGMP. CNP however lacks renal actions that may be due to 
the absence of a C-terminus amino acid (AA) sequence. We have recently reported the 
potent renal actions of the newest member of the natriuretic peptide family that is DNP 
characterized by the longest C-terminus (15 AA) of all the natriuretic peptides that may 
explain in part its potent renal actions. Our goal was to design a novel CNP-like chimeric 
peptide that possessed the cardiac unloading and anti-proliferative properties of CNP 
with minimal blood pressure lowering actions together with natriuresis, diuresis and GFR 
enhancing actions.
Methods: We designed, synthesized and defined the cardiorenal actions of a novel 
chimeric peptide CD-NP based on the 22-AA peptide CNP together with the 15-AA 
C-terminus of DNP and also compared CD-NP to BNP which functions via the NPR-A 
receptor. We also defined the anti-proliferative actions of CD-NP in cardiac fibroblasts. 
*p<0.05.
Results: In normal anesthetized dogs, CD-NP (10, 50 and 100 ng/kg/min) decreased 
MAP only at high dose (from 137±6 to 134±6 to 128±5 to 118±6* mmHg). PCWP 
decreased (from 6.4±0.4 to 5.2±0.5* to 4.4±0.6* to 3.6±0.5* mmHg) while GFR increased 
(from 37±3 to 33±2 to 50±8 to 55±6* ml/min). Sodium excretion increased (from 48±17 
to 123±23 to 326±51* to 462±69* μEq/min) as did urine flow (from 0.7±0.2 to 1.7±0.3 to 
4.0±0.7* to 4.5±0.7* ml/min). CD-NP (n=8) was less hypotensive (p<0.05) than equimolar 
BNP (n=8) in association with a greater increase in GFR (p<0.05). CD-NP suppressed 
cardiotrophin-1 stimulated cell proliferation determined by BrdU incorporation (p<0.05).
Conclusions: Our findings demonstrate the transformation of CNP into a novel chimera 
that possesses renal enhancing actions, cardiac unloading and anti-fibrotic properties. 
Importantly, its minimal hypotensive properties and beneficial renal actions are clinically 
of high priority as it may suggest a highly safe and efficacious peptide for intravenous 
infusion in cardiorenal disease states warranting further studies.
3:30 p.m.
1008-121 Saint John’s Wort Enhances Clopidogrel 
Responsiveness in Clopidogrel Resistant Volunteers 
and Patients by Induction of CYP3A4 Isoenzyme
Wei C. Lau, Paul A. Gurbel, David G. Carville, Kirk E. Guyer, Eric R. Bates, Lucille R. 
Hallock, Kevin P. Bliden, University of Michigan, Ann Arbor, MI
Background: Clopidogrel response variability has been shown to correlate with 
cytochrome P450 CYP3A4 metabolic activity. We hypothesized that a potent CYP3A4 
inducer, St. John’s Wort (SJW), would enhance clopidogrel responsiveness in clopidogrel 
resistant volunteers and patients receiving chronic clopidogrel therapy.
Methods: At baseline, clopidogrel 300mg was administered to 10 clopidogrel resistant 
volunteers and to 5 coronary stent patients receiving clopidogrel 75mg daily. After a 7 day 
and a 14 day washout period in volunteers and patients, subjects received 14 days of SJW 
300mg TID. On day 21 and 28 respectively, clopidogrel 300mg was again administered. 
Platelet aggregation was measured at 0 and 6 hours after clopidogrel 300mg at baseline, 
21 and 28 days respectively. Hepatic CYP3A4 activity was measured in volunteers using 
the erythromycin breath test at baseline and at 0 and 4 hours after clopidogrel 300mg on 
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day 21. P-selectin was measured in patients at 0 and 6 hours after clopidogrel 300mg at 
baseline and day 28.
Results: In volunteers, SJW decreased platelet aggregation after clopidogrel 300mg 
(55±14% vs. 37±14% using 20µmol/L ADP-induced aggregation, p=0.004), and increased 
CYP3A4 metabolic activity (2± 0.4% vs. 3± 0.6% 14CO2 exhaled/hour, p = 0.003). In 
patients on clopidogrel 75mg daily, SJW decreased platelet aggregation at 0 hours 
(69±6% vs 54±4%; p=0.007) and 6 hours (55±7% vs. 39±9%, p=0.02) after clopidogrel 
300mg and decreased mean fluorescence intensity for stimulated P-selectin expression 
at 0 hours (42±19 vs. 35±12, p = 0.03).
Conclusions: St. John’s Wort increased clopidogrel responsiveness in clopidogrel 
resistant volunteers and in patients receiving chronic clopidogrel therapy by induction of 
hepatic CYP3A4 isoenzyme activity.
3:30 p.m.
1008-123 The Relationship Between Plasma Fatty Acids 
Composition And Coronary Artery Disease In 
Hyperchoresterolemic Patients. ; Findings From JELIS
Hiroshige Itakura, Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji 
Matsuzawa, Yasushi Saito, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi 
Hishida, Toru Kita, Akira Kitabatake, Noriaki Nakaya, Toshiie Sakata, Kazuyuki Shimada, 
Kunio Shirato, JELIS Investigators, Ibaraki Christian University, Hitachi, Japan
Background: The Japan EPA (eicosapentaenoic acid) Lipid Intervention Study (JELIS) 
was a prospective randomized open-label blinded endpoint trial that examined the effects 
of EPA on hypercholesterolemia and in preventing coronary artery disease (CAD). We 
measured plasma fatty acids composition and analyzed it about connection with the onset 
of CAD.
Methods: We analyzed plasma fatty acid composition data from JELIS, a randomized 
trial of EPA + statin (EPA group; n=7,812) versus statin only (control group; n=7,722) in 
15,534 patients with total cholesterol level of at least 250 mg/dL (7.1 mmol/L). The primary 
endpoint was major coronary events (MCE: sudden cardiac death, fatal and nonfatal 
myocardial infarction (MI), unstable angina pectoris including hospitalization for ischemic 
episodes, and events of angioplasty/stenting or coronary artery bypass grafting). Plasma 
fatty acids composition was determined by capillary gas chromatography. We calculated 
the relationship between average level of plasma fatty acids during on-treatment period 
and the incidence of CAD.
Results: As a result of EPA intervention, oleic acid, n-6 fatty acid (linoleic acid and 
arachidonic acid) composition decreased. There were slight changes of palmitic acid and 
stearic acid composition. The EPA composition increased, but the docosahexaenoic acid 
composition did not increase. Relation between CAD and fatty acids composition, it was 
not clear in palmitic acid, but high composition of stearic acid significantly contributed 
(P=0.004) to the lowering of CAD. A high oleic acid/EPA ratio was a risk of CAD significantly 
(P=0.021). A high n-6 fatty acids/EPA ratio was also a risk of CAD significantly (P=0.014). 
A high EPA composition significantly contributed (P=0.018) to the prevention of CAD, but 
it was not significantly in docosahexeanoic acid.
Conclusions: Plasma fatty acids composition changes by treatment of 
hypercholesterolemia with EPA. Increase of oleic acid and n-6 fatty acids composition 
increase a risk of the CAD, but EPA and stearic acid composition reduce the incidence 
of CAD.
3:30 p.m.
1008-124 Statins Reduce The Risk of Death and The Occurrence 
of Adverse Cardiovascular Events in Patients with 
Dyslipidemia and Renal Dysfunction: A Meta-analysis 
of Randomized Placebo-Controlled Clinical Trials
Sandeep A. Saha, Adonis Saremi, Jose-Luis Velasquez-Cecena, Rohit R. Arora, Internal 
Medicine and Cardiology, The Chicago Medical School, North Chicago, IL
Background: Statins significantly reduce cardiovascular morbidity and mortality in 
various high-risk patient populations, but their role in patients with renal insufficiency is 
unclear. We therefore conducted a meta-analysis of randomized clinical trials to evaluate 
the role of statins in the prevention of cardiovascular events in dyslipidemic patients with 
varying degrees of renal dysfunction.
Methods: A total of 22,309 patients from 8 published randomized placebo-controlled 
trials were analyzed using the Mantel-Haenszel fixed effects model. Relative risks were 
computed for various cardiovascular outcomes, and compared using the Chi-square test 
(two-sided alpha error <0.05).
Results: When compared to placebo, statins significantly reduced the risk of all-cause 
mortality by 19% (p<0.00001) in patients with chronic kidney disease, with a cumulative 
risk reduction of 14% (p<0.0001) on pooled meta-analysis. The use of statins also 
significantly reduced the risk of adverse cardiovascular events (composite of cardiac 
death, non-fatal myocardial infarction, and invasive coronary revascularization) by 22% 
(p<0.00001), with significant benefit observed in all subgroups studied. The risk of 
cerebrovascular events, however, was not significantly affected.
Conclusions: Our meta-analysis revealed that statins significantly reduce the risk of 
death and occurrence of adverse cardiovascular events in dyslipidemic patients with 
renal dysfunction. 
3:30 p.m.
1008-125 The Long-Term Safety and Efficacy of Combined 
Simvastatin and Fenofibrate Therapy in Diabetic 
Patients with Dyslipidemia: The DIACOR Study
Heidi T. May, Robert R. Pearson, Jonathan R. Jensen, Benjamin D. Horne, Jeffrey L. 
Anderson, Jamie M. Whetstone, Joseph B. Muhlestein, LDS Hospital, Salt Lake City, UT, 
University of Utah, Salt Lake City, UT
Background: Type II diabetes (DM), a strong risk factor for cardiovascular disease (CVD), 
is often characterized by mixed dyslipidemia (MD). Many diabetic patients are unable to 
achieve optimal lipid levels with a single lipid-lowering agent. It has been suggested that 
combination statin and fibrate therapy might be more effective. To more fully establish 
safety and efficacy we performed the DIACOR study.
Methods: Patients with DM and no history of CAD were considered for the study 
(N=498). Eligible patients underwent a 6-8 week washout period, were enrolled if they 
demonstrated MD (having 2 of 3: LDL >100 mg/dL, triglycerides >200 mg/dL, or HDL <40 
mg/dL), and were randomized to receive simvastatin (S) 20 mg, fenofibrate (F) 160 mg, or 
the combination (C) for 12 weeks. After 12 weeks, all patients received C for 9 months.
Results: A total of 300 patients (age = 61±11 yrs, males = 55%) were randomized. 
Changes in lipids (mg/dL) for patients receiving monotherapy initially of F or S to C are: 
Change in Total 
Cholesterol
Change in 
LDL
Change in 
HDL
Change in 
VLDL
Change in 
Triglycerides
F to 
C -36.6, p<0.001
-33.8, 
p<0.001 -1.6, p=0.04 -4.0, p=0.003 -14.1, p<0.001
S to 
C -10.3, p=0.002 -3.2, p=0.30 1.2, p=0.07 -9.5, p<0.001 -52.0, p<0.001
No cases of rhabdomyolysis, clinical myopathy (CK>10 ULN), persistent myalgias, 
adverse hepatic events or serious drug-related adverse events were identified throughout 
the entire year of therapy. 
Conclusion: In this 1-year randomized trial of DM pts, combination therapy of S (20 mg) 
and F (160 mg) was safe, well-tolerated and more effective in positively affecting lipids 
than either form of monotherapy. Whether higher doses of statin in combination with F 
may be even more effective and safe remains to be determined.
3:30 p.m.
1008-126 Lipid-independent Effects of Statins on Cardiovascular 
Events in the Japanese Coronary Artery Disease 
Study: Comparison Between Hydrophilic and Lipophilic 
Statins
Masatoshi Fujita, Tsutomu Yamazaki, Dobun Hayashi, Ryozo Nagai, The JCAD Study 
Investigators, Faculty of Medicine, Kyoto University, Kyoto, Japan, University of Tokyo, 
Tokyo, Japan
Background: Statins may have a wide range of beneficial biologic effects in addition to 
lipid lowering, and these effects may differ according to their lipophilicity. We evaluated the 
pleiotropic effect of statins on cardiovascular events and compared their effects beyond 
lipid lowering between the hydrophilic and lipophilic statins.
Methods: Patients angiographically diagnosed as having higher than 50% narrowing in at 
least one branch of the coronary arteries were enrolled in the Japanese Coronary Artery 
Disease (JCAD) study. We analyzed 6,317 patients with a baseline LDL-cholesterol level 
of 70 to 130 mg/dL among 15,628 patients of the study. We divided the patients into two 
groups according to statin treatment and then its lipophilicity.
Results: We evaluated the incidence of all-cause cardiovascular events in 2,000 statin-
treated patients and 4,317 patients without statins during a mean follow-up period of 
983 days. Multivariate logistic regression analysis revealed independent predictors of the 
events to be statin treatment, age, hypertension, impaired glucose tolerance, congestive 
heart failure, left main trunk disease and the number of coronary artery involvement. 
After propensity score matching (n=1,641, for each group), Kaplan-Meier analysis 
showed 25% reduction in the incidence of events with statin treatment (hazard ratio, 
0.746, 95% confidence interval, 0.622-0.896, p=0.0016). The incidence of the events was 
also compared between 1,139 patients with the hydrophilic statin and 861 patients with 
lipophilic statins. Multivariate logistic regression analysis revealed independent predictors 
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of the events to be congestive heart failure and the number of coronary artery involvement. 
After propensity score matching (n=778, for each group), Kaplan-Meier analysis showed 
18% reduction in the incidence of events with lipophilic statin treatment (hazard ratio, 
0.815; 95% confidence interval, 0.603-1.102, p=0.1838).
Conclusion: Subgroup analysis of the JCAD study revealed a definite lipid-independent 
beneficial treatment effect of statins on all-cause cardiovascular events, and these 
favorable effects were comparable between the hydrophilic and lipophilic statins.
3:30 p.m.
1008-127 Association Between Baseline LDL-C, TG, and HDL-C 
Levels and the Lipid-altering and hsCRP Efficacy of 
Ezetimibe/simvastatin Versus Atorvastatin in Patients 
With Type 2 Diabetes and Hypercholesterolemia: The 
VYTAL Study
Ronald B. Goldberg, John R. Guyton, Theodore Mazzone, Ruth S. Weinstock, Adam 
Polis, Joanne E. Tomassini, Andrew M. Tershakovec, Diabetes Research Institute, Miller 
School of Medicine, University of Miami, Miami, FL, Merck & Co., Inc., West Point, PA
Background: Baseline LDL-C, TG and HDL-C levels are important factors to consider in 
the treatment of dyslipidemia in type 2 diabetes (T2DM) patients. The association of these 
factors with % changes from baseline in LDL-C, HDL-C, TG, non-HDL-C, Apo B, Apo A-I 
and hsCRP, and % patients who attained LDL-C <70 and <100 mg/dL was assessed in 
hypercholesterolemic, T2DM patients treated with Ezetimibe/simvastatin 10/20 and 10/40 
mg versus Atorvastatin 10, 20 and 40 mg.
Methods: Subgroup analysis of a multicenter, randomized, double-blind, 6 wk parallel 
study. Association of baseline LDL-C stratum, TG and HDL-C levels with efficacy 
measures was assessed at all doses and across doses.
Results: Greater % reductions in LDL-C, non-HDL-C and Apo B, and lower LDL-C target 
attainment were generally associated with increasing LDL-C stratum (see table). Baseline 
TG >150 mg/dL was associated with greater % increases in HDL-C and decreases in 
TG than TG <150 mg/dL. Reductions in hsCRP were greater at TG <150 mg/dL. Larger 
% increases in HDL-C and Apo A-I, smaller % decreases in non-HDL-C, and generally 
greater % decreases in TG were observed with baseline HDL-C <40 and <50 mg/dL 
than >40 and >50 mg/dL (men and women respectively). Treatment differences in the 
subgroups were consistent with the significantly greater effects of E/S versus A observed 
in the whole cohort.
Conclusions: Baseline LDL-C, TG and HDL-C levels may impact lipid treatment in T2DM 
patients and should be considered in the management of dyslipidemia in this setting. 
% Change From Baseline* (SE)
LDL stratum+ Treatment
LDL-C mg/dL Non-HDL
mg/dL
Apo B
mg/dL
HDL-C
mg/dL
TG#
mg/dL(mg/dL) Group N
>100-<130 A10 88 -35.6 (1.5) -32.2 (1.3) -27.9 (1.4) 4.1 (1.2) -19.8 (3.2)
>130-<160 A10 83 -37.9 (1.5) -34.4 (1.4) -31.2 (1.5) 4.2 (1.3) -24.3 (0.7)
>160-<190 A10 43 -39.4 (2.1) -35.3 (1.9) -28.4 (2.1) 2.9 (1.8) -21.0 (3.4)
>190 A10 23 -40.9 (2.9) -37.4 (2.6) -33.8 (2.8) 6.9 (2.4) -23.5 (3.4)
>100-<130 A20 85 -42.3 (1.5) -38.5 (1.4) -33.8 (1.5) 2.5 (1.3) -25.2 (2.1)
>130-<160 A20 84 -44.5 (1.5) -41.4 (1.4) -36.4 (1.5) 4.7 (1.3) -28.4 (1.4)
>160-<190 A20 47 -45.0 (2.0) -41.9 (1.8) -36.2 (1.9) 6.3 (1.7) -26.4 (4.9)
>190 A20 24 -45.7 (2.8) -41.5 (2.6) -36.0 (2.7) 6.1 (2.4) -19.0 (4.8)
>100-<130 A40 89 -50.1 (1.5) -45.6 (1.3) -40.1 (1.4) 1.1 (1.2) -29.2 (2.9)
>130-<160 A40 83 -50.0 (1.5) -44.4 (1.4) -39.5 (1.5) 3.2 (1.3) -30.0 (3.0)
>160-<190 A40 46 -52.2 (2.0) -47.4 (1.9) -38.3 (2.0) 3.5 (1.7) -28.8 (3.6)
>190 A40 23 -47.3 (2.9) -44.1 (2.6) -38.4 (2.8) 0.2 (2.4) -23.8 (8.8)
>100-<130 E/S20 86 -53.0 (1.5) -46.9 (1.4) -38.6 (1.4) 8.9 (1.3) -25.7 (2.4)
>130-<160 E/S20 83 -50.0 (1.5) -44.6 (1.4) -37.4 (1.5) 7.9 (1.3) -24.1 (2.8)
>160-<190 E/S20 47 -56.0 (2.0) -50.3 (1.8) -44.4 (2.0) 5.7 (1.7) -24.8 (4.5)
>190 E/S20 22 -56.8 (2.9) -51.3 (2.7) -44.6 (3.0) 7.9 (2.5) -33.5 (1.5)
>100-<130 E/S40 91 -54.5 (1.4) -48.2 (1.3) -41.6 (1.4) 5.7 (1.2) -25.3 (3.1)
>130-<160 E/S40 83 -56.0 (1.5) -50.3 (1.4) -43.2 (1.5) 6.0 (1.3) -28.5 (3.0)
>160-<190 E/S40 45 -59.8 (2.1) -54.6 (1.9) -47.2 (2.0) 6.9 (1.7) -33.6 (3.2)
>190 E/S40 23 -63.2 (2.9) -57.5 (2.6) -49.7 (3.0) 7.2 (2.4) -31.6 (4.3)
ES = Ezetimibe/simvastatin and A = Atorvastatin.
*LS Means; +LDL-C baseline stratum levels were determined one week before active 
therapy; #median
The effect of LDL-C stratum was significant with regard to % change from baseline in 
LDL-C (p=0.003),
Non-HDL-C (p<0.001) and Apo B (p=0.004); but was not significant with regard to % 
change from baseline in
HDL-C (p=0.807) or TG (p=0.740).
The interaction of LDL-C stratum with statin therapy was not significant with regard to 
% change from baseline
in LDL-C (p=0.160), HDL-C (p=0.531), Non-HDL-C (p=0.127), or TG (p=0.420); but was 
significant with
regard to % change from baseline in Apo B (p=0.013).
3:30 p.m.
1008-129 Non-Steroidal Anti-Inflammatory Drugs Antagonise the 
Irreversible Antiplatelet Effect of Aspirin
Patrick A. Gladding, Mark W. Webster, Helen Farrell, Irene Zeng, Robert Park, Nicola 
Ruijine, Greenlane Cardiovascular Service, Auckland, New Zealand
Background: Patients with cardiovascular disease taking some non-steroidal anti-
inflammatory drugs (NSAIDs) appear to have increased vascular events. One possible 
mechanism is that NSAIDs may compete with aspirin for binding at the active site of 
the Cyclooxygenase-1 enzyme. This study evaluates whether commonly used NSAIDs 
antagonise the antiplatelet effects of aspirin.
Methods: We assessed the effect of six NSAIDs (naproxen, ibuprofen, celecoxib, 
indomethacin, tiaprofenic acid slow acting (SA) and sulindac) on platelet function (PFA-
100 epinephrine closure time [CEPI]), urine 11-dehydro-thromboxane B2 (TxB2), and 
urine 6-keto-prostaglandin F1alpha and its dinor derivative (PGF1), in two groups of twelve 
healthy subjects, in a multiple crossover study. The effect of each NSAID was assessed 
at the end of a twelve-hour dosing interval. The NSAID was then given 2 hours before a 
300mg dose of aspirin, and platelet function assessed 24 hours later.
Results: At the end of a twelve hour dosing interval naproxen and tiaprofenic acid SA 
had a significant antiplatelet effect and prolonged the CEPI closure time. Ibuprofen, 
indomethacin and celecoxib had no significant antiplatelet effect. Ibuprofen (P<0.001), 
indomethacin (P<0.005), naproxen (P=0.05) and Tiaprofenic acid SA (P=0.01) prevent 
prolongation of PFA-100 closure time by aspirin.
Conclusions: Naproxen and tiaprofenic acid have a significant antiplatelet activity, as 
measured by a high shear stress platelet function analyzer, at the end of a twelve hour 
dosing interval. Patients recently administered ibuprofen, indomethacin, tiaprofenic acid 
or naproxen will be resistant to the antiplatelet effect of 300mg aspirin
3:30 p.m.
1008-130 Simvastatin Exerts its Anti-inflammatory Effect in 
Hypercholesterolaemic Patients Mainly by Decreasing 
the Serum Levels of Monocyte Chemoattractant 
Protein-1
Loukianos Rallidis, Eftichia Hamodraka, Georgios Moustogiannis, Katerina Fountoulaki, 
Maria Zolindaki, Dimitrios Kremastinos, University General Hospital, Attikon, Athens, 
Greece, General Hospital of Nikea, Piraeus, Greece
Background: Although in vitro studies have shown that statins attenuate the expression 
of monocyte chemoattractant protein-1 (MCP-1), clinical studies have shown conflicting 
data. We assessed the effect of simvastatin on serum levels of MCP-1, interleukin-6, tumor 
necrosis factor α, macrophage colony stimulating factor, C-reactive protein and serum 
amyloid A in hypercholesterolaemic patients without coronary heart disease (CHD).
Methods: Sixty consecutive hypercholesterolaemic (low density lipoprotein [LDL] 
cholesterol >160 mg/dl) patients < 70 years were randomly assigned in a 2:1 process 
to form two groups: the simvastatin group (n=40) placed on 40 mg of simvastatin for 
3 months and the control group (n=20) placed on hypolipidaemic diet for 3 months. 
Exclusion criteria included lipid lowering medication the previous 4 months, CHD, 
diabetes mellitus, hypertension and chronic inflammatory disease or any acute illness. 
Blood samples were taken at baseline and at the end of the study and analysed for lipids 
and inflammatory markers.
Results: Fifty-three subjects completed the study (35 from the simvastatin and 18 
from the control group). The two groups did not differ regarding age, sex, proportion 
of smokers, body mass index and baseline serum levels of lipids and inflammatory 
markers. From the inflammatory markers only MCP-1 (217.4 ± 48 versus 177 ± 74.7 
pg/ml, p<0.001) was decreased significantly after treatment with simvastatin. From the 
lipids total cholesterol, LDL cholesterol and triglycerides were also decreased significantly 
(p<0.001) after treatment with simvastatin. The reduction of MCP-1 was independent of 
lipid changes. There were no significant changes in the control group regarding the lipids 
and inflammatory markers after 3 months of hypolipidaemic diet.
Conclusions: Simvastatin, among a variety of inflammatory markers, significantly 
decreases only MCP-1 levels in hypercholesterolaemic non-coronary patients. The 
selective reduction of MCP-1 suggests that this molecule is probably a sensitive marker to 
detect the anti-inflammatory effect of statins in blood and an optimal target to favourably 
affect the atherosclerotic process in early stages.
3:30 p.m.
1008-131 Using Waist Circumference to Screen for Metabolic 
Syndrome in an Inpatient Population
Joseph Cherian, Seema Sidwani, Catherine Wood, Phenu Zachariah, Parag Patel, 
Advocate Lutheran General Hospital, Park Ridge, IL
Background: Waist circumference is an established criterion for clinical diagnosis of 
metabolic syndrome (MetS) by both International Diabetes Federation (IDF) and Adult 
Treatment Panel III (NCEP/ATP III). The efficacy of using this parameter in screening 
inpatients for MS with IDF guidelines was studied. Prevalence of MetS using IDF 
guidelines was compared to NCEP/ATP III criteria in the same inpatient population.
Methods: A three-month prospective study was conducted on 468 adult patients admitted 
to telemetry units (211 men and 257 women). Waist circumference measurements were 
performed on admission by nursing or housestaff. Additional data collected included 
fasting lipid panel, fasting plasma glucose and AM blood pressure.
Results: Compliance of measuring waist circumference initially was 85%. The sample 
included: 20% (92 patients) with coronary heart disease (or CHD equivalent) and 29% 
(137 patients) with diabetes. 72% (337) of all patients met waist measurement criteria 
using the IDF criteria. 88% (328) of patients meeting the waist circumference requirement 
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also met additional criteria for MetS using IDF guidelines. 72% (328) of all patients were 
classified with MetS using IDF guidelines versus 59% (275) using NCEP/ATP III guidelines 
(p <0.001). Prevalence of MetS in men using IDF was 71% and NCEP was 56%. The 
prevalence of MetS in women using IDF and NCEP was 70% and 60%, respectively.
Conclusions: Measuring waist circumference on admission increased identification 
of patients with MetS. IDF was superior to NCEP/ATP III criteria in identifying patients 
with MetS. Higher prevalence of MetS with IDF may be due to the reduced waist size 
criteria and is consistent with previously reported data. Our findings showed that waist 
measurement using IDF criteria had a sensitivity of 88% for MetS patient identification. 
Our results support published reports that prevalence of MetS has been increasing over 
the past decade. Incorporating waist circumference in the admission assessment clearly 
identifies the high risk MetS patient. Diagnosing MetS in the inpatient setting provides an 
opportunity to initiate aggressive treatment and risk factor reduction.
3:30 p.m.
1008-160 Prediction of Future Cardiovascular Disease by 
Monocyte Count in an Asymptomatic Population
Deirdre F. Waterhouse, Ronan A. Cahill, Charles J. McCreery, Aidan E. Buckley, Wexford 
General Hospital, Wexford, Ireland, St Vincent’s University Hospital, Dublin, Ireland
Introduction: Although atherogenesis is associated with systemic inflammation and 
local macrophage-monocyte interaction underlies atherosclerotic plaque disruption, the 
relationship between preclinical and overt cardiovascular disease (CVD) and systemic 
white blood cell (WBC) subtypes remains unclear.
Methods: 1383 asymptomatic individuals (795 men, 588 women) attending for 
executive health screening were examined clinically to determine their ten-year risk of 
developing overt cardiovascular disease (as estimated by both Framingham and SCORE 
calculations). In addition, all participants underwent full blood count and fasting lipid and 
glucose profiling. Cardiovascular risk was correlated with overall WBC and subtypes 
using both univariate and multiple regression analysis.
Results: Of all WBC subtypes, monocyte count was found to have the strongest, 
independent relationship with overall CVD risk (Framingham β = 1.364; p = 0.01; SCORE β 
= 2.931; p = <0.0005). Independent associations with BMI (β = 5.214; p = <0.0005), waist 
circumference (β = 21.866; p = <0.0005), systolic blood pressure (β = 10.738; p = 0.003), 
HDL cholesterol (β = -0.639; p = <0.0005) and triglyceride concentrations (β = 0.787; p = 
<0.0005) were also apparent from this study. Neutrophils, lymphocytes and basophils were 
variably (but less strongly) associated with increased cardiovascular risk parameters.
Conclusions: Monocyte count, a simple inexpensive test, is associated with increased 
cardiovascular risk and may potentially be useful in identifying at risk individuals at a 
preclinical stage.
3:30 p.m.
1008-161 Having A Hobby Produces Desirable Cardiovascular 
Prognosis By Maintaining Favorable Coronary 
Endothelial Function
Keishi Saihara, Shuichi Hamasaki, Akinori Masuda, Sanemasa Ishida, Tetsuro Kataoka, 
Akiko Yoshikawa, Masakazu Ogawa, Tsuyoshi Fukudome, Noya Oketani, Hideki Okui, 
Takuro Shinsato, Takuro Kubozono, Hitoshi Ichiki, So Kuwahata, Shoji Fujita, Kaai 
Tomita, Chuwa Tei, Kagoshima University, Kagoshima University, Japan
Background: Several reports have demonstrated psychosocial stress as a risk- and 
prognostic factor in coronary artery disease. Moreover, the prognostic value of coronary 
endothelial dysfunction has been demonstrated. Therefore, we investigated the effect of 
having a hobby on coronary endothelial function and cardiovascular prognosis.
Methods: A total of 176 patients (57 women, 61±14 yrs) with normal or mildly diseased 
coronary arteries (%diameter stenosis < 30%) underwent Doppler flow study of the left 
anterior descending coronary artery. Coronary vascular reactivity was examined by 
intra-coronary administration of papaverine, acetylcholine (Ach), and nitroglycerin using 
a Doppler guidewire. The patients enrolled in this study were divided into two groups 
according to whether they had a hobby or not. Hobby group consisted of 109 patients who 
enjoyed a hobby. Non-hobby group consisted of 67 patients who had no hobby. Follow-
up data was obtained by questionnaire surveys about major advanced coronary events 
(MACE). The composite endpoint of MACE, defined as cardiovascular death, non-fatal 
myocardial infarction, and coronary revascularization. Coronary vascular reactivity and 
MACE ratio were compared between the two groups. Statistical analysis was performed 
by the Mann-Whitney U test and Kaplan-Meyer analysis.
Results: The average follow-up period was 1100±576 days. There were no significant 
differences in age, gender, echocardiographic parameters, and coronary risk factors when 
comparing the two groups. The percent increase in coronary artery diameter induced by 
Ach in Hobby group was significantly greater than that in Non-hobby group (5.7±13.6% 
vs. 0.1±15.1%, P=0.03). Kaplan-Meyer curve analysis showed that MACE rate in Hobby 
group were significantly smaller than that in Non-Hobby group (P=0.003).
Conclusions: This preliminary study suggests that having a hobby is considered to be 
important for improving their cardiovascular prognosis by maintaining favorable coronary 
endothelial function in patients with normal or mildly diseased coronary arteries.
3:30 p.m.
1008-162 Impact of a Cardiovascular Limited Ultrasound 
Examination Using a Hand-Carried Ultrasound Device: 
Changes in Clinical Management Outcomes in a 
Primary-Care Clinic
Bruce J. Kimura, David J. Shaw, Donna L. Agan, Stan A. Amundson, Andrew C. Ping, 
Anthony N. DeMaria, Scripps Mercy Medical Center, San Diego, CA, University of 
California, San Diego, CA
Background: Although limited ultrasound imaging can detect carotid atheroma (CA), systolic 
dysfunction of the left ventricle (SD), left atrial enlargement (LAE), and abdominal aortic 
aneurysm (AAA), few data exist on the application of a formulated screening cardiovascular 
limited ultrasound examination (CLUE) during a typical outpatient visit using a hand-carried 
ultrasound device. Therefore, we evaluated the clinical impact of a CLUE designed to 
detect CA, SD, LAE and AAA on patient management in an outpatient medical clinic.
Methods: A convenience sample of 196 patients awaiting routine primary-care 
appointments underwent cardiovascular evaluation including chart review, CHD risk 
stratification by NCEP/ATP III guidelines and CLUE evaluation with a hand-carried 
ultrasound device (SonoSite 180) equipped with cardiac and vascular transducer probes. 
CLUE included a brief, 5 minute gray-scale scanning of the carotid arteries for CA, 
the heart for SD and LAE using the standard parasternal long-axis view, and the intra-
abdominal aorta for AAA. Clinical management recommendations were made if the CLUE 
finding was unsuspected and could affect CHD risk prevention strategies or result in 
referral for formal testing or consultation. The prevalence of an abnormal CLUE and its 
effect on clinical management was tabulated and stratified by CHD risk class and age.
Results: Patient mean age was 56 ±14 years (range: 22-95 yrs.); 42.9% were male; and 
32.7% were low, 30.1% were intermediate, and 37.2% were high-risk CHD classes. Of 
the 196 CLUE exams, abnormalities were seen in 36.2% (32.7% had CA, 3.1% had SD, 
6.1% had LAE, and 1.0% had AAA) and were related to increasing age, increasing CHD 
risk, and male gender. Overall, the CLUE exam resulted in new clinical management 
recommendations in 20% of cases, primarily in CHD risk prevention. In the intermediate 
CHD risk patients, CLUE was abnormal in 44% and resulted in the highest percentage of 
recommended management changes, in 39% of patients.
Conclusion: When applied to a clinic population, a brief cardiovascular ultrasound screening 
exam frequently demonstrates unsuspected findings that can change clinical management.
3:30 p.m.
1008-163 C-Reactive Protein, Traditional Risk Factors And 
Anthropometric Features In Chilean Children
Monica Acevedo, Pilar Arnaiz, Salesa Barja, Ximena Berrios, Pontificia Universidad 
Católica, Santiago, Chile
Background: C-reactive protein (CRP) is a novel cardiac risk marker. In adults, it has been 
related to metabolic risk factors and cardiovascular events. However, there are scarce 
data about CRP in children. We sought to evaluate the relationship between CRP and 
anthropometric features and classical risk factors in children.
Methods: Prospective study in the offsprings of healthy subjects who participated in a 
poblational study in Santiago, Chile. We applied a survey about traditional risk factors, and 
determined anthropometric measurements, fasting lipid profile, glycemia and C-reactive 
protein levels.
Results: We studied 88 children (51% boys), mean age 10 ± 2 yo. Mean CRP was 1 ± 
1.65 mg/L (median = 0.49). In both boys and girls, CRP significantly correlated with the % 
of total fat mass, subescapular to tricipital fold ratio, BMI, waist and LDL and triglycerides 
levels. Children in the highest CRP tertile presented with significantly higher BMI, % of 
total fat, LDL, and waist than children in the lower tertiles (table). Multivariate regression 
analysis showed that the most important factors for high CRP were the % of total fat 
(r=0.37, p=0.0006), waist (r=0.35, p=0.0008) and z score BMI (r=0.35, p=0.0006).
Conclusions: CRP levels in children were significantly associated with anthropometric 
measurements of obesity and high cholesterol. Fat body mass, waist and BMI were the 
best predictors of high CRP. The prognostic value of CRP in the early development of 
atherosclerosis in children deserves investigation.
CRP tertile 
<0.27 (mg/L)
CRP tertile 0.27 
- 0.69 (mg/L)
CRP tertile 
>0.69 (mg/L)
Variable Mean SD Mean SD Mean SD P trend*
Age (yo) 10 2 10 2 10 2 NS
BMI 18 3 19 3 21 4 0.0008
Total fat mass 
(%) 21 9 22 9 29 9 0.0004
LDLc (mg/dl) 77 20 79 20 84 25 0.04
HDLc (mg/dl) 55 10 53 13 55 10 NS
Triglycerides 
(mg/dl) 67 34 64 30 69 28 NS
Glycemia 
(mg/dl) 84 6 85 4 83 6 0.03
Waist (cm) 66 8 68 9 73 12 0.008
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1008-164 Genetic Variation in UDP-Glucuronosyltransferase 1 
Family Polypeptide A7 (UGT1A7) and Coronary Heart 
Disease: The Atherosclerosis Risk in Communities 
(ARIC) Study
Daniel A. Canos, Yu Yan, Christy L. Avery, Molly S. Bray, David J. Couper, Charles L. 
Poole, Andrew F. Olshan, Gerardo Heiss, Kari E. North, University of North Carolina, 
Chapel Hill, NC
Background:There is strong evidence supporting a causal association of cigarette 
smoking with atherosclerosis and its clinical manifestations but the mechanisms by which 
cigarette smoking causes coronary heart disease (CHD) are not well understood. UDP-
glucuronosyltransferase 1 family polypeptide A7 (UGT1A7) has been implicated in the 
conjugation and detoxification of the tobacco carcinogen benzo(a)pyrene. We conducted 
a series of case-cohort analyses to measure the association between smoking history 
and CHD events to estimate whether variation in UGT1A7 modifies these associations 
in the ARIC cohort.
Methods:We analyzed incident CHD cases 1987-1998 (n=1086) and a random sample 
within strata of age, sex and race (n=1065) at baseline from the 15,792 participants. 
We identified 13 tag single nucleotide polymorphisms (SNPs) in Caucasians and 16 tag 
SNPs in African Americans (AA), from a total of 21 SNPs. Associations of CHD with 
smoking status (ever/never) and genotype were evaluated by incidence rate ratios (IRR) 
with controls weighted proportionately to their person-time at risk. All analyses were 
adjusted for the sample-stratification factors and study center. Departures from additivity 
were assessed by estimating interaction contrast ratios (ICR).
Results:Several of the tag SNPs displayed interactions with smoking exposure. Among 
AA and Caucasians, rs1042640 had an association suggestive of antagonism of the 
causative effect of smoking on CHD [ICR=-1.2(-2.5, 0.2)] and [ICR=-0.6(-1.2, 0.1)], 
respectively. Among AA, the estimated IRRs for smoking alone, this genotype alone, and 
both exposures were 2.0(1.2, 3.2), 1.6(0.9, 2.8) and 1.4(0.8, 2.4), respectively. Similarly, 
the IRR estimates for Caucasians were 1.9(1.4, 2.5), 1.1(0.7, 1.5) and 1.3(1.0, 1.9), 
respectively. In contrast, SNP rs11563251 synergistically enhanced the effect of cigarette 
smoking on CHD [ICR=0.9(-0.3, 2.0)] in AA participants only. The estimated IRRs for 
smoking alone, genotype alone, and both exposures were 1.4(0.7, 2.6), 1.6(0.9, 2.9) and 
2.8(1.6, 5.1), respectively.
Conclusions:This pattern of results raises the possibility that UGT1A7 variants influence 
susceptibility to smoking-related CHD.
3:30 p.m.
1008-165 Secular Trends and Mortality Causes in Women Over 
the Last 24 Years in Argentina
Maria I. Sosa Liprandi, Paola S. Harwicz, Alvaro Sosa Liprandi, Instituto Medico de Alta 
Complejidad, Buenos Aires, Argentina
Background: Our aim was to analyse the contemporary trends in women mortality, from 
1980 to 2004 in Argentina, and evaluate the impact of cardiovascular mortality at different 
ages.
Method: We used the data base of vital statistics from the National Program of Health 
Statistics. The codification was based on the International Classification of Diseases 
(9th and 10th). We calculated the annual mortality rate in the general population and the 
specific rate adjusted for age and sex per 100,000 according to national census data. 
Spearman Rank Correlation test was used to study secular trends in mortality.
Results: Cardiovascular mortality decreased from 1980 (380/100,000) to 2004 (238/100,000) 
in both sexes (37% reduction, ρ=-0.97, p<0.0001). The downward trend was similar in men 
(36%) and women (33%). In 2003, the mortality for cardiovascular diseases in women was 
superior to all cancer combined (32% versus 18%) being stroke the main cause of death in 
women < 75 years old and heart failure in those older than 75.
Causes of Cardiovascular Mortality in 2003. Deaths per 100,000 population
Age 
Years
AMI 
Men
AMI 
Women
CHF 
Men
CHF 
Women
CAD 
Men
CAD 
Women
Stroke 
Men
Stroke 
Women
35-44 253 79 187 101 289 55 366 259
45-54 958 221 485 292 1155 255 1151 685
55-64 1715 523 1608 714 2340 649 1943 1094
65-74 2495 1163 3241 1917 3403 1515 2296 2085
>75 3138 3512 7579 12279 4645 5353 4895 7241
Since 1980, the relative frequency of cardiovascular deaths for females has exceeded 
those for men.
Conclusion: Cardiovascular mortality is the leading cause of death among women 
in Argentina. The highest impact was observed in women older than 75, doubling the 
mortality rate for heart failure and stroke in men.
3:30 p.m.
1008-166 Clusters Of Cardiovascular Risk Factors As Predictors 
Of Atrial Fibrillation And The Impact On Stroke.
Leonardo Tamariz, Bill West, Gordon Chen, Ana Palacio, University of Miami, Miami, FL
Background: Atrial fibrillation (AF) is the most common arrhythmia in clinical practice 
and is associated with an increased risk of stroke and mortality. Obesity, hypertension 
and diabetes are independent predictors for the development of AF. We evaluated the 
association between clusters of cardiovascular (CV) risk factors and AF.
Methods: Using claims data from a large health benefits company we identified 
381,252 subjects with at least one CV risk factor: hypertension, obesity, diabetes, and 
lipid abnormalities. We defined stroke using the corresponding ICD-9 code. Within this 
population we identified individuals with AF to determine the cross-sectional probability of 
having AF using logistic regression. Then in a retrospective cohort study of those with AF 
we evaluated the predictive value of the clusters of CV risk factors to identify those that 
developed stroke using cox proportional hazard models.
Results: We identified 13,200 individuals with AF with a mean age of 71±12.6 years. The 
prevalence of AF increased from 1% in subjects with one risk factor to 5% in subjects with 
four risk factors. The odds ratio of having AF in those with four risk factors compared to 
those with one was 1.4; 95% CI 1.2 - 1.6, after adjusting for demographics, mitral disease, 
heart failure and coronary artery disease. After a mean follow-up of 331±155 days, 383 
stroke cases were identified. The hazard ratio (HR) for stroke was 2.8; 95% CI 2.0- 3.8 in 
subjects with four risk factors compared to those with one risk factor, after adjusting for 
the same covariates. 
Conclusions: Patients with clusters of CV risk factors are at higher risk for AF and stroke. 
Whether the modification of risk factors reduces the rate of AF and stroke awaits further study.
3:30 p.m.
1008-167 Modular Secondary Prevention Based On Patient 
Choice Improves Risk Factor Profile And Knowledge 
After Acute Coronary Syndrome: A Randomized 
Controlled Trial.
Julie Redfern, Tom Briffa, Elizabeth Ellis, Saul B. Freedman, University of Sydney, 
Sydney, Australia, Concord Hospital, Sydney, Australia
Background: Cardiac rehabilitation (CR) as secondary prevention is problematic given 
low participation rates, short exposure and lower initial risk. We assessed effectiveness of 
an innovative modular program on coronary risk factor level, prevalence and knowledge 
in acute coronary syndrome (ACS) survivors not accessing CR.
Methods: ACS survivors were randomly allocated to either control (n=72) receiving 
conventional care or a modular group (n=72) receiving a module to lower blood cholesterol 
and up to two other modules including blood pressure (BP) reduction, quit smoking or 
increased exercise, according to need and preference. Modules were based on patient-
centered choice of care and goal setting. Outcome was blinded assessment coronary risk 
factors and knowledge at 12 months.
Results: Although well-matched at baseline, at 12 months, the modular group had 
significantly lower levels for most risk factors (Table) and fewer scored moderate-high on 
the LIPID risk score than controls (37% v 58%, p=0.016). Baseline risk factor knowledge 
was poor overall: however at follow-up significantly more modular participants were able 
to state the recommended levels for total cholesterol (TC) (76% v 30%), BP (64% v 30%) 
and physical activity (70% v 30%), (all with p<0.001 v control). 
Risk Factor
Baseline 12 months
Control(n=72) Modular (n=72) p Control (n=69) Modular (n=67) p
TC (mmol/L) 4.6±0.1 4.8±0.1 0.58 4.7±0.1 4.0±0.1 0.00
TC > 4mmol/L 83% 72% 0.23 78% 48% 0.00
LDL (mmol/L) 2.6±0.1 2.6±0.1 0.50 2.4±0.1 2.0±0.1 0.01
SBP (mmHg) 137.5±2.2 136.6±2.1 0.74 143.9±2.4 131.6±1.8 0.01
Physical activity 
(MET-mins) 267.0±31.6 314.7±37.9 0.34 715.1±103.5 1369.1±167.2 0.00
BMI (kg/m²) 30.5±0.7 29.5±0.7 0.33 31.2±0.7 28.9±0.7 0.02
Smoker 22% 19% 0.19 23% 9% 0.01
4 or more risk 
factors 31% 24% 0.35 43% 9% 0.00
LIPID risk score 4.7±0.4 4.5±0.4 0.64 5.2±0.4 3.7±0.3 0.01
TC = total cholesterol, LDL = low density lipoprotein cholesterol, SBP = systolic blood pressure, MET = metabolic 
equivalents, BMI = body mass index
Conclusion: Tailored modular secondary prevention emphasizing patient choice 
significantly improves coronary risk profile and knowledge compared with conventional 
care, providing an effective alternative to CR.
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3:30 p.m.
1008-168 Impact of Pharmacologic Management at Discharge 
for Complicated Risk Factors on Outcomes of Diabetic 
Patients Undergoing First Coronary Revascularization: 
Perspectives From CREDO-Kyoto Registry
Yutaka Furukawa, Satoshi Shizuta, Yoshisumi Haruna, Natsuhiko Ehara, Ryoji 
Taniguchi, Kozo Hoshino, Toshihiro Tamura, Masaki Kawanami, Makoto Kadoya, Eiichi 
Matsuyama, Shinji Miki, Akira Yoshida, Hiroyuki Nakajima, Hitomi Sasae, Takeshi 
Morimoto, Yukiko Imai, Satoshi Teramukai, Masanori Fukushima, Toru Kita, Takeshi 
Kimura, Kyoto University, Kyoto, Japan
Background: Aggressive pharmacologic management of each coronary risk factor is 
recommended for secondary prevention in diabetic patients with coronary artery disease 
(CAD). This study aimed to evaluate the impact of pharmacologic management at 
hospital discharge on long-term outcomes of diabetic patients with CAD undergoing first 
revascularization therapy.
Methods: We have enrolled 9,873 patients who underwent first elective percutaneous 
coronary intervention (PCI) or coronary bypass surgery (CABG) during 2000-2002 into 
the CREDO-Kyoto registry from 30 institutions. The database comprised 3,851 diabetic 
patients. After excluding patients undergoing combined surgery with CABG and patients 
with malignant diseases or in-hospital death, 3,363 patients were analyzed. All-cause and 
cardiovascular mortalities were evaluated and compared between the patients with and 
without statins, ACEI/ARB, β-blockers or calcium antagonists at discharge by Kaplan-
Meier analysis and log-rank test. A multivariate analyses using the Cox proportional 
hazards model was employed to assess independence of predictors for mortality.
Results: The median follow-up period was 3.6 years. Patients on statin therapy at 
discharge showed significantly lower all-cause (with statin vs. without statin, 4.7 % vs. 
9.3 %; p<0.0001) as well as cardiovascular (with statin vs. without statin, 3.0 % vs. 
6.4 %; p<0.0001) mortalities than those without statins, while other drugs were not 
associated with a decrease in all-cause or cardiovascular mortality. After adjustment for 
other potential risk factors including mode of revascularization (PCI vs. CABG), old age 
(≥65 years), sex, hypertension, current smoker, hypercholesterolemia, insulin therapy, 
multivessels disease and left main coronary artery disease, use of statins at discharge 
remained a significant predictor of lower all-cause (OR0.66, 95% confidence interval (CI) 
0.48-0.90; p<0.01) and cardiovascular (OR0.68, 95% CI 0.49-0.91; p<0.05) mortalities.
Conclusions: Pharmacologic management with statins started by hospital discharge 
was associated with lower long-term mortality in Japanese CAD patients undergoing first 
elective revascularization.
3:30 p.m.
1008-169 Weight Loss and Changes in Cardiovascular Risk 
Markers With a Low Glycemic Load Diet Compared 
With a Conventional Low Fat Recommended Diet: a 
Randomized Trial
Tor O. Klemsdal, Ingar Holme, Terje R. Pedersen, Serena Tonstad, Department of 
Preventive Cardiology, Ullevaal University Hospital, N-0407, Oslo, Norway
Background: There is currently considerably controversy regarding the best dietary 
approach to promote weight-loss and reduced cardiovascular risk.
Methods: A total of 202 patients aged 30-65 years, with a BMI between 28 to 40 (28 to 
35 for women) and at least one criterion of the metabolic syndrome, were randomized 
to receive dietary advice of either a low glycemic load diet (LGL-diet) or a Low-fat-diet. 
Both groups were prescribed a mild hypocaloric diet (-500 kcal per day), and attended 
9 separate dietary counseling sessions (baseline, week 2, month 1, 2, 3, 4, 5, 6, and 9). 
Body weight, waist circumference, blood pressure, heart rate and fasting blood samples 
for lipids, glucose, C-peptide, insulin, and CRP were collected at baseline, 3 months and 
12 months.
Results: 78 of 100 patients (78%) in the LGL-diet group, and 86 of 102 patients (84%) 
in the Low-fat-diet group completed the study, making this the largest study with the 
highest 12 month completion rate to our knowledge. From a baseline weight of 100.0/99.9 
kg, respectively, both groups experienced significant weight losses of approximately 5%, 
that peaked at 6 months, but were largely maintained after 12 months. At 3 months the 
LGL-diet group tended to experience a greater weight loss than the Low-fat group (-4.8 
kg versus -3.8 kg, p=0.06), however the opposite trend was observed after 12 months 
(-4.0 kg vs -4.3 kg, n.s.). At 12 months, the reduction in waist circumference was less in 
the LGL-diet group than in the Low-fat-diet group (-4.0 cm vs -5.8 cm, p=0.03). Beneficial 
effects in fasting lipids, glucose, insulin, C-peptide and CRP were seen in both groups, 
with no significant differences between groups.
Conclusion: Sustained weight loss of approximately 4 kg’s (i.e.-4%), and improvements 
in lipid- and glucose metabolism is feasible with both a low glycemic load diet and a low 
fat diet. The initial minor advantage of the LGL-diet at 3 months is not maintained after 
12 months, suggesting that the conventional low-fat dietary advice may be preferable in 
the long term.
3:30 p.m.
1008-170 Major Weight Loss prevents Long-term Left Atrial 
Enlargement in Patients with Morbid Obesity
Carolina A. Garza, Patricia A. Pellikka, Virend K. Somers, Elise Oehler, Michael G. Sarr, 
James B. Seward, Maria L. Collazo-Clavell, Francisco Lopez-Jimenez, Mayo Clinic, 
Rochester, MN
Background: No controlled studies have assessed the effect of long-term weight loss on left 
atrial volume (LAV), a measure of diastolic function and a risk factor for atrial fibrillation.
Methods: We reviewed 57 patients who underwent gastric bypass surgery for 
morbid obesity (BMI >40 kg/m2 or >35 kg/m2 with comorbidities) and had at least one 
echocardiogram before and after the operation. We excluded patients with cardiomyopathy 
with an attributable cause, pericardial disease, or severe valvulopathy. A control group 
was frequency-matched for body mass index (BMI) ±2 kg/m2, sex, age (±2 yr), and for 
follow-up time (±6 mo). We performed off-line measurements of LAV using the biplane 
area-length method, indexed to height and blinded to the amount of weight loss. Analyses 
were adjusted for potential confounders.
Results: Main results are shown in table. In the study population as a whole, there was 
a positive correlation between long-term change in body weight and change in LAV 
(R=0.22, p=0.006), independent of potential confounders, including changes in blood 
pressure at follow-up.
Conclusions: Because increased LAV is a measure of chronic elevation of filling pressure 
(i.e., diastolic dysfunction) and a risk factor for atrial fibrillation, our findings support the 
hypothesis that obesity is implicated in the increased prevalence of congestive heart 
failure and atrial fibrillation as reflected in LAV remodeling. 
Cases 
(n=57)
Controls 
(n=57)
p-value for
difference
P for 
Multivariate
analysis§
Male sex , N (%) 22 (39) 22 (39) 0.99
Age at enrollment, yr 51 ± 9 51 ± 9 0.71
BMI at enrollment, kg/m2 49 ± 9 48 ± 8 0.53
Follow-up, months 45 ± 25 41 ± 21 0.4
Change in weight, kg -42.4 ± 25 -3.5 ± 17.4 <0.0001
Change in systolic BP, mm Hg - 5.8 ± 27.5 - 5.4 ± 26.3 0.93
Change in diastolic BP, mm 
Hg - 4.7 ± 15
*
- 1.3 ± 18.1 0.28
Changes in diastolic 
parameters
(follow up minus baseline 
values)
LAV, ml 3.5 ± 22.3 15.0 ± 27.3† 0.02 0.01
LAV Indexed to height, ml/cm 0.02±0.13 0.09±0.16‡ 0.01 0.01
E/A ratio 0.11±0.40 0.08±0.39 0.04 0.03
Values represent number (%) or mean 
± SD.
*p<0.05; † p<0.001; ‡ p<0.0001 for intragroup comparison
§
 Adjusting for age, sex, hypertension, change in systolic and diastolic blood pressure, 
diabetes mellitus, coronary artery disease, atrial fibrillation and obstructive sleep 
apnea.
3:30 p.m.
1008-173 Sex, Work, Exercise, And Driving Following An 
ST-Elevation Myocardial Infarction - A GAP In The 
Guidelines
Alexander S. Asser, Allen Jay Solomon, The George Washington University, 
Washington, DC
Background: The current ACC/AHA Guidelines for the Management of Patients with ST-
Elevation Myocardial Infarction (STEMI) state that healthcare providers should discuss, in detail, 
issues of physical activity, return to work, resumption of sexual activity and travel, including 
driving, following an STEMI. However, these guidelines provide limited recommendations 
for returning to normal activities. Patients can begin daily walks immediately, resume sexual 
activity in 7-10 days, and drive in 1 week. As a result, we surveyed a group of cardiologists to 
assess whether their treatment patterns followed the ACC/AHA guidelines.
Methods: We sent surveys to 100 cardiologists in the Washington Metropolitan area who care 
for patients with STEMI. They were asked 5 questions pertaining to patients with an acute 
uncomplicated STEMI. The questions addressed the timing of returning to work, restarting sexual 
activity, restarting an exercise program, driving an automobile and length of hospitalization.
Results: We received responses from 75 cardiologists (15 Interventional Cardiologists), 
who represented 8 hospitals in the Washington metropolitan area. Twenty four 
cardiologists were University faculty, whereas 51 were in private practice. The most 
common recommendation about returning to work was 2 weeks (mean = 16.8 + 7.8 
days), however, the answers ranged from 1 - 6 weeks. The most common response 
about restarting an exercise program was also 2 weeks (21.2 + 20.4 days), with a range 
from no waiting period to 6 months. With regard to the resumption of sexual activity, the 
answers were similar to returning to work (16.1 + 9.8 days). The responses about driving 
were split evenly between 1 week and 2 weeks (11.8 + 8.2 days). Finally, the mean length 
of hospital stay was 3.20 + 1.07 days, with a range of 1 - 7 days.
Conclusion: There is a great amount of variability in the instructions given to similar patients 
experiencing an uncomplicated STEMI. In general, practicing cardiologists tend to be 
more conservative than the guidelines. The ACC/AHA Guidelines should establish clearer 
recommendations for cardiologists to follow when caring for patients following an acute STEMI.
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1008-202 Increased Pulse Pressure Reduces Coronary Flow 
Reserve in Patients With Chronic Aortic Regurgitation
Hideki Okui, Shuichi Hamasaki, Sanemasa Ishida, Tetsuro Kataoka, Masakazu Ogawa, 
Keishi Saihara, Koji Orihara, Tsuyoshi Fukudome, Takuro Shinsato, Takahiro Shirasawa, 
Etsuko Mizoguchi, Takuro Kubozono, Shoji Fujita, So Kuwahata, Akiko Yoshikawa, 
Takehiko Matsushita, Kaai Tomita, Aya Fukushima, Chuwa Tei, Kagoshima university, 
Kagoshima, Japan
Background: Combination of increased systolic aortic pressure with increased left 
ventricular oxygen demands and decreased diastolic aortic pressure with reduced 
coronary perfusion pressure in patients with aortic regurgitation (AR) may affect coronary 
blood flow physiology. We hypothesized that pulse pressure, expressing both increased 
systolic and decreased diastolic aortic pressure, can be a significant determinant of 
coronary flow reserve in patients with chronic AR.
Methods: Coronary flow reserve (CFR) was determined in 42 consecutive patients (59±16 
yrs) with moderate to severe AR. Forty-three age-matched patients without underlying 
cardiovascular disease served as controls. AR severity was estimated by measurement 
of regurgitant fraction using Doppler echocardiography. CFR was calculated as the ratio of 
papaverine-induced hyperemic coronary blood flow ( CBF) to basal CBF using a Doppler 
guidewire. We evaluated the associations of CFR with parameters including pulse 
pressure, systolic blood pressure, diastolic blood pressure, LV end-diastolic pressure, LV 
wall thickness, LV mass, LV volume, or the other.
Results: CFR in patients with AR was significantly lower than that in controls (1.91± 
0.90 VS 2.95 ± 0.72, p<0.001). In patients with AR, CFR had an inverse correlation with 
pulse pressure, systolic aortic pressure and LV wall thickness (r=-0.62, p<0.0001; r=-0.44, 
p<0.01; r=-0.35, p<0.05, respectively). Multiple regression analysis revealed that pulse 
pressure was the independent determinant of CFR in patients with AR (p<0.0001).
Conclusions: In patients with chronic aortic regurgitation, pulse pressure is a significant 
determinant of CFR, suggesting that reducing pulse pressure may be a therapeutic target.
3:30 p.m.
1008-203 Prevalence and Correlates of Microalbuminuria in 
Essential Hypertensive Subjects: Insights From The 
Hippokration Hellenic Hypertension (3H) Study
Costas Tsioufis, Kyriakos Dimitriadis, Efstathios Taxiarchou, Apostolis Kakkavas, Pavlos 
Pavlidis, Maria Selima, Themis Psarros, Eleftherios Tsiamis, Christodoulos Stefanadis, 
Ioannis Kallikazaros, Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: Microalbuminuria (MA) is a marker of subclinical atherosclerosis and it is 
related to unfavorable outcome. In this study we sought to determine the prevalence of 
MA in a large cohort of hypertensives and to investigate the relations of the albumin to 
creatinine ratio (ACR), with diverse clinical and biochemical cardiovascular risk factors.
Methods: A total of 1178 consecutive essential hypertensive subjects [604 men, aged 56 
years, office blood pressure (BP)=144/90 mmHg] that were included in the Hippokration 
Hellenic Hypertension (3H) study, an ongoing registry of hypertension-related target 
organ damage, were considered for analysis. According to ACR values determined as 
the mean of two non-consecutive morning spot urine samples, patients were divided into 
those with MA (ACR=22-300 mg/g in men and ACR=30-300 mg/g in women) and those 
without MA (ACR<22 mg/g in men and ACR<30 in women). Furthermore, all participants 
underwent venous blood sampling for estimation of metabolic profile.
Results: 149 patients (12.6%) had MA and when compared to those without MA 
(n=1029) exhibited higher office systolic BP (149 vs 144 mmHg, p=0.001), left ventricular 
mass index (108.9 vs 102.6 g/m2, p=0.007) and greater prevalence of type 2 diabetes 
(25 vs 12%, p<0.0001) and metabolic syndrome (50 vs 30%, p<0.0001). Moreover, 
microalbuminurics compared to normoalbuminurics had lower high-density lipoprotein 
(49.9 vs 53.5 mg/dl, p<0.05), heightened triglycerides (149 vs 122 mg/dl, p<0.0001), 
fibrinogen (339 vs 321 mg/dl, p=0.04) and homocysteine levels (14.1 vs 12.5 μmol/l, 
p=0.01). In the total population, ACR was associated with age (r=0.08, p=0.02), office 
systolic BP (r=0.109, p<0.0001), and triglycerides (r=0.122, p<0.05), while exhibited no 
relation to fibrinogen and homocysteine (p=NS). Multiple regression analysis revealed 
that office systolic BP and triglycerides were independent predictors of ACR (p<0.05).
Conclusion: Among hypertensives that participated in the 3H study 12.6% had MA 
and were characterized by adverse clinical and biochemical phenotype. These findings 
suggest that ACR determination is a useful tool to improve cardiovascular risk stratification 
in this setting.
3:30 p.m.
1008-204 Cross-Sectional Relationships of Urinary Albumin 
Excretion With Arterial Stiffness and Left Ventricular 
Mass in Essential Hypertensive Subjects: Data From 
The Hippokration Hellenic Hypertension (3H) Study
Costas Tsioufis, Kyriakos Dimitriadis, Dimitris Chatzis, Elena Vezali, Costas Michas, 
Konstantinos Giannakopoulos, Themis Psarros, Eleftherios Tsiamis, Christodoulos 
Stefanadis, Ioannis Kallikazaros, Department of Cardiology, Hippokration Hospital, 
Athens, Greece
Background: Microalbuminuria (MA) is related to atherosclerosis progression and adverse 
outcome. The aim of the study was to determine the prevalence of MA in a large cohort of 
hypertensives and to investigate the relationships of urinary albumin excretion, expressed 
as the albumin to creatinine ratio (ACR), with left ventricular mass and arterial stiffness.
Methods: A total of 1178 consecutive essential hypertensive subjects [604 men, aged 56 
years, office blood pressure (BP)=144/90 mmHg] that were included in the Hippokration 
Hellenic Hypertension (3H) study, an ongoing registry of hypertension-related target 
organ damage, were considered for analysis. According to ACR values determined as the 
mean of two non-consecutive morning spot urine, hypertensives were divided into those 
with MA (ACR=22-300 mg/g in men and ACR=30-300 mg/g in women) and those without 
MA (ACR<22 mg/g in men and ACR<30 mg/g in women). Furthermore, all participants 
underwent echocardiogaphic examination and arterial stiffness evaluation on the basis of 
carotid to femoral pulse wave velocity (PWV).
Results: 149 patients (12.6%) had MA and when compared to those without MA 
(n=1029) were older (58 vs 55 years, p<0.05), exhibited higher office systolic BP (149 vs 
144 mmHg, p=0.001) and greater prevalence of type 2 diabetes (25 vs 12%, p<0.0001) 
and metabolic syndrome (50 vs 30%, p<0.0001). Moreover, microalbuminurics compared 
to normoalbuminurics had higher left ventricular mass index (LVMI) (108.9 vs 102.6 
g/m2, p=0.007), relative wall thickness (0.45 vs 0.43, p<0.0001) and PWV values (8.5 
vs 8.1 m/sec, p<0.05), independently of confounders. In the total population, ACR was 
associated with office systolic BP (r=0.109, p<0.0001), LVMI (r=0.219, p<0.0001), and 
PWV (r=0.270, p<0.0001). By multiple regression analysis it was revealed that only office 
systolic BP and PWV were independent predictors of ACR (p<0.05 for both).
Conclusion: MA is observed in 12.6% of hypertensive subjects in the 3H study and it is 
accompanied by increased arterial stiffness and left ventricular mass. These findings support 
that ACR is an integrated sign of hypertension-induced cardiovascular adaptations.
3:30 p.m.
1008-205 Nifedipine Added to the Combination with Pravastatin 
and Olmesartan Shows Preventive Effect on Hypoxia-
Induced Left Ventricular Remodeling in Diabetes 
Mellitus
Chika Yamashita, Tetsuya Hayashi, Tatsuhiko Mori, Koichi Sohmiya, Akira Ukimura, 
Yoshikatsu Okada, Yasushi Kitaura, Yasuo Matsumura, Osaka University of 
Pharmaceutical Sciences, Takatsuki, Japan, Osaka Medical College, Takatsuki, Japan
Background: Intermittent hypoxia due to sleep apnea might increase cardiovascular 
events especially in diabetic patients. Although beneficial combination with statin and 
angiotensin-II receptor blocker (ARB) has been reported, it is controversial whether 
additional treatment with calcium channel blocker (CCB) is preferable or not. The aim 
of this study was to evaluate the triple combination with statin, ARB and CCB on left 
ventricular (LV) remodeling in diabetic mice exposed to hypoxia.
Methods: Male db/db mice at 8 weeks of age were kept under intermittent hypoxia (10% 
O2) or normoxia for 3 weeks. The mice were treated with pravastatin (40 mg/kg/day) as 
statin, olmesartan (3 mg/kg/day) as ARB, nifedipine (10 mg/kg/day) as CCB, or their 
combination as follows; statin+ARB, statin+CCB, ARB+CCB, and statin+ARB+CCB.
Results: Hypoxia caused hypertrophy of cardiomyocytes, and increased interstitial 
fibrosis (%Fibrosis), 4-hydroxy-2-nonenal protein (4-HNE), and TGF-β in LV myocardium. 
Although monotherapy with statin showed little effect, combination with ARB attenuated 
the hypoxia-induced LV remodeling without affecting cholesterol, plasma glucose, and LV 
pressure. Furthermore, addition of CCB to statin+ARB significantly decreased %Fibrosis 
and 4-HNE (Figure).
Conclusions: Triple combination with statin, ARB, and CCB prevented hypoxia-induced 
LV remodeling through suppression of oxidative stress in diabetic mice, which might be 
practical treatment for diabetic patients with sleep apnea. 
350A    ABSTRACTS - Vascular Disease, Hypertension and Prevention  JACC  March 6, 2007 
Va
sc
ul
ar
 D
is
ea
se
, 
H
yp
er
te
ns
io
n 
an
d 
P
re
ve
nt
io
n
3:30 p.m.
1008-206 Did Blood Pressure Medication Withdrawal Prior to 
Randomization Influence Subsequent Rates of Heart 
Failure in the Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial?
Richard Grimm, Barry R. Davis, Jeffrey A. Cutler, Linda B. Piller, Karen Margolis, 
Joshua Barzilay, Richard Dart, James F. Graumlich, Robert Murden, Otelio Randall, The 
ALLHAT Collaborative Research Group, for the ALLHAT Collaborative Research Group, 
University of Texas School of Public Health, Houston, TX
Background: Lower heart failure (HF) rates in participants assigned to chlorthalidone 
compared to amlodipine, lisinopril or doxazosin-based treatment was an unexpected 
finding in ALLHAT - a double-blind randomized hypertension treatment trial in 42,418 
patients at high risk for cardiovascular disease. Since most of the HF rate differences 
appeared shortly after randomization, a possible explanation is that diuretics deplete fluid 
volume and may mask symptoms and signs of HF. Thus, the switch from diuretic to non-
diuretic therapy at entry may have contributed to the early emergence of HF. At study 
entry, 90% of participants had been prescribed blood pressure medications; however, no 
data were obtained on the specific drugs or drug class.
Methods: ALLHAT clinics were queried at closeout for pre-randomization blood pressure 
medication in participants with hospitalized HF over the course of the trial. From only 
one mailed questionnaire, blood pressure drugs at entry were ascertained for 1374 
participants (about 2/3 of the total) with hospitalized HF. Using case-only analysis, we 
sought to discover if there were any interactions (interaction odds ratio [IOR] = ratio of 
ORs) between type of previous medication used and effects of subsequent ALLHAT 
treatments on HF outcomes.
Results: Among HF cases, about 39% had been on diuretics, 37% on ACE-inhibitors, 
17% on beta-blockers, and 47% on calcium channel blockers prior to study entry. 
For those taking diuretics prior to entry, the IOR of amlodipine vs. chlorthalidone for 
developing hospitalized HF during first year following randomization compared to the IOR 
of amlodipine vs. chlorthalidone for those not taking diuretics prior to entry was 1.08 (95% 
CI, 0.53-2.21, p=0.83). For lisinopril vs. chlorthalidone, this interaction OR was 1.33 (95% 
CI, 0.65-2.74, p=0.44), and for doxazosin vs. chlorthalidone, 1.31 (95% CI, 0.64-2.68, 
p=0.46). When we controlled for the use other classes of blood pressure medication the 
results were similar.
Conclusions: Acknowledging the problem of detecting interactions in general, we found 
no credible evidence that entry drugs explained the observed HF differences in ALLHAT.
3:30 p.m.
1008-207 Algal Docosahexaenoic Acid Lowers Diastolic Blood 
Pressure and Reduces Heart Rate in a Statin-Treated 
Cardiac Risk Population
Leonard M. Keilson, David Keller, Barb Perry, Sasha Jurgilas, Jim Blum, Benedict 
Farino, John Reynolds, Maine Center for Lipids and Cardiovascular Health, 
Scarborough, ME, Maine Medical Center, Portland, ME
Background: Fish or omega-3 fatty acid supplements have been recommended by the 
American Heart Association to reduce cardiac sudden death in patients with heart disease. 
Fish oil has been shown to reduce heart rate (HR), and increased HR has been related 
to fatal arrythmia. Fish oil is comprised of two omega-3 fatty acids, docosahexaenoic acid 
(DHA) and eicosapentaenoic acid (EPA). DHA is now highly purified from algae and may 
be administered as monotherapy. This study explored the effects of DHA monotherapy 
upon HR and blood pressure (BP) in a statin-treated coronary heart disease/risk 
equivalent (CHD/CRE) population.
Methods: Randomized double-blind placebo controlled trial. After a 4-week diet 
stabilization, CHD/CRE patients received either placebo or 2g DHA daily. Using standard 
protocols, HR and BP were measured by digital devices over a 6-week period (Omron 
HEM-907, Welch Allyn 5300P).
Results:Within the DHA group, HR fell by 5 BPM (p<0.001), diastolic BP fell by 5 mmHg 
(p<0.001). There was no change in systolic BP or body weight. There were no changes 
in renal or liver function.
Conclusions: Algal DHA is well-tolerated and effective in lowering HR and BP in a 
statin-treated CHD/CRE population. The importance of this finding for cardiac outcome is 
unclear and awaits further evaluation. 
Effect of Algal DHA Upon Heart Rate and Blood Pressure
DHA (n=19) Placebo (n=14)
Pre
Tx
Post
Tx
Chg
(Chg%)
p-value
(95% CI 
lower,upper)
Pre
Tx
Post
Tx
Chg
(Chg%)
p-value
(95% CI 
lower,upper)
Pulse 66 60 -6(-9%)
<0.001
(3,8) 70 69
-1
(-1%)
0.353
(-1,4)
SBP 133 132 -1(-1%)
0.362
(-2,6) 128 128
0
(0%)
0.909
(-4,4)
DBP 71 66 -5(-7%)
<0.001
(2,7) 74 74
0
(0%)
0.493
(-2,4)
3:30 p.m.
1008-208 Is Renal MRI/MRA an Appropriate Screening Tool in 
the Workup of Patients with Suspected Renovascular 
Hypertension?
Rajiv Agarwal, Raja Muthupillai, Scott D. Flamm, Cleveland Clinic Foundation, 
Cleveland, OH
Background: Secondary hypertension (HTN) is a common and treatable diagnosis. 
Patients with suspected renovascular HTN (R-HTN) require further workup, and 
physicians increasingly incorporate renal MRI/MRA for evaluation. However, the utility 
of renal MRI/MRA as a screening test across the age spectrum in suspected R-HTN is 
unknown.
Methods: From 2002 to 2005, 1050 patients (518 males, 532 females) underwent renal 
MRI/MRA on a 1.5T Philips MR system for suspected R-HTN. Pre and post gadolinium 
T1 and T2 weighted images, 3D MRA, and 3D phase contrast MRA were performed. Main 
renal arteries were assessed for degree of renal artery stenosis (RAS) and stenoses > 
moderate were considered significant. Patients were grouped based on decade of life 
(Table 1).
Results: 18.3% of patients (191/1050) who underwent renal MRI/MRA had a total of 244 
significant RAS lesions. The incidence of significant RAS was similar in males (17.6%) 
and females (18.8%), and increased with decade of life. The incidence of RAS was 0% 
in those < 40 years of age, 6% in patients 41-60 years old, and 27.3% in patients > 60 
years old.
Conclusions: In our study of 1050 patients with suspected R-HTN, RAS was identified 
with increasing incidence by decade of life above the age of 40 years. Our study suggests 
that the current use of renal MRI/MRA for R-HTN has high yield in patients > 60 years of 
age, is likely unwarranted in patients < 40 years of age, and for patients 41-60 years old a 
determination of cost-effectiveness may be necessary to assess appropriateness. 
Table 1: Breakdown of RAS by Age
Age 
Group
Total Patients 
in Age Group
Number of 
Significant 
RAS
Number of Patients 
with Significant RAS
% Patients with 
Significant RAS
11-20 10 0 0 0%
21-30 22 0 0 0%
31-40 59 0 0 0%
41-50 123 7 6 4.9%
51-60 209 18 14 6.7%
61-70 250 50 42 16.8%
71-80 292 113 89 30.5%
> 80 85 56 40 47.1%
Total 1050 244 191 18.3%
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804-3 Post Percutaneous Coronary Intervention Statin Usage 
and Long-term Mortality - Is Statin Intolerance a 
Predictor of Adverse Outcome?
Hector M. Medina, Hitinder S. Gurm, Samir Kapadia, Cleveland Clinic Foundation, 
Cleveland, OH
Background: Statins have been demonstrated to improve outcome of patients with 
Coronary Artery Disease (CAD). Previous data indicate that efforts to improve compliance 
with guidelines positively impact on statin use. The outcome of patients not receiving 
statins under such programs has not been defined.
Methods: All patients undergoing Percutaneous Coronary Intervention (PCI) are routinely 
discharged on statins as per institutional policy unless there are clear contraindications 
or prior history of intolerance. If possible, an effort is made to treat such patients with 
alternate lipid lowering therapies. We evaluated the outcome of 3981 patients that were 
discharged alive form our institution after undergoing PCI for stable or unstable CAD 
using uni and multivariate logistic regression models. All-cause mortality was our main 
outcome.
Results: Of the total cohort of 3981 patients, only 309 (7.7%) were not prescribed statins 
at discharge. On mean follow up of 18 months there were 25 deaths (8.1%) among patients 
not prescribed statins while those discharged on statins had a 2.7% mortality (log rank 
29, P<0.0001). This difference in survival remained significant after adjustment for age, 
left ventricular ejection fraction, renal function, lesion complexity, and extent of coronary 
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artery disease (Hazard Ratio 0.47, 95% CI 0.27-0.81, P=0.007). When the cause for 
lack of statin and mortality were evaluated, majority of deaths occurred in patients with 
pre-existing co-morbidities. The reason for lack of statin (deaths/n) was characterized as 
history of statin induced liver dysfunction (0/12), history of statin induced myopathy (4/48), 
prior hepatic dysfunction (4/25), low cholesterol (3/43), renal dysfunction (0/4), poor life 
expectancy (3/5), and others (11/72). No deaths occurred among patients receiving only 
non-statin lipid lowering therapy (n=101).
Conclusions: Institutional efforts to improve statin usage can be highly successful. 
Patients not discharged on statins or other lipid lowering agents under such programs 
have a markedly high long-term mortality. However, this risk may be related to the 
associated co-morbidities that lead to proscription of lipid lowering therapy.
7:15 a.m.
804-4 Increased Risk of Coronary Heart Disease After 
Recurrent Cerebrovascular Events - Findings From 
the Stroke Prevention by Aggressive Reduction in 
Cholesterol Levels (SPARCL) Study
Henrik Sillesen, Alfred Callahan, III, Justin Zivin, Pierre Amarenco, Larry B. Goldstein, 
Michael Hennerici, Amy E. Rudolph, Lisa Simunovic, Michael Szarek, K Michael A. 
Welch, for the SPARCL Investigators, Rigshospitalet, University of Copenhagen, 
Denmark
Background: In the SPARCL trial, atorvastatin 80 mg/day was associated with a 16% 
reduction for stroke, 35% for major coronary events (MCE) and 42% for any coronary 
heart disease (CHD) event in patients with recent TIA or stroke and no known CHD at 
randomization. However, the risk may be underestimated since patients who developed 
CHD between the entry event and randomization (average time 3 months) were 
excluded from the trial. The purpose of this analysis is to define the relationship between 
cerebrovascular events during the trial and subsequent CHD events and to evaluate if 
atorvastatin treatment was associated with significant protection from coronary events 
after a recurrent cerebrovascular event.
Methods: Cox regression models were fit with terms for treatment, gender and age and 
a time-dependent covariate for post-randomization stroke or TIA occurring prior to a first 
MCE or first CHD event.
Results: Sixteen percent of MCE and 14% of any CHD events occurred after a recurrent 
cerebrovascular event. Compared to the period between randomization and a first 
stroke or TIA, the risk of MCE was 63% higher (Hazard Ratio [HR] = 1.63, 95% CI: 1.12-
2.37, p=0.01) and the risk of any CHD event was 41% higher (HR=1.41, 95% CI: 1.03-
1.92, p=0.03) after a recurrent stroke or TIA during follow-up. In the placebo arm, the 
estimated risk of MCE was 1.7%/person/year and 2.5%/person/year for any CHD event 
after experiencing a recurrent stroke or TIA. Treatment with atorvastatin 80 mg/day was 
associated with a 53% reduction for MCE (HR=0.47, 95% CI: 0.23-0.99, p=0.045) and 
47% for any CHD event (HR=0.53, 95% CI: 0.29-0.98, p=0.042) after recurrent stroke or 
TIA, which was similar to the period before the first recurrent stroke/TIA.
Conclusions: The risk of MCE and CHD events was significantly higher following 
a recurrent stroke or TIA than in the period before the recurrent stroke. The benefit of 
atorvastatin in reducing the risk of MCE and CHD events is similar prior to and after 
recurrent stroke or TIA.
7:30 a.m.
804-5 Influence of Statin Treatment on the ADP 
Responsiveness of Platelets During Clopidogrel 
Treatment - A Randomised Comparison of 
Rosuvastatin, Atorvastatin and Simvastatin Co-
Treatment.
Rickard A. Malmstrom, Jan Ostergren, Leif Jorgensen, Paul Hjemdahl, Karolinska 
University Hospital, Solna, Sweden, AstraZeneca Sweden AB, Sodertalje, Sweden
Background: High-risk patients with atherosclerotic disease are frequently treated with a 
combination of clopidogrel (C) and statin. Atorvastatin (A) has been suggested to reduce 
the platelet inhibiting effect of C via a drug-drug interaction involving reduced formation 
of the active C metabolite via CYP 3A4. This randomized prospective study investigated 
possible interactions between C and A, simvastatin (S) and rosuvastatin (R; a “non-CYP 
3A4” metabolised statin) using ex vivo platelet function tests.
Methods: Patients (n=220) with coronary artery disease in a study comparing lipid 
lowering effects of A (20-80 mg OD) and R (10-40 mg OD) were studied before and after 
2 weeks treatment with C 75 mg OD after completed statin dose titration. A 3rd group was 
treated with open-label S 40 mg OD (n=23). In these and a subpopulation of R (n=24) and 
A (n=22) treated patients, ADP-stimulated platelet function was evaluated by whole blood 
flow cytometry (P-selectin expression (PS)) and aggregometry in platelet rich plasma 
(Agg). Aggregation using a platelet counting technique that has previously revealed statin 
interactions with C (Micros) was tested in all patients.
Results: C inhibited ADP-induced Agg by 40%, 57% and 51% respectively in patients 
on R (n=24), A (n=22) and S (n=23) treatment. ADP-induced PS was inhibited by 40%, 
54% and 47% respectively in patients on R, A and S treatment. Using the Micros method, 
as point-of-care, C inhibited aggregation to the same extent in patients on R (n=103) 
and A (n=97).
Conclusions: Neither A nor S treatment (CYP3A4 metabolized statins) attenuated the 
platelet inhibition by C treatment compared to R treatment. Our results indicate that there 
is no clinically important CYP 3A4 mediated interaction between clopidogrel maintenance 
treatment and statin co-treatment.
7:45 a.m.
804-6 Long-term Clinical Outcome of Supervised Exercise 
Rehabilitation Among Patients with Peripheral Arterial 
Disease
Shingo Sakamoto, Naoyuki Yokoyama, Satoshi Kasai, Yuiichi Tamori, Koichi Akutsu, 
Hideki Hashimoto, Hiroshi Nonogi, Satoshi Takeshita, National Cardiovascular Center, 
Osaka, Japan, University of Tokyo, Tokyo, Japan
Background: It is well established that exercise rehabilitation improves the walking ability of 
patients with peripheral arterial disease (PAD) who present with intermittent claudication. 
However, whether exercise rehabilitation prevents cardiac and cerebrovascular death 
(CCVD) of such patients is unknown. The aim of this study was to determine the clinical 
outcome of patients with PAD who undergo supervised exercise rehabilitation.
Methods: One hundred twenty-one patients (106 men; age, 68 ± 9 years) with PAD were 
enrolled in an exercise rehabilitation program. Sixty-five of these patients (53.7%) completed 
the 12 weeks, 3 day/week of supervised treadmill training. Outcomes were determined by 
reviewing hospital records or via telephone contact. CCVD was defined as cardiac death, 
cerebrovascular death, other vascular death (e.g., rupture/thrombosis of a major artery) or 
sudden death. Event-free survival was estimated by the Kaplan-Meier method and analyzed 
by log-rank test. Associations between CCVD and variables including exercise rehabilitation 
were assessed by multivariate Cox proportional hazards model.
Results: Median follow-up was 5.4 ± 3.9 years. Baseline characteristics did not differ 
significantly between patients who completed supervised exercise rehabilitation and those 
who did not. During the follow-up period, CCVD occurred in 16 patients (13.2%): cardiac 
death (n=8), cerebrovascular death (n=1), other vascular death (n=3) and sudden death 
(n=4). The Kaplan-Meier event-free survival rate was higher in patients who completed 
supervised exercise rehabilitation than in those who did not (80.5% vs. 56.7%, P = 0.02). 
Multivariate analysis showed independent predictors of CCVD to be diabetes mellitus 
(RR, 13.3; 95% CI, 2.8 to 64.2; P = 0.001), age (RR, 1.1; 95% CI, 1.0 to 1.2; P = 0.002) 
and completion of exercise rehabilitation (RR, 0.19; 95% CI, 0.06 to 0.57; P = 0.003).
Conclusions: Diabetes mellitus and age were the strongest predictors of CCVD. Exercise 
rehabilitation was associated with a significant reduction in CCVD. This is the first study 
to document a significant benefit of supervised exercise rehabilitation in reducing the risk 
of CCVD in patients with PAD.
8:00 a.m.
804-7 Utilization and Impact of Angiotensin-Converting 
Enzyme Inhibitors on Recurrent Ischemic Events 
Following Coronary Artery Bypass Graft Surgery
Dimitri Kalavrouziotis, Karen J. Buth, Roger J. Baskett, Queen Elizabeth II Health 
Sciences Centre, Halifax, NS, Canada
Background: The utilization of angiotensin-converting enzyme (ACE) inhibitors among 
patients following coronary artery bypass graft surgery (CABG) is unknown. Also, we 
examined the influence of early ACE inhibitor use on clinical outcomes one year after 
CABG.
Methods: All consecutive patients aged 65 years and over discharged alive following 
isolated CABG between 1996 and 2002 were identified (n = 2,266). Outpatient drug 
use was assessed using government prescription claims data. The primary outcome 
was freedom from a composite of all-cause mortality or hospital readmission for cardiac 
events or procedures. To reduce survival bias, a Cox proportional hazards model risk-
adjusted for comorbidities, time period, and concurrent cardiac medications was fit using 
a time-dependent variable for treatment initiation.
Results: The utilization of ACE inhibitors within 3 months post-discharge increased 
significantly during the study period in patients with: diabetes mellitus (27% vs. 69%), 
previous myocardial infarction (27% vs. 53%), and depressed left ventricular ejection 
fraction (LVEF) (40% vs. 71%) (discharge year 1996 vs. 2002, respectively, all p trend 
< 0.001). Of all patients dispensed a prescription for an ACE inhibitor within 3 months 
post-discharge, 90.5% were persistent users at one year. Post-CABG treatment with an 
ACE inhibitor had no effect on death or cardiac readmission (hazard ratio (HR) 0.98, 95% 
confidence interval (CI) 0.77-1.24, p = 0.86). The variables that emerged as independent 
predictors of the composite outcome were: diabetes mellitus, preoperative renal failure, 
LVEF < 0.40, repeat surgery, and urgent operation. Treatment with a statin (HR 0.45, 95% 
CI 0.34-0.58, p < 0.0001) and beta-blocker (HR 0.72, 95% CI 0.58-0.90, p = 0.004) were 
associated with increased freedom from death or readmission.
Conclusion: Although there have been significant improvements in the evidence-based 
utilization of ACE inhibitors among post-CABG patients, this therapy remains sub-optimal 
in patients with indications for treatment. In the general population of post-CABG patients, 
ACE inhibitors had no independent effect on mortality or recurrent ischemic events at one 
year post-CABG.
8:15 a.m.
804-8 Three Year Gain in Life Expectancy of Smoking 
Cessation after Coronary Bypass Surgery: A 30-year 
Follow-up Study
Ron T. van Domburg, Abdou Elhendy, Ad J. Bogers, Erasmus Medical Center, 
Rotterdam, The Netherlands
Objectives To investigate the effect of smoking cessation after venous coronary bypass 
surgery (CABG) on 30-year mortality.
Methods and Results We analyzed the 30-year clinical outcome of the 1041 first 
consecutive patients (age 53 years, 88% male) who underwent venous CABG between 
1971 and 1980. At the index operation 58% were smoking of whom 43% were able to 
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quit smoking in the first year after surgery. The median follow-up was 29 year (26-36 
year). The cumulative 10-, 20- and 30-year survival rates were 88%, 49% and 19%, 
respectively in the group of patients who quit smoking and 77%, 36% and 11% in the 
persistent smokers. After adjusting for all baseline characteristics smoking cessation 
remained an independent predictor of lower mortality (HR 0.62; 95%CI 0.51-0.75). We 
were able to assess the exact life expectancy (LE) by calculating the area under the 
Kaplan-Meier curves. LE was 20.0 years in the patients who quit smoking and only 17.0 
years in the persistent smokers (p<0.0001).
Conclusions Life style changes are important, not only to improve quality of life, but also 
extend survival. This is the first study demonstrating that patients who were able to quit 
smoking after CABG could prolong their life expectancy with an average of 3 years. 
ACC.ORAL CONTRIBUTIONS
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805-3 Cognition and Brachial Endothelial Responses in Older 
Adults with Cardiovascular Disease
Daniel E. Forman, Ronald A. Cohen, Karin F. Hoth, Athena Poppas, David J. Moser, 
John Gunstad, Robert H. Paul, Angela L. Jefferson, Andreana Haley, David F. Tate, 
Makoto Ono, Nicole Wake, Marie Gerhard-Herman, Brigham and Women’s Hospital, 
Boston, MA, VA Boston Health Care System, Boston, MA
Background: Healthy vascular endothelium throughout the body produces the vasodilator 
nitric oxide (NO). NO availability in one vascular bed correlates with NO availability in 
other vascular beds. Human studies have demonstrated the role of endothelium-derived 
NO in basal cerebral blood flow. We hypothesized that NO-mediated vasodilation of the 
brachial artery (BA) would correlate with vascular-mediated cognitive function in elderly 
patients with cardiovascular disease (CVD).
Methods: Eighty-eight patients (70.02 + 7.67 years) with mild to severe CVD were recruited 
from outpatient cardiology offices. Patients with clinical history of neurological disease or 
dementia were excluded. Ultrasound was used to assess flow-mediated endothelium-
dependent and nitroglycerin-mediated endothelium-independent BA vasodilation. 
Cognitive functioning was assessed using comprehensive neuropsychological testing.
Results: Hierachial multiple regression analyses revealed that endothelium mediated 
vasodilation correlated to neurocognitive testing performance, particularly to measures 
of attention-executive functioning and processing speed (R = .47, F(4, 80) = 5.76, p <. 
0001). Trail B neurocognitive tests correlated most strongly (β =-.35, p = .005), followed by 
the COWAT (β =.30, p= .01) and then Stroop (β = .28, p = .02). Endothelium-independent 
responses also correlated with neurocognitive performance (R = .27, F (1, 73) = 5.26, p 
=. 03). Clinical history of CVD risk factors (hypertension, smoking, hypercholesteremia) 
did not affect these relationships, nor did history of revascularization.
Conclusions: Endothelium-independent vasodilation of the brachial artery correlates with 
neurocognitive function in cardiovascular patients with no clinical evidence of dementia or 
cognitive impairment. This suggests that endothelial health is integral to cerebrovascular 
function and that abnormalities in endothelium-independent vasodilation are an early 
finding in cognitive dysfunction. Our data also demonstrate a broader relationship between 
vascular health and cognition, and raise the question whether improving vascular health 
may delay cognitive decline.
7:15 a.m.
805-4 Coronary Endothelial Dysfunction Associated with 
Depressive Mood in Patients without Coronary Artery 
Disease
Jin Won Kim, Young-Hoon Ko, Ji Hoon Kim, Cheol Ung Choi, Soon Yong Suh, 
Eung Ju Kim, Seung-Woon Rha, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, 
Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea
Background: The relation of depressive mood to coronary endothelial dysfunction is not 
documented. We investigated whether depressive symptomatology was associated with 
coronary endothelial dysfunction in patients without coronary artery disease (CAD).
Methods: In 160 patients without overt CAD and any medications, incremental 
acetylcholine (Ach; 20 µg, 50 µg and 100 µg/min) and nitroglycerin (NTG; 200 µg/min) 
were infused into the left coronary ostium. All patients were divided into two groups, 
depressive group (n=54, male 30, 51.8 yrs), as indicated by a Beck Depression Inventory 
(BDI) score ≥ 10 and a Hamilton Depression Rating Scale (HAM-D17) ≥ 7, and non-
depressive group (n=96, male 64, 51.3 yrs). The vascular response to each drug was 
quantitatively measured at the same site of left anterior descending artery.
Results: Patients in depressive group showed a significant vasoconstriction compared 
with patients in non-depressive group (p=0.017, 0.090, 0.004, respectively, Figure). 
Endothelium-independent vasodilatation to nitrates did not differ significantly between 
two groups (p=0.461, Figure). There were no differences of risk factors between two 
groups.
Conclusions: Depressive mood is associated with coronary endothelial dysfunction in 
patients without CAD, suggesting a possible mechanism by which depressive mood may 
act as a cardiovascular risk factor. 
7:30 a.m.
805-5 Adverse Cardiovascular Effects of Air Pollution in 
Patients With Coronary Heart Disease
Nicholas L. Mills, Hakan Tornqvist, Manuel C. Gonzalez, Elen Vink, Simon D. Robinson, 
Stefan Soderberg, Nicholas A. Boon, William MacNee, Ken Donaldson, Thomas 
Sandstrom, Anders Blomberg, David E. Newby, The University of Edinburgh, Edinburgh, 
United Kingdom, Umea University, Umea, Sweden
Background: Exposure to traffic-derived air pollution may worsen symptoms of angina 
and trigger acute myocardial infarction. The mechanisms for these associations are 
unknown. We conducted a controlled exposure of dilute diesel exhaust to determine the 
direct effect of air pollution on myocardial ischemia in patients with stable coronary heart 
disease.
Methods: In a double blind randomized cross-over study, 20 patients with prior 
myocardial infarction were exposed to dilute diesel exhaust (300 µg/m3) or filtered air 
during periods of rest and moderate exercise in a controlled exposure facility. During the 
exposure, myocardial ischemia was quantified by ST segment analysis using continuous 
12-lead electrocardiography.
Results: During both exposures, heart rate increased with exercise (P<0.001 for both) to 
a similar extent (P=ns; diesel exhaust versus filtered air). Exercise induced ST segment 
depression was present in all patients, but there was a marked increase in ischemic 
burden during exposure to diesel exhaust (-22±4 versus -8±6mVs, P<0.001). Diesel 
exhaust caused a 3-fold increase in maximal ST-segment depression (-49±12 versus 
17±15µV, P<0.05).
Conclusions: Brief exposure to dilute diesel exhaust promotes myocardial ischemia in 
patients with stable coronary heart disease. Our findings suggest an ischemic mechanism 
for the observations that exposure to combustion-derived air pollution is associated with 
adverse cardiovascular events including acute myocardial infarction. 
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805-6 Asymmetric Dimethylarginine and Reduced Nitirc Oxide 
Bioavailability in Young Black African Men
Narbeh Melikian, Stephen B. Wheatcroft, Ogah S. Okechukwu, Cliona Murphy, Philip 
J. Chowienczyk, Anthony Wierzbicki, Thomas AB Sanders, Edward R. Duncan, Ajay 
M. Shah, Mark T. Kearney, Cardiovascular Division, King’s College London School 
of Medicine, London, United Kingdom, Leeds Institute for Genetics, Health and 
Therapeutics, University of Leeds, Leeds, United Kingdom
Background Black Africans have a higher incidence of cardiovascular (CV) disease 
and greater endothelial dysfunction [secondary to reduced bioavailability of the anti-
atherosclerotic molecule nitric oxide (NO)] than white Europeans. This increased risk 
is not entirely accounted for by conventional risk factors for CV disease. We explored 
potential mechanisms of reduced NO bioavailability in young Black and White males.
Methods Endoothelial function [assessed by % brachial artery flow mediated dilatation 
(FMD)], inflammatory status [C-reactive protein (CRP)], oxidative stress [prostaglandin 
F2α (PGF2α)] and levels of leptin (a vasoactive peptide) and plasma asymmetric 
dimethyl arginine (ADMA; an endogenous competitive inhibitor of NO synthase) were 
assessed in each ethinic group.
Results 30 healthy Black and 28 White male subjects rigorously matched for CV risk 
factors were studied [mean age ± SE (years): 32.2±0.9 and 29.2±1.2 respectively; 
p=NS]. Anthropomorphic measurements, blood pressure, fasting lipids, glucose and 
renal function were similar in both groups. There was no difference in CRP (Blacks: 
0.8±0.1mg/L, Whites: 0.6±0.1mg/L p=NS), PGF2α (Blacks: 42.9±1.5pg/ml, Whites: 
39.2±1.5pg/ml p=NS) and leptin (Blacks: 64.1±10.2ng/ml, Whites: 47.8±9.8ng/ml 
p=NS) levels between the two ethnic groups. However, ADMA levels were significantly 
higher (Blacks: 0.34±0.02μmol/L, Whites: 0.25±0.03μmol/L p= 0.03) and % FMD 
lower (Blacks: 5.2±0.3, Whites: 6.3±0.4 p=0.02) in Blacks. Using univariate analysis 
there a significant negative correlation between FMD and ADMA (r = - 0.31, p=0.01), 
but not with CRP, PGF2α and leptin levels. In a stepwise, multivariate regression 
model, ADMA level was the only independent predictor of FMD [B±SE: -3.7±1.5, β: 
-0.31, t: -2.4, p 0.02, 95% CI: -6.8 - -0.6].
Conclusions Our findings indicate that circulating ADMA levels are significantly 
higher in healthy Black African males than in white European males. This may 
contribute to the lower NO bioavailability and higher incidence of CV disease seen 
in Black Africans.
8:00 a.m.
805-7 Coronary and Left Ventricular Angiographic Correlates 
of Chronic Kidney Disease Following Acute Myocardial 
Infarction - Data From the Survival And Ventricular 
Enlargement (SAVE) Trial
VINOD JORAPUR, Gervasio A. Lamas, Luis Morcillo, Pablo Guala, Paul A. Vignola, 
Sidney C. Smith, Greg C. Flaker, Scott D. Solomon, Marc A. Pfeffer, Mount Sinai 
Medical Center of Florida, Miami Beach, FL, Brigham and Women’s Hospital, Harvard 
Medical School, Boston, MA
Background: Chronic kidney disease (CKD) is associated with adverse outcomes 
following MI. It is not known if CKD is associated with a higher burden of CAD and 
adverse LV remodeling and if this explains the worse outcome.
Method: SAVE randomized 2231 patients 3 to 16 days post-MI with LVEF ≤40% 
and serum creatinine <2.5 mg/dl to captopril or placebo. Of these, 973 patients 
who underwent angiography a mean of 4 days post-MI were grouped by GFR 
(Table). CAD burden was quantified as: 1) number of vessels with stenosis >70% 
2) percent of evaluated coronary segments with stenosis 3) Gensini score and 4) 
presence of total occlusion. The LV angiographic variables analyzed were: EDV, 
ESV, EF, sphericity indices and MR.
Results: Patients with reduced eGFR were more likely to have multivessel disease, 
occluded arteries, a higher proportion of evaluated segments with disease, higher 
Gensini scores, lower LVEF, higher sphericity indices and more MR (Table). 
On multivariate analysis (adjusted for age, gender, diabetes, hypertension, 
smoking, family hx of CAD, angina, prior MI, PTCA and CABG), GFR group was 
independently correlated with Gensini score (coeff 5.0, 95% CI 2.4, 7.7 p<0.0001) 
and with percent of evaluated segments with >70% stenosis (coeff 0.95, 95% CI 
0.17, 1.73 p=0.017).
Conclusion: Mild to moderate CKD is independently associated with a greater 
burden of CAD and is associated with LV systolic dysfunction, adverse remodeling 
and MR, which may contribute to the increased risk associated with CKD in post-
MI patients. 
Coronary and LV angiographic parameters by GFR categories
Parameters
Group 1
GFR>75 
(N=380)
Group 2 GFR 
60-74 (N=305)
Group 3 GFR 
45-59 (N=217)
Group 
4 GFR 
<45
(N=71)
P value
Two or more vessels 
with>70% stenosis
153 
(40.3) 156 (51.2) 119 (54.9) 43 (60.5) <0.0001
% of evaluated segments 
in LCA and RCA with 
>30% stenosis
25.2 
(15.8) 29.3 (16.8) 30.0 (17.6)
31.6 
(14.6) <0.0001
% of evaluated segments 
in LCA and RCA with 
>50% stenosis
18.1 
(13.6) 21.9 (15.4) 23.2 (15.5)
24.6 
(14.9) <0.0001
% of evaluated segments 
in LCA and RCA with 
>70% stenosis
12.6 
(10.7) 15.5 (12.6) 16.2 (12.1)
17.9 
(12.3) <0.0001
Gensini score 59.2 (36.9) 67.8 (42.8) 71.2 (47.2)
74.9 
(47.9) <0.0001
LAD occlusion 148 (39.1) 131 (43.5) 101 (46.8) 29 (41.4) 0.156
Circumflex occlusion 48 (12.8) 63 (20.8) 54 (25.1) 15 (21.4) 0.001
RCA occlusion 89 (24.0) 98 (33.1) 66 (31.0) 27 (38.6) 0.007
Any occluded artery 216 (57.9) 203 (68.1) 141 (66.5) 49 (70.0) 0.01
LVEF (%) 32.2 (6.2) 31.3 (6.3) 30.7 (6.8)
31.5 
(7.3) 0.022
End-diastolic volume, ml 200.6 (62.9) 210.9 (79.0) 217.7 (75.6)
212.5 
(79.3) 0.077
End-systolic volume, ml 120.7 (47.7) 127.2 (55.7) 131.3 (53.8)
126.5 
(52.4) 0.150
Diastolic sphericity index 
length based
37.3 
(7.7) 38.6 (7.9) 39.1 (7.9)
40.8 
(8.1) 0.001
Systolic sphericity index 
length based
28.7 
(8.1) 29.2 (7.9) 30.0 (9.4)
31.4 
(8.3) 0.018
MR Grade ≥1, n (%) 40 (15.0) 52 (21.8) 30 (19.2) 17 (30.9) 0.017
GFR (ml/min/1.73m2) estimated by MDRD equation. Continuous variables are 
expressed as mean (standard deviation) and categorical variables as frequency (%).
8:15 a.m.
805-8 Cross-Sectional Relations of Pregnancy-Associated 
Plasma Protein-A Levels With C-Reactive Protein 
and Urinary Albumin Excretion Rate in Essential 
Hypertensive Subjects: A Novel Approach to Diffuse 
Atherosclerosis
Costas Tsioufis, Kyriakos Dimitriadis, Carmen Vasiliadou, Efstathios Taxiarchou, 
Costas Thomopoulos, Themis Psarros, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: Pregnancy-associated plasma protein-A (PAPP-A) is an emerging predictor 
of cardiovascular events, while urinary albumin excretion and subclinical inflammation are 
associated with atherosclerosis progression. In this study we examined the relationships 
of urinary albumin excretion, expressed as the albumin to creatinine ratio (ACR), with 
high-sensitivity C-reactive protein (hs-CRP) and PAPP-A in essential hypertensives.
Methods: Our population consisted of 80 newly diagnosed untreated non-diabetics 
with stage I to II essential hypertension [55 men, mean age=51 years, office blood 
pressure (BP)=144/92 mmHg]. According to the ACR values determined as the mean 
of two non-consecutive morning spot urine samples, the study population was divided 
into microalbuminurics (n=18) (mean ACR=30-300 mg/g) and normoalbuminurics (n=62) 
(mean ACR<30 mg/g). Moreover, all patients underwent ambulatory BP monitoring and 
venous blood sampling for estimation of hs-CRP and PAPP-A concentrations.
Results: Microalbuminurics compared to normoalbuminurics had higher 24-h systolic BP 
(138±18 vs 131±11 mmHg, p<0.05), while did not differ regarding age, sex, and metabolic 
profile (p=NS for all). Moreover, microalbuminurics compared to normoalbuminurics 
exhibited higher hs-CRP (5.6±1.1 vs 1.7±0.4 mg/l, p<0.0001) and PAPP-A levels (5.1±1.8 
vs 2.5±0.7 mIU/l, p<0.0001) In the total population, ACR was associated with 24-h systolic 
BP (r=0.284, p<0.05), hs-CRP (r=0.764, p<0.0001) and PAPP-A (r=0.617, p<0.0001), 
while PAPP-A was correlated with body mass index (r=0.308, p<0.005), hs-CRP (r=0.722, 
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p<0.005) and 24-h pulse pressure (r=0.225, p<0.05). Additionally, analysis of covariance 
revealed that hs-CRP and PAPP-A values were significantly different between groups 
after adjustment for confounders (p<0.05).
Conclusion: The augmented levels of hs-CRP and PAPP-A that accompany 
microalbuminuria support the notion that ACR reflects diverse proatherogenic pathways. 
Moreover, although PAPP-A has been considered only as a serological marker of plaque 
instability our findings suggest an earlier involvement of this metalloproteinase in the 
hypertensive atherosclerotic disease.
ACC.SYMPOSIUM / FEATURED ORAL ABSTRACT 
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612-5 Impact of Gene-based Intramuscular Interferon-
β Delivery on Diet-induced Atherosclerosis in 
Apolipoprotein E Knockout Mice
Yanming Huang, Matthew A. Hook, Kai Wang, Kwangdeok Lee, Xiaorong Zhou, 
Matthew Kiedrowski, Drew Hannaman, Robert M. Bernard, Claire F. Evans, Marc S. 
Penn, Cleveland Clinic, Cleveland, OH, Ichor Medical Systems, San Diego, CA
Background: Inflammation plays a crucial role in the development of atherosclerosis. We 
hypothesized that modifying inflammatory responses by gene-based intramuscular IFN-β 
delivery could have beneficial effects on plaque formation.
Methods: 36 male apolipoprotein E knockout mice were randomly allocated into three 
groups (n=12 each), fed with high-fat diet. In order to induce sustained IFN-β levels, 
the mice were treated with bilateral electroporation (EP)-mediated gene transfer into the 
tibialis muscles with injections of noncoding (Control) or IFN-β encoding plasmid. Animals 
were dosed with 10 μg in each leg, one group receiving only noncoding plasmid, another 
receiving only IFN-β encoding plasmid (Double treatment), and another receiving an 
injection of each plasmid (Single treatment).
Results: IFN-β treatment had no effects on lipoprotein levels. At 3 months, Oil red O 
staining of aortic sinus displayed pronounced atherosclerotic lesions in the control group. 
Both single and double IFN-β treatments revealed reduction of lesions area by 28.19% 
and 20.36% respectively compared to the control (Control 0.45±0.11; Single 0.32±0.11; 
Double 0.36±0.13 mm2, ANOVA P<0.05). The percent areas of lesion areas in the 
descending aorta of the treated groups were significantly inhibited (Control 12.12±5.87; 
Single 7.10±2.0, Double 6.41±1.52%, P<0.05). Consistent with an anti-inflammatory 
effect, the percent of area within the lesion occupied by macrophages of single and double 
treated groups trended down by 28.65 % and 27.87 % respectively. Quantification of the 
aortic sinus revealed significantly increased collagen content and area in plaque of the 
treated groups (Control 35.89±8.05; Single 45.43±9.76; Double 46.50±11.47%, P<0.05).
Conclusions: A single dose gene-based intramuscular IFN-β delivery decreased 
atherosclerotic lesion development in the ApoE null mouse and increased collagen 
deposition within the lesion proportion consistent with passivation of the plaque. Since 
IFN-β has been shown to be safe and is already approved for the treatment of multiple 
sclerosis, these data suggest further development of IFN-β for the prevention of acute 
coronary syndrome may be warranted.
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809-3 Multiple Splice Defects in ABCA1 cause Low HDL-C in a 
family with Premature Coronary Artery Disease
Jeffrey Rhyne, Myrna Mantaring, David Gardner, Michael Miller, University of Maryland 
Medical Center, Baltimore, MD
Background: Mutations at splice junctions causing exon skipping are rare and 2 different 
splice defects resulting in a pathologic phenotype has not been previously reported.
Methods: DNA from a 41 year-old male with low HDL-C (12 mg/dL) and a family history of 
premature CHD was screened using single-strand conformation polymorphism (SSCP) analysis. 
Results: Two novel splice variants in ABCA1 were identified. The first mutation was 
a single base pair change (T->C) in IVS 7, 6 bps downstream from the exon7/intron7 
junction. cDNA amplification and allelic subcloning identified skipping of Exon 7 that 
results in the elimination of 59 amino acids from the first extracellular loop of the ABCA1 
protein but does not result in premature truncation. The second mutation was a single 
base pair change (G->C) at IVS 31 +1, at the intron/exon junction of exon 32. This 
mutation causes skipping of exon 32, resulting in 7 novel amino acids followed by a stop 
codon and a predicted protein size of 1496 AA, compared to normal (2261 AA). Screening 
of family members (Figure), revealed that all exhibited low HDL-C in association with one 
or both defective alleles.
Conclusions: These data demonstrate that 2 different splice mutations may result in 
a pathologic phenotype. Therefore, a defective protein product with a normal coding 
sequence should raise the possibility of an abnormal splice domain.
Family with Low HDL (mg/dL) and ABC1 Splice Mutations causing Exon 
Skipping
ID TC TG HDL LDL ApoA1 ApoB Exon 7 Skipping Exon 32 Skipping
Father 189 245 35 105 149 110 YES no
Mother 155 293 31 65 139 87 no YES
Proband 101 56 12 65 70 59 YES YES
Sister 149 70 22 113 73 90 YES YES
Brother 159 176 24 100 109 94 no YES
Daughter 74 42 35 31 100 25 no YES
9:15 a.m.
809-4 Analysis of Multiple Methylation Derivatives of Amino 
Acids Suggests That Factors Independent of Nitric 
Oxide Synthase Inhibition Are Responsible for Their 
Prognostic Value for Cardiovascular Risk Prediction
Zeneng Wang, Leslie Cho, W. H. Tang, Stanley L. Hazen, The Cleveland Clinic 
Foundation, Cleveland, OH
Background: Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric 
oxide synthase (NOS), is reported to serve as a predictor of cardiovascular disease risk. 
However, the prognostic value of a family of alternative methyl-amino acid derivatives 
generated by related methylation pathways and sometimes possessing similar biological 
activities are unknown. For example, N-mono-methylarginine (MMA), the immediate 
precursor to ADMA, is a more potent albeit less abundant endogenous NOS inhibitor. 
Symmetric dimethylarginine (SDMA), an alternative methylation product of MMA, lacks 
NOS inhibitory activity, but like ADMA, inhibits arginine transporters. Herein we sought 
to examine the prognostic value of ADMA relative to SDMA, MMA, and Methyl-Lys, an 
independent methyl-amino acid.
Methods: Plasma was isolated from 1,000 consecutive consenting subjects undergoing 
diagnostic cardiac catheterization and future major adverse cardiac events (MACE = MI, 
stroke and death) were investigated. Plasma levels of ADMA, SDMA, MMA, and Methyl-
Lys were quantified simultaneously by HPLC with on-line tandem MS.
Results: Elevated (4th quartile for respective analyte) levels of either SDMA [2.2-fold 
(95%CI 1.3-3.5)] or ADMA [1.9-fold (95%CI 1.1-3.2)] predicted risk for future non-fatal MI 
or stroke. Both SDMA [4.6-fold (95%CI 1.8-11.7)] and ADMA [6.4-fold (95%CI 2.1-19.0)] 
similarly predicted risk for death, as well as future MACE (SDMA [2.9-fold (95%CI 1.9-
4.3)] and ADMA [2.9-fold (95%CI 1.9-4.5)]). In a multivariable logistic regression modeling 
adjusting for traditional cardiovascular risk factors, CRP and estimated GFR, both SDMA 
[2.1-fold, 95%CI 1.0 to 4.3] and ADMA [2.6-fold, 95%CI 1.3 to 5.4] remained independent 
predictors of MACE. No relationship between elevated levels of either MMA or Methyl-Lys 
and risk for MACE were observed.
Conclusions: Plasma ADMA and SDMA levels both predict prospective risks for non-fatal 
MI, stroke and death in a high risk population, whereas neither MMA nor Methyl-Lys 
shows prognostic value. These results suggest that factors other than NOS inhibition are 
responsible for the prognostic value of ADMA and SDMA.
9:30 a.m.
809-5 Fenofibrate Reduces Lipoprotein Associated 
Phospholipase A2 Mass and Oxidative Stress in 
Hypertriglyceridemia Subjects with the Metabolic 
Syndrome
Robert S. Rosenson, University of Michigan, Ann Arbor, MI
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a macrophage-
synthesized lipase that is primarily bound to small, electronegative LDL. Lp-PLA2 oxidatively 
modifies LDL and generates the proinflammatory byproducts oxidized non-esterified fatty 
acids (oxNEFA) and lysophosphatidylcholine. In this clinical trial, we examined whether 
fenofibrate reduces Lp-PLA2 mass and activity, and investigated whether the anti-
inflammatory effects of fenofibrate are related to changes in LDL subclasses.
Methods: In this double-blind, placebo-controlled trial, we investigate the effects of 
3-months treatment with fenofibrate (160 mg/d) on Lp-PLA2 mass and activity, LDL 
subclasses and oxidized fatty acids among 55 hypertriglyceridemic (≥ 150-600 mg/dL) 
subjects with the metabolic syndrome. Models were developed via stepwise regression 
for the fenofibrate-treated subjects with Lp-PLA2 mass as the response variable. Age and 
gender were forced in the models. LDL-C, small LDL particles, total LDL particles and 
oxidized-fatty acids (ox-FA) were available for selection.
Results: Fenofibrate treatment lowered fasting Lp-PLA2 mass by -13.2% (-19.0 to -
7.7) versus placebo -2.3% (-5.0 to 4.1) p = 0.0002. Lp-PLA2 activity did not change with 
fenofibrate therapy. Changes in Lp-PLA2 mass correlated with reductions in chemical LDL-
C (r = 0.29, p = 0.046), and NMR-measured total LDL particles (r = 0.69, p<0.0001) and 
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small LDL particles (r = 0.66, p<0.0001). In models that included small LDL, the effects of 
fenofibrate on Lp-PLA2 mass were attenuated (p = 0.082), but not in models that included 
LDL-C (p = 0.0001) and LDL particles (p = 0.005). Total ox-FA were reduced by 15.5% in the 
fenofibrate group compared with an increase of 11.5% in the placebo group (p=0.0013), but 
these changes were unrelated to changes in either Lp-PLA2 mass or Lp-PLA2 activity.
Conclusions: Among hypertriglyceridemia subjects with the metabolic syndrome, fenofibrate 
therapy reduced Lp-PLA2 mass, and these changes were associated with the lowering in 
small LDL particles. These data suggest that Lp-PLA2 may be a marker of macrophage 
activity and not an integral component of the anti-inflammatory effects of fenofibrate.
9:45 a.m.
809-6 High-Dose Atorvastatin Modifies the Protein Profile 
of Human Circulating Monocytes After an Acute 
Coronary Syndrome
Jose Tunon, Maria G. Barderas, Jose J. Jimenez-Nacher, Veronica M. Darde, Fernando 
De la Cuesta, Maria C. Duran, Nieves Tarin, Jose L. Martin-Ventura, Luis M. Blanco-
Colio, Lorenzo Lopez-Bescos, Fernando Vivanco, Jesus Egido, Fundacion Jimenez 
Diaz, Madrid, Spain, Universidad Complutense de Madrid, Madrid, Spain
Background: Aggressive treatment with high-dose atorvastatin (HDATV) reduces more 
effectively the incidence of cardiovascular events than moderate statin therapy. The 
mechanism of this benefit has not been fully elucidated. Novel proteomic techniques 
combining two-dimensional electrophoresis and mass spectrometry allow to examine the 
expression of multiple proteins at once in a given biological specimen.
Methods: Twenty-five patients with non-ST-elevation acute coronary syndrome were 
randomized to receive 80 mg/d atorvastatin (HDATV) (n=14) or conventional therapy 
(CT) (n=11), during two months. Blood was withdrawn at the end of treatment, and 
monocytes were extracted for proteomic analysis.
Results: Age, sex, total cholesterol, low-density lipoprotein (LDL), high-density 
lipoprotein (HDL), trigycerides, body mass index, the presence of hypertension, diabetes 
and smoking status were not significantly different between the two groups of patients. 
HDATV significantly reduced total cholesterol (p=0.038), LDL (p=0.017) and triglycerides 
(p=0.038), without affecting HDL (p=0.78). CT decreased only LDL levels (p=0.046). 
The expression of 20 proteins was significantly modified by HDATV. Among these were 
proteins involved in metabolism (chain A triosephosphate isomerase, pyruvate kinase 
3, phosphoglycerate kinase, adenosine triphosphate synthase, nuclease, chain A 
endonuclease, and chain A nuclease DNAse), stress response (paraoxonase I, heat-
shock proteins 70 and 60, and heat-shock cognate 71 kD protein), inflammation and 
thrombosis (annexins I and II, protein disulfide isomerase ER60, ficolins, and S100 
calcium binding protein A9), hydrolysis (cathepsin D proform), cell cycle regulation 
(stathmin), proliferation and angiogenesis (chain A ribonuclease inhibitor-angiogenin 
complex) and mitochondrial stability (prohibitin).
Conclusion: HDATV modifies the expression of 20 proteins involved in a broad spectrum 
of biological processes, in circulating monocytes from patients with non-ST-elevation 
acute coronary syndrome. Novel proteomic approaches may facilitate the study of the 
beneficial mechanisms of antiatherothrombotic drugs.
10:00 a.m.
809-7 Activation Of Peroxisome Proliferator-activated 
Receptor γ (PPAR- ) By Atorvastatin Is Mediated By 15-
deoxy-delta 12,14-PGJ2
Yochai Birnbaum, Yumei Ye, Shawn P. Nishi, Yu Lin, Ming-He Huang, Barry F. Uretsky, 
Jose R. Perez-Polo, University Of Texas Medical Branch, Galveston, TX
Background: HMG-CoA reductase inhibitors activate peroxisome proliferator-activated 
receptor γ (PPAR-γ). However, the mechanism is still unknown. Atorvastatin (ATV) 
upregulates and activates phospholipase A2 and cyclooxygenase-2. We investigated 
whether ATV activates PPAR-γ via 15-deoxy-delta-12,14-PGJ2 (15dPGJ2), a known 
endogenous ligand of PPAR-γ and a product of PGD2, and to compare the effects of 
Pioglitazone (PIO), a direct PPAR- γ activator, to that of ATV.
Methods: The first study involved measurement of myocardial 15dPGJ2 levels in the rat after 
a 3-day pretreatment with oral ATV (10 mg/kg/d), PIO (10 mg/kg/d), ATV+PIO, ATV+COX-1 
inhibitor (SC560) and ATV+COX-2 inhibitor (SC58125). We also assessed in human umbilical 
venous endothelial cells (HUVEC) whether ATV and PIO activate PPAR-γ via 15dPGJ2 using 
siRNA for PGD2 synthase. Both 15dPGJ2 levels and PPAR-γ activation were assessed.
Results: ATV and PIO increased myocardial 15dPGJ2 levels in the rat and HUVEC cells. 
siRNA inhibited this increase in both groups. Both ATV and PIO augmented PPAR-γ 
activation. Co-treatment with siRNA completely blocked the ATV effect but only partially 
inhibited the PIO effect (Figure).
Conclusions: Both ATV and PIO activate PPAR-γ and increase 15d-PGJ2 levels. 
Activation of PPAR-γ by ATV is mediated solely by 15dPGJ2, whereas PIO activates 
PPAR-γ both directly and indirectly via 15dPGJ2. PC- positive control. *- p<0.001 vs 
control; #- p<0.001 vs ATV; †- p<0.001 vs PIO. 
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1014-1 L-Methylfolate Enhances Flow Mediated Dilation in 
Patients with Abnormal Endothelial Function
Michal Kazimir, James V. Talano, Martin Matsumura, Diane Brzezinski, Sharon Kimmel, 
Teodoro Bottiglieri, Dana Wentzel, Janice Anderson, Lehigh Valley Hospital, Allentown, 
PA, SWICFT Institute, Naples, FL
Background: Chronic lowering of homocysteine (tHCY) has been shown to improve 
endothelial function as assessed by flow mediated dilatation (FMD) and is related to clinical 
outcomes. We hypothesized that immediate (90 min peak serum concentrations) and long 
term (eight weeks) oral supplementation with L-methylfolate with and without vitamins B6 
and B12 may have differing effects on FMD based on baseline endothelial function.
Methods: Patients (n=63) were randomized to three groups of L-methylfolate 2.8 mg (F), L-
methylfolate (2.8 mg) with methylcobalamin 2 mg and pyridoxal 5’-phosphate 25mg (F+B), or 
Placebo (P). FMD measurement and serum analysis was performed at baseline, 90 minutes 
post oral administration, and after 8 weeks of daily supplementation. Patients were further 
categorized into normal or abnormal FMD responders based on initial FMD > or < 8%.
Results: Baseline FMD values in normal baseline responders for F, F+B, and P were 
10.2%, 10.7%, and 11.0% and in abnormal baseline responders was 3.6%, 4.0%, and 
3.5%. There was no significant change in FMD for normal baseline responders from initial 
FMD to 90 minutes and over 8 weeks for each of P, F, or F+B (p=0.197, 0.461, 0.12, 
respectively). Abnormal baseline P responders had no change in FMD from initial FMD 
to 90 minutes (4.4%) or over 8 weeks (6.8%) (p=0.051). Abnormal baseline F responders 
had FMD response at 90 minutes to 8.0% (p=0.061) and a significant increase over 8 
weeks to 8.5% (p=0.015). Abnormal baseline responders F+B had a significant FMD 
response at 90 minutes to 8.0% (p=0.015) and to 6.4% over 8 weeks (p=0.021).
Conclusions: Immediate and long term oral L-methylfolate with or without B vitamins 
improves endothelial function in patients with abnormal baseline FMD response, but not 
in patients with normal baseline FMD. This data may explain the discordant results seen in 
recent large folic acid supplement trials and identify a patient population who will clinically 
benefit from folic acid supplementation.
11:00 a.m.
1014-2 Endothelial Dysfunction Increases Hypertensive 
Evolution and Mortality
Tatsuaki Murakami, Katsushi Misawa, Fukui Cardiovascular Center, Fukui, Japan
Background: Hypertension and endothelial dysfunction (ED) are thought to affect 
atherosclerotic processes, but we know little about the relationship between ED and 
evolutional mechanism of hypertension. This study assessed hypothesis that ED 
accelerates hypertensive evolution (HTE) and affects longevity of the patients.
Methods: ED was graded by ultrasonic measured reactive changes in lumen diameter of 
brachial artery after transient forearm occlusion (FMD) in consecutive 518 patients with 
suspected coronary artery disease. The enrolled patients were categorized into 3 groups 
according to the values of FMD, and we prospectively followed-up their HTE and fatal 
events for 36 months or more. HTE was defined as no less than two stage upgrade of 
hypertension proposed by JNCVI or new administration of an antihypertensive agent.
Results: For a mean follow-up period of 60 months with 100% follow-up, the patients 
with severe endothelial dysfunction (FMD<4%; Group-L, n=174) more frequently 
developed HTE compared to Group-M with mild endothelial dysfunction (4%≤FMD<8%, 
n=171) plus Group-H with preserved endothelial function (FMD 8% or more), [44(25.2%) 
versus 17(9.9%) plus 9(5.2%), p<0.001, by Kaplan-Meier analysis] and fatal outcome 
[15(8.6%) versus 4(2.3%) plus 2(1.2%), p<0.001]. Cox proportional hazard model 
analysis showed that severe endothelial dysfunction was the predictor for HTE (odds 
ratio=2.87, 95%confidential interval; 1.73-4.77, p<0.001) and the only predictor for future 
cardiovascular death (odds ratio=10.34, 95%confidential interval; 1.26-72.25, p=0.022) 
and all-causal death (odds ratio=5.87, 95%confidential interval; 1.12-52.34, p=0.009).
Conclusions: These results indicate that endothelial dysfunction increases hypertensive 
evolution and mortality of the patients.
11:00 a.m.
1014-3 Flow Cytometric Assessment Of Vasodilatator 
Stimulated Phosphoprotein (vasp): Prognostic Value Of 
Recurrent Cardiovascular Events After Acute Coronary 
Syndrome
Guillaume CAYLA, Jean Christophe MACIA, François ROUBILLE, Richard 
GERVASONI, Jean François SCHVED, Florence LECLERCQ, Clinique du coeur et des 
vaisseaux, hôpital Arnaud de Villeneuve, Montpellier, France
Background: Clopidogrel has shown to reduce the risk of cardiovascular events after 
acute coronary syndrome (ACS), but numbers of incidents still occur. Usual biological 
tests have shown that about 4 to 30 % of patients treated with clopidogrel do not display 
adequate antiplatelet response. VASP (Vasodilatator-stimulated phosphoprotein), an 
intraplatelet protein, depends on platelet P2Y12 receptors. Easily realizable in clinical 
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practice, flow cytometric assessment of VASP phophorylation seems to be an interesting 
tool, for testing clopidogrel response. The aim of this study was to evaluate prognostic 
value of clopidogrel response using flow cytometric assessment of VASP in patients 
admitted for ACS without persistent ST segment elevation.
Methods: We prospectively studied clopidogrel response in 49 patients treated with a 
loading dose of 300 mg of clopidogrel followed by a dose of 75 mg/ day, associated with 
75 mg of aspirin. For each patient we studied VASP phosphorylation using a platelet 
reactivity index (PRI) before treatment (baseline) and at day 1 and day 4. The relation 
between of these measurements and cardiovascular events (CVE) was prospectively 
examined over 6 months.
Results: Analysis of VASP (mean ± SD) showed a time decreased of PRI: 86 % ± 6 before 
treatment, 71% ± 13 at day 1, and 61 ± 16 at day 4 (p<0,001) with an important inter-
individual variability. Patients were stratified into 4 quartiles according to the PRI measured 
at day 4. Six events occurred during the six month follow-up and five of them were classified 
in the fourth quartile which represents the low responders. Mean PRI of patients with CVE 
was 76% ± 3 and 59 % ± 16 in patients without cardiovascular events (p=0,006). The best 
cut-off of PRI of VASP was 70 % to predict high risk patient after ACS.
Conclusions: Flow cytometric assessment of VASP phosphorylation in patients with 
ACS identifies low responders to clopidogrel therapy with increased risk of recurrent 
cardiovascular events.
11:00 a.m.
1014-4 Involvement Of EPIgenetic Variation In Restenosis After 
PCI
Douwe Pons, Pascalle S. Monraats, Florentine R. de Vries, Moniek P.M. de Maat, Aeilko 
H. Zwinderman, Robbert J. de Winter, Pieter A.F.M. Doevendans, Rene A. Tio, Rune R. 
Frants, Bas T. Heijmans, P. Eline Slagboom, Arnoud van der Laarse, Ernst E. van der 
Wall, J. Wouter Jukema, Leiden University Medical Center, Leiden, The Netherlands, 
Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands
Introduction: There is increasing evidence that epigenetic mechanisms regulate several 
processes known to be part of atherosclerosis and restenosis. Acetylation of histones, 
as performed by Histone Acetyl Transferases (HATs), is needed to allow transcription 
factors to bind to their recognition sequences on DNA and to initiate gene transcription. 
P300/CBP Associated Factor (PCAF) is a transcriptional coactivator with intrinsic HAT 
activity. Because of its established role in inflammation, proliferation and matrix formation, 
PCAF could be involved in the development of restenosis after PCI. Therefore, our aim is 
to examine the impact of polymorphisms in the PCAF gene on the risk of restenosis in a 
large patient-population undergoing PCI.
Methods: The GENetic DEterminants of Restenosis (GENDER) project is a multicenter 
prospective study, including 3104 consecutive patients after successful PCI, with Target 
Vessel Revascularization (TVR) as primary endpoint. We selected 9 SNPs from 8 haplotype-
blocks in the LD map of the PCAF gene provided by the international HAPMAP project.
Results: After multivariate analysis, the -2481 G/C promoter SNP was significantly 
associated with the risk of TVR (RR: 0.8, p=0.019). Analysis of the 16150 C/T, 39859 C/T 
and the 54516 T/C SNPs revealed haplotype effects of the C16150-T39859-T54516, C-C-C and 
T-C-T haplotypes on the risk for TVR when compared to the C-C-T reference haplotype 
(RR: 1.32, p=0.009, RR: 1.31, p=0.024, RR: 1.46, p=0.003, respectively), independent of 
clinical risk factors for restenosis. Furthermore, combining the 75071 T/A and the 92457 
C/T SNPs showed a significant effect of the T75071-C92457 haplotype when compared to the 
A-C reference haplotype (RR: 0.8, p=0.029).
Conclusions: We are the first to investigate epigenetic variation in restenosis and 
found a significant protective effect of the -2481C promoter variant on the risk for TVR. 
Furthermore, we observed significant haplotype effects in 2 different regions of the gene. 
Our results indicate that indeed epigenetic variation may play a role in restenosis after 
PCI. These findings could contribute to the unravelling of the restenotic process and may 
provide targets for future therapy.
11:00 a.m.
1014-5 Vascular Inflammation Evaluated By 18F-
fluorodeoxyglucose Positron Emission Tomography Is 
Associated With The Metabolic Syndrome
Nobuhiro Tahara, Minori Mizoguchi, Hisashi Kai, Sho-ichi Yamagishi, Masatoshi 
Ishibashi, Tsutomu Imaizumi, Department of Medicine, Division of Cardiovascular 
Medicine, Kurume University School of Medicine, Kurume, Japan, Department of 
Radiology, Kurume University School of Medicine, Kurume, Japan
Background: Inflammation is present in some atherosclerotic plaques. 18F-
fluorodeoxyglucose positron emission tomography (FDG-PET) is capable of identifying 
and quantifying vascular inflammation within atherosclerotic plaques. We investigated 
factors for carotid artery inflammation by FDG-PET.
Methods: FDG-PET imaging was performed in 216 consecutive patients (63±9 
years, men:women, 147:69) for cancer screening. Vascular inflammation in carotid 
atherosclerosis was quantified by measuring the standardized uptake value (SUV) of 
FDG into the artery.
Results: Multiple stepwise regression analysis revealed significant relationships between 
SUV and waist circumference (p<0.001), hypertensive medication (p<0.001), carotid 
intima-media thickness (p<0.001), HDL-cholesterol (p<0.01, inversely), homeostasis 
model assessment of insulin resistance (p<0.05), or high sensitivity C-reactive protein 
(p<0.05). Age- and gender-adjusted SUV of FDG was significantly higher (p<0.0001) 
in proportion to the accumulation of the number of the components of the metabolic 
syndrome. Thus the metabolic syndrome was associated with increased FDG uptake in 
carotid atherosclerosis.
Conclusions: Our present study may suggest that the metabolic syndrome is associated 
with inflammation in carotid atherosclerosis. 
11:00 a.m.
1014-6 Predictors for Developing a new Significant Lesion 
After Percutaneous Coronary Intervention: the Impact 
of Clinical Syndrome and The Smokers ‘Paradox’
Christos Deboneras, Konstantinos Toutouzas, Maria Drakopoulou, Virginia Markou, 
Andreas Synetos, Manolis Vavuranakis, Eleftherios Tsiamis, Costas Tsioufis, Elli 
Stefanadi, Christodoulos Stefanadis, First Department of Cardiology, University of 
Athens, Hippokration hospital, Athens, Greece
Background: The risk factors for the development of a new symptomatic lesion 
progression after percutaneous coronary intervention (PCI) are still under investigation. 
The aim of the present study was to investigate the predictors of development of a new 
lesion after percutaneous coronary intervention (PCI).
Methods: We included pts who had 2 coronary angiograms with a time interval greater > 
than 3 months. The first angiogram was performed due to either acute coronary syndrome 
(ACS) or stable angina (SA). The culprit lesion of the first angiogram was clearly identified 
by a combination of ECG, wall motion abnormalities, scintigraphic perfusion defects, 
and coronary angiogram. All pts underwent PCI for the treatment of the culprit lesion. 
In the second angiogram we investigated whether they had a new culprit lesion clearly 
differentiated from the culprit lesion of the first angiogram (primary endpoint). In all pts we 
recorded demographic, clinical, angiographic and procedural characteristics.
Results: We included 179 pts (mean age 63.2±10.8 years) with 2 angiograms during a 
follow-up period of 11.3±5.7 months. The majority of the study population was treated due 
to ACS (112 pts, 63%), while the rest had SA (67 pts, 37%). The primary endpoint was met 
in 48 pts (26%). The development of a new lesion was proven angiographically in all pts. 
We performed multivariate regression analysis including variables in which in the univariate 
analysis p value was <0.15. The strongest predictor for developing a new significant lesion 
was the clinical syndrome at baseline. Patients presenting with ACS had 3 times greater 
risk for developing new lesion after PCI (coefficient=3.01, p=0.003). Indeed, 43% of pts with 
ACS had a new lesion during the follow-up versus 18% of pts with SA (p < 0.01). However, 
current smoking was associated with lower risk (coefficient=0.3, p=0.01).
Conclusions: Patients presenting with ACS had a greater risk of developing a new 
significant lesion after PCI. Interestingly, current smokers seem to have lower risk of 
developing such lesions.
11:00 a.m.
1014-7 Immunotargeting of Vascular Inflammation
Elizabeth Hood, Monica Gonzalez, John Elliott, Karl Muffly, Joel A. Strom, Michael D. 
VanAuker, University of South Florida, Tampa, FL
Background: Inflammatory processes play a role in vascular disease. Expression of 
cellular adhesion molecules such as CD44 is upregulated in inflamed endothelium and 
therefore may promote atheosclerosis. This may provide a target for delivery of therapeutics 
specific to reducing or disrupting inflammation. Nonionic surfactant vesicles (niosomes) are 
potential stable, low cost drug delivery vehicles that have been shown in other contexts to 
be useful in lowering systemic doses of drug for efficacy. We addressed the hypothesis that 
niosomes could be synthesized that could specifically target the CD44 molecule.
Methods: Niosomes containing fluorescent green carboxyrhodamine dye were created 
using a combination of modified surfactants. Through a novel process we developed, we 
conjugated these to anti-CD44 (IM7) monoclonal antibodies to form “immuno-niosomes”. 
These were incubated with bovine aortic endothelial cells (BAECs) activated with TNF-α 
to express CD44. To verify and quantify binding, phase contrast and fluorescent images of 
post incubated cells were captured. Cells were DAPI blue stained to visualize the nuclei. 
The number of immuno-niosomes bound to cells was determined through a custom-made 
image analysis program. Binding density was defined as a ratio of the number of immuno-
niosomes per cell nucleus. Controls included cell incubation with unconjugated niosomes 
and BAECs pre-incubated with free IM7 to block binding sites.
Results: A subgroup of BAECs underwent immunohistochemical staining which verified 
expression of CD44 on the cell surface. Comparison of experiments with immuno-
niosomes versus controls revealed good selectivity and specificity. For a 1 hour incubation 
of immuno-niosomes at a concentration of 3.0x107 #/ml and a cell density of 2.20x105 
cells/cm2, binding density was 2.29 +/- 0.26 per cell.
JACC  March 6, 2007    ABSTRACTS - Vascular Disease, Hypertension and Prevention    357A 
Vascular D
isease, H
ypertension and P
revention
Conclusions: We have confirmed the capacity to develop monoclonal antibody conjugated 
niosomes targeted to specific cell receptors, namely CD44. Further exploration of the 
capacity of vesicle binding and subsequent uptake in endothelial cells of the immuno-
niosomes to test the potential to target inflammatory disease is warranted.
11:00 a.m.
1014-8 Involvement of the Interaction between Mediterranean 
Diet and Methylenetetrahydrofolate Reductase C677T 
Mutation on Oxidized Low Density Lipoprotein 
Concentrations; the ATTICA Study
Christina Chrysohoou, Demosthenes Panagiotakos, Christos Pitsavos, John Skoumas, 
George Dedoussis, Constadina Paliou, Akis Zeibekis, Lambros Papademetriou, 
Christodoulos Stefanadis, 1st Cardiology Clinic University of Athens, Athens, Greece
Background: The oxidative modification of low-density lipoprotein (LDL) has been 
suggested as a key element in atherogenesis, while Methylenetetrahydrofolate Reductase 
(MTHFR) C677T mutation has been associated with the development of coronary heart 
disease. We evaluated whether adoption of Mediterranean diet is associated with oxidised 
LDL levels, as well as the role of MTHFR C677T mutation in this relationship.
Methods: We studied demographic, lifestyle, clinical, biochemical and genetic 
information from 322 men (46 ± 13 years) and 252 women (45 ± 14 years), without any 
clinical evidence of cardiovascular disease, from Attica region, Greece (i.e. the ATTICA 
study). Among other characteristics we also measured oxidized (ox)-LDL levels, and the 
distribution of MTHFR. Adherence to the Mediterranean diet was evaluated through a 
special diet score
Results: The distribution of MTHFR genotypes was: 41% for homozygous normal (CC) 
genotype, 48% for heterozygous (CT) and 11% for homozygous mutant (TT) genotype. 
Ox- LDL levels were higher in TT as compared to CC and CT (70.8 ± 26 vs. 51.0 ± 
26 vs. 63.7 ± 24 mg/dl, p < 0.001). Greater adherence to the Mediterranean diet was 
inversely associated with ox-LDL levels (standardized Beta = -0.34, p < 0.001), after 
controlling for several confounding variables; however, stratified analysis revealed that 
adherence to the Mediterranean diet was associated with lower ox-LDL levels in TT and 
CT individuals (standardized Beta = -0.67, p = 0.001 and standardized Beta = -0.66, p = 
0.025, respectively), but not in CC (standardized Beta = -0.18, p = 0.10), after controlling 
for several potential confounders.
Conclusions: The observed gene-to-diet interaction on ox-LDL concentrations may 
provide a pathophysiological explanation by which Mediterranean diet could influence 
coronary risk in people with increased oxidative stress.
11:00 a.m.
1014-9 Coronary Endothelial Dysfunction and Hyperlipidemia 
are Independently Associated with Diastolic 
Dysfunction in Humans
Ahmad A. Elesber, Margaret Redfield, Charanjit Rihal, Abhiram Prasad, Shahar Lavi, 
Lilach Lerman, Amir Lerman, mayo clinic, rochester, MN
Background: Coronary endothelial dysfunction and diastolic heart failure (DHF) are both 
associated with myocardial ischemia and coronary artery disease (CAD) risk factors. 
However the association between coronary endothelial dysfunction and DHF remains 
unclear. The objective of the current study is to determine if coronary endothelial 
dysfunction and CAD risk factors are associated with diastolic dysfunction prior to the 
development of occlusive CAD or clinical heart failure.
Methods: One hundred and eighty one patients with normal ejection fraction and 
nonocclusive CAD (diameter stenosis <30%) who underwent coronary endothelial 
function studies were retrospectively identified. Left ventricular relaxation was assessed 
by tissue Doppler assessment of early diastolic ascent of the septal mitral annulus (Ea). 
Multivariate models were created to study the effects of the endothelium dependent 
vasodilatation to acetylcholine (%ΔCBF) and compare standardized coefficients (SC).
Results: Of 181 candidate patients, 160 had adequate assessment of diastolic relaxation. In 
the multivariate model, %ΔCBF (SC=0.16; p=0.014) was associated with a higher Ea, while 
older age (SC=-0.39; p<0.001); female sex (SC=-0.010; p=0.0064); higher left ventricular 
mass index (SC=-0.21; p=0.0029); higher fasting glucose (SC=-0.18; p=0.0082); and 
higher non-HDL cholesterol (SC=-0.19; p=0.0053) were associated with a lower Ea.
Conclusions: Coronary microcirculation endothelial dysfunction is independently 
associated with impaired relaxation in patients with normal ejection fraction in the absence 
of occlusive CAD and heart failure. Hyperlipidemia is associated with the presence of 
impaired relaxation even after adjusting for coronary vascular function and other risk 
factors known to modulate diastolic function. The current study suggests a common 
mechanism for the development of endothelial and diastolic dysfunction in humans.
11:00 a.m.
1014-10 Segmental Coronary Endothelial Dysfunction in 
Humans is Associated With Necrotic Core Plaques
Shahar Lavi, Jang-Ho Bae, Charanjit S. Rihal, Abhiram Prasad, David R. Holmes, Amir 
Lerman, Mayo Clinic, Rochester, MN
Background: Endothelial dysfunction and atherosclerosis are systemic disorders with 
segmental involvement. We tested the hypothesis that in patients without significant 
coronary artery disease, coronary artery segments with abnormal endothelial function 
have characteristics of plaque vulnerability.
Methods: Fifty seven lesions of eight patients without significant angiographic coronary 
disease were assessed for coronary endothelial function and analyzed with intravascular 
ultrasound using virtual histology software. Lesions were divided into two groups 
according to endothelial response to acetylcholine.
Results: Thirty lesions in segments with abnormal endothelial function had smaller lumen 
(8.0±1.7mm2 vs. 11.5±2.6mm2, p<0.001) and vessel area (13.0±3.3mm2 vs. 15.6±3.7mm2, 
p<0.01), but larger plaque burden (37.2±9.1% vs. 26.5±3.9 %, p<0.001) compared 
to 27 lesions in segments with normal endothelial response. Lesions with endothelial 
dysfunction had relatively higher dense calcium, and necrotic core than those with normal 
endothelial response (Figure). By multivariate analysis necrotic core plaques, and smaller 
lumen area were independently associated with coronary endothelial dysfunction.
Conclusions: In patients with early coronary atherosclerosis, endothelial dysfunction is 
localized to segments with vulnerable plaques characteristics. The study supports the 
relationship between endothelial dysfunction and plaque vulnerability. 
11:00 a.m.
1014-11 “Sticky Platelet Syndrome”: Platelet Hyperfunction, 
Alone or with Other Recognized Thrombophilias, 
Is Strongly Associated with Venous and Arterial 
Thrombosis
Haroon A. Faraz, Andrea Haggood, Maggie Jones, Venkata Parsa, Tannu Sahay, 
Eberhard Mammen, Judith C. Andersen, Wayne State University, Karmanos Cancer 
Institute, Detroit, MI
Background:  “Sticky Platelet Syndrome,” (SPS) an autosomal dominant variety of 
platelet hyperfunction defined by altered platelet threshold sensitivity to epinephrine 
and/or adenosine dinucleotide phosphate, was described in 1983 in families with early 
arterial>venous thrombotic events. Its molecular mechanism and population prevalence 
have not yet been determined.
Methods: An observational study was conducted to evaluate the prevalence of SPS in a 
large cohort of patients referred to our center for evaluation of thrombophilic predisposition. 
Records of all patients over a 6 year period were reviewed. SPS was identified when 
platelet aggregometry, performed on at least two occasions, at least 2 weeks apart, by 
standard methods in platelet rich plasma, revealed aggregation amplitudes of > 50% with 
epinephrine and/or ADP concentrations of 2 x 10-7M and 1 x 10-7M, respectively.
Results:  Of 919 such patients evaluated for a broad spectrum of thrombophilic 
predispositions, 341 (37%) exhibited aggregation criteria for the syndrome. 13% of 
patients had solitary SPS while 24% had co-existing thrombophilia.
211/341 patients were female (62%), 130 male (38%), 191 were African-American (56%), 
150 Caucasian (44%). Out of the 341 patients with SPS, 73% had venous thrombosis 
while 27% had arterial thrombosis. Among patients with SPS and co-existing thrombilias, 
50% had hyperhomocysteinemia, 35% had factor VIII activity >150%, 30% had 
antiphospholipid antibody syndrome, 20% had plasminogen activator inhibitor elevation 
and 11% had factor V leiden mutation
Conclusion:  SPS is commonly associated with venous and arterial thrombosis in 
patients undergoing evaluation for recognized causes of thrombophilia and is the only 
identified predisposition in 13% of population.
These observations suggest that evaluation for thrombophilic predisposition in patients 
of mixed ethnic background with venous and arterial thrombosis that does not include 
testing for platelet hyperfunction will miss an important, potentially easily modified 
abnormality in >10% with no other risk factors and in an additional >20% in whom it 
represents a collaborative risk factor.
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1014-12 Glucose Suppresses Endothelial Cell Proliferation By 
Inhibiting Adenosine-stimulated Erk1/2 Activation 
Shailesh Nandish, Sarvesh Jajoo, Debashree Mukherjea, Vickram Ramkumar, Southern 
Illinois University School of Medicine, Springfield, IL
Background: Delayed reendothelialization contributes to restenosis after percutaneous 
coronary interventions in patients with diabetes. Adenosine and adenosine analogs, acting on 
vascular endothelial cell adenosine A2A or A2B receptors have been shown to stimulate ERK1/2 
activity, VEGF production and increase cell proliferation. The purpose of this study was to 
explore the effects of transient exposure to high glucose on endothelial cell integrity.
Methods: Human umbilical vein endothelial cells (HUVECs) were incubated for 30 min with 
vehicle (0) or glucose (5-60 mM) and analyzed for ERK 1/2 activation by Western blotting. 
Inhibition of A2AAR -stimulated ERK1/2 phoshorylation by glucose was evaluated by treating 
HUVECs with glucose (5-60 mM) for 30 min, followed by R-phenylisopropyladenosine (R-
PIA, 1 μM) for 15 min. Further, inhibition of basal and R-PIA-stimulated proliferation of 
HUVECs by glucose were evaluated with MTS assay by treating HUVECs with adenosine 
deaminase (1 unit/ml) plus glucose and/or R-PIA for 24 h.
Results: Exposure of cells to glucose for 30 min inhibited the basal expression of 
ERK1/2 with the concentration producing 50% inhibition (IC50) being ~20 mM glucose. 
Cells exposed to 1 μM R- phenylisopropyladenosine (R-PIA) showed increased ERK1/2 
phosphorylation, which was reduced dose-dependently by glucose. There was a 
substantial reduction in R-PIA-stimulated ERK1/2-phosphorylation by 20 mM glucose, 
with progressive reductions at 40 and 60 mM concentration. In addition, we observed a 
significant increase in HUVECs proliferation with R-PIA. However, 10 and 20 mM glucose 
reduced the basal cell proliferation and blunted the proliferation induced by R-PIA.
Conclusions: Transient hyperglycemia could inhibit the maintenance of vascular 
endothelial cell integrity by endogenous adenosine through attenuation of cell proliferation 
(via ERK1/2), leading to dysregulation of vascular endothelial layer repair, thus contributing 
to the increased incidence of restenosis and stent thrombosis in patients with diabetes. 
Administration of exogenous adenosine analogs may attenuate the inhibitory action of 
glucose and aid in reendothelialization.
11:00 a.m.
1014-13 Statins Inhibit Cholesterol Crystallization and Prevent 
Perforation of Biological Membranes and Intima in 
Human Coronary Arteries of Patients With Acute 
Coronary Syndrome
George S. Abela, Kusai Aziz, Ruiping Huang, Joyce DeJong, Michigan State University, 
East Lansing, MI, E. W. Sparrow Hospital, Lansing, MI
Background: Recently we demonstrated that cholesterol crystallization is strongly 
associated with plaque rupture in humans and in vitro. We hypothesized that statins could 
stabilize plaques by altering cholesterol crystallization.
Methods: Pravastatin effect on crystallization was evaluated by melting cholesterol 
powder (2g) in tubes, adding pravastatin (0, 10, 20, 40, 60 or 80 mg) and allowing 
crystallization to measure volume changes. Crystal morphology was examined by 
scanning electron microscopy (SEM). Effect on membrane injury was evaluated by 
placing biological membranes (rabbit pericardium) in the path of growing crystals. 
Also, culprit human coronary arteries (CAs) from patients who died with acute coronary 
syndrome were cut longitudinally. One half segment was incubated with simvastatin; the 
other was control prior to SEM.
Results: Crystallized cholesterol expanded by a peak volume of 35% but pravastatin 
reduced or eliminated volume expansion in a dose dependent fashion (p<0.0001; 
ANOVA). Pravastatin altered pointed crystal geometries averting membrane damage 
(Figure). CAs incubated with simvastatin had markedly reduced number and size of 
crystals perforating the intima compared to matched controls.
Conclusions: Statins reduced expansion and altered crystal geometry averting 
membrane injury in vitro; and reduced the number and changed configuration of crystals 
in human CAs. Thus, statins may stabilize atherosclerotic plaques by preventing cap 
damage by cholesterol crystals. 
11:00 a.m.
1014-14 Asymmetric Dimethylarginine (ADMA) As A Mediator Of 
Inflammation And Coronary Microvascular Endothelial 
Dysfunction In Postmenopausal Women
akiko yoshikawa, Shuichi Hamasaki, Sanemasa Ishida, Tetsuro Kataoka, Masakazu 
Ogawa, Keishi Saihara, Hideki Okui, Tsuyoshi Fukudome, Takuro Shinsato, Naoya 
Oketani, Takahiro Shirasawa, Takuro Kubozono, Etsuko Mizoguchi, Hitoshi Ichiki, So 
Kuwahata, Shoji Fujita, Yuichi Ninomiya, Chuwa Tei, Department of Cardiovascular, 
Respiratory and Metabolic Medicine,Kagoshima University, Kagoshima, Japan
Background: It has been reported that endothelial dysfunction is associated with an 
cardiovascular risk. Asymmetric dimethylarginine (ADMA), the endogenous NO synthase 
inhibitor, has been reported to be a predictor of an increase risk of cardiovascular disease 
like the other established cardiovascular risk factors. This study was designed to examine 
the effect of ADMA on coronary endothelial function and to assess the relation of ADMA 
to the other parameters of metabolic disorder.
Methods: The study population consisted of 32 post menopausal women (70±6yrs) 
and 27 age matched men (67±10yrs) without significant coronary artery stenosis 
(%diameter stenosis<30%). Coronary vascular reactivity was examined by intra-coronary 
administration of papaverine, acetylcholine (Ach), and nitroglycerin using a Doppler 
guidewire. Plasma ADMA concentrations were measured by HPLC method. C-reactive 
protein (CRP), LDL-cholesterol, HDL-cholesterol, triglyceride, fasting blood sugar, 
HOMA-R, waist circum ference, and systemic blood pressure were evaluated. Estradiol 
and follicular stimulating hormone were also measured to estimate the relation to ADMA. 
Coronary vascular reactivity was compared between women and men.
Results: Plasma ADMA concentration was comparable between women and men 
(0.51±0.85vs. 0.50±0.56nmol/ml). In a multivariate analysis, the percent change in 
coronary blood flow induced by Ach highly and inversely correlated with plasma ADMA 
concentration (p=0.018) in women, but not in men. In a monovariate analysis, plasma 
ADMA concentrations positively correlated with C-reactive protein(r=0.54, p<0.01) and 
inversely correlated with HDL-cholesterol (r=-0.42, p<0.05) in women, which was not 
shown in men. Additionally, multivariate analysis showed that CRP was highly correlated 
with ADMA. Conclusion: These results suggest that ADMA is highly associated with 
endothelial dysfunction in the resistance coronary artery, which may be mediated by the 
expression of CRP in postmenopausal women.
Control # 07-A-350106-ACC
11:00 a.m.
1014-35 Atherosclerotic Plaque Inflammation and 
Calcification - a Negative Relationship Imaged using 
Fluorodeoxyglucose Positron Emission Tomography 
and Computed Tomography
James H. Rudd, Kelly Myers, Sameer Bansilal, Silvia Aguiar, Michael Farkouh, Josef 
Machac, J. H. Kim, Valentin Fuster, Zahi Fayad, Mount Sinai School of Medicine, New 
York
Background: Atherosclerosis is an inflammatory disease, and FDG PET can identify 
and quantify inflammation within atherosclerotic plaque. Calcification is a late stage of 
atherosclerosis which may have a stabilizing effect on the plaque. We examined the 
relationship between atherosclerotic plaque inflammation and calcification in several 
arterial beds using PET/CT imaging. We imaged a patient group with established vascular 
disease (post-CABG or PCI).
Methods: 26 patients underwent PET/CT imaging on a GE Discovery LS scanner. Aortic 
and carotid images were acquired 90 mins after 10 mCi FDG injection with CT used for 
coregistration and calcium scoring. To estimate FDG uptake into plaque, standardized 
uptake values (SUV) were calculated using ROI applied to the PET/CT images and 
corrected for blood FDG activity.
Results: Mean age was 62 years, with 40% females and 77% patients were taking 
statins.
Inflammation in one arterial territory was highly correlated with inflammation in other 
territories. Ascending aorta FDG vs. aortic arch FDG r=0.83, vs. descending aorta FDG 
r=0.83, vs.abdominal aorta FDG r=0.76 and vs. carotid FDG uptake r=0.41 (all p<0.05). 
But calcification and FDG uptake rarely overlapped - there was a significant negative 
correlation between aortic arch calcification and FDG uptake (r=-0.36, p<0.05). Similar 
trends were noted in the ascending and descending aorta and carotid arteries. Statin 
therapy was associated with less inflammation in the carotid arteries - mean (±SEM) SUV 
in statin group vs. non-statin group 1.45 (0.3) vs. 1.72 (0.2): p<0.05.
Conclusions: The systemic nature of atherosclerotic plaque inflammation is supported 
by strong correlations between FDG uptake measured in multiple arterial territories.
In individual arteries, the negative association between the degree of inflammation and 
calcification implies these represent different stages of disease. Finally, carotid artery 
inflammation appeared less severe in the presence of statin treatment. Our findings may 
have important implications for identifying high risk plaques and tracking their regression 
with appropriate therapy.
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1014-37 Balance Between Serum S100A12 and S100A8 Predicts 
Presence and Complications of Coronary Artery Disease.
Wei Xing Yan, Changjie Song, Eric Yamen, Saul B. Freedman, Carolyn L. Geczy, University 
of New South Wales, Sydney, Australia, Anzac Research Institute, Sydney, Australia
Background: The S100 proteins are implicated in inflammation and are involved in the 
pathogenesis of atherosclerosis. S100A12 has potent pro-inflammatory actions, whereas 
S100A8 is an important oxidant scavenger. We hypothesized that A12 level and A12/A8 
ratio would predict the presence of coronary atherosclerosis and its complications.
Methods: ELISA to detect S100A12 and S100A8 was performed on sera collected from 
normal controls (n=15) and patients with stable angina (SA, n=23), unstable angina (UA, 
n=11) and myocardial infarction (MI, n=17).
Results: S100A12 was 235±19 ng/ml in controls, 702±112 ng/ml in SA (p<0.0001), 921±188 
ng/ml in UA (p=0.002) and 1165±261 ng/ml in MI (p<0.0001 vs control). S100A12 correlated 
weakly with serum C-reactive protein (Spearman r=0.36, p= 0.016). S100A8 was 2±0.4ng/
ml in controls, 31±14ng/ml in SA (p=NS), 1±0.5ng/ml in UA (p=NS) and 126±28ng/ml in MI 
(p<0.0001 vs control). The mean±SEM ratios of S100A12/S100A8 are shown in the figure. 
Conclusions: S100A12 is increased in presence of coronary artery disease, and further 
in acute coronary syndromes. The ratio of S100A12/S100A8 is low in MI, driven by an 
increase in A12 and a marked increase in S100A8 level, while the ratio is elevated in UA, 
due to raised S100A12 and low A8. The balance of these S100 proteins reflects both the 
presence and instability of coronary atherosclerosis.
11:00 a.m.
1014-38 Utility of Diverse Inflammatory Markers in Risk 
Prediction of Coronary Atherosclerosis
Reshmaal Gomes Cumaranatunge, Taral Patel, Manthodi Kulangara Faisal, Atif Qasim, 
Roshanak Bagheri, Megan L. Wolfe, Robert Wilensky, Daniel J. Rader, Muredach P. 
Reilly, University of Pennsylvania School of Medicine, Philadelphia, PA
Background: Inflammation plays a key role in initiation and progression of atherosclerosis. 
Indeed, plasma levels of several inflammatory biomarkers predict atherosclerotic 
cardiovascular events. However, their relative value in acute and chronic atherosclerosis 
syndromes remains uncertain thus limiting application in clinical practice.
Methods: We performed a three-arm, nested case-control study of (1) no angiographic 
coronary artery disease (n=254), (2) stable coronary artery disease (n=293), and (3) 
acute coronary syndromes (n=225) randomly selected from a large angiographic cohort 
(PENN CATH; N=3,800). Plasma levels of hsCRP, myeloperoxidase (MPO), matrix 
metalloproteinase 9 (MMP-9), plasminogen activator inhibitor-1 (PAI-1), soluble intercellular 
adhesion molecule 1 (sICAM-1), and soluble vascular adhesion molecule 1 (sVCAM-1) 
were measured by ELISA in samples collected prior to cardiac catheterization.
Results: In age, gender, and race adjusted analyses, the top quartile of sICAM-1 [2.49 
(1.49-4.16) p=0.001] and hsCRP [1.72 (1.03-2.87) p=0.04] levels were associated (odds 
ratio and 95% CI) with chronic coronary artery disease but only sICAM-1 remained 
significant after adjusting for established risk factors, medications, and other inflammatory 
markers [2.28 (1.22-4.26) p<0.01]. In contrast, hsCRP [28.60 (11.90-68.70) p<0.001], 
PAI-1 [10.37 (4.79-22.45) p<0.001] and MPO [3.25 (1.60-6.62) p=0.001] were associated 
with ACS cases in adjusted analyses and PAI-1 [8.13 (3.53-18.75) p<0.001] and MPO 
[2.73 (1.25-5.95) p=0.01] remained significant predictors of acute coronary syndromes 
after further adjusting for hsCRP.
Conclusion: Diverse inflammatory markers have differential relationships with acute 
and chronic manifestations of coronary atherosclerosis. This supports the concept of 
distinct value of individual markers in specific clinical settings and integration of several 
biomarkers for greatest utility in risk prediction in clinical practice.
11:00 a.m.
1014-39 Sustained Release of Prostaglandin E1 Ameliorates the 
impaired Therapeutic Angiogenesis by Basic Fibroblast 
Growth Factor in Diabetic Murine Hindlimb Ischemia
Yuhong Huang, Akira Marui, Keiichi Hirose, Yoshio Arai, Hisashi Sakaguchi, 
Shyamal Chandra Bir, Jiro Esaki, Tadashi Ikeda, Yasuhiko Tabata, Masashi Komeda, 
Kyoto University, Kyoto, Japan
Background: Basic Fibroblast Growth Factor (bFGF) is a potent mitogen for vascular 
and other mesenchymal cells in vitro that can induce angiogenesis in vivo. Diabetes 
mellitus is identified as one of negative predictors of collateral vessel development, 
and angiogenic response by exogeneous bFGF is attenuated in diabetic model. As 
prostaglandin E1 (PGE1) is a potent vasodilator and can improve collateral blood flow, 
PGE1 may ameliorate the impaired angiogenic response by bFGF in diabetic murine 
hindlimb ischemia.
Methods: We used gelatin hydrogel microsphere (GM) as a release carrier for bFGF 
and poly lactide-co-glycolid (PLGA) for PGE1. Streptozotocin induced diabetic mouse 
with unilateral hindlimb ischemia were randomly divided into 4 groups (n=10-12 each): 
no treatment (group N), single intramuscular injection into the ischemic limb of 10 μg/
kg PGE1 incorporated PLGA (group P), 10 μg bFGF incorporated GM (group F) and 
combined therapy with bFGF and PGE1 (group FP). Blood flow was evaluated by 
laser Doppler perfusion image index (LDPII: ratio of ischemic- to- normal limb blood 
flow) 4 weeks after the treatment. Vascular density and maturity were evaluated by von 
Willebrand Factor staining and α-smooth muscle actin staining, respectively.
Results: See Table.
Conclusions: The combined therapy of sustained-release bFGF and PGE1 improves 
neovascularization and blood flow. This new strategy may contribute to a more effective 
therapeutic angiogenesis for ischemic limb in patients with diabetes.
Ischemic limb blood flow and histology
Group N(no 
treatment)
Group 
P(PGE1)
Group 
F(bFGF)
Group 
FP(bFGF+PGE1)
LDPII(%) 53.6± 5.6 57.9 ± 9.5 61.7 ± 7.7 77.1 ± 9.8* † ‡
Vascular 
density(vessels/mm2) 192 ± 41 306 ± 69* 354 ± 55* 418 ± 59* † ‡
Vascular 
maturity(vessels/mm2) 17 ± 9 30 ± 14* 28 ± 6* 46 ± 14* † ‡
*P<0.05 vs. Group N by ANOVA, †P<0.05 vs. Group P by ANOVA, ‡P<0.05 vs. Group 
F by ANOVA.
11:00 a.m.
1014-40 Endothelial Nitric Oxide Synthase Gene Polymorphism 
(G894T) seems to Attenuate Inflammation and 
Oxidation process in Cardiovascular Disease free 
subjects; the ATTICA study
Christina Chrysohoou, Christos Pitsavos, Demosthenes B. Panagiotakos, John 
Skoumas, Charalambos Antoniades, Karmen Vasiliadou, Dimitris Tousoulis, Lambros 
Papademetriou, Constadina Masoura, Christodoulos Stefanadis, 1st Cardiology Clinic 
University of Athens, Athens, Greece
Background: Recently a point mutation of guanine to thymine at nucleotide position 
894 (G894T) in the endothelial nitric oxide synthase (eNOS) gene has been associated 
with endothelial dysfunction and cardiovascular disease. However, the effect of this 
polymorphism on inflammatory and oxidative stress markers (C-reactive protein, white 
blood cell counts (WBC), amyloid - A, fibrinogen, homocysteine and oxidized LDL-
cholesterol) remains to be established.
Methods: During 2001 - 2002, we conducted a population-based study of 3045 participants 
from the general population according to age-gender distribution of Athens greater area 
(census 2001).In this work we studied 267 men (18-87 years old) and 327 women (18-
89 years old),without any evidence of oronary haert disease. DNA was extracted from 
peripheral leukocytes. For detection of G894T polymorphism of the eNOS gene, we used 
primer pairs to amplify a part of the eNOS gene containing exon 7 by polymerase chain 
reaction (PCR). ANCOVA was used to examine the associations between the genotypes 
and the investigated markers, after adjusting for several potential confounders.
Results: 10.6% of the participants were homozygotes (HOM), 40% heterozygotes (HET) 
and 49.4% normal (NOR). No association between the distribution of the polymorphism and 
sex of the participants was observed (p = 0.564). Compared to heterozygotes and normal, 
homozygotes had higher levels (mean±SD) of fibrinogen (HOM: 332±46 or HET: 329±33 
vs. NOR: 319±29 mg/dl, p = 0.009), higher levels of WBC counts (6,9±0.6 or 6,5±0.3 vs. 
6,1±0.9, p = 0.023), higher levels of homocysteine (13.7±2.3 or 12.8±3.9 vs. 12.1±2.5 mg/
dl, p = 0.041) and higher levels of oxidized LDL-cholesterol (68±21 or 61±22 vs. 59±20 mg/
dl, p = 0.008), after controlling for several confounders. No association was found between 
C-reactive protein and the distribution of G894T polymorphism of eNOS (p = 0.982).
Conclusions: Our results imply that the G894T polymorphism of eNOS gene is associated 
with elevated inflammatory process and oxidative stress. This may partially explain the 
increased prevalence of G894T polymorphism among patients with cardiovascular disease
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1014-41 ShortTerm Exposure to Secondhand Smoke Leads to 
Mobilization of Dysfunctional Endothelial Progenitor 
Cells in Non-smokers
Christian Heiss, Nicolas Amabile, Andrew C. Lee, Wendy May Real, Suzaynn Schick, 
David Lao, Maelene L. Wong, Franca S. Angeli, Petros Minasi, Matthew L. Springer, 
Katharine S. Hammond, John Balmes, Yerem Yeghiazarians, UCSF Cardiology, San 
Francisco, CA
Background: Cigarette smoking is an important modifiable cardiovascular risk factor. 
Even involuntary inhalation of secondhand smoke (SHS) has deleterious impact on the 
cardiovascular system. We investigated the acute effect of a short-term exposure to SHS 
on the number and function of circulating endothelial progenitor cells (EPCs).
Methods: Healthy young non-smokers (mean age 31 years; 7m, 2f) were exposed to 
controlled levels of SHS for 30 min. Blood was drawn before exposure, immediately 
following exposure, and at 1 h, 2.5 h, and 24 h after exposure Measurements were 
repeated in 6 individuals without SHS at least 1 week after the initial exposure (control). 
EPC populations were counted in whole blood as CD34+/KDR+ and CD133+/KDR+ cells 
with flow cytometry. EPCs were isolated from human peripheral blood on the basis of initial 
lack of adhesion and subsequent acquisition of adherence to fibronectin in culture, along 
with >90% LDL uptake and Ulex europeus agglutinin 1 binding. After 7 days of culture, 
the migratory capacity of EPCs was measured as follows: 20,000 cells were plated in the 
upper of two chambers divided by a membrane with 8 um pores, and chemoattractant 
vascular endothelial growth factor was added to the lower chamber. After 6 h, we counted 
the migrated cells on the lower side of the membrane.
Results: SHS mobilized EPCs: CD34+/KDR+ EPCs were significantly elevated at 1 and 
2.5 h as compared to baseline, CD133+/KDR+ EPCs were elevated immediately after 
SHS until 1 h post exposure. At 24 h after SHS and after control exposure, EPCs were 
not significantly different from baseline. Interestingly, there was a significantly lower EPC 
yield from ex vivo expansion suggesting impaired differentiation. EPCs isolated after SHS 
exhibited significantly impaired migration towards VEGF for up to 24 h.
Conclusions: Our results suggest that even short-term exposure to moderate amounts of SHS 
leads to mobilization of dysfunctional EPCs with impaired capacity to differentiate and migrate. 
SHS may exert its vascular toxicity in part through impairment in vascular maintenance.
11:00 a.m.
1014-42 Carotid IMT And Stiffness, Aortic Stiffness And Pulse 
Pressure: Association With Hormone Therapy In 
Postmenopausal Women: Baseline Findings From The 
CASHMERE Trial
Tabassome Simon, Pierre Boutouyrie, Sophie Christin-Maitre, Anne Gompel, Stephane 
Laurent, Christian Thuillez, Faiez Zannad, Isabelle Pithois-Merli, Damien Simoneau, 
Patrice Jaillon, Paris VI University Dept of Pharmacology, Paris, France
Background: Common carotid artery intima media thickness (CCA-IMT), aortic stiffness 
(carotid-femoral pulse wave velocity-PWV) and central pulse pressure (PP) are early 
markers of atherosclerosis. The influence of hormonal replacement treatments (HRT) on 
arterial parameters in post-menopausal women remains to be investigated.
Methods: Data of 665 post-menopausal hyperlipdemic women, screened for the 
CASHMERE trial, a double blind randomized trial comparing the effects of 12-month 
therapy with atorvastatin 80mg, versus placebo, associated or not with HRT, on the 
progression of CCA-IMT. Measurements were blinded for center, treatment and identity 
and core-lab quality control checked. Stepwise multivariate models were constructed 
from variables correlated in univariate analysis.
Results: Mean age was 58±6 years with a mean duration of menopause of 8±7 years. 
Age at menopause was 50±5 years. 17% were smokers, 23% had hypertension and 28% 
were current users of HRT. 
Independent 
determinants CCA-IMT (µm) Central PP (mmHg) PWV (m/s)
ß coef. R² increment P ß coef. R² increment P ß coef. R² increment P
Age at menopause
(5 years) 25 2.9 <0.001 3.0 4.0 <0.001 0.4 4.7 <0.001
Menopause duration
(5 years) 25 4.8 <0.001 3.5 7.2 <0.001 0.6 12.4 <0.001
Current use of HRT -37 2.3 0.002 -2.7 0.9 0.003 -0.3 0.9 0.01
Mean blood pressure
(10 mmHg) - - 7.0 32.4 <0.001 0.4 8.8 <0.001
Central PP
(10 mmHg) 9 1.3 0.004 - - - - - -
Total R² 13.2 48.3 24.0
R²: percentage of explained variance; ß coef: slope of the multivariate correlation
Conclusion: Duration and age at menopause were associated with thickening and 
stiffening of large arteries. Current users of HRT had significantly thinner and more 
distensible arteries than non users.
The protective effect of HRT on arteries of women close to the onset of menopause still 
remains to be demonstrated.
11:00 a.m.
1014-43 Carotid Artery Stenosis: Is It A Marker Of Poor 
Prognosis?
Jayant Nath, Ryan Ferrell, Ryan Ferrell, Mark Wiley, David Wilson, James L. Vacek, 
University of kansas medical center, kansas city, KS
Objective: Little data is available regarding clinical correlates and long-term outcomes. The 
aim of the study was to examine the association between severity of CAS and poor survival.
Method: We retrospectively identified 4417 patients (age 68 ± 12; male 53.8%) undergoing 
carotid Doppler study at University of Kansas Medical Center. Patients were categorized 
as normal, mild (<50%), moderate (50-69%) and severe (>70%) stenosis. Follow up 
data was available for 4.3 years (mean 660 ± 439 days). Kaplan-Meier and proportional 
hazards methods were used to compare differences in survival between grades of carotid 
artery stenosis.
Results: Severe disease noted in 340 (7.7 %), moderate in 1003 (22.9%), and mild in 
2720 (62.1%). Severity of CAS increased with age (mean age: normal 54.8 ± 14.2; mild 
68.0 ± 11.5; moderate 70.9 ± 10.1, severe 71.3 ± 9.7; ANOVA p=<0.0001). Patients with 
carotid artery disease had poorer survival than no disease (figure). When adjusted for 
age, left ventricular ejection fraction, body mass index, history of hypertension, diabetes, 
CVA/TIA, hyperlipidemia and coronary artery disease, moderate (HR 0.96, p=0.82) and 
severe (HR 0.89, p=0.66) CAS were no longer associated with poor survival.
Conclusion: Prognosis in patients with carotid artery disease is determined by traditional 
cardiovascular risk factors and determinants of survival. Carotid artery disease is not an 
independent predictor of mortality. 
11:00 a.m.
1014-44 Impaired Aortic Distensibility as an Independent Marker 
of Coronary Artery Disease
Eung Ju Kim, Hong Seog Seo, Ji Hun Kim, Soon Yong Suh, Cheol Ung Choi, Jin Won 
Kim, Mi Young Park, Hong Euy Lim, Seung Woon Rha, Jung Cheon Ahn, Woo Hyuk 
Song, Chang Gyu Park, Dong Joo Oh, Korea university, Seoul, South Korea
Background: Elastic properties of aorta have been known to be abnormal in patients with 
coronary artery disease (CAD). However, aortic distensibility (AD), one of the elasticity 
indexes, has not been ascertained whether it is independently associated with CAD.
Methods: We prospectively enrolled 305 subjects (107 patients with CAD and 198 
patients without it) among 373 consecutive patients undergoing coronary angiography 
for the assessment of suspected CAD. Patients with acute coronary syndrome, previous 
myocardial infarction, valvular heart disease more than mild, atrial fibrillation, history of 
coronary intervention or surgery and serum creatinine > 2mg/dl were excluded.
Aortic diameters were measured at a level 3 cm above the aortic valve using 
echocardiography. AD (cm2 X dyn-1 X 10-6) was calculated from the aortic diameters and 
brachial artery pressure using the formula: 2 x (change in aortic diameter)/(diastolic aortic 
diameter) x (change in blood pressure).
Results: Systolic, diastolic blood pressure and pulse rate were similar in both CAD and 
non-CAD patients. AD was significantly lower in patients with CAD than those without CAD 
(3.00±0.25 vs 1.15±0.30, p<0.001). In multivariate analysis, AD remained significantly 
associated with CAD (p<0.001) after adjustment for age, gender, hypertension, diabetes 
and antihypertensive drug therapy. Moreover, AD showed significant inverse relationship 
with the severity of CAD, expressed as one-, two-, and three-vessel disease (p<0.001).
Conclusions: Our findings suggest that impaired AD is an independent risk marker for 
CAD, as well as significantly associated with the severity of CAD.
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1014-45 Clinical Outcomes of Bifurcated Versus Non-bifurcated 
Lesions In Left Main Coronary Disease : Clinical 
Results of an European Retrospective Multicenter 
Study one Year After Elective Implantation of Sirolimus-
Eluting Stents in Unprotected Left Main Coronary 
Arteries
Paul Barragan, Jean Fajadet, Imad Sheiban, Patrick Serruys, Antonio Colombo, Ricardo 
Seabra-Gomes, Jean-Jacques Goy, Stéphan Cook, Clinique Pasteur, Toulouse, France, 
Polyclinique les fleurs, Ollioules, France
Background: Sirolimus-Eluting Stents (SES) were proven to significantly reduce rates of 
restenosis and reintervention compared to bare metal stents (BMS) in various types of 
coronary artery lesions. However, only limited data are available characterizing the safety 
and efficacy of SES after implantation in unprotected left main coronary (UPLM) arteries.
Methods: A multicenter, retrospective study collecting data from approximately 300 
patients from 14 European centers was initiated to assess the safety and effectiveness of 
SES for de-novo lesions in unprotected left main coronary arteries (UPLM). Consecutive 
patients were included if they were treated with SES for UPLM lesions between April 
2002 and December 2004. Non-elective and bailout stent implantations were excluded. 
The primary endpoint for analysis is cumulative MACE (Major Adverse Cardiac Events) 
defined as a composite of death, myocardial infarct and target vessel revascularization up 
to 1 year. Secondary endpoints include target lesion and target vessel revascularization 
(TLR, TVR) as well as angiographic parameters measured by quantitative coronary 
analysis (QCA) between 6-12 months.
Electronic data capture through a dedicated secure internet website was initiated in 
December 2005 and completed in July 2006. All site reported events were reviewed by an 
independent Clinical Events Committee.
Results: From the 291 patients reviewed by the independent core-lab for protocol 
adherence, 228 patients were included in the analyzes. Among this patient population, 
80.6 % was male and had a mean age of 68 years.
The overall MACE rate at 1 year is 14.0%.
36,6 % of these patients was treated in the Ostium and the shaft of the Left Main stem 
without involvement of the bifurcation.
The MACE rate in this sub-group of patients without involvement of bifurcation is 9.6% 
versus 15.9% once the bifurcation was involved. This difference is mainly driven by the 
need for repeat vascularization (2.4% versus 8%).
Further details will be presented at the time of the conference.
Conclusion: percutaneous intervention of unprotected left main with SES is efficacious 
and safe and may-be an alternative treatment modality to CABG. 
11:00 a.m.
1014-46 Simvastatin Enhances Endothelial Differentiation 
Of Peripheral Blood Mononuclear Cells In Lone 
Hypercholesterolemic Patients And Induces 
Proangiogenic Cytokine Il-8 Secretion From 
Monocytes: More Evidence Of Statin Pleiotropism.
Kyung Woo Park, Han-Mo Yang, Chang-Hwan Yoon, Hyun-Ju Cho, Hyun-Jae Kang, 
Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim, Seoul National University Hospital, 
Seoul, South Korea
Background: The pleiotropic effects of HMG CoA reductase inhibitors are well-known 
including regulation of angiogenesis and survival of endothelial progenitor cells (EPCs). 
However, the effects of statin on EPC differentiation, proangiogenic cytokines, and 
whether these effects are seen in humans are unknown.
Methods: Twenty-two lone hypercholesterolemia patients without any other modifiable 
cardiovascular risk factors or history of previous lipid lowering therapy were given Sv 
20mg/day for 4 weeks. Blood samples were drawn pre- and post-therapy for analysis. The 
in vitro effects of simvastatin were studied in a separate set of experiments.
Results: Sv treatment significantly increased the number of DiI-acLDL, UEA-1 lectin 
double positive EPCs and facilitated its appearance. By FACS analysis of freshly isolated 
PBMNCs, KDR (+) cells increased after Sv treatment while there were no differences in 
CD34, AC133, and VE-cadherin. Also, serum IL-8 was marked increased, while VEGF 
was only slightly increased. In vitro, PBMNCs co-cultured with Sv showed increased 
cluster formation at day 7 and facilitated the appearance and networking of EPCs 
compared with vehicle. Simvastatin-co-cultured PBMNCs showed significantly increased 
KDR (+) cells, in contrast to CD34, CD31, and VE-Cadherin (+) cells. Search for the 
source of IL-8 and VEGF in plasma after statin therapy revealed that IL-8 was mainly 
derived from monocytes and VEGF from smooth muscle cells. These cytokines were 
associated with increased EPC migratory function. The increase in IL-8 secretion from 
monocytes by statin treatment was associated with phosphorylation and inactivation of 
GSK3β, which was reversed by constitutive activation of GSK-3β.
Conclusion: Sv enhances endothelial differentiation of peripheral blood mononuclear cells 
in patients with lone hypercholesterolemia and increases proangiogenic cytokine IL-8 
secretion from monocytes. Our results may explain the proangiogenic effects associated 
with statin therapy and offer further evidence of statin pleiotropism.
11:00 a.m.
1014-47 Quantification of Endothelial Cell Activation in 
Ambulatory Patients With Compensated Heart Failure 
by a Novel Methodology: Human Endothelial Biopsy 
Coupled With Analysis of Protein Expression.
Sulejman Celaj, Duigu Onat, Thierry H. LeJemtel, Margherita Padeletti, Daichi Shimbo, 
Sanja Jelic, Paolo C. Colombo, Albert Einstein College of Medicine, Bronx, NY, 
Columbia University, New York, NY
Background: Systemic markers of oxidative stress and inflammation are increased in pts 
with heart failure (HF). This study examined whether endothelial cells are activated and 
thereby may contribute to systemic inflammation in ambulatory pts with compensated HF
Methods: We studied 5 pts (age 63±15 yrs, LVEF 28±8%) with compensated HF, and 
6 age-matched healthy subjects. ECs were collected from a forearm vein using J-wires 
inserted through a 20-gauge angiocath. Staining for vonWillebrand factor identified ECs 
in biopsy specimens. Quantitative immunofluorescence analysis was used to measure 
nitrotyrosine formation (intracellular marker of oxidative stress), cyclooxygenase-2 (COX-
2) and endothelial nitric oxide synthase (eNOS) expression. This method has been 
validated against immune blotting in cultured ECs (r
s
=0.99, P=0.001)
Results: : 500 to 2,000 ECs were collected. COX-2 was three-fold higher (*p<0.05) and 
nitrotyrosine formation two-fold higher (p=0.06) in ECs of HF pts when compared with 
healthy subjects while eNOS expression was similar (Figure). Results are expressed in 
arbitrary units (AU)
Conclusions: Endothelial biopsy coupled with analysis of protein expression is a 
minimally-invasive approach that allows evaluation of vascular inflammation, and 
ultimately the effect of acute and chronic treatment in pts with HF. Our preliminary results 
suggest that EC activation is present in pts with compensated HF on standard medical 
treatment 
11:00 a.m.
1014-76 Impaired Regulation of Arterial Shear Rate with Aging: 
Assessment Using Magnetic Resonance Imaging
Harry A. Silber, Joao A. Lima, David A. Bluemke, Sandeep N. Gupta, Thomas K. Foo, 
Pamela Ouyang, Johns Hopkins University School of Medicine, Baltimore, MD, General 
Electric Medical Systems, Milwaukee, WI
Background: Abnormal resting arterial shear rate is associated with atherosclerosis 
development and plaque vulnerability. Therefore, an impaired ability to normalize transient 
changes in shear rate may contribute to atherosclerotic disease and events. However, 
dynamic regulation of arterial shear rate has not been directly tested. Flow mediated 
dilation measures conduit artery dilation after the stimulus of increased shear rate, but 
does not measure the extent of shear rate restoration, which depends on both conduit 
and resistance artery function. In this study, we evaluated age-related differences in 
restoration of arterial shear rate during post-occlusion hyperemia.
Methods: We studied 63 subjects: 33 subjects (16 male/17 female) aged 26±5 years 
with no cardiovascular risk factors, and 30 subjects (14 male/16 female) aged 58±6 
years with no risk factors other than older age. Femoral arterial systolic shear rate was 
directly measured at rest (SSR
rest), during peak hyperemia immediately after release of 
a 5-minute occlusion (SSRpeak), and at 1 minute after release (SSR1min) using magnetic 
resonance imaging. Fractional restoration of shear rate (FracRes) was the amount at 1 
minute after cuff release that shear rate was restored toward its baseline level, relative 
to how much greater than baseline it was at peak hyperemia. Thus, FracRes = (SSRpeak 
- SSR1min) / (SSRpeak - SSRrest).
Results: SSR
rest was similar between older and younger subjects (429±124 vs. 393±79 
sec-1, p=0.07). SSRpeak was lower in older than younger subjects (680±236 vs. 843±157 
sec-1, p=0.001), which we have previously shown. SSR1min was similar between groups 
(496±153 vs. 476±113 sec-1, p=0.28). However, FracRes was lower in older than younger 
subjects (0.65±0.40 vs. 0.81±0.15, p=0.02).
Conclusion: Older age is associated with impaired regulation of arterial shear rate. The 
reduced ability to quickly normalize shear rate after acute changes may contribute to 
atherosclerosis development and events, and may help to explain why older age is an 
important risk factor for peripheral and coronary artery disease and events.
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1014-77 Mesenchymal Stem Cell Therapy in a Rabbit Hindlimb 
Ischemia Model
Dorota A. Kedziorek, Wesley D. Gilson, Matthias Stuber, Gary Huang, Erin Blush, 
Kennyata Cosby, Grigorios Korosoglou, Ana V. Soto, Jeff W.M. Bulte, Lawrence V. 
Hofmann, Dara L. Kraitchman, Johns Hopkins University, Baltimore, MD
Background: The goal for successful treatment of Peripheral Arterial Occlusive Disease 
(PAOD) is to restore a sufficient blood supply into the ischemic tissue. Amongst many 
experimental therapies, cell-based therapeutics offers an option to provide arteriogenic 
cytokines and cellular “building blocks” to enhance arteriogenesis. In the presented 
experiment, mesenchymal stem cells (MSCs) were magnetically labeled using 
magnetoelectroporation and delivered intramuscularly into an endovascular rabbit 
hindlimb ischemia model. Magnetic resonance imaging (MRI) was used for MSCs tracking 
(IRON MRI) and monitoring of arteriogenesis (T2-prepared MR angiography (MRA)).
Methods: MSCs were isolated from the bone marrow of male New Zealand White rabbits. The 
MSCs were expanded to P3 and electroporated in the presence of ferumoxide (2 mg of Fe/ml, 
Feridex). A non-surgical superficial femoral artery occlusion was created using percutaneous 
delivery of platinum coils. MEP-labeled MSCs (13x106) divided into 6 doses were injected 
into the medial left thigh muscles 24 hours after ischemic induction in 6 female rabbits. Control 
animals (n=6) received six diluted Feridex injections. MRI at 3T was performed immediately 
after injection, and 1 and 2 weeks post-injection followed by histology.
Results: MRA demonstrated development of collateral vasculature from the deep femoral 
artery. IRON MRI revealed longer persistence of the signal from Feridex in MSC-treated 
animals (seen up to 2 weeks post injection) compared to control animals. Prussian 
Blue and anti-dextran stainings of histological sections of the medial thigh showed the 
incorporation of magnetically labeled MSCs into the small vessel walls.
Conclusion: Detection of positive enhancement by IRON imaging up to 2 weeks post-
injection in MSCs-treated animals, but not Feridex alone, suggests that the bulk of the signal 
from IRON imaging is from viable, labeled MSCs and not free iron. Moreover, histological 
analysis suggests an active role of MSCs in the induction of new vasculature.
11:00 a.m.
1014-78 The Association Of Cryptogenic Arterial Emboli 
And Non-steroidal Anti-inflammatory Medications In 
Patients With And Without Atrial Septal Defect And 
Patent Foramen Ovale
Michael A. Ferguson, Steven M. Mackay, Suneil R. Ramchandani, John S. Thurber, 
Michael J. Curran, Thomas J. DeGraba, National Naval Medical Center, Bethesda, MD
Background: Non-aspirin non-steroidal anti-inflammatory drugs(NANSAIDs), have been 
associated with thromboembolic events. Cryptogenic arterial emboli are often presumed 
to be due to a paradoxical event in the presence of atrial septal defect(ASD) or patent 
foramen ovale(PFO), however the contribution of NANSAIDs to crytpogenic emboli 
in patients with ASD/PFO has not been studied. Our purpose was to investigate the 
relationship between NANSAIDs, cryptogenic emboli and ASD/PFO.
Methods: We divided patients presenting over a 5 year period into 3 groups: Group I-
patients with cryptogenic emboli and ASD/PFO on transthoracic echocardiography(TTE); 
Group II-an age matched cohort with cryptogenic emboli, but no ASD/PFO on TTE; Group 
III-an age matched cohort with ASD/PFO on TTE, but no history of emboli. Age, gender, 
prescription medications within 3 months, smoking status, and diabetes mellitus were 
recorded. We excluded patients taking antiplatelet/anticoagulant medications, or those 
with medical conditions predisposing them to thromboemboli. Odds ratios were performed 
by chi-square. Means were assessed with an unpaired t-test. Multivariate analysis was 
performed by logistic regression.
Results: Ninety patients were identified -30 in each group. Mean age was 54 + 12 years. 
There were no differences in clinical variables investigated between groups. NANSAID 
use was more prevalent in patients with cryptogenic events regardless of the presence 
of an ASD/PFO when compared to those without events [Group I 17/30(54%), Group II 
18/30(60%), Group III 8/30(27%)]. Multivariate analysis demonstrated significantly more 
NANSAID use in patients with cryptogenic emboli compared to those without embolic 
events(Group I vs. Group III, OR 3.60, 95%CI 1.22-10.64 p=0.02; Group II vs. Group III, 
OR 4.13, 95%CI 1.39 - 12.3 p=0.01).
Conclusions: In this cross sectional study we observed a significant association between 
NANSAID use and cryptogenic emboli irrespective of the presence of an ASD/PFO. Many patients 
with presumed paradoxical emboli from an ASD/PFO may have experienced the arterial embolic 
effects of NANSAIDs rather than a paradoxical etiology for their cryptogenic embolic event.
11:00 a.m.
1014-79 Ultrasound-Guided Thrombin Injection for the Treatment 
of Iatrogenic Upper Extremity Pseudoaneurysm
Meisam Moghbelli, Susan M. Begelman, John R. Bartholomew, Amjad AlMahameed, 
Teresa L. Carman, Douglas Joseph, Bobby Garcia, Susan Whitelaw, Heather L. Gornik, 
Cleveland Clinic, Cleveland, OH
Background: Arterial pseudoaneurysm (PSA) is a well-recognized complication of 
invasive angiography. Case series of lower extremity PSA have reported a success rate of 
greater than 95% for ultrasound-guided thrombin injection (UGTI). There is little published 
data regarding treatment of upper extremity PSA.
Methods: Database query for upper extremity PSA identified within a single vascular 
laboratory between January 1, 2000 and August 15, 2006. Demographic and clinical data 
were obtained by medical record review. Ultrasound images were reviewed for chamber 
size, tract characteristics, and outcome of treatment.
Results: 54 upper extremity PSA were identified in 52 patients (54% male). Mean age 
at presentation was 67.5 years. The brachial artery was the most common site (96.3%). 
Forty cases occurred as a complication of coronary or peripheral angiography, 10 occurred 
as a complication of arterial puncture, and 4 were associated with hemodialysis access. 
Median time from angiography to diagnosis of PSA was 2 days. In 25 cases (46.3%), 
UGTI was the initial treatment strategy. Thirteen were observed (24.1%), 8 were treated 
with ultrasound-guided compression (14.8%), and 8 were referred for primary surgical 
repair (14.8%). Of the PSA treated with UGTI, mean chamber size, tract length, and tract 
width were 3.0 cm, 0.6 cm, and 0.5 cm respectively. The primary success rate of UGTI 
was 72% (18/25). Two additional PSA were repaired with a second procedure. Mean 
thrombin dose was 500 units. Of the 5 PSA that failed UGTI, 4 were surgically repaired. 
Four patients experienced a complication of UGTI. One patient developed brachial vein 
thrombosis. One patient required surgical evacuation of hematoma. Two patients were 
treated with intravenous heparin for less than 24 hours: one for transient discoloration of 
the hand and a second for protruding thrombus into the brachial artery. In both cases, no 
further intervention was required.
Conclusions: UGTI is a safe and effective treatment of upper extremity PSA in selected patients. 
Success rates in this series are lower than those reported for lower extremity PSA. Additional 
investigation is warranted to determine the optimal management of upper extremity PSA.
11:00 a.m.
1014-80 Despite Increase in Diagnosis, Peripheral Artery 
Disease Patients Still Trail Coronary Artery Disease 
Patients in Statin and Aspirin Use: Results From a 
National Survey
Sameer A. Gafoor, Sahand Rahnama-Moghanam, Gilbert R. Upchurch, Jr., Peter K. 
Henke, Thomas W. Wakefield, James B. Froehlich, University of Michigan, Ann Arbor, MI
Background: Statins and aspirin are beneficial in both peripheral artery disease (PAD) 
and coronary artery disease (CAD) patients. However the frequency of PAD diagnosis 
and medication (statin and aspirin) use in the outpatient setting is unknown.
Methods: The National Ambulatory Medical Care Survey (NAMCS) is an outpatient office 
visit registry that is weighted to permit national estimates. We analyzed sampled patient visits 
from 1995 to 2003 for prevalence and medication use in PAD and CAD. We used specific 
ICD-9 codes for diagnoses and both generic and NAMCS-specific codes for medications.
Results: PAD office-visits increased from 2,714,309 in 1995 to 4,315,221 in 2003, while 
CAD visits remained stable. Statin and aspirin reporting for PAD patients increased 
over the time period (6.2% to 25.4%, p<0.05 for statins; 10.5% to 27.9%, p=0.058 for 
aspirin). However, PAD patients were less likely than CAD patients to have either statins 
or aspirins listed when averaged over the time period (13.9% vs. 21.4%, p<0.00001 for 
statins; 15.0 vs. 27.6%, p<0.0001 for aspirin).
Conclusion: Although prevalence, statin use, and aspirin use increased in PAD patients 
over the years noted, medication use still trails that of CAD patients. These data also 
suggest that both PAD and CAD patients are underprescribed statins and aspirin, 
medications known to decrease cardiovascular mortality. 
11:00 a.m.
1014-81 Clinical Characteristics and Outcomes of Behcet’s 
Disease with Cardiovascular Involvement
Jong Chan Youn, Sungha Park, Hye Jin Hwang, Chul-Min Ahn, Euiyoung Choi, Boyoung 
Joung, Young-Guk Ko, Seok-Min Kang, Donghoon Choi, Jong-Won Ha, Sejoong Rim, 
Moon Hyoung Lee, Yangsoo Jang, Namsik Chung, Won-Heum Shim, Seung-Yun Cho, 
Sung Soon Kim, Yonsei University College of Medicine, Seoul, South Korea
Background: Behcet’s disease (BD) is a multisystemic inflammatory disorder of unknown cause. 
The characteristics and outcomes of BD with cardiovascular involvement are not well known yet.
Methods: Between April 1985 and March 2006, 73 patients (52 men, 38±12 years) 
were identified to have cardiovascular involvement of BD. Demographic data and clinical 
variables including types of cardiovascular involvement, immunosuppressant use, 
treatment modality, and outcomes were analyzed.
Results: The duration between diagnosis of systemic BD and that of cardiovascular 
involvement were quite varied (3±5 years). Cardiovascular involvements of Behcet’s 
disease were categorized into arterial occlusions (17.3%), venous occlusions (28.8%), 
arterial aneurysms (28.8%), valvular involvement (22.1%), and arrhythmic disorders (2.9%). 
ESR (40±29 mm) and CRP (5.4±7.5 mg/dL) were elevated at the time of cardiovascular 
involvement in all the patients. Of the 104 lesions, 47 patients with 69 lesions (66.3%) were 
treated with immunosuppressant at the time of cardiovascular involvement. Endovascular 
treatment was done in 23 lesions (22.1%), while 37 lesions (35.6%) were treated surgically. 
The mean follow up duration was 5.3±4.2 years. The overall mortality was 19.7% and 
recur rate was 33.0%. The multiple logistic regression analysis revealed that the lack of 
immunosuppressant use at the time of cardiovascular involvement was revealed to be an 
independent predictor of lesion recurrence (β=0.354, p<0.001).
Conclusions: Cardiovascular involvement of BD is a distinct entity with higher rate 
of mortality and recurrence. Disease activity should be strictly controlled with proper 
immunosuppressive therapy.
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1014-82 Is It possible to Measure Noninvasively the Intima 
Thickness of Carotid Artery? Comparison of 40MHz 
Ultrasound with Histology in Rats
Yun Seok Choi, Ho Joong Youn, Yong Won Choi, Dong Hyun Lee, Chul Soo Park, Yong 
Seog Oh, Wook Sung Chung, Ki Bae Seung, Jae Hyung Kim, Kyu Bo Choi, The Catholic 
University of Korea, Seoul, South Korea
Background: Measurement of intimal thickness(IT), not whole of Intima media 
thickness (IMT)of the carotid artery(CA) is more important to evaluate an early phase of 
atherosclerosis than IMT.The aim of this study was to elucidate the relation between the 
IT using 40 MHz ultrasound and the histological IT in rats.
Methods: The IT and IMT of right CA using 40MHz transducer (VisualSonics, Canada) 
were estimated at nine normotensive Wistar-Kyoto rats (WKR) and thirty-eight spontaneous 
hypertensive rats (SHR). Right CCAs were fixated and stained with three different methods 
[Hematoxylin-Eosin stain for endothelial cell morphology(H-E stain), Verhoeff-van Gieson 
stain for elastic laminae(V-G stain), Masson-Trichrome stain for collagen(M-T stain)](Figure). 
The IT and IMT measured on the V-G stain and M-T stain using image-pro program were 
compared with IT and IMT on the 40MHz ultrasound imaging. 
Results:1.Mean IT on ultrasound and IT on histology in SHR group was 0.067±0.008mm 
and 0.016±0.002mm 2. Mean IT on ultrasound and IT on histology in SHR group were 
significantly thicker than those of WKR group.(p=0.001) 2. Mean IT was significantly 
thicker than IT in both group (p=0.002) 3. ITon ultrasound was closely related to histology 
IT in SHR group.(r=0.60,p=0.003) 
Conclusions: Our results suggest that IT on ultrasound in SHR reflects the intimal 
pathology.Therefore, measurement of IT using carotid ultrasound may be a promising 
noninvasive tool to assess the atherosclerosis in human.
11:00 a.m.
1014-83 Non-Coronary Atherosclerosis by Carotid Ultrasound 
for Predicting Future Cardiovascular Events
Kwame O. Akosah, Vicki L. McHugh, Michelle A. Mathiason, Patricia A. Perlock, Gundersen 
Lutheran Health System, La Crosse, WI, University of Virginia, Charlottsville, VA
Background: The role of non-invasive imaging in coronary heart disease prevention 
is becoming increasingly recognized. A recent statement by an international group of 
eminent cardiovascular specialists advocate for incorporation of imaging into prevention 
guidelines, however, evidence for outcomes is lacking. Our objective was to evaluate 
the prognostic significance of non-coronary atherosclerosis for predicting future 
cardiovascular events.
Methods: 253 subjects undergoing elective coronary angiography without prior diagnosis 
of coronary heart disease or on statin therapy were prospectively enrolled. Men < 55 
and women < 65 were included. Subjects underwent carotid ultrasound studies and had 
fasting blood drawn for lipid profiles and risk stratification.
Results: 236 subjects completed all tests (mean age 53 ± 8). 172 had calculated scores as 
low-risk. Mean LDL was 122 ± 30 mg/dL, and HDL was 51 ± 14 mg/dL. 72 were diagnosed 
with severe CAD. Sensitivity, specificity, and negative predictive values of non-coronary 
atherosclerosis for predicting CAD were 74%, 46%, and 79%, respectively. The OR for 
non-coronary atherosclerosis in predicting CAD was 2.2 (CI:1.2-4.0). At median follow 
up 32 months, 10 subjects developed 12 major cardiovascular events (MI=5, death=3, 
CVA=4). All but one major event occurred in subjects with non-coronary atherosclerosis. 
Minor events included revascularization (PCI=17, bypass=8) and new onset heart failure 
(n=11). Kaplan-Meier curves utilizing log-rank statistic demonstrated significant differences 
in event free survival in favor of subjects without non-coronary atherosclerosis for all events 
(p=0.015) and for major events (p=0.051). We adjusted for major risk factors and multiple 
risk factors (≥ 2) and CHD equivalent conditions. Non-coronary atherosclerosis remained 
independently predictive of all events. Kaplan-Meier analysis revealed that the risk for 
events was highest for the combination of multiple risk factors and the diagnosis of non-
coronary atherosclerosis versus all other groups (p=0.049).
Conclusions: : Non-coronary atherosclerosis identified severe CAD and predicted future 
major and minor events independent of risk status.
11:00 a.m.
1014-84 Hemodynamic Changes in Hyperthyroidism 
Related Pulmonary Hypertension: A Prospective 
Echocardiographic study
Chung Wah Siu, Xue-Hua Zhang, Cindy Yung, Annie WC Kung, Chu Pak Lau, Hung Fat 
Tse, The University of Hong Kong, Hong Kong, Hong Kong
Background: Reports suggest an association between hyperthyroidism and pulmonary 
hypertension (PHT). However, the potential mechanisms and implications of PHT related 
to hyperthyroidism is unclear. 
Methods and Results: We performed serial echo examinations in 75 hyperthyroid 
patients (pts) (age 43 ± 2 yrs, 47 women) to determine the prevalence, outcome and 
hemodynamic changes in regard to PHT. Detailed echo studies to estimate pulmonary 
artery systolic pressure (PASP), cardiac output (CO) and left ventricular filling pressure 
(LVP) were performed at baseline and 6 months after treatment. All pts had normal left 
ventricular systolic function and 35 pts (47%) had PHT with PASP ≥ 35mmHg. There were 
no significant differences in the clinical characteristics between pts with and without PHT 
(P>0.05). In pts with PHT, 25 pts had pulmonary arterial hypertension (PAH) alone with 
normal LVP and 10 pts had pulmonary venous hypertension (PVH) with elevated LVP. Pts 
with PAH had higher CO and heart rate (HR), and lower total vascular resistance (TVR) 
compared with pts without PHT. In contrast, pts with PVH had similar CO, HR and TVR 
as pts without PHT. These hemodynamic abnormalities were all reversible and PHT was 
resolved in pts with PAH or PVH after euthyroid. 
Conclusion: In pts with hyperthyroidism and normal systolic function, PHT was observed in 
47% of pts due to either an increase in CO (33%) or PVH (14%). The occurrence of PHT 
related to hyperthyroidism is largely asymptomatic and reversible after achieving euthyroid. 
11:00 a.m.
1014-85 Logistic Regression Models to Identify Predictors 
of Deep Venous Thrombosis and Pulmonary Arterial 
Thromboembolism after Total Knee Replacement Using 
Multislice CT
Masae Uehara, Nobusada Funabashi, Jin Miyagi, Yoko Mikami, Issei Komuro, Chiba 
University Graduate School of Medicine, Chiba, Japan
Background: To determine the predictors of the incidence of deep venous thrombosis 
(DVT) in lower extremities and pulmonary arterial thromboembolism (PAE) after total 
knee replacement (TKR), we evaluated the incidence of these events using multislice CT 
(MSCT) in logistic regression models.
Methods: 54 subjects (10 males, 53-81 years old, 37 with osteoarthritis, 12 with 
rheumatoid arthritis, the first consecutive 25 receiving anticoagulant therapies and the 
subsequent consecutive 29 not receiving it) underwent enhanced MSCT before and 
one week after TKR. 25 seconds after contrast injection, scanning of the thorax was 
performed for evaluation of PAE, and three minutes after contrast injection, scanning 
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of the lower extremities was performed for DVT with 1.25mm slice thickness. Logistic 
models for predicting DVT or PAE were constructed using age, sex, body mass index, 
anticoagulant therapy, total amount of operative bleeding (TAOB), and levels of fibrinogen 
degradation products, hemoglobin and AaDO2.
Results: No one had DVT nor PAE by MSCT before TKR. DVT, PAE, and both were 
detected in twelve, twelve, and three, respectively, after TKR. Hemoglobin and AaDO2 
the day after TKR and TAOB were significantly higher in 21 subjects with DVT or PAE 
than those without (P<0.05). In a logistic model for predicting the incidence of DVT or 
PAE, hemoglobin and AaDO2 levels the day after TKR and TAOB were associated with 
an increased incidence of DVT or PAE. (Relative risks 3.51, 1.19 and 1.01 (p<0.05), 
respectively). From box and whisker plots of hemoglobin and AaDO2 levels the day after 
TKR and TAOB, we speculated the significant border to predict DVT or PAE as 10.5g/dl for 
hemoglobin, 34 Torr for AaDO2 and 1280ml for TAOB. We made other logistic regression 
models as 1) hemoglobin more than 10.5 or less than 10.5g/dl, 2) AaDO2 more than 34 
or less than 34 Torr, and 3) TAOB more than 1280 or less than 1280ml and these factors 
also predicted DVT or PAE (relative risk 5.1 (hemoglobin more than 10.5), 6.3 (AaDO2 
more than 34 Torr), and 5.0 (TAOB more than 1280ml) (P<0.05).
Conclusions: Incidence of DVT or PAE after TKR was 39% in MSCT. High levels of TAOB, 
hemoglobin, and AaDO2 the day after TKR may be predictive indicators of DVT or PAE.
11:00 a.m.
1014-86 Rivaroxaban Once or Twice Daily: Similar Efficacy and 
Safety to Standard Therapy in Dose-Ranging Studies 
for the Treatment of Proximal Deep Vein Thrombosis
Harry R. Büller, Giancarlo Agnelli, Anthonie W.A. Lensing, Frank Misselwitz, Academic 
Medical Center, Amsterdam, The Netherlands, University of Perugia, Perugia, Italy
Background: Rivaroxaban - an oral, direct Factor Xa inhibitor - was evaluated in two 
dose-ranging studies for the treatment of patients with acute symptomatic proximal deep 
vein thrombosis (DVT) without symptomatic pulmonary embolism, relative to standard 
therapy (LMWH/heparin+vitamin K antagonist [INR 2-3]).
Methods: The EINSTEIN-DVT study included 543 patients, who received rivaroxaban 
20, 30, or 40 mg once daily (od) or standard therapy. The ODIXa-DVT study included 
613 patients, who received rivaroxaban 10, 20, or 30 mg twice daily (bid), 40 mg od, 
or standard therapy. The efficacy outcomes included recurrent venous thromboembolic 
(VTE) events (confirmed, symptomatic recurrent DVT or symptomatic, fatal or non-fatal 
PE); and asymptomatic deterioration of ultrasound (US) or perfusion lung scan (PLS) at 3 
weeks (ODIXa-DVT), or 3 months (EINSTEIN-DVT), compared with baseline.
Results: 
Rivaroxaban (total daily dose) Standard therapy
20 
mg
30 
mg 40 mg
60 
mg
ODIXa-DVT study (bid)
Recurrent VTE or deterioration in US or 
PLS at 3 weeks 3.0% 4.3% 5.7% 4.8% 2.9%
Recurrent VTE at 3 months 1.1% - 1.1%/3.0%* 1.0% 1.0%
Major bleeding 1.7% - 1.7%/1.7%* 3.3% 0%
EINSTEIN-DVT study (od)
Recurrent VTE or deterioration in US or 
PLS at 3 months 6.1% 5.4% 6.6% - 9.9%
Major bleeding 0.7% 1.5% 0% - 1.5%
*Results are shown as 20 mg bid/40 mg od
Conclusions: Rivaroxaban, given od or bid over a wide dose range, was as effective 
and safe as standard therapy for the treatment of acute, symptomatic DVT. At 3 months, 
the bid and od regimens performed similarly, compared with standard therapy. Therefore, 
rivaroxaban can be used for both the initial treatment and secondary prevention of VTE. 
For secondary prevention, these data support the use of long-term rivaroxaban 20 mg 
od for phase III studies.
11:00 a.m.
1014-87 Lipoprotein Associated Phospholipase A2 Inhibition 
Reduces Generation of Hydroxy-Fatty Acids
Robert S. Rosenson, Marina Vracar-Grabar, University of Michigan, Ann Arbor, MI
Background: Lipoprotein associated phospholipase A2 (Lp-PLA2) is an emerging 
cardiovascular risk marker. After LDL oxidation, Lp-PLA2 generates lysophosphatidylcholine 
and oxidized free fatty acids both of which have demonstrated proinflammatory and 
proapoptotic activities. Through the use of a selective inhibitor of Lp-PLA2 (SB-677116), 
we investigated whether Lp-PLA2 participates in the ex vivo generation of OH-FAs in 
whole blood.
Methods: The study population included 17 metabolic syndrome subjects with small 
LDL size <20.5 nm. No subjects were treated with lipid altering therapies or anti-oxidant 
treatment. Whole blood samples were incubated with SB-677116 for 6 h at two different 
concentrations (0.3 µM, 3.0 µM), and stimulated with LPS (10 μmol). Cytokine production 
was measured from whole blood specimens in 6 subjects.
Results: Incubation of blood with Lp-PLA2 inhibitor was accompanied by a concentration-
dependent reduction in Lp-PLA2 activity and OH-FA levels. Data for Lp-PLA2 activity, and 
9, 13, and 18 OH-FA levels (Table). With 3.0 µM inhibitor, there were significant reductions 
in the production of IL-1β (373±19 to 331±149 pg/mL, p<0.05) and IL-8 (3493±4350 to 
2992±2348 pg/mL, p<0.05).
Conclusions: Selective inhibition of Lp-PLA2 reduced levels of OH-FA levels generated 
in isolated whole blood of metabolic syndrome patients. These novel findings suggest 
that Lp-PLA2 inhibition may attenuate noxious downstream effects of lipid peroxidation 
that include inflammatory responses. 
Lp-PLA2, µm Lp-PLA2 Activity, nmol/min/ml Hydroxy-Fatty Acids, µmol/l
9 OH-FA 13 OH-FA Total OH-FA
0.0 24.64 ± 10.15 0.44 ± 0.0 0.36 ± 0.05 2.04 ± 0.29
0.3 2.05 ± 0.55* 0.34 ± 0.06† 0.27 ± 0.04 1.85 ± 0.24†
3.0 0.63 ± 0.10* 0.31 ± 0.04† 0.25 ± 0.03† 1.50 ± 0.19‡
Data are expressed as mean±SD. *p<0.001 vs. control, †p<0.05 vs. control, ‡p<0.0005 
vs. control.
11:00 a.m.
1014-88 Low Adiponectin expression In Epicardial Adipose 
Tissue Is Associated With The Severity Of Coronary 
Artery Disease.
Sonia Eiras, Elvis Teijeira-Fernandez, Maria Jesus Iglesias, Lilian Grigorian Shamagian, 
Jose Rubio, Jose Ramon Gonzalez-Juanatey, Unidad de Investigacion del Servicio de 
Cardiologia. Hospital Clinico Universitario, Santiago de Compostela, Spain
Background: Adipose tissue is one of the endocrine organs involved in the development 
of cardiovascular disease. Epicardial adipose tissue (EAT) has been recognized as a 
source of anti and pro-inflammatory cytokines involved in cardiovascular pathogenesis. 
Adiponectin is a hormone produced by EAT with antiatherogenic properties and low 
plasma adiponectin levels were associated with the severity of coronary artery disease 
(CAD). We sought to asses whether mRNA adiponectin levels of EAT are correlated with 
the severity of CAD.
Methods: Samples of EAT were taken from 51 patients (75% men) with BMI 28,37± 
3,7 and age 69±8,3 during coronary bypass or aortic valve replacement surgery. The 
number of coronary arteries with signaficative stenosis was evaluated by coronariography 
studies: 0, 1, 2 or 3. The adiponectin mRNA expression levels for comparative studies 
were determined by real time PCR.
Results: We observed a negative correlation between adiponectin mRNA levels in EAT 
and the number of affected coronary arteries, r = -0,521, (p<0.001). Adiponectin levels 
in patients without stenosis were 16,54±2,3 a.u. and in patients with stenosis; one artery 
(14,03±3,4 a.u.), two arteries (12,33±3,65 a.u.) and three arteries (11,67±3,81 a.u.).
Conclusions: We found a negative correlation between mRNA adiponectin levels in 
EAT and the extension of coronary artery disease. Low adiponectin levels in EAT may 
contribute to coronary artery disease. 
JACC  March 6, 2007    ABSTRACTS - Vascular Disease, Hypertension and Prevention    365A 
Vascular D
isease, H
ypertension and P
revention
11:00 a.m.
1014-89 Multi-functional Echogenic Liposomes For Image-
guided And Ultrasound-controlled PPAR Agonist 
Delivery
Shaoling Huang, Patrick Kee, David D. McPherson, Robert C. MacDonald, Northwestern 
University, Evanston, IL, University of Texas Medical Center, Houston, TX
Background: Peroxisome proliferator activated receptor (PPAR) agonists are novel drugs 
for atheroma treatment. Mechanism to enhance local delivery may have important clinical 
implications. Liposomes that co-encapsulate gas and drugs would provide directed 
ultrasound image-guided delivery and controlled drug release. 
Methods: Rosiglitazone, a prototype PPAR agonist was complexed with hydroxypropyl-
beta-cyclodextrin to improve solubility. Cationic liposomes containing rosiglitazone 
complexes were prepared by conventional procedures of hydrating the lipid film, 
sonication, freezing and thawing. A single, but critical, modification of this method 
involved pressurization of the lipid dispersion with air after sonication to encapsulate 
air into liposomes After equilibration, sample were frozen. The pressure is reduced 
to atmospheric and the suspension thawed. This provide drug encapsulation with a 
cavitation gas. The echogenicity of drug-loaded liposomes was measured using a 20 
MHz intravascular ultrasound catheter Ultrasound-triggered release was achieved by 
applying 1 MHz ultrasound at 2 W/cm2 for 10s. These liposomes co-encapsulating gas 
and rosiglitazone were incubated with cultured vascular smooth muscle cells to study 
their effects on cell proliferation.
Results: When complexed with hydroxypropyl-beta-cyclodextrin, solubility of 
rosiglitazone increased by 700X, allowing rosiglitazone to be encapsulated into the 
aqueous compartment of liposomes. This liposomal formulation contains excellent air 
content (30 µl per 5 mg liposomes) and rosiglitazone encapsulation efficiency (35%). A 
single ultrasound application triggered the release of 20% of encapsulated rosiglitzaone, 
resulted in a 50% inhibition of cellular proliferation. 
Conclusions: This drug delivery system possesses unique properties for cell targeting 
using cationic lipids, ultrasound detection by gas encapsulation, enhanced drug 
encapsulation of water-insoluble drug by drug-cyclodextran complexion and ultrasound-
triggered drug release.
11:00 a.m.
1014-118 The Pharmacokinetics of Torcetrapib/Atorvastatin Are 
Unaffected by Co-administration of Fenofibrate in 
Healthy Adult Subjects
Steven G. Terra, Kelly Diringer, Pfizer Global Research and Development, 
Groton/New London, CT
Background: Torcetrapib (T) is a potent and selective inhibitor of cholesteryl ester 
transfer protein which substantially raises HDL-C levels and reduces LDL-C levels. As T 
provides only modest reductions in LDL-C its initial development is in combination with 
atorvastatin (A) to enable comprehensive lipid management, control of atherosclerosis, 
and subsequent cardiovascular disease. It is possible that in some patients T/A may be 
administered concomitantly with other lipid-modifying agents such as fenofibrate (FENO). 
Here we describe a Phase 1 pharmacokinetic (PK) study assessing the effect of multiple 
doses of FENO (200 mg QD) on the PK profiles of a single dose T/A 60/40 mg in healthy 
subjects.
Methods: In this fixed-sequence, open-label, 2-period study, 58 subjects received a 
single dose of T/A 60/40 mg during Period 1 and multiple doses of fenofibrate 200 mg 
QD prior to and following another single dose of T/A 60/40 mg during Period 2. Plasma 
samples were analyzed for T, A, and fenofibric acid concentrations. Primary endpoints 
were area under the concentration-time curve to the last quantifiable concentration 
(AUClast) and maximum concentration (Cmax) for T and A.
Results: PK profiles for T, whether after single dosing of T/A alone, or with 
coadministration of a single dose of T/A on a background of multiple FENO doses, were 
largely superimposable, with ratios of the geometric means for AUClast and Cmax (T/A + 
FENO dosing versus T/A dosing) of ~110% (~90% CI; 105, 114) and ~92% (~90% CI; 
86, 99), respectively. Similarly, PK profiles for A were broadly comparable with ratios of 
the geometric means for AUClast and Cmax (T/A + FENO dosing versus T/A dosing) of 
~101% (~90% CI; 96, 106) and ~110% (~90% CI; 98, 124), respectively. The bounds of 
the 90% confidence intervals for the primary endpoints AUClast and Cmax for T and A were 
completely contained within the limits of 80% to 125%, thereby satisfying equivalence 
criteria. Observed adverse events were consistent with chronic administration of FENO; 
no subject was withdrawn due to an adverse event.
Conclusions: FENO had no effect on the pharmacokinetic parameters of either T or A.
11:00 a.m.
1014-119 Baseline Lipid Status Does Not Influence the Promotion 
of Coronary Atheroma Regression in Response to Use 
of High Dose Statin Therapy: Insights from ASTEROID
Stephen J. Nicholls, Ilke Sipahi, Tim Crowe, Joel S. Raichlen, Valerie A. Cain, E. Murat 
Tuzcu, Steven E. Nissen, Cleveland Clinic, Cleveland, OH, AstraZeneca, Wilmington, DE
Background: Lowering low-density lipoprotein cholesterol (LDL-C) with statins attenuates 
coronary plaque progression. Intensive LDL-C lowering in combination with elevating 
high-density lipoprotein cholesterol (HDL-C) with rosuvastatin 40mg daily promotes 
plaque regression. This study assessed the impact of baseline lipid status on the change 
in coronary atheroma burden following rosuvastatin therapy.
Methods: Subjects in ASTEROID were stratified by baseline levels of LDL-C, HDL-C 
and LDL-C/HDL-C above or below the mean and quintiles. Groups were compared with 
regard to the change in percent atheroma volume (PAV), atheroma volume in the most 
diseased 10-mm segment (AV-10), total atheroma volume (TAV) and percentage of 
subjects undergoing regression.
Results: Rosuvastatin therapy lowered LDL-C to 60.8 mg/dL and increased HDL-C by 
14.7%. This was accompanied by significant median reductions in PAV (-0.79%, p<0.001), 
TAV (-12.5 mm3, p<0.001) and AV-10 (-5.6 mm3, p<0.001). Regression of parameters was 
observed in subjects with baseline LDL-C, HDL-C or LDL-C/HDL-C above or below the 
mean (table). 
Median change in Parameter Baseline LDL-C (mean 130.4 mg/dL)
<Mean >Mean
PAV (%) -0.61 <0.001 -0.96 <0.001
AV-10 (mm3) -4.80 <0.001 -6.24 <0.001
TAV (mm3) -11.71 <0.001 -12.87 <0.001
Median change in Parameter Baseline HDL-C (43.1 mg/dL)
<Mean >Mean
PAV (%) -0.87 <0.001 -0.69 <0.001
AV-10 (mm3) -6.08 <0.001 -5.16 <0.001
TAV (mm3) -13.72 <0.001 -10.80 <0.001
Median change in Parameter Baseline LDL-C/HDL-C (mean 3.2)
<Mean >Mean
PAV (%) -0.69 <0.001 -1.05 <0.001
AV-10 (mm3) -4.74 <0.001 -6.14 <0.001
TAV (mm3) -10.71 <0.001 -15.63 <0.001
The proportion with regression of these parameters did not differ between low and high 
quintiles of baseline lipids (eg. for PAV LDL (61 v 66%), HDL (65 v 64%) or LDL/HDL 
(59 v 67%)).
Conclusion: Coronary plaque regression was observed in subjects regardless of baseline 
lipid status. This highlights the value of intensive modification of lipids in all patients with 
established coronary artery disease.
11:00 a.m.
1014-120 Statin Mediated Increases in HDL Cholesterol Promote 
Regression of Coronary Atherosclerosis: Insights from 
Intravascular Ultrasound
Stephen J. Nicholls, E. Murat Tuzcu, Ilke Sipahi, Adam W. Grasso, Paul Schoenhagen, 
Tingfei Hu, Kathy Wolski, Tim Crowe, Milind Y. Desai, Stanley L. Hazen, Samir R. 
Kapadia, Steven E. Nissen, Cleveland Clinic, Cleveland, OH
Background: Statins reduce low-density lipoprotein cholesterol (LDL-C) and slow 
progression of coronary atherosclerosis. However, no data exist describing the 
relationship between statin-induced changes in high-density lipoprotein cholesterol (HDL-
C) and disease progression.
Methods: The relationship between changes in LDL-C, HDL-C and atheroma burden was 
investigated in 1148 patients treated with a statin who underwent serial assessment by 
intravascular ultrasound in clinical trials.
Results: Statin therapy reduced LDL-C by 31.2% (P<0.001) and increased high-
density lipoprotein cholesterol (HDL-C) by 8.3% (P<0.001). The LDL-C/HDL-C ratio was 
reduced by 34.9% (P<0.0001). These changes were accompanied by an increase in 
percent atheroma volume (PAV) of 0.5±4.0% (P=0.008) and a decrease in total atheroma 
volume (TAV) of 2.6±24.5 mm3 (P<0.001). In univariate analysis, mean follow-up levels 
and treatment-induced changes in LDL-C, total cholesterol, non-HDL cholesterol and 
apolipoprotein B correlated strongly with the rate of progression. Treatment-mediated 
changes in HDL-C (r=-0.11, P<0.001) inversely correlated with atheroma progression. 
Both mean levels of LDL-C (P<0.0001) and increases in HDL-C (P<0.0005) remained 
independent predictors of regression in multivariate analysis. Substantial regression (-
9.0+/-21.9 mm3, p<0.001) was observed in patients with on-treatment levels of LDL-C 
less than the mean (85 mg/dL) and percent increases of HDL-C greater than the mean 
(+8.3%, P<0.001). A significant relationship was observed between the level of LDL-C/
HDL-C achieved with statin therapy and change in TAV (-7.3+/-20.4, -44+/-25.7 and 1.9+/-
25.8 mm3 with LDL-C/HDL-C <1.5, 1.5-2.0 and >2.0 respectively, P<0.001 for trend).
Conclusions: Statin therapy can regress coronary atherosclerosis when LDL-C is 
substantially reduced and HDL-C is increased more than 8%. These data demonstrate 
that statin benefits are derived from both reductions in atherogenic lipoproteins and 
increases in HDL-C. Optimal treatment of coronary disease patients should address both 
LDL-C and HDL-C.
11:00 a.m.
1014-121 Assessing Individual Response to Clopidogrel in 
Patients Undergoing Coronary Intervention
Richard I. Good, Anne McGarrity, Helen Miller, Stewart Hillis, Alison H. Goodall, 
Keith G. Oldroyd, Western Infirmary, Glasgow, United Kingdom, University of 
Leicester, Leicester, United Kingdom
Background: Individual variation in response to clopidogrel has been demonstrated and there 
is evidence that this may influence outcome following coronary intervention, including stent 
thrombosis. There is no ‘gold standard’ method to assess this variation but phosphorylation of 
vasodilator stimulated phosphoprotein (VASP-P) is thought to directly reflect inhibition of the 
platelet P2Y12 receptor, the target of clopidogrel. However, if clinical decisions are to be made 
in the acute setting a rapid and reliable point-of-care assay is required.
Methods: We sought to compare flow cytometric assessment of VASP-P(Biocytex) 
with a novel point-of-care assay (VerifyNow P2Y12, Accumetrics) for the assessment of 
clopidogrel response in 162 patients. Blood was collected in 3.2% sodium citrate, from 
patients immediately prior to coronary intervention. All patients were taking aspirin 75mg/
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day and had been loaded with clopidogrel 600mgs at least 2 hours prior to sampling. 
None of the patients had received GpIIbIIIa inhibitors within 14 days.
Results: VASP-P Platelet Reactivity Index (PRI %) ranged from 0-92.6% (mean 54.2%) 
and VerifyNow P2Y12 %inhibition ranged from 1-97% (mean 44.8%.) Correlation between 
the assays was good (figure 1.)
Conclusion:Both assays confirm a wide variation in individual response to clopidogrel and 
good correlation. However, before these assays can be incorporated into clinical practise 
their ability to predict clinical outcome needs to be assessed.
 
11:00 a.m.
1014-122 Patterns of HDL Levels in Patients With Non-ST-
segment Elevation Acute Coronary Syndromes and 
Association With Clinical Outcomes
Matthew T. Roe, Karen P. Alexander, Fang-Shou Ou, L. Kristin Newby, W. Brian Gibler, 
Charles V. Pollack, Jr., E. Magnus Ohman, Sidney C. Smith, Jr., Eric D. Peterson, Duke 
Clinical Research Institute, Durham, NC, University of North Carolina, Chapel Hill, NC
Background: The patterns and prognostic significance of low high-density lipoprotein 
(HDL) levels have not been characterized in patients with non-ST-segment elevation 
acute coronary syndromes (NSTE ACS).
Methods: We characterized HDL levels in patients with NSTE ACS (ischemic ECG 
changes and/or positive cardiac markers) from the CRUSADE initiative treated at 555 U.S. 
hospitals (January 2001-June 2006). Clinical characteristics and in-hospital outcomes 
were analyzed by categories of recorded HDL levels. Patients with recorded HDL levels 
<10 mg/dL or >100 mg/dL (n = 532) were excluded.
Results: Among 93,263 patients with NSTE ACS, 16,854 (18.1%) had very low HDL 
levels (10-30 mg/dL), 32,185 (34.5%) had low HDL levels (30-40 mg/dL), 35,875 (38.5%) 
had normal HDL levels (40-60 mg/dL), and 8349 (9.0%) had high HDL levels (60-100 
mg/dL). Clinical features and outcomes by HDL category are listed in the table. Compared 
with patients with HDL in the normal range, the adjusted likelihood of in-hospital mortality 
was higher in patients with very low HDL levels (odds ratio [OR] 1.19, 95% CI 1.05-1.35), 
but was similar in patients with low HDL levels (OR 1.00, 95% CI 0.91-1.10).
Conclusions: Almost one-fifth of patients with NSTE ACS have very low HDL levels and 
these patients are younger, more often male, have features of metabolic syndrome, and 
have a higher risk of mortality. Strategies designed to raise HDL levels warrant further 
exploration in this high-risk patient group. 
Table. Clinical Characteristics and In-Hospital Outcomes by HDL Category
HDL 10-30 
mg/dL
HDL 30-40 
mg/dL
HDL 40-60 
mg/dL
HDL 60-100 
mg/dL
Age (yrs)* 62 (52, 74) 64 (54, 75) 68 (57, 78) 72 (60, 81)
Females, % 23.0 29.7 46.6 65.5
Median BMI* 29 (26, 33) 29 (25, 33) 27 (24, 32) 26 (22, 30)
Diabetes mellitus, % 36.8 32.6 28.8 24.0
Triglycerides (mg/dL)* 163 (111, 253) 142 (100, 208) 111 (78, 161) 86 (62, 122)
LDL (mg/dL)* 92 (68, 118) 101 (78, 128) 103 (79, 131) 98 (74, 126)
Total Cholesterol/HDL 
ratio 6.7 5.0 3.9 2.8
Mortality, % 2.9 2.4 2.7 3.4
*Median, (25th, 75th percentile)
11:00 a.m.
1014-123 Daily Oral Administration of the Apolipoprotein 
A-I Mimetic Peptide D-4F in Patients With CHD or 
Equivalent Risk Improves High-Density Lipoprotein 
Anti-Inflammatory Function
Richard L. Dunbar, LeAnne T. Bloedon, Danielle Duffy, Robert B. Norris, Rajesh Movva, 
Mohamad Navab, Alan M. Fogelman, Daniel J. Rader, University of Pennsylvania, 
Philadelphia, PA
Background: High-density lipoprotein (HDL) is inversely associated with coronary heart 
disease (CHD). Low levels of HDL cholesterol and its major protein, apolipoprotein 
A-I (apoA-I), predict CHD events, and high-risk patients often have “pro-inflammatory 
HDL” characterized by high HDL inflammatory index. D-4F is a synthetic apoA-I mimetic 
peptide whose oral dosing improves the anti-inflammatory effects of HDL and markedly 
reduces atherosclerosis in mice. The effects of D-4F on HDL inflammatory function in 
humans are unknown.
Methods: Statin-treated patients with stable CHD or equivalent risk completed double-
blinded treatment with 13 consecutive doses of 100, 300, or 500 mg of D-4F in 25% 
sucrose (n=44) or matching placebo (25% sucrose) (n=15).
Results: Serial testing during day 13 showed peak D-4F levels by dose group of 3.6 
ng/mL (100 mg), 9.2 ng/mL (300 mg), and 37.1 ng/mL (500 mg), 1.7-2.5 hours post-
dose. Serial lipoprotein concentrations, including HDL-C and apoA-I, changed minimally. 
The change in fasting HDL-C was within 1 mg/dL of the pre-dose level in the 100mg 
and 300mg dose groups (p>0.5), but rose 2.9 mg/dL in the 500 mg group (p=0.05). The 
change in apoA-I was -1 mg/dL in the 100mg group, +3.5 mg/dL in the 300 mg group 
and +1.9 mg/dL in the 500 mg group (p>0.25). D-4F significantly lowered (improved) 
the post-dose HDL inflammatory index in the 500 mg group (-0.15, p=0.05) and the 300 
mg group (-0.21, p=0.01), compared to placebo. The magnitude of these changes was 
greatest 4- and 8-hours post-dose. The change in HDL inflammatory index 8-hours post-
dose was inversely related to the area under the curve of plasma D-4F (r=-0.38, p=0.04). 
The change in pre-dose HDL inflammatory index between days 1 and 13 did not differ 
significantly between D-4F and placebo.
Conclusions: While it did not substantially alter HDL cholesterol or apoA-I concentrations, 
13 daily doses of oral D-4F acutely improved the anti-inflammatory qualities of HDL 
in high-risk patients on statin therapy. These data are consistent with an important 
pharmacodynamic effect of daily oral D-4F, improved HDL anti-inflammatory function.
11:00 a.m.
1014-124 Randomised Placebo-Controlled Trial Of Nicotinic Acid 
In Patients With Coronary Heart Disease And Low HDL-
Cholesterol Despite 6 Weeks Statin Therapy (LOW Study)
Ian B.A. Menown, Margaret Duffy, Peter Sharpe, Lana Dixon, Daniel Flannery, Mazhar 
Khan, David McEneaney, Craigavon Cardiac Centre, Craigavon, United Kingdom
Background: Patients with coronary heart disease (CHD) and low HDL-Cholesterol (HDL-
C) despite statin therapy are at increased risk of recurrent cardiovascular events but use 
of adjunct nicotinic acid (NA) to increase HDL-C has previously been limited by flushing. 
We assessed the efficacy and tolerability of a new prolonged-release NA formulation and 
novel up-titration protocol.
Methods: Sixty NA-naive patients with established CHD and low HDL-C (<0.9mmol/l) 
despite >6 weeks statin therapy were prospectively randomized in double blind 1:1 fashion 
to receive NA or placebo with doses up-titrated using a novel protocol to >1.5g aiming 
to achieve a target HDL-C>39mg/dl [1mmol/l]. Pre-treatment patient counseling was 
undertaken and aspirin use advised. Clinical/lab assessment was obtained at baseline 
and 4 weeks following each dose titration.
Results: Baseline lipids met ATPIII criteria except HDL-C (mean 32mg/dl[0.81mmol]). 
Only 7 patients withdrew prematurely from the study (4 NA vs. 3 placebo;p=ns). For those 
completing the study (n=53), patients assigned to NA compared with placebo showed a 
greater (28% vs. 5%; p<0.001) increase in HDL-C (31 to 40mg/dl [0.80 to 1.02mmol/] vs. 
32 to 33.5mg/dl [0.82 to 0.86mmol/l]). The primary endpoint of HDL-C>39mg/dl [1mmol/l] 
was achieved in 52% receiving NA, but in none receiving placebo;p<0.001. No serious 
adverse events occurred in the NA group. One fatal and one non-fatal myocardial infarction 
occurred in the placebo group. Flushing was more common in the NA group (84% vs. 
31%;p<0.001), described as mild-moderate in 69% NA and 89% placebo patients;p=ns. 
More frequent up-titration of concurrent aspirin from 75mg to 300mg was undertaken in 
NA patients (32% vs. 7%;p=0.014). No persistent elevations in liver enzymes or creatine 
kinase were noted.
Conclusion: Nicotinic acid effectively raises low HDL-C to a clinically relevant target in 
patients with CHD and low HDL-C despite statin therapy. The new prolonged release 
formulation in conjunction with a novel up-titration protocol and appropriate aspirin usage 
appears to improve tolerability enabling compliance rates of >85% among unselected 
CHD patients in real-world practice.
11:00 a.m.
1014-125 Do Plant Sterols Provide Additional Cholesterol 
Reduction When Added to Statin-Based Combination 
Therapy?
Sunny A. Linnebur, Warren H. Capell, Joseph J. Saseen, Pamela Wolfe, University of 
Colorado at Denver and Health Sciences Center, Denver, CO
Background: National guidelines recommend therapeutic lifestyle changes, in addition 
to statins, bile-acid sequestrants (BASs), and niacin, to reduce low-density lipoprotein 
cholesterol (LDL-C) and coronary heart disease risk. Plant sterols (PSs) are a therapeutic 
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lifestyle change, and are available over-the-counter in food products. Both PSs and 
BASs provide additional LDL-C reduction in patients on statin therapy. However, data are 
lacking regarding LDL-C reductions when PSs are used in combination with BASs and 
statins, as might occur in typical patient care settings.
Methods: 60 patients with a LDL-C ≥100mg/dL on statin therapy were enrolled in this 10-
week double-blind study. For the first 4 weeks, all patients took open-label colesevelam 
3.75g/day in addition to their statin. Subjects were then randomized to the addition of 
either 2g/day PSs in orange juice (S-OJ; n=30) or placebo orange juice (P-OJ; n=30), 
dosed concomitantly with colesevelam for 6 weeks. LDL-C, high-density lipoprotein 
cholesterol (HDL-C), triglycerides (TGs), high sensitivity C-reactive protein (hsCRP), and 
apolipoprotein B (Apo B) were measured at baseline, 4 and 10 weeks.
Results: Fifty-five patients completed the study. Subject age averaged 57 ± 10 years 
and baseline mean LDL-C was 124.1 ± 22.1 mg/dL. After 4 weeks of colesevelam 
added to statin, median decreases in LDL-C and Apo B were 20% (p<0.0001) and 10% 
(p<0.0001), respectively; median increases in HDL-C and TGs were 6% (p=0.0004) 
and 16% (p<0.0001), respectively. Neither P-OJ nor S-OJ, when added to the statin/
colesevelam therapy, produced further change in LDL-C (p=0.75 comparing groups), or in 
any other outcome, beyond that of colesevelam. Adverse effects were mild.
Conclusions: Plant sterols appear to be ineffective at further lowering LDL-C when 
added to statin/BAS combination therapy and should not be recommended by clinicians. 
This lack of effect could be due to partially competing mechanisms of action between 
PSs and BASs.
11:00 a.m.
1014-126 Statin Therapy Decreases Contrast Induced 
Nephropathy In Patients Undergoing Cardiac 
Catheterization.
Lev Lubarsky, Manish Prakash Gupta, Jin W. Kim, Robert Schaller, Georgia 
Panagopoulos, Neil Coplan, Robert Bruno, Jordan L. Rosenstock, Lenox Hill Heart and 
Vascular Institute, New York, NY
Background: Contrast-induced nephropathy (CIN) affects 3-15% of patients undergoing 
cardiac catheterization, and may be affected by medications such as ACE inhibors (ACE-
I) or statin use. This study examined predictors of CIN in a randomized trial designed to 
determine the effect of ACE-I and Angiotensin Receptor Blocker (ARB) therapy on the 
incidence of CIN in high-risk patients (GFR<60ml/min). 
Methods: Patients were divided into 3 groups: Group 1 (ACE-I/ARB therapy, n=113), 
Group 2 (ACE/ARB discontinued for >24hours, n=107), and Group 3 (no exposure to 
ACE-I/ARB, n=63). Serum creatinine (Cr) was measured at baseline and on days 1 and 2 
post-catheterization. CIN was defined as >25% relative or >0.5 mg/dL absolute increase 
in serum Cr.
Results: Statins were used in 72% of all patients, and there was no difference in statin 
use between groups (p=0.76). In a multivariate analysis which included the known risk 
factors for CIN (age, DM, HTN, low EF, smoking, low GFR and hematocrit) only statin 
therapy and hematocrit were associated with a significant decrease in the incidence of 
CIN (table 1). ACE-I/ARB therapy during the PCI period did not change the incidence of 
CIN (5.3%, p=0.66), and there was no interaction between statin therapy and ACE-I/ARB 
therapy with respect to CIN.
Conclusion: Statin therapy was associated with a decrease in CIN in high risk patients 
undergoing PCI. These results suggest a possible pleomorphic effect of statin therapy.
Table 1: Multivariate comparison of factors predicting CIN 
Variable p value OR 95% C.I.
Statins 0.028 0.095 0.012 0.779
DM 0.215 0.355 0.069 1.823
HTN 0.65 0.6 0.06 5.84
Smoking 0.832 0.819 0.13 5.169
GFR 0.790 1.40 0.114 17.369
Sex 0.67 1.3 0.37 4.67
Age 0.844 0.99 0.922 1.069
EF<40 0.770 1.30 0.217 7.85
Hematocrit 0.034 0.81 0.666 0.984
11:00 a.m.
1014-127 Long-term Fish Consumption Offers Cardiovascular 
Protection In Healthy People Due To Its Anti-arrhythmic 
And Anti-inflammatory Properties; The Attica Study.
Christina Chrysohoou, Christos Pitsavos, John Skoumas, Xenophon Krinos, Lambros 
Papademetriou, Manolis Kambaxis, Vasilios Nikolaou, Demosthenes Panagiotakos, 
Manolis Economou, Christodoulos Stefanadis, 1st Cardiology Clinic University of 
Athens, Athens, Greece
Background: We sought to investigate whether diet enriched with fish and omega-3 
fatty acids is associated with changes of the electrical action potential duration as it is 
represented by the QT duration on a rest ECG, as well as, with various inflammatory 
markers, related to cardiovascular disease, in a cardiovascular disease free population 
based sample.
Methods: During 2001 - 2002 we randomly enrolled 1514 men and 1528 women (18-89 
years old), stratified by age-sex distribution (census 2001) from the Attica area, Greece. 
We studied several demographic, anthropometric, lifestyle, dietary and bio-clinical factors 
of the participants. Dietary habits were evaluated using a validated food frequency 
questionnaire. All subjects underwent a 12-lead surface ECG, where among several other 
indices QT duration was measured and QTc was calculated (Bazett’s rate corrected). 
After 12 hours fasting blood was collected by all participants under the proper conditions 
in order to measure among others white blood cell count, plasma levels of C-reactive 
protein, tumor necrosis factor - a, amyloid- A, interleukin-6 and homocysteine. The tested 
hypothesis was evaluated through multiple linear regression analysis, after controlling for 
several potential confounders.
Results: 88% of men and 91% of women reported fish consumption at least once a 
month. Compared to non fish consumers those who consumed > 300 gr/week had 13.6% 
shorter QTc duration (p<0.01), 33% lower CRP, 33% lower IL-6, 21% lower TNF-α, 28% 
lower SAA levels and, 4% lower WBC counts (all p < 0.05). Moreover, compared to non-
fish consumers people who ate 300 gr or more of fish per week had 29.2% lower likelihood 
of having QTc levels > 0.45 sec (p = 0.03). Significant results were also observed with 
lower quantities (150 - 300 gr / week) of fish consumption.Those findings were confirmed 
after adjusting for several confounders.
Conclusions: Long-term consumption of fish is independently associated with shorter 
QTc interval and with lower inflammatory markers levels, in free eating people without any 
evidence of cardiovascular disease. Thus, fish intake seems to provoke antiarrhythmic 
and anti-inflammatory cardiovascular protection at population level
11:00 a.m.
1014-128 Left Ventricular Function Rather Than Coronary 
Anatomy Predicts Survival in Patients With End Stage 
Renal Disease
Fadi G. Hage, Smalheiser Stuart, Gilbert J. Zoghbi, Gilbert Perry, Ami E. Iskandrian, Angelo 
M. de Mattos, Raed A. Aqel, University of Alabama at Birmingham, Birmingham, AL
Background: Cardiovascular disease is the major cause of mortality in patients with end 
stage renal disease (ESRD). We evaluated the efficacy of screening patients deemed at 
increased coronary artery disease (CAD) risk prior to kidney transplantation with stress 
myocardial perfusion imaging (MPI) and/or coronary angiography (CAG).
Methods: The records of 3698 patients with ESRD evaluated for kidney transplantation 
from 2001 to 2005 were reviewed for clinical characteristics, nuclear imaging, angiographic 
and interventional data. Mortality data was prospectively collected and verified against 
the social security death index.
Results: The mean age was 48±12 years with 42% women. MPI was done in 2207 
patients (60%) of whom 14% had ischemia. Of the entire cohort CAG was performed in 260 
patients (7%) and showed 3-vessel CAD in 86 patients (2%). 94 patients (3%) underwent 
coronary revascularization. Presence and severity of CAD on CAG was not predictive of 
survival over a mean follow up period of 30±15 months. Coronary revascularization did 
not impact survival (P=0.6) except marginally in patients with 3-vessel disease (P=0.053). 
The best predictor of survival was left ventricular ejection fraction (EF) with 2.7% mortality 
increase for each 1% EF decrease.
Conclusions: A strategy of CAD screening and revascularization in patients with ESRD 
awaiting transplantation did not impact survival except in the small subset with 3-vessel 
CAD. EF is a better predictor of survival than coronary anatomy and perfusion.
11:00 a.m.
1014-129 Evaluation of Coronary Artery Disease: Variations in 
Practice Patterns Across Six Countries
Nicola Maidwell, Wendy Nuttall, Manan Shah, Mitchell K. Higashi, GE Healthcare, 
Wauwatosa, WI, Xcenda, Palm Harbor, FL
Background: Guidelines have been advocated for the assessment of coronary artery 
disease (CAD) in symptomatic patients, however, regional variations in real-world practice 
patterns have not been studied.
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Methods: A prospective cohort study was initiated in six countries (France, Germany, 
Italy, Spain, UK, US). Three hundred and twenty cardiologists participated and each site 
enrolled up to 5 consecutive patients (N= 2,002): France (301), Germany (308), Italy 
(302), Spain (304), UK (299), US (488).
Results: Descriptive statistics were used to analyze variations among the six country 
patient populations. Age distribution <50 (13.9%), 51-60 (28.8%); 61-70 (31.2%), 71-80 
(19.8%), 80+ (5.5%) and gender (67.1% male) did not vary significantly across the six 
countries. The baseline cardiovascular risk profile for the entire cohort was low (11.5%), 
intermediate (55.7%), and high (32.1%). First test evaluation with a 12-lead resting ECG 
ranged from 76% (UK) to 97% (France) (P<0.0001). Second test evaluation with resting 
echocardiography ranged from 38% (US) to 76% (Germany) (P<0.0001) and stress ECG 
ranged from 19% (Spain) to 41% (UK) (P<0.0001). Third test evaluation with stress ECG 
ranged from 24% (US) to 65% (Germany) (P<0.0001) and stress myocardial perfusion 
ranged from 3% (Germany) to 48% (US) (P<0.0001). When risk profile was stratified 
by country, intermediate-risk patients ranged from 45.9% (France) to 61.0% (Germany) 
(P=0.0016) and high-risk ranged from 18.2% (Germany) to 44.9% (France) (P<0001).
Conclusions: Across the six countries, wide variations exist in the diagnostic evaluation 
of CAD. Future research should quantify and compare the healthcare costs, adverse 
cardiovascular events, and negative predictive value of optimal versus non-optimal 
diagnostic pathways in the evaluation of CAD.
11:00 a.m.
1014-130 Physical activity Attenuates Inflammation Process in 
people with Metabolic Syndrome: the ATTICA Study
Christina Chrysohoou, Demosthenes Panagiotakos, Christos Pitsavos, John Skoumas, 
Akis Zeibekis, Constadina Masoura, Lambros Papademetriou, Constadina Pitsavos, 
Manolis Kambaxis, Christodoulos Stefanadis, 1st Cardiology Clinic University of Athens, 
Athens, Greece
Background: Metabolic syndrome is a condition that promotes atherosclerosis and 
increases the risk of cardiovascular mortality and morbidity. We evaluated whether 
leissure time physical activity is associated with the levels of inflammatory and coagulation 
markers, in people with metabolic syndrome
Methods: From May 2001 to December 2002 we randomly enrolled 1514 men and 1528 
women (> 18 years old), without any clinical evidence of cardiovascular disease, stratified 
by age - gender (census 2001). The population of the study was divided into those who 
fulfilled the NCEP ATP III criteria for the metabolic syndrome (n = 701 or 33% men and 
13% women) and in to the rest of the participants (n = 2341). We assessed the relationship 
between self-reported physical activity status and inflammatory, and coagulation markers 
(i.e. C-reactive protein (CRP), serum amyloid-A (SAA), interleukin (IL)-6, tumor necrosis 
factor (TNF)-α, white blood cell (WBC) counts, fibrinogen (FIB)), after taking into account 
the effect of several confounders.
Results: Of the non-metabolic syndrome group, 56% of men and 58% of women were 
classified as sedentary, while of the metabolic syndrome group 58% men and 72% 
women were sedentary. After controlling for various potential confounders we found that 
physically active individuals with the metabolic syndrome had 36% lower levels of CRP, 
15% lower levels of WBC, 19% lower levels of SAA, 15% lower levels of TNF-α, 30% 
lower levels of IL - 6 and 15% lower levels of FIB, compared to sedentary (all P < 0.05). 
Similar results were observed in the non-metabolic syndrome group.
Conclusions:The adoption of a physically active lifestyle is independently associated with 
lower levels of the investigated inflammatory biomarkers in individuals with the metabolic 
syndrome. The latter may suggest a pathway for reducing cardiovascular events, even in 
high-risk people.
11:00 a.m.
1014-131 Impaired Left Ventricular Myocardial Performance in 
Obstructive Sleep Apnea
Abel Romero-Corral, Francisco Lopez-Jimenez, Patricia A. Pellikka, Eric J. Olson, Kent 
R. Bailey, Josef Korinek, Marek Orban, Virend K. Somers, Mayo Clinic, Rochester, MN
Background: Epidemiologic studies have shown that obstructive sleep apnea (OSA) may precede 
congestive heart failure (CHF), suggesting a deleterious effect on myocardial contractility.
Objective: To assess the left ventricular function in patients with suspected OSA.
Methods: A cross-sectional design of 85 subjects with suspected OSA who had their 
first polysomnography (PSG) and a complete echocardiographic study within 2 months of 
the PSG with no use of continuous positive airway pressure, ejection fraction (EF) > 45 
% and CHF. Subjects were divided using the apnea hypopnea index in: <5 (controls), 5 
-14 (mild OSA) and > 15 (moderate/severe [M/S] OSA). We calculated the left ventricular 
myocardial performance index (MPI) using the Doppler signal as (isovolumic contraction 
time + isovolumic relaxation time) / aortic ejection time. Other variables were measured 
using the American Society of echocardiography criteria. Analyses were performed 
blinded to the PSG results.
Results: We excluded 23 patients with suboptimal Doppler signals, EF < 45 % and CHF. 
Intraobserver and interobserver variability for the MPI was 4.4 % and 2.1%. The mean 
age was 64 ± 15 years and 83% were men. The left ventricular global function measured 
with the MPI was significantly affected by the severity of OSA; 0.29 ± 0.05 in controls, 
0.26 ± 0.07 in mild OSA and 0.41 ± 0.14 in M/S OSA (p value for trend < 0.001). This 
association remained significant (p value for trend < 0.05) even after adjustment for age, 
sex, body mass index, hypertension, smoking, dyslipidemia, diabetes mellitus, coronary 
artery disease and EF %. Left ventricular dimensions, EF % and shortening fraction was 
similar across OSA severity. The E/e’ ratio was affected by OSA severity (adjusted p value 
= 0.05), other parameters of diastolic function were not different.
Conclusions: OSA, particularly the severe form of the disease was associated to an 
impaired left ventricular function in patients with a preserved EF %. The MPI, a measure 
that combines both, systolic and diastolic function was found to be a sensitive and 
reproducible measure to assess the left ventricular function. These findings support the 
notion that OSA may contribute to the development of CHF.
11:00 a.m.
1014-160 Impact of Depression, Anxiety and Social Support on 
Risk of Hospitalization in Patients with Cardiac Disease
Grant Grissom, Richard E. Shaw, Sherill Lord, Tina Harralson, Sudha Reddy, Veronica 
Covalesky, Colin Movsowitz, Mark Hartnett, Barrie Huberman, Mark Wexman, James 
Mailhot, Eric Bernier, Carolyn Gray, Robert Phillips, Polaris Health Directions, Inc., 
Fairless Hills, PA, Sutter Pacific Heart Centers, San Francisco, CA
Background: Forty percent of patients with cardiovascular disease (CVD) exhibit serious 
symptoms of depression, which has been linked to higher morbidity and mortality, and 
more expensive re-hospitalizations. Social support may reduce the risk for adverse 
cardiac outcomes. This study examined the relationships of depression, anxiety and 
social support to hospitalization over a 5-month period.
Methods: The sample included 583 patients with CVD receiving treatment in one of 
four cardiac clinics: 350 men (60%) and 233 women (40%) who presented with history 
of myocardial infarction (37%), stroke (11%), coronary bypass or valve surgery (31%), 
angioplasty/stent (37%), and/or congestive heart failure (24%). A computerized system 
was used to assess depression severity (DS), anxiety severity (AS) and social support 
(SS). DS/AS scores were classified as normal (55%/60%), elevated (37%/28%) or high 
(8%/12%). SS scores were constructed from six items and classified as low (40%), 
moderate (43%) or high (17%). All patients were interviewed by phone or e-mail each 
month for 5 months. The average number of completed interviews per subject was 3.3 
(1,911/583). The average number of nights per month spent in the hospital (ANMH) was 
computed with data available for 1,911 subject-months during the 5-month period.
Results: Patients with high DS scores reported 7.8 times as many ANMH (1.87) as 
patients with normal (0.24) or elevated (0.55) DS scores. Patients with high AS scores 
reported 5.6 times as many ANMH (1.24) as those with normal (0.22) or elevated (0.42) 
scores. Patients with low SS scores reported 3 times as many ANMH (0.68) compared 
to patients with high (0.23) or moderate (0.30) SS scores. For subjects with DS scores 
above normal, those in the high, moderate and low SS groups reported an average of 
0.22, 0.49 and 0.92 ANMH.
Conclusions: Lower levels of social support and higher levels of depression or anxiety 
are associated with higher risk for hospitalization during the five months post-assessment 
in CVD patients. For patients with DS scores above normal, higher levels of SS are 
associated with lower levels of hospitalization, suggesting that social support may be 
protective, mitigating the impact of depression.
11:00 a.m.
1014-161 Regional Differences in the Prevalence of Hypertension 
and Dyslipidemia in US Urban Hispanic Populations
EunMee Lee, Simon S. Tang, Sean D. Candrilli, Stanley Bassin, Heather J. Laird, 
Stewart S. Levy, Nathan D. Wong, Pfizer, Inc., RTI Health Solutions, New York, NY, Heart 
Disease Prevention Program, UC Irvine, Irvine, CA
Background: The US Hispanic population consists of approximately 42.7 million (14% 
of total population). Hispanic populations living in different geographic areas of the US 
differ in their heritage: The majority of Hispanics living in Miami-Dade County are Cuban, 
whereas Puerto Ricans and other Hispanics or Latinos are predominant in New York 
County, and Mexicans make up the majority of Hispanics in Los Angeles (LA) and Harris 
Counties. Cardiovascular health status for Hispanics living in specific urban settings has 
not been carefully examined.
Methods: Hispanic Community Outreach programs were conducted in 4 urban 
communities in the US (Miami, New York, LA, Houston) during 2004 - 2006. Retrospective 
analyses of data collected included blood pressure (BP), fasting and non-fasting glucose 
and total cholesterol (TC) measurements in 5,288 participants.
Results: Prevalence of cardiovascular risk factors in each of the 4 urban cities is reported 
in the table below: 
Miami
(n = 372)
New York
(n = 254) 
LA
(n = 4,037)
Houston 
(n = 625)
Mean age, years 55.7 (c, e, f) 49.7 (a, b, c) 47.3 (b, d, f) 45.4 (a, d, e)
% female 65.1 (c) 75.2 (a, b, c) 60.0 (b, d) 65.0 (a, d)
% with diabetes 11.0 (c, e) 19.7 (a, b, c) 9.1 (b, d) 5.0 (a, d, e)
% with coronary heart 
disease 10.8 (e, f) 10.6 (a, b) 1.1 (b, d, f) 2.7 (a, d, e)
Mean systolic BP, mmHg 123.0 (e, f) 125.3 (a, b) 129.6 (b, f) 130.5 (a, e)
% with HTN 41.4 42.1 37.1 35.7
Mean TC, mg/dL 201.7 (c, f) 182.7 (a, b, c) 196.8 (b, d, f) 202.7 (a, d)
% with DYS 37.9 (e, f) 31.9 (b) 25.1 (b, f) 26.7 (e)
% with both HTN and DYS 20.4 (e, f) 19.3 14.8 (f) 14.4 (e)
Statistically significant differences (p< 0.05) are indicated for comparisons between (a) 
New York and Houston, (b) New York and LA, (c) New York and Miami, (d) Houston and 
LA, (e) Houston and Miami and (f) LA and Miami.
Diabetes, % with glucose ≥126 mg/dL (fasting) or ≥200 mg/dL (non-fasting) or on 
diabetes medication.
Coronary heart disease, self-report of heart disease or previous heart attack.
HTN, hypertension: % with BP ≥140/90 mmHg (≥130/80 mmHg in individuals with 
diabetes) or on antihypertensive medication.
DYS, dyslipidemia: % with TC ≥240 mg/dL (or TC≥200 mg/dL if with diabetes or prior 
coronary heart disease or on antilipidemic medication.
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Conclusion: Differing prevalence of cardiovascular risk factors such as HTN and DYS 
may be due to differences in mean age between the 4 communities examined. However, 
the dissimilar heritage of the communities may also explain the differences. Hispanic 
populations in LA and Houston appear to have similar risk factor profiles, which may 
reflect their predominantly Mexican heritages. Further research on different Hispanic 
subpopulations and their implications on cardiovascular risk are warranted.
11:00 a.m.
1014-163 Gender Differences in Framingham Risk and Survival 
After Percutaneous Coronary Intervention for Acute ST 
Segment Elevation Myocardial Infarction
Elizabeth Z. Grey, Norma L. Thiessen, Robert G. Hauser, Timothy D. Henry, Kalie 
Edelstein, Beth Dedrick-Cairns, Katie M. Menssen, Charlene Boisjolie, Minneapolis 
Heart Institute Foundation, Minneapolis, MN
Background: More women than men die after a first acute ST segment elevation myocardial 
infarction (STEMI), and fewer women than men receive aspirin and beta blockers after 
STEMI. These disparities may be explained, in part, because women are commonly 
perceived to be at lower risk for an acute coronary event than men. Moreover, it is possible 
that traditional methodologies for assessing coronary risk in women are inadequate. 
Accordingly, the aim of this study was to compare the Framingham Risk Score (FRS) and 
10-year coronary heart disease (CHD) risk and survival after STEMI for women and men 
who were transferred for emergency percutaneous coronary intervervention (PCI).
Methods: The records of consecutive STEMI patients who were treated with PCI at our 
center were reviewed. The following pre-STEMI historical information was sought from 
patients and their primary caregivers: Smoking; ambulatory blood pressure; total and 
HDL cholesterol; and presence or absence of diabetes mellitus. These data and patient 
age were used to calculate the FRS and 10-year CHD risk for women and men using the 
Risk Prediction Score Sheet.
Results: Since 2003, 839 patients (women/men: 229/610) underwent PCI for acute 
STEMI. Of these, adequate data were available to permit the calculation of the FRS and 
10-year CHD risk for 184 men and 68 women prior to the index STEMI. The FRS for 
women was 9.8±5.5 and 6.9±3.0 for men; these scores converted to a 7.3% 10-year 
CHD risk for women and a 15.9% 10-year CHD risk for men (P<0.0001). The time from 
presentation to a hospital and PCI, including transfer time, was 104±41.5 min for women 
and 100±42.6 min for men (P=0.29). The 30-day mortality was 6.1% for women (14/229) 
and 2.9% for men (18/610) (P=0.04).
Conclusions: In this large population of patients who presented with acute STEMI and 
underwent emergency PCI, the pre-event Framingham 10-year CHD risk was significantly 
lower and the 30-day mortality rate significantly higher for women compared to men. These 
observations suggest that the Framingham Risk Score may not adequately estimate the 
risk of coronary events in women. Studied are needed to determine if improved risk 
profiling and earlier preventive measures can reduce STEMI mortality in women.
11:00 a.m.
1014-164 The Association of Income with Cardiovascular 
Disease Burden
Aarti Patel, Sanjay Doddamani, Daniel Spevack, Robert J. Ostfeld, Montefiore Medical 
Center, Bronx, NY
Background: Disparity between income and cardiovascular disease prevalence has been 
reported. We examined whether this relationship exists in the lowest income borough in 
New York City (NYC).
Methods: A database at the Albert Einstein College of Medicine, was used to identify all 
patients living in the Bronx by zip code aged ≥ 18 who were seen as outpatients between 
January 1st, 1996 and September 8th, 2006 and who had the primary or secondary 
diagnosis of congestive heart failure (CHF), diabetes (DM), hypertension (HTN), or 
coronary artery disease (CAD) by ICD-9 code. The zip codes were a priori dichotomized 
into the 13 zip codes with the lowest per capita income (A) and the 12 zip codes with the 
highest per capita income (B), as defined by the 2000 US Census.
Results: Groups A and B had 106,487 and 114,357 subjects respectively. The mean age, 
percent male and weighted mean per capita income in Groups A and B are 42.2 ± 1.7yrs 
and 47.2 ± 3.6yrs, (p<0.001), 34% and 39% (p<0.001), and $10,215 ± 1,204 and $18,646 
± 6,713, (p<0.001), respectively. Disease burden by group is listed in Table 1. Group A has 
a higher percentage of CHF, DM, HTN and CAD.
Conclusions: In this borough of NYC, a lower per capita income is associated with a 
higher disease burden, yet younger mean age. Our single center findings support the 
presence of fiscally influenced health care disparities within a low income group. If 
confirmed, additional public health measures to address the health care needs of lower 
income individuals are warranted.
Table 1. Percentage of Disease by Group.
Variables Group A (%) Group B (%) p
CHF 1.6 1.1 < 0.001
DM 9.0 6.7 < 0.001
HTN 17.0 12.5 < 0.001
CAD 2.4 2.2 0.03
11:00 a.m.
1014-165 Rethinking Ethnic Cardiovascular Disease Risk: Urban 
Caucasian Risk Profile Shows Greater Similarity to 
Urban Minorities Than to Rural Caucasians
Steven M. Domsky, William P. Santamore, Carol J. Homko, Abul Kashem, Francis 
Menapace, Timothy McConnell, Alfred A. Bove, Temple University Hospital, Philadelphia, 
PA, Geisinger Medical Center, Danville, PA
Background: Different risk profiles for cardiovascular disease (CVD) based on either 
ethnicity or urban-rural environment have been reported, but little information exists to 
compare the contribution of each.
Methods: Our study consisted of inner city and rural underserved subjects who were 
enrolled in a CVD risk reduction trial. They had a 10% or greater 10-year CVD risk on the 
Framingham risk index. All subjects had a medical history, physical examination, blood 
analysis, and six-minute walk performed. Formal education level, income, diet, knowledge 
of CVD risk factors and perception of risk were assessed at baseline by questionnaire. We 
compared the baseline data by urban and rural community as well as by ethnicity.
Results: Data were available for 465 subjects. The rural group (n=254) was almost entirely 
Caucasian. The urban (n=211) group contained mostly minorities, but also consisted of 
28 Caucasian subjects. Statistically significant findings are the urban group is younger, 
with higher rates of smoking (43% vs. 13%) and diabetes (55% vs. 37%), a larger waist 
and C-Reactive Protein (CRP), but lower systolic blood pressure (SBP), total cholesterol, 
high-density lipoprotein (HDL), triglycerides and six-minute walk distance. The urban 
group had significantly lower scores in all seven measures of health knowledge, a less 
healthy diet, and lower income and education level. When the urban group was further 
stratified by race, the urban Caucasian group risk profile was statistically similar to the 
urban minority group and not the rural Caucasian group in the areas of waist size, SBP, 
fasting glucose, total cholesterol, HDL, CRP and six-minute walk distance. The urban 
Caucasian group additionally resembled the urban minority group with triglycerides and 
Framingham risk. The urban Caucasian group had income, education level, and health 
knowledge scores that were intermediate between the other two groups.
Conclusions: Our results show different CVD risk profiles of Caucasian and minority 
as well as urban and rural populations. The data suggests that either urban/rural status 
and/or medical access comprise a larger role than race or ethnicity in determining 
cardiovascular risk profile.
11:00 a.m.
1014-166 Genetic Polymorphisms In The Pregnancy-Associated 
Plasma Protein-A Are Associated With Acute 
Myocardial Infarction
Jong Chan Youn, Sungha Park, Hye Jin Hwang, Jung Sun Kim, Young-Guk Ko, Seok-
Min Kang, Donghoon Choi, Jong-Won Ha, Yangsoo Jang, Won-Heum Shim, Namsik 
Chung, Yonsei University College of Medicine, Seoul, South Korea
Background: Pregnancy-associated plasma protein-A (PAPP-A) is a high molecular 
weight, zinc binding matrix metalloproteinase that is known to be abundantly expressed in 
ruptured plaques. Previous studies have shown PAPP-A to be a significant marker of plaque 
instability and cardiovascular events in patients with acute coronary syndromes. Because 
the activity of PAPP-A may be modulated by gene variants in the PAPP-A genes, we tried to 
determine the association of PAPP-A gene with acute myocardial infarction (AMI).
Methods: We analyzed 4 single nucleotide polymorphisms (SNPs) of PAPP-A gene 
variants, as well as 7 other polymorphisms of cytokine genes that have been reported 
to have functional significance (RANTES G-403A, MCP1 G-2518A, CRP A2147G, CRP 
G-717A, AGER G557A, LTA T26A, IL-6 G-572C) for possible association with AMI in 170 
unrelated AMI patients and in 170 unrelated age, sex matched controls.
Results: The average age of the study population was 62.2±11.4 in AMI patients and 
62.6±10.4 in healthy control. Multiple logistic regression analysis with risk factors such as 
age, male gender, smoking, hypertension, diabetes mellitus, and dyslipidemia revealed 
PAPP-A IVS6+95 C allele to be associated with increased risk of AMI (Dominancy; odds 
ratio: 2.13, 95% CI: 1.12 to 4.07, p=0.022, Co-dominancy; odds ratio: 1.89, 95% CI: 1.14 
to 3.16, p=0.015).
Conclusions: We discovered, for the first time, that PAPP-A IVS6+95 C allele is an 
independent risk factor for AMI even after adjustment for traditional risk factors. The 
determination of such genotype contributing to AMI could provide a new tool for identifying 
high risk individuals.
11:00 a.m.
1014-167 Socially Vulnerable Myocardial Infarction Patients Have 
A Higher Risk Of Dying Or Suffering Re-infarction. Are 
Extended Rehabilitation Programs A Solution?
Kirsten M. Nielsen, Lucette Meillier, Mogens L. Larsen, Department of internal medicine 
and cardiology, Aarhus Sygehus University Hospital, Aarhus, Denmark, Deparment of 
Public Health, County of Aarhus, Aarhus, Denmark
Background: Socially vulnerable patients are more likely to suffer re-infarction in the year 
following first episode of myocardial infarction (MI). We aimed to compare the prognosis 
among socially non-vulnerable patients being offered the standard rehabilitation 
programs (SRP) as compared to socially vulnerable patients being offered an extensive 
rehabilitation programs (ERP).
Methods: We identified 508 consecutive patients below age 70 with first episode of MI 
admitted to Aarhus University Hospital during 2000 to 2004. Patients identified during 
the first two years of the study period were offered SRP and were used as age-matched 
controls (N=205). Patients identified the last two years of the study (N=303) were assigned 
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to either SRP (socially non-vulnerable patients) or ERP (patients living alone or at low 
educational level). By use of Danish registers there were complete one year follow-up as 
concerns deaths or readmissions for MI.
Results: Among controls 133 (65%) patients signed informed consent and participated in 
SRP of whom 78 were socially vulnerable. Among the actively treated 246 (81%) signed 
informed consent and participated in rehabilitation of whom 130 were socially vulnerable 
and were offered ERP.
Conclusion: Socially vulnerable patients are more likely to die or suffer re-infarctions. 
We were not able to improve the prognosis by use of ERP to socially vulnerable patients 
as compared to a historic control group. Problems with time-trends should be dealt with 
in randomized studies.
Socially vulnerable patients________________Socially non-vulnerable patients
Extended 
rehabilitation Controls Total Standard rehabilitation Controls Total
+Re-MI 3 4 7 1 4 5
-Re-MI 127 74 201 115 51 166
P=0.275 P=0.020
+Deceased 1 0 1 0 3 3
-Deceased 129 78 207 116 52 168
P=0.437 P=0.011
Total 130 78 208 116 55 171
11:00 a.m.
1014-168 Impact of Population Based Primary Prevention 
Strategies on Cardiovascular Risk Factors in India: A 
Demonstration Project in Indian Industrial Population
Srinath K Reddy, Dorairaj Prabhakaran, Panniyammakal Jeemon, Shifalika Goenka, 
Lakshmy Ramakrishnan, K.R Thankappan, B.V.Murali Mohan, Prasanth Joshi, 
Alak Barua, All India Institute of Medical Sciences, New Delhi, India, Initiative for 
Cardiovascular Health Research in the Developing Countries, New Delhi, India
Background: The baseline survey of ‘sentinel surveillance study in Indian industrial 
population’ demonstrated relatively high levels of CVD risk factors. Reports on population 
based intervention strategies to reduce the CVD risk factors are not available from Indian 
population.
Methods: Ten large/ medium industries (defined as industries employing 1500-5000 
people), in the organized sector (both public and private sectors) were selected from 
several parts of India. The study involved two independent cross sectional surveys 
of major risk factors of CVD. A health intervention programme was designed and 
implemented in selected seven industries. The baseline risk factor data was compared to 
the after intervention risk factor data in seven of these industries who participated in the 
health intervention programme.
Results: In total 19,972 individuals participated in the baseline survey and 6,172 
individuals in the second survey. We carried out an intermediate evaluation of our 
intervention strategy after one year of intervention. As compared to the baseline survey, at 
the end of one year, self reported overall physical activity levels and fruits and vegetable 
consumption increased by 17.1% and 36.3% respectively among the study subjects. 
Almost one third (31.3%) of the study population reported conscious effort to decrease fat 
consumption since the baseline survey. The age adjusted prevalence of CVD risk factors 
including overweight (BMI > 23 kg/m2), central obesity (waist Circumference > 90 cm in 
males; > 85cm in females), tobacco use, hypertension and dyslipidemia (total cholesterol/ 
HDL-cholesterol ratio > 4.5) decreased significantly in both men and women. Overall, 6.1 
mm of Hg (95 % CI: 5.4-6.8) mean reduction in systolic blood pressure and 5.6 mm of Hg 
in mean reduction in diastolic blood pressure (95 % CI: 5.2-6.1) was noted.
Conclusions: The data suggest that lifestyle intervention programmes can be 
implemented and can have positive impacts on intermediate cardiovascular disease 
outcomes in developing countries.
11:00 a.m.
1014-169 Antihypertensive Efficacy of the Direct Renin Inhibitor 
Aliskiren When Added to Hydrochlorothiazide 
Treatment in Patients With Extreme Obesity and 
Hypertension
Margaret F. Prescott, Sam W. Boye, Stephanie Le Breton, Deborah L. Keefe, Jens 
Jordan, Novartis Pharmaceuticals Corporation, East Hanover, NJ, Franz Volhard Clinical 
Research Center, Berlin, Germany
Background: Extreme obesity (grade 3; body mass index [BMI] ≥40 kg/m2) is associated 
with higher mortality compared with grade 1 or 2 obesity. Hypertension is prevalent (>70%) 
in grade 3 obesity, but BP control is difficult as need for multiple antihypertensives increases 
with rising BMI. No clinical trial data exist to guide BP-lowering therapy in this group.
Methods: A post-hoc subgroup analysis of patients with grade 3 obesity (n=54) in a 
randomized, double-blind study in 489 obese patients (BMI ≥30 kg/m2) with hypertension 
(baseline sitting diastolic BP [DBP] 95-<110 mmHg). Patients non-responsive (defined 
as DBP 90-<110 mmHg) to 4 wks single-blind hydrochlorothiazide (HCTZ) 25 mg were 
randomized to additional double-blind aliskiren (ALI) 150 mg, irbesartan (IRB) 150 mg, 
amlodipine (AML) 5 mg or placebo (PBO) od for 4 wks, followed by 8 wks on double the 
initial dose of ALI, IRB or AML.
Results: At wk 12 endpoint, ALI/HCTZ provided significantly higher BP control rates 
(<140/90 mmHg) than AML/HCTZ (p<0.05) or PBO/HCTZ (p<0.01) in patients with grade 
3 obesity. BP control with ALI/HCTZ was higher in patients with extreme obesity than 
those with BMI 30-<40 kg/m2; PBO/HCTZ, IRB/HCTZ and AML/HCTZ showed lower 
control rates in patients with grade 3 obesity than in less obese patients.
Conclusions: ALI/HCTZ provides highly effective BP control similar to IRB/HCTZ in 
the ‘hard-to-treat’ group of patients with grade 3 obesity and hypertension, and shows 
improved BP control over AML/HCTZ and HCTZ alone in this group. 
Antihypertensive efficacy results at wk 12 endpoint (intent-to-treat) 
population
Parameter ALI/HCTZ IRB/HCTZ AML/HCTZ PBO/HCTZ
Grade 3 obesity (BMI ≥40 kg/m2)
No. of patients 16 10 16 12
SBP, mmHg -14.7±2.8 -17.3±3.5 -11.6±2.8 -7.1±3.2
DBP, mmHg -13.8±2.0 -10.6±2.4 -10.8±2.0 -5.9±2.2*
BP control rate 68.8% 50.0% 43.8%* 16.7%**
BMI 30-<40 kg/m2 
No. of patients 97 106 102 101
SBP, mmHg -15.7±1.1 -16.3±1.1 -14.2±1.1 -9.4±1.1***
DBP, mmHg -11.8±0.8 -13.2±0.8 -11.4±0.8 -9.3±0.8*
BP control rate 56.7% 59.4% 53.9% 34.7%**
Changes from baseline in SBP and DBP are least squares mean±SEM changes 
(ANCOVA with treatment, region and baseline BP). BP control rates (<140/90 mmHg) 
were compared using a logistic regression model. A total of 489 patients were included 
in the intent-to-treat population; efficacy data were available for 460 patients at the wk 
12 endpoint. * p<0.05 ** p<0.01 and *** p<0.0001 vs ALI/HCTZ.
11:00 a.m.
1014-170 Renin System Suppression With the Oral Direct 
Renin Inhibitor Aliskiren Administered Alone or in 
Combination: A Pooled Analysis of 1093 Patients With 
Hypertension
Addison A. Taylor, David R. Anderson, Vipin Arora, Andrew Satlin, Margaret F. Prescott, 
Baylor College of Medicine, Houston, TX, Novartis Pharmaceuticals Corporation, East 
Hanover, NJ
Background: Angiotensin-converting enzyme inhibitors (ACEI) and diuretics increase 
plasma renin activity (PRA), a marker of renin system activation, by different mechanisms 
that lead to increased renin release from the kidney. We investigated whether combination 
with the direct renin inhibitor aliskiren neutralizes the increased PRA associated with 
these treatments.
Methods: A pooled analysis of the effects of aliskiren on PRA and renin concentration 
(RC, measured by chemiluminescence) was conducted across 4 randomized, double-
blind trials in patients with hypertension. Changes in log-transformed PRA and RC with 
pooled aliskiren, comparator and combination treatment groups were compared with 
pooled placebo using an analysis of covariance model with treatment as factor and 
baseline value as covariate.
Results: Increases in RC stimulated by the ACEI ramipril and the diuretic 
hydrochlorothiazide (HCTZ) were associated with a rise in PRA (Table). However, 
aliskiren monotherapy significantly reduced PRA from baseline by >70% (p<0.0001 
vs placebo) despite dose-dependent increases in RC. When combined with ramipril or 
HCTZ, aliskiren 300 mg significantly suppressed PRA (p<0.0001) despite synergistic 
increases in RC (Table). These reductions in PRA were comparable to those seen with 
aliskiren monotherapy.
Conclusions: Aliskiren reduces PRA, and thereby provides suppression of the entire 
renin system, when given alone or in combination with agents that increase PRA. 
Treatment group n % change in PRA n % change in RC
Placebo 101 +11.5 99 +12.2
Aliskiren 150 mg 107 -74.7† 106 +95.3†
Aliskiren 300 mg 186 -71.5† 190 +146.7†
Aliskiren 600 mg 64 -75.0† 63 +228.5†
Ramipril 10 mg 74 +110.6† 72 +67.9*
Aliskiren 300 mg/Ramipril 10 mg 75 -44.3† 77 +315.2†
HCTZ 25 mg 38 +71.9 36 +108.4***
Aliskiren 300 mg/HCTZ 25 mg 39 -62.3† 38 +1210.9†
Table shows % changes from baseline in geometric mean PRA and RC in selected 
treatment groups. All renin measurements were made after 8 weeks of active treatment. 
*p<0.05, ***p<0.001, †p<0.0001 vs placebo.
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1014-171 Angiotensin II Production During Exercise Is 
Augmented In Patients With A Hypertensive Response 
To Exercise
Chi Young Shim, Jong-Won Ha, Sungha Park, Jin-Mi Kim, Jeong-A Ahn, Eui-Young 
Choi, Donghoon Choi, Namsik Chung, Yonsei Cardiovascular Center and Research 
Institute, Seoul, South Korea
Background: Although a central pressor effect of angiotensin II (AT II) has been 
implicated in the pathogenesis of hypertension, the mechanisms of hypertensive 
response to exercise (HRE) are unclear. We hypothesized that a HRE is associated with 
augmented AT II response during exercise.
Methods: Thirty-six subjects with HRE {difference of peak and baseline SBP ≥ 60 
mmHg in men, ≥ 50 mmHg in women during supine bicycle exercise (25W, 3 min 
increments)}(Group I, M:F=1:1, age 49±15) and 36 age and gender-matched controls 
without HRE (Group II) were evaluated. All subjects have baseline blood pressure < 
140/90 mmHg, normal systolic LV function and a negative exercise echocardiogram for 
inducible myocardial ischemia. The subjects who were treated with any antihypertensive 
drugs were excluded. The blood was sampled at rest and immediate after peak exercise 
for measurement of renin, AT II, aldosterone, and catecholamine.
Results: There were no significant differences in baseline systolic and diastolic blood 
pressures, renin, AT II, aldosterone and catecholamine level between two groups. The 
renin, aldosterone and catecholamine were increased during exercise but there were 
no significant differences between groups. However, AT II (11.4±19.3 vs. 31.3±46.1, 
p=0.02) during exercise and the magnitude of increment of AT II during exercise (1.4±5.7 
vs. 16.1±30.5, p=0.007) were significant higher in Group II. Conclusion: HRE was 
associated with augmented production of AT II during exercise.
11:00 a.m.
1014-172 The Impact of Age on Blood Pressure Reduction Due 
to Atenolol and Amlodipine in the Blood-Pressure 
Lowering Arm of the Anglo-Scandinavian Cardiac 
Outcomes Trial
Neil R. Poulter, Choon-Lan Chang, Peter S. Sever, Bjorn Dahlof, Wedel Hans, Imperial 
College London, London, United Kingdom, Sahlgrenska University, Gothenburg, Sweden
Background: Latest British guidance on selecting first-line hypertension therapy is based 
primarily on age. Using the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure 
Lowering Arm (ASCOT-BPLA) database the blood pressure (BP) lowering efficacy of 
atenolol and amlodipine by age was evaluated to validate (or not) this guideline.
Methods: Mean systolic (S) and diastolic (D) BP reduction achieved by amlodipine 5 
and 10mg and atenolol 50 and 100mg in each of 4 age strata (<45, 45-55, 56-65, >65 
years) after randomisation to the ASCOT-BPLA trial among those who were not on 
antihypertensive treatment at baseline were compared.
Results: 1964 subjects (mean age 61 years) on randomisation to 5mg amlodipine and 
50mg atenolol had mean SBP and DBP levels of 172.9/100.2mmHg and 172.3/100.7mmHg 
respectively. Changes in BP’s after initial drug doses are tabulated.
Amlodipine produced lower BP’s than atenolol at all ages over 44 years. BP lowering 
on amlodipine increased significantly with age but decreased non-significantly on 
atenolol. Increasing amlodipine to 10mg and atenolol to 100mg lowered BP further by 
10.1/5.8mmHg and 5.9/3.5mmHg respectively. BP trends by age on the higher doses 
were similar to those shown for lower doses but were not significant on either drug.
Conclusion: Increasing age had a highly significant positive effect on the BP-lowering 
efficacy of amlodipine but a non-significant adverse effect on the efficacy of atenolol. 
These data support recommendations in the latest British Guidelines. 
Age strata Mean BP changes (mmHg)
[years] Amlodipine (n=1185) Atenolol (n=779)
40-79 -15.49(14.07) -9.25(8.34) -10.26(15.69) -8.05(8.40)
<45 -11.86(11.05) -7.78(7.07) -13.30(11.43) -8.34(7.77)
-55 -13.15(12.87) -8.30(6.80) -10.79(14.07) -7.81(8.05)
-65 -15.10(14.16) -9.35(8.48) -11.04(16.07) -8.18(8.16)
>65 -17.60(14.60) -9.81(8.98) -8.68(16.31) -8.00(8.97)
p* <0.0001 0.01 0.06 0.97
* trend by age strata
11:00 a.m.
1014-173 Aliskiren-Based Therapy Lowers Blood Pressure More 
Effectively Than Ramipril-Based Therapy in Patients 
With Hypertension: A 6-Month, Randomized, Double 
Blind Trial
Karl Andersen, Myron H. Weinberger, Brent Egan, Christian M. Constance, Mohammed 
A. Ali, James Jin, Deborah L. Keefe, Landspitali University Hospital, Reykjavik, Iceland, 
Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background: Hypertension is a chronic condition requiring effective and sustained 
treatment to improve outcomes. This randomized, double-blind study compared the 
long-term efficacy and tolerability of the oral direct renin inhibitor aliskiren and the ACE 
inhibitor ramipril, alone and in combination with hydrochlorothiazide (HCTZ), in patients 
with hypertension (mean sitting diastolic blood pressure [msDBP] 95-109 mmHg).
Methods: After a 2-4 week placebo run-in, 842 patients were randomized to aliskiren 150 mg 
(n=420) or ramipril 5 mg (n=422), and patients were treated for 26 weeks. Dose titration (to 
aliskiren 300 mg/ramipril 10 mg) and subsequent HCTZ addition (12.5 mg, titrated to 25 mg if 
required) were permitted at Weeks 6, 12, 18 and 21 for patients with BP ≥140/90 mmHg.
Results: 687 patients (81.6%) completed the active treatment period. At endpoint (Week 
26), the aliskiren group had significantly superior least squares (LS) mean reductions 
from baseline in msDBP (-13.2 vs -12.0 mmHg, p=0.025) and mean sitting systolic BP (-
17.9 vs -15.2 mmHg, p=0.004) compared with the ramipril group. Superior BP reductions 
(msSBP/msDBP) were also observed with aliskiren monotherapy (LS mean: -14.0/-11.3 
mmHg) over ramipril monotherapy (LS mean: -11.3/-9.7 mmHg) at Week 12 (p<0.01). At 
endpoint, BP control rates (<140/90 mmHg) were significantly h igher with aliskiren- than 
ramipril-based therapy (61.4% vs 53.1%, p=0.021). Fewer patients in the aliskiren group 
required addition of HCTZ (46.1%) or titration to HCTZ 25 mg (21.9%) than in the ramipril 
group (49.5% and 31.3%, respectively). Aliskiren therapy was well tolerated. The overall 
rate of adverse events (AEs) was similar with aliskiren (61.3%) and ramipril (60.4%), 
and discontinuation due to AEs was relatively infrequent in both groups (aliskiren, 5.7%; 
ramipril, 4.7%). Cough was more frequent with ramipril (9.5%) than aliskiren (4.1%).
Conclusions: Aliskiren-based therapy was well tolerated and produced sustained BP 
reductions in patients with hypertension over 6 months, which were superior to those 
seen with ramipril-based therapy. Aliskiren therefore represents a highly effective option 
for the treatment of hypertension.
11:00 a.m.
1014-202 Systemic and Coronary Hemodynamics of Intravenous 
Clevidipine in Normal Pigs: A Comparison with 
Nitroprusside and Nitroglycerin
Yan-Ping Cheng, Anguo Gu, Judah Weinberger, Geng-Hua Yi, Cardiovascular Research 
Foundation, Orangeburg, NY
Background: Clevidipine is an ultrashort-acting vasoselective calcium antagonist under 
development for acute control of blood pressure. The objective of this study was to 
compare the acute systemic and coronary hemodynamic effects of clevidipine in normal 
anesthetized pigs to those of widely used vasodilators sodium nitroprusside (SNP) and 
nitroglycerin (NTG).
Methods: Eight pigs were used in a randomized cross-over study design. Systemic and 
coronary hemodynamics were measured in all animals after intravenous delivery of test 
and control substances, with intervening washout periods. Regional myocardial perfusion 
(RMP) was measured using colored microspheres.
Results: Clevidipine decreased mean aortic pressure (MAoP), total peripheral resistance 
(TPR) and coronary artery resistance (CAR) in a dose-dependent fashion. There was no 
reflex increase in heart rate or central venous pressure. Doses of NTG and SNP were 
chosen to provide quantitatively similar effects on systemic hemodynamics. However, 
at doses which provided comparable amounts of systemic vasodilation, clevidipine had 
significantly increased epicardial coronary blood flow (CBF) and RMP compared to NTG 
or SNP (see Table).
Conclusions: Clevidipine effectively reduced MAoP, TPR, and induced marked coronary 
vasodilatation in normal, anesthetized pigs. These findings suggest that clevidipine is a 
superior agent for coronary arterial vasodilatation and enhancing RMP compared with 
SNP and NTG.
Percent changes from baseline, mean±SEE
Dose MAoP TPR CBF CAR RMP
NTG 5.0μg/kg/min -21±6 -12±8 -24±1 4±9 -25±8
SNP 2.8μg/kg/min -20±8 -13±3 1±16 -19±6 -10±5
CLV 2.8μg/kg/min -20±3 -17±3
36±6
*P<0.01
†P<0.05
-41±2
*P<0.001
†P<0.05
40±5
*P<0.01
†P<0.001
*
 CLV vs. NTG, †CLV vs. SNP
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1014-203 Morning Hypertension and Sympathetic Overactivity 
among Patients with Obstructive Sleep Apnea
Takatoshi Kasai, Koji Narui, Tomotaka Dohi, Hisashi Takaya, Sugao Ishiwata, Minoru 
Ohno, Tetsu Yamaguchi, Shin-ichi Momomura, Sleep Center, Toranomon Hospital, 
Tokyo, Japan
Background: Morning surge in blood pressure (BP) is associated with the increased 
cardiovascular and cerebrovascular events among patients with hypertension (HT). It 
was reported that obstructive sleep apnea (OSA) was strongly associated with both 
daytime and nighttime HT and it was suggested that increased sympathetic overactivity 
induced by OSA resulted in such HT. In addition, continuous positive airway pressure 
(CPAP) treatment for OSA improves these HT. However, there were few reports which 
showed the relation between OSA and morning HT (MHT).
Methods: We investigated 431 consecutive patients who were not administered 
antihypertensive agents and underwent overnight polysomnography (PSG) in our institute 
from January to December, 2005. Blood pressures were obtained in the early morning 
and just before overnight PSG. MHT was defined as average BP [(morning BP+ nighttime 
BP)/2] ≥ 135/85 mmHg with blood pressure surge (morning BP-nighttime BP) ≥ 15/10 
mmHg. After initial PSG, the second PSG with CPAP was performed. Anthropometric 
data, PSG findings and LF/HF, which was computed from the analysis of heart rate 
variability using electrocardiogram during PSG, were assessed and compared between 
first and second PSG.
Results: Sixty two patients (14.3%) had morning hypertension and patients with MHT 
revealed significantly older (54.3±10.5, P<0.01), higher BMI (28.0±3.7 kg/m2, P<0.01), 
apnea-hypopnea index (54.5±22.9 events/h, P<0.01), arousal index (48.8±21.3 events/
h, P<0.01) and LF/HF (7.83±5.15, P<0.05). At the second PSG with CPAP treatment, 
either average BP (mean SBP: from 153.7±10.8 to 141.4±16.1 mmHg, P<0.01, mean 
DBP: 96.2±8.8 to 87.6±10.8 mmHg, P<0.01) or BP surge (from 17.6±11.6/15.5±5.3 to 
2.2±23.6/6.5±10.4 mmHg, P<0.01) was significantly decreased, and the LF/HF was also 
reduced in patients with MHT (from 7.83±5.15 to 4.94±3.72, P<0.05).
Conclusions: The prevalence of MHT among patients with OSA was high, and this might 
be associated with the increased risk of cardiovascular and cerebrovascular events 
among patients with OSA. In addition, increased sympathetic overactivity induced by 
OSA might affect the MHT. However, these might be improved by CPAP.
11:00 a.m.
1014-204 Blood Pressure Lowering Effects Persist Following the 
Last Dose of Long-Term Therapy With Aliskiren, an Oral 
Direct Renin Inhibitor
Deborah L. Keefe, Karl Andersen, Myron H. Weinberger, Christian M. Constance, 
Mohammed A. Ali, James Jin, Andrew Satlin, Novartis Pharmaceuticals Corporation, 
East Hanover, NJ, Landspitali University Hospital, Reykjavik, Iceland
Background: Sustained BP-lowering effects of antihypertensives after stopping 
therapy may be of value in minimizing effects of poor compliance. This study compared 
effects on BP of stopping therapy after 6 months of double-blind treatment with the oral 
direct renin inhibitor aliskiren (ALI) or ramipril (RAM), alone and in combination with 
hydrochlorothiazide (HCTZ), in patients with hypertension.
Methods: Patients (mean sitting diastolic blood pressure [msDBP] 95-109 mmHg; median 
BP 151/98 mmHg) were randomized to ALI 150 mg (n=420) or RAM 5 mg (n=422) for 26 wks 
after a 2-4 wk placebo run-in. Dose titration (to ALI 300 mg/RAM 10 mg) and subsequent 
HCTZ addition were permitted at Wks 6, 12, 18 and 21 for inadequate BP control (≥140/90 
mmHg). Patients completing the active-controlled treatment period were re-randomized to 
their current regimen or placebo for a 4-wk double-blind post-treatment phase.
Results: After 6 months of active treatment, ALI-based therapy provided significantly 
superior (p<0.05) least squares (LS) mean msSBP/DBP reductions from baseline (17.9/13.2 
mmHg) compared with RAM-based therapy (15.2/12.0 mmHg). In all, 675 patients entered 
the post-treatment period; minimal BP changes were observed with continued ALI- or RAM-
based therapy (LS mean: +0.8/+0.4 mmHg vs +1.4/+1.6 mmHg). After 4 wks, BP in the 
ALI and RAM groups was significantly lower than in the corresponding placebo groups 
(p<0.0001). Most of the BP increase after stopping RAM-based therapy occurred by end of 
Wk 1 (+8.0/+4.6 mmHg), whereas BP increased more gradually after stopping ALI-based 
therapy (Wk 1: +5.2/+2.4 mmHg). As a result, median BP levels exceeded 140/90 mmHg 
more rapidly after stopping RAM than ALI (after 1 and 4 wks, respectively). ALI-based 
therapy was well tolerated during the post-treatment period; overall incidence of adverse 
events was similar in the ALI groups (active, 22.4%; placebo, 19.0%), and comparatively 
lower than in the RAM groups (active, 29.7%; placebo, 29.4%).
Conclusions: BP-lowering effects persisted for longer after stopping aliskiren- than 
ramipril-based therapy in patients with hypertension. Median BP levels did not exceed 
140/90 mmHg until 4 weeks after the last aliskiren dose.
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812-3 Waist-To-Hip Ratio Is a Superior Predictor of 
Atherosclerosis Compared with Body Mass Index in 
a Population-Based Sample: Observations from the 
Dallas Heart Study
Raphael See, Shuaib Abdullah, Darren K. McGuire, Amit Khera, Mahesh Patel, Jason 
Lindsey, Scott Grundy, James A. de Lemos, University of Texas Southwestern Medical 
Center, Dallas, TX
Background: While obesity is associated with cardiovascular mortality in the general 
population, it is unclear if obese subjects have an increased burden of atherosclerosis. 
We sought to determine the relationship of different measures of obesity with subclinical 
atherosclerosis.
Methods: Using data from the Dallas Heart Study, a population-based probability sample 
of subjects ages 30-65, we assessed the association between sex-specific quintiles of 
obesity measures (body mass index (BMI); waist circumference (WC); waist-to-hip ratio 
(WHR)) and prevalent coronary artery calcium (CAC; defined as score >10 Agatston 
units) measured by electron-beam computed tomography. Logistic regression was used 
without and with adjustment for traditional cardiovascular risk factors.
Results: In univariable analyses on data from 2,744 subjects, using the 1st quintile 
for reference, CAC prevalence was significantly higher only in the 5th quintile of BMI, 
whereas it increased stepwise across quintiles of WC and WHR (p-trend <0.0001 for 
each). Results are shown in the figure, with a J-shaped relationship noted with BMI, and 
linear relationships with WC and WHR. The adjusted odds ratios for prevalent CAC for 
the 5th vs. 1st quintile was 1.27 (95% CI 0.88-1.84) for BMI; 1.34 (0.92-1.97) for WC; and 
1.91 (1.30-2.80) for WHR.
Conclusions: In a large population-based cohort, WHR was strongly and independently 
associated with atherosclerosis compared with BMI or WC, and therefore may be the 
preferred measure of obesity. 
11:15 a.m.
812-4 The Implication of Obesity on Total Antioxidant 
Capacity and Inflammatory Process in apparently 
Healthy men and women: the ATTICA Study
Christina B. Chrysohoou, Christos Pitsavos, John Skoumas, Lambros Papademetriou, 
Demosthenes Panagiotakos, Constadina Masoura, Constadina Paliou, Christodoulos 
Stefanadis, 1st Cardiology Clinic University of Athens, Athens, Greece
Background: We evaluated the association of obesity with various markers of chronic 
inflammation and serum total antioxidant capacity (TAC), in a population-based sample 
of 3042 adults
Methods: During 2001 - 2002 we randomly enrolled 1514 men and 1528 women (18-89 
years old); the sampling was stratified by the age-sex distribution of the region (census 
2001). Among several variables we also measured serum TAC, various inflammatory 
markers (C-reactive protein, tumor necrosis factor α, amyloid A, white blood cells, 
interleukin-6), weight, height, waist and hip circumferences. Waist circumference greater 
than 102 cm for men and 88 cm for women was considered as an indicator of central fat.
Results: Mean waist circumference was 98 ± 13 cm in men and 84 ± 22 cm in women (p 
< 0.001). Central fat prevailed in 53% of men and 45% of women (p < 0.001). Compared 
to participants with normal body fat distribution, those with central fat exhibited 53% higher 
C-reactive protein levels, 30% higher tumor necrosis factor - α levels, 26% higher amyloid A 
levels, 17% higher white blood cell counts and 42% higher interleukin-6 levels (all p < 0.05). 
We observed that all inflammation markers were related to BMI (index for obesity), waist 
and to waist-to-hip ratio (indices for central fat), in both genders. Moreover, the models 
that included waist or waist-to-hip ratio as independent variable had higher explanatory 
ability (i.e. R2) than the models included BMI, after adjusting for all potential confounders. 
Furthermore, male participants with central fat exhibited 5% lower TAC concentrations 
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compared to normal (214±35 vs. 226±33 μmol/l, p =0.04) and female participants with 
central fat exhibited 7% lower TAC concentrations (256±38 vs. 239±27 μmol/l, p = 0.03).
Conclusions: Our results suggest a relationship between body fat, central adiposity, 
inflammation process and antioxidant capacity, irrespective of age and other potential 
confounders, like smoking, physical activity, dietary habits, blood pressure, glucose and 
lipid levels, presuming that a disproportionate accumulation of visceral fat mass could 
be partially associated with increased coronary risk, through increased inflammation and 
oxidation process
11:30 a.m.
812-5 Metabolic Syndrome Predicts Cardiovascular Outcome 
Independently Of Left Ventricular Hypertrophy: The 
Strong Heart Study. 
Giovanni de Simone, Richard B. Devereux, Marcello Chinali, Mary J. Roman, Elisa T. 
Lee, Helaine E. Resnick, Barbara V. Howard, Weill-Cornell Medical College, New York, 
NY, Federico II University, Naples, Italy
Background: Metabolic syndrome (MetS) is associated with increased prevalence of 
echocardiographic LV hypertrophy (LVH), a potent predictor of cardiovascular outcome. It is unclear 
whether LVH predicts cardiovascular risk both in the presence and absence of MetS. Whether 
MetS predicts CV risk independently of presence of LVH has also never been investigated.
Methods: Participants to the 2nd examination of the Strong Heart Study were studied. 
We selected 2,758 participants (1,746 women) without prevalent coronary heart disease, 
congestive heart failure and renal insufficiency (plasma creatinine>2.5 mg/dL). MetS was 
defined according to the WHO criteria, based on previous longitudinal analyses in the 
SHS cohort. Echocardiographic LV hypertrophy was defined as LV mass index>47 g/m2.7, 
a population specific partition value, previously reported.
Results: At the time of the 2nd exam, MetS was present in 1,648 participants (60%), 65% 
of whom were women. Diabetes (by ADA criteria) was present in 12% of participants 
without, and 69% of those with Mets (p<0.0001). LVH was identified in 554 subjects 
(20%), 406 of whom (60%) had MetS (p<0.0001 vs subjects without MetS). After 
controlling for age, sex, LDL-cholesterol, smoking habit, plasma creatinine and diabetes, 
subjects with MetS had 2.02-fold higher probability of LVH than those without MetS (95% 
C.I.: 1.56-2.62, p<0.0001). Risk of composite fatal and non-fatal cardiovascular events 
was higher in the presence of LVH, both in subjects without MetS (RR=2.03 [95% C.I.: 
1.34-3.08]) and in subjects with MetS (RR=1.64 [95% C.I.: 1.31-2.04]; both p<0.0001), 
independently of the above covariates. Risk of follow-up cardiovascular events remained 
1.47-fold higher (95% C.I.: 1.14-1.88, p<0.003) in subjects with than in those without 
MetS, even independently of LVH, in addition to ajustment for effect of age, sex, LDL-
cholesterol, smoking habit, plasma creatinine, and diabetes.
Conclusion: LVH is a strong predictor of cardiovascular outcome both in the presence 
and the absence of MetS. MetS by WHO definition is associated with increased risk of 
subsequent cardiovascular events, independently of potential confounders, also including 
diabetes and LVH.
11:45 a.m.
812-6 Abdominal Obesity, Body Mass Index and Physical 
Activity: How do they modify the Framingham Risk 
Score?
Veronica Krämer, Monica Acevedo, Lorena Orellana, Marcelo Fernandez, Jose A. 
Rodriguez, Gaston Chamorro, Ramon Corbalan, Pontificia Universidad Católica de 
Chile, Santiago, Chile
Background: Abdominal obesity and sedentary behavior are considered cardiovascular 
(CV) risk markers. However, there are little data to what extent they add to CV risk 
prediction. We sought to determine the changes in Framingham score using abdominal 
obesity, body mass index (BMI) and time dedicated to exercise as indicators of CV risk.
Methods: We prospectively studied 1892 subjects (660 women, mean age = 54±13 yo) 
without history of CHD or CVD. We assessed CV risk factors and determined BMI, blood 
pressure, fasting lipid profile and glycemia and waist. Abdominal obesity was determined 
using both cutoffs proposed by the International Diabetes Federation 2005 and ATP III. 
We classified the subjects in those doing <1, 1-2 and ≥3 times/week of physical activity 
≥ 30 minutes each time.
Results: 51% exercised <1, 23% did it 1-2 and 26% ≥3 times/week. Mean waist and 
BMI were 98±10cm and 28±4 kg/m2 in males, and 82±11cm and 25±4 kg/m2 in females, 
respectively. Direct and significant correlations were found between Framingham score and 
waist and Framingham score and BMI, independently of the times/week of exercise. The 
table shows the 10-year CV risk according to waist (IDF cutoffs), BMI and physical activity.
Conclusions: Abdominal obesity and BMI confer an important increase in CV risk, 
independently of time dedicated to exercise, in both men and women. Physical activity 
might have a protective role only in obese men. These results emphasize the importance 
of considering waist and BMI in the assessment of CV risk. 
Noon
812-7 The Impact Of Body Mass Index On Mortality n 35,607 
Patients With Preserved Systolic Function -- The 
“Obesity Paradox” Revisited
Carl J. Lavie, Jr., Richard V. Milani, Ochsner Health System, New Orleans, LA
Background - The prevalence of obesity is increasing at alarming rates in Westernized 
societies. Although obesity is a risk factor for most cardiovascular diseases and overall 
mortality, several studies, particularly of patients with reduced systolic function, have 
noted a “paradox” between obesity and subsequent prognosis. 
Methods - We followed 35,607 patients (60±15 years; 53% female) referred for 
echocardiography to determine the impact of body mass index (BMI; mean 29.2±6.7 
kg/m2) and obesity on subsequent all-cause mortality during an average follow-up of 
3.1 years. Patients with ejection fraction < 50% as well as those with significant aortic 
stenosis were excluded. 
Results - During follow up, 2,328 patients died and their BMI was significantly lower 
(27.3±6.8 versus 29.3±6.6 kg/m2; p<0.0001) compared with 33,279 survivors. Although 
survivors also had significantly younger age (p<0.0001), lower relative wall thickness 
and LV mass indices (both p<0.0001), in COX-proportional hazard regression analysis, 
higher BMI was an independent predictor of better survival (Chi-square 32.6; p<0.0001). 
In addition, in a subgroup of 11,709 obese patients (BMI ≥ 30 kg/ m2), mortality was 50% 
lower than in 23,898 non-obese (3.9% vs 7.8%; p<0.0001). However, within this obese 
subgroup, higher BMI was associated with worse survival (Chi-square 14.4; p<0.0001). 
Conclusions - Although these results support a paradox between BMI and subsequent 
mortality in a large echo referral population, among those with frank obesity, higher BMI 
is associated with worse survival. These data would support weight reduction efforts 
targeted specifically toward those with more marked degrees of obesity.
12:15 p.m.
812-8 Waist Circumference And The Risk Of Heart Failure
Satish Kenchaiah, Howard D. Sesso, J. Michael Gaziano, Brigham and Women’s 
Hospital, Boston, MA, University of California Irvine Medical Center, Orange, CA
Background. Elevated body-mass index (BMI, weight ÷ height2) - an estimate of 
generalized adiposity - has been associated with an increased risk of heart failure (HF). 
Whether waist circumference (WC) - a measure of regional adiposity - also predicts HF 
risk is unknown.
Methods. We used Cox proportional-hazards models to investigate the effect of WC to 
the incidence of HF among 18,045 men in the Physicians’ Health Study (mean age, 62 
years). We evaluated WC as both a continuous (per 5 cm increase) and a categorical 
(normal ≤102 and high >102 cm) variable. We also performed analyses stratified by BMI 
categories (lean <25, overweight 25 to 29.9, and obese ≥30 kg/m2).
Results. During a mean follow-up of 9.3 years, 609 participants developed new-onset HF. 
After adjustment for age, hypertension, diabetes, dyslipidemia, smoking, alcohol intake, 
physical activity, myocardial infarction, and randomized aspirin/beta-carotene, every 5 
cm increase in WC was associated with a 7% (95% CI 5 - 9%, p<0.0001) increase in HF 
risk. Compared to participants with normal WC, those with high WC had a 77% (95% CI 
50 - 110%, p<0.0001) increase in HF risk. This association remained robust even after 
adjustment for BMI. In multivariable analyses stratified by BMI categories, WC predicted 
HF risk in lean and overweight, but not obese, participants (Table).
Conclusions. Higher WC is associated with an increased risk of HF. Measuring WC may 
provide incremental information on HF risk in lean and overweight, but not necessarily 
obese, individuals. 
Table. Hazard Ratio (HR) of Heart Failure According to Waist Circumference and 
Body-Mass Index Categories
No. Events/No. at Risk (%)
Body mass index
categories
(Kg/m2)
Waist circumference (cm)
Multivariable
HR (95% CI)
p-valueNormal
(≤ 102)
High
(> 102)
Lean
(<25)
256/8856
(2.89)
24/345
(6.96)
1.61 (1.08-2.42)
0.021
Overweight
(25 to <30)
132/4899
(2.69)
133/2712
(4.90)
1.43 (1.12-1.84)
0.005
Obese
(≥30)
4/107
(3.74)
60/1126
(5.33)
0.97 (0.35-2.72)
0.96
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11:00 a.m.
814-3 A Biomarker for Diagnosing Acute Aortic Dissection: 
Preliminary Experience with the Smooth Muscle 
Troponin-Like Protein, Calponin
Toru Suzuki, Alessandro Distante, Federico Sabino, Antonella Sizza, Massimo Villani, 
Santi Trimarchi, Jorge Salerno, Silvano Fracella, Gianfranco Ignone, Giovanni De 
Rinaldis, Richard Nowak, Robert Birkhahn, Judd Hollander, Francis Counselman, 
Eduardo Bossone, Kim Eagle, The University of Tokyo, Tokyo, Japan
Background: Early diagnosis of acute aortic dissection (AD) remains challenging. 
Biochemical diagnosis has great potential to aid in the early diagnosis and therefore 
hasten effective treatment.
Methods: An immunoassay of the troponin troponin-like protein of smooth muscle, 
calponin, was developed (Biosite, San Diego, CA), and its use in
biochemical diagnosis of acute AD was studied. Levels were compared in
72 patients with AD (38 males, age 72 ± 14 (SD) years, time from onset 12 ± 11 hrs) to 
155 controls which were patients suspected of AD at presentation (98 males, age 63 ± 14 
years, time from onset 6 ± 75 hrs). The normal reference of the assay was 0.96 ± 0.31, 95 
95th th percentile 1.66, ng/ml, n=30.
Results: Patients with acute AD showed elevations in plasma calponin levels (4.12 
± 5.44 ng/ml) as compared to controls (2.38 ± 3.07 ng/ml). Calponin more accurately 
diagnosed patients with type A as compared to type B disease (Type A 5.24 ± 6.65 ng/ml, 
n=44, vs. Type B 2.31 ± 2.13 ng/ml, n=25; area under the curve on receiver operating 
characteristics curve analysis for type A and type B were 0.70 and 0.59, respectively; see 
figure). Calponin levels were persistently elevated for at least the first 48 hours.
Conclusions: Calponin levels were elevated in acute AD compared to controls and offers 
potential for use as an early diagnostic biomarker for acute AD. Further validation studies in 
acute dissection and analyses of the assay’s characteristics in other conditions are needed. 
11:15 a.m.
814-4 Emergency Treatment of Acute Type B Dissection: Is 
Surgery Still Justified? Results from The International 
Registry of Aortic Dissection (IRAD).
Rossella Fattori, Thomas T. Tsai, Truls Myrmel, Stuart J. Hutchison, Santi Trimarchi, 
Stephan Kische, Stefanos Demertzis, Jeanna V. Cooper, Kim A. Eagle, Reed E. Pyeritz, 
Eric M. Isselbacher, Christoph A. Nienaber, On Behalf of the International Registry of 
Acute Aortic Dissection (IRAD) Investigators, University of Michigan Medical Center, 
Ann Arbor, MI, University of Rostock, Rostock, Germany
Background: Optimal treatment strategy for patients with acute type B dissection is still a 
matter of debate. In the International Registry of Acute Aortic Dissection (IRAD), multiple 
clinical characteristics, imaging findings and in-hospital outcome were analysed in 
patients with acute type B dissection subjected to emergency open surgery, endovascular 
treatment, or medical therapy.
Methods: Information on 290 clinical variables were compared, including patient 
demographics, medical history, clinical presentation, physical findings, imaging studies, 
details of medical, surgical and endovascular management, in-hospital clinical events, 
length of stay, and in-hospital mortality.
Results: Of the 1554 patients with acute aortic dissection enrolled in IRAD between 
1996 and 2005, 571 (36.7%) suffered from acute type B aortic dissection. Of these, 390 
patients were treated medically and 125 were managed with standard open surgery 
(interposition grafting or fenestration, in 59 patients) or an endovascular approach (stent-
graft placement or percutaneous fenestration, in 66 patients). Patients who underwent 
emergency endovascular or open surgery were younger (mean age 58.8, p <0.001) than 
their counterparts treated conservatively, and had male preponderance with hypertension 
in 76.9%. Patients submitted to surgery presented with a wider aortic diameter (5.36 ± 
1.7 cm) than patients treated by interventional techniques (4.62 ± 1.3 cm) or by medical 
therapy (4.47 ± 1.4 cm), p=0.003. Total in-hospital stay was significantly longer with 
conventional open surgery than with stent-graft treatment (24.1 ± 21.0 days vs 14.3 
± 8.9 days, p= 0.01). In-hospital complications occurred in 21% of patients subjected 
to endovascular technique and in 40% of patients after open surgical repair (p=0.04). 
In-hospital mortality was significantly higher after open surgery (33.9%) than after 
endovascular treatment (10.6%, p=0.002).
Conclusion: In IRAD, endovascular treatment of type B dissection is gaining momentum 
because of its less invasive nature and apparently less morbidity; larger randomized trials 
or comprehensive registries are needed to assess impact on outcomes.
11:30 a.m.
814-5 Carotid Stenting in Patients With Prior Carotid 
Endarterectomy is Associated With Favorable 
Outcomes in Community Practice: Insights From The 
Large German Multicenter ALKK CAS - Registry.
Rajendra H. Mehta, Ralf Zahn, Matthias Hochadel, Thomas Ischinger, Wolfgang 
Schmalz, Karl Eugene Hauptmann, Bernd Mark, Uwe Zeymer, Norbert Treese, Ernst 
Roth, Jochen Senges, On Behalf of the German ALKK-CAS Registry, Duke Clinical 
Research Institute and Duke University Medical Center, Durham, NC, Klinikum and 
Institut für Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany
Background: Repeat surgery for recurrent stenosis after carotid endarterectomy (CEA) 
remains a challenging treatment option that has high morbidity and mortality. Carotid 
artery stenting (CAS) is an attractive alternative treatment option for these patients (pts). 
However, data on the safety and efficacy of CAS in large number of pts are less known.
Methods: We evaluated 3070 pts undergoing CAS enrolled in a German Registry (1996-
2006, 31 sites). We compared the clinical and imaging features and in-hospital outcomes 
of pts with and without prior CEA undergoing CAS.
Results: Of 3070 pts in the Registry, 223 (7.3%) had CAS for restenosis after prior CEA. 
The median age was similar in pts with and without prior CEA (70 vs. 71 yrs). Ipsilateral 
neurological symptoms occurred in half the pts in both groups with fewer pts in prior CEA 
group having symptoms <180 days of CAS (68% vs. 83%, p=0.002). While peripheral 
vascular disease was more common in the prior CEA group, other comorbid conditions, 
imaging findings, medical treatments and procedural factors did not differ between the 2 
groups. In-hospital events were low and not significantly different between those with and 
without prior CEA (Table). 
In-hospital events in patients with and without prior CEA
Events All (n=3070)
Prior CEA 
(n=223)
No Prior CEA 
(n=2847)
P 
value
Ipsilateral TIA (%) 2.8 1.9 2.8 0.392
Ipsilateral major stroke (%) 1.5 1.4 1.5 1.000
Contralateral ischemic event-
any (%) 1.4 0.5 1.5 0.365
Myocardial infarction (%) 0.1 0.4 0.1 0.202
Death (%) 0.4 0.0 0.4 0.880
All non-fatal ipsilateral strokes or 
death (%) 1.7 1.4 1.7 1.000
Local fibrinolysis (%) 0.2 0.0 0.2 -
Groin complications (%) 1.4 1.3 1.4 1.000
Re-intervention (%) 0.4 0.7 0.4 0.466
Carotid surgery (%) 0.6 0.7 0.6 0.596
Conclusions: Our data in large number of pts undergoing CAS in recent contemporary 
community practice attest to low risk of in-hospital events in pts with restenosis after prior 
CEA. This low risk along with the less invasive nature of CAS should make it an attractive 
and perhaps the preferred option for the treatment of these pts.
11:45 a.m.
814-6 Incidence of a Left Main Stenosis Among High Risk 
Patients Presenting for Elective Vascular Surgery and 
Long-Term Outcomes
Edward O. McFalls M.D., Herbert B. Ward, Gordon Pierpont, Heba S. Wassif, Sara T.N. 
Murray, Steve Goldman, Greg C. Larsen, Fred Littooy, William Krupski, Thomas Moritz, 
Domenic Reda, VA Medical Center, Minneapolis, MN
Background: Among high risk patients undergoing coronary angiography prior to 
vascular surgery, the prevalence of a left main stenosis (LMCS) and the long-term 
outcome following the vascular operation are unclear.
Methods: The Coronary Artery Revascularization Prophylaxis (CARP) Trial was a 
multicenter study which tested the long-term benefit of coronary artery revascularization 
prior to elective vascular surgery. Patients with a LMCS were ineligible and followed in the 
nonrandomized registry. The present cohort includes randomized and non-randomized 
patients who were referred for preoperative coronary angiography and underwent 
vascular surgery.
Results: One thousand, forty-eight patients were referred for coronary angiography prior 
to elective vascular surgery because of either multiple cardiac risks or an abnormal stress 
imaging test prior to elective vascular surgery. Two hundred and thirty-three patients 
(22.2%) had normal or non-obstructive coronary artery disease (CAD) and forty-eight 
patients (4.6%) had a LMCS (≥50%). As shown in the Table, the 2.5 year postoperative 
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survival in patients with a LMCS is improved with preoperative coronary artery bypass 
surgery (CABG). *P<0.01 vs LMCS with preoperative CABG.
Conclusions:  In this cohort of the CARP Trial, a LMCS was noted in 4.6% of high risk 
patients undergoing elective vascular surgery. The data suggest that preoperative CABG 
may improve long-term survival in patients with a LMCS who undergo vascular surgery. 
Probability of Survival at 2.5 Years Following Vascular Surgery
No CAD 
(N=233)
LMCS with preoperative CABG 
(N=35)
LMCS with no preoperative CABG 
(N=13)
0.83 0.84 0.52*
Noon
814-7 Association of Peripheral Vascular Disease and All-
Cause Mortality in Patients With Rheumatoid Arthritis
Matthew A. Kaminski, Mehdi H. Shishehbor, Taral Patel, Saif Anwaruddin, Julie C. 
Huang, Arman T. Askari, Cleveland Clinic, Cleveland, OH
Background: Several studies have observed an increased cardiovascular morbidity 
and mortality in patients with rheumatoid arthritis (RA), possibly due to the inflammatory 
nature of the disease. Whereas the presence of peripheral vascular disease (PVD) is a 
harbinger of adverse cardiovascular events in the general population, its relationship to 
outcomes in patients with RA has only recently been recognized.
Methods: The electronic medical records at our institution were reviewed for all patients 
with diagnosis of RA between January 2000 and July 2006. Demographic, clinical, and 
medication data were then extracted. All-cause mortality was obtained by using the Social 
Security Death Index. We used multivariable logistic regression analysis to assess the 
association between PVD and all-cause mortality.
Results: A total of 6,235 patients with RA were identified. Of these 129 had documented 
PVD. Patients with PVD were more likely to be male, have a history of tobacco use, 
diabetes, hypertension, hyperlipidemia, and coronary artery disease, and to be on statin 
therapy. There were 181 deaths over 6 year period.. Documented PVD was strongly 
associated with all-cause mortality (10.8% versus a 2.7%, P<0.001). After adjusting 
for several confounders including age, gender, history of coronary artery disease, 
hypertension, hyperlipidemia, current smoking, obesity, and concomitant medications 
(statins, aspirin, disease-modifying anti-rheumatic drugs), PVD remained independently 
associated with all-cause mortality (HR 2.318; 95% CI:1.251-4.296, P < 0.0001).
Conclusions: In patients with RA, PVD was strongly associated with all-cause mortality. Moreover, 
presence of PVD may identify individuals with RA that are at increased risk of death.
12:15 p.m.
814-8 Differences in Responsiveness of Platelets to Shear 
in Patients With Peripheral Artery Disease (PAD) and 
Coronary Artery Disease (CAD) in the Effect of Lipid 
Modification on Peripheral Arterial Disease After 
Endovascular Intervention Trial (ELIMIT)
Vijay Nambi, Kay T. Kimball, Angela L. Bergeron, Shawna L. Johnson, Joel D. Morrisett, 
Jing-Fei F. Dong, Alan B. Lumsden, Christie M. Ballantyne, Paul F. Bray, Baylor College 
of Medicine, Houston, TX
Background: Information on differences in platelet function between patients with 
peripheral arterial disease (PAD) and coronary artery disease (CAD) is limited.
Methods: Men with symptomatic PAD (ABI <0.9; n=29 from Effect of Lipid Modification on 
Peripheral Arterial Disease after Endovascular Intervention Trial) were compared with age 
matched men with CAD (post coronary artery bypass grafting; n=40) but no PAD (all on 
aspirin, no clopidogrel). Under fluid shear stress rates of 5000 and 10000 sec-1 (typically 
found in arterioles and moderately stenosed arteries, respectively) we measured the % 
shear-induced platelet aggregation (SIPA) and % increases in shear-induced P-selectin 
expression (SIPE) (P-selectin is a marker of platelet activation). Analyses of variance 
adjusted for age, aspirin dose and statin use were used to estimate differences between 
the groups.
Results: Mean age of patients with PAD and CAD was 62.5 and 61.8 years respectively. 
Increases in SIPA and SIPE were significantly different (all p<0.001) between PAD and 
CAD patients. Logistic regression analyses differentiated the two groups (% SIPE 5000 
and 10000 were the most discriminating; classified 89% of all patients, 89% with PAD, 
90% with CAD accurately).
Conclusion: Shear dependent platelet assays differentiated platelet function in men with 
PAD and CAD. In vivo depletion of intracellular ADP due to activation by increased shear 
from extensive atherosclerosis may have led to less responsiveness of PAD platelets to 
ex vivo shear.
Shear-induced platelet reactivity (mean ± SD)
PAD CAD p-value
% SIPA at 5000 sec-1 44.39 + 14.0 66.0 + 17.4 <0.0001
% SIPA at 10000 sec-1 83.2 + 9.24 91.39 + 4.68 <0.0001
% increase SIPE at 5000 sec-1 25.4 ± 21.8% 107% ± 56.3% <0.0001
% increase SIPE at 10000 sec-1 176% ± 112% 293% ± 172% 0.0010
ACC.ORAL CONTRIBUTIONS
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11:00 a.m.
815-3 Genetic Polymorphisms On Alpha2 Sub-Unit Of Platelet 
Integrin Alpha2Beta1, Modify Platelets’ Activation 
Only In The Presence Of Advanced Atherosclerosis 
Or Endothelial Dysfunction: Effects On The Risk For 
Myocardial Infarction In Young Individuals
Dimitris Tousoulis, Charalambos A. Antoniades, Carmen Vasiliadou, Kyriakoula Marinou, 
Costas Tentolouris, George Latsios, E. Gerodimou, G. Triantafyllou, Gerasimos 
Siasos, Nikolaos Koumallos, Christodoulos Stefanadis, Athens University, A Cardiology 
Department, Athens, Greece
Background: Platelet integrin α2β1 participates in platelet activation, as a receptor for 
collagen. Platelets activation is characterized by the release of soluble CD40-ligand 
(sCD40L) and P-selectin (P-Sel). We examined the effect of C807T and A1648G 
polymorphisms on α2β1 gene, on the risk for myocardial infarction (MI) and the release 
of sCD40L and sP-sel during the acute phase of MI and one year after the event, and in 
healthy individuals stratified according to endothelial function.
Methods. Two hundred nineteen patients with acute premature MI (aged 48.8±3.2 
years) and 387 controls were recruited. Sixty seven of the patients and 232 matched 
controls were recalled after 1 year, for the follow-up study. Endothelial function was 
evaluated by gauge-strain plethysmography.
Results. The genotypes distribution were for 807TT/CT/CC: 34/112/73 in patients 
and 30/214/143 in controls (p<0.05) and for 1648GG/AG/AA: 161/50/8 in patients and 
300/77/10 in controls (p=NS). The adjusted risk for MI in 807TT was 2.30(95%CI:1.19-4.44) 
p=0.01. During the acute phase of MI, both sCD40L and P-sel were higher in 807CT+TT 
(12.8±1.2pg/ml and 68.2±4.9ng/ml respectively) compared to CC (7.1±0.9pg/ml and 
39.9±3.7ng/ml respectively, p<0.01 for both). One year after the event, sCD40L and P-sel 
remained higher in CT+TT (8.7±0.9pg/ml and 51.1±3.6ng/ml) compared to CC(4.4±0.9pg/
ml and 37.2±2.6ng/ml, p<0.01 for both). In healthy controls, sCD40L and P-sel was not 
different in CC (4.2±0.5pg/ml and 31.1±3.1ng/ml) compared to CT+TT (5.3±0.3pg/ml and 
35.8±1.8 p=ns for both). However, among “healthy” subjects with endothelium-dependent 
dilatation<median, sCD40L and P-sel were higher in CT+TT (6.2±0.4pg/ml and 42.8±3.1) 
compared to CC (4.3±0.5pg/ml and 36.1±3.3ng/ml p<0.05 for both).
Conclusions. Genetic polymorphism C807T on platelet integrin α2β1 is a risk factor for 
premature MI, and it affects the release of sCD40L and P-selectin during the acute phase 
of MI, an effect observed in the same patients one year after the event, but not in healthy 
subjects. Among healthy individuals, the presence of 807T allele is associated with higher 
sCD40L and P-selectin only in the presence of endothelial dysfunction.
11:15 a.m.
815-4 Inhibition Of Platelet Aggregation By Clopidogrel Is 
Unaffected By The CYP2C19 681G>A Polymorphism In 
Patients With Coronary Artery Disease
Simon MG Smith, Robert Buckland, Martina E. Daly, Robert F. Storey, University of 
Sheffield, Sheffield, United Kingdom
Background: It has been proposed that the CYP2C19 681G>A single nucleotide 
polymorphism (SNP; rs4244285) may explain variability in individual response to clopidogrel 
(CLOP). We investigated whether this SNP influenced CLOP response in patients with 
coronary artery disease undergoing percutaneous coronary intervention (PCI).
Methods: Platelet aggregation (PA) was assessed by whole blood single-platelet counting 
using ADP 10µM before CLOP administration and 4 h post CLOP 600mg in 79 patients 
undergoing elective PCI. CLOP efficacy was measured both as % relative inhibition of PA 
and absolute inhibition (ΔPA) from baseline at 4 hours. CK-MB and TnI were measured 
following PCI. Genotyping for the CYP2C19 681G>A SNP was performed using PCR and 
restriction enzyme digestion.
Results: PA results showed wide inter-individual variation post CLOP and were similar 
between genotypes both at baseline and post CLOP (Figure). Inhibition of PA was 
unaffected: ΔPA 47 ± 4% (GG) v 43 ± 7% (GA/AA)(p = 0.55). CLOP resistance (≤ 10% 
ΔPA) was present in 11/62 (18%) GG patients and 2/17 (12%) A-allele carriers (p = 0.43). 
Results for AA homozygotes (n = 5) were similar to heterozygotes (n = 12). Genotype did 
not influence the incidence of elevation of CK-MB (21%) or Troponin I (56%).
Conclusions: The CYP2C19 681G>A SNP does not influence CLOP efficacy in patients 
with coronary artery disease. 
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815-5 Variability Of Antiaggregant Response To Clopidogrel In 
Healthy Subjects: First Correlation To Platelet P2Y12 ADP-
Receptor Occupancy In 3 Selected Platelet-Response Groups
Ludovic Drouet, Claire Bal dit Sollier, Lionel Hovsepian, IVS - INSERM U689, Paris, 
France, SGS-ASTER, Paris, France
Background: As seen with other medications’ response, there is some variability in 
platelet responsiveness to clopidogrel. We sought to monitor in controlled conditions 
the evolution of both inhibition of platelet aggregation (IPA) and binding to platelet P2Y12 
ADP thienopyridine-sensitive receptors (R) in healthy subjects categorized by platelet 
response to clopidogrel.
Methods: Healthy male subjects (n=451) were screened in a run-in phase comprising 
7 days’ treatment with clopidogrel 75 mg/day. After a washout period, subjects selected 
according to their antiaggregant response were then randomized in a double-blind, 
placebo-controlled study period. These subjects were assigned to one of 3 clopidogrel-
response groups, referred to as ‘average’ (within 40-60% of IPA to ADP 5µM versus 
baseline), ‘high’ (>80%) and ‘low’ (<10%). Clopidogrel 75 mg/day (n=10/group) or placebo 
(n=2/group) was administered for 10 days, followed by a single dose of clopidogrel 300 
mg on Day 11. IPA to ADP 5µM and binding of 33P-2MeS-ADP to platelet P2Y12-R were 
measured repeatedly.
Results: The incidence of ‘low’ responders was low (3.7 %), whereas ‘high’ responders were 
the most prevalent (24.0%). Types of response to clopidogrel were maintained between the 
screening and evaluation phases, despite individual variability of IPA between consecutive 
clopidogrel treatment periods. The P2Y12-R density and affinity in platelets were not different 
between groups in the basal state. In each group of responders, treatment with clopidogrel 
for 10 days induced a significant reduction in unbound P2Y12-R versus placebo, but no 
changes in receptor affinity. This reduction was correlated with IPA response (Pearson test: 
r = 0.54). A loading dose of clopidogrel increased both the IPA and the inhibition of binding 
to P2Y12-R in ‘low’ responders, but less so in the other two groups.
Conclusion: In a population of healthy subjects, the variability of the antiaggregant response 
to clopidogrel appears to be linked to differences in P2Y12-R occupancy. A loading dose 
further to a standard regimen of clopidogrel improves both antiaggregant response and 
P2Y12-R occupancy in a subset of the healthy subjects categorized as low responders.
11:45 a.m.
815-6 Impact of Higher Clopidogrel Loading and Maintenance 
Dose on Platelet Function and Antithrombosis 
in Patients Undergoing Percutaneous Coronary 
Intervention Measured by Thromboelastogram
Angel Caldera, Manu Pillai, William Hartley, Rafael Gonzalez, Vishal Patel, Jaromir 
Bobek, Santhosh Koshy, Nasser Lakkis, Baylor College of Medicine, Houston, TX
Background: . Research has suggested that a 600 mg loading dose (LD) of clopidogrel 
at the time of coronary intervention (PCI) achieves greater platelet inhibition than the 300 
mg loading dose. Thromboelastography (TEG) may further elucidate the antithrombotic 
effects of a higher loading and maintenance dose
Methods: 41 patients underwent PCI and were randomized to a 300 mg LD of clopidogrel 
compared to a 600 mg LD. Patients who received 600 mg LD of clopidogrel continued 
with 75 mg of clopidogrel bid (Group 1) while the 300 mg LD group continued with 75 
mg daily qd (Group 2).
Results: Baseline characteristics were similar among groups. Reaction time (R), or 
time to thrombin induced fibrin generation was significantly prolonged in Group 1 but 
not Group 2 (p<0.0001, p=0.67). K time, or the measure of speed to reach a predefined 
clot strength was significantly increased in Group 1 but not Group 2 (p=0.005, p=0.57). 
Angle α, which measures the rapidity of fibrin build up and cross linking was significantly 
decreased in Group 1 but not Group 2 (p=0.032,p=0.821). Maximum Amplitute (MA), the 
direct function of fibrin and platelet bonding was significantly changed in Group 1 but not 
Group 2 (p<0.001, p=0.588). Coagulation Index(CI), which describes the patients overall 
coagulation was significantly changed in Group 1 but not Group 2 (p=0.002, p=0.708).
Conclusions: Clopidogrel therapy with a LD of 600 mg and 75 mg bid for one month 
significantly depresses platelet function and may have additional antithrombotic properties. 
Clopidogrel Dosing Assessed by TEG
TEG
600 mg 
Clopidogrel 
LD 0 hrs
600 mg 
Clopidogrel 
LD at 4 hrs
600 mg 
Clopidogrel 
LD at 24 hrs
75 mg 
Clopidogrel BID 
at 1 month
P value One 
way ANOVA
R 6.407 9.239 7.157 9.433 <0.001
K 1.663 2.193 1.921 2.381 0.0052
Angle 65.53 60.94 64.01 58.64 0.0324
MA 35.11 50.10 67.80 39.43 <0.001
CI 0.536 -1.792 -0.341 -2.733 0.0016
Noon
815-7 Effect of Increased Maintenance Dose of Clopidogrel on 
Platelet Aggregation
John Holt, Wendell S. Akers, Julie Oestreich, Steven Steinhubl, University of Kentucky, 
Lexington, KY
Background: There is increasing evidence that variability in response to clopidogrel may 
be related to inadequate dosing. While previous studies have found that clopidogrel 
dosing at 150mg daily increases the mean level of platelet inhibition compared to 75mg 
daily, it is unknown whether this is true in all patients or just in select individuals.
Methods: Platelet aggregation measured by changes in ADP-induced light transmittance 
aggregometry (LTA) and the VerifyNow P2Y12 assay was evaluated in 20 patients treated 
with aspirin and 75mg of clopidogrel daily for at least one month. The dose of clopidogrel was 
increased to 150 mg per day and platelet aggregation studies were repeated after one month.
Results: The mean level of 5 μM ADP-induced platelet aggregation in patients taking 
clopidogrel 75mg per day by LTA was 34 ± 13%. When the clopidogrel dose was 
increased to 150 mg per day the mean aggregation by LTA was 32 ± 11%. However, 
platelet aggregation measured by the VerifyNow P2Y12 assay was reduced from 180 
± 60 PRU to 139 ± 76 PRU when the clopidogrel dose was increased to 150 mg per 
day. Irrespective of the assay, ~1/3 of individuals demonstrated no decrease in platelet 
aggregation when clopidogrel was increased to 150 mg per day.
Conclusion: The results to date indicate that increasing doses of clopidogrel do not lead 
to increased platelet inhibition in a significant proportion of patients, and substantial inter-
patient variability continues to be observed at clopidogrel doses of 150 mg per day.
12:15 p.m.
815-8 Platelet Aggregometry and Receptor Binding to Predict 
the Magnitude of Antithrombotic and Bleeding Time 
Effects of Clopidogrel in Rabbits
Pancras C. Wong, Robert Rehfuss, Earl J. Crain, Carol A. Watson, Ji Hua, Jeffrey S. 
Bostwick, Xiaosui Jiang, William A. Schumacher, Martin L. Ogletree, Bristol-Myers 
Squibb Company, Pennington, NJ
Background: Inhibition of ex vivo ADP-induced platelet aggregation (IPA) is the gold 
standard in assessing the antiplatelet effects of P2Y12 antagonists. Target IPA levels that 
produce clinically relevant antithrombotic effects or bleeding have not been established. 
Thus, we examined standard IPA, a modified IPA and receptor binding as predictors of 
antithrombotic and bleeding time (BT) effects of clopidogrel (clopi), a selective P2Y12 
antagonist, in rabbits.
Methods: Rabbits were dosed with clopi (0.3, 1, 3, 10 and 30 mg/kg p.o.) or vehicle, once 
daily for 3 days. Antithrombotic (% thrombus weight reduction) and BT (fold-increase 
over control) activities were evaluated in models of electrically-induced carotid artery 
thrombosis and cuticle bleeding, respectively (n=5 to 6 per group). Standard and modified 
IPA were measured in the absence and presence of P2Y1 blockade, respectively. Both IPAs 
were indicated by % inhibition of peak platelet aggregation to 20 µM ADP as determined 
in citrated platelet-rich plasma by light transmission aggregometry. % Inhibition of [33P]-
2MeS-ADP binding to washed platelets in the presence of P2Y1 blockade was defined as 
P2Y12 receptor occupancy.
Results: Clopi produced dose-dependent effects on thrombosis, BT and P2Y12 receptor 
occupancy with ED50s (doses for half-maximal efficacy, mg/kg) of 1.1±0.3, 5.6±0.5 and 
1.8±0.2 respectively. Clopi at the maximal dose produced a standard IPA of 57±5%, an 
antithrombotic effect of 85±1%, a BT increase of 6.0±0.4-fold and P2Y12 receptor occupancy 
of 87±5%. At a dose that produced a low standard IPA of 17±4% and P2Y12 receptor 
occupancy of 39±5% with a moderate increase in BT of 2.0±0.1-fold, clopi achieved a 
significant antithrombotic activity of 55±2%. At all dose levels, standard IPA underestimated 
antithrombotic efficacy but tracked better with BT effects. Modified IPA and P2Y12 receptor 
occupancy quantified well the magnitude of clopi’s antithrombotic effect.
Conclusions: In rabbits treated with clopi, low standard IPA is associated with significant 
antithrombotic effects. Modified IPA and P2Y12 receptor occupancy appear to predict the 
magnitude of clopi’s efficacy, but standard IPA may be a better predictor of BT.
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1020-1 Effects of Diet-Induced Weight Loss in Obese Males on 
Cardiac and Vascular Function
Cynthia Piantadosi, Matthew I. Worthley, Andrew McAinch, Gary A. Wittert, Stephen G. 
Worthley, Royal Adelaide Hospital, University of Adelaide, Adelaide, Australia
Background: Obesity is associated with myocardial and vascular dysfunction, the extent 
of reversibility of these abnormalities with acute weight loss remains uncertain. The aim of 
this study was to determine the acute effects of rapid diet-induced weight loss on cardiac 
and vascular function.
Methods: Obese male subjects. Inclusion subjects aged 18-65 years, Body Mass Index 
(BMI) >30kg/m2, waist circumference >103cm, with no previous history of cardiovascular 
disease and currently on no prescription medications were studied. Weight loss was 
induced using a low calorie diet (~800 Kcal/day) KICSTART™ (Pharmacy Health 
Solutions Pty Ltd, Sydney, Australia) over an 8 week period. At baseline and 8 weeks 
cardiac and vascular function were evaluated via Magnetic Resonance Imaging (MRI: 
1.5 T Seimens Sonata). Endothelial function was evaluated using a brachial forearm cuff 
occlusion flow-mediated dilatation (FMD) technique. With arterial stiffness evaluated via 
aortic distensibility, evaluated in the descending aorta at the level of the pulmonary artery. 
Data is shown as mean ± SEM and comparisons made utilizing a t-test.
Results: Thirty-five obese men age 43.3±9.9 yrs were evaluated. At baseline the cohort 
had a BMI 37.1±4.6 kg/m2 with a waist circumference 111.2± 12.6 cm. All men completed 
the study and lost weight (13.1 ± 4.78 kg, range 5.1-21.8kg, p<0.01). Weight loss induced 
improvements in EF from 51 ± 1.3% to 57 ± 1.3% (p<0.01) along with improvements in 
both arterial stiffness, as evaluated by aortic distensibility, from 2.6 ± 0.3 10-3.mmHg-1 to 
3.5 ± 0.4 10-3.mmHg-1 (p=0.02) and endothelial function with FMD increasing from 3.7 ± 
1.1% to 9.9 ± 1.6% (p<0.01).
Conclusion: Significant weight loss over an 8 week period in obese males improves left 
ventricular systolic function. Beneficial vascular effects were also observed as represented 
by significant improvements in endothelial function and arterial stiffness.
3:30 p.m.
1020-2 Long Pentraxin 3 Is More Specific Than C-reactive 
Protein as a Marker for Vascular Inflammation
Taro Shiga, Koji Maemura, Yasushi Imai, Daiji Kawanami, Norihiko Takeda, Jiro Ando, 
Toshihiro Morita, Ichiro Manabe, Dobun Hayashi, Hiroshi Ohtsu, Akira Sugiyama, Kyoko 
Miyamoto, Mina Sagara, Yukio Ito, Tsutomu Yamazaki, Yasunobu Hirata, Tatsuhiko 
Kodama, Ryozo Nagai, Department of Cardiovascular Medicine, Graduate School of 
Medicine, University of Tokyo, Tokyo, Japan
Background: C-reactive protein (CRP) is an established marker to predict cardiovascular 
events. The long pentraxin 3 (PTX3) shares structural homology with CRP and is 
produced abundantly by vascular endothelial cells and macrophages while CRP is 
mainly produced in the liver. Thus PTX3 is expected to be a more specific marker for 
cardiovascular inflammation.
Methods and Results: We established a high sensitivity assay method for PTX3, 
and examined plasma PTX3 and serum CRP levels in 269 consecutive patients who 
underwent coronary angiography (20 to 89 years old age, 74 % male). The correlation 
between the concentrations of PTX3 and CRP was not significant (Spearman’s ρ=0.158), 
suggesting that PTX3 is independent of CRP as a marker for cardiovascular events. 
Notably, PTX3 levels in patients taking statins or aspirin were lower than those in control 
patients. Among all enrolled patients, PTX3 but not CRP levels were significantly higher 
in the acute coronary syndrome (ACS) group than other groups. Only after exclusion of 
patients with intercurrent diseases that may affect CRP levels, both PTX3 and CRP levels 
were higher in unstable angina group than stable angina group. However, the analysis by 
ROC showed PTX3 was superior to CRP for the detection of UAP (Figure). Finally neither 
PTX3 nor CRP showed any apparent correlation with the number of diseased vessels.
Conclusions: Plasma PTX3 levels were elevated in UAP patients. PTX3 may reflect 
active inflammation that leads to plaque rupture more specifically than CRP.
3:30 p.m.
1020-4 Obesity is Associated with Impaired Human Coronary 
Endothelial Function
Matthew I. Worthley, Ronak S. Kanani, Yi-Hui Sun, Yichun Sun, Stephen G. Worthley, 
David M. Goodhart, Michael J. Curtis, Todd J. Anderson, Foothills Medical Centre, 
Calgary, AB, Canada, Royal Adelaide Hospital, Adelaide, Australia
Background: Obesity is well established as an independent risk factor for cardiovascular 
disease. Peripherally evaluated endothelial dysfunction is associated with obesity, 
however little is known if this link also exists in the coronary circulation.
Methods: Stable patients with minor non-critical coronary artery disease were evaluated. 
Baseline clinical characteristics were evaluated prior to cardiac catheterization, including 
the evaluation of Body Mass Index (BMI, kg/m2). Macrovascular effects were evaluated 
via quantitative coronary angiography with microvascular effects evaluated by assessing 
coronary blood flow (CBF) utilizing a 0.014” Doppler Flo-wire. Endothelial dependent 
effects were measured by assessing effects of acetylcholine (Ach, 10-7 & 10-6 M). 
Endothelial independent mechanisms were evaluated via response to intracoronary 
nitroglycerin (GTN) or adenosine via evaluating coronary flow velocity reserve (CFVR). 
The cohort was divided into low and high BMI with a primary endpoint to evaluate effects 
of Ach on coronary blood flow. The data are shown as mean ± SE and analyzed by single 
factor ANOVA.
Results: 83 patients were evaluated. As predetermined, a significant difference was 
observed between the low BMI (BMI 24.5 ± .3 kg/m2) and high BMI (BMI 31.7 ± .7 kg/m2) 
(p<0.01) group. Results are summarized in the table. 
Low BMI (n=41) High BMI(n=43) P value
Microvascular
(CBF)
Ach
(% change) 95 ± 17 52 ± 10 0.04
Adenosine
(CFVR) 2.9 ± .12 2.7 ± .12 0.28
Macrovascular
(vessel diameter)
Ach
(% change) 2.5 ± 2.7 0.6 ± 2.9 0.64
GTN
(% change) 11.1 ± 3.9 8.7 ± 2.1 0.6
Conclusion: Human coronary endothelial dependent microvascular function is impaired in 
obese compared to non-obese subjects.
3:30 p.m.
1020-5 Sodium Nitrite is a Potent Venodilator
Abdul R. Maher, Prasad Gunaruwan, Khalid Abozguia, Thomas Palin, Philip James, 
Michael Frenneaux, Cardiovascular Medicine, University of Birmingham, Birmingham, 
United Kingdom, University of Wales College of Medicine, Cardiff, United Kingdom
Background: Nitric Oxide may act locally or may undergo one of several metabolic 
conversions in the blood, including conversion to nitrite. It has been proposed that in 
hypoxic conditions nitrite can be reduced to Nitric Oxide resulting in vessel dilation. We 
reasoned that if this is correct then in vivo nitrite would have a more marked dilator effect 
in capacitance than in resistance vessels. To investigate this we simultaneously studied 
the effects of intra-arterial infusion of Nitrite upon forearm blood flow (FBF) and venous 
capacitance in healthy volunteers.
Methods: We studied eleven healthy volunteers. Following a baseline infusion of 0.9% 
Saline we infused sodium nitrite at incremental doses of 40nmol/min, 100nmol/min, 
400nmol/min and 1micromol/min, measuring Forearm Blood Flow (FBF) using standard 
strain gauge plethysmography and Forearm Venous Volume (FVV) using radionuclide 
plethysmography from which volume-pressure relationships were generated. Changes in 
FBF, and in FVV in the infused arm were corrected for those in the control arm. Plasma 
nitrite was measured at each stage in venous blood from both arms.
Results: Nitrite produced a venodilation (corrected for the control arm) of (Mean±SEM) 
8.2%±4.0%, 10.3%±2.8%, 20.6%±4.2% and 37.7%±4.9% at 40nmol/min, 100nmol/min, 
400nmol/min and 1micromol/min respectively (P<0.001). The increase in FBF was not 
significant (FBF-ratio increased from 1.2±0.2 to 1.8±0.2 (P=NS)).
Venous plasma nitrite increased from 602nm±67nm at baseline to 2840nm±186 at peak 
dose (P<0.01) and from a baseline of 624nm±61nm to 54893nm±9532nm at peak dose 
(P<0.01) in the control and infused arms respectively.
Conclusions: Nitrite is a potent dilator of venous capacitance vessels at concentrations 
where arterial blood flow is only modestly affected. While at peak dose the plasma nitrite 
levels are supra-normal and hence represent a pharmacological effect, a significant 
venodilation is seen at a dose of 400nmol/min which is accompanied by plasma nitrite 
levels close to the normal physiological range. This is potentially relevant in conditions 
such as Chronic Heart Failure, in which subtle changes in pre-load can result in significant 
effects on cardiac output.
3:30 p.m.
1020-6 Baseline C-reactive Protein Levels And Angiographic 
Restenosis After Coronary Stenting. A Meta-analysis
Giuseppe Ferrante, Giampaolo Niccoli, Luigi M. Biasucci, Filippo Crea, Catholic 
University of Sacred Heart, Rome, Italy
Background: Previous studies have shown conflicting results about the relashionship 
between baseline C-reactive protein (CRP) blood levels and the occurence of angiographic 
restenosis after percutaneous coronary intervention (PCI). We performed a meta-analysis 
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to assess if elevated baseline CRP levels above a pre-specified threshold value of at least 3 
mg/L are associated with an increased risk of angiographic restenosis after PCI with stent.
Methods: We searched Pubmed for all relevant studies that clearly reported on baseline 
blood CRP levels and subsequent restenosis occurence. Restenosis was defined as 
binary angiographic instent stenosis ≥ 50%. We selected 15 studies, of which 8 were 
excluded: 6 because of missing CRP threshold value, 2 because of missing relevant 
information. We perfomed a random inverse variance weighted meta-analysis, after 
calculating the log odds ratio with its standard error for every study. Heterogeneity and 
publication bias were assessed.
Results: Seven studies including 2114 patients were included. The mean follow up 
was 6.3 months (range)(5.8-10). Higher pre-procedural CRP levels were significanltly 
associated with the occurence of angiographic restenosis, odds ratio (OR) 1.79 (95% 
confidence interval [CI]) (1.12-2.88), p = 0.02. Heterogeneity was found: chi2 22.66, p = 
0.0009. The threshold value of elevated baseline CRP level ranged from 3 mg/L in two 
studies, to 5 mg/L in four studies, to 10 mg/L in 1 one study. Thus, a sensitivity analysis was 
performed after excluding the study with 10 mg/L threshold value: the summary estimate 
after pooling data was 1.76 (1.01-3.04), OR (95% CI), p =0.04, being in agreement with 
the result of initial meta-analysis. Also a metaregression showed no influence of threshold 
CRP value on the log odds ratio of restenosis, p = 0.64. No publication bias was detected, 
p= 0.3 (egger test), p= 0.36 (begg test).
Conclusions: Higher pre-procedural CRP levels were significantly associated with an 
increased risk of angiographic restenosis after PCI with stent. Further research is needed 
to assess any causal relation of elevated basal CRP level to restenosis after PCI.
3:30 p.m.
1020-7 Selective Loss of Inhibition on Vascular Smooth Muscle 
Cells Proliferation by RGS2 in Vascular Remodeling
Yuanjie Mao, Lin Xue, Yuyan Wang, Zongdong Yu, Lei Meng, Wenhui Ding, Yongfen Qi, 
Ulrike Mende, Jialin Su, Yong Huo, Peking University First Hospital, Beijing, People’s 
Republic of China, Rhode Island Hospital & Brown University, Providence, RI
Background: Activation of Gq protein-coupled receptors (GPCR) could increase vascular 
smooth muscle cells proliferation and be involved in vascular remodeling. Regulators of 
G protein signaling (RGSs) are a family of proteins with GAP (GTPase-activating protein) 
activity which could accelerate hydrolysis of GTP and terminate G protein signaling. Whether 
RGSs with negative fine-tuning effects on Gq protein signaling,such as RGS2, RGS3, and 
RGS4, could be involved in pathogenesis of vascular remodeling remained unknown.
Methods: Aortic endothelium denudation was performed in Wistar rats with balloon 
catheter. At day 1, 3, 7, and 14 following balloon injury, the rats were sacrificed and 
aortas were taken out for RGS determination. Primary VSMCs were isolated and and 
proliferation of VSMCs was measured by MTT assay and cell counting.
Results: RGS2, RGS3, and RGS4 mRNA could all be detected by RT-PCR. Their mRNA 
levels were also determined by real-time PCR after RT. Comparing with sham group, 
RGS2 in endothelium-denuded aorta decreased by 25% (P<0.05) at day 3. RGS3 and 
RGS4 mRNA levels were unchanged. When administer valsartan(20mg/kg/d)from one 
week before balloon injury , neointima formation could be inhibited without change in 
blood pressure. Aortic RGS2 mRNA in valsartan treated rats at day 3 after endothelium 
denudation was not significantly different from sham group. Proliferation of RGS2 plasmid 
transfected rat VSMCs stimulated by angiotensin II (A II), endothelin-1 (ET-1), and 
phenylephrine (PE) was inhibited by 6.2%, 9.2%, and 25% (P<0.05), respectively. Rat 
VSMCs transfected by RGS2 siRNA plasmid showed down-regulation of endogenous 
RGS2. Proliferation of VSMCs with down-regulated RGS2 stimulated by A II, ET-1 and PE 
was increased by 25.3%, 21.7%, and 17.1% (P<0.05), respectively.
Conclusion: RGS2 with inhibiting effect on VSMCs proliferation was selectively down-
regulated in endothelium denuded rats aorta. The selective loss of fine-tuning effects of 
RGS2 on VSMCs could be pathogenic in vascular remodeling, which might be a potential 
target for treating vessel diseases.
3:30 p.m.
1020-8 Carbon Monoxide Donors or Heme Oxygenase-1 
Overexpression Block Interleukin-18-Mediated NF-kB-
PTEN-Dependent Human Cardiac Endothelial Cell Death
Miguel Zabalgoitia, Raymond F. Reagan, David E. Stec, John M. Rimoldi, Anthony J. 
Valente, Bysani Chandrasekar, Department of Veterans Affairs South Texas Veterans 
Health Care System, San Antonio, TX, University of Texas Health Science Center, 
San Antonio, TX
Background: Heme oxygenase-1 (HO-1), an inducible stress-response gene, is 
expressed in myocardial constituent cells and converts heme to free iron, carbon 
monoxide (CO) and biliverdin. While CO exerts anti-inflammatory and pro-survival 
effects, biliverdin and its byproduct bilirubin exert anti-oxidant effects. We investigated 
whether HO-1 overexpression, or treatment with the CO donors, would inhibit Interleukin-
18-mediated endothelial cell death. .
Methods: Human cardiac microvascular endothelial cells (HCMEC) were treated with 
interleukin (IL)-18. mRNA expression was analyzed by Northern blotting/RNase protection 
assay, protein levels by immunoblotting, NF-kB activation by EMSA, ELISA, and reporter 
assays, and apoptotic cell death by cytochrome c release, annexin V staining, and 
quantifying fragmented DNA. We also investigated the signal transduction pathways 
involved in HO-1-mediated rescue of IL-18-mediated cell death.
Results: Treatment of HCMEC with IL-18: (i) increased NF-kB DNA binding and reporter 
gene activities; (ii) induced PTEN-promoter-reporter activity, mRNA expression, and 
protein levels; and (iii) stimulated HCME cell death by apoptosis. (iv) IL-18-mediated 
PTEN transcription was enhanced by ectopic expression of wild type p65, but inhibited by 
adenoviral transduction with dnIkB-a, dnp65, and dnIKKb. (v) IL-18-mediated cell death 
was blocked by adenoviral HO-1 overexpression. Furthermore, (vi) hemin and cobalt 
(III) protoporphyrin IX inhibited NF-kB activation, PTEN induction and HCME cell death. 
Similarly, (vii) CO donors tricarbonyldichlororuthenium II dimer and CORM-3 attenuated, 
and treatment with hemoglobin potentiated, IL-18-mediated cell death. Likewise, (viii) 
treatment with biliverdin and bilirubin attenuated IL-18-mediated NF-kB activation and 
HCME cell death.
Conclusions: Results demonstrate that IL-18 is a potent inducer of endothelial cell death, 
and HO-1 overexpression, CO or biliverdin attenuates IL-18-mediated NF-kB activation 
and PTEN-dependent endothelial cell death. Thus HO-1 overexpression or CO donors 
may exert cardioprotective effects.
3:30 p.m.
1020-9 Adjusted Clopidogrel Dosing in Patients With 
Insufficient Platelet Inhibition After Elective Coronary 
Stenting Caused a More Robust and Consistent Platelet 
Inhibition in the Entire Cohort
Dietmar Trenk, Willibald Hochholzer, Barbara Mueller, Christian Stratz, Peter 
Schmiebusch, Christian M. Valina, Hans-Peter Bestehorn, Heinz Joachim Buettner, 
Franz-Josef Neumann, Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
Background: Inadequate platelet inhibition carries a substantially increased risk of cardiac 
complications in patients with coronary stents. The EXCELSIOR study demonstrated a 
7-fold increased risk of major adverse cardiac events after elective stenting (PCI), if peri-
interventional ADP-induced (5 µM) platelet aggregation was >14 %. We investigated, 
whether an impaired initial response heralds inadequate platelet inhibition during long 
term treatment and whether an increase in the maintenance dose of clopidogrel can 
improve platelet inhibition in patients with impaired initial response.
Methods: The EXCELSIOR-ACT study enrolled 117 patients receiving clopidogrel 600 mg 
at least 2 h before PCI and assessed platelet aggregation (5µM ADP) at 24 h, and at 14 
and 28 days after PCI. Patients with residual platelet aggregation >14% at 24 h received a 
further bolus dose of clopidogrel 300 mg followed by an increased daily dose of 150 mg. All 
other patients were treated with clopidogrel 75 mg daily. A sub-cohort of the EXCELSIOR 
trial (n=54) with chronic dosing of 75 mg clopidogrel daily served as control group.
Results: Platelet aggregation was <14% in 78 out of 117 patients enrolled in EXCELSIOR-
ACT, while 39 patients had a residual platelet aggregation >14% at 24 h. Patients with 
impaired response at 24 h and an increased chronic dose of clopidogrel 150 mg had a 
similar platelet inhibition at 14 (14.3±8.0%) and 28 days (14.9±10.5%) as patients with 
an adequate response receiving standard doses of clopidogrel 75 mg/day (12.0±12.2%, 
day 14; 11.3±10.9%, day 28). Platelet inhibition in the EXCELSIOR cohort was 22 [28] % 
(median [interquart.range]) at day 28, while testing of platelet inhibition and adjustment 
of maintenance dose in patients with inadequate inhibition improves the consistency of 
chronic platelet inhibition at day 28 (median 10 [14]%; p<0.0001).
Conclusions: Compared to a maintenance dose of 75 mg clopidogrel in all patients, 
testing of platelet inhibition and increase of maintenance dose to 150 mg in patients 
with inadequate inhibition only results in significant improvement of platelet inhibition in 
individual patients and more robust and consistent platelet inhibition in the entire cohort.
3:30 p.m.
1020-10 Status of Estrogen Receptors in Menopause:  
Active or not?
Stéphanie Gagnon, Vikie Lamontagne, Caroline Lemieux, Isabelle Cloutier, Jean-
François Tanguay, Montreal Heart Institute, Montreal, PQ, Canada, Montreal University, 
Montreal, PQ, Canada
Background: Randomized trials comparing estrogen to placebo failed to confirm the 
benefits of estrogen to reduce cardiovascular diseases. In these studies, women were 
in menopause on average for 10 years, a parameter that could have serious impact on 
estrogen receptors (ERs) expression and signaling activity.
Methods: To study the impact of long-term estrogen deprivation on ERs expression, 
menopause was induced in C57BL/6 female mice by ovariectomy (OVX). After 3, 7½ 
or 15 weeks, mice were euthanized and proteins extraction was performed in carotid 
arteries. To measure signaling activity, 3 or 15 weeks OVX mice were either implanted 17-
beta-estradiol (17βE) pellet for 7d (0,033mg) or 28d (0,133mg) or challenged with 1μg of 
17βE for 6h or 36h prior sacrifice. ERs protein expression and p42/44 mitogen activated 
protein kinases (MAPK) activity were measured by western blot.
Results: Neither ERα nor ERβ protein expression varied time-dependently in SHAM-
operated mice. After estrogen deprivation, ERα protein expression remained stable for 3 
weeks, followed by an 86% increase at week 7.5 and a marked drop of 89% at week 15 
as compared with SHAM-operated mice. No difference was observed between SHAM-
operated and OVX mice for ERβ expression. Interestingly, activity of p42/44 MAPK varied in 
function of treatment type and term. A 17βE challenge for 36h after 3 weeks OVX increased 
p42/44 MAPK activity by 247% and 352% as compared to vehicle and 15 weeks OVX mice 
respectively. To the opposite, 17βE hormonotherapy (HT) did not influence p42/44 MAPK 
activity in mice treated 3 weeks after OVX. However, a 28d treatment on 15 weeks OVX 
mice raised p42/44 MAPK activity by 175% compared to vehicle.
Conclusions: A 17βE challenge can activate p42/44 MAPK signalization early after 
menopause but not after long-term estrogen deprivation. P42/44 MAPK activity is 
reduced 15 weeks after OVX but can be reactivated by a long-term treatment with 17βE 
HT. A reduction of ERα expression 15 weeks after OVX could partially explain these 
results. Further studies on ERs expression and activity following 17βE treatments may 
help to both readdress estrogen impact on cardiovascular diseases and lead to optimized 
therapies in post-menopausal women.
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1020-11 Serial Observation of Shear Stress and Atherosclerotic 
Plaque Formation by a Newly-Developed Topographic 
Shear Stress Imaging System with Use of Three-
dimensional Intravascular Ultrasound.
Yusaku Fukumoto, Takafumi Hiro, Takashi Fujii, Genta Hashimoto, Tatsuhiro Fujimura, 
Masunori Matsuzaki, Yamaguchi University, Ube, Japan
Background: It has been speculated that a vessel portion with low shear stress is likely 
to form atheromatous plaque. However, few studies assessed the relationship in vivo 
between shear stress and plaque formation. We recently developed an user-friendly 
program of color mapping of shear stress with 3D intravascular ultrasound ( IVUS ) ( J 
Am Coll Cardiol, 2005 ). This study serially observed the longitudinal change in plaque 
thickness along coronary vessel wall with use of 3D-IVUS compared to the shear stress 
distribution at the baseline.
Methods: Fifteen patients ( 63 ± 10 y.o. ) with a fair control of coronary risk factors were 
imaged with IVUS at the baseline and the follow-up period ( mean 23 ± 15 months, range 9 
to 52 months ). The lumen contour was obtained from the 3D-IVUS, and then transformed 
to a mesh polygon structure. This structure was used for the shear stress calculation with a 
finite element analysis. The flow was considered as a laminar stable flow. A color mapping 
of shear stress was performed on the surface of the mesh polygon. The degree of serial 
plaque formation was defined as year-adjusted percent change of thickness. This degree 
was compared with the value of shear stress for at least 20 portions for each patient.
Results: This study demonstrated that a vessel portion with low shear stress is prone to 
have additional plaque layers on the original one over the observation period. Furthermore, 
the degree of plaque formation was inversely correlated with the ratio of the value of shear 
stress at the point of interest to that at the reference portion ( r=0.68, p<0.05 ).
Conclusions: This color-mapping program of shear stress clarified the inverse 
relationship between shear stress and plaque formation. Therefore, this system might be 
useful to predict the plaque formation along the coronary vessel wall.
3:30 p.m.
1020-12 Gender differences in Insulin Resistance among Asian 
Indians. Atherosclerosis in Asian Indians: Multiple Risk 
Factor Study Assessment (AHIMSA)
Krishnaswami Vijayaraghavan, Vicki Camacho, Michelle Jeffries, Mathew Budoff, Ranjita 
Misra, Eliot Brinton, Scottsdale Cardiovascular Research Institute, Scottsdale, AZ
Background: Asian Indians (AI) differ from non-Hispanic Whites in terms of their 
traditional risk factors for cardiovascular disease (CVD). It is not clear if the risk factors 
are different between AI men and women. The purpose of the study was to examine the 
differences between men and women in terms of the risk factors for atherosclerosis.
Methods and Results: A large population study in AIs is ongoing in the U.S. As part of the 
study, 105 randomly selected subjects underwent a telephone interview for a questionnaire, 
anthropometric measurements and blood collection for emerging and traditional risk factors 
of CVD. Electron Beam Tomography (EBT) was also performed to assess Coronary Calcium 
(CAC).Carotid Intimal Thickness measurement and Endothelial Function assessment by 
Flow Mediated Vasodilatation response of Brachial Artery was also performed.
Results: Mean Age was 49+/- 9; Males were 62%. Compared to women, men had lower 
mean HDL (53 vs. 44 mg/dl; p=0.001), HDL2 (12.3 vs. 8.8; p<0.001), and Adiponectin 
levels (9.3 vs. 5.3; p<0.001). Men had higher mean Homocysteine levels( 11.4 vs. 9; 
p= 0.002), Diastolic Blood Pressure ( 74 vs. 70 mmHg; p=0.04), Fasting Insulin levels( 
7.4 vs. 5.8 units ;p=0.026), Triglyceride levels( 142 vs. 105 mg/dl; p=0.011) and Waist 
to Hip ratio( 0.95 vs. 0.87; p<0.001). Prevalence of Metabolic Syndrome was higher in 
men (53% vs. 34 %; p= 0.05). Positive Calcium Score by EBT was higher in men (41% 
vs. 19%; p=0.028). There was no difference between men and women in mean HsCRP 
levels, Carotid Intimal Thickening and Endothelial Dysfunction.
Conclusion: 1. Parameters of Insulin Resistance are more common in Asian Indian men 
than women. 2. Prevalence of Atherosclerosis is higher in men than women of Asian 
Indian origin as detected by Electron Beam Tomography.3.An opportunity exists for 
Asian Indian men to increase exercise, follow dietary guidelines and prevent the onset of 
Diabetes and it’s complications including atherosclerosis.
3:30 p.m.
1020-13 The Impact Of Acute Consumption Of Corn Oil, Liver 
Oil, Olive Oil Or Soya Oil On Endothelial Function And 
Oxidative Stress Status, In Healthy Adults
Nikos Papageorgiou, Dimitris Tousoulis, Charalambos Antoniades, Costas Tentolouris, 
Stella Brilli, Costas Tsioufis, Kostantinos Toutouzas, Christodoulos Stefanadis, Athens 
University, A Cardiology Department, Athens, Greece
Background: Evidence suggests that consumption of different types of oil may have 
different effects on cardiovascular risk. However, the exact role of corn oil, liver oil and 
olive oil on endothelial function in humans is unknown. We evaluated the effect of acute 
consumption of corn oil, liver oil and olive oil on endothelial function in healthy adults.
Methods. The study population consisted of 28 healthy adults (aged 28.1±1.3 years old). 
Subjects were randomly allocated into 4 groups to receive a single oral amount of corn oil 
(n=7), liver oil (n=7) or olive oil (n=8) or soya oil (n=6). Endothelial function was evaluated 
by gauge-strain plethysmography at baseline and after 1, 2 and 3 hours. Endothelium 
dependent dilation was defined as the %change of flow from baseline to the maximum 
flow during reactive hyperemia. Oxidative stress status was determined by total lipid 
peroxides (PEROX).
Results. EDD was significantly decreased 1 hour after consumption of corn oil (from 
81.6±10.8% to 64.9±7.6% p<0.05 vs baseline) and remained at the same levels at 
2 (64.9±12.8%, p=NS vs 1hour) and 3 hours (63.9±10.2%). EDD was slightly but 
not significantly increased 1 hour after consumption of liver oil (from 63.6±10.2% to 
83.5±15.4% p=NS), remained at the same levels after 2 hours (85.5±12.2% p=NS vs 
baseline) and returned to baseline at 3 hours (64.2±13.2%, p=NS vs baseline). Acute 
consumption of olive oil or soya oil had no effect on endothelial function, since EDD 
remained unchanged at 1, 2 and 3 hours. PEROX remained unchanged in all groups 
(from 125±32, 147±39, 140±27 and 102±16 to 128±40, 164±49, 148±32 and 90±19 U/L 
for corn oil, liver oil, olive oil and soya oil respectively, p=NS for all).
Conclusions. Consumption of corn oil leads to impaired endothelial function, while liver 
oil may improve endothelial function in humans, while oxidative stress does not seem to 
be involved in these effects. These findings suggest that consumption of different types of 
oil may affect vascular endothelium in a different way, partly explaining the important role 
of dietary oil consumption on cardiovascular risk.
3:30 p.m.
1020-14 Prediction of Impairment Factors for Evaluation of 
Patency of Drug Eluting Stent and Bare Metal Stents 
in Coronary Arteries Using 64-Slice Computed 
Tomography in Logistic Regression Models
Koki Nakamura, Nobusada Funabashi, Masae Uehara, Kenji Okubo, Kazushi Suzuki, 
Makoto Terao, Yuzuru Mita, Fumiaki Maeda, Yoko Mikami, Issei Komuro, Chiba 
University Graduate School of Medicine, Chiba, Japan, Awa Medical Association 
Hospital, Tateyama, Japan
Background: To perform the prediction of impairment factors for evaluation of patency 
of drug-eluting stents (DES) versus bare metal stents (BMS) in coronary arteries using 
64-multislice CT using logistic regression models.
Methods: 49 consecutive subjects, with 78 stents (17DES, 61BMS) (34 LAD, 13 LCx, 
and 31 RCA) underwent enhanced ECG-gated MSCT (Light Speed VCT). Stents were 
classified into 3 categories based on stent implantation site: (1) RCA (2) LAD (3) LCx. 
Logistic models were made in each category for predicting impossibilities of evaluation 
of patency of stents using sex, age, heart rate, body mass index (BMI) (kg/m2), diabetes 
mellitus [DM], stent size (mm), and type of stent (DES or BMS).
Results: In CT, patency was confirmed in 65% DES (83, 75 and 43% with 3.5, 3, and 2.5 
mm diameters, respectively), and in 77% BMS (67, 79, 81, 100 and 57% with 4, 3.5, 3, 
2.75 and 2.5 mm diameters, respectively). 10% BMS revealed a low CT area inside the 
stents (2 with 4, 1 with 3.5, and 3 with 3mm diameter) with significant stenosis. 3% BMS 
revealed total occlusion (1 each with 3.5 and 2.5mm diameter). Patency of 35% DES 
(17, 25, and 57% with 3.5, 3, and 2.5mm diameter, respectively) and 23% BMS (33, 21, 
19, 0 and 43% with 4, 3.5, 3, 2.75 and 2.5mm diameter, respectively) was unconfirmed. 
In logistic regression models, significant predictors of impossibilities of evaluation of 
patency of stents were, by category: (1) BMI (positive predictor) and stent size (negative 
predictor) (relative risks, 1.513 and 0.059 [95% Confidence Intervals (CIs): 1.086-2.108, 
and 0.00375-0.9147, respectively])); (2) BMI (positive predictor) and stent size (negative 
predictor) (relative risks, 1.504 and 0.033 [95% CIs: 1.0616-2.1322, and 0.00214-0.5176, 
respectively]); (3) BMI (positive predictor) (relative risk, 1.539 [95% CIs: 1.0654-2.227]). 
Type of stent was not a significant predictor in any category.
Conclusions: 64-slice-MSCT is a non-invasive diagnostic-modality with potential for 
evaluating patency of DES with a low incidence of restenosis. However, when BMI is 
high, or stent size is small, it remains difficult to perform accurate evaluation of patency of 
stents regardless of whether DES or BMS is used.
3:30 p.m.
1020-34 A Novel, Rationally Engineered Heparin (M118) Prevents 
Thrombosis More Effectively Than Unfractionated 
Heparin In A Canine Model of Deep Arterial Injury.
Ian Fier, Mark A. Nedelman, YiWei Qi, J Luis Guerrero, Ganesh Venkataraman, 
Momenta Pharmaceuticals Inc., Cambridge
Background: M118 is a novel, rationally engineered heparin (REH) being developed 
as a predictable anticoagulant for patients with ACS. The antithrombotic efficacy and 
anticoagulation activity of M118 were compared with that of unfractionated heparin (UFH) 
in a canine model of deep arterial injury. 
Methods: Beagle dogs (n=24) were instrumented and the right femoral artery (RFA, 
saline control) was injured by external application of constant current (300 uA). Time to 
occlusion (TTO) was recorded for each vessel. Following occlusion of the control artery, 
the left FA was treated with an iv bolus plus 90 min continuous infusion of UFH (75 U/kg 
+ 1 U/kg/min, n=6) or M118 (37.5, 75 or 150 anti-Xa IU/kg + 1 IU/kg/min, n=6/dose), and 
injured in a similar manner to the control artery. Time to occlusion (TTO) was measured 
in each artery. Arterial flow rate, thrombus weight, bleeding time, and hematology/
coagulation parameters were measured for a maximum of 180 minutes post-injury.
Results: 
Thrombotic and coagulation parameters of experimental groups
Treatment Occlusion(%) Thrombus Weight (mg)
TTO 
(min)a
ACT 
(sec)b
Anti-Factor 
Xab
Anti-Factor 
IIab
Control 
(RFA) 24/24 (100%) 24.0 ± 9.2 59 ± 25 69 ± 6 0.00 ± 0.00 0.00 ± 0.00
UFH (Grp 
1) 5/6 (83%) 19.4 ± 9.5
132 ± 
42e
163 ± 
55 e 2.89 ±1.31 0.95 ± 0.19
M118 
(Grp 4) 3/6 (50%) c 24.5 ± 12.2
165 ± 
23e 101 ± 7
 d 1.20 ± 0.16d 0.64 ± 0.12d
M118 
(Grp 2) 2/6 (33%) c 19.8 ± 6.2
161 ± 
41e
108 ± 
13 d 1.66 ± 0.37 0.87 ± 0.39
M118 
(Grp 3) 1/6 (17%) c,d 12.8 ± 6.0e
165 ± 
36e 131 ± 16 2.93 ± 1.3 1.39 ± 0.74
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ACT = Activated clotting time; aTTO >180 min was set at 180 min;bValue recorded at 60 min 
after initiation of test article infusion;cP<0.05 vs. control;dP<0.05 vs. UFH;eP<0.01 vs. control
Conclusion: M118 dose-dependently inhibited the formation of occlusive thrombosis 
and was more effective than UFH despite lower anticoagulant activity measured by 
ACT, aPTT, anti-Xa and anti-IIa activity. These findings suggest that M118 may provide 
important benefits over UFH and support its evaluation in phase I clinical trials.
3:30 p.m.
1020-35 Effect of Statins on Thermal Heterogeneity of 
Atherosclerotic Plaques in Patients With Diabetes 
Mellitus.
Konstantinos Toutouzas, Virginia Markou, Maria Drakopoulou, Chrysoula Patsa, 
John Karabelas, Manolis Vavuranakis, Christodoulos Stefanadis, First Department of 
Cardiology, University of Athens, Hippokration hospital, Athens, Greece
Background: Infiltration of inflammatory cells is observed in lesions of patients (pts) 
with diabetes mellitus (DM) and acute coronary syndromes (ACS). Local inflammatory 
involvement can be evaluated by coronary thermography. The present study aimed to 
investigate if pts with DM have increased local heat generation compared to non-diabetic 
pts and the effect of statins on plaque temperature.
Methods: We enrolled pts undergoing percutaneous coronary interventions: 45 pts 
with DM and 63 without DM matched for demographic and angiographic characteristics. 
Forty-three pts suffered from ACS and 65 from chronic stable angina (CSA). Coronary 
thermography was performed and temperature difference (DT) between the atherosclerotic 
plaque and the proximal vessel wall was measured.
Results: Pts with DM had increased DT compared to non-DM (0.17±0.18ºC vs 
0.09±0.02ºC, p=0.01). Among pts with DM those with ACS (n=21) had greater DT than 
CSA (0.29±0.31ºC vs 0.09±0.08ºC, p=0.007). In pts with ACS, DT was increased in pts 
with DM compared to non-DM (0.29±0.31ºC vs 0.15±0.21ºC, p=0.02), similarly in CSA 
(0.09±0.08ºC vs 0.05±0.04ºC, p=0.006). Pts with DM under statins (n=23) had lower DT 
compared to untreated pts (0.11±0.12ºC vs 0.22±0.21ºC, p=0.02).
Conclusions: Pts with DM have increased local inflammatory involvement and especially 
pts with ACS, as shown by coronary thermography. Pts with DM receiving statins had 
decreased DT, suggesting that statins have a favorable effect in culprit lesions of pts 
with DM. 
3:30 p.m.
1020-36 Inhibition of Platelet Aggregation: A Novel Effect of C-
reactive Protein
Rolf P. Kreutz, Jason Yoho, Udaya S. Tantry, Kevin P. Bliden, Paul A. Gurbel, Sinai Center 
for Thrombosis Research, Baltimore, MD
Background: C-reactive protein (CRP) is implicated in the pathogenesis of 
atherosclerosis. CRP inhibitors are currently being considered in the treatment of acute 
coronary syndromes (ACS). However, the effect of CRP on thrombosis and inflammation 
in healthy individuals remains controversial. Both anti-aggregatory and pro-thrombotic 
properties of CRP have been described.
Methods: Twenty venous blood samples from healthy individuals were used for in vitro 
studies using highly purified recombinant CRP. Samples were incubated with CRP at a 
concentration (25mg/l); a concentration reported in patients with ACS ; and analyzed by 
light transmittance aggregometry (LTA), thrombelastography (TEG) and flow cytometry.
Results: CRP inhibited platelet aggregation in platelet rich plasma in response to 
ADP 5uM (74±16 vs 30±12%, p<0.001), arachidonic acid 1uM (AA) (65±31 vs 8±22%, 
p<0.001), and collagen 2ug/ml (65±35 vs 33±29%, p<0.001). CRP did not activate 
platelets and did not affect ADP-stimulated expression of p-selectin (29±18% vs 30±18% 
positive platelets, p=0.33) or activated GPIIb/IIIa (12.8±12 vs 12.2±13 MFI, p=0.7). CRP 
non-significantly decreased ADP-induced (48±18 vs 38±19, p=0.14) maximum platelet-
fibrin clot strength.
Conclusion: CRP markedly inhibits platelet aggregation induced by multiple agonists 
in platelet rich plasma. However, CRP does not affect the expression of receptors after 
agonist stimulation suggesting that the antiaggregatory properties of CRP result from 
effects on fibrinogen-GPIIb/IIIa interactions. The novel antiplatelet effect of CRP deserves 
further investigation.
3:30 p.m.
1020-37 The Release of the Long Pentraxin 3(PTX3) in 
Vulnerable Plaques in Vivo
Satoro Suwa, Kenji Inoue, Seigo Ito, Iwao Okai, Katsumi Miyauchi, Shinya Okazaki, 
Yasumasa Fujiwara, Masataka Sumiyoshi, Hiroyuki Daida, Juntendo Shizuoka Hospital, 
Shizuoka, Japan, Juntendo Nerima Hospital, Tokyo, Japan
Background: Elevated plasma levels of the pentraxin protein family member C-reactive 
protein (CRP) is associated with increased risk of cardiovascular disease in high-risk 
subjects. The long pentraxin member, PTX3, unlike CRP, is expressed in vascular cells 
including, endothelial cell (EC), smooth muscle cells, and neutrophils, but not in liver. 
Interestingly, PTX3 was suppressed by statin mostly in EC, as revealed by gene chip 
analysis. Therefore we believe that PTX 3 represents a ‘vascular CRP’. The present study 
was designed to investigate the plasma levels of PTX3 in various vascular diseases 
including abdominal aortic aneurysm (AA), arteriosclerosis obliterance (ASO), and acute 
coronary syndrome (ACS).
Method: Plasma samples were obtained from 252 consecutive subjects admitted to a 
university hospital for coronary artery assessment by coronary angiography. From these 
subjects, we analyzed the plasma levels of PTX3 in 8 patients with AA, 14 patients with 
ASO, and 40 patients with ACS. Additionally, we collected plasma samples from 17 
patients with ACS who underwent primary PCI with the use of a embolization protection 
device and aspiration catheter (PercuSurge GuardWire). The Guardwire balloon was 
placed just distal to the site of the lesion prior to the major branch, where the thrombus 
could embolize. Using the aspiration catheter, without inflating the balloon of the 
Guardwire, 9 aspirations were done across the lesion. PTX3 were measured in blood 
obtained from the distal site of coronary occlusion and from the aorta.
RESULTS: Compared to the AA (2.77 ng/mL (95% CI: 2.17-3.36) ) or ASO (3.01 ng/mL 
(95% CI: 2.02-4.01) ) group, PTX3 levels were significantly higher in the ACS group (5.20 
ng/mL (95% CI: 4.16-6.24) ). The plasma levels of PTX3 were significantly higher in the 
aspirated blood at the distal site of coronary culprit lesion than in the peripheral arterial 
blood or aorta (P<0.05).
CONCLUSIONS: These findings indicate that plasma levels of PTX3 are increased in 
‘active’ vascular disease, but not in ‘chronic’ vascular disease, and originate mainly from 
the site of ruptured plaques relative to the systemic circulation. 
3:30 p.m.
1020-38 Inhalation of Particulate Air Pollution Impairs Vascular 
Function in Man
Nicholas L. Mills, Andrew J. Lucking, Jon Beveridge, Laura Flint, Finny Paterson, 
Nicholas A. Boon, Paul Fokkens, Anders Blomberg, Thomas Sandstrom, Ken 
Donaldson, Flemming R. Cassee, David E. Newby, The University of Edinburgh, 
Edinburgh, United Kingdom, Department of Public Health and the Environment, 
Bilthoven, The Netherlands
Background: Exposure to traffic derived air pollution may be a trigger for acute myocardial 
infarction. We have previously demonstrated impairment of vascular function following 
inhalation of dilute diesel exhaust at concentrations occuring in the urban environment. 
Diesel exhaust contains a number of potentially important gaseous and particulate air 
pollutants. We aim to determine the constituents of diesel exhaust responsible for the 
adverse vascular effects in man.
Methods: Sixteen healthy volunteers were exposed to dilute diesel exhaust (1x106 
particles/cm3), elemental carbon nanoparticles (4 x106 particles/cm3), filtered diesel 
exhaust (<1,000 particles/cm3), or filtered air (<100 particles/cm3) for two hours in a 
randomised double blind cross-over study. Bilateral forearm blood flow was measured 
before and during unilateral intra-brachial infusions of bradykinin, acetylcholine, sodium 
nitroprusside and verapamil 6-8 hours following each exposure.
Results: Inhalation of dilute diesel exhaust increased systolic arterial pressure compared 
to filtered air (147±3 vs. 134±3mmHg, P<0.001). Whilst there was a dose dependent 
increase in blood flow with each vasodilator (P<0.001 for all), this response was 
attenuated with bradykinin (P<0.05), acetylcholine (P<0.05) and sodium nitroprusside 
(P<0.001) infusions following dilute diesel exhaust. Diesel exhaust filtration reduced 
particulate concentration by 1,000-fold, but did not affect levels of volatile and gaseous 
pollutents. Exposure to filtered diesel exhaust or carbon nanoparticles had no effect on 
arterial pressure or endothelium-dependent and -independent vasodilatation.
Conclusion: Inhalation of dilute diesel exhaust, but not gaseous pollutants or carbon 
nanoparticles, markedly impairs the regulation of vascular tone in man. These findings 
suggest that the adverse vascular effects of diesel exhaust are determined by 
combustion derived particles and provide a potential mechanism that links air pollution 
to the pathogenesis of atherothrombosis. We suggest that environmental health 
policy interventions to reduce particulate emissions may decrease the risk of adverse 
cardiovascular events.
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1020-39 Hepatocyte Growth Factor is A Key Paracrine Molecule 
Mediating the Angiogenic and Therapeutic Effects of 
Adipose Stromal Cells.
Liying Cai, Brian H. Johnstone, Todd G. Cook, Zhong Liang, Dmitry Traktuev, Kenneth 
G. Cornetta, Elliot D. Rosen, Keith L. March, Indiana Center for Vascular Biology and 
Medicine, Indianapolis, IN
Background The use of adipose stromal cells (ASC) for promoting repair of tissues is a 
promising potential therapy, but the mechanisms of their action are not fully understood. 
We previously demonstrated tissue salvage by ASCs in acute myocardial infarction 
and peripheral ischemia models, and have shown that ASCs secrete significant levels 
of hepatocyte growth factor (HGF) and VEGF which contributes to endothelial cell 
survival. To determine the specific contribution of HGF to ASC effects in vitro and in 
vivo, we employed knockdown of HGF using lentiviral-delivery of a small interfering RNA 
(siRNA).
Methods and Results Human ASCs were transduced with a dual-cassette lentiviral 
construct expressing the green fluorescent protein reporter gene and either a siRNA 
targeting the HGF gene (iHGF), or a non-coding sequence (control). Transduction efficiency 
was >95% as determined by flow cytometric analysis of fluorescent cells. Transduction of 
ASCs with iHGF (ASC-iHGF) reduced HGF levels by >80% (p<0.01) without affecting 
growth or expression of unrelated genes. The proliferation of endothelial cells increased 
by 1.7-fold in growth-factor-deficient minimal medium when supplemented with a 1:1 
mixture of control ASC conditioned medium (CM) (p<0.01). This growth stimulation was 
absent when CM from ASC-iHGF was added. The specificity of this effect was confirmed 
by pre-treating ASC CM with a neutralizing HGF antibody. Angiogenic sprout formation by 
endothelial cells was 2.0-fold higher when cultured in the CM from control ASC compared 
to minimal medium (p<0.005). This stimulation was abolished when CM from ASC-iHGF 
was used. The effect of iHGF on in vivo potency of ASC was assayed in a mouse hindlimb 
ischemia model. Relative perfusion (ischemic/non-ischemic limb) by day 15 was 84+4% 
(mean + sem) in mice treated systemically with control ASCs, which was significantly 
greater (p<0.5) than both the saline (58+6%) and iHGF-ASC (69+5%) groups.
Conclusions These results indicate that secretion of HGF is necessary for the potency 
of ASCs both in vitro and in vivo. This directly supports the emerging concept that local 
factor secretion by donor cells is a key element of cell-based angiogenesis and tissue 
support.
3:30 p.m.
1020-41 Effects of the ACE Inhibitor Perindopril on Markers of 
Inflammation in Response to Physical Stress: Studies 
in the Metabolic Syndrome
Christopher S. Vaccari, Syed T. Rahman, Qamar A. Khan, Sameer Nagamia, Bobby V. 
Khan, Emory University School of Medicine, Atlanta, GA
Background: ACE inhibitors are well-established in the treatment of a variety of 
cardiovascular diseases. Inflammatory processes are important in the pathogenesis 
of atherosclerosis and potentially represent an important target of future diagnostic 
and therapeutic options in heart disease. We sought to determine if the ACE inhibitor, 
perindopril, has beneficial effects on vascular inflammation in patients with the metabolic 
syndrome that are exposed to physical stress.
Methods: We randomized 30 normotensive patients who met criteria for metabolic 
syndrome to the ACE inhibitor perindopril (4 mg/day, n=15), or placebo (n=15) in a double 
blind manner for 4 weeks. The patients underwent an exercise treadmill study to a level 
of 8 METS, and serum soluble levels of the inflammatory markers interleukin-6 (IL-6) and 
vascular cell adhesion molecule-1 (VCAM-1) were determined at baseline and at 1 and 
30 minutes after completion of the treadmill study.
Results: In the placebo group, physical stress increased levels of sIL-6 from baseline 
at 1 and 30 minutes after the treadmill study was completed (baseline: 10.9±2.4, 1 
min:19.9±2.8, 30 min: 20.2±2.3 ng/dl). In comparison to placebo, treatment with perindopril 
significantly reduced sIL-6 levels at baseline by 22% and at 1 and 30 minutes by 30% and 
33%, respectively (baseline: 8.6±1.3, 1 min: 14.0±2.1, 30 min: 13.6±2.4 ng/dl, p<0.005 
perindopril vs placebo at all time points). In comparison to placebo (baseline: 341±43, 1 
min:723±111, 30 min: 857±142 ng/dl), levels of sVCAM-1 in perindopril treated patients 
were reduced at baseline by 25% and at 1 and 30 minutes by 31% and 37%, respectively 
(baseline: 267±41, 1 min:452±79, 30 min: 554±86 ng/dl, p<0.005 perindopril vs placebo 
at all time points). Perindopril therapy caused no hypotension in the study population.
Conclusions: Our findings indicate that in response to physical stress, the addition of 
an ACE inhibitor to a normotensive population with the metabolic syndrome differentially 
regulates markers of vascular inflammation, potentially explaining the vascular protection 
against the pathogenesis of atherosclerosis seen with these agents.
3:30 p.m.
1020-42 Widespread Coronary and Myocardial Activated T 
Lymphocytic Infiltrate in Acute Myocardial Infarction
Antonio Abbate, Rossana Bussani, Giovanna Liuzzo, Giuseppe Biondi-Zoccai, Elena 
Barresi, Pasquale Mellone, Luigi M. Biasucci, Furio Silvestri, Alfonso Baldi, George W. 
Vetrovec, Filippo Crea, Virginia Commonwealth University, Richmond, VA
Background. T-lymphocyte activation within atherosclerotic plaque, and widespread to 
the myocardium has been shown in patients with acute coronary syndromes. Aim of this 
study was to define the presence of activated T lymphocytes in the myocardium and the 
epicardial coronary arteries in patients with acute myocardial infarction.
Methods. The presence of activated T lymphocyte infiltrate was evaluated post-mortem in 
12 subjects dying <4 weeks of AMI (Group 1) and 12 dying >4 months after AMI (Group 2), 
and compared to fndings in 12 subject with active lymphocytic myocarditis (Group 3), and 
12 control subjects (Group 4). Light-microscopy was performed to measure the number of 
activated T-lymphocytes (CD3+/DR+) in the myocardium and coronary artery wall.
Results. Activated T-lymphocyte infiltrate was found in the peri-infarct and remote 
myocardium in all cases in Groups 1-3, and none of Group 4. However, necrosis adjacent 
to activated lymphocytes was found in Group 3 but not in Groups 1 and 2 (P<0.001). 
Activated T lymphocytes within the epicardial coronary artery wall were found in both 
the infarct- and non-infarct-related arteries in 92% and 83% of cases in Groups 1 and 2, 
respectively, and none of the cases in Groups 3 (P<0.001). Group 4 had no evidence of 
coronary inflammation.
Conclusions. This study shows for the first time the presence of a diffuse immune-specific 
infiltrate in both coronaries and myocardium in the myocardium of subjects with AMI. The 
presence of both coronary and myocardial infiltrates in AMI and of myocardial infiltrate 
only in myocarditis suggests a different etiologic agent and the presence of antigen that 
is common to the coronary arteries and the myocardium in AMI and localized to the 
myocardium in myocarditis.
3:30 p.m.
1020-43 Atorvastatin Abrogates the Deterioration of Endothelial 
Function Induced by Acute Inflammation in 
Dyslipidemic Patients
Konstantinos Aznaouridis, Charalambos Vlachopoulos, Anna Dagre, Constantina 
Masoura, Carmen Vasiliadou, Ioanna Dima, John Skoumas, Christos Pitsavos, 
Christodoulos Stefanadis, 1st Cardiology Department, Athens Medical School, 
Hippokration Hospital, Athens, Greece
Background: Acute inflammation is associated with a deterioration of endothelial 
function, which is a determinant of cardiovascular risk. It has not been defined whether 
atorvastatin modifies the effects of acute inflammation on endothelial function in 
dyslipidemic patients.
Methods: We generated an acute, mild inflammation by Salmonella Typhi vaccination in 
50 volunteers with mild hypercholesterolemia (mean age 41 years). They were studied 4 
days after randomly taking atorvastatin 40 mg or placebo at bedtime. Endothelial function 
as assessed with flow-mediated dilation (FMD) of the brachial artery, circulating high-
sensitivity interleukin-6 (IL-6) and fibrinogen were measured before and 8 hours after 
vaccination.
Results: In the placebo group, vaccination caused a significant decrease of FMD at 8 
hours (by 2.73%, P<0.01, left figure). Atorvastatin significantly blunted the decrease of 
FMD after vaccination (P<0.05 by 2-way ANOVA, left figure). Atorvastatin did not mitigate 
the prominent vaccination-related increase of IL-6 (P=NS, middle Figure). On the other 
hand, atorvastatin abrogated the increase of fibrinogen after vaccination (P<0.05, right 
Figure).
Conclusions: In dyslipidemic patients, atorvastatin does not fully abrogate the increase 
of inflammatory markers but effectively blunts the deterioration of endothelial function 
caused by acute inflammation. This finding provides valuable insights into the protective 
effect of atorvastatin on the cardiovascular system. 
3:30 p.m.
1020-44 High Molecular Weight Form of Adiponectin Levels 
Independently Predict the Progression of Carotid 
Atherosclerosis in Male Patients with Metabolic 
Syndrome
Tetsuro Matsuoka, Shinji Kihara, Koji Tomita, Yoshihiro Chimori, Hitoshi Miki, 
Departmant of Internal Medicine, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, 
Japan
Background: Adiponectin, an adipocyte-derived antiatherogenic protein, has recently 
been recognized as an important molecule in the pathophysiology of metabolic syndrome 
(MetS). It circulates in serum as a relatively low molecular weight (LMW) trimer or hexamer 
form, and as a high molecular weight (HMW) multimeric form. The aim of this study was 
to prospectively assess the influences of serum LMW and HMW adiponectin levels on the 
progression of carotid atherosclerosis in human MetS subjects.
Methods: Ninety consecutive male patients (aged 66.5±8.8 years) with MetS, as defined 
by the Adult Treatment Panel III criteria, underwent carotid ultrasonography at baseline 
and then again after 1.5±0.3 years. Mean intima-media thickness (mIMT), obtained from 
8 segments of bilateral carotid arteries, was recorded and its increase per year (ΔmIMT) 
was calculated. Serum LMW and HMW adiponectin concentrations and conventional risk 
factors for atherosclerosis were also evaluated at baseline.
Results: HMW adiponectin correlated negatively with triglycerides, fasting plasma glucose 
(FPG) and glycohemoglobin A1c (r=-0.365, P=0.001, r=-0.444, P<0.001 and r=-0.321, 
P=0.003, respectively), while LMW adiponectin had a significant correlation only with 
triglycerides (r=-0.273, P=0.013). At baseline, mIMT was significantly correlated to age 
and systolic blood pressure (r=0.449, P<0.001 and r=0.258, P=0.019, respectively), but 
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not correlated to either HMW or LMW adiponectin. ΔmIMT showed significant correlations 
positively with FPG (r=0.260, P=0.018) and negatively with HMW adiponectin and high-
density lipoprotein cholesterol (r=-0.361, P=0.001 and r=-0.232, P=0.036, respectively). 
But no significant correlation was observed between ΔmIMT and LMW adiponectoin. 
Moreover, multiple linear regression analysis also revealed that HMW adiponectin was 
associated with ΔmIMT independently of other parameters (β=-0.354, P=0.007).
Conclusions: This study demonstrated that the lower serum HMW adiponectin 
concentration was related to greater increase in carotid IMT, indicating that HMW 
adiponectin levels independently predict the progression of carotid atherosclerosis in 
MetS patients.
3:30 p.m.
1020-45 Lower Plasma Adiponectin Levels and Higher 
Oxidative Stress are Associated With in Vivo Thin-cap 
Fibroatheroma in Patients Wth Sable Agina Pctoris
Takahiro Sawada, Junya Shite, Toshiro Shinke, Hiromasa Otake, Yusuke Tanino, Daisuke 
Ogasawara, Hiroyuki Kawamori, Hiroki Kato, Naoki Miyoshi, Mitsuhiro Yokoyama, Kobe 
University Graduate School of Medical Science, Kobe, Japan
Background: Recent reports have shown that several serum markers can predict acute 
coronary syndrome (ACS). However, their association with thin-cap(<65μm) fibroatheroma 
(TCFA) which was considered as vulnerable plaques predisposed to induce ACS.
Methods: We examined 97 plaques from 42 patients with stable angina pectoris (SAP) 
by cooperative use of virtual histology intravascular ultrasound (VH-IVUS) and optical 
coherence tomography (OCT). By VH-IVUS, percent plaque volume(%PV: plaque volume 
/ external elastic membrane (EEM) volume) and remodeling index (RI: EEM area at 
minimum lumen diameter / average EEM area) were calculated. Plaque burdens were 
classified into fibrotic, fibro-fatty, dense calcium and necrotic core (NC) component by VH 
software.We defined definite TCFA as follow.(1) %PV > 30% (2) focal NC-rich plaques, 
being in contact with the lumen by VH analysis. (3) fibrous cap thickness < 65μm by 
OCT measurement. Inflammatory markers (high sensitive CRP (hsCRP), IL-6), marker 
of oxidative stress, urinary 8isoprostane(U-8iso), and adiponectine were measured in the 
patients with or without definite TCFA.
Results: Among 97 plaques, 48 plaques (49.5% 48/97) were selected as IVUS derived 
TCFA by VH-IVUS, and 52.1% (25/48) of plaques were diagnosed as definite TCFA by 
OCT. Definite TCFA showed higher %PV and RI than non-TCFA (%PV; 58.6±7.2 vs 
45.8±7.8% P<0.0001, RI; 1.20±0.15 vs 1.03±0.08 P<0.001). Among 42 patients , 21 
patients (50%) had at least one definite TCFA. Serum adiponectin levels of patients with 
definite TCFA was significantly lower than that without definite TCFA (13.4±6.5, 6.6±3.2, 
p<0.001), and U-8iso / creatinine of the patients with definite TCFA was higher than that 
without definite TCFA (283.9±186.8 vs 120.5±42.5 pg/mg Cr, p<0.01). There were no 
differences in inflammatory markers between the two groups.
Conclusions: The patients with definite TCFA tended to be with increased oxidative 
stress and lowered adiponectin level. These markers may have a potential to predict 
future coronary events caused by plaque rupture.
3:30 p.m.
1020-46 Serum Atherogenicity Reduction: The Novel Way to 
Atherosclerosis Prevention And Treatment
Igor A. Sobenin, Alexander N. Orekhov, Institute of General Pathology and 
Pathophysiology, Moscow, Russian Federation, Institute for Atherosclerosis Research, 
Moscow, Russian Federation
Background: The ability of blood serum taken from atherosclerotic patients to induce 
lipid accumulation in primary culture of human aortic intimal cells (serum atherogenicity) 
is highly correlated with the prevalence and severity of atherosclerosis. It is well known 
that deposition of intracellular cholesterol and subsequent foam cell formation is a key 
feature of early atherosclerotic lesion at the level of arterial wall. However, the role of 
serum atherogenicity in atherogenesis remained unclear.
Methods: To elucidate the relationship between serum atherogenicity and atherosclerosis 
progression, the two-year prospective study has been performed in asymptomatic men 
with subclinical carotid atherosclerosis evaluated by high resolution B-mode ultrasound.
Results: In 41 patient with initially non-atherogenic serum the increase of blood serum 
atherogenicity correlated with the increase of intima-media thickness (IMT) of common 
carotid arteries (r=0.345; p=0.027). Spontaneous uprise of serum atherogenic potential 
observed during follow-up was contingent with the progression of early atherosclerotic 
lesions (chi-square 9.714, p=0.008). In 165 patients blood serum taken at the baseline 
induced 1.2-3.9-fold increase in cholesterol content of cultured cells, i.e. was atherogenic. 
The changes in serum atherogenicity correlated with the dynamics of IMT (r=0.155, 
p=0.047). At the same time, the complete removal of serum atherogenic potential in treated 
patients was contingent with atherosclerosis regression (chi-square 8.572, p=0.014).
Conclusions: The uprise of blood serum atherogenicity is related to atherosclerosis 
progression, and the elimination of atherogenicity induces the regression of atherosclerotic 
lesions. The novel principle of direct antiatherosclerotic therapy based on inhibition of 
cholesterol deposition in arterial wall has been developed.
3:30 p.m.
1020-47 Experimental Application of Bevacizumab-Eluting 
PC Coated Stent for Inhibition of Vasa Vasorum of 
Atherosclerotic Plaque.
Konstantinos Toutouzas, John Karabelas, Maria Drakopoulou, Virginia Markou, 
Chrysoula Patsa, Andreas Synetos, Nicholas Kipshidze, Eleftherios Tsiamis, 
Christodoulos Stefanadis, First Department of Cardiology, University of Athens, 
Hippokration hospital, Athens, Greece
Background: Atheromatosis is associated with development of a dense net of vasa 
vasorum (vv), in which vascular endothelial growth factor (VEGF) is of important role. 
Bevacizumab, an antibody specific for VEGF, has recently been applied in the clinical 
field. We hypothesized that local delivery of bevacizumab by stent would inhibit the 
development of vv at the stented arterial segment in an atheromatic rabbit model.
Methods: We used 10 New Zealand rabbits under atherogenic diet for 3 weeks. We 
immersed a BiodivYsio stent into a solution of 4 ml bevacizumab (Avastin, Roche) 
according to previous studies. Both eluting stents and non eluting BiodivYsio stents were 
implanted in the middle segment of the 2 iliac arteries of the animals, with the same 
procedural characteristics. Tissues were obtained for histological analysis. Sacrifice, 
following repeat angiogram was scheduled after 28 days.
Results: The procedure of stent loading with bevacizumab and stent implantation was 
successful. There was no acute or subacute thrombosis. Iliac artery lumen diameters before 
and immediately after stent placement were similar in both groups. At euthanasia stent 
lumen diameters, measured by angiography, were similar in both groups and additionally 
gross pathologic analysis did not show any evidence of vascular necrosis. Neointimal area 
(1.09±0.09 vs 1.22±0.11 mm2, p<0.001), mean maximal neointimal thickness (0.09±0.01 
vs 0.12±0.02 mm, p<0.001), and mean neointimal area (1.07±0.09 vs1.21±0.13 mm2, 
p<0.001) were less in the bevacizumab-treated segments. Bevacizumab-treated arterial 
segments demonstrated significantly decreased microvessel density compared with 
the control group (p<0.001), and VEGF immunoreactivity was markedly decreased 
in the media and adventitia of bevacizumab group evaluated by semiquantification. 
Endothelialization, inflammation and injury scores were similar between the two groups.
Conclusions: Bevacizumab-eluting stent implantation in rabbit iliac arteries is safe, and 
inhibits neovascularization and neointimal hyperplasia. The clinical application of this new 
approach for the treatment of vulnerable plaques is justified.
3:30 p.m.
1020-76 Aortic Valve Calcifications Are Associated with an 
Ischemic Perfusion Study in Individuals with Minimal 
Coronary Calcifications
John S. Ho, John Cannaday, Shannon FitzGerald, Yvette Henderson, Tiffany Newman, 
Dana Weilbacher, Nina Radford, Cooper Clinic, Dallas, TX
Background: The absence of significant coronary artery calcifications (CAC) is 
associated with a low risk of subsequent cardiovascular events. Rare cases of clinically 
significant heart disease do, nevertheless, occur in individuals with a low CAC score. 
This study attempts to identify whether calcifications outside of the coronary arteries or 
traditional cardiovascular risk variables are associated with ischemia in individuals with 
a minimal amount of CAC.
Methods: From 1998-2006, 613 patients with an Agatston CAC score 0-10 were referred 
for stress echocardiography or myocardial perfusion imaging (MPS). An abnormal stress 
echocardiogram was defined as a new wall motion abnormality with exercise stress. An 
abnormal MPS was defined as a reversible perfusion defect on either Th-201 stress-delay 
reinjection or Tc-99m sestamibi or tetrafosmin rest-stress protocols.
Results: There was a very low rate (1.1%) of ischemia in this group. Seven of 312 (2.2%) 
exhibited ischemia on perfusion imaging. None of the 301 stress echocardiograms 
were abnormal. Traditional risk factor analysis was not predictive of the presence of 
inducible ischemia. No significant differences in age, gender, or self-reported status 
of hyperlipidemia, diabetes, tobacco use, hypertension, or family history of premature 
heart disease were noted among those with or without ischemia. Contrary to previous 
belief, those with ischemia were not more likely to be younger or female. Aortic valve 
calcifications were, however, found to be significantly associated with ischemia (p=0.05). 
Patients with any aortic valve calcification exhibited more than a five-fold likelihood of 
having ischemia versus those without any aortic valve calcifications (28.6% vs 4.6%). 
Conclusion: Detection of extra-coronary calcifications, particularly of the aortic valve, 
adds diagnostic value to computed tomography of the chest and identifies individuals who 
may benefit from intensive medical therapy to lower their risk of adverse vascular events, 
even those with minimal CAC.
3:30 p.m.
1020-77 Feasibility of MRI to Quantify Blood Flow Reserve in 
Lower Extremities
Hosakote M. Nagaraj, Amol Pednekar*, Cecilia Corros, Himanshu Gupta, Steven G. 
Lloyd, University of Alabama at Birmingham, Birmingham, AL, *Phillips Medical Systems 
North America, Bothell, WA
Background: Peripheral arterial disease (PAD) is a common disorder. Establishing the 
clinical or functional significance of a discrete arterial stenosis can be difficult and flow 
reserve quantification might be useful in such clinical characterization of PAD.
Objective: We propose a system using Phase Contrast MRI (PC-MRI) to estimate the 
exercise induced blood flow reserve in the lower extremity
Methods: PC-MRI was done on 6 normal volunteers to assess the blood flow in the 
superficial femoral artery (SFA) in legs at the mid thigh level. An ECG-gated cine PC-MRI 
sequence was used on a 3 Tesla MR scanner (QFlow, Intera, Philips Medical Systems). 
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An ergometer to allow resistive unilateral plantar flexion of the foot (0.5Watts) was used 
for 4 minutes exercise. This was followed by PC-MRI immediately and after 3 minutes of 
rest.Peak flow velocity, average blood flow and flow reserve were determined. The mean 
flow reserve was calculated as (post exercise flow-pre exercise flow)/ pre exercise flow
Results: Fig. A demonstrates an example of peak velocity data in the exercising leg SFA 
at baseline, post-exercise and after 3 minutes rest. The mean blood flow is shown in Fig. 
B. The mean flow reserve was 170 ± 109 %
Conclusions: Regional blood flow in the SFA is increased with unilateral plantar flexion 
at sub-maximal levels of exercise and returns to baseline after a brief recovery. This 
technique of using PC-MRI quantification of exercise induced flow reserve may be useful 
to determine functional severity in patients with PAD. 
3:30 p.m.
1020-78 Erectile Dysfunction and Coronary Artery Disease 
Confer an Almost Similar Inflammatory and 
Endothelial/Prothrombotic Activation
Charalambos Vlachopoulos, Konstantinos Aznaouridis, Nikolaos Ioakeimidis, 
Konstantinos Rokkas, Carmen Vasiliadou, Athanassios Askitis, Athanassios Tsokanis, 
Christodoulos Stefanadis, 1st Cardiology Department, Athens Medical School, 
Hippokration Hospital, Athens, Greece
Background: Erectile dysfunction (ED) is associated with increased cardiovascular 
outcomes. To quantify the inflammatory and endothelial/prothrombotic activation that 
accompanies ED, we measured blood levels of several markers/mediators and we 
compared patients with ED versus patients with coronary artery disease (CAD) and 
normal erectile performance.
Methods: We screened consecutive patients with known CAD who were referred for 
evaluation of possible ED and consecutive patients presenting with ED symptoms 
of recent onset without known CAD. Vasculogenic ED was detected with a SHIM 
score<21 and penile Doppler. Presence of CAD was evaluated with non-invasive tests 
and coronary angiography as required. Blood levels of inflammatory and endothelial-
prothrombotic markers, such as high sensitivity C-reactive protein (hsCRP), interleukin-6 
(IL-6), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), fibrinogen, von Willebrand 
factor (vWF), tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 
(PAI-1) were measured in all subjects.
Results: We analyzed 46 patients (mean age 59 y) with CAD only (CAD/no ED) and 
25 patients (mean age 58 y) with ED only (no CAD/ED). Between the two groups, we 
observed no significant differences regarding the level of hsCRP (1.57±1.04 [mean±SD] 
mg/L in patients with ED only vs. 1.67±0.76 mg/L in patients with CAD only, P=NS), 
IL-1β (0.63±0.37 vs. 0.50±0.25, P=NS), TNF-α (1.41±0.42 vs. 1.47±0.47, P=NS), vWF 
(85.9±23.7 vs. 79.3±11.6 %, P=NS), fibrinogen (293±52 vs. 279±47 mg/dL, P=NS), and 
t-PA (11.2±5.6 vs. 10.8±3.1 ng/mL, P=NS). On the other hand, men with CAD alone had 
mildly increased IL-6 level (3.83±1.45 vs. 3.16±1.94 pg/mL, P<0.05) and decreased PAI-
1 level (37.3±13.2 vs. 48.5±21.0 ng/mL, P<0.05) compared with men with ED alone.
Conclusions: The inflammatory and endothelial/prothrombotic activation observed in 
men with ED alone is not significantly different compared with men with CAD alone. These 
findings emphasize the pathophysiological involvement of inflammation and endothelial 
dysfunction in the pathogenesis of ED and may provide a potential explanation for the 
increase of cardiovascular risk in such patients.
3:30 p.m.
1020-79 Aortic Stiffness is Increased in Patients With Hepatitis 
C Virus Seropositivity
Charalambos Vlachopoulos, Emmanouil Manesis, Katerina Baou, Nikolaos Ioakeimidis, 
George Papatheodoridis, John Koskinas, Athanasios Archimandritis, Christodoulos 
Stefanadis, 1st Department of Cardiology, Athens Medical School, Hippokration 
Hospital, Athens, Greece
Background: Chronic systemic inflammation impairs vascular function and plays 
a critical role in cardiovascular disease. Aortic stiffness and wave reflections are 
independent prognosticators of cardiovascular risk. Aim of this study was to assess 
whether chronic hepatitis B (HBV) or hepatitis C (HCV) infection affects aortic stiffness 
and wave reflections.
Methods: A total of 46 consecutive patients with chronic hepatitis who had never 
been treated with interferon were studied: 30 patients (47±16yrs) were positive for 
HCV infection and 16 patients (53±11yrs) were positive for HBV infection. 46 healthy 
individuals were recruited to compare each of the two subgroups and they were matched 
for age, gender and risk factors. Aortic stiffness was evaluated with carotid-femoral pulse 
wave velocity (PWV) and wave reflections with augmentation index (AIx) of the aortic 
pressure waveform.
Results: Patients with HCV infection had higher PWV than controls, indicating increased 
aortic stiffness (7.5±1.4 vs. 6.7±1.4 m/s, P<0.05), while AIx did not differ (figure). PWV and 
AIx in the subjects with HBV infection were similar to those in the control subjects. Systolic 
and diastolic pressures between patients with hepatitis and controls did not differ.
Conclusions: Patients with HCV have impaired aortic elastic properties, whereas HBV 
does not influence aortic stiffness. These findings are important to further characterize 
the increase of cardiovascular risk in patients with hepatitis C virus seropositivity. 
3:30 p.m.
1020-80 Tear Size and Location Impacts False Lumen Pressure 
in an Ex-Vivo Model of Chronic Type B Aortic 
Dissection
Thomas T. Tsai, Marty Schlicht, Khalil Khanafer, Ramon Berguer, Joseph L. Bull, Daniel 
G. Montgomery, Doug Valassis, David M. Williams, Kim A. Eagle, University of Michigan 
Medical Center, Ann Arbor, MI, University of Michigan School of Engineering, Ann 
Arbor, MI
Background: Follow-up outcomes are poor in patients with type B aortic dissection. 
Partial thrombosis of the false lumen has been associated with increased mortality which 
may be explained by the obstruction of previously patent reentry tears by thrombus. 
We examined the impact of intimal tear size, tear number and location on false lumen 
pressure.
Methods: In an ex-vivo model of chronic type B aortic dissection connected to a pulsatile 
pump, simultaneous pressures were measured within the true and false lumen at different 
heart rates and systemic pressures. Experiments were performed in different dissection 
models with tear sizes of 6.4 mm and 3.2 mm in the following configurations; Model A: 
proximal and distal tear; Model B: proximal tear only
Results: Within each dissection model, diastolic false lumen pressure was significantly 
higher than diastolic true lumen pressure (p<0.001 for each comparison). Diastolic false 
lumen pressure was highest in the model with smaller tear size and only a proximal tear 
(p<0.001) (Figure)
Conclusions: In this model of chronic type B aortic dissection, diastolic false lumen 
pressures were the highest in the setting of smaller proximal tear size and the lack of 
distal reentry tears. This could explain the association of partial thrombosis of the false 
lumen with poorer long term outcomes.
Figure. Pressure Waveforms. A: Model A with 6.4 mm proximal entry and 6.4 mm distal 
reentry tear; B: Model B with proximal 6.4 mm entry tear only; C: Model B with 3.2 mm 
entry tear only 
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3:30 p.m.
1020-81 Functional Status in Peripheral Artery Disease is 
Predicted by Both Abnormal and Low-Normal Ankle-
Brachial Index: The National Health and Nutrition 
Examination Survey (NHANES)
Sahand Rahnama-Moghadam, Steven R. Erickson, Peter Henke, Gilbert R. Upchurch, 
Jr., James B. Froehlich, University of Michigan Medical Center, Ann Arbor, MI
Background: Low ankle-brachial index predicts outcome in PAD patients. We sought to 
determine the relationship between low and low-normal ABI and functional and health status.
Methods: Using the National Health and Nutrition Examination Survey (NHANES) 2003 
dataset, we labeled patients with an ABI normal (>1.0); low-normal (0.9-1.0); or PAD (<0.9). 
Functional and health status questionnaire responses were the dependent variables for 
this analysis. Multiple questions assessed functional status, including limitations in daily 
activity; conducting household chores; attending social events; assessment of intensity of 
daily activity; assessment of level of walking ability; and general health status. Multivariate 
regression models including age, gender, income, presence or absence of diabetes, 
ischemic heart disease and hypertension, determined prediction of survey response by 
ABI category. The survey sampling design was accounted for using population weights 
in the regression models.
Results: Table shows adjusted odds ratio of having functional impairment survey 
response, for PAD or low-normal ABI categories, compared with normal ABI. (The 
magnitude of the relationship varied among models). 
Survey Response PAD ABIOR (95% CI)
Low-Normal ABI
OR (95% CI)
Walk a lot 0.59 (0.43-0.80) 0.89 (0.67-1.17)
Unable to attend social events 3.04 (1.17-7.93) 1.68 (0.52-5.42)
Unable to go out by self 2.28 (1.25-4.14) 1.10 (0.41-2.94)
Unable to do chores 2.48 (1.17-5.24) 3.25 (1.53-6.92)
Maintain activity level 0.57 (0.38-0.84) 0.75 (0.57-0.97)
Difficulty walking a ¼ mile 3.81 (1.99-7.32) 2.63 (1.15-6.02)
Difficulty climbing stairs 2.39 (1.08-5.29) 1.06 (0.43-2.62)
Report general health as poor 2.36 (1.48-3.75) 2.96 (1.16-7.52)
(significant OR in bold)
Conclusion: Both low and low-normal ABI predict poor functional and health status. 
ABI identifies PAD patients who may require additional medical treatment and social 
intervention, even those with technically normal ABI.
3:30 p.m.
1020-82 The Influence of Renal MRI/MRA Diagnosed Renal 
Artery Stenosis on Glomerular Filtration Rate 
and Renal Parenchymal Volume in Patients with 
Atherosclerotic Renovascular Hypertension
Rajiv Agarwal, Samir Amin, Raja Muthupillai, Scott D. Flamm, Cleveland Clinic 
Foundation, Cleveland, OH
Background: In patients with renovascular hypertension (R-HTN), prompt therapy can 
avoid ischemic death of the affected kidney. MRI/MRA can diagnose renal artery stenosis 
(RAS) and simultaneously assess renal parenchymal volume. However, the influence of 
severity of RAS on renal volume and glomerular filtration rate (GFR) is unknown.
Methods: 1050 patients underwent renal MRI/MRA for R-HTN. Main renal arteries were 
assessed for degree of RAS. GFR was calculated by the MDRD equation, and kidney 
volumes by the disc-summation method. Similar data was obtained for an additional 200 
patients without evidence for RAS.
Results: 24.2% of patients (252/1050) had evidence for RAS. MDRD GFR could be 
calculated for 108 of these patients, and 75 patients without RAS. (Table 1)
Conclusions: In patients with suspected R-HTN, MDRD GFR correlates inversely with 
severity of RAS. The decrease in GFR is statistically significant for mild RAS compared 
to no RAS, and moderate RAS compared to mild RAS. However, GFR is not significantly 
different between moderate and severe RAS. Renal volumes are significantly reduced 
in mild RAS compared to no RAS, and in severe RAS compared to moderate RAS. Our 
study suggests that there is incremental decline in renal function when the severity of 
RAS progresses from none to moderate; however, MDRD GFR plateaus once moderate 
RAS develops. The decline in renal volumes is greatest at both ends of the spectrum 
of RAS. In patients with ≥ moderate RAS, renal volumes demonstrate greater changes 
than MDRD GFR. 
Table 1: Severity of RAS vs. MDRD GFR and Renal Parenchymal Volume
Severity of RAS by 
MRI/MRA n
Age 
(years)
Serum 
Creatinine 
(mg/dL)
Serum Urea 
Nitrogen 
(mg/dL)
Serum 
Albumin 
(g/dL)
Calculated GFR 
(mL/min per 1.73 
m2 ± SD)
Affected Kidney 
Volume (mm3)
≥Severe 50 76 2.4 47 3.6 29.2 ± 15.9 107
Moderate 29 74 2.3 47 3.5 31.2 ± 16.8 130
Mild 29 69 1.8 33 3.8 41.7 ± 20.4 135
None 75 61 1.7 32 3.6 54.8 ± 33.3 164
For GFR: p=<0.05 for none vs. mild and mild vs. moderate; p=NS for moderate vs. severe
For Volume: p=<0.05 for none vs. mild and moderate vs. severe; p=NS for mild vs. moderate
3:30 p.m.
1020-83 T-Wave Inversion in Precordial Leads in Acute 
Pulmonary Embolism: Indicator of Recovery of Right 
Ventricular dysfunction
Sung-Eun Kim, Duck-Hyoung Yoon, Jun-Hee Lee, Kyoo-Rok Han, Dong-Jin Oh, Dae-
Gyun Park, Kangdong Sacred Heart hospital, Hallym University, Seoul, South Korea
Background: Right ventricular (RV) dysfunction is associated with poor prognosis in acute 
pulmonary embolism (APE). We aimed to determine the role of electrocardiography and 
biomarkers in identifying RV dysfunction (RVD) and predicting the recovery from it in APE.
Methods & Results: We examined 46 consecutive patients (20 without RVD; 26 with 
RVD) diagnosed as APE using CT-angiography from January 2004 to April 2006. RVD 
was assessed by serial echocardiography. On event, immediate echocardiography, 
and measurement of BNP and cardiac enzyme were performed. We compared 
electrocardiographic findings and biomarkers for early detection of RVD. T-wave inversion 
(TWI) in leads V1 to V3 was better than biomarkers such as cardiac enzyme and BNP 
for early detection of RVD (Table 1). TWI in leads V1 to V3 had sensitivity of 69% and 
specificity of 95%, and diagnostic accuracy of 80%. We were able to check follow-up 
echocardiography in 15 patients with RVD just when precordial TWI normalized. With 9 
days of median recovery time (range from 2 days to 60 days), all of 15 patients showed 
normalization of RV dilatation or RV hypokinesia, or disappearance of paradoxical septal 
motion. TWI persisted only throughout the period of RVD, in contrast to transient S1Q3T3 
pattern detected only during early phase.
Conclusions: This study suggested that TWI in leads V1 to V3 was better than 
biomarkers for early detection of RVD, and normalization of TWI could be a good indicator 
for identifying recovery of RVD before echocardiography in APE.
Table 1.Electrocardiographic patterns and biomarkers according to RV 
dysfunction
Entire study 
population(N 
= 46)
Pts. With RV 
dysfunction (Group 
B; N=26)
Pts. without RV 
dysfunction (Group 
A; N=20)
P value 
(between 
group A and B)
T-wave 
inversion in 
leads V1-V3
41% 69% 5% <0.0001
S1Q3T3 
pattern 22% 31% 10% 0.150
Right bundle 
branch block 15% 19% 10% NS
Sinus 
tachycardia 22% 27% 15% NS
Elevation of 
BNP 70% 83% 50% NS
Elevation of 
TnI 12% 18% 0% NS
Elevation of 
CK-MB 27% 32% 18% NS
Elevation of 
myoglobin 52% 50% 55% NS
3:30 p.m.
1020-84 A Simple Measurement of Time to Maximum Tricuspid 
Regurgitant Jet Identifies Right Ventricular Dysfunction 
in Pulmonary Hypertension
Angel Lopez-Candales, Navin Rajagopalan, Beth Gulyasy, Kathy Edelman, Raveen 
Bazaz, University of Pittsburgh, Pittsburgh, PA
Background: Assessment of right ventricular (RV) systolic function can be difficult in 
pulmonary hypertension (PH). However, since tricuspid regurgitation (TR) is commonly 
encountered in PH, we sought to study whether the time to maximum peak of the TR 
(tmpTR) jet would be useful in assessing RV function in PH.
Methods: Maximal tricuspid annular motion (TAPSE), RV fractional area change 
(RVFAC), pulmonary artery systolic pressure (PASP) and tmpTR corrected for heart rate 
were measured in 103 patients (mean age 54 ± 15 years). The ability of tmpTR to detect 
PH and RV dysfunction was assessed using receiver-operating characteristic (ROC) 
curves to provide a value that can be useful in the identification of PH patients at risk.
Results: When analyzing tmpTR corrected for heart rate against variables of RV function, 
a very strong negative correlation was noted for both RVFAC (R = -0.76; p<0.0001) and 
TAPSE (R = -0.70; p<0.0001). However, a logarithmic relationship was noted between 
tmpTR and PAP (R = 0.87; p < 0.0001). Representative spectral Doppler signals from 
three patients are shown with tmpTR demonstrated by the arrows and measured intervals 
in an individual without PH, moderate PH and severe PH. ROC curves indicated that 
a tmpTR value greater than 228 ms identified PH (p<0.0001, AUC 0.977) and RV 
dysfunction (PH (p<0.0001, AUC 0.907).
Conclusion: Based on these results, it appears that a simple measurement of tmpTR 
greater than 228 ms is useful in identifying RV dysfunction in patients with PH. 
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1020-85 Development of a Real-time fluorescence Imaging 
In Vivo Clot Lysis method: Alcohol- and Polyphenol 
(quercetin and catechin)-induced Effects
Wensheng Pan, Francois M M. Booyse, Herman Grenett, Dale A. Parks, Edlue M. 
Tabengwa, University of Alabama at Birmingham, Birmingham, AL
Background: The cardioprotective benefit of moderate wine consumption may be due 
to effects of the alcohol and non-alcoholic polyphenols in wine. Both alcohol and wine 
polyphenols exert protective biological effects, including, increased fibrinolytic capacity. 
Recently we demonstrated that low ethanol increased fibrinolysis in vivo using an 
established pulmonary microembolism mouse model. In these studies we developed a 
real-time non-invasive in vivo model of pulmonary microembolism in the mouse to evaluate 
the effect of alcohol and polyphenols, catechin and quercetin on in vivo fibrinolysis.
Methods: The pulmonary microembolism model was modified by using a non radioactive 
fluorescent Cy5.5 dye to label fibrinogen, used in the preparation of fibrin microparticles 
instead of 125I. The Cy5.5-labeled fibrinogen was mixed with fresh plasma, CaCl2 and 
thrombin to form fibrin clots. Fluorescent-labeled fibrin micropartices, were injected 
into tail veins of mice treated with alcohol (7.5%, v/v), quercetin (0.33mg/kg), catechin 
(0.495 mg/kg) or vehicle for 4-6 weeks. Real-time fluorescent imaging of clot dissolution/
clearance (decrease in florescence intensity) was made every 10 minutes (min), up to 
180 min. Aortas from these mice were analyzed for t-PA, u-PA and PAI-1 mRNA levels 
(Real-time PCR).
Results: Ten min after injection fluorescent fibrin microparticles were lodged in the 
lung. Fluorescent imaging of the fibrin microparticles demonstrated a time-dependent 
spontaneous clot lysis. Clot lysis rates were 1.5- to 3-fold higher in ethanol-, catechin- and 
quercetin-treated mice compared to controls. In addition, t-PA/u-PA mRNA levels were 
increased ~2.5- to 4-fold in these animals. Furthermore, there was a concomitant ~60% 
decrease in PAI-1 mRNA levels in these animals.
Conclusions: These findings provide a novel non-invasive, real-time method of 
evaluating in vivo clot lysis in a mouse model. Furthermore, these results demonstrate the 
role of alcohol, catechin and quercetin in increased fibrinolysis and changes in fibrinolytic 
protein expression in vivo. These effects can be expected to contribute to reduced 
atherothrombotic risk associated with moderate alcohol consumption.
3:30 p.m.
1020-86 Assessment of Inter- and Intra-individual Variability of 
Platelet Function Profiles in Patients on Standard and 
High Clopidogrel Maintenance Doses
Dominick J. Angiolillo, Steven Shoemaker, Bhaloo Desai, Hang Yuan, Ronald Charlton, 
Luis Guzman, Martin M. Zenni, Theodore A. Bass, Marco A. Costa, University of Florida-
Shands Jacksonville, Jacksonville, FL
Background: A broad variability in clopidogrel-induced antiplatelet effects has been 
described. However, most studies have been limited to the acute phases of treatment. 
If variability of platelet function profiles persists in the chronic phases of treatment and if 
high maintenance dose regimens may influence response profiles are unknown.
Methods: A total of 40 diabetes mellitus patients on chronic clopidogrel therapy were 
randomized to 1-month treatment with standard (75mg; n=20; Group A) or high (150mg; 
n=20; Group B) maintenance dose. To define inter- and intra-group variability of clopidogrel 
effects, cumulative distribution curves of absolute change of platelet aggregation (PA) 
and inhibition of PA (IPA) were used. PA was assessed at baseline and 1-month after 
randomization using light transmittance aggregometry using 20μM ADP stimuli.
Results: PA reduced in Group B (67±6 vs 52±13;p<0.0001), while there were no 
changes in Group A (65±9 vs 63±7;p=ns) leading to an overall increase in IPA in 
Group B (p<0.0001). However cumulative distribution curves showed a marked 
individual variability in clopidogrel-induced antiplatelet effects independent of the 
dose regimen (Figure).
Conclusions: A broad variability in inter- and intra-individual parameters of platelet 
function is present even in patients on chronic clopidogrel therapy. Although dose 
intensification can enhance platelet inhibition, this does not overcome variability in 
responsiveness which characterizes this antiplatelet agent.
3:30 p.m.
1020-87 Phosphorylated Akt Is Critical to the Differentiation of 
Bone Marrow Stem Cells into Endothelial Cells
Jian Xu, Xinfeng Liu, Kalpna Gupta, Yuehua Jiang, Hong Hao, Catherine Verfaillie, Jay 
Zweier, Zhenguo Liu, The Ohio State University Medical Center, Columbus, OH, The 
University of Minnesota Medical School, Minneapolis, MN
Background: Serine/threonin protein kinase Akt plays a central role in cell survival and 
proliferation, and in the function of endothelial nitric oxide synthase (eNOS). In this study, 
experiments were designed to investigate the role of Akt signaling in bone marrow stem 
cell differentiation into endothelial cells.
Methods: Adult mouse bone marrow stem cells were used as the source of stem cells 
that were induced to differentiate into endothelial cells in serum-free medium with 
vascular endothelial growth factor. The stages of differentiation were closely monitored 
with morphology and expression of endothelial cell markers von Willebrand factor (vWF) 
and CD31. The differentiating cells were collected at min 0, 5, 10, 15, 30, 60, day 1, 3, 
5, 7, 10, 14, and 21 after the initiation of differentiation to evaluate the expression of 
Akt, vWF, CD31, eNOS, and stem cell specific marker Oct-4 with Western blot analysis, 
quantitative real-time PCR, and immunofluorescence staining.
Results: The differentiating cells started to express vWF, CD31 and eNOS from day 5 and 
reached the maximal levels at day 14 during differentiation. On the other hand, the expression 
of Oct-4 decreased dramatically on day 1 after the initiation of differentiation, and became 
undetectable by day 5. There was a low level of Akt phosphorylation in the undifferentiated bone 
marrow stem cells. The level of Akt Phosphorylation was increasing 5 min after the initiation 
of differentiation, and reached a plateau by day 7. Interestingly, constitutive phosphorylation 
of Akt was observed in the differentiating cells at day 14. Inhibition of Akt Phosphorylation 
by a specific PI3 kinase inhibitor LY294002 significantly impaired bone marrow stem cell 
differentiation into endothelial cell with dramatic reduction in the expression of endothelial 
markers vWF and CD31. The eNOS expression was also significantly decreased in the cells 
exposed to LY294002. Downregulation of the phosphorylated Akt by LY294002 did not result 
in cell death during the course of differentiation.
Conclusions: These data indicate that phosphorylated Akt plays an important role in 
bone marrow stem cell differentiation into endothelial cells in vitro.
3:30 p.m.
1020-88 Aging Related Myocardial Intolerence to Stress: 
Recapitulated in Adults by KATP Channel Blockade and 
Improved with KATP Channel Activation
Sandeep Sagar, Jenny Maguire, Jeffrey T. Jacob, Claudia C. Cabrera Aguilera, Andrew 
Oberlin, Srinivasan Sattiraju, Atul Singla, Andre Terzic, Arshad Jahangir, Mayo Clinic, 
Rochester, MN
Aging increases the vulnerability of the heart to stress, but the mechanisms are not 
clear. ATP-sensitive K+ (KATP) channels protect against cardiac injury. The increased 
susceptibility of the senescent myocardium may be related to an age associated 
reduction in KATP channel responsiveness.
Tolerance of the heart to stress was assessed in adult (6 months) and aged (24 months) 
rats challenged with isoproterenol (ISO, 0.1-30 mg/kg). The left ventricular size (LVEDS), 
function (LVEF), monophasic action potential duration (APD) and survival was monitored 
in the presence and absence of the KATP channel blocker, glyburide (GLY, 5μM/kg) and 
opener, diazoxide (DZ, 15 µg/kg).
Despite similar stress, aged rats were unable to withstand the sustained increase in 
heart rate and contractility. Adults maintained reduction in ventricular size and increased 
contractility, while the aged hearts decompensated with early cardiac dilatation and 
reduction in function (Fig A-B). ISO challenge (5mg/kg) was lethal in aged (100% vs. zero 
mortality in adults; Fig C-D). GLY pretreatment increased vulnerability of adults to cardiac 
failure and mortality, while DZ pretreatment improved tolerance of aged, reducing mortality 
(Fig C-D). GLY sensitive shortening of APD with ISO in adults was not present in aged.
Thus the reduced tolerance of the aging heart to stress can be recapitulated in the 
adult with KATP channel blockade and improved in the aged with KATP channel activation, 
indicating its role in adaptation to stress with aging. 
3:30 p.m.
1020-89 A Rapid Genotyping Assay for Polymorphisms 
Affecting the Dose-Response to Warfarin Therapy
Jeffrey L. Anderson, William A. Hinz, Jessica L. Clarke, Jason T. McKinney, Zachary 
P. Nicholas, Samera FS Khan, Amanda Grove, Stephanie Barton, Benjamin D. Horne, 
Joseph B. Muhlestein, Scott Stevens, John F. Carlquist, LDS Hospital, Salt Lake City, 
UT, University of Utah, Salt Lake City, UT
Background: Inter-individual variability in dose-response to warfarin is influenced in part 
by polymorphisms in the CYP2C9 and vitamin K epoxide reductase complex subunit 
1 (VKORC1) genes. We previously showed that carriage of at least one variant was 
associated with an 18-72% reduction in maintenance dose of warfarin. The Clinical 
Pharmacology Subcommittee of the FDA Advisory Committee for Pharmaceutical 
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Science has recommended CYP2C9 and VKORC1 genotyping to optimize warfarin 
dosing. We now describe a rapid genotyping method genotype-guided warfarin dosing 
without delaying initiation of anticoagulation therapy.
Methods: Buccal swab DNA was extracted, BuccalAmpTM DNA Extraction Kit, 
(EPICENTRE® Biotechnologies) and polymerase chain reaction (PCR) amplified with 
Simple Probes® (Roche Diagnostics) for the CYP2C9 *2 and *3 and the VKORC1 T-
1173C polymorphisms using the Rapid Cycler (Idaho Technology) followed by high-
resolution melting profile analysis on the HR-1TM (Idaho Technology).
Results: The test was validated by comparison with sequencing. There was 100% 
concordance for VKORC1 (n=140) and CYP2C9*3 (n=96) and 98% concordance for 
CYP2C9*2 (n=51); a single homozygous *2 wild-type sample was mis-genotyped as a 
heterozygote by melting analysis due to a rare mutation in that sample. Patients in the 
COUMAGEN randomized prospective trial were genotyped (n=110). Genotype frequencies 
for these samples were: 2C 9*2 WT= 0.80, Het = 0.20, Mut = 0.0; 2C9*3 WT = 0.90, Het = 
0.82, Mut = 0.09; VKORC1 WT = 0.41, Het = 0.43, Mut = 0.16. The turn-around time was 
estimated for 13 of these samples. The median was 68 min (range: 48 -134 min).
Conclusions: Here we first demonstrate the clinical feasibility of rapid genotyping to 
guide anticoagulation therapy in “real-time”. This rapid test method will allow same visit 
application of genotyping to enable genetic-driven dosing in clinical trials and practice with 
the goal of improving anticoagulant efficiency and safety. The success of this approach 
also may have broader implications for the practical use of clinical pharmacogenetics.
3:30 p.m.
1020-118 Effect of Atorvastatin in Patients With Metabolic 
Syndrome and Type 2 Diabetes: Subgroup Analysis of 
the Collaborative Diabetes Study (CARDS)
D. John Betteridge, Michael Szarek, David DeMicco, Helen Colhoun, Andrew Neil, 
Graham Hitman, Paul Durrington, John Fuller, The Middlesex Hospital, University 
College London, London, United Kingdom
Background and Aims: In CARDS, treatment with atorvastatin 10 mg/day vs placebo 
resulted in a 37% reduction of major CV events in patients with type 2 diabetes mellitus 
(T2DM) and no history of CHD. This analysis investigates whether similar benefits of 
atorvastatin were achieved in CARDS participants who also met the criteria for metabolic 
syndrome (MetS).
Methods: The IDF criteria for diagnosis of MetS (central obesity + ≥2 of the following: 
diabetes, treated hypertension or high blood pressure, high triglyceride and low HDL-C) 
were applied to baseline data of the CARDS cohort. The primary end point was time to 
first occurrence of the following: acute hospital-verified CHD events (CHD death, non-fatal 
MI, resuscitated cardiac arrest, unstable angina), coronary revascularization, or stroke.
Results: Of the 2838 patients in CARDS, 2232 (79%) met the criteria for MetS. Relative 
to patients that did not meet the criteria, those with MetS were more likely to be female 
(P<0.0001) and less likely to be current smokers (P<0.0001) or have a history of retinopathy 
(P=0.0015). Patients with MetS also had a shorter duration of diabetes (P<0.0001), and 
higher levels of albumin-creatinine ratio (P=0.0039) than those without MetS. After a median 
follow up of 3.9 years, a primary event occurred in 65 MetS patients receiving atorvastatin 
compared with 104 receiving placebo (HR=0.59; 95% CI 0.43-0.80, P=0.0008). There was 
no evidence of heterogeneity in treatment effect by MetS status (P=0.4577). Significant 
reductions were observed in acute coronary events (HR=0.63; 95% CI 0.43-0.93) and 
stroke (HR=0.39; 95% CI 0.21-0.73) but not coronary revascularization (HR=0.74; 95% CI 
0.41-1.35). Quartile of urinary albumin was related to the risk of a primary end point in the 
MetS group (P=0.0126) with patients >23.5 mg/L having twice the risk relative to patients 
≤3.9 mg/L. Greater waist circumference conveyed higher risk among those in the MetS 
group with BMI below the median (P=0.0291) but not above (P=0.1028).
Conclusion: Treatment with atorvastatin 10 mg significantly reduced major CV events in patients 
with T2DM and MetS. Urinary albumin was significantly related to risk in this subgroup.
3:30 p.m.
1020-119 Dose-Dependent Effect of Rosuvastatin on High-
Density Lipoprotein Kinetics in the Metabolic 
Syndrome
Esther M. Ooi, Gerald F. Watts, Paul J. Nestel, Dmitri Sviridov, Hugh R. Barrett, 
University of Western Australia, Perth, Australia
Background: The ASTEROID Trial demonstrated that intensive statin therapy of 40 mg/
day rosuvastatin could regress coronary atherosclerosis. Regression was associated 
with both reduction in low-density lipoprotein (LDL) cholesterol and increase in high-
density lipoprotein (HDL) cholesterol concentrations. The mechanism underlying the 
increase in HDL cholesterol remains unclear.
Methods: In a randomized double blind crossover trial of five-week therapeutic periods 
with placebo (P), 10 mg/day rosuvastatin (R10) or 40 mg/day rosuvastatin (R40), with two-
week placebo washout between each period, we investigated the dose-dependent effect of 
rosuvastatin on HDL particle kinetics in twelve dyslipidemic men with the metabolic syndrome.
Results: There was a significant dose-related increase in HDL cholesterol (R10 +4.4% 
R40 +9.7%, p=0.011), HDL particle size (R10 +3.1%, R40 +8.2%, p=0.019) and LpAI 
concentration (R10 +7% R40 +17%, p=0.030). The increase in LpAI concentration was 
associated with a significant dose-related reduction in triglyceride concentration (R10 
-23% R40 -42%, p<0.001) and LpAI fractional catabolic rate (FCR) (P 0.50±0.03, R10 
0.42±0.03, R40 0.38±0.03, pools/day, p=0.004) with no changes to LpAI production rate 
(PR). There was a significant dose-dependent reduction in LpAI:AII FCR (P 0.30±0.01, 
R10 0.27±0.02, R40 0.24±0.02, pools/day, p<0.001) with concomitant reduction in LpAI:
AII PR (P 11.49±0.72, R10 10.89±0.96, R40 8.98±0.70, mg/kg/day, p<0.01), and hence 
no changes in LpAI:AII concentration.
Conclusions: The data suggest that rosuvastatin has a dose-dependent effect on HDL 
cholesterol and LpAI concentrations and this was primarily related to reduction in LpAI 
fractional catabolism and triglyceride concentration. These findings provide a potential 
mechanistic explanation for the effect of a rosuvastatin in raising HDL cholesterol in the 
metabolic syndrome and protecting against atherosclerosis.
3:30 p.m.
1020-120 Cardiovascular Outcomes in Patients with Diabetes 
Mellitus, Metabolic Syndrome, or Neither Condition 
with New Diagnosis of Coronary Artery Disease
Wael A. AlJaroudi, John L. Petersen, Eric Yow, Linda K. Shaw, Darren K. McGuire, Eric 
D. Peterson, Robert A. Harrington, Duke University Medical Center, Durham, NC
Background: The impact of Metabolic Syndrome (MS) on cardiovascular outcomes in 
patients with coronary artery disease (CAD) has not been well established.
Methods: We identified patients with new diagnosis of CAD between 1998 and 2001 
in the Duke Database. Diabetes Mellitus (DM) was defined by prior clinical diagnosis, 
use of medications, or fasting glucose ≥126 mg/dl. MS was defined by having ≥3 of the 
following: fasting glucose ≥100 mg/dl and <126 mg/dl; low HDL cholesterol (<35mg/dl for 
men, <40mg/dl for women), triglycerides >150mg/dl; Body Mass Index ≥27kg/m2, and 
hypertension. Follow up for death, myocardial infarction (MI) and stroke was obtained 
every 6 months. Cox proportional hazards models were generated to determine predictors 
of cardiovascular outcomes including death, death/MI, and death/MI/stroke.
Results: We identified 5994 patients: DM (N = 1952), MS (N = 2356), and No MS/DM 
(N = 1686). Median follow up was 5.1 years. Patients with MS versus those with No 
MS/DM were 3 years younger. Significant predictors of cardiovascular outcomes included 
age, male gender, Charlson index, NYHA class, valvular disease, ejection fraction, 
revascularization, peripheral and cerebrovascular disease, smoking, and statin use. 
Compared with patients with No MS/DM, DM but not MS was associated with increased 
adjusted odds for death, death/MI and death/MI/stroke (Figure 1).
Conclusions: In a population of patients with incident CAD, MS in the absence of DM is 
not associated with worse cardiovascular outcomes. 
3:30 p.m.
1020-121 Do Statins Improve Survival in Patients with Diastolic 
Dysfunction?
Vinod Raxwal, Samantapudi Daya, Shubham Gupta, Mark Wiley, James Vacek, David 
Wilson, Kansas University medical Center, Kansas City, KS
Background: Studies have suggested a beneficial role of statin therapy in patients with 
diastolic dysfunction. However the data is limited with a short follow up.
Methods: From our echocardiography database we studied 4262 patients that had 
preserved LV ejection fraction (>54%) and impaired diastolic function. Patients were 
stratified into two groups according to their statin usage. Mild diastolic dysfunction was 
defined as E/A<1 at rest, moderate as E/A2 (restrictive). Survival curves of patients 
grouped by medication status were calculated by the Kaplan-Meier method and compared 
with the log-rank test. Logistic regression model was used to evaluate the significance of 
difference of statin usage.
Results: Mean age of the studied population was 63±13 years. Diabetes was present in 
16% patients, 17% had CAD and 53% had HTN. Mild diastolic dysfunction was present in 
77%, 22% patients had moderate and 1% had severely impaired relaxation. Forty percent 
of the patients were on statin. In the statin group mean level of total cholesterol was 
173mg/dl, LDL of 97 mg/dl and HDL of 49 mg/dl versus in the control group cholesterol 
levels was194 mg/dl, LDL 115 mg/dl and HDL 53 mg/dl respectively (p<0.01). During a 
mean follow up of 1.7±1 years 253 deaths occurred, 3% in the group taking statin and 9% 
in the group not taking statin (p<0.01).
Conclusion: Statin therapy appears to improve survival in patients with diastolic 
dysfunction. In patients with diastolic dysfunction statin therapy might be considered. 
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3:30 p.m.
1020-122 Elevated Fibrinogen, Higher Body Mass Index and 
Diabetes Mellitus are Associated With Lower Platelet 
Inhibition in Patients Treated With Clopidogrel
Lawrence Ang, Vachaspathi Palakodeti, Sotirios Tsimikas, Ahmer Khalid, Guilherme 
Bromberg-Marin, Zaheib Idrees, Joon Choi, Shahin Keramati, Ehtisham Mahmud, 
University of California, San Diego, San Diego, CA
Background: Heterogeneity in platelet inhibition (PI) response to clopidogrel exists. 
We sought to determine the PI response with clopidogrel in patients with cardiovascular 
disease (CVD) and to identify factors predictive of lower PI.
Methods: We prospectively enrolled 82 patients (age 66±13.3 yrs, 67.1% male) with CVD 
treated with clopidogrel (75 mg daily ≥ 7 days, n=51; or 600 mg load 24 hours prior, n=31). 
PI was measured with a bedside platelet function assay VerifyNow-P2Y12 (Accumetrics, 
San Diego, CA) along with evaluation of factors known to affect platelet aggregation.
Results: The PI in the group was 45.2±26.2% (normal distribution). The presence of diabetes 
(PI: 34.8±21.2% vs 52.5±27.4% non-diabetics, p=0.002) and increasing body mass index (BMI 
kg/m2) were associated with lower PI [BMI <25, PI=59.5±25.1%; BMI 25-30, PI=42.7±25.7%; 
BMI 30-40, PI=38.2±25.4%; BMI >40, PI=36.4±8.7%; p=0.002]. Elevated fibrinogen (≥375 
mg/dl) inversely correlated with lower PI (r=-0.80, p<0.001). Diabetics with fibrinogen ≥375 
mg/dl achieved the lowest PI (25.1±12.4%) while non-diabetics with fibrinogen <375 mg/dl 
achieved the highest PI (53.3±28.7%; p<0.001). Age, gender, smoking status, dyslipidemia, 
and CRP levels were not associated with PI achieved with clopidogrel.
Conclusion: Elevated fibrinogen, higher BMI and diabetes are associated with lower 
PI with clopidogrel in patients with CVD. These findings may help to understand the 
heterogeneity in PI response to clopidogrel and clinical outcomes. 
3:30 p.m.
1020-123 Pravastatin Increases Circulating Level of Adiponectin 
via Up-regulation of Gene Expression of Adiponectin 
in Visceral Adipose Tissue but not in Subcutaneous 
Adipose Tissue in Patients With Coronary Artery 
Disease
Saito Shin, Takayuki Fujiwara, Tomohiro Osanai, Ken Okumura, Hirosaki university 
school of medicine The second department of internal medicine, Hirosaki, Japan
Backbrounds: Adiponectin, produced and secreted by adipose tissues, has been reported 
to improve insulin sensitivity and prevent type 2 diabetes and atherosclerosis. It is said 
that pravastatin therapy results in a 30%-reduction in the new occurrence of diabetes. 
Little is known about the relationship between statin therapy and adiponectin in humans.
Methods: Thirty-five patients with coronary artery disease undergoing coronary artery 
bypass surgery (CABG) were enrolled after written informed consent was obtained. Fifteen 
patients with the serum low density lipoprotein (LDL)-cholesterol level >100 mg/dl were 
treated with oral pravastatin at 10 mg/day for 2 months before CABG (Group A), whereas 
the other 20 with LDL-cholesterol <100 mg/dl were not (Group B). Paired samples of the 
subcutaneous adipose tissue and thymic gland replaced by visceral adipose tissue were 
harvested during CABG, and the gene expressions of adiponectin and tumor necrosis 
factor (TNF)-α were analyzed by real-time reverse transcription-polymerase chain 
reaction. Blood sample was also obtained during CABG, and the plasma adiponectin and 
TNF-α levels were measured by enzyme linked immunosorbent assay.
Results: At the time of CABG, the levels of the serum lipids and medications except for statin 
were similar between the 2 groups. The log-transformed plasma adiponectin level was higher 
in Group A than in Group B (1.91±0.1 vs 1.57±0.1, p<0.05), but the plasma TNF-α level was 
similar. The gene expression of adiponectin in the visceral tissue was higher by 3 fold in 
Group A than in Group B (p<0.0001), but that in the subcutaneous tissue was not different 
between the 2 groups. TNF-α gene expression was similar between the 2 groups in each 
tissue. The log-transformed plasma adiponectin level was positively correlated with the gene 
expression of adiponectin in the visceral tissue (r=0.34, p<0.05).
Conclusion: Pravastatin upregulates the gene expression of adiponectin in the visceral 
adipose tissue, thereby increasing its circulating level. This may explain the beneficial 
effects of pravastatin therapy.
3:30 p.m.
1020-124 Triglycerides Predict AMI Mortality in Older Persons: 
Findings from the EPESE study.
Huma Ali, Yun Wang, Judith Lichtman, James Revkin, JoAnne Foody, Yale University, 
New Haven, CT, Griffin Hospital, Derby, CT
Background: While triglycerides (TG) have been deemed an independent risk factor for 
CAD, their role regarding mortality remains controversial. Whether TG are an important 
risk factor in older persons remains to be determined.
Methods: We utilized data from the Established Populations for the Epidemiologic Studies 
of the Elderly (EPESE) to examine the relationship between TG and cardiovascular 
mortality (MI, CAD and HF) in 4,128 subjects in whom non-fasting serum measurements 
were obtained in 1987-88. Baseline and followup sociodemographic, clinical and functional 
information were obtained through serial exams and interviews. Cox proportional hazard 
models assessed the association between TG and 5 year cardiovascular mortality.
Results: In total, 4,128 patients were included in the analysis; mean age 78.7 years, 
63.9% females and 88.2% white. Mean TG level was 178.4 mg/dL and mean HDL was 
48.1 mg/dL. After adjustment for sociodemographic, clinical and functional characteristics, 
elevated TG (>150 mg/dL) was associated with an increase in 5-year AMI mortality {HR 
=1.64, 95% CI (1.03-2.62), p = 0.03}. No associated was seen with 5 year CAD, or CHF 
mortality, {HR =0.72 (0.5, 1.05), p=0.09}, {(HR= 0.76 (0.46-1.28) p=0.35} respectively.
Conclusion: In a large representative sample of older community-dwelling adults non fasting 
TG levels were associated with long-term AMI mortality. Whether interventions to lower 
elevated triglycerides will improve outcomes in older persons remains to be determined.
. 
3:30 p.m.
1020-125 The Impact of Statin Therapy on the Incidence of Atrial 
Fibrillation- A Meta-analysis
Manish Undavia, Satish Tiyyagura, Michael Lou, Zyad Younan, Steve Furer, Joseph 
Anthony Gomes, Paul Schweitzer, Davendra Mehta, Avi Fischer, Mount Sinai Medical 
Center, New York, NY, Beth Israel Medical Center, New York, NY
Background: Increasing evidence suggests a possible role of inflammation in the 
pathogenesis of atrial fibrillation (AF). Statins by virtue of their pleiotropic effects have been 
suggested to reduce the occurrence of AF. Previous studies describing the use of statins in 
reducing AF burden have been limited by small sample sizes and disparate populations.
Objectives: The purpose of this study was to perform a meta-analysis of the effect of 
statin therapy on the incidence of AF.
Methods: Clinical trials evaluating the role of statin therapy and AF occurrence were 
retrieved. Studies were included if details of the lipid lowering therapy were available 
and the primary endpoint was occurrence of AF. Data from each article were abstracted 
independently by two authors using a standardized protocol. Summary estimates of the 
effect of statins on AF were made using a random-effects model.
Results: 3401 pts (25 %F, age range: 61 to 73 yrs, F/U: 1 wk to 6.5 yrs) from 10 trials met the 
prespecified search criteria. Thirty three percent of patients had a h/o AF, 35 % of pts had h/o 
CAD, and 6 % pts had h/o either heart failure or cardiomyopathy. Twenty four percent of pts 
on a statin developed AF as compared to 35 % on no statin (RR: 0.72, 95 % CI: 0.55 to 0.94, 
P=0.01). Conclusion: These results suggest that statin therapy may have a potential utility 
in both primary and secondary prevention of AF.Larger randomized prospective studies are 
needed to evaluate the precise mechanism and whether this is a class effect. 
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1020-126 The Association between Adherence to the 
Mediterranean Diet and Fasting Indices of Glucose 
Homoeostasis; the ATTICA Study
Demosthenes B. Panagiotakos, Christina Chrysohoou, Christos Pitsavos, John 
Skoumas, Constadina Masoura, Lambros Papademetriou, Ioanna Papaioannou, 
Christodoulos Stefanadis, 1st Cardiology Clinic, University of Athens, Athens, Greece
Background: We investigated the association between adherence to Mediterranean diet 
and fasting indices of glucose homoeostasis, in a Greek adult population
Methods: During 2001 - 2002 we randomly enrolled 1514 men and 1528 women (18-89 
years old) without history of CVD, from the Attica area. Diabetes mellitus (type 2) and 
impaired fasting glucose (IFG) were defined according to the established ADA criteria. 
Insulin resistance was evaluated by HOMA-IR. Dietary habits were assessed through 
a validated food frequency questionnaire and a diet score (range 0-55) was developed 
(higher values means greater adherence to the Mediterranean diet).
Results: The overall prevalence of diabetes type 2 was 7.9% in men and 6.0% in women 
(P = 0.05). Mean diet score was 26.3±6.8 in normoglycemic, 25.7±6.4 in IFG and 22.2±5.8 
in diabetic subjects (p < 0.001). In normoglycemic subjects who were in the upper tertile 
of the diet score we observed 7% lower glucose (p<0.05), 5% lower insulin (p<0.05) and 
15% lower HOMA-IR (p<0.01) levels compared to subjects in the lower tertile of the diet 
score. Additionally, in diabetic / IFG participants who where in the upper tertile of the diet 
score we observed 15% lower glucose (p<0.05), 15% lower insulin (p<0.05) and 27% 
lower HOMA-IR (p<0.01) levels compared to those in the lower tertile. However, multiple 
regression analysis, adjusted for age, sex, BMI, waist-to-hip ratio, physical activity, 
smoking status, and presence of hypertension and hypercholesterolemia, confirmed the 
previous associations in normoglycemic, but not in diabetic / IFG people.
Conclusions: An inverse association was observed between adherence to Mediterranean 
diet and indices of glucose homeostasis, only in normoglycemic people.
3:30 p.m.
1020-127 Impact of Diabetes Mellitus on Local Inflammatory 
Activity in Non-culprit Lesions: an Additional 
Inflammatory Trigger?
Maria Drakopoulou, Konstantinos Toutouzas, John Karabelas, Andreas Synetos, 
Eleftherios Tsiamis, Athanasios Manginas, Dimitrios Alexopoulos, Christodoulos 
Stefanadis, First Department of Cardiology, University of Athens, Hippokration hospital, 
Athens, Greece
Background: In patients (pts) with type 2 diabetes mellitus (DM) local inflammatory 
activation in culprit lesions is observed. The impact however of DM on non-culprit 
lesion inflammation has not been extensively investigated. The aim of this study was to 
investigate whether pts with type 2 DM have increased local heat generation in non-culprit 
lesions compared to pts without DM.
Methods. We included pts with acute coronary syndrome (ACS) or stable angina (SA) 
undergoing percutaneous coronary intervention in culprit lesions, having an intermediate 
non-culprit lesion. The non-culprit lesion had to be clearly identified from the culprit 
lesion by the combination of precrisis and intercrisis ECG findings, left ventricular wall 
motion abnormalities, scintigraphic defects, and angiographic lesion morphology. 
Local inflammatory activation of non-culprit lesions was estimated by measuring the 
temperature difference (ΔT), assigned as the difference between the proximal vessel wall 
temperature from the maximal temperature at the atherosclerotic plaque.
Results. The total study population consisted of 80 pts: 22 (mean age: 64.40±10.45 
years) with type 2 DM and 58 (mean age: 60.67±8.96 years) without DM, serving as 
control group matched for age, type of clinical syndrome, statin, aspirin intake, and 
angiographic stenosis (%). Mean ΔT in non-culprit lesions was 0.07±0.07°C. Pts with ACS 
had higher ΔT compared to patients with SA (ACS: 0.10±0.07°C vs SA: 0.05±0.05°C, 
p<0.01). Pts with type 2 DM had increased thermal heterogeneity compared to non-
diabetic patients (ΔT: 0.11±0.9ºC vs 0.06±0.05ºC, p<0.01). Pts with type 2 DM and 
ACS had increased thermal heterogeneity compared to non-diabetic pts with ACS 
(0.14±0.09ºC vs 0.08±0.04ºC, p<0.01). Furthermore, in SA group pts with DM type 2 had 
also increased thermal heterogeneity compared to non-diabetics (mean ΔT: 0.09±0.08ºC 
vs 0.04±0.04ºC, p=0.02).
Conclusions. Patients with type 2 DM have increased thermal heterogeneity in non-
culprit lesions compared to pts without DM. Thus, a widespread inflammatory activation 
is observed in pts with DM. These results may explain the unfavorable clinical outcome 
in pts with DM and ACS.
3:30 p.m.
1020-128 Impact of Renal Dysfunction, Glucometabolic Status 
and Quality of Care on 1 Month Mortality After Acute 
Myocardial Infarction
Francois Schiele, Marie-France Seronde, Vincent Descotes-Genon, Marie-Cecile 
Blonde, Pierre Legalery, Nicolas Meneveau, Fiona Ecarnot, Alfred Penfornis, Didier 
Ducloux, Jean-Pierre L. Bassand, Investigators of the “Réseau Franc-Comtois de 
Cardiologie”, University Hospital Jean Minjoz, Besancon, France
Background Pts admitted for acute myocardial infarction (AMI) with diabetes, stress 
hyperglycaemia (SH) or chronic renal dysfunction (RD) are at higher risk & receive fewer 
effective therapies. It is unclear if this risk is related to quality of care (QoC).
Methods Prospective registry of AMI pts. SH was defined as admission glucose >140mg/
dL in the absence of diabetes. Renal function was considered normal if glomerular 
filtration rate (GFR) was ≥60 (GFR1), mild RD 30-60 (GFR2), severe RD <30ml/min 
(GFR3). QoC was assessed by a compliance score, calculated based on rate of use of 5 
guidelines-recommended treatments (GRT).
Results Of 1388 pts included, 323(23%) had diabetes & 224(16%) SH. Only 763(55%) 
had normal renal function, 491(35%) had mild & 134(9.5%) severe RD. Pts with SH + 
RD had a higher risk profile at admission and received fewer GRT. At 1 month, mortality 
was 8%, and was significantly higher in pts with SH (18%) vs diabetics (9%) or pts with 
normal glucometabolic status (5%). Mortality rate was also higher in pts with impaired 
renal function (GFR1:1.3%; GFR2: 12.8%; GFR3: 23.1%). Multivariable analysis identified 
SH (OR=2.5), GFR group (GFR2 vs GFR1: OR=4.4, GFR3 vs GFR1: OR=5.1), TIMI risk 
index (OR=1.3 per 10% increase), STEMI (OR=2.2) & QoC (OR=0.78 per 10% increase 
in compliance score) as independent predictors of mortality.
Conclusions: In pts with AMI, SH and GFR <30ml/min/m² are independent predictors of 
mortality, even after adjustment for TIMI risk index and QoC. 
3:30 p.m.
1020-129 Serum Adiponectin as a Surrogate Marker of Metabolic 
Syndrome: A Prospective Cohort Study
Jang-young Kim, min-soo Ahn, Yonsei uinversity wonju college of medicine, wonju, 
South Korea
Background: A growing body of evidence suggests that hypoadiponectinemia may play 
a significant role in the development of the metabolic syndrome (MetS). It is obscure 
about the significance of serum adiponectin as a surrogate marker for MetS itself and 
components of MetS in a general population.
Methods: We performed a cohort study conducted on a senior (age > 40 years) population 
with 1,437 men and 2,071 women without history of cardiovascular disease and cancer. 
We defined MetS according to the Asian modified criteria of Adult Treatment Panel III report 
and followed components of MetS comprising of clinical and laboratory characteristics. 
Serum adiponectin concentrations were measured by radioimmunoassay.
Results: The mean adiponectin levels for men exhibiting 0, 1, 2, 3, 4, or 5 components of 
MetS were 11.19, 10.08, 8.09, 7.14, 6.21, and 5.11 µg/L, respectively (p for trend <0.001), 
while those in women were 15.65, 14.03, 12.38, 11.04, 9.75, and 9.32 µg/L, respectively 
(p for trend <0.001). Adiponectin concentration was correlated negatively with waist 
circumference, triglyceride, hsCRP, fasting glucose, and insulin, and correlated positively 
with high-density lipoprotein and age in both sexes (p <0.001). Multiple logistic analyses 
demonstrated that circulating adiponectin had a strong protective effect against Mets [odd 
ratio; 0.34 (95% confidence interval 0.26 to 0.43) in males, 0.35 (0.28 to 0.44) in females].
Conclusion: Serum adiponectin levels are strongly associated the phenotype of MetS, 
as well as components of MetS in a general population.
3:30 p.m.
1020-130 Obesity and Atrial Fibrillation - A Meta Analysis
Nikolas Wanahita, Franz H. Messerli, Sripal Bangalore, Jonathan S. Steinberg, Beth 
Israel Medical Center, New York, NY, St Luke’s-Roosevelt Hospital Center, New York, NY
Background: The pathogenetic mechanisms tying obesity to an excessive cardiovascular 
morbidity and mortality are ill understood and may be multifactorial. Obesity has been 
shown to be associated with atrial enlargement and ventricular diastolic dysfunction, both 
of which are risk factors for developing atrial fibrillation (AF). Nevertheless, the association 
between increased body mass index (BMI) and AF is yet to be established.
Methods: The Medline and Cochrane databases were searched from 1966 to September 
2006 for English language, prospective, population-based, cohort studies looking into the 
association between BMI or BMI category and risk of developing AF. Bibliographies of retrieved 
articles were searched for further studies. Of the 4 eligible articles, one was excluded for not 
using the World Heath Organization (WHO) BMI category. Normal weight by WHO criteria is 
defined as BMI <25.0 kg/m2; overweight, 25.0 to <30.0 kg/m2; and obese, ≥30 kg/m2.
Results: Three large population-based cohort studies that enrolled 68,273 patients 
from the United States and 2 European countries were included in our analysis. 53 
percent of these patients were women and the mean age of these patients was 56 ± 
2 years. Analysis was done using a fixed effect method. Among men, being overweight 
is associated with a risk ratio (RR) of 1.47 (95% confidence interval [CI], 1.23 - 1.72) 
for developing AF vs. being normal weight and being obese with a RR of 1.72 (95% CI, 
1.04 - 2.86) for developing AF vs. normal weight men. Among women, being overweight 
is associated with a RR of 1.45 (95% CI, 1.11- 1.85) for developing AF vs. being normal 
weight and being obese with a RR of 2.00 (95% CI, 1.61 - 2.50) for developing AF vs. 
normal weight women.
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Conclusion: These data demonstrate that the risk of developing AF increased in parallel 
with BMI in both men and women. This systematic review identifies AF as yet another 
pathogenetic factor by which overweight and obesity potentially increase cardiovascular 
and cerebrovascular morbidity and mortality.
3:30 p.m.
1020-131 Which Psychological Risk Factors Best Predict 
Mortality In Coronary Patients?
Carl J. Lavie, Jr., Richard V. Milani, Ochsner Health System, New Orleans, LA
Background - Numerous studies have indicated the adverse prognostic impact of 
psychological distress in patients with coronary heart disease (CHD). Although most of 
these studies have emphasized the role of depression, anxiety and hostility may also 
adversely affect prognosis. However, to our knowledge, the relative importance of these 
variables for predicting mortality in CHD patients is largely unknown. 
Methods - We utilized validated behavioral questionnaires in 712 patients (64 ± 11 years; 
72% male; body mass index 28.7 ± 5.2 kg/m2) with prior history of major cardiac events 
to determine the impact of depression, anxiety and hostility on all-cause mortality by 
National Death Index during mean 3.5 year follow-up. 
Results - (See table) The prevalence of high symptoms of anxiety, depression and 
hostility were 13%, 12% and 5%, respectively. Although symptoms of anxiety and hostility 
both predicted mortality in CHD patients, depression symptoms had the highest risk, 
being associated with a 4 - 5 fold increased risk of death over 3.5 years compared with 
patients without depression. 
Conclusions - Psychological risk factors strongly predict mortality in CHD patients, with 
depression carrying the highest mortality risk. Although anxiety and hostility symptoms 
were also associated with higher mortality, they do not appear to add additional risk 
to patients with depression. These results emphasize the importance of evaluating 
depression in the secondary prevention of CHD.
MORTALITY% 
YES NO P-VALUE
Depression (D) 27% 6% <0.0001
Anxiety (A) 15% 8% <0.01
Hostility (H) 13% 8% <0.05
D + A 23% 8% <0.0001
D + H 19% 8% <0.05
3:30 p.m.
1020-160 Rosuvastatin Regulates Extracellular Matrix By 
Reducing Mmp-2 And -9 And Increasing Timp-2 Levels 
In Patients With Heart Failure
Dimitris Tousoulis, Yannis Andreou, Charalambos Antoniades, Carmen Vasiliadou, 
Costas Tentolouris, Kostantinos Zisimos, Christodoulos Stefanadis, Athens University, A 
Cardiology Department, Athens, Greece
Background: In the failing human myocardium there are reciprocal increases in the 
activity of matrix metalloproteinases (MMPs) and decreases in the activity of tissue 
inhibitors of metalloproteinases (TIMPs). These alterations are regarded as early 
contributory mechanisms for the initiation and progression of heart failure. Recent studies 
suggest that HMG-CoA reductase inhibitors and xanthine oxidase inhibitors may exert 
favorable effects in patients with heart failure (HF). However, their effects on circulating 
levels of MMPs and TIMPs in such patients have not been investigated.
Methods: A total of 42 clinically stable patients with systolic HF (NYHA II-III, 93% male, 
mean age 64±11 years, mean LVEF 29±7%, 74% ischemic) who were already on optimal 
conventional cardiovascular treatment were randomized to either rosuvastatin 10 mg/day 
or allopurinol 300 mg/day and followed up for 4 weeks. Serum levels of MMP-2, -9, TIMP-
1, -2 were measured before and after 4-week treatment using ELISA.
Results: Plasma MMP-2 and MMP-9 were decreased in the rosuvastatin group (from 
251±52 ng/mL and 399±206 ng/mL to 215±47 ng/mL and 295±168 ng/mL respectively, 
p<0.001 and p<0.05 respectively), but not in the allopurinol group (from 243±72 ng/mL 
and 372±159 ng/mL to 247±65 ng/mL and 304±159 ng/mL respectively, p=NS for both). In 
the rosuvastatin group, TIMP-2 was significantly increased (from 85±17 ng/mL to 93±16 
ng/mL, p<0.05), while TIMP-1 was slightly increased (from 356±103 ng/mL to 382±89 
ng/mL, p=0.14). In the allopurinol group, no significant changes were observed regarding 
the levels of TIMP-1 and TIMP-2 (from 380±74 and 87±16 ng/mL to 393±77 and 93±19 
ng/mL respectively, p=NS for both).
Conclusions: Short-term rosuvastatin administration affects extracellular matrix 
remodeling by reducing MMP-2 and -9 levels and increasing TIMP-2 levels in patients 
with HF. These findings provide further insights into the role of statins in patients with HF.
3:30 p.m.
1020-161 The Prevalence of the Metabolic Syndrome in Cardiac 
Rehabilitation Patients
Thomas Draper, Melvyn Rubenfire, Richard Salmon, Kevin Reid, William Saxon, George 
Faircloth, Brenda Wright, Richard Leighton, Barry Franklin, Neil Gordon, University 
of Michigan Health System, Ann Arbor, MI, St. Joseph’s Candler Health System, 
Savannah, GA
Background: The metabolic syndrome (MetS) is a constellation of interrelated 
cardiovascular disease (CVD) risk factors of metabolic origin. We assessed the prevalence 
of MetS in a very large multicenter cohort of patients participating in cardiac rehab and the 
impact of the recent changing definition related to fasting blood glucose levels (FBG).
Methods: 4,411 consecutive adult (age = 66±11 years) males (70.8%) and females who 
enrolled in phase 2 cardiac rehab (CVD = 94.8%) had data on all 5 MetS risk factors 
(HDL-C, hypertension, triglycerides, abdominal girth, FBG) using both the AHA/NHLBI 
revised (FBG >100 mg/dl) and original criteria (FBG > 110 mg/dl).
Results: Prevalence of MetS utilizing original FBG criteria was 48.7% (n = 2,105), and increased 
to 58.6% (n = 2,628) prevalence rate with the lower FBG; an increase of 24.8% (p<0.001).
Conclusions: 1) Whether the AHA/NHLBI ATP III revised or original FBG criteria are 
used, MetS is very common at entry into a phase 2 CR program; 2) the findings are 
particularly relevant when developing comprehensive risk reduction interventions with an 
emphasis on targeted nutrition and exercise recommendations.
3:30 p.m.
1020-162 Prevalence of Low High-Density Lipoprotein 
Cholesterol in Ambulatory Patients with Coronary Heart 
Disease (CHD) or CHD Risk Equivalents
Jen-liang Lin, Alawi A. Alsheikh-ali, Paul Abourjaily, Dineli Ahearn, Jeffrey T. Kuvin, 
Richard H. Karas, Tufts-new England Medical Center, Boston, Ma
Background: Recent national guidelines increase the focus on low density lipoprotein 
cholesterol (LDL-C) lowering and set aggressive new targets in high risk patients. 
They also re-emphasize the role of high-density lipoprotein cholesterol (HDL-C) as an 
independent risk factor for coronary heart disease (CHD). However, it remains unclear 
what proportion of patients who have well controlled LDL-C levels continue to have low 
HDL-C. We sought to determine the prevalence of low HDL-C in an ambulatory population 
with CHD or a CHD risk equivalent across various levels of LDL-C.
Methods: Using electronic medical records from a large adult primary care clinic, we 
identified patients with CHD or a CHD risk equivalent who had concurrently measured 
LDL-C and HDL-C levels in the preceding year (2004). A CHD risk equivalent was defined 
as diabetes mellitus (DM), peripheral vascular disease, abdominal aortic aneurysm, or 
carotid artery disease complicated by a stroke or a transient ischemic attack. Patients 
were categorized by LDL-C levels as follows: LDL-C >100 mg/dL, LDL-C 71-100 mg/dL, 
and LDL-C ≤ 70 mg/dL. Low HDL-C was defined as < 40 mg/dL in a male, and < 50 
mg/dL in a female.
Results: Our search identified 1,512 high risk patients, the majority (66%) of which had 
low HDL-C. Compared to patients with optimal HDL-C values, those with low HDL-C were 
younger (62 vs 64 years, p < 0.05), more likely to be female (48 % vs 40 %, p < 0.01), 
and to have DM (74 % vs 66 %, p < 0.01) or hypertension (73 % vs 68 %, p < 0.01). Low 
HDL-C was prevalent across all levels of LDL-C, but most prevalent in patients with LDL-
C ≤ 70 mg/dL (79 % versus 64 % in patients with LDL-C > 100 mg/dL and 66 % in those 
with LDL-C 71-100 mg/dL, p < 0.01). The high prevalence of low HDL-C was seen in 
patients on statins (67 %) as well as those not on statins (64 %, p = NS). Niacin or fibrate 
use was rare (< 5 %) and was not different in patients with low HDL-C versus those with 
optimal HDL-C levels.
Conclusion: In a contemporary ambulatory population with CHD or a CHD risk equivalent, 
low HDL-C was prevalent across all levels of LDL-C and independent of statin use. HDL-C 
raising therapies were underutilized. This represents a large unmet opportunity for further 
CHD prevention.
3:30 p.m.
1020-163 Metabolic Syndrome Versus Diabetes Mellitus Type 
II and Global Risk Scores for Predicting Future 
Cardiovascular Events
Kwame O. Akosah, Vicki L. McHugh, Michelle A. Mathiason, Gundersen Lutheran Health 
System, La Crosse, WI, University of Virginia, Charlottsville, VA
Background: : Recent trends in increasing rates of obesity, and type II diabetes, with 
subsequent increase in rates of metabolic syndrome, is a major public health concern. 
However, there is lack of consensus about the impact of metabolic syndrome on coronary 
heart disease. An important question is whether or not metabolic syndrome provides 
information that is independent and additive to the risk components of the syndrome. Our 
objective was to compare the risk associated with metabolic syndrome versus type II diabetes 
and global risk scores for severe coronary artery disease (CAD) and future events.
Methods: 253 individuals (men ≤ 55, women ≤ 65) scheduled for elective coronary 
angiography were prospectively studied. Those with history of coronary heart disease 
(CHD) or on lipid therapy were excluded. All had clinical risk scores calculated and fasting 
blood drawn. Severe CAD was defined as stenosis ≥ 50%. Future cardiovascular events 
were defined as death, myocardial infarction (MI), and stroke.
Results: Complete data was available on 236 subjects (mean age 53+ 8; 55% women). 
Severe CAD was diagnosed in 72 subjects (31%). 28% of subjects met criteria for 
metabolic syndrome. Subjects were categorized into 4 risk groups. Group 1 (n=50) had 
metabolic syndrome without diabetes, Group 2 (n=34) had diabetes, Group 3 (n=136) 
was low risk (10 yr risk < 10%), and Group 4 (n=6) had risk ≥ 20%. After median follow-up 
of 32 months, 10 subjects suffered 12 major events (death=3, MI=5, and stroke=4). The 
rate of diagnosis of severe CAD was not different between Group 1 compared to Group 
2 (p=NS) or Group 4 (p=NS), but was significantly higher when compared to Group 3 
(p=0.001). Event rate was 8% for Group1 and 8.8% for Group 2 (p=0.999) versus 1.5% 
for Group 3 (p=0.046). 90% of subjects suffering major events had either frank diabetes 
or metabolic syndrome. 
Conclusions: Metabolic syndrome is associated with risk for severe CAD. The risk for 
future cardiovascular events in subjects with metabolic syndrome may be as high as 
that for type II diabetes. The risk of metabolic syndrome for CHD is present before the 
development of frank diabetes. Metabolic syndrome and type II diabetes identified nearly 
all subjects at risk for future events.
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1020-164 The J-shape Relationship of Alcohol Consumption with 
lipid levels, Inflammatory and Heamostatic factors, in 
general population; the Attica Study
Christina Chrysohoou, Demosthenes B. Panagiotakos, Christos Pitsavos, John 
Skoumas, Lambros Papademetriou, Stella Brili, Constadina Paliou, Manolis Kambaxis, 
Akis Zeibekis, Christodoulos Stefanadis, 1st Cardiology Clinic University of Athens, 
Athens, Greece
Background: According to epidemiologic studies alcohol consumption is considered to 
have ambiguous effect on the cardiovascular risk. The aim of this work is to evaluate the 
association between chronic alcohol consumption and several clinical and biochemical 
parameters related to the coronary risk in cardiovascular disease free men and women.
Methods:The “ATTICA” study is a population -based cohort that was randomly enrolled 
1876 participants from the greater area of Athens during 2001-02. Of them 903 were 
men and 973 women (+18 years old). We investigated the association between alcohol 
consumption and arterial blood pressure, fibrinogen levels, glucose concentration, total 
cholesterol, HDL and LDL, apolipoprotein A1 & B, Lp(a), uric acid, leucocytes count, 
triglycerides, C-reactive protein and homocysteine levels.
Results: Nutrient analysis of the data showed that 279 (42%) males and 98 (12%) 
females consumed at least one wineglass of alcohol per day. Multivariate analysis, after 
controlling for several potential confounders showed a consistent positive association 
between alcohol intake (none, 1-2, 3-4, 5+ wine glasses/day) and arterial blood pressure 
levels, uric acid, triglycerides, and total cholesterol. Additionally, a J-shape association was 
observed between alcohol consumption and HDL (insignificant), non-HDL cholesterol, 
homocysteine, apolipoproteins A1 and B, lipoprotein (a), fibrinogen, C-reactive protein 
and leucocytes levels. The most beneficial values of all these biochemical and clinical 
parameters were found in alcohol intake of 100 - 200 ml. Conclusions. The controversial 
association between alcohol intake and cardiovascular disease seems that it can be, 
partially, explained through the J-shape relation of several biochemical parameters 
related to atherosclerosis and the amount of alcohol consumption.
3:30 p.m.
1020-165 Self Reported Depression is Associated with Decreased 
but Considerable Benefit from Phase 2 Cardiac 
Rehabilitation
Thomas Draper, Melvyn Rubenfire, Katherine Smith, Richard Salmon, Kevin Reid, 
William Saxon, George Faircloth, Brenda Wright, Richard Leighton, Barry Franklin, Neil 
Gordon, University of Michigan Health System, Ann Arbor, MI, St. Joseph’s Candler 
Health System, Savannah, GA
Background: Depressed patients with cardiovascular disease (CVD) are less likely 
to take prescribed drugs and adhere to appropriate lifestyle changes. We sought to 
determine whether depression impacts the benefit of cardiac rehab (CRehab).
Methods: 14,007 patients in 37 centers in the US were stratified by self reported current 
or past depression to compare the effect of CRehab on CVD risk factors assessed at 
baseline and following 12 weeks of participation.
Results: Depression was present in 2,767 patients (19.75%) (mean age 64.2±11.5 yrs) 
and 11,240 had no depression (age 66.5±11.6 yrs). Those with depression at baseline 
were less likely to complete the exit evaluation (depression, 41.7% vs non-depressed 
47.9%, P<.05). Improvements (each P<.05) in classic CVD risk factors were observed for 
patients with and without a self-reported history of depression who had abnormal baseline 
values based on national guidelines (table). Though highly relevant and significant, the 
magnitude of benefit in those with depression was less for reduction in total and LDL-C, 
triglycerides, and diastolic BP. Patients with depression were more often current cigarette 
smokers (depression, 10.6% vs non-depressed 5.7%; P<.05); however, about 18% of 
each group successfully quit.
Conclusions: Patients with self-reported current and past depression may derive less, 
but still gain considerable benefit from CRehab. The effect of depression on long term 
compliance with the principles of CRehab needs to be determined. 
Change in Value from Baseline
History of 
Depression
No 
Depression
P Value between 
groups
Total Cholesterol -36 mg/dl -47 mg/dl P <.05
LDL-C -26 mg/dl -32 mg/dl P <.05
HDL-C 4 mg/dl 4 mg/dl NS
Triglycerides -37 mg/dl -49mg/dl P <.05
Fasting Glucose -18 mg/dl -15mg/dl NS
Systolic BP -10 mmHg -10 mmHg NS
Diastolic BP -10 mmHg -11 mmHg P <.05
Weight -3.7 lbs -3.9 lbs NS
Smoking at 
Baseline 10.6% 5.7% P <.05
Quitting Smoking 17.8% 19.3% NS
3:30 p.m.
1020-166 A Simple Additive Risk Score Discriminates Patients 
at Heightened Risk of Early Adverse Events During 
Medical Management Following Diagnostic Cardiac 
Catheterisation
Nick Newall, Roger Moore, Paul Browning, Rod H. Stables, Cheng Hok Toh, Alan 
Shenkin, Mark Jackson, David R. Ramsdale, Arrowe Park Hospital, Upton, United 
Kingdom, The Cardiothoracic Centre, Liverpool, United Kingdom
Aims To apply a simple clinical risk score derived from an additive multivariate Cox 
regression model in discriminating high risk subgroups of patients receiving contemporary 
medical therapy following diagnostic cardiac catheterisation (CC).
Methods The Score was defined by sum: Age >65 (2), Unstable symptoms within two 
months (3), Insulin dependent diabetes (3), one, two or three vessel disease (1,2,3 
respectively), LVEF <50% or NYHA class > II (2), aortic stenosis (4), peripheral arterial 
disease (3), HDL<1 mmol/l (2), neutrophil count > 4.0 x 109 (2). The distribution of risk 
scores among 2445 patients were plotted against rates of death or non-fatal myocardial 
infarction (MI) prior to cardiac intervention within one year of CC . The time in days to 
exceed a priori defined 1,2.5 and 5% death or MI rates for each clinical risk score was 
determined from life tables taken from Kaplan-Meier curves for each risk score.
Results The risk of death or non-fatal MI rose exponentially from <1% to 37% from the 
lowest to highest risk score (0->14). The number of days to exceed the predefined death 
or MI rates fell dramatically for risk scores of 9 or more (12.9% of the study population).
Conclusions This simple clinical risk score discriminates high and low risk subgroups 
of patients on contemporary medical therapy. The small proportion of patients with high-
risk scores experienced greatly accelerated times to death or non-fatal MI, identifying 
subgroups for whom delayed cardiac intervention may be particularly hazardous.
Time in days to death or non fatal MI by SCORE
SCORE < 4 4 5 6 7 8 9 10 >10
Days to 1% death or MI >365 115 76 127 115 62 3 2 16
Days to 2.5% death or MI >365 294 142 >365 188 95 6 4 20
Days to 5% death or MI >365 >365 >365 >365 >365 179 220 36 34
3:30 p.m.
1020-167 Simplified Scoring System to Predict Atrial Fibrillation 
After Coronary Artery Bypass Surgery
MacArthur A. Elayda, Vei-Vei Lee, James M. Wilson, Texas Heart Institute, Houston, TX, 
St. Luke’s Episcopal Hospital, Houston, TX
Background: We developed a simplified scoring system to identify and predict patients 
(pts) who are at high risk of atrial fibrillation (AF) occurence after coronary artery bypass 
surgery (CABG). AF is a common and important complication of cardiac surgery. 
Predicting their occurrence is essential for future prevention and possibly decrease in 
resource utilization and length of hospital stay.
Methods: Data on 8463 pts who underwent CABG from January 1996 to June 2005 
were obtained from the Texas Heart Institute Research Database. To develop an AF risk 
index, 6751 pts (80%) were assigned to the derivation set (DS) and 1712 pts (20%) to 
the validation set (VS). Logistic regression utilizing a forward stepwise variable selection 
was developed to determine which risk factors (RF) were associated with the incidence 
of AF. Parameter estimates of RF were multiplied by 10 to determine risk scores (RS). 
The resulting multivariable risk index had adequate discriminative power under the ROC 
curve of 0.74 in the DS.
Results: Three RS group categories were identified by the total RS for each pt: Low risk 
( RS<10), Medium risk (RS=10-20), and High risk (RS>20).In the DS the incidence of 
postoperative AF: 11.3%, 25.1%, and 34.7%, respectively. The RF associated with AF 
were advanced age (>50 years), obesity (BMI>30), congestive heart failure, pulmonary 
disease, peripheral vascular disease, hypertension, history of AF, low ejection fraction 
(<30) and urgent surgery. Reduced risk were associated with intake of nitrates and the 
female gender. In the VS the incidence of AF is 9.2%, 21.8%, and 31.7% for low, medium 
and high risk pts.
Conclusions: We identified and validated a model for pts who had CABG and at risk for 
AF based on the analysis of a single center experience. This simple scoring system can be 
used to assist in decision making specifically directed toward prevention of postoperative 
AF and to provide information to pts and their physicians.
3:30 p.m.
1020-168 Aliskiren-Based Therapy Provides Long-Term 
Suppression of Plasma Renin Activity That Persists 
After Treatment Withdrawal in Patients With 
Hypertension
Myron H. Weinberger, Karl Andersen, Christian M. Constance, Mohammed A. Ali, 
James Jin, Margaret F. Prescott, Indiana University School of Medicine, Indianapolis, IN, 
Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background: Hypertension can be treated by inhibiting the enzyme renin, the point of 
activation of the renin system. The oral direct renin inhibitor aliskiren (ALI) suppresses 
plasma renin activity (PRA) whereas ACE inhibitors increase PRA by reducing negative 
feedback on renin release. We report the effects of ALI- or ramipril (RAM)-based therapy, 
and of stopping treatment, on PRA and renin concentration (RC) in a subset of patients 
with hypertension in a 6-month trial.
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Methods: After a placebo run-in, 842 patients (mean sitting diastolic BP 95-109 mmHg) 
were randomized to ALI 150 mg or RAM 5 mg. Dose titration and HCTZ addition were 
allowed after Wk 6 for inadequate BP control. Patients completing active treatment were 
re-randomized to current regimen or placebo during a 4-wk withdrawal phase.
Results: BP reductions were superior (p<0.05) with ALI- versus RAM-based therapy at 
Wk 26 (17.9/13.3 vs 15.2/12.0 mmHg) and persisted for longer after stopping ALI than 
RAM. ALI-based therapy reduced PRA while RAM-based therapy increased PRA at 
Wk 26; RC increased in both groups. In patients who stopped ALI-based therapy, PRA 
increased gradually but remained 48% below Wk 0 baseline at Wk 30 (p<0.05); PRA 
returned to baseline in those stopping RAM.
Conclusions: Aliskiren-based therapy produced sustained reductions in BP and PRA 
over 6 months. Significant PRA reductions persisted 4 wks after stopping aliskiren, 
suggesting that aliskiren had continued inhibitory effects on the renin system beyond its 
plasma half-life. 
Geometric means for PRA (ng/mL/h)
Active treatment Aliskiren (n=103) Ramipril (n=100)
Week 0 0.83 0.96
Week 26 0.30* 2.33*
% change from Week 0 -63% +143%
Withdrawal Aliskiren Placebo Ramipril Placebo
Week 0 0.90 (n=55) 0.77 (n=44) 0.97 (n=43) 0.99 (n=48)
Week 26 0.31 (n=54) 0.31 (n=40) 3.02 (n=44) 1.99 (n=46)
Week 30 0.29*(n=53)
0.40*
(n=42)
3.09*
(n=44)
0.72+
(n=49)
% change, Week 30 from Week 
26
-5%
(n=52)
+21%
(n=38)
+2%
(n=43)
-66%
(n=44)
% change, Week 30 from Week 0 -68%(n=53)
-48%
(n=42)
+210%
(n=42)
-24%
(n=46)
*p<0.05 vs baseline (Week 0); +p<0.05 vs Week 26. Geometric means were calculated 
from the logarithm of the biomarker data. % change values were derived from the ratio 
of the geometric means. PRA was measured in a subset of 203 patients.
3:30 p.m.
1020-169 Blood Pressure Control With Clevidipine Compared 
to Nitroglycerin in the Treatment of Perioperative 
Hypertension: Primary Results From the Randomized 
ECLIPSE Trial
Solomon Aronson, Cornelius McKown Dyke, Dean Kereiakes, Albert Cheung, Kevin 
Stierer, Mark Newman, Duke University Medical Center, Durham, NC
Background: Hypertension is an important risk factor that predicts perioperative outcome. 
Uncontrolled or poorly controlled blood pressure (BP) is associated with an increased risk 
of morbidity and mortality in the cardiac surgical setting. Although nitroglycerin (NTG) is 
commonly utilized to control BP during and after cardiac surgery because of its presumed 
safety profile, it can be associated with efficacy limitations. Clevidipine (CLV) is a novel, 
third-generation, ultrashort-acting, IV dihydropyridine calcium channel blocker under 
development for the treatment of acute hypertension. Its ability to control BP compared 
with NTG or its safety has not been previously studied. These analyses are the first to 
demonstrate the relationship between CLV and NTG for the management of preoperative 
elevated BP.
Methods: Patients undergoing cardiac surgery were randomized (1:1) to CLV or NTG 
within the NTG limb of the ECLIPSE program. BP control over time was represented 
by measuring the area under the curve (AUC) for all deviations outside a prespecified 
systolic BP range. Systolic BP tolerance ranged from 75-145 mmHg in the pre- and post-
operative settings and 65-135 mmHg in the intra-operative arena.
Results: Of 548 patients enrolled in the NTG study, 270 received CLV and 278 received 
NTG. The primary safety and AUC endpoint are presented. 
BP Control Analysis
Parameter CLV(n=270)
NTG
(n=278) P-value
AUC (median mmHg x min/h) 4.14 8.87 <0.001
30-Day Primary Endpoint Analysis
Parameter CLV NTG P-value
Death 7/254 (2.8) 9/266 (3.4) 0.68
Myocardial Infarction 8/248 (3.2) 8/260 (3.1) 0.92
Stroke 4/247 (1.6) 6/260 (2.3) 0.58
Renal Dysfunction* 17/250 (6.8) 21/260 (8.1) 0.58
* Serum creatinine level ≥2.0 mg/dL and an increase from baseline of ≥0.7 mg/dL 
and/or requirement for dialysis.
Conclusion: Clevidipine was as safe as, and more effective than NTG for controlling 
hypertension in the perioperative care of cardiac surgical patients.
3:30 p.m.
1020-170 Echocardiographic Epicardial Adipose Tissue Is 
Related To High Sensitivity C-reactive Protein In 
Hypertensive Patients.
Jong Chan Youn, Sungha Park, Hye Jin Hwang, Yei Im, Hyun Joon Shin, Young-Guk Ko, 
Seok-Min Kang, Donghoon Choi, Jong-Won Ha, Yangsoo Jang, Namsik Chung, Yonsei 
University College of Medicine, Seoul, South Korea
Background: Recent studies suggest that epicardial adipose tissue (EAT) is a source 
of inflammatory mediators and may function as an endocrine organ that contributes to 
the systemic inflammatory burden. We hypothesized that in hypertensive patients, EAT 
is related with hsCRP, which has been proven to be reliable and important markers of 
cardiovascular risk.
Methods: 190 consecutive patients with treated essential hypertension (109 men, 
56±11 years) were enrolled. EAT on the free wall of right ventricle was measured from 
parasternal long- and short-axis views. Clinical variables and laboratory findings including 
hsCRP were analyzed.
Results: The thickness of EAT varied between 0.94 and 9.21 mm (3.1±1.2 mm). Patients 
with metabolic syndrome (MS) as defined by the NCEP criteria had thicker EAT compared 
to non MS hypertensive patients (3.3±1.4 vs 2.9±1.2 mm, p<0.05). EAT was significantly 
correlated with hsCRP (r=0.344, p<0.001) as well as with age (r=0.359, p<0.001), fasting 
blood sugar (r=0.218, p=0.009), brachial ankle pulse wave velocity (r=0.322, p=0.001). 
Multivariate regression analysis revealed EAT thickness to being an independent predictor 
of hsCRP (ß=0.348, p<0.001) when controlled for age, systolic blood pressure, BMI, LDL 
cholesterol, triglyceride, HDL cholesterol and HOMA index.
Conclusions: Echocardiographic EAT could be applied as an easy and reliable indicator 
of inflammatory burden and cardiovascular risk in hypertensive patients. 
3:30 p.m.
1020-171 The Effects Of Two Different Blood Pressure Control 
Strategies On Cardiac Structures And Functions In 
Hemodialysis Patients
Meral Kayikcioglu, Murat Tumuklu, Gulay Asci, Oner Ozdogan, Huseyin Toz, Devrim 
Bozkurt, Timur Kose, Soner Duman, Mehmet Ozkahya, Levent H. Can, Ali Basci, Ercan 
Ok, Ege University Medical School Cardiology Department, Izmir, Turkey, Ege University 
Medical School Nephrology Department, Izmir, Turkey
Background: Hypertension is a significant problem in hemodialysis (HD) patients. Most 
dialysis centers use anti-hypertensive drugs to control blood pressure (BP). Effective 
volume control is an alternative approach for BP lowering. In this study, we compared 
these two strategies.
Methods: This cross-sectional study included 430 patients from 2 different HD centers: 
CenterA practicing “effective volume control based” and CenterB practicing “anti-
hypertensive drugs based” strategy.“Effective volume control” was described as control 
of BP by strict salt restriction and ultrafiltration without using anti-hypertensive drugs 
and achieving a cardiothoracic index < 0.48. All patients underwent echocardiographic 
evaluation in interdialytic period.
Results: Anti-HT drug utilization was 7% in CenterA and 36% in CenterB (p<0.01); 
interdialytic weight gain was significantly lower in CenterA (2.3±0.8 vs 2.9±1.3, p<0.001, 
respectively). Similar BP control was achieved by both approaches. However CenterA, 
had lower left atrial (LA) volume and left ventricular mass index (LVMI). Frequencies of 
left ventricular hypertrophy (LVH), systolic and diastolic dysfunctions were also lower in 
CenterA.
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Conclusions: : Although similar BP control can be achieved by using anti-hypertensive 
drugs or strict volume control strategy in HD patients, strict volume control strategy is 
better in preserving cardiac functions. 
comparison of BP lowering strategies
Centers LA-Volume (ml/m2) LVH(n, %)
EF
(%)
IVRT
(msec)
DT
(msec)
DT
(msec)
A (n: 197) 29.5±10.0 108 (64) 68±10 88±19 233±63 233±63
B (n: 233) 36.7±21.6 * 168 (86) * 63±09 * 120±26 * 282±70 * 282±70 *
*p: 0.001
3:30 p.m.
1020-173 Economic Evaluation of the Anglo-Scandinavian 
Cardiac Outcomes Trial (ASCOT)-Blood Pressure 
Lowering Arm (BPLA): A Sub-study on Incremental 
Cost-Effectiveness of Amlodipine-Based Regimen vs. 
Atenolol-Based Regimen in Primary Prevention Among 
Hypertensive Patients With Additional Risk Factors
Peter Lindgren, Simon Tang, Martin Buxton, Thomas Kahan, Neil Poulter, Björn Dahlöf, 
Peter Sever, Hans Wedel, Jan Buch, Bengt Jönsson, for the ASCOT Investigators, 
European Health Economics, Stockholm, Sweden, Pfizer Inc, New York, NY
Background: The ASCOT-BPLA randomized 19,257 hypertensive patients with ≥3 
additional cardiovascular risk factors to an amlodipine + angiotensin-converting enzyme 
inhibitor (AM) or an atenolol + diuretic (AT) regimen, showing a reduction in strokes (HR, 
0.77; 95% CI, 0.66, 0.89) and any total cardiovascular events and procedures (HR 0.84; 
95% CI, 0.78, 0.90) favoring AM.
Methods: A prospective cost-effectiveness analysis was conducted. Costs for resources 
(study drug, concomitant medications, hospitalization, ambulatory visits) were estimated, 
applying medical/drug costs from the United Kingdom. The measure of effectiveness was 
the total number of cardiovascular events/procedures. Data from the intention-to-treat 
population during the trial (median 5.5 years) was used. Revascularization procedures were 
assumed to be divided between percutaneous coronary intervention (PCI) and coronary 
artery bypass grafting (CABG) according to the occurrence in the general population.
Results: Mean costs of drugs for AM and AT were 1,662 GBP and 408 GBP. The mean 
combined medical costs of outpatient visits, concomitant medications, diagnosis-related 
group costs and other related hospitalizations were 5,944 and 6,421 GBP.
Conclusion: In ASCOT-BPLA, AM proved cost-effective vs. AT in avoiding any 
cardiovascular events/procedures at a willingness-to-pay level of ≥US$ 25,000 (Table). 
This cost-effectiveness was irrespective of procedures used (PCI vs. CABG).
Table
Incremental 
cost (95% CI)
Total CV events/
procedures avoided 
(95% CI)
Incremental cost-
effectiveness ratio 
(95% CI)
AM vs. AT 
regimen
US$ 1,479 
(1,065, 1,892) 0.060 (0.041, 0.080)
US$ 24,209 (14,854, 
40,186)
AM vs. AT 
regimen (90% 
PCI)
US$ 1,551 
(1,149, 1,961) 0.060 (0.041, 0.080)
US$ 25,789 (16,156, 
42,621)
AM vs. AT 
regimen (90% 
CABG)
US$ 1,406 
(982, 1,817) 0.060 (0.041, 0.080)
US$ 23,376 (13,848, 
40,172)
GBP:US$ currency conversion based on 1 GBP ~ US$ 1.903 (http://www.xe.com/ucc). 
CI, confidence interval; CV, cardiovascular; AM regimen, amlodipine-based (+ ACE 
inhibitor) regimen; AT regimen, atenolol-based (+ diuretic) regimen; PCI, percutaneous 
coronary intervention; CABG, coronary artery bypass grafting
3:30 p.m.
1020-202 Ambulatory Blood Pressure Monitoring Improves 
The Prediction Of On-Treatment Risk In The Anglo-
Scandinavian Cardiac Outcomes Trial (ASCOT)
Eamon Dolan, Alice Stanton, David Collier, Gordon McInnes, Patrick Dicker, Simon Thom, 
Mark Caulfield, Eoin O’Brien, Cambridge University Hospitals NHS Foundation Trust, 
Addenbrook’s Hospital, Cambridge, United Kingdom, Conway Institute of Biomolecular 
and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland
Background: Baseline measurements of ambulatory blood pressure (ABP), are superior 
to clinic blood pressure measurements (CBPM) in predicting cardiovascular mortality. The 
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) has recently reported that statin 
therapy is beneficial in hypertensive patients, irrespective of baseline cholesterol level, 
and that an amlodipine based regimen prevents more major cardiovascular events than 
an atenolol-based regimen. A key aim of the ABPM sub-study of ASCOT was to assess 
the prognostic value of on-treatment ABPM
Methods: Between 6 months and 6 years post randomization to study treatments, 1909 
participants from 4 ASCOT centers, underwent repeated CBPM (median number per 
participant = 11) and ABPM (median = 3). The a priori primary end-point was a composite 
of all cardiovascular events (fatal and non-fatal, myocardial infarction and stroke) and 
procedures (angioplasty and bypass procedures) (n = 173)
Results: Using Cox proportional-hazards modeling, with adjustment for age, sex, smoking 
status, presence or absence of diabetes mellitus, serum cholesterol concentration, 
body-mass index, treatment group and CBPM, ambulatory systolic (SBP) and diastolic 
blood pressure (DBP) were independent risk factors for new cardiovascular events. The 
adjusted relative risk of cardiovascular events associated with a 1 standard deviation 
(SD) increment in ABP was 1.19 (95 percent confidence interval, 1.02 to 1.40; P<0.05) 
for daytime SBP, 1.24 (1.06 to 1.44; P< 0.01) for nighttime SBP, and 1.29 (1.10 to 1.52; 
P< 0.005) for 24-hour SBP. For DBP, the corresponding relative risks of cardiovascular 
events associated with a 1 SD increment were 1.13 (95 percent confidence interval, 0.91 
to 1.39; P=NS), 1.24 (1.04 to 1.46; P<0.05), and 1.29 (1.05 to 1.59; P<0.05) respectively
Conclusions: In treated hypertensive patients, biennial ABP measurement provides 
additional prediction of cardiovascular events to that provided by six monthly CBPM. 
Further studies are now warranted to assess if up-titration of antihypertensive therapy 
was guided by ABP, rather than CBPM, whether further reductions in cardiovascular 
morbidity and mortality could be achieved.
3:30 p.m.
1020-203 Effect of Gender and Ethnicity on Effectiveness of 
Therapeutic Lifestyle Changes in Patients With 
Prehypertension
Venkata V. Bavikati, Laurence S. Sperling, Richard D. Salmon, George C. Faircloth, Terri 
L. Gordon, Barry A. Franklin, Neil F. Gordon, Emory University, Atlanta, GA, Intervent 
Coordinating Center, Savannah, GA
Rationale: Although national clinical guidelines promulgate therapeutic lifestyle changes 
(TLC) as a cornerstone in the management of prehypertension, recent research has 
focused on the use of pharmacotherapy due to the perceived ineffectiveness of TLC.
Background: In this study of 2,478 ethnically diverse (African Americans, n = 448; 
Caucasians, n = 1,881) men (n = 666) and women (n = 1,812) with prehypertension 
who were not taking antihypertensive medications (age = 48+10 years), we evaluated 
the clinical effectiveness of TLC in normalizing their blood pressure (BP) without using 
drug therapy.
Methodology: Subjects were evaluated at baseline and after an average of 6 months 
of participation in a community-based program of TLC. At baseline, all subjects met 
the criteria for prehypertension as defined by the Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 
(JNC 7). Subjects did not have known atherosclerotic heart disease, diabetes, or chronic 
kidney disease. TLC included exercise training, nutrition, weight management, and 
smoking cessation interventions.
Results: Baseline BP (125+8/79+3 mmHg) decreased by 6+12/3+3 mmHg (p <0.001) 
with TLC. In subjects with a baseline systolic BP of 120-139 mmHg (n=2,082), systolic BP 
decreased by 7+12 mmHg (p <0.001) with TLC. In subjects with a baseline diastolic BP 
of 80-89 mmHg (n=1,504), diastolic BP decreased by 6+3 mmHg (p <0.001) with TLC. 
Based on JNC 7 criteria, 952 (39%) subjects normalized their BP with TLC (p <0.001). 
The magnitude of reduction in BP was similar in African Americans (-7+12/-5+3 mmHg) 
and Caucasians (-7+12/-6+3 mmHg). In contrast, the magnitude of reduction in BP was 
greater (p <0.001) in women (-8+12/-6+3 mmHg) versus men (-6+11/-5+3 mmHg).
Conclusions: The present study adds to previous research by reporting on the 
effectiveness (rather than the efficacy) of TLC in an ethnically diverse group of men and 
women with prehypertension. Although further research is warranted, these data show 
that while many patients with prehypertension can normalize their BP, there are gender-
related differences in BP responsiveness to TLC.
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820-3 Rosuvastatin Arrests Progression of Carotid Intima 
Media Thickness in Low-Risk Individuals: Main Results 
of the METEOR Study
John R. Crouse, III, Diederick E. Grobbee, Daniel H. O’Leary, Michiel L. Bots, Greg W. 
Evans, Michael K. Palmer, Ward A. Riley, Joel S. Raichlen, on behalf of the METEOR 
Study Group, Wake Forest University School of Medicine, Winston Salem, NC, 
AstraZeneca, Wilmington, DE
Background: Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin 
(METEOR) was an international randomized, double-blind placebo (PL)-controlled trial 
comparing the effects of daily rosuvastatin (RSV) 40 mg and PL on progression of carotid 
intima media thickness (IMT) in low-risk individuals.
Methods: METEOR studied 876 eligible asymptomatic individuals over 104 weeks (men 
45-70, women 55-70) with Framingham 10-year risk <10% but with minimal evidence of 
atherosclerosis (MaxIMT all sites; mean 1.16mm) and modest LDL-C levels (mean 154 
mg/dL). Changes in IMT were analyzed over treatment period with a multi-level, repeated-
measures, mixed-effects model using data on maximum thickness for all 12 carotid sites 
(primary endpoint), and similar data for the common carotid artery (CCA), the internal 
carotid artery (ICA) and the carotid bifurcation (bulb) (secondary endpoints).
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Results: 
RSV
n=624 (ITT)
PL
n=252 (ITT) P-value
IMT slope (mm/year)
MaxIMT all sites* -0.0014 +0.0131 <0.0001
MaxIMT CCA sites -0.0038 +0.0084 <0.0001
MaxIMT ICA sites +0.0039 +0.0145 0.023
MaxIMT bulb sites -0.0040 +0.0172 <0.0001
% change LDL-C† -48.8 -0.3 <0.0001
% change HDL-C† +8.0 +2.8 <0.0001
% change LDL-C/HDL-C† -51.2 -0.6 <0.0001
% change ApoB/ApoA-I -41.5 -4.5 <0.0001
P-values shown for between groups; *Primary endpoint; †Time-weighted average
RSV treatment arrested progression of MaxIMT all sites as well as segment-specific 
MaxIMT, while PL individuals experienced progression. IMT slope for RSV compared 
to baseline (regression) was negative (P=0.32), however for the secondary endpoint 
MaxIMT CCA regression was significant. RSV was well tolerated, with similar % AEs 
leading to discontinuation (RSV 11.1%, PL 7.8%).
Conclusion: RSV 40 mg arrested carotid IMT progression over 2 years. METEOR results 
demonstrate that RSV treatment can beneficially affect the atherosclerotic process even 
in very-low-risk asymptomatic individuals.
4:15 p.m.
820-4 Intensive Lowering of the LDL-C/HDL-C Ratio With 
High Dose Statin Therapy Promotes Regression of 
Obstructive Coronary Artery Disease: Insights From 
ASTEROID
Adam W. Grasso, Stephen J. Nicholls, Tingfei Hu, Ilke Sipahi, Joel S. Raichlen, Valerie 
A. Cain, E. Murat Tuzcu, Sorin J. Brener, Steven E. Nissen, The Cleveland Clinic, 
Cleveland, OH
Background: Statins attenuate progression of angiographic coronary artery disease 
(CAD). ASTEROID reported that intensive lipid lowering with high dose rosuvastatin 
promoted plaque regression, measured by intravascular ultrasound. This study 
investigated the relationship between changes in lipid parameters and progression of 
angiographic CAD in ASTEROID.
Methods: The relationship between lipid parameters and changes in the extent of CAD 
was investigated in 382 patients who underwent serial quantitative coronary angiography 
before and while receiving treatment with rosuvastatin 40mg daily for 24 months.
Results: Rosuvastatin therapy resulted in a 51.8% reduction in LDL-C, a 12.4% elevation 
in HDL-C, and a 56.2% reduction in the LDL-C/HDL-C ratio from 3.2 to 1.3. There was a 
small decrease in average minimum lumen diameter (%ΔMLD) from baseline to follow-
up (2.24 mm to 2.21 mm, P<0.001), and a small increase in average percent diameter 
stenosis (%ΔS) from 18.1% to 18.7%, P=0.003. Subjects with on-treatment LDL-C 
< median (56 mg/dL) experienced less progression than those with LDL-C ≥ median 
(%ΔMLD of -0.2% v -0.6%, P=0.009; %ΔS of +0.8% v +1.3%, P=0.13). Patients with 
on-treatment HDL-C > median (45 mg/dL) also experienced less progression than those 
with HDL-C ≤ median (%ΔMLD of -0.3% v -0.5%, P=0.05; %ΔS of 0% v +2.4%, P=0.008). 
A direct relationship was observed between changes in angiographic parameters and 
the LDL-C/HDL-C ratio on treatment, with subjects in the lowest quartile (<0.89) having 
evidence of regression (median %ΔMLD of +0.28% and -0.95% in the low and high 
quartiles, P=0.002; median %ΔS of -0.87% and +3.66% in these quartiles, P=0.03). 
Regressors and non-regressors showed significant differences for baseline HDL-C, and 
for on-treatment HDL-C and the LDL-C/HDL-C ratio.
Conclusion: Intensive modification of lipid levels with high dose rosuvastatin had a 
beneficial impact on the rate of angiographic progression. Discordance between changes 
in angiographic and ultrasonic parameters likely reflects remodeling, and requires further 
investigation. Achieving very low levels of the LDL-C/HDL-C ratio can result in regression 
of obstructive CAD.
4:30 p.m.
820-5 MRC/BHF Heart Protection Study (HPS): Mortality, 
Cancer Incidence and Major Vascular Events During 4 
Years Post-trial Follow-up of HPS
Richard Bulbulia, Louise Bowman, Karl Wallendszus, Sarah Parish, Jane Armitage, 
Rory Collins, Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom
Background: During the scheduled treatment period of HPS, 20,536 patients at 
increased vascular risk were allocated 40mg simvastatin or matching placebo. An 
average 1.0 mmol/L reduction in LDL cholesterol maintained for around 5 years produced 
relative reductions in major vascular events (MVE) of 24% and in all-cause mortality of 
13%, chiefly driven by a 17% reduction in vascular deaths. The absolute benefits on 
MVE increased year-on-year, suggesting that more prolonged treatment might result in 
larger benefits. There were no adverse effects on non-vascular mortality or cancer during 
the “in-trial” period, although prolonged “post-trial” observation is required to detect any 
delayed deleterious effects.
Methods: 4 years “post-trial” follow-up of all 17,519 surviving participants for non-fatal 
events reported by participants in mailed annual questionnaires (80% response rate) or 
via primary care physicians, supplemented with cause-specific mortality and site-specific 
cancer incidence via central registries.
Results: During 4 years of follow-up after the scheduled treatment period, statin use 
and lipid levels were similar in the groups previously allocated simvastatin or placebo. 
During this post-trial period there were 1746 vascular and 1433 non-vascular deaths, and 
1444 cancers. There were no significant differences in: vascular deaths (9.8% previously 
allocated simvastatin vs 10.1% previously allocated placebo; RR 0.97 [95% CI 0.89 - 
1.07]); non-vascular deaths (8.1% vs 8.2%; RR 0.99 [0.89 - 1.09]); or cancers (8.2% vs 
8.3%; RR 0.98 [0.89 - 1.09]). Analyses of about 3500 MVEs will be reported.
Conclusions: The achieved survival benefit associated with an average of 5 years 
allocation to simvastatin is maintained after treatment stops. No adverse effects on 
cancer incidence or non-vascular mortality were seen in this extended follow-up. Further 
analyses of the much larger numbers of MVEs, for which larger benefits were observed 
during the treatment period, allows more reliable assessment of the persistence of 
benefits. These findings support the prompt initiation and continuation of statin therapy in 
individuals at increased vascular risk.
4:45 p.m.
820-6 Evidence for Cholesterol Hyperabsorbers and 
Hyperproducers Based on Comparative LDL 
Reductions Achieved by Ezetimibe Versus Statins
Janek Senaratne, Jo Griffiths, Karen MacDonald, Christine Simpson, Brian Wirzba, 
Manohara P. J. Senaratne, Grey Nuns Hospital-University of Alberta, Edmonton, AB, 
Canada
Background: Blood cholesterol comes from endogenous production (inhibited by statins - 
STA) and intestinal absorption of dietary/biliary cholesterol (inhibited by ezetimibe - EZE). 
It has been postulated that some individuals may be hyperproducers of cholesterol while 
others hyperabsorbers. The present study investigated this hypothesis by comparing the 
LDL reduction to STA versus EZE.
Methods: Consecutive patients (Pts) who received STA monotherapy followed by EZE/STA 
combination therapy were included. Data was collected prospectively and entered into a 
SPSS database. The percent LDL reductions by STA and EZE were correlated. In addition, 
the expected LDL levels for each Pt on STA and on EZE/STA therapy were calculated using 
the expected mean percent LDL reductions reported in the Physician’s Desk Reference for 
EZE and for the STA dosage used. The difference between expected and actual LDL levels 
on STA and on EZE/STA was calculated for each Pt and correlated.
Results: There were 109 Pts - age = 58.3 ± 1.0 yrs (mean ± SEM); male = 88 (80.7%); 
female = 21 (19.3%); diabetes = 15 (13.8%); hypertension = 49 (45.0%); smokers = 48 
(44.0%); weight = 86.7 ± 1.8 kg; BMI = 29.6 ± 0.5 kg/m2. The total cholesterol, LDL, HDL, 
and triglycerides were respectively (in mmol/L): Baseline - 6.33 ± 0.11, 4.33 ± 0.09, 1.09 
± 0.02, and 1.94 ± 0.07; on STA - 4.38 ± 0.09, 2.67 ± 0.07, 1.03 ± 0.02, and 1.48 ± 0.06; 
on EZE/STA - 3.46 ± 0.08, 1.90 ± 0.06, 0.98 ± 0.02, and 1.29 ± 0.05. STA reduced LDL by 
36.7 ± 1.5% while adding EZE resulted in a further reduction of 28.1 ± 1.4%. The percent 
LDL reduction by STA was negatively correlated to the percent reduction by EZE (r = 
- 0.29, p = 0.002). Linear regression analysis of the same revealed a slope of - 0.32 (p = 
0.002). The difference between expected and actual LDL levels on STA was negatively 
correlated to that on EZE/STA (r = - 0.38, p < 0.001). Regression analysis: slope = - 0.59 
(p < 0.001).
Conclusion: The magnitude of the additional LDL reduction by EZE appears to be 
inversely correlated to the reduction by STA. This suggests that some Pts may be 
hyperabsorbers while others may be hyperproducers. Thus, one could expect a favourable 
response to EZE in Pts with a less than expected response to the initial dose of STA.
5:00 p.m.
820-7 ISIS 301012, an Antisense Inhibitor of Apolipoprotein 
B, Produces Significant Additional Reduction of LDL-C 
and Apolipoprotein B in Hypercholesterolemic Subjects 
on Statins not Meeting Target
John Kastelein, Fatima Akdim, Mieke Trip, Eric Sijbrands, J. Wouter Jukema, JoAnn 
Bradley, Mark Wedel, John Su, Emil Chuang, Evan Stein, Frank Visseren, Academic 
Medical Center, Amsterdam, The Netherlands, Isis Pharmaceuticals, Inc., Carlsbad, CA
Background: The objective of this study is to determine safety and efficacy of ISIS 
301012, an antisense inhibitor of apoB, in hypercholesterolemics already on moderate, 
stable doses of statin monotherapy, but failing to meet their LDL-C target.
Methods: This is a double-blind, randomized, placebo-controlled, dose escalation study 
in 50 subjects on a stable dose of atorvastatin or simvastatin (≤ 40 mg/day) and baseline 
LDL-C between 100 and 220 mg/dL. Subjects (10 per dose group) were randomized 4:1 
to receive 30, 100, 200, 300 or 400 mg/dose of ISIS 301012 or placebo, respectively. 
Study drug was administered by s.c. injection using a loading regimen in the first week (3 
doses) followed by once weekly doses for 3 more weeks.
Results: Data (median % change from baseline) from the first 4 cohorts are shown. 
Marked reductions in LDL-C and apoB were observed at doses ≥ 200 mg, with negligible 
changes in the placebo group. Non-HDL cholesterol was reduced by 47 % in the 300 
mg cohort. Results are dose-dependent. The most common adverse event was mild, 
painless erythema at injection sites. One subject displayed an isolated ALT >3x ULN 30 
days after last dose. No serious adverse events occurred. 
Placebo 30 mg 100 mg 200 mg 300 mg 400 mg
LDL-C - 4 5 - 18 - 13 - 51 ongoing
apoB - 5 - 1 - 10 - 22 - 53 ongoing
Non-HDL-C - 5 5 - 16 - 12 - 47 ongoing
(interim data at day 36)
Conclusion: ISIS 301012 had a satisfactory safety profile and produced significant lipid 
reduction when administered in combination with statins. Greater LDL-C and apoB 
reductions are anticipated in the 400 mg dose group which is currently being enrolled. 
Final data will be presented at the meeting.
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820-8 Long-Term Effects of Niacin-Simvastatin 
Combination Compared to High Dose Simvastatin 
on Lipids, Apolipoproteins, Lipoprotein Particles 
and Inflammatory Markers in Patients with Carotid 
Atherosclerosis
Subha L. Airan-Javia, Megan L. Wolfe, Ronald L. Wolf, Emile R. Mohler, III, Daniel J. 
Rader, Muredach P. Reilly, University of Pennsylvania, Philadelphia, PA
Background: Low HDL levels, regardless of LDL levels, are strong predictors of 
cardiovascular events. While studies have shown that combination statin and niacin 
therapy provides greater lipid modification than either drug alone, there is sparse data 
on the longer-term effects of this combination, the comparison with high-dose statins, or 
effect on lipid subclasses and inflammatory markers.
Methods: In a 12 month double-blind 3-arm trial of Simvastatin 20mg/Placebo (S20; 
N= 25), Simvastatin 80mg/Placebo (S80; N=24) or Simvastatin 20mg/Niacin ER 2G 
(S/N; N=26), of patients with carotid atherosclerosis (age 71; 72% male; 62% on statin 
at enrollment, baseline LDL 110 mg/dL; HDL 42 mg/dL), effects on fasting plasma 
lipoproteins, lipoprotein particles (NMR) and inflammatory markers were examined. 
Analysis of variance was performed on the between group differences in change in lipids 
and biomarkers at 12 months.
Results: S/N (-38%) and S80 (-31%) had similar effects on LDL and both had greater effects 
than S20 (-3%, p<0.001 vs S/N p=0.04 vs S80). S/N had greater effects on triglycerides 
(TG) (S/N -27%; S80 -2%; S20 +6%; p=0.003), apoB (S/N -34%, S80 -17%, S20 +4%; 
p<0.001) and small, dense LDL particles (S/N -50%; S80 -22%; S20 +3%; p<0.001). S/N 
raised HDL-C (24%) to a greater extent than S80 (4%, p=0.001) and S20 (0%, p<0.001) 
but, like S80 and S20, S/N had no effect on apoA-I levels. However, S/N increased the 
number of large HDL particles (S/N 55%; S80 12.5%; S20 1%; p=0.002). In addition, S/N 
lowered Lp(a) (S/N -6%; S80 4%; S20 3%; p<0.001) and plasma PAI-1 levels (S/N -14%; 
S80 +7%; S20 +30%; p=0.045) but had no effects on other inflammatory markers.
Conclusions: The combination of Niacin ER 2G and Simvastatin 20mg not only achieved 
similar LDL lowering as Simvastatin 80mg, but induced a much greater increase in HDL 
and decreases in apoB levels, small LDL particles, Lp(a) and PAI-1. Future studies are 
warranted to evaluate the effect of this combination, compared to high dose statins, on 
atherosclerotic CVD.
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651-5 Low Levels of Paraoxonase Activity are Associated with 
Systemic Oxidative Stress, Extensive Coronary Artery 
Disease and Need for Coronary Revascularization
Tammy Bhattacharyya, Stephen J. Nicholls, Stephen G. Ellis, Xia Yang, Hooman 
Allayee, Eric J. Topol, Aldons J. Lusis, Stanley L. Hazen, Cleveland Clinic, Cleveland, 
OH, University of California Los Angeles, Los Angeles, CA
Background: Paraoxonase (PON) is an HDL-associated esterase/lactonase with reported 
atheroprotective properties. The relationship between PON activity and genotype with 
indices of systemic oxidative stress, extent of coronary artery disease (CAD) and need 
for revascularization has not been fully elucidated in humans.
Methods: In 1,402 sequential subjects undergoing diagnostic coronary angiography 
the relationship between PON and arylesterase activity and PON genotypes with levels 
of oxidized fatty acids determined by mass spectrometry, extent of CAD and need for 
coronary revascularization was studied.
Results: Subjects with the lowest tertile of paraoxonase activity and the PON1 Q192R 
genotype had the highest systemic levels of oxidized fatty acids (P<0.001 for all analytes). 
Angiography revealed CAD in 87%, significant stenosis (>50%) in 72% and extensive 
disease (Duke score >42) in 36%. Subjects with CAD had lower levels of PON (1102+/-22 
v 1346+/-73 nmol/mL, p<0.001) and arylesterase (340+/-3 v 383+/-8 umol/mL, P<0.001) 
activity. On multivariate analysis, subjects with the lowest quartile of PON (OR 1.9 (2.3-
2.9), P<0.001) and arylesterase (OR 2.9 (1.7-4.9), p <0.001) activity were more likely to 
have significant obstructive disease (stenosis >50%). Subjects with the lowest quartile 
of PON (OR 1.6 (1.2-2.2), P<0.01) and arylesterase (OR 2.3 (1.6-3.1), P<0.001) activity 
were more likely to have extensive angiographic disease (Duke score >42). Subjects with 
the PON1 Q192R (OR 1.1 (0.9-1.3), P=0.60) and PON2 C311S (OR 0.9 (0.6-1.1), P=0.33) 
mutants were no more likely to have CAD than wild type. Subjects expressing the A99A 
mutant of PON3 were more likely to have a stenosis >50% (OR 1.6 (1.4-1.8), P<0.001). 
The highest rate of revascularization was observed in subjects with the lowest quartile of 
PON (OR 1.4 (1.1-1.7), P<0.05) and arylesterase (OR 1.4 (1.1-1.7), P<0.05).
Conclusion: Both biochemical and genetic indices of reduced PON activity are 
associated with increased oxidative stress, more extensive CAD and a greater need for 
revascularization. These results provide a mechanistic link whereby PON may contribute 
to the ability of HDL to prevent atherosclerotic CAD.
ACC.ORAL CONTRIBUTIONS
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832-3 Chronic Treatment With Folic Acid Improves 
Nitric Oxide Bioavailability And Decreases 
Superoxide Production In Human Vessels, Through 
Tetrahydrobiopterin-Mediated Improvement Of eNOS 
Coupling
Charalambos A. Antoniades, Cheerag Shirodaria, Justin Lee, Mark Carptree, Chandi 
Ratnatunga, Ravi Pillai, Stefan Neubauer, Keith Channon, University of Oxford, Oxford, 
United Kingdom
Background. Folic acid lowers homocysteine and improves endothelial function, but its 
direct effects on vascular function are unclear. We hypothesized that treatment with folic 
acid may affect endothelial function and superoxide (O2-) production in human vessels 
through an improvement of tetrahydrobiopterin (BH4)-mediated eNOS coupling.
Methods. In a double-blind placebo controlled study, 54 patients with CAD received 
folic acid 5mg/d (n=20) or 400µg/d (n=20) or placebo (n=14) for 6 weeks before CABG. 
Vasomotor responses to acetylcholine (ACh) were evaluated in SV segments harvested 
during CABG. Vascular O2- production was determined in the presence and absence 
of eNOS inhibitor LNAME by lucigenin chemiluminescence. Vascular biopterins were 
determined by HPLC.
Results. Vasomotor responses to ACh were improved in both 5mg/d and 400 µg/d 
compared with placebo (Fig a). Vascular O2- was lower in SV and IMA of patients treated 
with folic acid 400μg/d (1.6±0.2 and 1.6±0.3 RLU/sec/mg) or 5mg/d (1.6±0.3 and 1.7±0.2 
RLU/sec/mg) compared to placebo (2.5±0.3 and 3.4±0.9 RLU/sec/mg, p<0.05 vs both 
treated groups). Folic acid reversed the LNAME inhibitable O2- in IMA (Fig b), in parallel 
with increased vascular BH4 levels (Fig c).
Conclusions. In a population without folate suplementation, even low-dose folic acid 
decreases O2- production and improves NO bioavailability in vessels from patients with CAD. 
These effects are partly due to increased BH4 bioavailability and improved eNOS coupling. 
7:15 a.m.
832-4 Endothelial Progenitor Cells do not Incorporate into 
New Vessels but Indirectly Augment Angiogenesis: 
Insights From a Novel In Vitro Human Angiogenesis 
Assay
Daniel Sieveking, Andrew Buckle, David Celermajer, Martin K.C. Ng, Heart Research 
Institute, Sydney, Australia, Royal Prince Alfred Hospital, Sydney, Australia
Endothelial Progenitor Cells (EPCs) promote revascularization of ischemic tissue. Owing 
to the inability of in vivo studies to resolve the cellular relationships between EPCs and 
new vessels, it remains debated as to whether EPCs incorporate into new vessels or 
augment neovascularization in a paracrine fashion. We report a novel, endothelial cell 
(EC) specific, in vitro angiogenesis assay that overcomes the caveats of matrigel-based 
methods, permitting more accurate assessment of the role of EPCs in angiogenesis.
Tubulogenesis was assessed by co-culture of differentiated ECs (including Human 
Umbilical Vein Endothelial Cells (HUVECs), Human Coronary Artery Endothelial Cells 
(HCAECs) or Human Microvascular Endothelial Cells (HMVECs)) with a pre-formed 
monolayer of human fetal lung fibroblasts (MRC5). Tubules were visualized using EC 
specific markers (von Willebrand factor, CD31) and assessed using image analysis 
software (Image J). The tubulogenic capacity of human DiI-AcLDL+/Ulex lectin+ EPCs 
(tagged with a non-transferable fluorescent dye) was assessed in co-culture with MRC5 
cells with and without HUVECs using 3D immunofluorescence microscopy.
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Branched interconnecting EC-specific tubules formed with all differentiated ECs after 
72 hours. Addition of both pro-, and anti-angiogenic agents modulated tubule formation 
appropriately (VEGF 5ng: +120% ± 10% and 1μM Anti-VEGF: -44% ± 7% versus control 
as 100% respectively, P < 0.001) Blinded inter-observer error for image analysis was 
5.7%. EPCs, along with hepatocytes and smooth muscle cells, failed to form tubules when 
cultured in isolation with fibroblasts even after 14 days culture. When cultured with equal 
concentrations of HUVECs, EPCs enhanced the degree of tubule formation (166% ± 6% 
versus HUVECs + MRC5s alone P < 0.001), yet failed to incorporate into EC tubules.
This novel angiogenesis assay provides a simple, reproducible and powerful in vitro 
method to assay endothelial cell-specific tubulogenesis. EPCs neither form tubules nor 
incorporate into EC derived tubules but appear to augment angiogenesis in a paracrine 
fashion, with implications for clinical applications of cell therapies for angiogenesis.
7:30 a.m.
832-5 Short Term Treatment With ApoAI Milano Induces 
Atherosclerotic Plaque Regression, and Signs of 
Plaque Stabilization. In Vivo MRI Study.
Borja Ibanez, Gemma Vilahur, Antonio Pinero, Walter S. Speidl, Giovanni Cimmino, M 
Urooj Zafar, Brian G. Choi, Gregg Goldschlagger, Valentin Fuster, Juan J. Badimon, 
Mount Sinai School of Medicine, New York, NY
Background: ApoAI-Milano is a mutant form of ApoAI that has shown to regress 
established atherosclerotic (AT) lesions in humans after 5 weeks of treatment. Magnetic 
Resonance Imaging (MRI) is an accurate non-invasive tool to sequentially monitor 
changes of AT plaques. The aim of this study was to investigate the effects of short-term 
administration of recombinant Apo AI-Milano (rApoAI-M) on lesion volume in a rabbit 
model of experimental AT, as well as protein expression at the vascular level.
Methods: AT lesions were experimentally induced in rabbits (n=22) by a combination of 
9-months of atherogenic diet plus 2 aortic balloon denudations. MRI images (T2W and 
PDW) were acquired using a 1.5T MRI system (Siemens) by scanning 33 consecutive 
abdominal aorta segments (3 mm thickness, no gap) at baseline. Thereafter, animals 
were randomized into rApoAI-M (ETC-216; Pfizer): 2 i.v injections (75mg/Kg) at days 0 & 
7, or placebo. Seven days after second dose, another MRI was performed. Ten animals (5/
group) were sacrificed inmediately. The 10 most diseased segments of each animal were 
selected to analyze the change of plaque-volume (a total of 220 segments were analyzed, 
110 per group). Inflammation was analyzed in the aortic wall by Western-blot.
Results: Both groups showed similar mean plaque volume at baseline: 29.9±0.6 in 
rApoAI-M vs 30.1±0.5 mm3 in placebo (p=NS). Short term rApoAI-M treatment induced 
a 4.7% decrease in plaque volume (p=0.002 vs baseline) compared to 3.3% increase in 
placebo (p=NS) resulting in a difference of 8.4% (rApo AI-M 28.5±0.5 mm3 vs 31.1±0.6 
mm3 in placebo; p=0.006).
Levels of COX-1 were similar in both groups. In contrast, the expression of COX-2 
was significantly lower in rApoAI-M treated rabbits compared to placebo (p=0.04). 
Histological analysis is ongoing.
Conclusions: Our data show that short term treatment (2 doses) with rApoAI-M induces a 
significant (8.4%) regression of established atherosclerotic plaques and an enhancement 
of plaque stabilization in the rabbit model of atherosclerosis, suggesting that interventions 
directed towards raising HDL, may have a dual effect by not only facilitating regression of 
AT lesions but also by changing them into a more “stable” type of lesion.
7:45 a.m.
832-6 Sumative Effect of ALT-711 And Exercise in Improving 
Age-Related Arterial Stiffness, Myocardial Dysfunction 
and Ventricular-Vascular (VV) Coupling
Alexandre M. Benjo, Huon Tran, Anthony R. White, Laxmi Pellakuru, Gaurav Gupta, 
Sungwoo Ryoo, Lakshmi Santhanam, Joao PL Daher, Craig Lussman, Dan Nyhan, 
Gary Gerstenblith, Artin Shoukas, Benjamin Levine, Dan E. Berkowitz, Johns Hopkins 
Hospital, Baltimore, MD
Background: Advanced glycation end-products (AGE) are important in cardiovascular 
(CV) disease in elderly and diabetics. Moreover, exercise itself alters both ventricular and 
vascular compliance, though this may be limited by advanced age.
Methods: We hypothesized that an AGE-crosslink broker, ALT-711 1mg/kg/day (A, N=6), 
4 weeks of treadmill exercise (E, N=8) or both (AE, N=7) would improve CV function in 
aged rats (O=24months) as measured by Pulse Wave Velocity (PWV), aortic endothelial 
function (EF), PV loops, NO, and eNOS and phosphorylated (P)eNOS expression. We 
also followed a 6 month young (Y) control cohort.
Results: EF, NO, eNOS and (P)eNOS were decreased in O vs Y (P<0.05). PWV was 
increased in O vs Y (P<0.05). End-systolic elastance (Ees), dP/dt, end-diastolic pressure 
volume relationship (EDPVR) and tau were impaired in O vs Y (P<0.05 values). AE 
significantly improved EF responses to Ach in O and also increased NO and (P)eNOS. 
While both A and E significantly and independently decreased PWV in O (5.3+/-0.5, 
5.2+/-0.8 vs. 7.2+/-0.6m/sec; p<0.005 for each); combined AE decreased PWV closer to 
the Y phenotype (4.6+/-0.5 vs 3.8+/-0.3m/sec) (Figure). Combined AE also significantly 
improved parameters of contractility (dP/dt, Ees) and relaxation (EDPVR) and tau in O 
more than did A or E alone.
Conclusion: These data suggest that AGE contribute to age-related CV disease and 
impaired ventricular function. VV coupling abnormalities with aging can be reversed by 
ALT-711 in combination with exercise. 
8:00 a.m.
832-7 Vascular Stiffness is Attenuated by Arginase Inhibition 
in Aged Rats
Alexandre M. Benjo, Anthony R. White, Sungwoo Ryoo, Hyun Lim, Gaurav Gupta, 
Mirinda Anderson, Laxmi Pellakuru, Artin Shoukas, Gary Gerstenblith, Daniel Nyhan, 
Dan E. Berkowitz, Johns Hopkins Hospital, Baltimore, MD
Background: Age related vascular stiffness (VS) is independently associated with adverse 
outcomes and seems to relate to changes in nitric oxide (NO) signaling. We demonstrated 
that Arginase (Arg) regulates endothelial NO, that it is upregulated with age and that Arg 
inhibition restores ex vivo NO signaling and endothelial function in old rats’ vessels. We 
hypothesized that Arg inhibition can decrease age-related VS in vivo.
Methods: 24 months rats were implanted with osmotic pumps with specific Arg inhibitor 
S-2-boronoethyl-L-cysteine (O) or placebo (C) for 1 month; a young (Y) cohort, 6 months, 
received placebo. VS was determined pre and post-treatment by pulse wave velocity 
(PWV) with an ECG triggered 10 MHz Doppler (Indus Instr). Colorimetric determination 
of urea in aortic tissue was used to quantify Arg activity. Data were analyzed with paired 
t-tests and one-way and repeated ANOVA (GraphPad Prism 4).
Results: Vascular Arg activity was significantly higher in C compared to Y (532±31.85 vs. 
427±11.87, p<0.001); however, in O animals, vascular Arg activity was similar to Y (429±9.45). 
Otherwise PWV was significantly higher (~2 fold) in C vs. Y and Arg inhibition significantly 
decreased PWV in O indicating that Arg is a modulator of VS in old rats (Figure 1).
Conclusions: Arg inhibition decreases VS associated with the aging, as measured by 
PWV, most likely by a NO dependent mechanism. This has important implications for 
therapies to improve vascular compliance and ventricular-vascular coupling in aging. 
8:15 a.m.
832-8 Could Anti-peptides For Vascular Endothelial Growth 
Factor And Receptor Reduce The Neointima Formation 
In Balloon-injury Carotid Model In Rat?
Jong-Min Lee, Keon-Woong Moon, Ki-Dong Yoo, Hee-Jeong Yoon, Sung-Ho Her, 
Seung-Won Jin, Chul-Soo Park, Hee-Yeol Kim, Doo-Soo Jeon, Wook-Sung Chung, 
Chul-Min Kim, Ki-Bae Seung, Daejeon St’s Mary Hospital, The Catholic University of 
Korea, Daejeon, South Korea
Background: Vascular endothelial growth factor (VEGF) is a potent endothelial cell-
specific mitogen, which enhances vascular permeability and stimulates angiogenesis. 
However, it is not known whether anti-peptides can reduce neointima formation in cases 
of vascular injury. This study was undertaken to test the hypothesis that anti-VEGF 
peptides could reduce the neointima hyperplasia induced by balloon injury.
Methods: Antipeptides for VEGF (dRK6) and VEGF receptor-1 (anti-flt-1) were 
synthesized. Male Sprague-Dawley rats, weighing 300-350 g, were divided three groups 
and then phosphate buffer or 0.5 mg/kg of dRK6 or 0.5 mg/kg of anti-flt-1 injected 
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subcuatenously 2 days before carotid balloon-injury and then injected daily for a period 
of 2 weeks.
Results: Neointima formation was suppressed in both the dRK6 and anti-flt-1 treatment 
groups versus untreated controls at 2 weeks post carotid balloo-injury (neointimal area ; 
control group 0.44 ± 0.09 mm2, dRK6 group 0.25 ± 0.05 mm2, anti-flt-1 group 0.19 ± 0.05 
mm2, P<0.01). Anti-flt-1 peptide and dRK6 reduced the number of proliferative BrdU-
labeled cells in the neointima (BrDU (+) cell ; control group 16.4 ± 10.6%, dRK6 group 
3.7 ± 2.1%, anti-flt-1 group 5.9 ± 3.4%, P<0.05). VEGF and VEGFR-1 expression were 
increased in the neointima of controls after balloon injury, but dRK6 and anti-flt-1 both 
inhibited VEGFR-1 expression. In addition, inflammatory response, such as monocyte 
chemoattractant protein-1 (MCP-1) and interleukin (IL-6), was evident in controls, but 
inhibited in both dRK6 and anti-flt-1 treatment group.
Conclusions: Anti-peptides for vascular endothelial growth factor and receptor reduced 
the inflammation and therefore neointima formation in balloon injured rat carotid arteries. 
Anti-peptides for vascular endothelial growth factor and receptor reduced the inflammation 
and therefore neointima formation in balloon injured rat carotid arteries.
ACC.ORAL CONTRIBUTIONS
833 
Prediction of Cardiovascular Disease
Tuesday, March 27, 2007, 7:00 a.m.-8:30 a.m.
Room 275-276-277
7:00 a.m.
833-3 Glycemic Control Associated with Reductions in 
Myocardial Infarction and Coronary Artery Bypass 
Graft
JoAnne M. Foody, Wenhui Wei, Yun Wang, Joseph E. Thomas on behalf of the 
GlucoHeart Study Team, Section of Cardiovascular Medicine, Yale University School of 
Medicine, New Haven, CT, sanofi-aventis US, Bridgewater, NJ
Background: The association of glycemic control with CV events in diabetic patients 
is not well understood. We sought to determine the relationship between glycemic 
control and subsequent cardiovascular events in a sample of 69,418 diabetics from a US 
managed healthcare population in which A1c levels were available.
Methods: Retrospective data were obtained from the Integrated Health Care Information 
System database. Diabetic patients were assessed 6 months prior to index A1C (I-A1C) 
and followed for the occurrence of acute myocardial infarction (AMI) or coronary artery 
bypass graft (CABG) surgery (at mean follow up of 27 months). 
Results: Patients were 54% male, mean age 57y, and I-A1C 7.6%. Cox proportional 
hazards regression, adjusting for demographics, comorbidity and medications, at 
baseline, showed I-A1C was related to AMI/CABG (incidence rate = 1.32, 1.61, 1.93, & 
1.88 per 1000 patient years), in 4 I-A1C groups: <6%, 6-7%, 7-9% and >9% respectively. 
I-A1C < 6% trended toward lower risk of AMI/CABG and I-A1C < 7% was associated 
with significant risk reduction compared to more poorly controlled patients. Compared to 
<6% group, AMI hazard risk elevated 33% in 7-9% (p<0.001) and 57% (p<0.001) in >9% 
group, similar in CABG (38%, p<0.001; 56%, p<0.001). Subgroup analysis excluding 
prior AMI/CABG showed almost identical survival pattern.
Conclusions: Glycemic control is related to the risk of AMI and CABG. Treating to lower 
A1c target may reduce the risk of AMI and CABG in patients with diabetes. 
7:15 a.m.
833-4 Serum Myeloperoxidase Levels Are Associated with the 
Future Risk of Coronary Artery Disease in Apparently 
Healthy Individuals
Marijn C. Meuwese, Matthijs Boekholdt, Stanley L. Hazen, Robert Schaub, Nicholas 
E. Day, Robert Luben, Erik S. Stroes, Kay-Tee Khaw, Academic Medical Center, 
Amsterdam, The Netherlands, Cleveland Clinic Foundation, Cleveland, OH
Background: Myeloperoxidase (MPO) mediates a wide array of pro-atherogenic 
effects, including induction of oxidative damage to LDL and HDL, reduction of nitric 
oxide bioavailability, and development of vulnerable plaque. Recent studies highlight the 
prognostic value of MPO as an independent predictor of adverse outcomes in patients 
with history of chest pain or suspected acute coronary syndrome. In the present study we 
evaluated whether elevated serum MPO levels in apparently healthy individuals predict 
increased risk for future development of coronary artery disease (CAD). 
Methods: : MPO was determined by ELISA (PrognostiX, Cleveland, Ohio, USA) in 
baseline serum samples of a case-control study nested in the EPIC-Norfolk study, a 
community-based prospective population study (n=25,663) of apparently healthy men 
and women at intake between 40 and 79 years old. Cases (n=1,138) developed CAD 
during 6-year follow-up. Controls (n=2,237) matched for age, gender and enrollment time, 
remained free of CAD.
Results: MPO levels were significantly higher in cases than controls (p<0.001) and 
correlated with CRP (ρ=0.25, p<0.001) and white blood cell count (ρ=0.33, p<0.001). Risk 
of future CAD increased in consecutive quartiles of MPO concentration, with an odds ratio 
(OR) of 1.49 in the top vs. bottom quartile (95% CI: 1.20-1.84, p for linearity=0.001). After 
adjustment for traditional risk factors the OR in the top quartile remained significant at 1.36 
(95% CI: 1.07 -1.73). Elevated MPO levels (>600 pM) similarly predicted increased risk of 
future CAD among subjects with either LDL < 130 mg/dL, HDL > 50 mg/dL, or CRP < 2.0 
mg/L (OR(95% CI): 1.77(1.24-2.53), 1.57(1.26-1.97), or 1.24(1.00-1.53), respectively).
Conclusions: Elevated MPO levels predict future risk of CAD in apparently healthy 
individuals. These studies support the notion that inflammatory activation precedes the 
onset of cardiovascular events by many years.
7:30 a.m.
833-5 An International Risk Prediction Model for Recurrent 
Cardiovascular Events in the REACH Registry
Peter W.F. Wilson, Deepak L. Bhatt, Jean Dallongeville, Ralph D’Agostino, Kim Eagle, 
Shinya Goto, Philip Greenland, Alan T. Hirsch, Chiau-Shuong Liau, E. Magnus Ohman, 
Joachim Rother, Christopher Reid, Jean-Louis Mas, P. Gabriel Steg, on behalf of the 
REACH Registry Investigators; Emory University School of Medicine, Atlanta, GA
Background: The capability of cardiovascular (CV) risk factors to predict recurrent CV 
events in a “real world” setting is not well characterized. The REduction of Atherothrombosis 
for Continued Health (REACH) Registry provides a global, well-defined, outpatient 
population with known CV disease.
Methods: A prediction model was developed based on 18,802 men and 9,430 women 
with known CV disease (CAD, CVD and/or PAD) at entry from N. America/W. Europe, 
and for whom full baseline and 1-year data were available. At 1 year, 709 CV events (CV 
death, MI, stroke) in men and 417 in women were reported. A single sex-adjusted model 
is shown since results were similar in separate sex models.
Results: (Table) Statin therapy, number of vascular beds affected, diabetes, smoking, 
cardiac failure and history of CV event(s) <1 year were significantly associated with 
next CV event (c-statistic=0.67, Hosmer-Lemeshow [H-L] chi square 4.06, denoting 
good calibration). We used those variables to predict next CV events in 15,675 REACH 
subjects living outside N. America/W. Europe (c-statistic=0.66 both sexes and H-L chi 
square 23.2, showing less effective calibration). Conclusion: This prediction model is the 
first to estimate risk for recurrent CV events in outpatients. Risk factors, burden of disease 
and treatment are all related to increased risk for a subsequent CV event.
Table. Multivariable-adjusted hazard ratios and p values for the variables considered in 
the developmental data set 
Variable (unit) HR per unit p value
Gender (male) 1.02 0.7087
Age (year) 1.03 <0.0001
Smoking (current vs other) 1.42 <0.0001
Diabetes (y/n) 1.60 <0.0001
Number of vascular beds (CAD,CVD,PAD) (1, 2, or 3) 1.00, 1.20, 1.44 0.0013
CV event in past year (y/n) 1.47 <0.0001
Cardiac failure (y/n) 1.78 <0.0001
Statins (y/n) 0.72 <0.0001
Acetyl salicylic acid (y/n) 0.87 0.0352
Hypertension therapy (y/n) 1.18 0.2187
Number at risk 27,632
Number of events 1,126
CAD=coronary artery disease; CVD=cerebrovascular disease; PAD=peripheral arterial 
disease
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833-6 Risk Factors for Angina in Women Without 
Atherosclerosis: The Dallas Heart Study
Divijani D. Puttagunta, James de Lemos, Darren K. McGuire, Alice Y. Chang, Scott M. 
Grundy, Amit Khera, Donald W. Reynolds Cardiovascular Clinical Research Center, 
Dallas, TX, University of Texas Southwestern Medical Center, Dallas, TX
Background: Angina that occurs in women without coronary atherosclerosis is associated 
with significant morbidity, yet its risk factors are poorly understood.
Methods: Subjects ages 30-65 who completed a modified Rose Angina Questionnaire 
and coronary artery calcium (CAC) scanning by EBCT in the Dallas Heart Study were 
included. Among women without CAC, the associations between angina and traditional 
and novel risk factors were assessed in univariable and multivariable analyses.
Results: Among the entire cohort of 2742 subjects, the prevalence of angina was similar 
between men and women (7.0% v. 7.8%, p=0.6). While angina was associated with an 
increase in prevalent CAC in men (41% v. 27%, p=0.006), no significant relationship was 
observed in women (19% v. 15%, p=0.2). In subjects without CAC, there was a trend towards 
increased angina in women compared with men (7.4% vs 5.7%, p=0.1). Angina in women 
without CAC was associated with black race, family history of MI, metabolic syndrome and 
higher C-reactive protein, BMI and HOMA-IR (table). After multivariable adjustment, only 
race, BMI and family history of MI were associated with angina (p<0.05 each).
Conclusion: Angina in women is not related to subclinical atherosclerosis, and its 
risk factors are different from the traditional spectrum of risk factors associated with 
atherosclerosis. Further studies are needed to determine if modifying the risk factors for 
angina in women can improve morbidity. 
Odds Ratio for Angina (95% CI)
Traditional risk factors Unadjusted Adjusted
Age (10-years) 1.03 (0.9-1.3)
Black Race 2.1 (1.4-3.3) 2.2 (1.2-4.2)
Smoking 1.2 (0.8-1.7)
Hypertension 1.3 (0.9-1.8)
Diabetes 1.4 (0.8-2.4)
Hypercholesterolemia 1.4 (0.8-2.2)
High triglycerides 1.2 (0.7-1.9)
Low HDL 1.3 (0.9-1.8)
Family history
of premature CAD 2.0 (1.3-3.2) 3.2 (1.9-5.5)
Menopause 1.3 (0.8-2.0)
Non-traditional risk factors
Metabolic syndrome 1.7 (1.2-2.3)
Sedentary 1.2 (0.9-1.8)
CRP (1 mg/L) 1.03 (1.0-1.06)
BMI (5 kg/m2) 1.2 (1.1-1.4) 1.3 (1.1-1.5)
HOMA-IR 1.04 (1.0-1.07)
8:00 a.m.
833-7 Current Imaging Recommendations Minimally Change 
the Distribution of Cardiovascular Risk in Dallas 
County: Findings From the Dallas Heart Study
Mahesh J. Patel, James A. de Lemos, Darren K. McGuire, Raphael See, Jason B. Lindsey, 
Scott M. Grundy, Amit Khera, Donald W. Reynolds Cardiovascular Clinical Research 
Center, Dallas, TX, University of Texas - Southwester Medical Center, Dallas, TX
Background: Current recommendations advocate limiting atherosclerosis imaging 
to intermediate risk (IR) subjects (10-year CHD risk 10-20%). We sought to determine 
the implications of this recommendation on the distribution of risk in a population-based 
sample.
Methods: Subjects ages 30-65 in the Dallas Heart Study were stratified into 3 groups 
using the Framingham risk score (FRS) [<10% = lower risk (LR); 10-20% = IR; >20%, 
diabetes, or history of myocardial infarction = high risk (HR)]. Coronary artery calcification 
(CAC) was measured by EBCT scan. We determined the proportion of IR subjects who 
would be promoted to HR based on CAC score ≥ 400 or > 75thile for age and gender.
Results: Among the 2700 participants, 16.0% of men and 1.0% of women were in the 
IR group. After implementing current imaging recommendations, only 2.7% of men and 
0.7% of women were promoted to HR status (Figure). Overall, 5.1% of men and 1.8% of 
women had CAC ≥ 400 with 25%, 24%, and 51% in LR, IR, and HR groups respectively 
in men, and 50%, 11%, and 39% in women.
Conclusions: Few women are at IR and thus eligible for atherosclerosis imaging. The 
distribution of risk categories changed minimally in both sexes after implementing current 
imaging screening recommendations, and fewer IR subjects had severe CAC compared 
with LR subjects. These findings demonstrate the limitations of imaging strategies 
targeting only IR subjects by FRS and highlight the need for novel approaches for 
incorporating atherosclerosis imaging into CHD risk assessment. 
8:15 a.m.
833-8 Does Metabolic Syndrome Predict Progression of 
Calcified Coronary Atherosclerosis? The Relationship 
Between the ‘Metabolic Score’ and Coronary Artery 
Calcium Progression
Allen J. Taylor, Hongyan Wu, Jody Bindeman, Carole Byrd, Kelly Bauer, Patrick G. 
O’Malley, Walter Reed Army Medical Center, Washington, DC
Background: Metabolic syndrome has been associated with the extent of coronary 
artery calcium (CAC). However, its relationship to the progression of CAC is not fully 
understood. In a prospective rescan substudy of the Prospective Army Coronary Calcium 
(PACC) Project, we examined the relationship between the metabolic score and the 
progression of CAC.
Methods: 200 healthy male participants (mean age, 47.8±2.8 years) with CAC from 
the PACC Project volunteered to undergo a second EBT scan and repeat risk factor 
assessment 4.2 ± 1.3 years after their original scan. All results were independently 
examined, blinded to baseline data. A change in CAC score ≥15% per year was 
defined as clinically-significant progression. Prediction of clinically-significant CAC 
progression was evaluated using multivariable logistic regression models, and principal 
component analysis, controlling for age, race, socioeconomic status, education and other 
cardiovascular risk factors such as family history, serum LDL-C and C reactive protein.
Results: CAC progression occurred in 52.5%. The mean and median of the rate of 
annual CAC progression was 41.3% and 18.3%. Individuals with CAC progression 
had significantly more metabolic syndrome components than those without clinically-
significant CAC progression (1.1 vs. 0.8; P=0.03). In the multivariable logistic regression 
analysis, metabolic score was a significant independent predictor after controlling for 
age, race, socioeconomic status, education level and other cardiovascular risk factors 
such as family history, LDL-C, and C-reactive protein. Each additional component of the 
metabolic syndrome was associated with an independent 38% increase in the odds of 
CAC progression (Odds Ratio=1.38; P = 0.05). Principal component analysis showed 3 
factors (metabolic syndrome, C-reactive protein and socioeconomic status) accounting 
for 55% of the variance in CAC progression.
Conclusions: Metabolic syndrome is not only associated with the baseline CAC score, 
but also is associated with its progression over 4 years. Individuals with clustering of risk 
factors such as the metabolic syndrome may be an optimal target population for serial 
CAC monitoring for progression.
ACC.ORAL CONTRIBUTIONS
838 
Hypertension: Cardiac and Arterial 
Remodeling
Tuesday, March 27, 2007, 9:00 a.m.-10:30 a.m.
Room 275-276-277
9:00 a.m.
838-3 A Unifying Explanation Of The Aortic Pulse Waveform In 
Humans
Justin E. Davies, Darrel P. Francis, Charlotte H. Manisty, Nearchos Hadjiloizou, Jazmin 
Aguado-Sierra, Iqbal S. Malik, Rodney A. Foale, Alun D. Hughes, Kim H. Parker, Jamil 
Mayet, International Centre for Circulatory Health, St Mary’s Hospital & Imperial College, 
London, United Kingdom
Background: Despite more than 200 years of research, no model has been able to fit all 
the aortic pressure waveform with physiologically interpretable parameters. We propose 
that the arterial waveform is composed of two components1) an arterial windkessel 
which stores ejected blood during systole and discharges it during diastole and 2) waves 
originating from the left ventricle and distal reflection sites.
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Methods: In 18 subjects (age 54±13 years) we measured simultaneous pressure and 
velocity in the aorta. The windkessel component of the pressure wave was calculated, and 
forward and backward waves were identified as previously described. The peak contribution 
of each component was calculated after subtraction of the diastolic pressure.
Results: In the human aorta, the initial rise in pressure was due to a wave arising from the 
left ventricle. This wave was responsible for 36.4mmHg (45%) of the total rise in pressure. 
Windkessel pressure was responsible for 40.6mmHg (50%) of the total pressure rise. 
Reflected waves were responsible for 4.8mmHg (5%) of the total rise in pressure.
Conclusions: Using this new approach we have shown that the aortic pressure wave 
consists of three principal components. The systolic rise in pressure in the aorta is 
largely determined by a windkessel and waves arising from the left ventricle. Reflected 
waves make only a minor contribution. Waves do not contribute to the pressure and 
flow in diastole. Diastolic pressure is due to capacitative discharge of pressure from the 
windkessel.
9:15 a.m.
838-4 Prehypertension is Associated with Increased 
Aortic Stiffness but not Muscular Artery Stiffness: A 
Population-based Study
Julio A. Chirinos, Josefina Medina-Lezama, Humberto Zea-Diaz, Carolina Cuba, Zoila 
Valdivia, Fernando F. Corrales, Oscar L. Morey, Juan F. Bolanos, Sheyla Paredes, Paola 
Villalobos, Julio Chirinos Pacheco, Santa Maria Catholic University School of Medicine, 
AQP, Peru
Background: Several studies support the existence of a prehypertensive state, and 
the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of 
High Blood Pressure (BP) established pre-hypertension (preHTN) as a new BP category 
due to its prognostic implications. Aortic stiffness is increased in hypertension (HTN), 
but whether individuals with preHTN demonstrate abnormal aortic stiffness has not 
been investigated in population-based studies. We compared aortic and muscular artery 
stiffness among subjects with normal BP, pre-HTN and HTN.
Methods: We studied 1089 subjects (434 with normal BP, 343 with preHTN and 312 
with HTN) participating in a population-based study (PREVENCION Study). Pulse wave 
velocity (PWV) was measured with simultaneous doppler and the foot-to-foot method. 
Carotid-femoral (CF-) PWV was used as a marker of aortic stiffness, whereas carotid-
radial (CR) and femoral-pedal (FP) PWV were used as indicators of muscular artery 
stiffness. Differences were analyzed with weighted linear modeling.
Results: A progressive increase in CF-PWV was observed from the normal BP to the 
HTN group (ANOVA p<0.0001). Subjects with preHTN demonstrated significantly higher 
CF-PWV (9.46 m/s; 95%CI=9.08-9.84) than normal subjects (8.25 m/s; 95%CI=7.97-
8.53; p<0.001), whereas the HTN group demonstrated the highest values (11.04 m/s; 
95%CI= 10.52-11.57). Differences in CF-PWV persisted after adjustment for age, gender, 
mean BP and heart rate (ANCOVA p<0.001). Adjusted values for CF-PWV were 8.73 m/s 
(95%CI=8.35-9.11) for the normal BP group, 9.22 m/s (95%CI=8.82-9.62) for the preHTN 
group and 10.0 m/s (95%CI=8.99-11.01) for the HTN group. CR-PWV and FP-PWV did 
not significantly differ between the groups.
Conclusions: Pre-HTN is associated with increased aortic stiffening, and this increase 
is not fully accounted for by BP levels per se. These results suggest that structural aortic 
abnormalities (rather than purely functional stiffening from increased distending pressure) 
are present in preHTN. Further studies are needed to evaluate the role of aortic stiffness as 
a therapeutic target to prevent the development of HTN among subjects with pre-HTN.
9:30 a.m.
838-5 Circulating Endothelial Cells, Arterial Stiffness 
And Cardiovascular Mortality Risk Stratification In 
Hypertension
Christopher J. Boos, Manas KARPHA, D. GARETH BEEVERS, GREGORY YH LIP, City 
Hospital, Birmingham, United Kingdom
Background: Given the growing burden of cardiovascular (CV) disease, there is 
increasing interest in strategies to help predict future CV risk.
Methods: We investigated the relationship between endothelial dysfunction, arterial 
stiffness and predicted risk of CV death. We studied three patient groups aged 35-74 
years old: healthy controls (HC, n=63) and 2 hypertensive (HT) groups- ‘high-risk’ HT 
subjects (HHT, n=65) and patients with treated, previously diagnosed malignant phase 
HT (MHT, n=43). We measured comparative indices of arterial stiffness (stiffness index, 
SI using digital volume photoplethysmography), endothelial dysfunction (circulating 
endothelial cell [CEC] counts/mL from venous blood using the immunobead technique) 
and 5-year predictive risk of future CV death (Pocock scoring system).
Results: CEC counts, SI and 5-year predicted risk of CV death were significantly higher 
in both HT groups, compared with HCs (table 1). CECs significantly correlated with SI in 
both the HHT (r=0.61; p<0.0001) and MHT groups (r=0.59, p<0.0001). There were also 
strong correlations between CEC, SI and predicted 5-year risk of CV death in the two HT 
groups. On multiple linear regression analysis, both the arterial SI and CECs remained as 
significant predictors of the calculated 5-year risk of CV death (R2 = 0.36; p<0.0001).
Conclusion: There is a consistent association between CECs, arterial stiffness and the 
predictive 5-year risk of CV death among patients with HT. 
Table 1. Comparative circulating endothelial cell counts (CEC), stiffness index 
(SI) and calculated 5-year risk of cardiovascular (CV) death (Pocock) 
Healthy 
Control (HC)
High-risk 
hypertensive (HHT)
Malignant 
Hypertensives
(MHT)
P value
CEC/mL 5.2 (2.9) 7.2 (3.8) 10.2 (7.0) <0.0001a,b,c
SI (m/s) 9.1 (1.5) 10.1 (1.7) 10.6 (2.4) 0.0002a,b
5-year CV mortality 
risk (%) 0.9 (0.6 - 1.9) 1.5 (0.8 - 3.7) 1.7 (0.6- 4.5) 0.005a,b
Results expressed as mean (SD, standard deviation) and median† (IQR, interquartile 
range). For significant differences (p<0.05) between groups aHC and HHT; bHC and 
MHT cHHT and MHT
9:45 a.m.
838-6 Beta 1-Adrenergic Receptor Gene Modulates the Effect 
of Heart Rate on Arterial Stiffness: The Bogalusa Heart 
Study
Wei Chen, Sathanur R. Srinivasan, Gerald S. Berenson, Eric Boerwinkle, Tulane 
University, New Orleans, LA
Background: Heart rate and sympathetic nervous activity are important determinants 
of arterial stiffness. However, whether the relationship between heart rate and arterial 
stiffness is modulated by the β1-adrenergic receptor (β1-AR) gene is not known. This 
study examines the genetic modulation by β1-AR gene polymorphism (Arg389Gly) on the 
effect of heart rate on arterial stiffness in young adults.
Methods: The study cohort included 183 blacks and 502 whites aged 19-44 years enrolled 
in the Bogalusa Heart Study. Aorta-femoral pulse wave velocity (af-PWV) was measured 
by echo-Doppler.
Results: Heart rate was significantly associated with af-PWV in blacks, whites and 
the total sample. However, there was no difference in heart rate between carriers and 
noncarriers of Gly389 allele in both blacks and whites. Carriers vs noncarriers of Gly389 
allele showed higher values of af-PWV (5.29 m/sec vs 5.19 m/sec, p<0.01) in whites, but 
not in blacks (5.40 m/sec vs 5.37 m/sec, p=0.524). In multivariate regression analysis 
for the total sample, both heart rate and Gly389 allele were significantly and positively 
associated with af-PWV, adjusting for race, sex, age, body mass index and pulse pressure. 
Furthermore, the adverse positive relationship between heart rate and af-PWV was noted 
only among carriers of Gly389 allele (comparison of slopes p=0.018).
Conclusions: These results indicate that the allelic variation (Arg389Gly) of the β1-AR 
gene modulates arterial stiffness and its association with heart rate in young adults.
10:00 a.m.
838-7 Haemodynamic Load and Left Atrium Size in the Early 
Stages of Essential Hypertension: The Effect of Pulse 
Pressure and Nocturnal Blood Pressure Fall
Efstathios Taxiarchou, Costas Tsioufis, Pavlos Stougiannos, Maria Selima, Giorgos 
Chartzoulakis, Konstantinos Giannakopoulos, Christodoulos Stefanadis, Ioannis 
Kallikazaros, Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: Left atrial (LA) enlargement is a common finding in hypertensive patients 
and might be an index for future adverse cardiovascular events. Similarly, increased pulse 
pressure (PP) as well as absence of nocturnal blood pressure (BP) fall is associated with 
unfavourable outcome in this setting. The aim of this study was to evaluate the relationship 
between ambulatory BP parameters and LA size.
Methods: 235 consecutive, newly diagnosed subjects (aged 52±10 years), with untreated 
stage I-II essential hypertension [office BP =151/97 mmHg] were classified according 
to their nocturnal BP fall on 24-hour ambulatory BP monitoring to non-dippers (those 
with<10% nocturnal systolic and diastolic BP fall, n=92) and dippers (the remaining 
subjects, n=143). All subjects underwent complete echocardiographic study and LA 
volume was indexed for body surface area to estimate LA volume index (LAVI).
Results: Non-dippers compared to dippers did not differ regarding sex, body mass 
index, office and 24-h systolic and diastolic BP and biochemical profile (p=NS for all 
cases). However, non-dippers compared to dippers had significantly increased 24-h 
pulse pressure (PP) (53±9 vs 50±8 mmHg, p<0.05) while they did not differ significantly 
regarding left ventricular mass index (106.0±29 vs 102.6±26 gr/m2), LA diameter (3.9±0.3 
vs 3.9±0.4 cm) and LAVI (21.7 vs 21.9 ml/m2). In the entire population LA diameter 
and LAVI exhibited positive relationships with 24-h PP (r=0.145, p<0.05 and r=0.219, 
p=0.001, respectively), day PP (r=0.156, p<0.05 and r=0.221, p=0.001, respectively) 
and night PP (r=0.132, p<0.05 and r=0.193, p<0.005, respectively). Multiple regression 
analysis models revealed that among components of ambulatory BP, only 24-h PP was 
an independent predictor of LAVI (p<0.005).
Conclusions: Ambulatory PP but not circadian BP variation seems to determine the 
LA enlargement in hypertensive patients. Whether the abovementioned association 
contributes to the high cardiovascular risk observed in patients with wider PP remains to 
be determined in future studies.
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838-8 Left Ventricular Geometric Patterns in the African 
American Study of Kidney Disease and Hypertension 
(AASK) Cohort
Tine L. de Backer, Gail Peterson, Alexandra J. Lansky, Larry Agodoa, Larry Appel, 
Karen Brittain, Jennifer Gassmann, Cindy Kendrick, Michael Lipkowitz, Jackson T. 
Wright, Robert A. Phillips, Cardiovascular Research Foundation, New York, NY, NIDDK, 
Bethesda, MD
Background: Left ventricular hypertrophy (LVH), a major complication of hypertension, 
and abnormal LV geometric patterns increase the risk for cardiovascular morbidity and 
mortality. Because of prognostic significance we evaluated the distribution of the different 
geometric patterns and associated factors in the AASK cohort.
Methods: 599 AASK patients had an echocardiogram (echo) and ambulatory BP monitoring 
(ABPM) in the baseline phase of the AASK cohort. To ensure data quality, echos were 
obtained by trained technologists at local AASK centers with a standardized protocol, and 
read centrally at the AASK Cardiovascular Core Lab. Type of geometric pattern was based 
on the relative wall thickness (RWT >0.44) and presence or absence of LVH on echo.
Results: The distribution of patterns shows 7.5% normal geometry, 23% concentric 
remodeling, 55% concentric LVH and 14.5% eccentric LVH. As shown in the table, compared 
with the overall group, the concentric LVH group was younger, had a higher BMI, a higher day 
and night systolic BP and a higher 24h pulse pressure. GFR was lower in the concentric LVH 
group and 15.6% of the concentric LVH pts had micro-albuminuria (UACR>0.22).
Conclusions: The study showed that only 7.5% of the AASK population had a normal 
geometry. The most common abnormal LV geometry was concentric hypertrophy and 
this was associated with higher BP, worse renal function and microalbuminuria. Long 
term follow-up, which is planned for the AASK cohort, will relate the geometric patterns 
with prognosis.
Distribution and factors associated with different LV geometric patterns
All (n=599)
Normal 
geometry 
(n=45, 7.5%)
Concentric 
remodeling 
(n=138, 
23%)
Concentric 
LVH 
(n=329, 
55%)
Eccentric 
LVH (n=87, 
14.5%)
p
Variable n (%) or 
mean+sd
n (%) or 
mean+sd
n (%) or 
mean+sd
n (%) or 
mean+sd
n (%) or 
mean+sd p
Age (y) 60.1+10.1 60.9+9.60 62.2+10.1 58.6+9.98 62.1+10.1 0.0009
BMI (kg/m2) 31.2+6.98 28.3+6.27 27.8+5.22 33.0+7.37 31.2+5.70 0.0001
Estimated GFR 
(ml/min/1.73m2) 44.2+16.5 50.7+17.2 44.6+16.7 43.6+15.8 46.5+7.8 0.008
Microlbuminuria 
(UACR>0.22) 12.6 4.4 5.1 15.6 17.2 0.0028
Average Day SBP 
(mmHg) 138+17 129+12.4 133+17.2 141+16.8 138+16.6 0.0001
Averag Night SBP 
(mmHg) 134+21 122+16.7 130+19.7 138+21.3 134+20.1 0.0001
24h Pulse Pressure 
(mmHg) 56.1+12.5 50.1+10.2 52.1+11.8 58.4+12.6 56.5+11.9 0.0001
ACC.POSTER SESSION
1026 
Vascular Disease, Hypertension and 
Prevention
Tuesday, March 27, 2007, 9:00 a.m.-12:30 p.m.
Hall H
11:00 a.m.
1026-1 Preserved Endothelial Function in Subjects with Morbid 
Obesity: a New Obesity Paradox?
Francesca Graziani, Luigi M. Biasucci, Vittoria Rizzello, Salvatore Brugaletta, Giovanna 
Liuzzo, Caterina Guidone, Gertrude Mingrone, Filippo Crea, catholic university of sacred 
heart, rome, Italy
Background:. Morbid obesity (MO) is defined by a BMI>40 and its incidence is arising 
in developped and developing countries. Although many data link visceral adiposity with 
endothelial dysfunction, the first step of atherogenesis, there are no data about endothelial 
function in morbidly obese patients.
Therefore we investigated endothelial function in a group of MO subjects, compared to a cohort 
of patients with visceral adiposity (waist circumference >102 cm men, >88 cm women).
Methods: We enrolled 36 healthy subjects, aged between 40 and 60, 16 MO: BMI >40 
and 20 with visceral adiposity and a BMI 25-39 (OOW) . We evaluated intima-media 
thickness (IMT) by carotid ultrasonography and flow-mediated dilation (FMD) by brachial 
artery ultrasound. Peripheral blood was analyzed for the frequency of endothelial 
progenitor cells (EPCs) at flow- citometry. Serum levels of hs-C reactive protein (CRP) 
and leptin were also assessed.
Results: IMT values did not differ between the two groups, conversely FMD was 
significantly higher in MO (27.8;7-72%) than in OOW (14; 6.5-44% P=0.01). EPCs were 
higher in MO, but not significantly(mean 0.74 vs 0.16% P=0.06) and correlated with waist 
circumference (P=0.01; R=0.44). CRP levels were significantly higher in MO (mean 
14.3 mg/L; SD±13.00) than in OOW (mean 4.4 mg/L;SD±7.3 P<0.0001) and its levels 
correlates with BMI (R=0.42 P<0.0001) and waist circumference (R=0.43 P<0.001). Also 
leptin levels were significantly higher in MO ( median, range: 55.9 ng/mL;24-575) than 
in OOW (22.7;2.10-404 P<0.0001) and its levels correlated with waist circumference 
(R=0.71 P<0.0001) and BMI (R=0.66 P<0.0001) Conclusion: Our study demonstrates 
that MO subjects, compared to OOW subjects, are characterized by a better endothelial 
function and a higher number of circulating EPC, although they present a markedly 
increased inflammatory condition. These findings suggest important differences in the 
pathogenetic mechanisms linking MO vs OOW in atherosclerotic diseases
11:00 a.m.
1026-2 Mechanisms of Platelet Hyperreactvity in Type I and 
Type II Diabetes
Simona Giubilato, Luigi M. Biasucci, Andrea Leo, Silvia Riondino, Dario Pitocco, 
Domenico D’Amario, Giovanna Liuzzo, Giovanni Ghirlanda, Fabio Pulcinelli, Filippo 
Crea, catholic university, Rome, Italy, La Sapienza University, Rome
Background: Evidences from clinical trials suggest that aspirin is less effective in reducing 
cardiovascular events in both type I and II diabetic patients, compared to nondiabetics.
Despite of different pathogenetic and atherothrombotic implications, chronic 
hyperglycemia, in both diabetes types, could affect response to aspirin (ASA) in terms of 
impaired platelet membrane acetylation and protein glycation.
Methods: we sought to investigate TxA2 production following platelet stimulation with 
collagen and platelet COX-1 and COX-2 expression in 50 type II diabetics, in 15 type I 
diabetics and in 50 nondiabetics, all under chronic aspirin treatment.
Results: TxA2 production in response to collagen was significantly higher (p<0.005) both 
in type I (807.4±280.5 pg/108 cells) and in type II (896.4±232.3 pg/108 cells) diabetic 
patients compared to nondiabetics (130.5±31.5 pg/108 cells). The in vitro addition of 
aspirin prior to stimulation reduced collagen-induced TxA2 formation (32.3+10.2 pg/108 
cells in type I and 46.3+9.6 pg/108 cells in type II). Expression of both isoforms of 
cyclooxygenase, demonstrated that while COX-1 was highly expressed in all groups, 
COX-2 was expressed in all diabetic patients, both of type I and type II, analyzed but only 
in 40% nondiabetics, suggesting that the residual TxA2 produced, might be consequent 
to COX-2 activation.
Conclusion: Our study demonstrates that both type I and Type diabetes are less sensitive to 
aspirin, due to a persistent TxA2 production, compared to nondiabetics, suggesting a reduced 
inhibitory action on platelet COX-1 and the expression of platelet COX-2. Our data strongly 
suggest that an extensive protein glycation secondary to hyperglicemia may reduce aspirin 
ability to acetylate target platelet proteins in diabetic patients of both type I and II.
11:00 a.m.
1026-3 Calcium Activated Potassium Channels Contribute to 
Protease Activated Receptor Type 1 (PAR-1) Induced 
Vasodilatation in Man
Ninian N. Lang, Ingibjorg J. Gudmundsdottir, David E. Newby, University of Edinburgh, 
Edinburgh, United Kingdom
Background: As well as playing an important enzymatic role in the coagulation cascade, 
thrombin exerts major vascular effects through the activation of Protease Activated 
Receptor type 1 (PAR-1). We have recently demonstrated that PAR-1 agonism causes 
arterial vasodilatation in man through an unknown mechanism. By blocking calcium-
activated potassium channels (KCa), we examined the role of endothelium-derived 
hyperpolarising factor (EDHF) in PAR-1 induced vasodilatation.
Methods: Bilateral forearm blood flow was measured by venous occlusion plethysmography 
in 8 healthy volunteers who attended on two occassions. Intra-brachial SFLLRN (PAR-1 
agonist; 5 - 50 nmol/min), bradykinin (30 - 300 pmol/min) and sodium nitroprusside (2 - 8 
µg/min) were infused sequentially. In a double blind randomised crossover design, agents 
were co-infused with tetraethylammonium [TEA] (a KCa antagonist) or saline placebo.
Results: TEA did not affect baseline blood flow but it attenuated SFLLRN (see figure) 
and bradykinin induced vasodilatation (p<0.03 for both). Endothelium-independent 
vasodilatation to SNP was unaffected.
Conclusions: EDHF and specifically functional KCa contribute to PAR-1 induced arterial 
vasodilatation in man. Wider understanding of the vasomotor actions and mechanisms 
of PAR-1 will help inform the clinical development of novel anti-thrombin and PAR-1 
antagonist therapies.
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1026-4 Impact of High Clopidogrel Maintenance Dosing on 
Thrombin Generation in Patients with Diabetes Mellitus
Dominick J. Angiolillo, Steven Shoemaker, Bhaloo Desai, Hang Yuan, Ronald Charlton, 
Luis Guzman, Martin M. Zenni, Theodore A. Bass, Marco A. Costa, University of Florida-
Shands Jacksonville, Jacksonville, FL
Background: Patients with diabetes mellitus (DM) have hyper-reactive platelets. 
Activated platelets not only lead to the formation of aggregates, but also play a pivotal role 
in triggering the coagulation cascade by inducing thrombin generation. The hypothesis of 
this study is that, in addition to enhancing platelet inhibition, more aggressive antiplatelet 
treatment regimens also reduce thrombin generation rates in DM patients with hyper-
reactive platelets.
Methods: A cohort of 50 DM patients on chronic clopidogrel (75 mg/day) treatment was 
studied. Patients with enhanced platelet reactivity (defined as > 50% maximum platelet 
aggregation following 20μM ADP stimuli) were eligible for the study and randomized to 
either standard (75 mg/day) or high (150 mg/day) maintenance dose clopidogrel therapy 
for one-month. In addition to platelet aggregation using light transmittance aggregometry, 
the onset of thrombin induced platelet-fibrin clot formation, a marker of the speed of 
thrombin generation was assessed by thrombelastography.
Results: Following screening of individuals’ platelet function profiles, 30 DM patients 
with high platelet reactivity were identified . Platelet aggregation (%) significantly reduced 
after one-month treatment in patients (n=15) randomized to the high maintenance dose 
(66.2±5 vs 51.0±13; p<0.0001), while no changes were observed in patients (n=15) on 
standard dosing (63.8±8 vs 62.0±7; p=0.5). The speed of thrombin generation (min) 
was prolonged (5.5±1.4 vs 6.6±1.4; p=0.03) in the high maintenance dose group, while 
no changes were observed in patients on standard dosing (5.8±1.4 vs 5.6±1.0; p=0.7). 
Intergroup group comparisons were also statistically significant for platelet aggregation 
(p=0.01) and thrombin generation (p=0.03) profiles.
Conclusions: In addition to enhancing platelet inhibition, the selective use of a high 
maintenance dose of clopidogrel in a high risk cohort of DM patients reduces thrombin 
generation, contributing to the overall antithrombotic properties of this drug.
11:00 a.m.
1026-5 LY518674, a Potent and Selective Peroxisome 
Proliferator Activated Receptor Alpha Agonist, 
Reduces Triglycerides, Total Cholesterol, Low Density 
Lipoprotein-Cholesterol, and Apolipoproteins B and C3
Daniel C. Howey, Cynthia Harris, Eyas Abu-Raddad, Nagy Farid, Ming-Dauh Wang, Eli 
Lilly and Company, Indianapolis, IN
Background: LY518674 is a potent and selective agonist of peroxisome proliferator-
activated receptor alpha (PPARα).
Methods: This Phase 1 study was a randomized, placebo-controlled, dose-escalation 
study of LY518674 in obese but otherwise healthy subjects given single- (SD) and 
multiple-doses (MD). Dose selections were based on safety assessments consisting of 
physical exams, subject interviews, and laboratory tests from prior doses. During SD, 32 
subjects received placebo or LY518674: 0.1, 1, 10, 30, or 60 mg. During MD, 35 subjects 
received placebo or LY518674: 0.025, 0.1, 1 or 10 mg daily for 14 days. The results, 
%-change from baseline with 95% confidence intervals, have two-sided P-values <0.05 
when compared to placebo.
Results: The study included 69 subjects (32% female) with mean age of 43 years and 
mean Body Mass Index of 31. During SD, mild gastrointestinal symptoms occurred 
following 30 mg and increased in frequency and severity following 60 mg. LY518674 
affected fasting triglycerides (TG) and postprandial TG in a dose-responsive fashion from 
24 to 36 hours after administration. The maximum effect occurred between 1 and 10 
mg. During MD, LY518674 was well-tolerated up to 1 mg. Severe myopathy occurred in 
1 subject after 2 weeks at 10 mg. LY518674, at doses up to 0.1 mg, reduced TG up to 
45.7% (-58.5, -28.9), total cholesterol up to 23.5% (-30.1, -16.2), low-density lipoprotein 
cholesterol (LDL-C) up to 28.6% (-38.2, -17.6), apolipoprotein B up to 24.9% (-33.3, -
15.5) and apolipoprotein C3 up to 43.5% (-52.7, -32.5). Apolipoprotein A2 increased by 
44.6% (31.3, 59.1) at 1 mg per day. There was no effect on high-density lipoprotein or 
apolipoprotein A1 after 14 days.
Conclusions: When administered to obese but otherwise healthy subjects for 14 
days, LY518674 significantly reduced TG, total cholesterol, LDL-C, apolipoprotein B, 
apolipoprotein C and increased apolipoprotein A2.
11:00 a.m.
1026-6 Fibrous Cap Thickness of Culprit Plaque in Subjects 
With Acute Coronary Syndromes is Related to 
Individual Plaque Characteristics and Not to the 
Presence of Systemic Cardiovascular Risk Factors: An 
Intravascular Optical Coherence Tomography Study.
Owen Christopher Raffel, Masanori Takano, Guillermo J. Tearney, Denise A. DeJoseph 
Gauthier, Brett E. Bouma, Ik-Kyung Jang, Massachusetts General Hospital & Harvard 
Medical School, Boston, MA
Background: Cardiovascular (CV) risk factors predict acute coronary syndromes (ACS). 
Most ACS occur due to rupture of the thin fibrous cap of vulnerable plaque. Autopsy 
studies have show that 95% of these caps are < 65 µm
Aim: To evaluate using optical coherence tomography (OCT), the relationships between 
culprit plaque fibrous cap thickness (FCT) and both the presence of CV risk factors & local 
culprit plaque characteristics in patients presenting with ACS.
Methods: OCT imaging was performed on the culprit plaque in patients with ACS. FCT 
was measured at its thinnest point. Lipid was semi-quantified as the number of involved 
quadrants on the cross-sectional image. Macrophage density was calculated as the 
normalized standard deviation of the optical signal within the fibrous cap.
Results: 38 plaques were analyzed. Median FCT was 52µm (22-216). 61% of plaques had 
FCT <65µm. There was no association between FCT and the presence of hypertension, 
dyslipidemia, diabetes or a history of smoking. There was a significant inverse relationship 
between FCT and plaque lipid content (p=0.015 for trend, Figure A). Similarly FCT and 
fibrous cap macrophage density were inversely correlated (r=-0.585, p<0.001). Using a 
65µm cut off, plaques with a FCT<65µm had a significantly higher mean macrophage 
density than plaques with FCT≥ 65µm (7.06 vs 4.62, p<0.001, Figure B).
Conclusion: Culprit plaque fibrous cap thickness in patients with an ACS correlates with 
plaque lipid content and macrophage density but not with CV risk factors. 
11:00 a.m.
1026-7 Chronic Stress Induces a Pro-Inflammatory Response: 
Implications for Cardiovascular Disease
James A. Andrews, Kristi Andrews, JinSong Wang, Zofia Zukowska, Mary-Susan 
Burnett-Miller, Medstar Research Institute, Cardiovascular Research Institute, 
Washington, DC, Georgetown University, Department of Physiology and Biophysics, 
Washington, DC
Background: Stress is associated with cardiovascular disease. The aim of this study 
was to examine the pro-inflammatory responses to chronic stress. The effects of chronic 
stress on circulating cytokines and lipids were investigated in a murine model.
Methods: C57BL/6J ApoE knockout mice were subjected to daily cold stress (1 hr/day) 
for 4 weeks. Blood was collected immediately after the last chronic stress episode 
(episodal effects), and one day after the last chronic stress episode (cumulative effects). 
Unstressed, age-matched mice served as controls. IL-1β, IL-10, IFNε, MCP-1 and TNFα 
were measured using a LincoPlex kit. Lipids were measured using a clinical autoanalyzer. 
Data are presented as average ±SD.
Results: IL-1β (7.6 ±2.8 ng/mL vs. 2.1 ±1.4 ng/mL, p<0.001), IL-10 (29.6 ±6.4 ng/mL vs. 
11.2 ±6.5 ng/mL, p<0.001), IFN-γ (9.6 ±4.4 ng/mL vs. 0.4 ±0.5 ng/mL, p<0.001), MCP-1 
(34.9 ±18.9 ng/mL vs. 17.8 ±16.0 ng/mL, p=0.05), TNF-α (3.2 ±2.2 ng/mL vs. 1.8 ±0.6 
ng/mL, p=0.03), and LDL cholesterol (630 ±73 mg/dl vs. 542 ±83 mg/dl, p=0.01) were all 
elevated immediately following the last chronic stress episode in comparison to controls 
(n=10). Cumulative effects of chronic stress showed decreased IL-1β (0.03 ±0.07 ng/mL 
vs.2.74 ±3.72 ng/mL, p=0.02, n=5, n=11) and decreased MCP-1 (13.72 ±7.78 ng/mL vs. 
34.12 ±22.41 ng/mL, p=0.007, n=5, n=12), compared to controls.
Conclusion: Immediately after a stress episode, there is a cytokine surge and an increase 
in LDL levels. However, one day following the last stress episode there is a decrease 
in several pro-inflammatory cytokines compared to controls, possibly representing an 
overcompensatory response. Chronic stress leads to large fluctuations in circulating 
cytokine levels not observed in unstressed animals. Overall, stress is a dynamic process, 
resulting in a pro-inflammatory response that could contribute to cardiovascular disease.
11:00 a.m.
1026-8 Incidence of Coronary Artery Ectasia and Its 
Relationship with Coronary Endothelial Dysfunction in 
Asian Population
Seung-Woon Rha, Cheol Ung Choi, Soon Yong Suh, Jin Won Kim, Eung Ju Kim, Chang 
Gyu Park, Hong Seog Seo, Dong Joo Oh, Cardiovascular Center, Korea University Guro 
Hospital, Seoul, South Korea
Background: Coronary artery ectasia (CAE) has been known to be associated with 
coronary morbidity but consensus on its incidence and clinical significances especially 
relationship with coronary artery spasm is not clearly defined. We investigated the 
incidence of CAE and its relationship with endothelial dysfunction.
Methods: The study consisted of 696 patients (pts, Male 382, Age 59.2±8.1 years) who 
underwent diagnostic coronary angiography. Among them, a total 400 pts underwent 
acetylcholine (Ach) provocation test by injecting incremental doses of 20, 50 and 100 μg 
to left coronary artery. CAE was defined an abnormal dilatation of coronary artery wall 
greater than 1.5 times of normal coronary artery.
Results: The incidence CAE was found in 2.0% (14/696) in study population. Among 
the 14 CAE pts, 9 pts (Male 7, Age 56±11.2 years) received Ach provocation test due 
to typical history of variant angina. Typical severe spasm was induced in 77.7% of the 
pts (7/9) with either lower dose of Ach (50 μg, 57.1%, 4/7) or higher dose of Ach (100 
μg, 42.9%, 3/7). Only one pt had diffuse severe spasm throughout the whole coronary 
artery including ectatic segment (1/7, 14.3%) and most of severe spasms were observed 
mainly at mid or mid to distal left anterior descending artery (LAD, 6/7, 85.7%). The severe 
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spasms were frequently found between the borders of ectatic portion and normal portions. 
Fixed coronary lesions were observed in 28.6% (2/7) and typical myocardial bridging in 
mid LAD was observed in 28.6% (2/7), too. Typical chest pain was reproduced in 57.1 % 
(4/7) without obvious ST-T change.
Conclusion: The incidence of CAE in a routine clinical practice is 2%. Greater than 
77% of pts had Ach induced endothelial dysfunction and significant proportion of CAE 
pts might be associated with coronary vasospasm and related coronary morbidity. This 
CAE associated endothelial dysfunction was frequently observed between the borders of 
ectatic and normal coronary artery segment.
11:00 a.m.
1026-9 Exogenous Nitric Oxide Increases the Expression 
of Oct-4 and May Modify Bone Marrow Stem Cell 
Differentiation into Endothelial Cells in vitro
Ling Chu, Yuehua Jiang, Hong Hao, Catherine Verfaillie, Jay Zweier, Zhenguo Liu, The 
Ohio State University Medical Center, Columbus, OH, The University of Minnesota 
Medical School, Minneapolis, MN
Background: Nitric oxide (NO) is important in modulating cell growth and differentiation. 
This study was designed to investigate the role of NO in the bone marrow stem cells and 
their differentiation into endothelial cells in vitro.
Methods: Adult mouse bone marrow multipotent progenitor cells were used as the source 
of stem cells. The biological behavior of the stem cells was evaluated by assessing the cell 
proliferation, morphology, and expression of Oct-4 with real-time PCR in the presence or 
absence of NO donor DETA-NONOate. To demonstrate the effect of exogenous NO on cell 
differentiation, the bone marrow stem cells were induced to differentiate into endothelial 
cells with or without DETA-NONOate. The stages of differentiation were closely monitored 
with morphology and expression of endothelial cell marker von Willebrand factor (vWF).
Results: Oct-4 expression was significantly increased by 57.5% ± 25.4 (n = 5, p < 0.05) in 
stem cells exposed to DETA-NONOate in a concentration-dependant manner. However, 
the cell proliferation was significantly decreased when treated with DETA-NONOate for 
48 hrs (1,680±26 cells/cm2 for control, 1,221±29 cells/cm2 for 50 uM, and 543±77 cells/
cm2 for 100 uM, n = 6, p < 0.05). There was no cell death during incubation with DETA-
NONOate. When the stem cells were exposed to DETA-NONOate (100uM) for the first 
48 hrs during differentiation, the expression of vWF was increased by 17.7% at day 14 
in the differentiating cells. However, vWF expression was decreased in the differentiating 
cells at day 14 or cell death occurred if the cells exposed to DETA-NONOate over 72 
hrs during differentiation. To demonstrate any dependence of DETA-NONOate on cyclic 
GMP, experiments were repeated in the presence of specific guanylyl cyclase inhibitor 
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) or cGMP analog 8-Br-cGMP. The 
effect of DETA-NONOate on cell proliferation and Oct-4 expression of the stem cells was 
not affected by ODQ or 8-Br-cGMP.
Conclusions: These data indicate that exogenous NO plays an important regulatory 
role in the biological behavior and differentiation of bone marrow stem cells through a 
mechanism independent of cGMP.
11:00 a.m.
1026-10 The Effects of Rosiglitazone versus Glyburide on 
Endothelial Function and Oxidative Stress in Patients 
with Type 2 Diabetes
Aaron S. Kelly, Andrea M. Thelen, Daniel R. Kaiser, Alan J. Bank, St. Paul Heart Clinic, 
St. Paul, MN, University of Minnesota, Minneapolis, MN
Background: The literature is inconclusive regarding the effect of rosiglitazone on 
endothelial function and limited data exist addressing its potential role in reducing oxidative 
stress in humans. We sought to compare the effects of rosiglitazone and the sulfonylurea 
glyburide on endothelial function and oxidative stress in a head to head trial.
Methods: Patients with type 2 diabetes (n = 36) were randomized to receive 6-months of 
either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following 
variables were measured in a fasted state pre- and post-treatment: glucose and insulin, 
homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood 
pressure, lipids, C-reactive protein (CRP), 8-isoprostane, asymmetric dimethylarginine, 
oxidized LDL cholesterol, ultrasound assessment of brachial artery flow-mediated dilation 
(FMD), endothelium-independent dilation (EID), brachial and carotid artery distension, 
distensibility, and compliance. Changes in variables between groups over time were 
compared with 2X2 (group by time) ANOVA.
Results: Both rosiglitazone and glyburide treatment resulted in significant and equivalent 
decreases in glucose (p<0.0001) and HbA1c (p<0.0001), with a trend toward decreased 
HOMA (p = 0.09). Compared to glyburide, rosiglitazone significantly decreased C-peptide 
(p<0.01) with a trend toward decreased fasting insulin (p = 0.05). No differences between 
groups were noted for blood pressure or lipids. Rosiglitazone reduced CRP compared to 
glyburide (p<0.01), but no differences were observed between groups for the markers 
of oxidative stress. Rosiglitazone significantly improved FMD (rosiglitazone: 4.8 ± 
0.8% to 6.8 ± 0.8% vs. glyburide: 6.5 ± 1.0% to 5.5 ± 0.8%, p<0.05) with trends toward 
improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). There 
were no differences between groups for the other measures of arterial stiffness or EID.
Conclusion: Compared to glyburide, rosiglitazone improves endothelial function and 
CRP in patients with type 2 diabetes. Despite these beneficial cardiovascular effects, 
rosiglitazone does not reduce markers of systemic or vascular oxidative stress.
11:00 a.m.
1026-11 Atherogenic Vascular and Lipid Phenotypes in Juvenile 
Type 1 Diabetes are Influenced by HLA-Related 
Diabetes Susceptibility
Michal Odermarsky, Anita Nilsson, Åke Lernmark, Petru Liuba, Lund University Hospital, 
Lund, Sweden, Malmö University Hospital, Malmö, Sweden
Background: Expression of certain human leukocyte antigens (HLA) on islet endothelial 
cells (ECs) is a central vascular event in the pathogenesis of type 1 diabetes mellitus 
(DM-1). Previous studies demonstrating the ability of other vascular ECs to process and 
present HLA antigens on their surface support the hypothesis that similar HLA-mediated 
autoimmune events may take place in other vascular beds as well. We investigated 
whether the HLA-DQ2/8 genotype, which confers the highest risk for DM-1, could 
influence early atherosclerosis in youths with DM-1.
Methods: Brachial artery endothelium-dependent, flow-mediated dilation (BA-FMD) 
and carotid artery intima-media thickness (CA-IMT), as well as markers of systemic 
inflammation (C-reactive protein, fibrinogen, and orosomucoid), HbA1C, LDL, HDL and 
total cholesterol (TC), were assessed in 83 children and adolescents with DM-1 (mean 
age: 14 years). HLA genotypes were determined in dried blood spots by polymerase 
chain reaction followed by DELFIA® hybridization assay.
Results: HLA-DQ2/8 was detected in 33 patients (“DQ2/8+”). When this group was 
compared to the remaining patients (“DQ2/8-“), we observed no differences in HbA1C, 
inflammatory markers, diabetes duration, IMT, and TC (p>0.2). In the “HLA DQ2/8+” 
group, LDL-to-HDL ratio was significantly elevated (1.8 vs 1.3, p<0.01), while BA-FMD 
was only slighlty decreased (5.1 vs 6.4 %, p=0.1) as compared to the “DQ2/8-“ group. 
When patients were further categorized in relation to CRP (cut-off value of 1 mg/L), BA-
FMD was significantly lower (2.9%, p<0.001) and LDL-to-HDL ratio increased further 
(2.3, p<0.001) in the subgroup of “DQ2/8+”&“CRP>1” patients compared to the remaining 
three subgroups (“DQ2/8-”&”CRP<1”, “DQ2/8-”&”CRP>1”, and “DQ2/8+”&”CRP<1”). The 
brachial artery responses to sublingual nitroglycerine (endothelium-independent agonist) 
were similar in all subgroups (p>0.5).
Conclusion: The diabetes-predisposing HLA-DQ2/8 genotype appears to interfere 
with endothelial and lipid-related mechanisms of early atherosclerosis, possibly, in part, 
through inflammatory pathways.
11:00 a.m.
1026-12 Alcohol Induces Tissue Plasminogen Activator 
Expression Through p38 Mitogen Activated Protein 
Kinase, Sp1 and NF-κb in Human Endothelial Cells
Wensheng Pan, Francois M. Booyse, Edlue M. Tabengwa, University of Alabama at 
Birmingham, Birmingham, AL
Background: Moderate alcohol consumption reduces the risk for coronary heart disease 
(CHD). This cardioprotective benefit may be mediated, in part, by alcohol-induced tissue 
plasminogen activator (t-PA) gene expression and subsequent increased fibrinolysis. 
We have previously shown that low concentrations of ethanol up-regulate t-PA gene 
transcription in cultured human endothelial cells (ECs). These studies describe the 
signaling pathways and regulatory elements involved in the up-regulation of t-PA gene 
transcription by ethanol.
Methods: Cultured human umbilical vein ECs (HUVECs) were transiently transfected with 
t-PA promoter deletion fragments ligated to a luciferase reporter gene, incubated in the 
absence/presence of ethanol (0.1%, v/v) and luciferase activity measured. Responsive 
fragments were incubated with nuclear extracts from control or ethanol-treated HUVECs 
and subjected to electrophoretic mobility shift assays (EMSA). Effects of ethanol on 
mitogen activated protein kinase (MAPK) activation was assessed by Western blot 
analysis, using phospho-specific antibodies. HUVECs were pre-incubated with MAPK 
inhibitors (10-20 μM) prior to alcohol treatment and measurement of t-PA mRNA levels 
(Real-time PCR) and promoter activity (luciferase activity).
Results: A 40-bp t-PA promoter region was identified, located between positions -561 
and -522 (relative to +1 start site) that was responsive to ethanol. This region contains 
putative binding sites for Sp1 and NF-κB. EMSA analysis identified ethanol-enhanced 
Sp1 and NF-κB binding to this region. Mutation of either site resulted in ~50% reduction in 
ethanol responsiveness, but was completely abrogated by disruption of both sites. Finally, 
the ethanol-dependent activation of t-PA mRNA and promoter activity was inhibited only 
the p38 MAPK inhibitor.
Conclusions: Results indicate that ethanol-induced t-PA expression requires activation 
of p38 MAPK signaling and both Sp1 and NF-κB binding for the transcriptional up-
regulation of t-PA gene expression. These studies provide new insights into mechanisms 
by which (moderate) alcohol increases fibrinolysis to afford cardioprotection by reducing 
overall thrombotic risk.
11:00 a.m.
1026-13 Arterial-Ventricular Interaction Assessment on the 
Basis of Non-Invasive Wave Intensity Parameters Most 
Precisely Predicts Risk of Death in Cardiomyopathy 
Patients Referred for Transplantation
Henryk Siniawski, Michael Jurmann, Axel Unbehaun, Hans B. Lehmkuhl, Michael 
Dandel, Yuguo Weng, Roland Hetzer, Deutsches Herzzentrum Berlin, Berlin, Germany
Background: Wave intensity (WI) is a new noninvasive method which helps to assess 
the left ventricle coupled with the arterial system. WI used to assess arterial-ventricular 
interaction to predict the risk of death in pts referred for heart transplantation was 
compared to standard invasive and non-invasive parameters.
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Methods: The ambulatory group (group 1) consisted of 150 consecutive out-pts (age 
48.7 ± 12 years; 110 men) with end-stage dilative cardiomyopathy studied between July 
2001 and December 2004. The follow-up period was 31 ± 8 months.
Group 2 consisted of 11 consecutive pts (age 50 ± 11 years; 6 men) with sinus rhythm but 
cardiac decompensation who were admitted for assist device implantation (shock group).
There were no demographic differences between the groups.
Non-invasive WI parameters from the common carotid artery, Doppler mitral filling values and 
cardiac output were analyzed using ALOKA 5.500. Complete invasive data were also recorded 
on the day of investigation. Data are expressed as mean ± SD. Statistical significance was 
assumed for p <0.05. Multivariate analyses were used for risk factor assessment.
Results: There were no significant differences in echocardiographic parameters or cardiac 
index between the groups. Group 1 pts had significantly higher first peak than shock pts 
(5400 ± 2200 vs. 2900 ± 1200, p=0.0005) but the second peak did not vary significantly. 
Lower first to second peak relation, as well as a significant (p<0.001) elevation of PCP 
(± 9.7 mmHg vs 27 ± 3.3 mmHg), was observed in group 2. During follow-up 25/150 pts 
(17%) died on the waiting list for transplantation. The following predisposing factors for 
death in group I were identified on the basis of the values found in the shock group: low 
first peak (OR 45.6, CI 14.5-143.3, p<0.001) and high ß value (OR 2.7, CI 1.04-7.0, p < 
0.05). No invasive data (including PCP and cardiac output) or non-invasive data (EF, EDD, 
mitral flow pattern) were statistically significant for the risk of death.
Conclusions: Precise prediction of heart failure requires definition of the ventricular-
arterial coupling state using WI and ß values. These are more accurate than standard 
invasive and non-invasive assessment of heart function.
11:00 a.m.
1026-14 RANTES and T Cell Modulation of Adipocyte Function
Sudip Ghosh, Huaizhu Wu, Xiao-Yuan D. Perrard, Christie M. Ballantyne, Baylor College 
of Medicine, Houston, TX
Background: Obesity is associated with chronic inflammation and insulin resistance 
characterized by overproduction of proinflammatory cytokines such as tumor necrosis 
factor-α (TNF-α) and monocyte chemoattractant protein-1 (MCP-1). Using a mouse model 
of diet-induced obesity (DIO), we previously found that T cells, regulated on activation 
normal T-cell expressed and secreted (RANTES), and RANTES receptor CCR5 were 
significantly increased in adipose tissue of DIO mice compared to leans. We investigated 
the effect of RANTES and T cells on preadipocyte/adipocyte function.
Methods: Murine 3T3-L1 and human preadipocytes were differentiated to adipocytes in 
vitro. We cocultured mouse splenic T cells or RANTES with 3T3-L1 cells. Adipogenesis 
was monitored visually, and triglyceride (TG) accumulation was quantitated by Oil Red O 
staining. 2-[1-14C] deoxy-D-Glucose or oleic acid uptake by adipocytes was examined 
by liquid scintillation counting. Lipolysis was measured as glycerol release. Expression of 
RANTES, MCP-1, and interferon-γ-inducible protein-10 (IP-10) was examined by RNase 
protection assay.
Results: TNF-α increased RANTES mRNA by 60-fold in 3T3-L1 adipocytes and by 13-
fold in human adipocytes, indicating that RANTES is an adipokine. RANTES (10-100 
ng/ml) significantly inhibited insulin-stimulated glucose uptake by 3T3-L1 adipocytes 
by up to 53%, but RANTES did not affect lipolysis, insulin-stimulated oleate uptake, 
or adipogenesis. T cells, activated with concanavalin A and cocultured with 3T3-L1 
preadipocytes, markedly inhibited adipogenesis, with inhibition of TG accumulation by 
60% in direct contact and 48% separated by a transwell. Treatment of mature 3T3-L1 
adipocytes with activated T cells significantly increased expression of RANTES (6-fold), 
MCP-1 (5-fold), and IP-10 (10-fold) when used directly and increased expression of MCP-
1 and IP-10 by 3.8- and 5.2-fold through transwell.
Conclusions: RANTES expression is increased in adipocytes with proinflammatory 
stimuli, which would recruit T cells into adipose tissue. Cross-talk between T cells 
and adipocytes in turn can modulate adipocyte function and may contribute to insulin 
resistance in obesity.
11:00 a.m.
1026-34 Effects of Sustained Ingestion of Cocoa on Endothelial 
Function in Adults with BMI between 25- 35 kg/m2: A 
Randomized, Single Blind, Placebo Controlled Trial
Valentine Njike, Zubaida Faridi, David Katz, Yale Prevention Research Center, Derby, CT
Background: Cocoa is considered the one of the most concentrated sources of the 
procyanidin flavonoids, catechin and epicatechin. Numerous studies indicate that there 
is a strong inverse correlation between consumption of wine, green tea and fruits and 
vegetables - other foods rich in flavonoids- and cardiovascular disease. Endothelial 
function has been used extensively to evaluate the acute and sustained effects of foods 
and nutrients on cardiac risk and can provide a direct measurement of the effect of dark 
chocolate consumption on vascular physiology.
Methods: Objective: To assess the sustained effects of consumption of cocoa on 
endothelial function measured as flow mediated dilation (FMD) of the brachial artery in 
adults with BMI between 25 and 35 kg/m2. 
Design: Randomized, single-blind, placebo controlled crossover trial.
Subjects/Setting: 45 subjects recruited from the general population of southwestern 
Connecticut (CT); the study site was the Yale Prevention Research Center Vascular 
Laboratory, Derby, CT.
Subjects were randomly assigned to one of the three groups (1) cocoa without sugar (2) 
cocoa with sugar and (3) placebo and underwent endothelial function testing using high 
frequency ultrasound pre and post daily ingestion of 22 gms./8 oz. of sugar free cocoa, 
cocoa with sugar or placebo for 6 weeks.
Main Outcome Measure: Endothelial function, assessed as flow-mediated vasodilatation 
(FMD) of the brachial artery were assessed pre and post sustained ingestion of 22gms./8 
oz of sugar free cocoa, cocoa with sugar or placebo.
Results: Thirty nine subjects completed the trail. FMD improved from baseline values 
following ingestion of cocoa with no sugar (2.4 ± 2.6; p<.0001) and cocoa with sugar (1.5 
± 2.7; p=0.0024). As compared to placebo, cocoa with no sugar and cocoa with sugar 
groups significantly improved FMD (i.e. 2.4 ± 2.6 vs. -0.8 ± 3.4; p<.0001 and 1.5 ± 2.7 vs. 
-0.8 ± 3.4; p=0.0021 respectively).
Conclusions: In this sample of healthy adults with BMI between 25 kg/m2 and 35 kg/m2, 
dark chocolate ingestion significantly improved endothelial function.
11:00 a.m.
1026-35 HDL Cholesterol is an Independent Risk Factor for 
Progression of Intimal-Medial Thickness: Results from 
the Atherosclerosis Risk in Communities (ARIC) Study
Brad C. Astor, Fleur Lee, Paul M. Muntner, Johns Hopkins University, Baltimore, MD, 
Pfizer, Inc., New York, NY
Background: While HDL cholesterol is an established factor for coronary heart disease, 
its association independent of LDL cholesterol is less certain. Ultrasound assessed intimal-
medial thickness (IMT) may help elucidate the role of HDL-cholesterol in progression of 
early atherosclerosis.
Methods: Longitudinal data from the Atherosclerosis Risk in Communities (ARIC) 
Study (n=12,615), including three measurements of IMT over nine years of follow-up, 
were analyzed to study the role of HDL-cholesterol with progression of sub-clinical 
cardiovascular disease.
Results: At baseline, mean IMT was 77.0, 73.6, 70.7, and 67.5 micrometers among 
participants with HDL-cholesterol levels of <40, 40-49, 50-59, and 60+ mg/dL, respectively (p-
trend<0.001). A strong, graded, association between HDL-cholesterol and IMT progression 
remained after adjustment for several potential confounders, including LDL-cholesterol 
level (Table). Also after adjustment, including LDL-cholesterol, each one standard deviation 
lower HDL-cholesterol (18 mg/dL) was associated with a 7.4 (standard deviation=1.9) 
micrometers greater IMT progression per 5-year follow-up period (p<0.001).
Conclusions: This study indicates that HDL-cholesterol may be an important modifiable 
risk factor for the progression of sub-clinical cardiovascular disease.
Five-year change (standard error) in intimal-medial thickness, by HDL-
cholesterol level
HDL-cholesterol 
level, mg/dL
Using baseline HDL-
cholesterol level, micrometers
Using most recently measured HDL-
cholesterol level, micrometers
60+ 0.0 (reference) 0.0 (reference)
50-59 7.7 (5.0) 8.1 (6.0)
40-49 9.2 (5.9) 19.1 (5.8)
<40 15.1 (6.0) 21.2 (5.9)
p-trend 0.014 <0.001
Adjusted for age, sex, race, follow-up time, prevalent CHD at baseline, and LDL-
cholesterol.
11:00 a.m.
1026-36 High Urinary 8-Iso-Prostaglandin F2α Concentration 
Reflects Plaque Instability in Early Stage Coronary 
Atherosclerosis (A 3-Dimensional Intravascular 
Ultrasound Study)
Takashi Hitsumoto, Mao Takahashi, Takuo Iizuka, Kouji Shirai, Toho University Sakura 
Hospital, Sakura, Japan
Background: Urinary 8-iso-prostaglandin F2α concentration (U-8-iso) is established to be 
a reliable oxidative stress marker, furthermore, some researchers have been reported the 
relation between U-8-iso and coronary atherosclerosis. On the other hand, it is well-known 
that coronary artery plaque is frequently detected on angiographycally normal portion. The 
purpose of this study is to clarify relationship between U-8-iso and early stage coronary 
atherosclerosis using a 3-dimensional intravascular ultrasound (3-D IVUS) study.
Methods: 66 subjects with normal coronary artery diagnosed by coronary angiography 
were enrolled. Proxymal range of left anterior descending coronary artery was observed 
by IVUS using autopullback methods. Subjects were divided into two groups by central 
value of U-8-iso (100pg/mg Cr, GroupH (high) or GroupL (low)).
Results: GroupH had significantly high %plaque volume than GroupL (30±9% vs 20±6%, 
p&lt;0.0001), furthermore, multiple regression analysis clarified that U-8-iso was selected 
an independent variables for %plaque volume (t=4.1, p=0.0001). On the other hand 
GroupH had high incidence of abnormal plaque quality such as eccentricity (73% vs 58%, 
p=0.2), calcification (64% vs 33%, p=0.01) and low echo area (27% vs 3%, p=0.006) into 
plaque than GroupN.
Conclusions: Data indicate that high U-8-iso reflects not only increase of plaue volume 
but also abnormal plaque quality in early stage coronary atherosclerosis, suggesting that 
high U-8-iso had a possibility to predict the occurrence of acute coronary syndrome.
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1026-37 Novel Laser Doppler Assessment of Microvascular 
Endothelial Function Correlates With Body Mass Index
Gareth A. Milborrow, Alan Murray, John Allen, Ian F. Purcell, Freeman Hospital, 
Newcastle Upon Tyne, United Kingdom
Background: The obesity epidemic is a significant health problem and increases the 
risk of atherosclerosis and cardiovascular disease. Laser Doppler flowmetry is a novel, 
non-invasive technique to assess microvascular endothelial dysfunction, a key event in 
the development of atherosclerosis.
Methods: We measured microvascular blood flow following transdermal administration 
of: 1) 1% Acetylcholine Chloride solution, (endothelium dependent vasodilatation); 
2) 1% Sodium Nitroprusside solution, (endothelium independent vasodilatation). 24 
normotensive, non-smoking, healthy subjects (13 males, age 27± 5.7 years) with a body 
mass index (BMI) range from 20.17 to 34.21 (mean 25.75) were studied.
Results: Blood flow was quantified in arbitrary perfusion units (APU). There was a 
significant inverse linear correlation between BMI and endothelium-dependent flow (r = 
-0.41; p=0.02). There was no correlation between BMI and endothelium-independent flow 
(r = - 0.01; p=0.47). 
Conclusions: Assessment of the skin microvasculature by laser Doppler demonstrates 
that increasing BMI is associated with deteriorating endothelium-dependent vasodilatation 
of the microvasculature in contrast to endothelium-independent vasodilation which is 
preserved.
11:00 a.m.
1026-38 Parental Coronary Heart Disease Increases Vulnerability 
of the Arterial Wall to Metabolic Syndrome and Aging: 
The Bogalusa Heart Study
Wei Chen, Sathanur R. Srinivasan, Gerald S. Berenson, Tulane University, New Orleans, LA
Background: Genetic susceptibility is considered as an important mediator of the impact 
of cardiovascular risk factors on coronary heart disease (CHD). This study assessed the 
hypothesis that parental CHD, a surrogate measure of genetic susceptibility, increases 
the vulnerability of arterial structure-function dynamics to the adverse effects of metabolic 
syndrome and the aging process even in asymptomatic young adults with parental CHD.
Methods: The study cohort consisted of 1073 black and white subjects (31% black, 43.4% 
male) aged 25-44 years enrolled in the Bogalusa Heart Study. Arterial structure-function 
dynamics was assessed in terms of carotid artery intima-media thickness (IMT) measured 
by B-mode ultrasound and aorta-femoral pulse wave velocity (af-PWV) by echo-Doppler. 
Metabolic syndrome was defined by the NCEP guidelines.
Results: Subjects with positive parental history of CHD had greater carotid IMT (0.839 vs 
0.802 mm, p=0.017), higher af-PWV (5.4 vs 5.2 m/sec, p=0.097) and higher prevalence of 
metabolic syndrome (12.1% vs 7.6 %, p=0.019), compared with those without such history. 
Carotid IMT and af-PWV were significantly increased with increasing number of components 
of metabolic syndrome and age (both p<0.001). Further, the number of metabolic syndrome 
components associated more strongly with carotid IMT in subjects with parental history of 
CHD (β=0.05, p<0.001) than those without such history (β=0.03, p<0.001), with p=0.008 
for comparison of slopes. Likewise, after adjusting for metabolic syndrome components, 
carotid IMT increased relatively more with age in subjects with parental history of CHD 
(β=0.012, p<0.001) than those without such history (β=0.007, p<0.001), with p=0.023 for 
comparison of slopes. af-PWV showed similar but nonsignificant differences in slopes with 
increasing number of metabolic syndrome components and age.
Conclusions: Parental CHD increases the susceptibility of arterial structure-function 
dynamics, especially carotid artery IMT, to metabolic syndrome and aging process even 
in asymptomatic young adults.
11:00 a.m.
1026-39 Impaired Therapeutic Potential of Bone Marrow-Derived 
Endothelial Progenitor Cells in the Metabolic Syndrome 
and Diabetes Mellitus.
Michael A. Kuliszewski, James W. Kowalewski, Michael R. Ward, Alexandra H. Smith, 
Matthew Sibbald, Duncan J. Stewart, Michael J.B. Kutryk, Howard Leong-Poi, St. 
Michael’s Hospital, Toronto, ON, Canada
Diabetes mellitus and the metabolic syndrome are associated with impairment of 
circulating endothelial progenitor cells (EPCs), but their effects on bone marrow (BM)-
derived EPCs have not been well characterized. We compared the angiogenic potential 
of EPCs derived from the BM of Obese Zucker (OZ) rats (Metabolic Syndrome), Zucker 
Diabetic fatty (ZDF) rats, with control Lean Zucker (LZ) rats.
Methods: Mononuclear cells were isolated from the BM of LZ, OZ and ZDF rats (6 and 12 
wk old) (n=6 for each). At day 0, EPC number was determined by FACS (KDR+/CD45dim). 
After 7 days in culture, EPC differentiation was quantified by VEGFR-2 expression, and 
apoptosis was measured by Annexin. In vitro EPC function was determined by migration 
and matrigel tube formation assays. In vivo angiogenic potential of BM-derived EPCs was 
assessed by intramuscular injection in the ischemic hindlimb of athymic mice (n=6 per 
group). Tissue perfusion was measured serially using Laser Doppler imaging.
Results: BM-derived EPC numbers were similar in all groups, irrespective of age or risk 
factors. The percentage of EPCs exhibiting mature endothelial markers was significantly 
reduced in an age independent manner in OZ and ZDF rats, compared to LZ. The rate of 
apoptosis was increased in an age dependent manner in the OZ and ZDF groups vs LZ 
(2.7±1.8% (OZ 6wk) and 2.4±0.7% (OZ 12wk) and 3.5±2.1% (ZDF 6wk) and 8.4±3.8% 
(ZDF 12wk) vs 1.1±0.8% (LZ), p=NS for OZ, p<0.05 for ZDF). The migratory potential 
of BM-derived EPCs and their in vitro tube formation was impaired in OZ and ZDF rats 
compared to LZ. In vivo data from the hindlimb ischemia model showed similar restoration of 
perfusion using LZ and 6 week ZDF (pre-diabetic) EPCs. There was impaired angiogenesis 
using BM-EPCs from OZ and 12 week ZDF rats (normalized perfusion 0.37±0.01 (OZ 6wk), 
0.44±0.08 (OZ 12wk) and (0.41±0.09 (ZDF 12wk) vs 0.66±0.08 (LZ).
Conclusions: Despite normal numbers, in the presence of the metabolic syndrome and 
diabetes, BM-derived EPCs develop similar phenotypic and functional impairment when 
cultured, resulting in reduced angiogenic capacity in vivo. This may potentially limit the 
use of BM-derived EPCs for therapeutic angiogenesis in patients with these conditions.
11:00 a.m.
1026-40 Adrenomedullin and Adrenotensin Increase RGS2 in 
Vascular Smooth Muscle Cells via Different Pathway
Yuanjie Mao, Lin Xue, Yuyan Wang, Lei Meng, Zhaoshu Tang, Jialin Su, Yong Huo, 
Peking University First Hospital, Beijing, People’s Republic of China
Backgroud: Arenomedullin (Adm) and Adrenotensin (Adt) differently regulate vessel tone 
and growth of vascular smooth muscle cells (VSMCs), although they are two peptides 
derived from the same molecule, preproadrenomedullin. Adm could potently dialate 
blood vessel, decrease blood pressure, and inhibit proliferation of VSMCs, while Adt 
could contract blood vessel and stimulate proliferation of VSMCs. Regulators of G protein 
signaling (RGSs) are a family of proteins with GAP (GTPase-activating protein) activity 
which could accelerate hydrolysis of GTP and terminate G protein signaling. Whether 
RGSs in VSMCs with negative fine-tuning effects on Gq protein signaling,such as RGS2, 
RGS3, and RGS4, could also be differently regulated by Adm and Adt, so as to possibly 
play a role in the regulatory effects of Adm and Adt on VSMCs is unknown.
Methods: VSMCs were isolated from Wistar rat aorta and passages 3-6 were used for 
study. After cultured in serum-free medium for 24 hr, VSMCs were treated with Adm, Adt, 
and angiotensin II (A II) for 0.5 hr to 24 hr. RNA was extracted and real-time PCRwas 
done after RT to determine RGS2, RGS3, and RGS4 mRNA levels. VSMCs were also 
pre-treated with forskolin 10-5 M, SQ 22536 10-4 M, or chelerythrine chloride 10-5 M to 
evaluate the mechanism of RGS regulation.
Results: RGS2, RGS3, and RGS4 mRNA were all present in VSMCs demonstrated by RT-
PCR. Adm dose-dependently increased RGS2 up to 35 times early at 0.5 hr (p < 0.01), while 
Adt and AII dose-dependently increased RGS2 mRNA up to 4-5 times at 1 hr (p < 0.05). 
RGS3 were decreased by Adm, while increased by Adt and A II, but the changes were not 
statistically different. RGS4 was roughly unchanged. Forskolin 10-5 M also increased RGS2 
mRNA. PKA inhibitor SQ 22536 10-4 M could antangonize effect of Adm on RGS2, but not 
Adt. PKC inhibitor chelerythrine chloride 10-5 M could antagonize effect of Adt, but not Adm 
on RGS2. Conclustion: RGS2, but not RGS3 and RGS4 inVSMCs could be increased 
by Adrenomedullin (Adm) and adrneotensin (Adt). Adm increase RGS2 via PKA, and Adt 
increase RGS2 via PKC. The selective regulation of RGS2 in VSMCs via different pathway 
might play a role in the regulation of growth and tone of VSMCs.
11:00 a.m.
1026-41 Ethnic and Geographic Differences in Coronary 
Atherosclerotic Plaque Composition: A Report from the 
Global Virtual Histology Intravascular Ultrasound (VH-
IVUS) Registry
Gary S. Mintz, Junko Honye, William Wijns, Takahiko Suzuki, Patrick W. Serruys, 
Osamu Katoh, Martin B. Leon, Cardiovascular Research Foundation, New York, NY, 
Nihon University School of Medicine, Tokyo, Japan
Background: Virtual histology (VH) classifies plaque as calcified, fibrotic, fibrofatty, or 
necrotic core based on radiofrequency intravascular ultrasound (IVUS) data.
Methods: 3221 unselected pts with coronary artery disease undergoing diagnostic or 
interventional procedures were enrolled in a global registry. Clinical parameters, biomarkers, 
and volumetric greyscale IVUS quantification and IVUS-VH plaque composition analysis of 
the entire pullback length (4.9±2.2cm) were performed on 990 pts.
Results: Overall, plaque volume measured 334±206mm3; plaque area measured 
6.9±2.75mm2; and plaque burden (plaque/vessel) measured 44±9%. As shown in the 
Table (VH-IVUS data is expressed as median [IQR]), despite less frequent use of statins, 
coronary arteries in Japanese pts were characterized by more fibrotic plaque (p<0.001 
vs both Europe and North America) and more fibrofatty plaque (p=0.06 vs Europe and 
p<0.001 vs North America), but no difference in calcification and necrotic core (as a % of 
total plaque volume) although the average necrotic core CSA (mm2) was higher in Japan 
than in Europe and North America (p<0.05 and p=0.09). 
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North America Europe Japan p-Value
N 330 538 122
Acute coronary syndrome (%) 43.1 40.5 34.4 ns
Hypertension (%) 74 71 56 <0.001
Diabetes (%) 29 20 33 <0.001
Statin use (%) 69 70 40 <0.001
Plaque burden (%) 44±9 43±9 46±9 <0.001
%Necrotic core 6.1 (2.9-8.6) 5.9 (3.0-8.5) 6.1 (2.9-8.7) ns
%Calcified plaque 4.4 (1.3-6.3) 4.0 (1.3-5.5) 3.7 (1.3-4.9) ns
%Fibrotic plaque 28 (23-35) 28 (23-35) 32 (27-37) <0.001
%Fibrofatty plaque 8.6 (5.2-11.3) 9.3 (5.4-12.0) 10.2 (6.5-13.6) <0.001
Conclusions: Volumetric VH-IVUS analysis showed distinct ethnic and geographic 
population differences in coronary atherosclerotic plaque composition especially when 
Japanese pts were compared to pts in Europe and North America. These pathoanatomic 
differences may help explain different rates of events (acute coronary syndromes and 
restenosis) among these pt groups.
11:00 a.m.
1026-42 Obstructive Sleep Apnea is the Strongest Risk for 
Thoracic Aortic Expansion
Naoki Serizawa, Dai Yumino, Keiko Gomita, Katsuya Kajimoto, Atsushi Takagi, Nobuhisa 
Hagiwara, Hiroshi Kasanuki, Tokyo women´s Medical University, Tokyo, Japan
Background: Obstructive sleep apnea (OSA) is well known to be associated with 
hypertension. However, the relationship between OSA and thoracic aortic expansion 
(TAE) has been unclear. We aimed to clarify the association of OSA with TAE.
Methods:We examined polysomnography and chest computed tomography (CT) among 
89 consecutive patients (mean age 62.2 ± 13.2 yrs, 73 males) who were referred for 
OSA to our hospital. OSA was defined as an apnea hypopnea index (AHI) ≥ 10/hr by 
polysomnography. TAE was defined if the diameter of ascending aorta ≥ 35 mm. We 
compared the groups with and without TAE/ OSA by independent factors associated 
using multiple logistic regression analysis.
Results: A total of 66 patients (74.1%) were defined as OSA. The diameter of ascending 
aortic in patients with OSA was significantly greater than that that without OSA (37 ± 4.6 
vs. 31± 4.3 mm, P<0.0001). CT demonstrated TAE in 47(53%) patients. In each group, we 
analyzed age, male, body mass index (BMI), presence of OSA, hypertension, diabetes 
mellitus. Univariate analysis indicated that TAE was significantly associated with male 
(OR 4.3, 95% 1.26-14.6, P=0.01), age (OR 1.05, 95%CI 1.01-1.08, P=0.01) and OSA 
(OR 8.88, 95%CI 2.70-29.2, P<0.0001). Multivariate analysis also demonstrated that TAE 
was associated with age (OR 1.05, 95%CI 1.00-1.09, P=0.03). Moreover, OSA was the 
strongest risk for TAE (OR 6.97, 95%CI 1.88-25.9, P<0.01).
Conclusions: Age and OSA appeared to be an independent risk associated with TAE. In 
the present study, OSA was the strongest risk for TAE Further investigation is warranted 
to elucidate the mechanism underlying between TAE and OSA.
11:00 a.m.
1026-43 Effect of Statin Therapy on Central Aortic Pressures 
and Hemodynamics: Principal Results of the Lipid 
Lowering Arm of the Conduit Artery Function 
Evaluation study (CAFE-LLA).
Bryan Williams, Peter S. Lacy, Kennedy J. Cruickshank, Simon Thom, Alice Stanton, 
David Collier, University of Leicester, Leicester, United Kingdom
Background: Statins reduce the risk of cardiovascular events in people with hypertension. 
Recent interest has focussed on the potential for statins to favorably influence large 
artery function and central aortic blood pressures. CAFE-LLA, a sub-study of the 
Anglo Scandinavian Cardiac Outcomes Trial (ASCOT), investigated the impact of long-
term statin therapy on derived central aortic pressures and hemodynamics in a major 
prospective, placebo-controlled clinical outcomes trial of treated hypertensives.
Methods: CAFE-LLA utilized the 2x2 factorial design of ASCOT which had compared two 
blood pressure lowering strategies and a lipid-lowering arm (ASCOT-LLA, atorvastatin 
10mg vs. placebo). CAFE-LLA recruited 891 patients randomized to ASCOT-LLA. Radial 
artery applanation tonometry and pulse wave analysis was used to derive repeated 
central aortic pressures and hemodynamic indices over a 2.5 yr follow-up.
Results: Atorvastatin lowered LDL-Cholesterol by 32.5 mg/dl (95%CI: 28.6 - 36.3) vs. 
placebo (p<0.001). Of note, time-averaged brachial blood pressure (BP) was similar 
in treated hypertensive patients randomized to either atorvastatin or placebo [brachial 
systolic BPΔ: -0.1mmHg (-1.8-1.6) p=0.9; brachial pulse pressure PPΔ -0.02 mmHg (-1.6 
- 1.6) p=0.9]. Importantly, atorvastatin therapy did not influence central aortic pressures 
[aortic SBPΔ -0.5 mmHg (-2.3 - 1.2) p=0.5; aortic PP Δ -0.4 mmHg (-1.9 - 1.0) p=0.6] and 
had no influence on augmentation index (p=0.5), time to pulse wave reflection (p=0.3) 
or heart rate (p=0.7) compared to placebo. Moreover, there was no interaction between 
the BP treatment strategy and statin therapy in the factorial design (aortic SBP F=0.56, 
p=0.46; aortic PP F=0.44, p=0.51) with regard to central aortic pressures.
Conclusions: CAFE-LLA has unequivocally shown that the addition of statin therapy does 
not significantly influence central aortic pressures / hemodynamics in treated hypertensive 
patients. These novel findings imply that statins complement the benefits of BP-lowering 
in hypertensive patients predominantly via pressure-independent mechanisms and have 
important implications for risk reduction strategies in hypertensive patients.
11:00 a.m.
1026-44 Increased Risk of Incident Stroke Associated with the 
Cyclooxygenase 2 (COX-2) G-765C Polymorphism 
in African-Americans: The Atherosclerosis Risk in 
Communities Study
Shun Kohsaka, Kelly A. Volcik, Aaron R. Folsom, Kenneth K. Wu, Christie M. Ballentyne, 
James T. Willerson, Eric Boerwinkle, Texas Heart Institute, Houston, TX, Human 
Genetics Center, University of Texas Health Science Center, Houston, TX
Background: A hallmark feature of atherosclerosis is inflammation mediated by 
prostaglandins (PGs) catalyzed by the enzyme cyclooxygenase (COX). The present study 
explored whether the COX-2 G-765C polymorphism contributes to increased incidence 
of coronary heart disease (CHD) or stroke in the large prospective Atherosclerosis Risk 
in Communities (ARIC) Study.
Methods: Incidences of CHD and stroke were identified through annual follow-up and 
hospital and death certificate surveillance. The study included 1,488 incident CHD and 
527 stroke events after an average of 14 years of follow-up. The frequency of the -765C 
variant allele was markedly different between African-Americans and whites, therefore all 
analyses were performed separately by race. Due to the small number of persons with 
the -765CC genotype, heterozygous and homozygous variant genotypes were combined 
for this analysis.
Results: The COX-2 G-765C polymorphism was not a significant predictor of CHD in 
either racial group, but it was a significant predictor of incident stroke in African-Americans. 
After adjustment for age and gender, the hazard rate ratio for developing stroke for the 
CG+CC genotypes relative to the GG genotype was 1.34 (95% confidence interval [CI] 
1.03-1.74, p=0.03) in African-Americans. This result was essentially unchanged when 
established predictors such as smoking, diabetes and hypertension were added to the 
model (HRR 1.34, 95%CI 1.03-1.76, p=0.03).
Conclusion: We have found the COX-2 G-765C polymorphism to be a risk factor for 
incident stroke in African-Americans. This study provides additional evidence for utilizing 
inflammation-related genetic polymorphisms for identifying individuals at increased risk 
for stroke.
11:00 a.m.
1026-45 Platelet Glycoprotein 1b Alpha T145M Dimorphism 
As A Risk Factor For The Recurrent Cardiac Events 
In Post Infarction Patients With Claudication.
Grzegorz M. Pietrasik, Wojciech Zareba, Ilan Goldenberg, Daniel Ryan, Arthur J. Moss, 
Patricia Severski, University Of Rochester Medical Center, Rochester, Ny
Background: Platelet glycoprotein 1B alpha is involved in platelet adhesion in the 
response to injured endothelium. The 145Met allele of GP 1B alpha T145M dimorphism 
is associated with cardiovascular disease. We hypothesized that the Met allele of T145M 
dimorphism is associated with an increased risk of the recurrent cardiac events among 
post-infarction (MI) patients with claudication.
Methods: The risk of recurrent cardiac events (cardiac death, nonfatal MI or unstable 
angina) by the presence of the 145Met allele was analyzed in the cohort of 910 patients: 
with (n=67) and (n=843) without claudication.
Results: The frequencies of 145 Met allele among patient with and without claudication 
were 15% and 20%, respectively (p=0.342). The 145 Met allele was associated with higher 
rate of recurrent cardiac events (Figure). Patients with the 145 Met allele and claudication 
had higher recurrent cardiac events (adjusted HR 4.08, 95% CI 1.43-11.66, p=0.01), 
whereas, among patients without history of cla udication, 145 Met allele was not associated 
with increased risk of cardiac events (adjusted HR 1.11, 95% CI 0.58-2.12, p=0.745).
Conclusions: Our finding indicate that among the post MI patients with advanced 
atherosclerotic process, the 145M allele of T145M dimorphism contributes significantly to 
the risk of recurrent cardiac events.
FIGURE.
Cumulative Probability of combined endpoints in patients with claudication and 145 
Met genotype. p =0.015
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1026-46 The Influence of Oxidized Phospholipids and Lp(a) 
Lipoprotein on Coronary Artery Disease is Conditional 
upon Genotype at the Interleukin-1 Region
Sotirios Tsimikas, Gordon W. Duff, Peter B. Berger, John Rogus, Kenneth Huttner, 
Kenneth S. Kornman, Joseph L. Witztum, University of California San Diego, La Jolla, CA
Background: Oxidized phospholipids (OxPL) detected by monoclonal antibody E06 circulate 
on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. 
We previsouly showed that the OxPL/apoB ratio was a strong predictor of coronary artery 
disease (CAD). In this study, we tested the hypothesis that the influence of OxPL/apoB and 
Lp(a) lipoprotein on CAD is conditional upon haplotypes in the IL-1 gene family.
Methods: OxPL/apoB and Lp(a) levels were measured in 504 patients undergoing 
coronary angiography. CAD was defined as >50% diameter stenosis. Three single 
nucleotide polymorhpisms (SNPs) in the IL-1 gene cluster, IL-1A(+4845) (G/T), IL-
1B(+3954) (C/T), and IL-1B(-511) (C/T) were used to classify patients as either IL-1(+) or 
IL-1(-). The composite genotypes of these three SNPs comprising the IL-1(+) group are 
associated with increased plasma levels of IL-1 and C-reactive protein (CRP).
Results: Among IL-1(+) patients, those in the highest quartile of OxPL/apoB had a significantly 
higher risk of CAD compared with those in the lowest quartile (OR 2.52, P<0.01). This effect 
was strongly accentuated in patients ≤60 years old (OR 6.92, P=0.0001). In contrast, in IL-1(-) 
patients, OxPL/apoB levels showed no association with CAD in any group. Substituting Lp(a) 
for OxPL/apoB gave similar results for both genotype groups, except in patients ≤60 years old 
where OxPL/apoB was predictive of CAD even with Lp(a) in the model. These findings were 
independent of all other measured risk factors, including CRP.
Conclusions: The influence of OxPL and Lp(a) on CAD is found predominantly in 
patients with IL-1(+) genotypes These data suggest a novel and clinically-relevant 
biological link between pro-inflammatory IL-1 genotypes, oxidation of phospholipids and 
genetic predisposition to CAD in younger individuals.
11:00 a.m.
1026-47 Simvastatin Attenuates Plaque Inflammation -
Evaluation By 18f-fluoro-2-deoxyglucose Positron 
Emission Tomography-
Nobuhiro Tahara, Minori Mizoguchi, Hisashi Kai, Masatoshi Ishibashi, Tsutomu 
Imaizumi, Department of Medicine, Division of Cardiovascular Medicine, Kurume 
University School of Medicine, Kurume, Japan, Department of Radiology, Kurume 
University School of Medicine, Kurume, Japan
Background: Inflammation plays a key role in progression and destabilization of 
atherosclerotic plaque. 18F-fluoro-2-deoxyglucose positron emission tomography 
(18FDG-PET) is a promising tool for visualizing inflammation of atherosclerotic plaque. 
Anti-inflammatory action is one of the pleiotropic effects of statins. We investigated 
whether simvastatin attenuates plaque inflammation by using 18FDG-PET co-registered 
with computed tomography. 
Methods: Forty-three consecutive subjects, who underwent 18FDG-PET for cancer 
screening and had 18FDG uptakes in the thoracic aorta and/or the carotid arteries, were 
randomized to either statin group receiving simvastatin (n=21) or diet group receiving 
dietary managements (n=22). The maximum standardized uptake values (SUVs) were 
measured in individual plaques, and were averaged for analysis of the subject-wise 
results. The responses were assessed after 3-month treatments. PET revealed 117 and 
123 18FDG-positive plaques in the statin and diet groups, respectively.
Results: Simvastatin, but not diet alone, attenuated plaque 18FDG uptakes and 
decreased the SUVs (p<0.01). Simvastatin reduced low-density lipoprotein cholesterol 
(LDL) by 30% (p<0.01) and increased high-density lipoprotein cholesterol (HDL) by 15% 
(p<0.01), whereas LDL and HDL levels were not changed in the diet group. In the statin 
group, the decrease in the SUV was well correlated with the HDL elevation (p<0.01), but 
not with the LDL reduction.
Conclusions: 18FDG-PET visualized plaque inflammation and simvastatin attenuated 
it. The LDL-independent effects of simvastatin may participate in the beneficial effect. 
18FDG-PET has a potential for visually monitoring plaque inflammation and therapeutic 
effectiveness of statins.
11:00 a.m.
1026-76 Influence of serum Gamma glutamyl transferase on 
Vascular Compliance in Young Adults: The Bogalusa 
Heart Study
Dharmendrakumar A. Patel, Sathanur R. Srinivasan, Wei Chen, Ji-Hua Xu, Gerald S. 
Berenson, Tulane University, New Orleans, LA
Background: Impaired vascular compliance is an independent predictor of early vascular 
damage and related adverse cardiovascular (CV) outcome. However, information is scant 
regarding the association of gamma glutamyl transferase (GGT), a liver function enzyme 
with important role in maintaining glutathione antioxidant defense, with measures of 
vascular compliance in young adults.
Methods: This aspect was examined in biracial (black-white) community-based sample of 
692 young adults (43% male, 71% white) both longitudinally (baseline age: 17-32 years, 
average follow-up period: 12 years) and cross-sectionally at follow-up (mean age: 37.8 
years). Along with repeat observations of cardio-metabolic risk factors and liver enzymes, 
pulsatile arterial function was assessed in terms of large artery (capacitive) compliance, 
small artery (oscillatory) compliance, and systemic vascular resistance by noninvasive 
radial artery pressure pulse contour analysis at follow-up.
Results: Cross-sectionally, black versus whites and women versus men had lower large 
and small artery compliances (p<0.01 for race, p<0.0001 for gender) and higher systemic 
vascular resistance (p 0.001 for race, p=0.01 for gender). All three vascular compliance 
measurements were significantly correlated with GGT after adjusting for age, race, gender, 
cigarette smoking, alcohol consumption, and body surface area. In multivariate analysis, 
independent of other risk factors, GGT was a significant predictor of large artery compliance, 
small artery compliance, and systemic vascular resistance. Similar findings were observed 
in longitudinal cohort over 12 year period where baseline GGT was independently predictive 
of small artery compliance and systemic vascular resistance at follow-up.
Conclusions: These findings by showing an inverse association of GGT with arterial 
compliance and positive association with systemic vascular resistance, both longitudinally 
and cross-sectionally, underscore the clinical implications of GGT on vascular functions 
and thus, future CV risk.
11:00 a.m.
1026-77 A High Ankle Brachial Index Is Associated With 
Increased Cardiovascular Disease Morbidity And Worse 
Quality Of Life
Matthew A. Allison, Michael H. Criqui, William R. Hiatt, Alan T. Hirsch, Joseph Coll, 
University of California San Diego, La Jolla, CA
Background: ABI values >= 1.30 have been associated with cardiovascular disease 
(CVD) risk factors and with increased coronary artery calcium scores, but the relationship 
to quality of life (QoL) has not been previously evaluated. This study tested the hypothesis 
that an ABI >= 1.30 would be associated with worse quality of life compared with ABI 
values in the normal range (1.00-1.29).
Methods: The PAD Awareness, Risk and Treatment: New Resources for Survival 
(PARTNERS) program was a national cross-sectional study of 7000 patients over the 
age of 50 years recruited from 350 primary care sites. All sites performed the ABI using a 
Doppler probe and a standardized technique. Subjects completed a study questionnaire 
providing information on medical history, lower extremity symptoms, CVD events and 
quality of life using the SF-36 and walking impairment questionnaire (WIQ).
Results: The mean age was 70.8, 53% were female, over 83% were hypertensive, 37% 
were diagnosed with diabetes mellitus and 48% were either current or former cigarette 
smokers. The mean ABI was 1.00 ± 0.21 and 323 (4.5%) had an ABI >= 1.30 in either leg. In 
a multivariable logistic regression model containing all CVD and socioeconomic risk factors, 
diabetes (Odds Ratio: 1.5, 95% CI: 1.1 - 2.0), current smoking (0.5, 0.3 - 0.9) and male sex 
(2.4, 1.6 - 3.2) were significantly associated with an ABI >= 1.30. Compared to those with 
an ABI from 1.0 to 1.29, the odds for coronary artery bypass graft (CABG) and deep venous 
thrombosis (DVT) were significantly higher (1.6, 1.0 - 2.7 and 2.3, 1.2 - 4.6; respectively) in 
the high ABI group while the odds for peripheral neuropathy and CHF were of borderline 
significance (1.5, 1.0 - 2.5 and 1.5, 0.9 - 2.7). With adjustment for CVD risk factors and leg 
pain, those in >= 1.30 group had impaired quality of life as defined by their significantly 
higher odds for the lowest quartile of SF-36 vitality (OR: 1.4), SF-36 role emotional 
(1.3), WIQ walking distance (1.4), WIQ walking speed (1.4) and WIQ stair climbing (1.3). 
Conclusion: Individuals with a high ABI have higher rates of CVD co-morbidities, as well as 
major decrements in quality of life across many major functional domains.
11:00 a.m.
1026-78 Improved Ex-Vivo MR Imaging of Human Aortic 
Atherosclerosis with Macrophage-Specific 
Immunomicelles
Michael J. Lipinski, Juan Carlos Frias, Vardan Amirbekian, Venkatesh Mani, Juan 
Gilberto S. Aguinaldo, Karen Briley-Saebo, Dan Sandberg, Davis Massey, Valentin 
Fuster, George W. Vetrovec, Zahi A. Fayad, Mount Sinai Medical Center, New York, NY, 
Virginia Commonwealth University Health System, Richmond, VA
Background: Magnetic resonance imaging (MRI) using immunomicelles targeting 
macrophages may enable detection of high-risk lesions prior to an atherothrombotic event. 
While our group demonstrated that immunomicelles improve detection of atherosclerosis 
in mice, the goal of this study was to determine if immunomicelles targeting the 
macrophage scavenger receptor-B (CD36) improve detection and characterization of 
human atherosclerosis.
Methods: Human aorta with moderate to severe atherosclerosis was harvested at 
autopsy. Biotinylated Gd-containing micelles, anti-CD36 immunomicelles and FC-micelles 
were created. Using a 1.5 T Siemens clinical scanner, T1, T2, and PDW 3-dimensional 
scans were performed on 16 aorta pieces. Post-contrast scans were repeated after 
24 h incubation in one of the 3 contrast agents. T1 analysis and cluster analysis were 
performed comparing immunohistopathology with MRI to determine signal-to-noise ratio 
(SNR) in lipid-rich plaque, fibrous plaque, and the whole aorta. P-values<0.05 were 
considered statistically significant.
Results: Micelles had a mean diameter of 125 nm, average of 14,900 Gd-ions, 
and relaxivity of 37 mM-1s-1. Pre and post-contrast T1 analysis demonstrated that 
immunomicelles increased SNR by 52.5% (p<0.0001) while FC-micelles increased 
SNR by 17.2% (p<0.0001) and micelles increased SNR by 18.7% (p<0.0007). 
Immunomicelles increased SNR significantly greater than the FC-micelles or micelles on 
2-way ANOVA (p<0.001). Confocal fluorescent microscopy demonstrated colocalization 
of immunomicelles with macrophages while the micelles and FC-micelles were found 
diffusely throughout the plaque. 2-way ANOVA demonstrated that immunomicelles had a 
greater increase of SNR in fibrous plaque vs lipid-rich plaque (75% vs 44% respectively, 
p<0.001) while micelles and FC-micelles had a greater increase in lipid-rich plaque.
Conclusions: Macrophage-specific immunomicelles improved detection and 
characterization of human aortic atherosclerosis with MRI. Thus, immunomicelles could 
help identify high-risk human plaque.
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1026-79 Immunolocalization of Platelet Glycoprotein IIb/IIIIa 
and P-selectin, and Neutrophil-Platelet Association in 
Human Carotid Unstable Plaques
Chizuko Kitabayashi, Yoshihiko Ikura, Masashi Nakagawa, Nobuyuki Shirai, Hajime 
Yamashita, Shoichi Ehara, Misao Nishikawa, Takahiko Naruko, Masahiko Ohsawa, Minoru 
Yoshiyama, Makiko Ueda, Osaka city University Graduate School of Medicine, Osaka, Japan
Background:. Thrombotic complications of carotid atherosclerotic plaques are important 
pathomechanisms of ischemic stroke. We have previously demonstrated that neutrophils 
play an important role in the destabilization of human coronary atherosclerotic plaques 
(Circulation 106;2894-2900, 2002). Platelets are recognized as an important modulator of the 
inflammatory process, and a close association between activated platelets and neutrophils 
may contribute to plaque destabilization in human carotid plaques. Precise identification 
of activated platelets requires simultaneous detection of P-selectin and glycoprotein(GP) 
IIb/IIIa. In the present study, we collected frozen samples of human carotid atherosclerotic 
plaques, and immunohistochemically investigated the localization of activated platelets and 
platelet-neutrophil association in human carotid atherosclerotic plaques.
Methods: We investigated frozen tissues of 25 endarterectomy specimens for extracranial high-
grade ICA stenosis, surgically obtained. Frozen samples were studied with antibodies against 
platelet GPIIb/IIIa, P-selectin, neutrophils (CD66b, CD11b, myeloperoxidase. and elastase), 
smooth muscle cells, macrophages, and glycophorin A (a protein specific for erythrocytes).
Results: P-selectin-positive activated platelets were frequently aggregated in the 
unstable carotid plaques, and were close to regions of dense neutrophil infiltration. 
Moreover, these unstable carotid plaques contained plaque hemorrhage with staining 
positivity of glycophorin A.
Conclusions: The present study, based on the analysis of frozen sections, demonstrated 
precise identification of activated platelet aggregates, which were simultaneously positive 
for GPIIb/IIIa and P-selectin, and a close association between activated platelets and 
neutrophils, in human unstable carotid plaques. This suggests that platelet-neutrophil 
association may be an important factor to induce plaque destabilization of human carotid 
atherosclerotic lesions..
11:00 a.m.
1026-80 Safety and Efficacy of IVUS-guided Lumen Re-entry 
Devices for the Percutaneous Revascularization of Chronic 
Total Occlusions of the Superficial Femoral Artery
Eduardo Infante de Oliveira, Vivek Rajagopal, Matthews Chacko, Christian 
Simpfendorfer, Brian K. Jefferson, Christopher Bajzer, Deepak L. Bhatt, Samir Kapadia, 
Cleveland Clinic, Cleveland, OH
Background: Percutaneous revascularization of superficial femoral artery (SFA) chronic 
total occlusions (CTO) often fail due to the inability to regain access to true lumen distal 
to the occlusion. The safety and efficacy of intravascular ultrasound (IVUS)-guided lumen 
re-entry devices for the treatment of SFA CTOs remain uncertain.
Methods: We evaluated the characteristics and outcomes of patients with SFA CTO 
undergoing revascularization attempt with a lumen re-entry device (LRD) in our institution 
between August 2003 and August 2006.
Results: A total of 349 patients underwent revascularization of SFA. LRD used in 20 
patients in an attempt to regain true lumen access after failure to do so with conventional 
wires. In those patients, the mean age was 70±10 years and 55% were men. The 
lesions were all classified as type D by the TransAtlantic InterSocietal Consensus 
(TASC) classification. Re-entry into the true lumen was achieved in 16 patients (80%) 
followed by successful stent delivery in all patients. The device failed to cross in one 
patient due to proximal vessel tortuosity and calcification and in three patients the device 
was successfully advanced but re-entry into the true lumen re-entry unsuccessful. 
In successful re-entry, the added procedure length was less than 10 minutes. The 
mean ankle-brachial index was 0.6±0.1 before procedure compared to 0.9±0.1 post-
procedure. In patients with successful re-entry, one patient developed an arterio-venous 
fistula which was successfully treated with a covered stent and another had a small 
arterial perforation related to stent deployment distant from the re-entry site which was 
conservatively managed. One patient with unsuccessful re-entry had vessel perforation 
with minor bleeding which stopped after reversal of anticoagulation. Repeat target vessel 
revascularization was necessary in 3 patients.
Conclusions: IVUS-guided lumen re-entry devices facilitate safe and successfully re-
entry into the true lumen of chronically occluded SFAs improving stent delivery and 
procedural success in the percutaneous treatment of SFA CTOs.
11:00 a.m.
1026-81 Systolic Tissue Doppler Velocity of the Ascending Aorta 
is an Index of Vascular Remodeling and Stiffness
Edgar L. Tay, Lingli Gong, Hla-Yee Daw, Lieng H. Ling, National University Hospital, 
Singapore, Singapore, National University of Singapore, Singapore, Singapore
Background: Increased aortic stiffness characterizes aging and many common 
cardiovascular conditions. Tissue Doppler imaging (TDI) has been used to assess 
stiffness of the abdominal but not ascending aorta (AAo). The latter shows greater 
translational motion during ventricular systole, the determinants of which are unknown.
Methods: We prospectively studied 91 subjects (63% males) - 37 healthy volunteers 
and 54 pts with aortic root diameter ≥40 mm, no prior cardiac surgery, no significant 
valvular pathology and left ventricular ejection fraction ≥50%. Maximal systolic velocity of 
the anterior AAo wall (SVAAo) was measured using color TDI with motion tracking. AAo 
stiffness index (β) was calculated from anatomical M-mode AAo diameter measurements 
made 2 cm above the sinotubular junction during end-diastole and at maximum aortic 
valve opening. Aortic augmentation index (AI) and central aortic systolic pressure were 
determined using the Sphygmocor™ device.
Results: See Table. Mean SVAAo was 4.5±1.4 cm/s. SVAAo correlated significantly 
(inversely) with age, body surface area-indexed AAo diameter, central aortic systolic 
pressure, β and AI but not LV stroke volume.
Conclusion: SVAAo correlates with direct and surrogate markers of vascular remodeling 
and stiffness and may be a useful noninvasive index of AAo disease. 
Mean±SD Correlation with SVAAo (Spearman’s 
rho) P value
Age (yrs) 54±18 -0.32 0.0028
Indexed AAo diameter 
(mm/m2) 19.2±6.8 -0.52 <0.0001
Central aortic systolic 
pressure 108±18 -0.39 0.0004
β 19.6±16.4 -0.25 0.019
AI (%) 27±15% -0.37 0.0009
LV stroke volume (ml) 74±19 -0.12 0.26
11:00 a.m.
1026-82 Perivascular Adipose Tissue With Chlamydophyla 
Pneumoniae Antigens Is Associated With Positive 
Remodeling In Severe Abdominal Aortic Atherosclerosis.
Maria L. Higuchi, Marcia M. Reis, Ronaldo Y. Onishi, Noedir AG Stolf, Heart Institute 
(InCor) Sao Paulo, Sao Paulo, Brazil
Background:Aortic perivascular fat tissue has been linked to development of 
atherosclerosis, having chemotatic cytokine activity and inflammation in experimental 
animals. Positive remodeling in human coronary arteries has been associated with 
increased adventitial inflammation in association with Chlamydophyla pneumoniae 
(CP) antigens. Severe aortic abdominal atherosclerosis (SAA) may be associated with 
negative or positive vascular remodeling. Purpose - To investigate in SAA if there is a 
relationship between the vascular perimeter and medial thickness versus amount of 
adventitial adipose tissue and CP antigens. 
Methods - Vascular perimeter and medial layer thickness of 19 abdominal aortas 
presenting severe atherosclerosis at necropsy were measured at the Leica image 
analysis system. The extent of plaques and thrombosis detected macroscopically, and 
adipose tissue and CP antigens at the histology were semiquantitatively evaluated 
according to the criteria: 0 absent, 1+ scarce, 2+ moderate and 3+ severe. 
Results - CP antigens were present at the adventitial fat tissue. Negative correlation was 
observed between adipous tissue and medial thickness (r= -0,67; r=0,01). Positive correlations 
were observed between CP antigens at the adventitial fat tissue versus vascular perimeter 
(r=0,4; p=0,09); and CP at intimal fat versus CP at medial layer (r=0,57, p-0,01). 
Conclusion - Perivascular adipose tissue containing CP antigens may have a role in the 
development of aortic abdominal atherosclerosis associated with positive remodeling.
11:00 a.m.
1026-83 Ultrasound Biomicroscopy of Rat Carotid Intima and 
Wall Thicknesses
Anton Razuvaev, Kent Lund, Joy Roy, Ulf Hedin, Kenneth Caidahl, Karolinska Institutet, 
Stockholm, Sweden
Background: High frequency ultrasound for small animal research (ultrasound 
biomicroscopy, UBM) has recently become available. We evaluated the possibility to 
accurately determine carotid wall layers in the rat and to study treatment effects by UBM.
Methods: Balloon injury of the left carotid artery was performed on 15 male Sprague-
Dawley rats. Carotid arteries of all animals were examined by Vevo 770 UBM (VisualSonics 
Inc, Canada) using 55 MHz probe at day 1, 7, 14 and 21 after the injury. Whole vessel 
wall, intima and media thickness as well as lumen diameter were measured at different 
levels. Histomorphometric analyses were performed on sections from day 21. We also 
evaluated the effect of Picropodophyllin, an inhibitor of intimal hyperplasia.
Results: We found that there was good agreement (Bland-Altman test) and correlation 
between histological measurements and UBM. Whole wall thickness correlated well (r 
= 0.97; r2 = 0.93 p<0.0001) and even intima measurements related (r = 0.74, r2 = 0.54, 
p<0.01). We could follow vessel wall and diameter changes as a response to balloon 
injury. Injured wall (histology 131±38 µm vs. UBM 137±35 µm) differed markedly (both 
p<0.0001) to uninjured wall (histology 41±3 µm vs. UBM 51±3 µm). Furthermore, the 
therapeutic effect of the Picropodophyllin (Figure, to the right) could be assessed. 
Conclusions: High frequency ultrasound provides a non invasive, in vivo visualization of rat 
vasculature. It allows us to study individual vascular wall changes and therapeutic effects.
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1026-84 Left Atrial Volume as an Indicator of Left Heart Disease 
in Patients with Pulmonary Hypertension
Walter Abhayaratna, Joseph Murphy, Sue Ann Ness, Katrina Abhayaratna, Marion 
Barnes, Michael McGoon, Teresa Tsang, Mayo Clinic, Rochester
Background: Pulmonary hypertension (PH) is caused by a heterogeneous group of 
disorders; some intrinsic to the lung and others secondary to left heart disease (LHD). 
Differentiation between etiologies is important as clinical treatments differ significantly. 
We hypothesized that LA size, a marker of pressure/volume overload in LHD, would not 
be increased in patients with pulmonary arterial hypertension (PAH) without LHD.
Methods: Maximum LA volume (LAV) was quantified by echocardiography in 268 patients 
who were referred to a large PH Clinic during 2000-2001. PH etiology was classified 
according to current guidelines without reference to LA size. Pulmonary capillary wedge 
pressure (PCWP) was determined by invasive methods in 119 patients.
Results: LAV correlated modestly with PCWP (ρ=0.44, p<0.0001). The proportion of 
patients with LA dilatation (LAV>=28ml/m2) varied according to PH etiology and atrial 
fibrillation (AF)/flutter status (Table). After adjusting for gender (p=NS), age, AF/flutter 
status and indexed left ventricular mass (all p<0.0001), patients with PAH in association 
with recognized risk factors (associated PAH) (OR 3.8; p=0.01) and PH due to pulmonary 
and/or LHD (OR 7.8; p<0.0001) were more likely to have LA dilatation when compared to 
patients with idiopathic PAH or thromboembolic PH.
Conclusions: LA enlargement was uncommon in patients in sinus rhythm with idiopathic 
and thromboembolic PH. In the determination of PH etiology, LAV may be useful as a 
non-invasive indicator of LHD. 
Median LAV, ml/m2 (IQR) LAV >= 28ml/m
2
, n (%)
Sinus rhythm AF/flutter
Idiopathic PAH (n=48) 22 (16-26) 5 (12) 4 (57)
Associated PAH (n=91) 26 (22-34) 27 (38) 12 (60)
Left Heart Disease (n=26) 44 (36-68) 8 (80) 16 (100)
Lung Disease/Hypoxia (n=34) 33 (24-42) 11 (42) 7(100)
Thromboembolic (n=18) 23 (19-25) 2 (9) 1 (50)
Nonspecific (n=51) 32 (24-51) 16 (50) 18 (95)
11:00 a.m.
1026-85 Pulmonary Hypertension In Patients With Long Term 
Arteriovenous Access For Hemodialysis
Nishant Kumar Nerella, Iman Husain, Elsayed Mohamed, Winston Lee, Sheldon 
Greenberg, Gerald Hollander, Maimonides Medical Center, Brooklyn, NY
Background: Pulmonary hypertension is classified into two groups, primary pulmonary 
hypertension, where no cause is identified after thorough investigation and secondary 
pulmonary hypertension, with known risk factors. One of the risk factors discussed in the 
literature as a cause of pulmonary hypertension is arteriovenous (AV) fistula. The aim of 
our study, therefore, is to establish the incidence of pulmonary hypertension in chronic 
renal failure patients on hemodialysis AV access.
Methods: The subjects for the study included patients with vascular access for 
hemodialysis, with an echocardiogram done before and atleast 3 months after AV access 
placement. Any patient with preexistent pulmonary hypertension, any other known causes 
of pulmonary hypertension, moderate to severely reduced ejection fraction, moderate 
to severe valvular heart disease, or congenital heart disease were excluded from the 
study. The patient’s echocardiogram was analyzed for pulmonary artery pressures using 
standard methods. Mean pulmonary artery pressure greater than 25mm of Hg or systolic 
pulmonary artery pressure of greater than 35mm of Hg were taken as cut off values. 
The data was then analyzed to estimate the incidence of pulmonary hypertension in this 
group of patients.
Results: Out of total of 99 patients with echocardiogram done after fistula placement, 45 
had pulmonary hypertension (prevalence 45.5%).
13 out of 57 patients had new onset pulmonary hypertension after the fistula placement 
with no other apparent cause (incidence 22.8%).
There was trend towards more severe pulmonary hypertension with time post fistula 
placement.
Conclusion: 1) There is a very high incidence and prevalence of pulmonary hypertension 
in patients with long term AV access for hemodialysis. 2) With longer follow up periods 
pulmonary hypertension appears to be more severe suggesting that the process may be 
progressive. Prospective studies are needed.
11:00 a.m.
1026-86 Strain Analysis Identifies Regional Right 
Ventricular Contractile Inhomogeneity After 
Pulmonary Endarterectomy: 2-Dimensional Strain 
Echocardiographic Study
Tomas Palecek, Josef Korinek, David Ambroz, Pavel Jansa, Jaroslav Lindner, Michael 
Aschermann, Krishnaswamy Chandrasekaran, Ales Linhart, 2nd Department of Internal 
Cardiovascular Medicine, General University Hospital, First Faculty of Me, Prague, 
Czech Republic, Division of Cardiovascular diseases, Mayo Clinic College of Medicine, 
Rochester, MN
Background: Chronic throembombolic pulmonary hypertension (CTEPH) causes right 
ventricular (RV) dysfunction. Pulmonary endarterectomy (PEA) leads to a significant 
improvement of RV global function which can be assesed by systolic tricuspid annular 
motion (TAM). However,changes in regional RV function is not well known. The aim of 
study was to assess early changes in regional and global systolic function of RV free wall 
induced by PEA with 2-dimensional strain echocardiography (2D-SE).
Methods: Ninteen patients (53±14 years, 15 males) with CTEPH underwent 
echocardiography before and 3 weeks after PEA. Pulmonary artery systolic pressure 
(PASP) was estimated from the peak tricuspid regurgitant velocity. RV Fractional area 
change (FAC) was calculated by planimetry, and (TAM) were assessed from apical 4-
chamber view. In addition, RV free wall digital clips were stored for off-line 2D-SE analysis. 
Regional end systolic strain (ES) was measured at the basal, mid and apical segments of 
RV free wall. Global ES of the entire RV free wall was also measured.
Results: PASP significantly decreased from 90±19mmHg to 34±17mmHg (p<0,001), 
and FAC significantly increased from 0.22±0.09 to 0.34±0.10 (p<0.001). However, 
TAM significantly decreased from 14±3mm to 11±3mm (p<0.001). ES of the basal and 
mid segments of RV free wall as well as global ES significantly increased after PEA 
(-6.8±3.3% vs. -14.9±3.7%, -5.1±4.6% vs. -12.1±5.0%, -7.4±2.9% vs. -12.9±3.2%; 
p<0.001; respectively). There was no change in apical ES (-10.0±5.6% vs. -11.8±4.2%, 
p=NS).
Conclusions: PEA resulted in the significant improvement of systolic function of basal 
and mid, but not apical segments of RV free wall early after the surgery. This was 
recognized only by 2D-SE. TAM did not indicate improvement of global RV function as 
compared to global ES and FAC, thus does not seem to be a reliable index of RV systolic 
function after PEA.
11:00 a.m.
1026-87 Combined Valsartan (Vn) and Simvastatin (Sn) Therapy 
Decreases Early and Late Manifestations of Vulnerable 
Atherosclerostic Plaque in Diabetic Hyperlipidemic 
Pigs: A Longitudinal Intravascular Ultrasound (IVUS) 
and Histology Study
Michael Jonas, Yiannis S. Chatzizisis, Ahmet Umit Coskun, Anna Maria Spognardi, 
Adam Groothuis, Ross B. Gerrity, Philip Seifert, Benjamin Stone, William Daley, Charles 
L. Feldman, Elazer E. Edelman, Peter H. Stone, Campbell Rogers, Brigham And 
Women’s Hospital, Boston, Ma, Harvard-mit Division Of Health Science & Technology, 
Cambridge, MA
Background: We investigated anti-atherosclerotic synergism, beyond cholesterol and 
blood pressure lowering effect, between Vn and Sn in a diabetic, hyperlipidemic pig 
model of human-like coronary atherosclerosis.
Methods and Results: 27 streptozotocin-induced diabetic pigs were fed a high fat+ 
cholesterol diet, allocated to Vn (320mg/d) plus Sn (40mg/d) or control, and followed for up 
to 32 weeks. Weight, BP, cholesterol and blood glucose were similar between the groups. 
Serial coronary IVUS analysis revealed a significant reduction in early atherosclerotic plaque 
initiation and late progression in the Vn+Sn group (Fig A). Coronaries harvested at 32 wks 
were snap frozen and 4-5 segments from each artery analyzed histologically. Compared 
to Vn + Sn group, the control group showed increased plaque burden (by histologic 
Intima/Media ratio), with severe proximal plaque distribution (Fig B). CD-45 immunostain 
highlighted a differential vessel wall inflammatory response between Vn + Sn and controls 
(Fig C) .Oil Red-O staining revealed increased intimal lipid content in controls.
Conclusions: Early Vn + Sn therapy reduces initial formation and late progression/
maturation of coronary atherosclerotic plaque. Atherosclerotic plaque in controls show 
increased vulnerability, with large, highly inflammatory and lipid laden lesiopns distributed 
in proximal coronary bed. The propensity for proximal vulnerable plaque formation was 
altered by Vn + Sn therapy. 
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1026-88 β-adrenergic Stimulation Acutely Increases Myocardial 
Distensibility - A PKA, PKC And Na+/H+ Exchanger 
Mediated Effect
Inês Falcão-Pires, Ana P. Fontes-Sousa, Cármen Brás-Silva, Adelino Leite-Moreira, 
Porto, Portugal
Background:Recent studies suggested that titin phosphorylation by PKA induces 
an increase of myocardial distensibility. As β-adrenergic stimulation is one of the 
most important stimuli for PKA activation, the present study investigated its effects on 
myocardial distensibility, as well as some of the underlying mechanisms.
Methods:Effects of increasing concentrations of isoproterenol (ISO; 10-10-10-5M) were 
evaluated in isolated right papillary muscles from New-Zealand White-rabbits (Krebs-Ringer: 
1,8mM CaCl2, 35ºC) in the absence (n=9) or presence of: (i)PKA inhibitor, KT5720 (10-
6M;n=9); (ii)PKC inhibitor, chelerythrine (CHE; 10-5M;n=9); or (iii)Na+/H+ exchanger inhibitor, 
5-(N-metil-N-isobutil)-amiloride (MIA; 10-6M;n=8). Reported parameters include: active 
tension (AT;mN/mm2), maximum velocities of tension rise and decline (dT/dt
max
 and dT/dt
min, 
respectively;mN/mm2/s), passive tension (PT;mN/mm2) and muscle length (L; L/L
max
). Only 
significant results (means±SEM,p<0.05) are given, expressed as % change from baseline.
Results:At baseline, ISO induced concentration-dependent positive inotropic and 
lusitropic effects maximal at 10-5M, which increased 106.6±17.9% AT, 296.9±35.8% 
dT/dt
max
 and 198.9±21.1% dT/dt
min. These effects were not significantly affected by 
any of the inhibitors used in this study. Concerning myocardial distensibility, increasing 
concentrations of ISO progressively increased resting muscle length up to 1.03 L/L
max
. 
Correcting muscle length to its initial value resulted in a 27.1±5.22% decrease of RT, 
indicating decreased stiffness or an increase of myocardial distensibility. This effect was 
almost abolished by the inhibition of PKA, PKC or Na+/H+ exchanger.
Conclusions:This study demonstrated that β-adrenergic stimulation increases myocardial 
distensibility, modulated by the activation of PKA, PKC and Na+/H+ exchanger. This effect 
represents a novel mechanism of modulation of the diastolic properties of the myocardium 
by the sympathetic nervous system. This might have pathophysiologic implications in heart 
failure, where an hyperactivation and β-adrenoceptor desensitization is present.
11:00 a.m.
1026-89 Dietary Salt Restriction Accelerates Myocardial Fibrosis 
But Not Hypertrophy Of Cardiomyocyte In Volume 
Overloaded Rat Heart
Tatsuhiko Mori, Daisuke Kurumazuka, Chika Matsumoto, Tetsuya Hayashi, Yasuo 
Matsumura, Osaka Medical College, Takatsuki, Japan, Osaka University of 
Pharmaceutical Sciences, Takatsuki, Japan
Background: No report showed the increased cardiac fibrosis despite increased serum 
aldosterone level by salt restriction. In this study, we examined the effect of salt restriction 
in volume overloaded rats heart.
Methods: Nine-weeks old male Sprague Dawley rats were underwent aorto-venous 
fistula (AVF) and were treated with low salt diet (0.02% NaCl in diet chaw) (LS) or normal 
salt diet (0.6% NaCl) (NS). Two weeks later, cardiac function and heart tissues were 
examined.
Results:AVF increased right ventricular (RV) systolic pressure but salt restriction did not 
affect to the level (46.6 mmHg in LS and 52.5 mmHg in NS vs. 23.0 mmHg in sham 
surgery). Both diet exhibited similar left ventricular (LV) systolic pressure (109 in LS and 
114 mmHg in NS). Heart weight to body weight ratio was similar between groups (3.9 
in LS and 4.4 mg/g in NS). Despite no difference of cardiac function and heart weight 
in both diets, cardiac fibrosis was significantly increased in LS compared with NS (16.8 
vs. 8.6 %). Mean diameter of cardiomyocyte was not different between groups (19.4 vs. 
17.7 um). LS exhibited more increased expression of nitrotyrosine and TGF-beta in LV 
than NS assessed by immunohistochemistry. Spironolactone (200mg/kg/day by gavage) 
had no effect on systemic blood pressure but significantly suppressed heart weight 
and fibrosis in LS. Conclusion: Our findings showed that the salt restriction to volume 
overloaded heart exhibited marked myocardial fibrosis in LV, which was independent of 
blood pressure. Increased signal through mineral corticoid receptor seems to be involved 
in the mechanism.
11:00 a.m.
1026-118 Location of Tendon Xanthomata and Prevalence of 
Coronary Artery Disease Among Heterozygous Familial 
Hypercholesterolemia Patients.
John Skoumas, Christos Pitsavos, Lambros Papadimitriou, Constantina Masoura, 
Christina Chrysohoou, Demosthenes Panagiotakos, Nikolaos Giotsas, Constantina 
Paliou, Christodoulos Stefanadis, 1st Cardiology Department, University of Athens, 
Ippokration Hospital, Athens, Greece
Background: The accumulation of cholesterol in tendons lead to the development of 
Tendon xanthomata (TX), which is pathognomonic for the diagnosis of heterozygous 
familial hypercholesterolemia (hFH).
The aim of this study was to investigate the association of the location of TX with the 
prevalence of Coronary Artery Disease (CAD) and other biochemical parameters.
Methods: The study population consisted of 524 patients (mean age 41 years old, 234 
men and 290 women) with hFH who were examined in the Lipid Outpatient Clinic of the 
1st Cardiology Department of University of Athens. All subjects were screened for the 
presence of TX on the extensor tendons of upper extremity and on Achilles tendon, while 
the lipidemic profile and the prevalence of CAD were recorded.
Results: 372 hFH subjects, mean age 39.8 years old did not exhibit TX, while 151 
persons (87 males and 64 females), mean age 43.8 years old, did. Among persons with 
TX, the frequency distribution of TX was 30.3%, mean age 45.7 years old, in the upper 
extremities, 38.1%mean age 40.8 years old in the lower extremities, and 31.6%, mean 
age 45.7years old in both upper and lower extremities. Among these three subgroups we 
conducted a multifactorial analysis, which revealed that the lowest levels of apolipoprotein 
A were observed in persons with TX in both upper and lower extremities (141.5mg/dl 
upper vs. 143.3mg/dl lower vs.127.0mg/dl upper and lower extremities, p=0.014 ). We 
also reported that the levels of Total Cholesterol (p=0.21) LDL-Cholesterol (318.3mg/dl 
vs.323.7mg/dl vs.349.6mg/dl, p=0.16) , HDL Cholesterol (p=0.2), Triglycerides (126.6mg/
dl vs.130.8mg/dl vs.126.9mg/dl, p=0.89), apolipoprotein Β, Glucose and of fibrinogen 
did not differ between hFH individuals with TX in upper, lower, and both upper-lower 
extremities respectively.
Another multifactorial analysis of our data showed that the prevalence of CAD 
statististically differed between persons with TX in the upper, lower and both extremities 
(30.8% vs. 20.5% vs. 48.7%, p=0.008, respectively).
Conclusion: The location of TX, and especially the simultaneous presence in upper and 
lower extremities seems to be related with an exacerbation of the prevalence of CAD.
11:00 a.m.
1026-120 Effects of Intensive vs. Standard Statin Therapy on 
Lipids and Inflammation in Racial/Ethnic Groups. An 
Analysis from PROVE IT-TIMI 22
Annemarie Armani, Jie Qin, Sabina A. Murphy, Carolyn H. McCabe, Christopher P. 
Cannon, Brigham and Women’s Hospital, Boston, MA
Background: Lipid-lowering therapy with statins reduces the risk of cardiovascular 
events, but less is known about the lipid-lowering effects of statin therapy among different 
racial and ethnic groups.
Methods: The Pravastatin or Atorvastatin Evaluation and Infection Therapy-
Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial compared intensive 
therapy (atorvastatin, 80 mg) and moderate therapy (pravastatin, 40 mg) in patients after 
ACS. Baseline, clinical, and safety data were compared among whites (n=3776), blacks 
(n=188), Hispanics (n=128), and Asians (n=47).
Results: Compared with whites, intensive statin therapy resulted in less LDL reduction in 
blacks (mean -36.2% vs. -42.1% whites; 2-way p=0.038), while prava 40 mg resulted in 
greater LDL reduction in Asians (-34.2% vs. -12.0% whites; 2-way p=0.0006). Therefore, 
the differences in LDL-lowering between intensive vs. moderate statin regimens were more 
modest in the black and Asian groups (-24.3% and -12.6%, respectively), compared with 
the -30.1% observed in the whites. Blacks were also least likely, while Asians most likely, 
to achieve LDL <70 mg/dL and CRP <2.0 mg/L (17.1% blacks vs. 44.1% whites, 48.2% 
Hispanics, and 58.3% Asians on atorva 80mg; p<0.001). Asians appeared to have a trend 
toward highest drug discontinuation due to adverse events, notably in the prava 40mg group. 
(prava 40mg; 31.6% vs. 10.9% in whites, 13.3% in blacks and 9.7% in Hispanics, p=0.033).
Conclusions: Compared with whites, blacks appear to receive less lipid-lowering from 
intensive therapy and less often reach a “dual goal” with control of both LDL and CRP, 
while Asians appear to receive greater lipid lowering from even moderate statin therapy. 
Evaluation of effects in different racial and ethnic groups is an important area requiring 
further investigation, including how these differential effects may ultimately affect 
cardiovascular outcomes.
11:00 a.m.
1026-121 Comparison Of Outcomes In Patients Randomized To 
Warfarin According To Anticoagulant Control: Results 
From Sportif III And V.
Harvey D. White, Michael Gruber, Jan Feyzi, Hung-Fat Tse, Steen Husted, Gregory W. 
Albers, Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New 
Zealand, UW-Madison Department of Biostatistics, Madison, WI
Background: Warfarin reduces stroke risk in patients with atrial fibrillation (AF) but 
International Normalized Ratio (INR) monitoring is required. However, target INRs are 
frequently not achieved and the risk of death, stroke, systemic embolism, myocardial 
infarction and bleeding may be related to INR control.
Methods: Of 3665 patients with AF randomized to receive warfarin in the SPORTIF 
(Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation) III and V trials 
INRs were available in 3587 patients. Mean follow-up for these patients was 16.6±6.3 
months. Participants were divided into three equal groups - good, moderate and poor 
control - according to time in the INR range 2.0-3.0. Outcomes were compared according 
to INR control.
Results: Target INRs were achieved >75%, 60-75% and <60% of the time in the good, 
moderate and poor control groups, respectively. 
Ischemic Events & Bleeding Per 100 Patient - Years
Poor 
Control
Moderate 
Control
Good 
Control p p
% % % Poor vs Poor vs
N=1190 N=1207 N=1190 Good Moderate 
Death 4.20 1.84 1.69 <.01 < .01
Strokes/Systemic 
Embolism 2.10 1.34 1.07 0.02 0.09
Myocardial Infarction 1.38 0.89 0.62 0.04 0.22
Major Bleeding 3.85 1.96 1.58 < .01 <.01
Conclusions: In patients with AF taking warfarin the risks of mortality, stroke/systemic 
embolism, myocardial infarction and major bleeding are related to INR control. Good INR 
control is important to improve patient outcomes.
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1026-122 Periprocedural Aprotinin Use is Associated With an 
Increase in Adverse Events: An Analysis of 2,761 
Patients Undergoing Coronary Artery Bypass Graft 
Surgery
Robert R. Pearson, Charles M. Van Gorder, Heidi T. May, Benjamin D. Horne, Tami L. 
Bair, Donald L. Lappé, LDS Hospital, Salt Lake City, UT, University of Utah, Salt Lake 
City, UT
Background: Aprotinin is used to reduce bleeding during surgery, by modulating the 
intrinsic pathways of both coagulation and fibrinolysis. It has been previously shown 
that aprotinin significantly reduces bleeding, hospital length of stay and mortality in 
patients undergoing cardiovascular surgery. Very recently, it has been postulated that 
aprotinin may actually be associated with an increase in adverse events. The purpose 
of this study was to determine if there was an association between aprotinin use and 
death or myocardial infarction in patients undergoing CABG surgery in a multi-hospital 
cardiovascular system.
Methods: Patients undergoing coronary artery bypass graft surgery (N=2761) were 
matched 4:1 on age (±5 years), sex, case status (elective, emergent, or urgent), and year 
of hospitalization (2000-2005). Patients were excluded if they received pre-surgery plavix, 
2b/3a inhibitors, and warfarin. Logistic regression was utilized to determine differences 
between cases and controls for in-hospital and 30-day MI and death.
Results: There were 565 cases and 2196 controls. Age averaged 67.1 (±9.5) years and 
83.7% were male. Case and control incident events occurred in 3.7% vs 2.1% and 3.0% 
vs. 0.9% for in-hospital death and MI, respectively. For 30-day death and MI, case and 
control events occurred in 0.2% vs 0.3% and 3.5% vs 0.8%, respectively. Aprotinin use 
was associated with increased risk of in-hospital death (OR=1.77, p=0.03), in-hospital 
MI (OR=3.55, p<0.0001), and 30-day MI (OR=4.44, p<0.0001), but not for 30-day death 
(OR=0.56, p=0.59).
Conclusion: This retrospective analysis documented an intriguing association between 
the use of aprotinin and a significant increase in in-hospital and 30-day MI and in-
hospital death in patients undergoing CABG surgery. Death at 30-days was not found to 
be significantly increased. Before these findings are utilized in clinical decision making, 
further studies are warranted in larger and more diverse surgical populations.
11:00 a.m.
1026-123 Use of Aspirin Among Patients with Atherothrombotic 
Disease in the United States: The REduction of 
Atherothrombosis for Continued Health (REACH) 
Registry
Christopher P. Cannon, Karen Rhee, Deepak L. Bhatt, William E. Boden, Brigham and 
Women’s Hospital, Boston, MA, Cleveland Clinic, Cleveland, OH
Background: Although aspirin has proven efficacy in the prevention of ischemic events 
in patients with atherothrombosis, it remains largely underutilized despite its low cost and 
wide availability.
Methods: The REduction of Atherothrombosis for Continued Health (REACH) registry 
is an ongoing international, prospective, longitudinal study of over 68,000 patients with 
atherothrombosis managed in primary care offices. Subjects >45 years with symptomatic 
vascular disease (coronary artery [CAD], cerebrovascular [CVD], or peripheral arterial 
[PAD]) or with >3 atherothrombotic risk factors were enrolled. Logistic regression was 
employed to determine aspirin use at baseline in the U.S. population.
Results: Approximately 65% of patients in the U.S. were treated with aspirin. Patients 
with a prior history of ischemic vascular disease had a 240% (CI=210-270%) higher 
likelihood of being treated with aspirin. Being female, African American, Asian, or retired 
significantly decreased the likelihood of using aspirin by 25% (95%CI=20-29%), 17% 
(CI=9-24%), 29% (CI=16-40%), and 8% (CI=2-13%), respectively.
Aspirin use in patients with any of the major manifestations of vascular disease are 
shown: 
Aspirin dose, 
mg/day
Total
(n=23149)
Patients with 
CAD
(n=13920)
Patients with 
CVD
(n=4835)
Patients with 
PAD
(n=2145)
No aspirin 8049 (34.8%) 3958 (28.4%) 1961 (40.6%) 755 (35.2%)
1-74 112 (0.5%) 47 (0.3%) 61 (1.3%) 12 (0.6%)
75-99 9339 (40.3%) 5741 (41.2%) 1723 (35.6%) 862 (40.2%)
100-324 330 (1.4%) 233 (1.7%) 64 (1.3%) 35 (1.6%)
>325 5319 (23%) 3941 (28.3%) 1026 (21.2%) 481 (22.4%)
Conclusion: Nearly one third of U.S. patients with established vascular disease are 
not treated with aspirin for secondary prevention. Among aspirin users, more are CAD 
patients and the majority receive low-dose therapy.
11:00 a.m.
1026-124 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is 
Associated with CHD Mortality in a High Risk Cohort
Matthew A. Allison, Michael H. Criqui, J. Jeannete Nelson, Julie O. Denenberg, 
University of California San Diego, La Jolla, CA
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel inflammatory 
biomarker that produces oxidized free fatty acids and lysophosphatidylcholine during 
oxidation of LDL cholesterol. In some community-based studies, Lp-PLA2 has been 
shown to be independently predictive of future fatal and non-fatal cardiovascular disease 
(CVD) events. We tested the hypothesis that Lp-PLA2 is independently predictive of 
mortality in high risk patients from a vascular laboratory.
Methods: After completion of the San Diego Claudication questionnaire, 501 patients 
were evaluated for the presence of peripheral arterial disease (PAD) and existing other 
CVD. At the baseline visit, subjects also had venous blood collected and stored at -70°C, 
which was thawed and analyzed for Lp-PLA2 activity. Vital status was determined on all 
participants 3, 5 and 7 years later.
Results: The mean age was 68.2, 88% were male, 87% were non-Hispanic White, 39.1% 
were diagnosed with PAD, 9.2% with other CVD and 28.5% with both PAD and other 
CVD. Lp-PLA2 activity was significantly positively correlated with body mass index, hip 
and waist circumference, total and LDL cholesterol, triglycerides and was negatively 
correlated with HDL cholesterol. Over the entire follow-up period, 299 (59.7%) patients 
died, of whom 167 died from CVD. Eighty-eight of the CVD deaths were due to coronary 
heart disease (CHD). At 5 and 7-years of follow-up and with adjustment for age, sex, 
smoking, hypertension, diabetes and family history of premature CHD, a 1-SD increment 
in Lp-PLA2 activity was associated with a 40% and 32% higher risk for CHD mortality, 
respectively (p = 0.03 for both). Additional adjustment for HDL cholesterol reduced these 
risks (HRs: 1.19 and 1.24, p = ns). There were no significant interactions between PAD 
and Lp-PLA2 for CHD mortality. Conclusion: In a vascular laboratory patient population 
with a high mortality rate and after adjustment for traditional CVD risk factors, higher 
levels of LpPLA2 activity were significantly associated with CHD mortality at both 5 
and 7 years of follow-up. This relationship was attenuated but not eliminated by further 
adjustment for HDL cholesterol.
11:00 a.m.
1026-125 The Effects of Extended Release Niacin on Carotid 
Intimal Media Thickness, Endothelial Function, and 
Inflammatory Markers in Patients with the Metabolic 
Syndrome
Martin Thoenes, Asahiko Oguchi, Sameer Nagamia, Christopher S. Vaccari, Guillermo 
E. Umpierrez, Bobby V. Khan, Emory University School of Medicine, Atlanta, GA, Institut 
fur klinische Pharmakologie, Technische Universitaet, Dresden, Germany
Background: Elevated triglycerides (TG) and low serum high density lipoprotein (HDL) are 
characteristics of the metabolic syndrome. Impaired endothelial function in a pro-inflammatory 
vascular environment is a hallmark in the progression of the metabolic syndrome. We 
sought to determine whether treatment with extended release (ER) niacin is associated with 
beneficial effects on carotid intimal medial thickness (cIMT), endothelial function, lipid levels, 
and inflammatory markers such as high sensitivity C-reactive protein (hsCRP).
Methods: 45 subjects that met the ATP III criteria for the metabolic syndrome were enrolled 
into the study. The subjects were randomized in a double-blind manner and at a 1:2 ratio 
to either placebo or ER niacin (1000 mg/day) for 12 months. Flow mediated dilation (FMD), 
cIMT, and serum levels of high sensitivity C-reactive protein (hsCRP) were obtained.
Results: In comparison to placebo, treatment with ER niacin for 12 months increased 
HDL-C significantly (placebo-pre: 39±6, post: 38±5 mg/dl, NS) (niacin-pre:37±5, post: 
47±6 mg/dl, p<0.005 pre vs post). Similarly, niacin decreased TG significantly (placebo-
pre: 184±15, post: 189±23 mg/dl, NS) (niacin-pre: 193±27, post: 123±24 mg/dl, p<0.005 
pre vs post). In the niacin group, there was a reduction in hsCRP; (niacin-pre: 2.34±0.21, 
post: 1.61±0.17 mg/L, p<0.005 pre vs post) (placebo-pre:2.22±0.24, post: 2.17±0.21 mg/
L, NS). There was a significant increase in FMD in the niacin group, whereas no change 
in FMD was seen in placebo (placebo-pre: 4.5±0.5, post: 4.4±0.8 percent, NS) (niacin-
pre: 4.3±0.6, post: 5.8±0.4 percent, p<0.005 pre vs post). There was an increase in cIMT 
in placebo, whereas there was no change in the niacin group(placebo-pre: 0.71±0.07, 
post: 0.79±0.09 mm, p<0.05 pre vs post) (niacin-pre: 0.72±0.10, post: 0.71±0.08 mm, 
NS). There was no change in fasting glucose in either group, and ER niacin was well-
tolerated by the study population.
Conclusions: ER niacin is effective in improving components of dyslipidemia, endothelial 
function, and markers of inflammation in the metabolic syndrome. These findings suggest 
a role of ER niacin in the primary prevention against cardiovascular diseases.
11:00 a.m.
1026-126 Role of Gender in the Development of Coronary 
Artery Disease in Greek Cohort of Familial Combined 
Hyperlipidemia
Constantina Masoura, Christos Pitsavos, Ioannis Skoumas, Lambros Papadimitriou, 
Konstantinos Aznaouridis, Christina Chrysohoou, Marina Toutouza, Nikolaos Giotsas, 
Christodoulos Stefanadis, Hippocration Hospital, Athens, Greece
Background: Familial Combined Hyperlipidemia (FCH) is a commonly inherited 
dyslipidemia, characterized by a varied expression of hypertriglyceridemia and 
hypercholesterolemia, and a high risk of premature coronary artery disease (CAD). Aim 
of the present study was to estimate the prevalence of CAD in a large population with 
FCH and to evaluate the role of lipid and non-lipid risk factors according to gender.
Methods: We studied 880 untreated patients with FCH (565 males). Lipid and lipoprotein 
variables were measured in all participants. CAD was defined as a documented history of 
previous myocardial infarction, coronary revascularization, angina pectoris with positive 
stress test or abnormal coronary angiogram (stenosis of >50% in a major vessel).
Results: The prevalence of CAD was 22.2% in men and 4.6% in women (P<0.001). Males 
were younger (45±11 vs. 54±9 years, P<0.001) and they had an increased prevalence of 
smoking (44.6 vs. 30.8%, P<0.001) compared with females. Both genders had similarly 
(P=NS) increased body-mass index (28.1±3.3 vs. 27.5±4.0 kg/m2) and prevalence of 
hypertension (41.7 vs. 39.7%), metabolic syndrome (52.6 vs. 46.8%) and diabetes (14.1 
vs. 12.8%). Women had increased level of total cholesterol (300±48 vs. 280±56mg/dl, 
P<0.001), low-density lipoprotein cholesterol (207±50 vs. 183±52 mg/dl, P<0.001), 
apolipoprotein-B (175±38 vs. 162±39 mg/dl, P<0.001), fibrinogen (327±68 vs. 303±67 
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mg/dl, P<0.001) and lipoprotein-a (34±36 vs. 27±28 mg/dl, P=0.005) compared with 
men. Moreover, women had a higher concentration of high-density lipoprotein cholesterol 
(46±10 vs. 38±9 mg/dl, P<0.001) and apolipoprotein A1 (153±25 vs. 133±20 mg/dl, 
P<0.001). On the other hand, men have higher levels of uric acid (6.0±2.2 vs. 4.5±1.4 
mg/dl P<0.001) and triglycerides (316±159 vs. 266±151 mg/dl, P<0.001). In multivariate 
analysis, presence of CAD was associated with male gender independent of the above 
mentioned differences between the two genders.
Conclusions: The overall prevalence of CAD in males with FCH is almost 5-fold 
increased compared with females with FCH. Male gender is associated with a significant 
risk of CAD, independent of lipidemic profile and other risk factors.
11:00 a.m.
1026-127 Outcomes in Patients with a Previous Vascular 
Intervention Enrolled in the REduction of 
Atherothrombosis for Continued Health (REACH) 
Registry in the United States
William E. Boden, Phillipe Gabriel Steg, Kim A. Eagle, Deepak L. Bhatt, Buffalo General 
and Millard Fillmore Hospitals, Buffalo, NY, Cleveland Clinic, Cleveland, OH
Background: Atherothrombosis is a systemic vascular disease and leading cause of 
death worldwide. The prevalence and outcomes in patients with this disease who have 
undergone a previous vascular intervention is poorly characterized.
Methods: The REACH registry is an ongoing international, prospective, observational 
study of over 68,000 outpatients >45 years with documented vascular disease or at risk 
for atherothrombosis (>3 risk factors). Data on 26,336 patients in the U.S. were collected 
at baseline and at 12+3 months. Of these, 12,490 (47%) were patients with coronary 
artery disease (CAD) and/or peripheral arterial disease (PAD) who underwent previous 
percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG).
Results: Baseline characteristics of symptomatic patients with a prior revascularization reveal: 
CAD patients with prior 
vascular intervention 
(n=11782)
PAD patients with prior 
vascular intervention (n=1578)
Male 8086 (68.6%) 997 (63.2%)
Caucasian 10050 (85.3%) 1274 (80.7%)
African American 736 (6.2%) 153 (9.7%)
>65 years old 7757 (65.8%) 1074 (68.1%)
Systolic blood pressure 
>150 mmHg 1893 (16.1%) 341 (21.6%)
Diabetes 5082 (43.1%) 846 (53.6%)
Prior carotid surgery 988 (8.4%) 266 (16.9%)
Current smoker 1359 (11.5%) 336 (21.3%)
Use of β-blockers 7740 (65.7%) 830 (52.6%)
Diuretics 5480 (46.5%) 827 (52.4%)
Aspirin 9452 (80.2%) 1117 (70.8%)
Other antiplatelets 3079 (26.1%) 506 (32.1%)
Statins 9748 (82.7%) 1220 (77.3%)
Oral anticoagulant 1819 (15.4%) 317 (20.1%)
The 12-month composite of cardiovascular death, nonfatal stroke and nonfatal myocardial 
infarction for the overall REACH population was 2.4%, whereas for those with CABG or 
PCI, it was 2.8% and 1.9%, respectively. Compared to nondiabetics, diabetics in this 
population had roughly twice the risk of this composite outcome: (overall, 1.9% vs 2.8%; 
CABG, 1.8% vs 4%; PCI, 1.6% vs 2.4%).
Conclusion: Nearly half of U.S. patients in REACH had undergone prior vascular 
intervention, yet this high-risk subset showed underutilization across several drug 
classes. Diabetics with CAD or PAD and prior revascularization had double the event rate 
of their nondiabetic counterparts.
11:00 a.m.
1026-128 Patients with Metabolic Syndrome Demonstrate High 
Platelet Reactivity and Increased Procoagulant Markers
Suzan Fattohy, Joseph DiChiara, Kevin Bliden, Udaya S. Tantry, Paul A. Gurbel, Sinai 
Center for Thrombosis Research, Baltimore, MD
Background: Patients with metabolic syndrome undergoing percutaneous coronary 
intervention (PCI) are at high risk for ischemic events. High platelet aggregation, non-
responsiveness to antiplatelet therapy, and procoagulant effects may explain increased risk.
Methods: Patients undergoing percutaneous coronary intervention (PCI) (n=247) were 
treated with clopidogrel and aspirin. Metabolic syndrome (MS) was diagnosed based 
on Adult Treatment Panel (ATP) III criteria. Light transmittance aggregometry (LTA), and 
thrombelastography (TEG) were used to assess platelet reactivity, and platlet-fibrin clot 
characteristics.
Results: Thirty two percent of patients (n=79) had metabolic syndrome. Despite similar 
pretreatment platelet reactivity between groups, patients with metabolic syndrome 
exhibited overall poorer platelet inhibition by clopidogrel. Metabolic syndrome patients 
also had a higher clotting index (CI), greater platelet-fibrin clot strength (MA), and a 
shorter time for thrombin generation (R) (Table)
Conclusions: Patients with metabolic syndrome undergoing PCI exhibit a poorer 
response to clopidogrel than patients without metabolic syndrome. The latter novel 
observation in conjunction with hypercoaguabilty provide a rationale for modification of 
current antithrombotic strategies in these patients. 
MS+ Group (n=79) MS-Group (n=168) MS+ vs. MS-p-value
Baseline 24 hr Baseline 24 hr Baseline 24 Hr
MA 70.9±5.5 - 67.2±5.1 - <0.0001 -
R 4.4±1.6 - 4.8±1.5 - 0.057 -
CI 2.8±2.1 - 2.1±1.9 - 0.009 -
ADP Agg (TEG) 77.4±16 66.7±20 72.5±16 43.9±20 0.026 <0.0001
LTA Agg (5 μM ADP) 62.5±9 43.5±12 62.5±11 35.6±13.8 NS <0.0001
LTA Agg (20 μM ADP) 76±9 61.3±11 76±7.6 52.7±14.5 NS <0.0001
11:00 a.m.
1026-129 Cardiovascular Risk in US Urban Hispanic Populations: 
Regional Data from Community Outreach Programs
Sean D. Candrilli, EunMee Lee, Simon S. Tang, Stanley Bassin, Heather J. Laird, 
Stewart S. Levy, Nathan D. Wong, RTI Health Solutions, Pfizer, Inc., New York, NY, Heart 
Disease Prevention Program, UC Irvine, Irvine, CA
Background: The US Hispanic population represents the fastest-growing and largest 
minority group; however, the potential differences in cardiovascular risk among Hispanics 
of different origin (Cuban, Mexican, Puerto Rican, South or Central American or other 
Spanish culture) are unknown. The concentration of Hispanics of different origin varies 
according to the US geographic area.
Methods: Hispanic Community Outreach Programs were conducted in 4 urban 
communities (Miami, New York [NY], Los Angeles [LA], Houston) during 2004 - 2006. We 
examined the burden of conventional cardiovascular risk factors (RF), diabetes (DM), and 
coronary heart disease (CHD) in Hispanic adults. Estimated 10-year Framingham CHD 
risk was calculated among those without CHD or DM.
Results: Risk factor burden and 10-year CHD risk in Hispanics by geographic region 
are shown in the table. Approximately half to two-thirds had at least two risk factors or 
DM/CHD. There was greater variation between regions in those at intermediate (10-20%) 
risk (15.6% in Miami versus 5.5% in NY) or with DM/CHD (26% in NY versus 7.5% in 
Houston). Similar risk burden observed in LA and Houston may reflect their similarly 
predominant Mexican populations. 
Miami
(n = 372)
NY
(n = 254) 
LA
(n = 4,037)
Houston 
(n = 625)
Mean age, years 55.7 (c, 
e, f)
49.7 (a, 
b, c)
47.3 (b, 
d, f) 45.4 (a, d, e)
% female 65.1 (c) 75.2 (a, b, c) 60.0 (b, d) 65.0 (a, d)
0-1 RF* (%) 32.0 (c, 
e, f)
39.8 (a, 
b, c) 47.6 (b, f) 49.8 (a, e)
2-3 RF* (%) 38.2 (c) 27.6 (a, b, c) 36.1 (b) 37.1 (a)
≥4 RF* (%) 10.8 (e, f) 6.7 6.2 (f) 5.6 (e)
DM or CHD (%) 19.1 (c, 
e, f)
26.0 (a, 
b, c)
10.0 (b, 
d, f) 7.5 (a, d, e)
Mean ten-year CHD risk (%)** 5.8 (c, e, f) 3.6 (c) 4.4 (f) 4.2 (e)
% with ten-year CHD risk <10% 61.3 (e, f) 66.1 (a, b) 75.0 (b, f) 77.1 (a, e)
% with ten-year CHD risk 10-20% 15.6 (c) 5.5 (a, b, c) 12.1 (b) 12.5 (a)
% with ten-year CHD risk >20% or 
DM or CHD 23.1 (e, f) 28.4 (a, b) 12.9 (b, f) 10.4 (a, e)
Statistically significant differences (p<0.05) are indicated for comparisons between (a) 
NY and Houston, (b) NY and LA, (c) NY and Miami, (d) Houston and LA, (e) Houston 
and Miami and (f) LA and Miami.
*RF = conventional risk factors in those without DM or CHD: age (male ≥ 45 
years or female ≥ 55 years); current smoker; hypertension (≥ 140/90 mmHg, or 
on antihypertensive medication); total cholesterol or ≥240mg/dL or on cholesterol 
medication; low high-density lipoprotein cholesterol <40mg/dL; family history of early 
CHD.
** Mean ten-year CHD risk (%) for those without DM or CHD.
Conclusion: A substantial number had more than 1 RF, but the variation in DM/CHD 
and estimated CHD risk among Hispanics from different US geographic regions warrants 
further investigation among Hispanic subpopulations into the reasons for these differences 
and their implications on healthcare delivery.
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1026-130 Cardiometabolic Risk Factor Profile of United States 
and Caribbean-born Blacks
Ayotunde Bamimore, Melaku Demede, Tiffany Cohen, John Feng, Girardin Jean-Louis, 
Ferdinand Zizi, Luther T. Clark, State University of New-York Downstate Medical Center, 
Brooklyn, NY
Background: African Americans have the highest coronary heart disease [CHD] 
mortality rate of all ethnic groups in the United States. Caribbean-born blacks [CBB] have 
been reported to have lower CHD mortality than U.S-born blacks [UBB] and whites. In 
this study, we evaluated the burden of cardiac and cardiometabolic risk factors in UBB 
versus CBB.
Methods: We prospectively studied consecutive patients hospitalized with symptoms 
suggestive of myocardial ischemia for cardiac and cardiometabolic risk factors during a 
one-year period.Patients agreed to participate in our Cardiovascular Outcomes Research 
Group [CORG] registry developed at 4 State University of New York, Downstate affiliated 
hospitals.
Results: The study cohort comprised 275 non-hispanic blacks [mean age 62 ± 13], 45% 
were UBB and 55% were CBB. On admission, myocardial infarction was diagnosed 
in 33% of UBB and 36% of CBB. CBB were more often male [48% versus 39.2%: 
p=NS], smoked less [15.9% versus 35%; p= 0.001], less often had a previous history 
of myocardial infarction [13.5% versus 23.6%; p =0.04], but were similar in age [CBB 
mean age= 63.5yrs versus 61.2 yrs;p=NS], hypertension prevalence [CBB = 98.6% 
versus UBB = 98.3%; p= NS], dyslipidemia [Triglyceride ≥150 in CBB =15% versus UBB= 
15.7%;p=NS:HDL <40 in male CBB = 63.9% versus male UBB= 64.3%;p=NS :HDL < 
50 in female CBB = 57.6% versus female UBB =73.8%;p=NS;total cholesterol ≥ 200 in 
CBB=22.2% versus UBB=13.1%;p=NS] and also had similar prevalence of obesity [BMI≥ 
30 in CBB= 33.6% versus UBB= 40.4%;p=NS]. Diabetes was very common in both CBB 
and UBB [57.9% versus 47.9%], higher in CBB but the difference was not significant.
Conclusion: Although CBB smoke less, they have a similarly high prevalence of cardiac 
and metabolic risk factors as UBB. Diabetes is particularly prevalent. These findings 
suggest that CBB in the United States have very high CHD risk factor burdens and 
portend a CHD mortality rate similar to or greater than their U.S-born counterparts.
11:00 a.m.
1026-131 The Adoption of the 2000 European Society of 
Cardiology and American College of Cardiology 
Guidelines on Acute Coronary Syndrome Eliminated 
the Gender Difference in First Year Survival
Victor Novack, Donald Cutlip, Nicky Lieberman, Avi Porath, Soroka University Medical 
Center, Beer Sheva, Israel
Background: Gender gap in short and long term mortality following acute coronary 
syndrome (ACS) remains one of the most intriguing topics in cardiology. We examined the 
hypothesis that the transition to the 2000 European Society of Cardiology and American 
College of Cardiology guidelines, including the switch form CK MB to troponin, will narrow 
the difference in ACS mortality between men and women.
Methods: We conducted a retrospective population based cohort study of all ACS 
admissions to seven tertiary hospitals of the Clalit Sick Fund - the largest Israeli HMO 
during 5 year period (1999-2004). We used the day of transition to troponin as a proxy of 
guideline adoption by the hospitals.
Results: The number of ACS admissions during the two periods- CK MB and troponin 
- was 26,548 (20,206 patients, 287 hospital-months) and 18,725 (15,584, 185 hospital-
months), respectively. In both periods, female patients were older than male patients 
(71.5±11.6 vs. 64.3±13.3 and 72.4±11.8 vs. 64.8±13.3 years, p<0.001 for both), had 
lower rates of previous ischemic heart disease (39.3% vs. 44.0% and 39.1% vs. 43.2%. 
p<0.001 for both), but higher rates of diabetes (27.9% vs. 21.5% and 31.7% vs. 23.2%, 
p<0.001 for both). The rate of coronary intervention during the hospitalization remained 
higher in men then in women -33.6% vs. 47.6% during CK MB and 40.9% vs. 55.7% 
during troponin periods (p<0.001 for both). Multivariate analysis adjusted for background 
comorbidities, age, type of ACS and in-hospital coronary intervention demonstrates that 
female gender was a predictor of worse 1 year mortality compared to male - hazard ratio 
of 1.34 with 95%CI of 1.24 to 1.45 before during the CK MB period, but not during the 
troponin period - hazard ratio of 1.04 with 95%CI of 0.94 to 1.14.
Conclusions: Adoption of troponin as a more sensitive biomarker of myocardial damage 
is associated with eliminating of the gender gap in one-year mortality of the ACS patients. 
However, even after adjustment for the background patients’ characteristics and type of ACS, 
female patients continue to have lower rate of in-hospital coronary intervention than males.
11:00 a.m.
1026-160 Glomerular Filtration Rate and N-Terminal Pro-Brain 
Natriuretic Peptide as Predictors of Cardiovascular 
Mortality in Vascular Patients
Ramin Shadman, Matthew A. Allison, Michael H. Criqui, University of California San 
Diego, La Jolla, CA
Background: Glomerular filtration rate (GFR) and nt-proBNP have been shown to 
predict mortality endpoints in free-living and limited vascular populations, independent of 
traditional cardiovascular risk factors. However, their prognostic power in an unrestricted 
vascular population with a history of peripheral arterial disease (PAD) or other 
cardiovascular disease (CVD) is poorly understood.
Methods: A total of 412 subjects from a vascular cohort with a history of either PAD 
alone (n=161), CVD alone (n=58), or both (n=193) were included in this prospective 
cohort analysis and followed for an average of 6.7 years. Outcome variables were all-
cause mortality, mortality from ischemic heart disease (IHD) and mortality from any CVD. 
The prognostic role of baseline GFR and serum nt-proBNP levels for mortality outcome 
measures was determined using multivariate survival analysis.
Results: Overall, increasing increments of GFR (per 10 ml/min/1.73 m2) were significantly 
protective for all-cause mortality (HR 0.84, p 0.002), IHD death (HR 0.85, p 0.042), 
and any CVD death (HR 0.88, p 0.031). Conversely, nt-proBNP (per log unit) was not 
a significant predictor of any mortality endpoint. In subgroup analysis which stratified 
according to a history of either PAD, other CVD, or both, GFR showed strong associations 
with mortality in subjects with a history of other CVD only but weak associations in those 
with a history of PAD only. Though nt-proBNP did not demonstrate a significant prognostic 
role in any of the subgroups, the data were suggestive for patients with PAD only.
Conclusions: In the vascular population, GFR is a robust predictor of all-cause, 
cardiovascular, and ischemic cardiac mortality. With adjustment for renal function, nt-
proBNP was not significantly associated with any mortality endpoint. Notably, GFR had 
the greatest predictive ability in the population with prior CVD whereas nt-proBNP showed 
only a modest association in the subset with PAD only. These findings suggest that both 
of these markers likely have a prognostic role for various mortality endpoints, but must be 
selectively considered for subsets of the vascular population for greatest clinical utility.
11:00 a.m.
1026-161 High-Sensitive C-Reactive Protein Improves CHD Risk 
Assessment Independent of Coronary Artery Calcium 
in Women but Not in Men - Data from the Heinz Nixdorf 
Recall Study
Stefan Möhlenkamp, Nils Lehmann, Axel Schmermund, Andreas Stang, Susanne 
Moebus, Eva-Maria Beck, Lothar Volbracht, Klaus Mann, Rainer Seibel, Dietrich 
Grönemeyer, Karl-Heinz Jöckel, Raimund Erbel, University Clinic Essen, Essen, 
Germany, University Witten/Herdecke, Mülheim / Bochum, Germany
Background: The value of coronary artery calcium (CAC) and high-sensitive (hs)CRP 
for risk stratification has not been studied in an unselected general population. In a cross-
sectional analysis of the ongoing Heinz Nixdorf Recall cohort study, we analyzed age-
adjusted prevalence rate ratios (RR) of CHD.
Methods: 4487 (93.2%) subjects without and 327 (6.8%) of 4814 subjects with CHD 
(age 45-75 years) were screened including CAC and hs-CRP. Age-adjusted RRs for 
prevalence of CHD in relation to risk factors were determined. The following categories 
were used: 1) CAC <100, 100-399 and ≥400 or >75th percentile, and 2) hs-CRP ≤1mg/L, 
1-3mg/L, >3mg/L.
Results: RRs for established risk factors (BMI>30, age, smoking, diabetes, hypertension, 
dyslipidemia, history of stroke or peripheral artery disease (PAD)), ranged between 1.3 
(95%-CI=1.0-1.7) for BMI>30 in men and 5.0 (95%-CI=1.7-14.4) for a history of PAD in 
women. For high vs. low hs-CRP-values a significant RR was found in women (RR=2.5, 
95%-CI=1.3-4.6, p<0.01) but not in men (RR=1.1, 95%-CI=0.8-1.5, p=NS). RRs for high 
vs. low CAC were 18.2 (95%-CI=10.6-31.3) in men and 5.9 (95%-CI=3.4-10.2) in women, 
p<0.01 for both. In each CAC category, RRs increased with increasing hsCRP in women 
but not in men (Fig.1).
Conclusions: RRs of CHD were higher for CAC vs. hcCRP and established risk factors 
in men and women. Higher RRs in each CAC category with increasing hsCRP in women 
suggests an independent and complementary value of hsCRP in addition to CAC in 
women but not in men.
11:00 a.m.
1026-162 The Association between the Prevalence of Obesity 
and Adherence to the Mediterranean Diet; the ATTICA 
study.
Demosthenes B. Panagiotakos, Christos Pitsavos, Christina Chrysohoou, John 
Skoumas, Lambros Papademetriou, Constadina Masoura, Stella Brili, George Pounis, 
Manolis Kambaxis, Constadina Paliou, Christodoulos Stefanadis, 1st Cardiology Clinic 
University of Athens, Athens, Greece, Harokopio University, Athens, Greece
Background: Obesity is now considered as a serious health problem, since it has been 
associated with the occurrence of atherosclerotic disease and many other metabolic disorders 
. The benefits of the Mediterranean diet on human health have been attributed to the control 
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of blood pressure levels, markers of systemic chronic inflammation and platelet aggregation. 
However, data regarding the association between the adoption of Mediterranean diet and the 
prevalence of obesity are sparse in the literature.In this work we sought to evaluate whether 
greater adherence to the Mediterranean dietary pattern is associated with lower prevalence 
of obesity in a free-eating population-based sample of Greek adults.
Methods: Cross-sectional survey, that randomly enrolled 1514 men (18-87 years old) 
and 1528 women (18-89 years old), without history of cardiovascular disease. Among 
others, anthropometric indices were measured and frequency of various foods consumed 
during a usual week was recorded. Adherence to the Mediterranean diet was assessed 
by a diet - score that incorporated the inherent characteristics of this diet. Results. The 
prevalence of overweight and obesity was 53% and 20%, in men and 31% and 15% 
in women. An inverse relationship was observed between diet score, waist-to-hip ratio 
(r = -0.31, p < 0.001) and BMI (r = -0.4, p < 0.001), after adjusting for sex and age. 
Greater adherence to the Mediterranean diet (i.e. highest tertile) was associated with 
51% lower odds of being obese (odds ratio = 0.49, 95% CI 0.42 to 0.56) and 59% lower 
odds of being central obese (odds ratio = 0.41, 95% CI 0.35 to 0.47) as compared to a 
non-Mediterranean diet (i.e. lowest tertile), after controlling for age, sex, physical activity 
status, metabolic and other variables. Conclusion. We observed an inverse relationship 
between the adherence of a Mediterranean dietary pattern and the prevalence of obesity, 
in a free-eating population-based sample of men and women, irrespective of various 
potential confounders.
11:00 a.m.
1026-163 Reduction in Left Atrial Size 2 Years After Marked 
Weight Loss Achieved With Bariatric Surgery
James Gallagher, Nathan Segerson, Michael Strong, Robert Pendleton, Ted Adams, 
Steve Hunt, Sheldon E. Litwin, University of Utah, Salt Lake City, UT
Background: Obesity is associated with increased risk of heart failure, atrial fibrillation 
and mortality. Increased left atrial (LA) size is a risk factor for these outcomes. Little is 
known about the effects of marked weight loss on LA size.
Methods: We studied 200 severely obese patients at baseline and 2 years after 
randomization to nonsurgical therapy (NonSurg, n=125) or gastric bypass surgery (GBS, 
n=75). Echocardiograms were used to measure LA minor axis dimension, superior-
inferior dimension and LA volume (biplane method of discs).
Results: The 2 groups had similar LA dimensions and volumes at baseline (p=ns). At 2 
year follow-up, the GBS patients had significant decreases in BMI, systolic blood pressure 
(SBP) and heart rate vs. the NonSurg group (Table, * p <0.05 vs. NonSurg). LA minor 
axis and superior-inferior dimension both significantly decreased in the patients who 
had GBS while LA volume tended to decrease (p = 0.1) at 2 years in the GBS vs. the 
NonSurg subjects. At the 2 year follow up, LA superior-inferior dimension correlated with 
BMI (r=0.40, p < 0.001) and SBP (r=0.28, p < 0.001) but not with HgbA1C, insulin or 
diastolic BP.
Conclusion: Marked weight loss following Roux-en-Y GBS is accompanied by a 
significant reduction in LA dimensions. The reduction in LA size was related to the degree 
of weight loss and the magnitude of reduction in systolic BP. Given the known prognostic 
significance of LA volume, these findings suggest that GBS may have a long-term 
favorable effect on cardiovascular outcomes.
Changes in left atrial size 2 years after GBS or Nonsurgical treatment
BMI 
(kg/
m^2)
SBP 
(mmHg)
LA superior-inferior 
dimension (cm)
LA minor axis 
dimension (PLAX; 
cm)
LA volume 
(biplane (ml)
NonSurg 
Baseline 44±;6 128±;18 4.8±;0.6 3.6±;0.4 68±;19
GBS 
Baseline 47±;8 121±;16 4.8±;0.5 3.6±;0.6 67±;17
Nonsurg 2 
year 43±;7 124±;18 4.8±;0.5 3.6±;0.6 67±;18
GBS 2 
year 31±;7* 114±;16* 4.6±;0.6* 3.4±;0.4* 63±;18
11:00 a.m.
1026-164 Differences in Risk Factor-Adjusted Subclinical 
Cardiovascular Disease in Mexican-Americans versus 
Non-Hispanic Caucasians: An Echocardiographic/
Computed Tomographic Study
Julius M. Gardin, Zuhair Allebban, Nathan D. Wong, Sharon K. Sklar, Rene L. Bess, Ted 
W. Kurtz, H. A. Pershadsingh, Ann M. Spence, Robert C. Detrano, St. John Hospital and 
Medical Center, Detroit, MI, University of California, Irvine, Irvine, CA
Background: Mexican Americans (MA) exhibit increases in various cardiovascular 
disease (CVD) risk factors (e.g., diabetes, obesity, etc) compared to non-Hispanic 
Caucasians (C). MA also reportedly have lower CVD mortality rates than C. We 
hypothesized this apparent paradox might relate to lower levels of subclinical disease 
per risk factor level in MA.
Methods: We studied 105 adult MA (42 men, 63 women, age 46 ± 14 yrs) and 100 C (59 
men, 41 women, age 50 ± 11 yrs) using blood tests, transthoracic echo, and CT coronary 
artery calcium (CAC) scans.
Results: Despite higher BMI, triglycerides and glucose in MA (p= 0.04 to 0.0006), MA 
demonstrated lower of subclinical disease measures than C (% with CAC score > 0: 
mean 13% vs. 26%, p< 0.04 and LV mass: mean 150 vs 162 gm, p< 0.07). (Table). After 
age- and gender-adjustment, CAC and LV mass/Ht2.7 were associated with ethnicity and 
BMI. In multivariate analyses, MA ethnicity remained associated with lower LV mass/Ht2.7 
and lower % with CAC score >0 (P < 0.002). Ethnicity (MA vs C), BMI, and LDLc were the 
most important predictors for LV mass/Ht2.7. For % with CAC score >0, age, gender and 
ethnicity, diastolic BP and LDLc were the most important predictors.
Conclusion: Ethnicity is a significant predictor of subclinical disease. Despite higher 
levels of selected CVD risk factors in MA adults, they appear to have lower levels of 
subclinical disease than do C. This may explain their apparently lower CVD mortality 
rates than C. Longitudinal and genetic studies provide additional insights. 
MA C
(N=105) (N=100) 
Risk Factors Mean ± SD Mean ± SD P Value
Age (yrs) 46 ± 13 49 ± 11 <0.03
BMI (kg/m2) 30 ± 7 28 ± 4 <0.003
Diastolic BP (mm Hg) 72 ± 10 75 ± 9 0.1
Total Cholesterol (mg/dl) 199 ± 36 204 ± 37 0.3
LDLc (mg/dl) 111 ± 29 124 ± 30 0.002
Triglycerides (mg/dl) 173 ± 116 125 ± 66 0.0006
Glucose (mg/dl) 91 ± 13 89 ± 21 0.04
Current or previous smoker(%) 40% 61% 0.08
Subclinical Disease
CAC (% with score >0) 13% 26% 0.04
LV Mass (g) 150 ± 43 162 ± 50 0.07
11:00 a.m.
1026-165 Racial Differences in Access and Utilization of Cardiac 
Rehabilitation
Moneera Haque, Larry Hamm, Jonathan Whiteson, Samer Ellahham, Georgetown 
University, Washington, DC, George Washington, Washington, DC
Background: The established benefits of cardiac rehabilitation (CR) for patients with 
coronary artery disease are compelling and have demonstrated reductions in both 
morbidity and mortality. However, some reports suggest that only 10-20% of eligible 
patients in the United States currently participate in formal CR programs. The purpose of 
this study was to identify the racial differences in utilization of CR programs.
Methods: Cardiac patients who met the selection criteria of the American College of 
Cardiology guidelines of eligibility for CR were evaluated to determine factors associated 
with accessing CR programs. Enrollment was confirmed by chart abstraction. Prospective 
factors related with referral were entered into a logistic regression analysis to determine 
factors linked with referral and enrollment rates.
Results: The rate of referral was significantly lower for African Americans (crude odds 
ratio [OR] = 3.59; 95% confidence interval [CI] = 1.65-4.63). Only 32% of women in the 
study report enrollment, with fewer African-American women in contrast with white women, 
14% versus 28% (P=.03). African Americans with annual incomes <30,000 dollars were 
69% less likely to be referred to cardiac rehabilitation (P=.01) and 70% less likely to 
enroll compared to white with incomes >30,000 dollars (P=.01). Despite controlling for 
education, socioeconomic status, age, and insurance, race was still independently linked 
with referral for cardiac rehabilitation (OR=1.91; 95% CI=1.12-3.42).
Conclusions: Despite the demonstrated efficacy, outpatient CR remains underused 
and inconsistently accessed, particularly for women and minorities in both referral and 
enrollment rates with marked discrepancy in not only referral rates for African Americans, 
but also poorer enrollment rates. The decreased utilization of such services only serves 
to further pronounce the disparity in cardiac outcomes. Automatic referral systems should 
be considered to increase utilization and reduce such disparities.
11:00 a.m.
1026-166 Relation of Fasting Glucose Levels to Prevalance of 
Atherosclerotic Cardiovascular Disease
Devang M. Desai, Andrew Teklinski, Howard S. Rosman, Julius M. Gardin, James J. 
Maciejko, St. John Hospital and Medical Center, Detroit, MI
Background: Atherosclerotic cardiovascular disease (ASCVD) is a common complication 
of diabetes mellitus and impaired glucose tolerance (IGT). The risk of cardiovascular 
events among diabetics and individuals with IGT is similar to that of normoglycemic 
patients with a prior myocardial infarction. Current guidelines identify impaired fasting 
glucose as levels between 100mg/dL and 125mg/dL, and normal fasting glucose values 
as those below 100mg/dL. We hypothesized that the relation of fasting glucose levels 
to ASCVD is linear, with the prevalence of clinical cardiovascular disease beginning to 
increase even among individuals currently categorized as normoglycemic.
Methods: We evaluated the prevalence of ASCVD relative to fasting glucose levels in 
a cross-section of patients at high risk for ASCVD. Five hundred and fifty-six randomly 
selected patient charts were retrospectively reviewed from our Preventive Cardiology 
Clinic. Fasting glucose levels were correlated with the presence or absence of ASCVD.
Results: ASCVD prevalence significantly increased with increasing fasting glucose levels 
(p<0.005). Despite no significant differences in age, presence of hypertension, BMI, or 
family history of ASCVD, a significantly higher prevalence of ASCVD was observed 
among patients with fasting glucose levels between 90 and 99mg/dL vs. lower levels 
(29.0% versus 9.8% p<0.0005). As glucose levels increased to 126mg/dL, the prevalence 
of ASCVD continued to rise in parallel. No difference in the prevalence of ASCVD was 
observed among patients with fasting glucose levels of 70 to 79mg/dL versus 80 to 89mg/
dL (9.2% versus 9.8% p=0.98).
Conclusions: Our findings suggest that the lower glucose concentration for defining 
“impaired fasting glucose” should be 90mg/dL. Our data also suggest that the ASCVD risk 
in both IGT and overt diabetes mellitus patients is increased, and that both these patient 
subsets should be treated aggressively and similarly in regard to ASCVD risk.
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1026-167 Cardiovascular Determinants of Improved Exercise 
Capacity After Marked Weight Loss From Gastric 
Bypass Surgery
Theophillus Owan, Divya kapoor, Kimberly Morley, zachary williams, ted adams, steve 
hunt, Sheldon E. litwin, University of Utah, Salt Lake City, UT
Background: Obesity is associated with an increased risk of developing heart failure. 
Impaired left ventricular (LV) diastolic filling has been proposed as a mechanism that 
contributes to exercise intolerance in obesity, however, this has not been proven. The 
effects of weight loss on diastolic function are unknown.
Methods: We prospectively studied 837 severely obese patients 2 years after 
randomization to nonsurgical therapy (NonSurg) or Roux-en-Y gastric bypass surgery 
(GBS). We measured E and A velocities and E wave deceleration time (DT) from pulsed 
wave Doppler recordings at the tips of the mitral leaflets, and early (Ea) and late (Aa) 
diastolic annular velocities. We investigated the association of diastolic parameters with 
total treadmill time using linear regression models
Results: At the 2 year follow up visit, exercise capacity improved by 40% in GBS vs. 
NonSurg subjects (p < 0.01). GBS subjects had lower A velocity, higher E/A, higher Ea, 
and lower Aa velocities. In univariate analysis, age and systolic blood pressure were 
negatively associated with exercise capacity (p<0.01). Diastolic parameters negatively 
associated with exercise capacity included A, DT and E/Ea while E/A had a positive 
correlation (p<0.01). In multivariate analysis age, gender and BMI were significantly 
associated with exercise capacity (p<0.01). After adjusting for these variables only E/A 
had an independent association (p<0.01) with exercise capacity while E/Ea showed a 
trend (p=0.057).
Conclusion: In this large study of morbidly obese patients we find a significant association 
of E/A with exercise capacity independent of age, gender and BMI and in the absence 
of clinical signs of heart failure. These findings suggest that diastolic filling, in addition to 
age, weight and gender may contribute to exercise intolerance in obesity. Moreover, for 
the first time we show that marked weight loss may improve these abnormalities.
11:00 a.m.
1026-168 Economic Impact of Amlodipine in Normotensive 
Coronary Artery Disease Patients: Subgroup Analyses 
of Participants in the CAMELOT Trial
Joseph Menzin, Luke Boulanger, Simon Tang, Kamlesh M. Thakker, Steven E. Nissen, 
Boston Health Economics, Inc, Waltham, MA, Cleveland Clinic Foundation, Cleveland, OH
Background: In the Comparison of Amlodipine vs Enalapril to Limit Occurrences of 
Thrombosis (CAMELOT) study, over 2 years, normotensive coronary artery disease 
(CAD) patients randomized to amlodipine besylate 10 mg daily had a 28% and 18% lower 
rate of cardiovascular (CV) hospitalization relative to placebo (P<0.05) and enalapril 20 
mg daily (P=0.09).
Methods: We assessed the effects of amlodipine on the rate of hospitalization and CV-
related healthcare costs (study medication, concomitant medication and hospitalization) 
in CAMELOT subpopulations defined by age, gender, blood pressure, statin use, and 
presence of diabetes, metabolic syndrome or impaired fasting blood glucose.
Results: Compared to both enalapril and placebo, amlodipine reduced rates of CV 
hospitalization the most among those who were female, age 65+ years, statin users and 
with metabolic syndrome (see Table). In these groups, mean 2-year per-patient costs 
of CV-related care were estimated to be approximately $1,000-5,000 lower. In contrast, 
the effects of amlodipine on CV hospitalizations and costs were most limited for younger 
patients, males, and those not dispensed a statin.
Conclusions: This analysis suggests that the economic effects of amlodipine in the 
CAMELOT study were greatest in selected subgroups of normotensive CAD patients 
defined based on age, gender and statin use.
Table. Percentage of patients with one or more CV-related hospitalizations, 
by subgroup
Amlodipine vs. enalapril Amlodipine vs placebo
Measure Relative reduction 95% CI Relative reduction 95% CI
Age, 65+ years 0.66 0.35-1.00 0.57 0.29-0.85
Female 0.54 0.26-0.82 0.58 0.29-0.91
Below average systolic BP 0.79 0.50-1.12 0.71 0.44-0.97
Statin dispensed 0.77 0.53-0.97 0.69 0.47-0.85
Diabetes 0.64 0.30-1.03 0.65 0.31-1.04
Metabolic syndrome 0.64 0.37-0.88 0.68 0.40-0.96
Impaired fasting glucose 0.64 0.29-1.19 0.55 0.24-0.95
11:00 a.m.
1026-169 Are Coronary Revascularization and Myocardial 
Infarction a Logical Combined Endpoint in 
Hypertension Trials? The LIFE Study
Silvana Cicala, Giovanni de Simone, Eva Gerdts, Björn Dahlöf, Lars H. Lindholm, 
Richard B. Devereux, Division of Cardiology, Weill Medical College of Cornell University, 
New York, NY
Background: A composite endpoint icluding MI and/or coronary revascularization has 
been considered in some clinical trials involving hypertensive patients. However, it is 
unclear whether coronary revascularization identifies patients with sufficiently similar 
atherosclerotic disease to constitute a homogenous trial endpoint.
Objectives: To examine the risks of cardiovascular (CV) mortality, all-cause death, stroke 
and peripheral arterial revascularization predicted by initial occurrence of MI or coronary 
revascularization in the setting of the high-risk subjects in the LIFE study.
Methods: A total of 9113 patients were studied after exclusion of patients experiencing CV 
death within 7 days after MI or undergoing coronary revascularization within 24 hours after 
MI. Univariate Cox regression models and multivariate models adjusted for randomized 
treatment type, Framingham risk score and time-varying systolic blood pressure were 
developed to assess the hazard ratios (HRs) and 95% confidence intervals (CIs) for CV 
mortality, all-cause mortality, stroke and peripheral arterial revascularization subsequent 
to MI or coronary revascularization.
Results: In multivariate Cox regression models, the HRs of CV mortality, all-cause 
mortality, stroke and peripheral arterial revascularization were 4.0 (95% CI, 2.5-6.3, 
p<0.0001), 2.5 (95% CI, 1.7-3.8, p<0.0001), 1.9 (95% CI, 1.2-2.8, p=0.003) and 2.5 (95% 
CI, 1.5-4.1, p<0.0001), respectively, in patients whose first event was MI. In similar models 
initial occurrence of coronary revascularization was not associated with increased risks of 
CV mortality, all-cause death or stroke (p=0.24 to 0.48); coronary revascularization was 
associated with a higher likelihood of subsequent peripheral arterial revascularization 
(HR=2.2, 95% CI, 1.2-4.3, p=0.012).
Conclusions: Risks of subsequent CV death, all-cause mortality and stroke were strongly 
associated with MI, but not with coronary revascularization as first coronary heart 
disease event. Inclusion of coronary revascularization in a composite endpoint for trials in 
hypertensive patients should be employed with caution.
11:00 a.m.
1026-170 Blood Pressure Lowering And cGMP Activating Actions 
Of Oral Human BNP In Experimental Hypertension
Alessandro Cataliotti, Horng H. Chen, Paul M. McKie, Fernando L. Martin, Guido 
Boerrigter, Lisa C. Costello-Boerrigter, Denise M. Heublein, Kenneth D. James, John C. 
Burnett, Jr., Mayo Clinic, Rochester, MN
Background: BNP is a vasodilating, natriuretic, anti-hypertrophic, anti-fibrotic, lusitropic 
and RAAS suppressing hormone of cardiac origin. Therefore, BNP emerges as a 
potential anti-hypertensive agent yet as a peptide its use has been limited to intravenous 
administration. The objective of the current study was to define the ability of an advanced 
oral conjugated human BNP (CONJ-hBNP054) in an experimental hypertension (HTN) to 
be absorbed, activate cGMP and reduce mean arterial pressure (MAP).
Methods: We investigated the effects of oral CONJ-hBNP054 or vehicle in 6 dogs that 
received continuous intravenous infusion of angiotensin II (ANG II; 20 μg/kg/min, 1 
ml/min for over 4 hrs) to induce HTN. At baseline (BL), MAP and blood collection for 
plasma human BNP (hBNP), cGMP, and ANG II determination was obtained followed 
by continuous ANG II infusion. After 30 min of ANG II administration, dogs received 
oral CONJ-hBNP054 (400 μg/kg) or vehicle in a random crossover fashion (one week 
of interval). Blood sampling and MAP measurements were repeated 30 min after ANG 
II administration, and 10, 30, 60, 120, 180 and 240 min after oral CONJ-hBNP054 or 
vehicle. *p<0.05 vs ANG II
Results: hBNP was not present in canine plasma at BL and was not detected at any 
time in the vehicle group. In contrast, hBNP was detected throughout the duration of the 
study after CONJ-hBNP054 (peak concentration at 30 min 1060±327 pg/ml). After ANG 
II, cGMP was not activated with vehicle, while it increased with CONJ-hBNP054 (from 
14.4±1 with ANG II to 30.7±4* at 10 min, 43.1±7* at 30 min and 41.3±6* pmol/mL at 60 
min; p<0.0001 between groups). In the presence of sustained ANG-induced HTN, no 
changes occurred in MAP after vehicle. Importantly, CONJ-hBNP054 reduced MAP (from 
138±1 with ANG II to 142±2* at 30 min; 124±2* at 60 min and 130±2* mmHg at 120 min; 
p<0.0001 between groups). No differences between vehicle and CONJ-hBNP054 were 
observed in ANG II concentrations throughout the study
Conclusions: We report for the first time that a novel oral conjugated hBNP activates 
cGMP and significantly reduces MAP in a model of HTN. These findings advance an 
innovative strategy of orally administered BNP protein therapy for cardiovascular diseases 
such as HTN.
11:00 a.m.
1026-171 Beneficial Effect of Angiotensin-II Type 1 Receptor 
Blocker Antihypertensive Treatment on Arterial 
Stiffness. The Role of Smoking
Stella-Maria Kyvelou, Gregory Vyssoulis, Eva Karpanou, Dionyssis Adamopoulos, 
Charalambos Vlachopoulos, George Antonakoudis, Panagiota Pietri, Dennis Cokkinos, 
Christodoulos Stefanadis, 1st Cardiology Department, Athens Medical School, 
Hippokration Hospital, Athens, Greece
Background: Arterial stiffness has been recognised as a significant predictor of 
cardiovascular risk, while experimental data indicate that angiotensin II receptor blocker 
(ARB) treatment reduces arterial stiffness. Moreover, smoking affects notoriously arterial 
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stiffness. The purpose of the present study was to assess the effect of ARB treatment on 
arterial stiffness in hypertensive patients and to reveal any possible differences between 
smokers and non-smokers.
Methods: We evaluated 100 consecutive, nondiabetic, high renin activity patients 
(mean age 52 years, 47 men) with uncomplicated essential hypertension. All patients 
were responders to irbesartan monotherapy (from 164/100 to 127/82 mmHg) at maximal 
dose (300mg/day). Patients were further divided in smokers (n=32) and non-smokers 
(n=68). Large artery stiffness and arterial wave reflections [carotid-radial pulse wave 
velocity (PWVc-r), carotid-femoral pulse wave velocity (PWVc-f) and augmentation index 
(AIx) application tonometry] were measured at drug-free baseline and after 6-month of 
irbesartan monotherapy.
Results: All arterial function indices were decreased after irbesartan monotherapy (AIx: 
from 26.2 to 20.56 %, P<0.01, PWV-f: from 7.7 to 7.2 m/sec, P<0.02 and PWV-r: from 
8.8 to 8.1 m/sec, P<0.001). Multivariate regression analysis of covariance revealed that 
PWVc-r change was independent of systolic blood pressure (SBP) change (P<0.001). 
Furthermore, when comparing smokers to non-smokers we noted a greater decrease in 
smokers in both PWVc-r (-1.2 vs -0.4m/sec, P=0.02) and PWVc-f (-0.9 vs -0.36m/sec, 
P<0.002) after 6 months monotherapy with irbesartan.
Conclusions: Chronic ARB treatment may affect favorably arterial stiffness and wave reflections 
in hypertensive patients. This beneficial effect is more prominent in chronic smokers.
11:00 a.m.
1026-172 The Association of Angiotensin Converting Enzyme 
(ACE) gene Insertion/Deletion polymorphism with 
Carotid Augmentation index in Hypertensive Patients
Se-Jung Yoon, Sungha Park, Chanmi Park, Young-Guk Ko, Donghoon Choi, Yangsoo 
Jang, Namsik Chung, Cardiology division, Yonsei University Medical center, Seoul, 
South Korea, Cardiovascular Research Institute and Genome Center, Yonsei University 
Medical center, Seoul, South Korea
Background: The insertion/deletion (I/D) polymorphism of the human angiotensin-
converting enzyme (ACE) gene has functional significance in determining the circulating 
ACE activity. The degree of renin- angiotensin-aldosterone activation is important in the 
pathophysiology of arterial stiffening. However, studies regarding the association of I/
D polymorphism with arterial stiffness using augmentation index in hypertensive, asian 
population have not been done. We sought to determine whether there is a significant 
correlation between I/D polymorphism and augmentation index(AI) in treated hypertensive 
patients, independent of hemodynamic, clinical variables that affect AI.
Methods: A total of 600 treated hypertensive patients were enrolled in this study(M:F 
= 377:223, mean age : 56.0±10.4 years). The ACE I/D polymorphism was determined 
by polymerase chain reaction and amplification of intron 16 of the ACE gene. Carotid 
waveforms were recorded from multi-element tonometry sensors at the left carotid using 
the VP-2000 PWV system.(Nippon Colin Ltd)
Results: The genotype frequency of ACE I/D was II(35.5%), ID(48.3%), DD(16.2%) which 
did not deviate from the Hardy-Weinberg equlibrium. The augmentation index revealed 
significant difference according to the genotypes(II : ID : DD = 23.5 ± 14.7 : 21.1±16.2 
: 17.1±19.3, P=0.006). The presence of II or ID genotype, assuming codominant effect 
of the I allele, was significantly associated with increased carotid augmentation index, 
independent of age, systolic BP, height, heart rate, gender, presence of diabetes and 
smoking in hypertensive patients[ß=0.061, R2 = 0.546, P = 0.029].
Conclusions: The result of this study demonstrated that the ACE gene insertion(I) polymorphism 
is a significant determinant of increasing carotid AI in treated hypertensive patients.
Key Words
Polymorphism, genetics, ACE, Augmentation index, arterial stiffness
This work was supported by a grant of Ministry of Health and Welfare, Republic of Korea 
(00-PJ6-PG5-23-0001)
11:00 a.m.
1026-173 Tissue-Specific Angiotensin-Converting Enzyme (ACE) 
Inhibitors in Prevention of Cardiovascular Disease in 
Patients with Diabetes Mellitus and Preserved Left 
Ventricular Function: A Pooled Bayesian Meta-Analysis
Christopher D. Lang, Sandeep A. Saha, Janos Molnar, Rohit R. Arora, Chicago Medical 
School, North Chicago, IL
Background: The role of angiotensin converting enzyme (ACE) inhibitors in patients 
with depressed left ventricular function is well established. However, their role in diabetic 
patients with preserved ventricular function is uncertain. A systematic Bayesian meta-
analysis of randomized placebo-controlled trials was conducted to evaluate the role 
of tissue ACE inhibitors in prevention of cardiovascular disease among patients with 
diabetes mellitus and preserved left ventricular function.
Methods: Randomized placebo-controlled trials were selected of at least 12 months’ 
duration, in patients with diabetes mellitus and preserved left ventricular function who 
had experienced a prior cardiovascular event or were at high cardiovascular risk. 10,328 
patients (43,517 patient-years) from 4 selected trials were studied. Odds ratio estimations 
were made using pooled data from the 4 trials. Bayesian meta-analysis of sequential trials 
and sensitivity analysis of therapeutic response were computed.
Results: Calculations of the Bayesian probability of benefit of tissue ACE inhibitors 
indicate reduced risk of cardiovascular mortality (Pb =0.991), myocardial infarction (Pb 
=0.999), and the need for invasive coronary revascularization (Pb =0.995) when compared 
to placebo. The risk of overall mortality tended to be lower among patients randomized to 
tissue ACE inhibitors (Pb =0.967), while the risk of stroke (Pb =0.907) and hospitalization 
for heart failure (Pb =0.923) were impacted.
Conclusion: Pooled Bayesian meta-analysis of randomized placebo-controlled trials 
suggests that tissue ACE inhibitors decrease the probability that patients will suffer 
myocardial infarctions and cardiovascular death, and tend to reduce overall mortality in 
diabetic patients with preserved left ventricular function and high cardiovascular risk.
11:00 a.m.
1026-202 The Role of Quinapril in the Presence of a Weight Loss 
Regimen: Endothelial Function and Markers of Obesity 
in Patients with the Metabolic Syndrome
Sameer Nagamia, Srikanth Sola, Anbu Pandian, Faiz Cheema, Christopher S. Vaccari, 
Nadya Merchant, Bobby V. Khan, Emory University School of Medicine, Atlanta, GA, 
InVasc Therapeutics, Atlanta, GA
Background: We sought to determine whether a combination of an ACE inhibitor and 
dietary modification resulting in weight loss regulates endothelial function and markers of 
obesity in the metabolic syndrome.
Methods: 44 patients with the metabolic syndrome were placed on a reduced calorie and 
fat regimen to lose weight. Subjects were treated in a crossover fashion and in a double 
blinded manner to placebo for 24 weeks and the ACE inhibitor quinapril for 24 weeks. We 
measured serum markers of adiponectin and leptin. We measured endothelial dependent 
flow mediated dilation in these patients (FMD).
Results: There was a change of metabolic parameters after 24 weeks of therapy in each 
study group. In comparison to baseline, serum adiponectin increased by 18 percent after 
24 weeks in the placebo group (baseline: 1.40± 0.08 pg/ml, 24-weeks: 1.65 ± 0.10 pg/
ml; p=0.031 vs baseline), and serum leptin decreased by 16 percent after 24 weeks 
in the placebo group (baseline: 30.2± 4.5 pg/ml, 24-weeks: 24.9 ± 2.9 pg/ml; p=0.041 
vs baseline). Furthermore, these findings were augmented in the quinapril group. There 
was an increase in serum adiponectin leptin levels by 37 percent (baseline: 1.40±0.12 
pg/ml, 24-weeks: 1.96±0.11 pg/ml, p=0.012 vs baseline, p=0.022 quinapril vs placebo 
at 24 weeks) and a reduction of serum leptin levels by 36 percent (baseline: 29.6 ± 4.2 
pg/ml, 24-weeks: 16.1 ± 2.9 pg/ml, p<0.001 vs baseline, p=0.009 quinapril vs placebo at 
24 weeks). Also, in comparison to baseline, the FMD was increased by 13 percent in the 
placebo group after 24 weeks (baseline: 4.80 ± 0.61%; 24 weeks: 5.51 ± 0.59%, p=0.055 
vs baseline) and by 43 percent in the quinapril group (baseline: 4.72 ± 0.55%; 24 weeks: 
7.00 ± 0.49%, p<0.001 vs baseline, p<0.001 quinapril vs placebo at 24 weeks).
Conclusions: Dietary modification resulting in weight loss improves endothelial function 
and markers of obesity. Moreover, this effect is potentiated with a combination of weight 
loss and quinapril. These results may attenuate progression of pathophysiology seen in 
the metabolic syndrome.
11:00 a.m.
1026-203 A Polymorphism in Promoter Region of Cytochrome 
P450 4A11 Gene is Associated with a New Onset of 
Hypertension: the Tanno and Sobetsu Study
Hiroshi Akasaka, Ken Sugimoto, Tomohiro Katsuya, Shigeyuki Saitoh, Hirofumi Ohnishi, 
Toshio Ogihara, Kazuaki Shimamoto, Second Department of Internal Medicine, Sapporo 
Medical University, Sapporo, Hokkaido, Japan, Department of Geriatrics, Osaka 
University Graduate School of Medicine, Suita, Osaka, Japan
Background: The cytochrome P-450 4A (CYP4A) arachidonic acid (AA) monooxygenases 
oxidize endogenous AA to 20-Hydroxyeicosatetraenoic acid (20-HETE). The 20-HETE 
metabolite has the capacity to act in either a prohypertensive or antihypertensive manner 
depending on its expression at renovascular or tubular sites, respectively. The CYP4A11 
gene is one of candidate genes of predisposing factors to human hypertension, and 
previous association study suggested the association between a polymorphism (T8590C) 
of CYP4A11 gene and hypertension. To assess the relationship between new onset of 
hypertension and polymorphisms of CYP4A11, we carried out a prospective, genetic 
epidemiological study in Japanese general population, the Tanno and Sobetsu study.
Methods: A total of 980 subjects (386 men and 594 women, aged 58.2±9.3 years at 
baseline) from the residents of Tanno town and Sobetsu town were enrolled in this 
study at baseline in 1994 and have been followed until 2002. The genotypes of 2 
polymorphisms (-845A/G in promoter and T8590C in exon 10) were determined by the 
TaqMan PCR method. Hypertension was defined as systolic blood pressure ≥140 mmHg 
or diastolic blood pressure ≥90 mmHg or current use of antihypertensive medication. 
Written informed consent was obtained from all subjects, and a local ethical committee 
approved the study protocol.
Results: At baseline, 608 subjects were normotensive. After 8 years’ follow-up, 391 
subjects remained in normotensive (NT group), but the other 217 subjects without 
hypertension have come to be hypertensive (new onset HT group). The percentage 
of subjects with -845A homozygotes was significantly higher in the NT group than in 
the new onset HT group, and the percentage of those with 8590T homozygotes was 
significantly higher in the new onset HT group. Multiple logistic regression analysis 
showed an independent relationship between a new onset of hypertension and -845A/G 
after adjusting confounding factors such as sex, age, body mass index, and systolic blood 
pressure at baseline.
Conclusions: A promoter variant in the CYP4A11 gene can be a new candidate 
polymorphism for genetic susceptibility to a new onset of hypertension.
JACC  March 6, 2007    ABSTRACTS - Vascular Disease, Hypertension and Prevention    415A 
Vascular D
isease, H
ypertension and P
revention
11:00 a.m.
1026-204 Secular Trends of Cardiovascular Risk Factors in 
Children According to Left Ventricular Mass and Body 
Mass Index: A Twenty Year Echocardiographic Study
Sandra A. Witt, Betty J. Glascock, Philip Khoury, Thomas R. Kimball, Cincinnati 
Children’s Hospital, Cincinnati, OH
Background: The prevalence of overweight children has risen dramatically in recent 
decades with reported estimates indicating over 9 million children in the United States 
being effected. However, it is unknown if increased left ventricular (LV) mass, a significant 
cardiovascular risk factor is also being effected in normal children . The aim of this study 
was to evaluate changes in LV mass and body mass index (BMI), both known correlates 
of cardiovascular risk, in today’s children versus those of a generation ago.
Methods: The echocardiography database at Cincinnati Children’s Hospital was queried 
for all patients between 2-17 years of age who 1) underwent echo between either 
1984-1990 (Era 1) or 2004-2006 (Current Era) and 2) were without any heart disease 
or systemic disease which would impact cardiac anatomy/physiology. M-mode LV end-
diastolic dimension, posterior wall thickness, and intraventricular septal thickness were 
measured, and LV mass was calculated and indexed by dividing by height raised to a 
power of 2.7. In addition, patient age, gender and weight were noted, and BMI and BMI 
z values were calculated. Multiple regression analysis was performed to investigate 
determinants of LV mass.
Results: 455 patients were identified in Era 1 and 548 in the Current Era (559 boys, 444 
girls). The mean BMI was significantly higher in the Current Era (18.8±3.7 vs 17.9±3.2 
p<0.0001). Indexed LV mass was significantly higher in the Current Era (36±9 vs 33±9 
g/ht2.7, p<0.0001). As expected, multiple regression analysis showed older age and male 
gender to be statistically significant and independent determinants of higher LV mass. In 
addition, higher BMI and Current Era were also statistically significant determinants of 
higher LV mass.
Conclusions: Today’s children have higher LV mass and BMI than their counterparts of 
a generation ago. Higher LV mass is in part due to higher BMI. These data indicate that 
not only prevention of this current trend is needed but intervention is required. Pediatric 
cardiologists should include the assessment of LV mass and BMI when identifying if a 
child is both healthy and normal from a cardiac standpoint.
ACC.ORAL CONTRIBUTIONS
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Obesity and Cardiovascular Risk: Part II
Tuesday, March 27, 2007, 11:00 a.m.-12:30 p.m.
Room 206-207
11:00 a.m.
840-3 Waist Circumference Reduction, not Body Mass Index, 
Improves Endothelial-Dependent Vasodilatation After 
Acute Coronary Syndrome
Shinichiro Miyazaki, Yoshikazu Hiasa, Takefumi Takahashi, Riyo Ogura, Yoshikazu 
Ohara, Naoki Suzuki, Shinobu Hosokawa, Koichi Kishi, Ryuji Ohtani, Tokushima Red 
Cross Hospital, Komatsushima, Japan
Background: Endothelial function predicts recurrence of adverse cardiac events 
in patients with acute coronary syndrome (ACS). More importantly, the recovery of 
endothelial function is associated with cardiac event free survival. The aim of this study 
was to elucidate the clinical factors related to the improvement of endothelial function 
after ACS.
Methods: Using high-resolution ultrasound, flow-mediated dilation (FMD) of the brachial 
artery was assessed in 77 patients 2 weeks and 6 months after ACS. According to the 
previous reports, we measured glucose and insulin levels in plasma (fasting and 2h after 
oral glucose tolerance), low-density lipoprotein, high-density lipoprotein, triglycerides, high 
sensitive C-reactive protein, blood pressure, body mass index, and waist circumference 
at baseline and at 6 months.
Results: At baseline, a significant negative correlation was found between waist 
circumference, BMI and FMD (r=-0.54, p<0.0001; r=-0.38, p=0.005), whereas no 
correlation was found between other variables and FMD. At 6 months, the improvement 
of FMD was positively correlated with the degree of waist circumference reduction 
(r=0.73, p<0.0001), but not BMI (p=ns). In a multivariate regression analysis, only waist 
circumference reduction was an independent predictor of improved FMD (p=0.01). 
Conclusion: Waist circumference reduction, but not BMI, is strongly associated with 
improvement of endothelial-dependent vasodilatation after ACS. 
11:15 a.m.
840-4 Cardiovascular Risk, Obesity and Myocardial Blood 
Flow in Postmenopausal Women
Apurva A. Motivala, Patricia A. Rose, H. Myra Kim, Catherine Bartnick, Claire S. 
Duvernoy, Veterans Affairs Healthcare System, Ann Arbor, MI, University of Michigan, 
Ann Arbor, MI
Background: Increased body mass index (BMI) is consistently associated with increased 
cardiovascular mortality in postmenopausal women. Whether this is due to obesity itself 
or the accompanying increase in cardiovascular risk factors (CRF) remains controversial. 
We examined the relation of myocardial blood flow (MBF) and maximal myocardial 
flow reserve (MFR) -- an established predictor for cardiovascular mortality, to BMI in 
postmenopausal women with no coronary heart disease (CHD).
Methods: 60 postmenopausal women underwent dynamic N-13 ammonia positron 
emission tomography for the measurement of MBF and MFR. BMI and CRF were 
recorded for each subject.
Results: Subjects were divided into 3 groups by BMI. 
Group 1 Group 2 Group 3
Normal weight
(n=21)
Overweight
(n=21)
Obese
(n=18)
BMI (Range 20 - 44) 18-24 25-29 ≥ 30
Age 59 ± 7 58 ± 4 59 ± 6
Subjects with ≥ 1 CRF 6 7 12
Rest Pressure-Rate Product (PRP) 6729 ± 1232 8048±1540** 10101±2710*†
Rest MBF(ml/min/g) 0.86 ± 0.18 1.03 ± 0.34* 1.04 ± 0.22*
Adenosine MBF 2.71 ± 0.65 2.69 ± 0.63 2.49 ± 0.78
MFR 3.25 ± 0.91 2.88 ± 1.17* 2.50 ± 0.94*
*p<0.05 vs. Grp 1, **p<0.001 vs. Grp 1, †p<0.001 vs. Grp 2
The overweight and obese groups showed significantly higher resting PRP and MBF, and 
lower MFR (adenosine / resting MBF) than the normal weight group. These correlations 
persisted even after adjusting for CRF and age using multiple regression models (p=0.04). 
Furthermore, when we analyzed only the subjects without any CRF, adenosine MBF and 
MFR remained significantly lower in the obese compared to normal weight subjects.
Conclusions: Our results show that in overweight and obese postmenopausal women, 
an increasingly higher BMI is independently associated with a progressively lower MFR, 
due to an increase in resting PRP and resting MBF coupled with a decrease in maximal, 
adenosine-induced MBF. These findings provide, for the first time, a mechanistic link 
between obesity and CHD in this population.
11:30 a.m.
840-5 Ventricular Vascular Coupling in Obesity is Affected by 
an Adverse Temporal Profile of Wave Reflections and 
Ventricular Ejection: A Population-Based Study
Julio A. Chirinos, Josefina Medina Lezama, Humberto Zea Diaz, Oscar L. Morey, Juan 
F. Bolaños, Zoila Valdivia, Carolina Cuba, Fernando Corrales, Paola Villalobos, Sheyla 
Paredes, Julio Chirinos Pacheco, Santa Maria Catholic University School of Medicine, 
AQP, FL
Background: Obesity is independently associated with an increased risk of heart failure 
(HF), but the mechanisms of this association are incompletely understood. Increased 
left ventricular (LV) systolic tension over time occurs in obesity and correlates with its 
severity. Interactions between LV contraction and wave reflections are major determinants 
of LV systolic tension and afterload. We evaluated the association between obesity and 
time-dependent parameters of the aortic pressure waveform relating to LV ejection and 
wave reflection.
Methods: We studied 1150 subjects participating in a population-based study 
(PREVENCION Study). Aortic pressure waveforms were obtained with radial applanation 
tonometry and the transfer function of the Sphygmocor device. Using multiple linear 
regression, we assessed the correlation between (log) body mass index (BMI) and time 
parameters (milliseconds from onset of LV ejection) of the aortic pressure waveform .
Results: After adjusting for age, gender, heart rate, mean and pulse pressure, BMI 
indepedently predicted a longer time to the 1st systolic peak (β=27.5±6; p<0.0001), 
with a propotional delay in the inflection point that marks the onset of the reflected wave 
(β=25.9±5; p<0.0001). However, the time to the 2nd systolic peak (resulting from wave 
reflection) was actually shortened (β=-14.6±7; p=0.03) resulting in a shortening (β=-
42.6±9; p<0.0001) of the time period between the 1st systolic peak (time of peak flow) 
and 2nd systolic peak (at which the flow-opposing effects of the reflected wave are close 
to maximal). In addition, BMI independently predicted a significanlty longer left ventricular 
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ejection time (LVET; β=21.5±7; p=0.002) and longer time between the 2nd systolic peak 
and the end of LV ejection (β=36.2±7; p=0<0001).
Conclusions: Obesity is associated a delay in primary peak flow, an earlier 2nd systolic 
peak, and a prolongation of LVET, resulting in a more prolonged overlap between the 
flow-promoting LV contraction and the flow-opposing effects of wave reflections. These 
abnormalities in ventricular-vascular coupling likely decrease the energetic efficiency of 
the LV and may be implicated in the risk of HF associated with obesity.
11:45 a.m.
840-6 The Metabolic Syndrome is Associated with Increased 
Stiffness of Large Arteries but not of Muscular Arteries: 
A Population-Based Study
Julio A. Chirinos, Josefina Medina Lezama, Humberto Zea-Diaz, Carolina Cuba, 
Zoila Valdivia, Fernando Corrales, Oscar Morey, Juan F. Bolanos, Mauricio Postigo 
MacDowall, Edgar Munoz, Julio Chirinos Pacheco, Santa Maria Catholic University 
School of Medicine, AQP, Peru
Background: Aortic stiffness measured from pulse wave velocity (PWV) is an 
independent predictor of cardiovascular risk. Increased aortic stiffness is associated with 
high blood pressure (BP), obesity and other cardiovascular risk factors, but the relative 
contribution of individual components of the metabolic syndrome (MS) as determinants 
of arterial stiffness has not been investigated in population-based studies. We examined 
the contribution of MS components according to ATPIII criteria and their clustering as 
determinants of large and muscular artery PWV.
Methods: We studied 1069 subjects participating in a population-based study 
(PREVENCION Study). PWV was measured with simultaneous doppler and the foot-
to-foot method. Carotid-femoral (CF) PWV was measured as a marker of aortic stiffness 
whereas carotid-radial (CR) and femoral-pedal (FP) PWV were used as indicators of 
muscular artery stiffness.
Results: In a multiple regression model containing all 5 individual MS components, 
high BP (ß=2.03 m/s; 95%CI=1.56-2.50; p<0.0.0001), high triglycerides (ß=0.54 m/s; 
95%CI=0.11-0.98; p=0.005) and low HDL (ß=-0.72 m/s; 95%CI=-1.08 to -0.38; p<0.001) 
were significant predictors of CF-PWV. After adjustment for age and gender, high BP and 
low HDL reimained significant predictors of CF-PWV. Furthermore, a significant interaction 
between abdominal obesity and high BP was found, and abdominal obesity predicted 
a higher CF-PWV in hypertensive (ß=0.7 m/s; 95%CI=0.23-1.19; p<0.0001), but not in 
normotensive subjects. After adjustment for age, gender, smoking, LDL cholesterol and 
heart rate, mean CF-PWV for subjects with 0-1, 2, 3 or 4-5 MS components were 8.87, 
9.31, 9.54 and 10.14 m/s, respectively (ANCOVA P=0.0008). CR-PWV and FP-PWV did 
not independently correlate with the number of MS components.
Conclusions: The MS is associated with increased large artery stiffness. This association 
is not entirely accounted for by high BP, but also relates to the clustering of metabolic 
abnormalities. Abdominal obesity and high BP appear to have a synergistic (rather than 
additive) effect on CF-PWV. Increased arterial stiffness may be an important mediator of 
increased cardiovascular risk in the MS.
Noon
840-7 Graded Relationship Between Adiponectin Levels 
and Arterial Stiffening in Newly Diagnosed Essential 
Hypertensive Subjects
Kyriakos Dimitriadis, Costas Tsioufis, Carmen Vasiliadou, Dimitris Tsiachris, Efstathios 
Taxiarchou, Platonas Missovoulos, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokratio Hospital, Athens, Greece
Background: Adiponectin is an emerging marker of atherosclerosis progression, while 
increased arterial stiffness is associated with unfavorable cardiovascular outcome. In this 
study we examined the relation of plasma adiponectin levels with arterial stiffening in 
essential hypertensive patients.
Methods: 295 newly diagnosed untreated non-diabetic patients with stage I to II essential 
hypertension [192 men, mean age=50 years, office blood pressure (BP)=148/95 mmHg] 
were divided into three groups according to carotid to femoral pulse wave velocity 
(PWV) values, assessed by means of a computerized method (Complior SP): Group 
A (PWV<7.39 m/sec), group B (PWV=7.4-8.5 m/sec) and group C (PWV>8.5 m/sec). 
Additionally, venous blood samples were drawn for estimation of lipid profile and 
adiponectin levels.
Results: For the pooled population, body mass index (BMI) was 26.17±3.4 kg/m2, 
adiponectin levels were 9.1±5.3 μg/ml, left ventricular mass index (LVMI) was 106.8±21 
g/m2 and PWV was 8.1±1.3 m/sec. In the total population, plasma adiponectin levels were 
negatively related with BMI (r=-0.192, p=0.001), office systolic BP (r=-0.187, p=0.001), 
and PWV (r=-0.248, p=0.0001). Additionally, PWV was associated with waist to hip 
ratio (r=0.202, p<0.05), and office systolic BP (r=0.279, p=0.0001). Patients in group A 
(n=101) compared to subjects in group B (n=99) and C (n=95) had lower office systolic 
BP (142±14 vs 147±12 vs 154±15 mmHg, respectively; p<0.05 for all cases) and lower 
LVMI (101.2±14 vs 114.5±12 vs 121.2±18 g/m2, respectively; p<0.05 for all), while did 
not differ regarding metabolic profile (p=NS). Furthermore, patients in group C exhibited 
lower levels of adiponectin compared to group B and A (6.5±3.8 vs 9.4±4.5 vs 11.2±3.1 
μg/ml, respectively; p<0.05 for all cases). Analysis of covariance revealed that adiponectin 
values remained significantly different between groups after adjustment for confounding 
factors (p<0.05).
Conclusion: In newly diagnosed essential hypertension, there is a decrease in adiponectin 
values throughout augmenting PWV tertiles. These findings denote the interrelationships 
of hypoadiponectinemia with diffuse vascular dysfunction, in this setting.
12:15 p.m.
840-8 Are Fatness and Fitness Related to Microvascular 
Reactivity in Hypertensive Diabetics?
Harry A. Silber, Pamela Ouyang, Dhananjay Vaidya, Brian H. George, Anita C. Bacher, 
Kristina Potrekus, Jeanne P. Wingo, Kerry J. Stewart, Johns Hopkins University School 
of Medicine, Baltimore, MD
Background: While increased fatness and reduced fitness are known risk factors for 
macrovascular disease, the relationships of general and abdominal fatness and fitness 
with impaired microvascular vasodilator function, an early marker of microvascular 
disease are unknown.
Methods: Subjects were 71 sedentary males (n=49) and females (n=22) with type 2 
diabetes and mild hypertension (SBP between 120-159 or DBP between 80-99 mmHg), 
on usual care medicines, who were studied at baseline after being recruited for an exercise 
training study. Fitness was measured as maximal oxygen uptake on a treadmill. General 
fatness was measured by dual energy X-ray absorptiometry (DXA) and abdominal 
fatness by MRI. Peak systolic flow and diameter were measured in the brachial artery 
by ultrasound during peak hyperemia after release of a 5-minute occlusion. Shear rate 
during peak post-occlusive hyperemia, which reflects microvascular vasodilator function, 
was calculated as peak flow/((3)(diameter at peak flow)). Associations of shear rate with 
fitness and fatness were examined with stepwise multiple regression, which was adjusted 
for baseline arterial size, gender, HbA1C, and SBP.
Results: Mean (SD) age was 56.9±5.8 years, BP was 127±13 / 72±9 mmHg, maximal 
oxygen uptake was 21.6±5.0 ml/kg/min, total abdominal fat was 609.3±148.3 cm2, total 
percent body fat was 35.1±6.7%, and hyperemic shear rate was 1118±4426 sec-1. In the 
final model, decreased hyperemic shear rate was associated with increased baseline 
arterial diameter, which explained 19% (p=.001) of the variance whereas increased 
abdominal fatness explained an additional 11% of the variance. Lower fitness explained 
an additional 5% of the variance in hyperemic shear rate with borderline significance 
(p=.07). General fatness was not associated with hyperemic shear rate.
Conclusions: A novel finding is that among fitness and fatness parameters, increased 
abdominal fatness was the strongest determinant of impaired microvascular vasodilator 
function. Whether reducing abdominal fatness will improve vascular health in persons with 
diabetes and hypertension deserves further research.
ACC.ORAL CONTRIBUTIONS
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Hypertension: Benefits of 
Antihypertensive Therapy
Tuesday, March 27, 2007, 2:00 p.m.-3:30 p.m.
Room 260-261-262
2:00 p.m.
848-3 Prevention of Myocardial Infarction by Antihypertensive 
Drugs: An Updated Network Meta-analysis
William J. Elliott, Peter M. Meyer, RUSH Medical College, Chicago, IL
Background: Lowering blood pressure with drug therapy prevents myocardial infarction 
(MI), but whether 1 drug type is better than others is controversial. Traditional meta-
analyses of β-blockers or angiotensin receptor blockers (ARBs) vs. any other drug have 
alleged inferiority of these drug classes; a meta-regression comparing calcium channel 
blockers (CCBs) with angiotensin converting-enzyme (ACE-) inhibitors claimed superiority 
for the latter.
Methods: We performed a network meta-analysis (which accounts for both direct and 
indirect comparisons; Stat Med., 2002;21:2313) to compare the relative effectiveness of 5 
classes of drugs with placebo or no treatment (Placebo).
Results: In 75 arms of 64 trials involving 405,703 subjects, initial therapy (and the number 
of patients with incident MI/number of subjects at risk) included: Placebo: 3965 of 82,216 
(4.82%); ACE-inhibitor: 4497 of 62,380 (7.21%); ARB: 1935 of 28,478 (6.79%); β-blocker: 
2535 of 63,548 (4.00%); CCB: 4021 of 83,959 (3.00%); and Diuretic: 3779 of 66,411 
(5.69%). Using Placebo as the standard of comparison (42 arms), the incoherence was 
fairly large (ω = 0.028), and the odds ratios, 95% confidence intervals, and P-values were:
Drug Class # of Arms Odds Ratio (95% CI) P-value
ACE-I 22 0.80 (0.74-0.86) < 0.0001
ARB 12 0.87 (0.79-0.96) 0.0062
β-blocker 19 0.81 (0.74-0.88) < 0.0001
CCB 28 0.79 (0.73-0.85) < 0.0001
Diuretic 26 0.81 (0.75-0.88) < 0.0001
Conclusions: Unlike previous individual meta-analyses, but similar to the network meta-
analysis (JAMA, 2003;289:2534-44) that included data from only 42 trials and 192,478 
patients, these results suggest that all antihypertensive drugs significantly prevented MI 
better than placebo in clinical trials.
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848-4 Clinical Benefit of Antihypertensive Therapy on 
Cardiovascular Events in Obese Patients with Coronary 
Artery Disease. A CAMELOT Trial Sub-Analysis
Sanjeev P. Bhavnani, Stephen J. Nicholls, Harry Shi, Kamlesh M. Thakker, E Murat 
Tuzcu, Paul D. Thompson, Steven E. Nissen, University of Connecticut, Hartford, CT, 
The Cleveland Clinic Foundation, Cleveland, OH
Background: Obesity is associated with an increase in clinical events in patients with 
coronary artery disease (CAD). This study investigated the impact of intensive blood 
pressure lowering in patients with CAD stratified according to body mass index (BMI).
Methods: The CAMELOT Trial assessed the effects of amlodipine 10 mg, enalapril 20 
mg, or placebo over 2 years in 1991 patients with angiographically documented CAD 
and diastolic blood pressure < 100 mm Hg. The impact of therapy on the incidence of 
cardiovascular events, composite and major components (hospitalization for angina, 
revascularization and non-fatal myocardial infarction) stratified according to baseline BMI 
was evaluated using log-rank and Cox proportional hazard analysis.
Results: Baseline demographics were similar across BMI groups, except for an increase 
in diabetes with a higher BMI. Reductions in the rate of cardiovascular events with 
amlodipine were more evident in obese patients (HR=0.60, p=0.005). This was due to 
reductions in hospitalization for angina (HR=0.61, p=0.06), revascularization (HR=0.56, 
p=0.009) and non-fatal myocardial infarction (HR=0.28, p=0.04). Treatment with enalapril 
was nonsignificant across all BMI tertiles (Table).
Conclusions: The clinical benefit of intensive blood pressure lowering in patients with 
established CAD becomes increasingly important in the obese patient. This supports the 
need for intensive risk factor modification in the setting of obesity. 
Endpoint Placebo Amlodipine
P Value
Amlodipine vs. 
Placebo
Enalapril
P Value
Enalapril 
vs. Placebo
BMI <25 kg/m2 (n=264)
Cardiovascular Events 
(%) 27.2 24.1 0.75 20.8 0.34
Hospitalization for 
angina (%) 17.3 9.2 0.14 14.6 0.60
Revascularization (%) 13.6 19.5 0.27 15.6 0.73
Non-fatal MI (%) 3.7 5.7 0.54 3.1 0.80
BMI 25-29.9 kg/m2 (n=824)
Cardiovascular Events 
(%) 19.1 14.1 0.14 18.7 0.92
Hospitalization for 
angina (%) 11.9 7.1 0.05 11.5 0.90
Revascularization (%) 14.8 11.2 0.25 13.7 0.76
Non-fatal MI (%) 2.2 2.2 0.94 1.4 0.54
BMI ≥30 kg/m2 (n=903)
Cardiovascular Events 
(%) 25.6 16.6 0.005 21.4 0.28
Hospitalization for 
angina (%) 12.5 7.8 0.06 13.4 0.69
Revascularization (%) 17.2 10.1 0.009 14.0 0.32
Non-fatal MI (%) 3.4 1.0 0.04 1.3 0.10
2:30 p.m.
848-5  Role Of Metabolic Syndrome, Independent Of Its 
Components, In Prediction Of Cardiovascular 
Outcomes In Hypertensive Patients Of ASCOT- BPLA
Ajay K. Gupta, Neil R. Poulter, Bjorn Dahlof, Peter S. Sever, Hans Wedel, on behalf 
of ASCOT investigators, International Centre of Circulatory Research, NHLI, Imperial 
College, London, United Kingdom
Background: Controversy exists whether metabolic syndrome (MS) adds to 
cardiovascular disease (CVD) prediction, beyond the predictive value of its individual 
components. We addressed this question among hypertensive patients in ASCOT- BPLA
Material and Methods: Among 19257 hypertensive patients in ASCOT-BPLA, 8091 (42%) 
had MS at baseline (defined using modified ATPIII criteria; replacing waist circumference 
with BMI >30 kg/m2). Three separate Cox proportional models were developed to assess 
predictability of MS, for each of 11 pre-specified cardiovascular outcomes (see Figure)
Results: Unadjusted MS (Model 1) was associated with significantly increased risk 
of coronary disease outcomes but not for other cardiovascular (CV) outcomes (see 
Figure). In Model-2, after adjusting for age, sex and ethnicity, MS also predicted other CV 
outcomes significantly. When individual components of MS were included also included 
(Model-3), MS was associated with significantly increased risk for stroke (p=0.03) and all 
cause mortality (p=0.04) but not for coronary outcomes
Conclusion: MS remains an independent predictor for stroke and all cause mortality but not 
for coronary events after adjusting for the risk associated with its individual components.
Figure: Risk of CVD associated with MS, when adjusted for age, sex, ethnicity and 
components of syndrome itself.
2:45 p.m.
848-6 Effects of Candesartan versus Losartan on Insulin 
levels, Lipid Profile and Blood Pressure in Patients With 
Mild Hypertension, Hyperinsulinism and Dislipidemia
luis J. lunar, rita M. freites, maria E. serafin, endocrinlogycal foundation, caracas, 
Venezuela, louis braille foundations, caracas, Venezuela
Aim: To investigate the effect of two oral antihypertensive agents with similar mechanism 
(Candesartan versus losartan), on insulin levels, lipid profile and blood pressure, were 
compared in patients with hypertension, hyperinsulinism and dislipidemia .
Patients: 276 patients (mean age 47.5 years) with mild hypertension (sitting diastolic 
blood pressure (90-100 mmHg) (WHO grade I or II), hyperinsulinism and dislipidemia, 
after a 4-week placebo run-in period, were randomized to double-blind study to receive 
treatment with Candesartan 8 mg/day or Losartan 50 mg/day for up to 6 months. Dose 
was increased to 16 mg/day of Candesartan or losartan 100 mg/day if diastolic blood 
pressure remained ≥ 80 mmHg. after 4 weeks of treatment. Lifestyle modification was 
allowed, but no concomitant antidislipidemic drugs were permitted.
Results: At baseline, mean 24-hour systolic/diastolic BP was 130.7 ± 11.6 / 93.2 ± 5.2mm 
Hg in the Candesartan-treated group versus 132.5 ± 10.1 / 96.9 ± 4.2mm Hg in the 
Losartan-treated patients. At 6 months, mean 24-hour systolic BP was reduced by a mean 
18.4 mm Hg with Candesartan versus only 10.3 mm Hg with Losartan (p = 0.0001). Mean 
24-hour diastolic BP fell by 16.9 mm Hg and 10.9 mm Hg with Candesartan and Losartan 
treatment, respectively (p = 0.003). Fasting serum insulin levels were significantly (p < 
0.05) lower following 6 months’ treatment with Candesartan versus Losartan (9.9 ± 1.3 
mU/L vs. 20.3 ± 17.1 mU/L, respectively), as were post-prandial insulin levels (41.6 ± 
33.1 mU/L vs. 49.0 ± 41.4 mU/L, respectively). Candesartan therapy was also associated 
with improvement (reduction) in Fasting levels of total cholestetol decreased by 18.0 
mg/dl during treatment versus 9.6 mg/dl with Losartan. Fasting triglycerides levels were 
relatively unchanged with both oral antihypertensive agents.
Conclusion: Oral antihypertensive agents with similar mechanisms of action appear to 
have significant effects on insulin levels, lipid profile in patients with mild hypertension, 
hyperinsulinism and dislipidemia. Candesartan may be useful in lowering insulin levels 
and lipid profile, particularly those with mild hypertension
3:00 p.m.
848-7 Angiotensin Receptor Blocker Not Calcium 
Channel Blocker Reduced Plasma Osteopontin 
Level In Essential Hypertensive Patients With No 
Cardiovascular Evenets.
Mie Kurata, Takafumi Okura, Jun Irita, Daijiro Enomoto, Ken-ichi Miyoshi, Seiko Manabe, 
Tomikazu Fukuoka, Jitsuo Higaki, Ehime University, Toon city, Japan
Background: We had reported that plasma osteopontin (OPN) level was correlated with 
hypertensive target organ damages and the plasma OPN level was determined by CRP 
and aldosterone. In this study, we estimated the effect of antihypertensive therapy to OPN 
level. We hypothesized angiotensin receptor blocker (ARB) and calcium channel blocker 
(CCB) affects the different effect to OPN level.
Methods: Thirty-three ambulating patients with essential hypertension were enrolled in 
this study. Mean age was 60 years, 17 patients received ARB (losartan 8, candesartan 
6, telmisartan 3) and 16 were amlodipine. The patients with angina pectoris, myocardial 
infarction, stroke, diabetes mellitus, chronic kidney disease, autoimmune disease and 
malignant tumor were excluded. During follow up period, anti-hypertensive drugs, statin 
or anti-platelet drugs were not changed. Mean follow up periods was 254 days and we 
evaluated blood pressure, CRP, plasma aldosterone concentration and plasma OPN level 
using ELISA kit. The ARB group and CCB group were matched for age, blood pressure, 
lipid level, aldosterone and OPN level.
Results: Systolic blood pressure(SBP) was decreased same grade in two groups 
(CCB:26mmHg ARB:25mmHg). There were no patients who occurred major 
cardiovascular events during the follow up periods. The plasma OPN levels were 
changed 768±178 ng/mL to 938±40ng/mL in CCB, 713±254 ng/mL to 644±45ng/mL in 
ARB (p<0.001 and p=0.480, respectably) . The delta OPN, calculated pre OPN level 
minus post OPN level was 69.8ng/mL in ARB and -169ng/mL in CCB (p=0.0014). In 
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both groups, post treatment delta CRP and aldosterone were higher in CCB than ARB. 
(log natural CRP: -1.93±1.05, -2.83±0.90, p=0.018, aldosterone: 9.45±2.76, 6.53±4.11, 
p=0.028, respectably). We performed stepwise regression analysis of post-treated OPN 
level using age, SBP, aldosterone, and CRP as covariant. CRP was the only independent 
determinant factor for OPN (β=0.507, F=6.566, p=0.019).
Conclusions: We showed that plasma OPN level changed different pattern using ARB and 
CCB. Blocking rennin-angiotensin-aldosterone system is important to manage the OPN.
3:15 p.m.
848-8 The Effect of Valsartan Compared to Valsartan/
Hydrochlorothiazide on Plasma Levels of Cellular 
Adhesion Molecules: The Val-MARC Trial
David Conen, Brendan M. Everett, Robert J. Glynn, Paul M. Ridker, Brigham and 
Women’s Hospital, Boston, MA
Background: The Val-MARC trial showed that valsartan significantly reduced high 
sensitivity C-reactive protein levels, an effect that was blood pressure independent and not 
found for valsartan/hydrochlorothiazide (HCT). It is unknown whether valsartan influences 
other inflammatory biomarkers such as soluble intercellular adhesion molecule 1 (sICAM-
1) or vascular adhesion molecule 1 (sVCAM-1). Reducing sICAM-1 and sVCAM-1 may 
be of clinical interest as they are elevated in hypertensive patients and in patients at risk 
for cardiovascular events.
Methods: 1202 patients with stage 2 hypertension participating in the Val-MARC trial 
randomly received either valsartan (n=617) or valsartan/HCT (n=585). Baseline levels of 
sICAM-1 and sVCAM-1 were compared to those after 6 weeks of therapy.
Results: After 6 weeks, median sICAM-1 levels were reduced by both valsartan alone 
(-3 (-24, 16) ng/ml, p=0.01) and valsartan/HCT (-3 (-22, 17) ng/ml, p=0.03), such that 
the between group difference for sICAM-1 was not statistically significant (p=0.67). The 
median percentage change from baseline was small in both groups (-1.3% and -1.1%). 
After 6 weeks, median sVCAM-1 levels were reduced by both valsartan alone (-11 (-68, 
40) ng/ml, p=0.0005) and valsartan/HCT (-26 (-86, 37), p<0.0001); the between group 
difference for sVCAM-1 was of borderline statistical significance (p=0.05). The median 
percentage change from baseline was small (-1.9% and -4.2%). In both study arms, 
the reduction of sICAM-1 and sVCAM-1 was independent of blood pressure reduction 
(Spearman r=0.03 and r=0.07 for the relationship of change in systolic blood pressure 
with change in sICAM-1 and sVCAM-1, respectively).
Conclusion: In this randomized trial, valsartan and valsartan/HCT induced statistically 
significant, but clinically small reductions of sICAM-1 and sVCAM-1. Changes in sICAM-1 
and sVCAM-1 were independent of changes in blood pressure.
ACC.ORAL CONTRIBUTIONS
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2:00 p.m.
849-3 Stat3 Signal Transduction Pathway Correlates with 
Proliferation and Apoptosis of Rat Vascular Smooth 
Muscle Cells
Mei Tang, Yan Huang, Ming Bai, Zheng Zhang, Cardiology Department,The First 
Affiliated Hospital of Lanzhou University, Lanzhou, People’s Republic of China
Background: It has been confirmed that inhibitior of 3-hydroxy-3-methylglutaryl coenzyme 
A (HMG-CoA) reductase significantly decreases the incidence of ischemic cardiovascular 
complications. However, the effect of HMG-CoA reductase inhibition on the proliferation 
and apoptosis of vascular smooth muscle cells (VSMCs) remains unknown. In this study 
we demonstrated for the first time that inhibition of VSMCs proliferation and induction of 
apotosis by Atorvastatin, a HMG-CoA reductase inhibitor, which is mediated by signal 
transducer and activator of transcription 3 (Stat3) pathway and further confirmed our 
findings by using Stat3 antisense oligonucleotide.
Methods: Rat aortic VSMCs were prepared routinely and maintained in Dulbecco’s 
modified Eagle’s medium supplemented with fetal calf serum (FCS). VSMCs were treated 
with Stat3 antisense oligonucleotide and Atorvastatin at different times (24h, 48h and 
72h). Western blot and immunohistochemistry were used to measure the expression of 
Stat3, p-Jak2 p-Stat3, Cyclin D1 and Bcl-2 proteins. MTT assay and flow cytometry were 
used to measure the proliferation and apoptosis of VSMCs.
Results: Immunohistochemistry results showed that Stat3 was expressed mainly 
in cytoplasm, p-Stat3 in nucleus. Stat3 antisense oligonucleotide and Atorvastatin 
inhibited the cells proliferation and induced apoptosis in a dose,time-dependent manner 
accompanied by significant decreased Stat3 activity (P<0.01), and resulted in significant 
down regulation of Cyclin D1 and Bcl-2 (P<0.01).
Conclusions: Stat3 signal pathway mediates the effects of HMG-CoA reductase inhibitior 
on VSMCs proliferation and apoptosis. Furthermore, Stat3 antisense oligonucleotide 
inhibits VSMCs proliferation and induces apoptosis through down-regulating the 
expression of Cyclin D1 and Bcl-2. It provides us with a new theraputic method that 
targets Stat3 pathway for vascular restenosis desease.
2:15 p.m.
849-4 Increased Neointimal Formation After Vascular Injury In 
The Thrombospondin-2 Knockout Mice Is Not Mediated 
By Cd36 Pathway
Kai Wang, Xiaorong Zhou, Eric J. Topol, Yingrui Wang, Maria Febbraio, Roy Silverstein, 
Edward Plow, Marc S. Penn, Cleveland Clinic, Cleveland, OH
Thrombospondin 2 (TSP-2), a matricellular glycoprotein with potent antiangiogenic activity 
mediated by CD36, has been implicated in tissue repair and foreign body responses. 
However, the role TSP-2 on the neointimal formation after arterial injury and its relation 
with CD36 are unknown. In this study we evaluated the role of TSP-2 on neointimal 
formation in the mouse carotid artery injury model, and the potential role of CD36. 
Methods and Results. TSP-2 and CD36 knockout mice, and wild type mice for TSP-
2 (WT-1) and CD36 (WT-2), respectively, were used. The common carotid artery was 
injured using an angioplasty inflation device at the pressure of 1.5 atm for 30 seconds. 
The endothelium was then denuded by air-desiccating the carotid artery for 3 minutes 
using an air-filled syringe. The animals were sacrificed after 21 days, and morphometric 
analysis was performed. The results showed more neointimal formation in TSP-2 knockout 
mice when compared with WT. The CD36 null mice had less neointimal formation after 
arterial injury when compared to WT (Table). 
Conclusion: The results show that endogenous TSP-2 plays critical role in the inhibition 
of neointimal formation after vascular injury, and that the effects of TSP-2 are not 
mediated by CD36.
Table 
TSP-2 -/-
(n=14)
WT-1
(n=16)
CD36-/-
(n=10)
WT-2
(n=8)
Luminal area (mm2) 0.100±0.055 0.105±0.033 0.095±0.026 0.121±0.023
Neointimal Area (IA, mm2) 0.029±0.022* 0.012±0.009 0.003±0.002§ 0.020±0.010
Medial Area (MA, mm2) 0.031±0.016 0.034±0.016 0.028±0.011 0.045±0.012
External Elastic Lamina (mm2) 0.157±0.057 0.144±0.053 0.127±0.031 0.184±0.047
IA/MA 0.918±0.039* 0.323±0.191 0.150±0.14§ 0.477±0.179
* P< 0.05 when compared with WT-1 and CD36-/-, §* P< 0.05 when compared with WT-2
2:30 p.m.
849-5 12/15-Lipoxygenase Transgenic Mice Have More 
Neointimal Formation Than C57BL/6 Mice in Response 
to Wire Endothelial Denudation
Hamid Deliri, James W. Chumley, John M. Sanders, Kimberly D. Woods, Coleen A. 
McNamara, University of Virginia Health System, Cardiovascular Research Center, 
Charlottesville, VA
Background: 12/15-lipoxygenase enzyme (12/15-LO), homologous to human 15-
lipoxygenase, has been implicated in the pathogenesis of vascular disease. Vascular 
smooth muscle cell (VSMC) proliferation is a key component of the response to injury in 
vascular disease. VSMC derived from transgenic mice overexpressing 12/15-LO (12/15-
LOtg) grow faster than VSMC from control C57BL/6 mice (B6) in vitro. Hypothesis: 
Following endothelial denudation, 12/15-LOtg will have more neointimal formation as 
compared to B6.
Materials/Methods: Real-time PCR was used to confirm overexpression of 12/15-LO 
in the 12/15-LOtg. 12/15-LOtg and B6 mice were placed on Western diet at 10-12 weeks 
of age. After one week, wire endothelial denudation of the left common carotid artery 
(LCCA) was performed. Mice were euthanized 28 days following injury and the LCCAs 
were removed and paraffin embedded. Beginning at a point 240µm proximal to the 
carotid bifurcation, eight consecutive sections (each 120µm apart) were Movat stained. 
The neointimal area was then analyzed using Image-Pro software. Mann-Whitney two-
tailed U-test was used for data analysis. Data is presented as mean±SEM.
Results: Twenty 12/15-LOtg (11 m, 9 f), and 24 B6 (15 m, 9 f) were entered in the study. 
Male B6 weighed more than male 12/15-LOtg (32.9±0.51 gr. vs.28.4±0.61 gr., p<0.001). 
Cholesterol or triglycerides levels were not statistically different between the groups. B6 
had higher HDL levels (123.7±5.0 mg/dL vs. 85.7±5.0 mg/dL, p<0.001 in males, and 
71.5±5.7 mg/dL vs. 60.6±9.3 mg/dL, p=0.021 in females), and lower LDL levels (39.8±1.6 
mg/dL vs. 56.6±4.0 mg/dL, p<0.001 in males, and 39.5±3.4 mg/dL vs. 63.5±4.6 mg/dL, 
p<0.001 in females) than 12/15-LOtg. Neointimal area was statistically larger in female 
and male 12/15-LOtg groups than in corresponding B6 groups (3427.1±606.7 µm2 vs. 
1169.9±441.8 µm2, p=0.002 in males, and 7768.3±2012.0 µm2 vs. 518.7±210.1 µm2, 
p=0.004 in females).
Conclusion: Neointimal formation after endothelial denudation is accelerated in 12/15-
LOtg. Interestingly, HDL was lower and LDL was higher in 12/15-LOtg. Further studies are 
needed to evaluate the potential mechanisms by which 12/15-LO modulates vascular 
lesion formation.
2:45 p.m.
849-6 Vascular Stenosis Response to Balloon-Injury 
is Inhibited Following Local Intramural Delivery 
of Rapamycin with avb3-Integrin-Targeted 
Perfluorocarbon Nanoparticles
Tillmann Cyrus, Huiying Zhang, John S. Allen, Ralph W. Fuhrhop, Samuel A. Wickline, 
Gregory M. Lanza, Washington University, Saint Louis, MO
Background: The effectiveness of local drug delivery to inhibit restenosis has been 
demonstrated using drug eluting stents. However, the implantation of metal-based stents 
is not always feasible or desired. The objective of the present study was to determine if 
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intramural delivery of avb3-integrin targeted nanoparticles with rapamycin could inhibit 
neointimal hyperplasia without prolonging endothelial healing following angioplasty.
Methods: Femoral arteries of NZW rabbits were subjected to balloon stretch injury. αvβ3-
targeted PFC nanoparticles with 0.31 mol% rapamycin were injected into one artery while 
the contralateral vessel received either non-targeted particles, targeted particles without 
drug, or saline control.
Results: Microscopic analysis following H&E and Carstair’s stains showed significantly 
delayed and diminished neointima formation in arteries exposed to rapamycin 
nanoparticles (Figure 1). At 4 weeks, the neointimal area in rapamycin nanoparticle 
treated arteries was 82% smaller when compared to the non-drug treated controls. No 
significant differences were observed among the various controls. Importantly, the rate 
of endothelial healing following rapamycin treatment was not prolonged relative to the 
saline control (Figure 2).
Conclusions: Local intramural delivery of rapamycin with αvβ3-integrin-targeted 
nanoparticles immediately after balloon angioplasty diminished acute neointima and 
stenosis formation but did not adversely affect endothelial healing. 
3:00 p.m.
849-7 Pioglitazone Reduces Neointimal Response by 
Suppression of the Early Inflammatory Reaction via 
NFkB Dependent MCP-1 Mediated Pathway in a Porcine 
Coronary Stent Model
Takatoshi Kasai, Katsumi Miyauchi, Takayuki Yokoyama, Kan Kajimoto, Eiji Ikeda, Naozumi 
Kubota, Hiroyuki Daida, Juntendo University, Department of Cardiology, Tokyo, Japan
Background: Clinical trial showed pioglitazone reduced restenosis after coronary 
intervention, but the mechanism is still unknown. Enhanced inflammatory reactions was 
strongly correlated with neointimal hyperplasia after coronary stenting. Pioglitazone have 
anti-atherogenic effects through the inhibition of the production of inflammatory cytokines. 
We hypothesized that pioglitazone might inhibit the early inflammatory reaction, resulting 
in prevention of neointimal hyperplasia after stenting in porcine coronary.
Methods & Results: Pioglitazone (150 mg/day) or placebo was administered orally to 
10 pigs (20 coronaries) in each, from 7 days before stenting until the time of euthanasia 
at 3 or 28 days after stenting. The coronary arteries were injured with an oversized bare 
metal stent. On day 0, insulin sensitivity was greater in pioglitazone-treated pigs than in 
untreated pigs (Kitt 5.87±0.68 vs. 4.14±1.65, P=0.003), whereas fasting blood glucose 
did not differ between groups. Early inflammatory cell adhesion on the vascular surface 
of the stent site was evaluated by scanning electron microscopy and was significantly 
suppressed in pioglitazone-treated group comparing with the control (% of site occurring 
greater infiltration: 40.8 vs. 60.9%, P=0.002). Immunohistochemistry revealed that % 
positive area of MCP-1 and activated NFkB in the intima was significantly less in the 
treatment group than in the control group (MCP-1: 12.7 vs. 37.0%, P<0.0001, NFkB: 
21.8 vs. 32.5%, P=0.009). On Day 28, intravascular ultrasound analysis showed 
pioglitazone significantly reduced neointimal area at the stent site than in the control 
(3.04±0.90 vs. 4.03±1.15mm2, P=0.0008). Morphometric assessment of stent-section 
also showed significantly reduced in neointimal area and %stenosis in the pioglitazone 
group compared to the control (neointimal area: 1.85±0.58 vs. 3.10±1.21mm2, P=0.0018, 
%stenosis: 25.6 vs. 39.2%, P=0.013), whereas there were no difference in the mean 
injury score between two groups.
Conclusions: Pioglitazone might inhibit neointimal hyperplasia after stenting through a 
reduction of early inflammatory reactions via NFkB dependent MCP-1 mediated pathway.
3:15 p.m.
849-8 Human Cord Blood Endothelial Progenitors Decrease 
Neointimal Hyperplasia in SCID Mouse Vein Grafts
Shoukang Zhu, Anuj Malhotra, Pascal J. Goldschmidt, Lisheng Zhang, Robert W. 
Storms, Neil J. Freedman, Chunming Dong, Duke Medical Center, Durham, NC
Background: Neointimal hyperplasia is a leading cause of vein graft failure. 
Reendothelialization limits vascular remodeling by regenerating an intact endothelium. 
Human umbilical cord blood (UCB) contains a reservoir of stem/progenitor cells, including 
endothelial progenitor cells (EPCs). The Aim of this study was to determine whether 
human UCB EPCs could differentiate into endothelial cells (ECs) in vivo, accelerating 
reendothelialization and ameliorating neointimal hyperplasia in a carotid artery bypass 
graft model in SCID mice.
Methods: End-to-side carotid artery bypass grafting was performed in SCID mice using an 
1-cm portion of inferior vena cava from congenic donor animals. 3x105 lineage negative 
(lin-) UCB or empty vehicle was injected via contralateral internal jugular vein immediately 
prior to and again 2 weeks after surgery. Mice were sacrificed at 4 weeks. Immunostaining 
of human HLA-ABC, PECAM-1, Mac1 and CD45 and Verhoeff’s elastic and Masson’s 
trichrome stain was performed on serial sections to determine the engraftment and 
identity of human cells and neointimal hyperplasia in the mice. FACS analysis for HLA-
ABC was performed to assess UCB engraftment in the bone marrow (BM).
Results: Cells expressing human HLA-ABC antigen were detected in the vein grafts, liver 
and lungs, with no evidence of cell fusion. Colocalization of HLA-ABC and PECAM-1 were 
found in the endothelial layer lining the inner lumen of the grafts, with greatest presence 
at the proximal anastamosis site with a frequency of 17.8 ± 2.5 cells per 40x power field. 
Morphometric analysis of the grafts (n=16 animals) showed that the area of the neointima 
was decreased by more than 1/3 (p<0.01) in animals receiving lin - UCB. Flow cytometry 
revealed engraftment of human cells in the BM of 5 of 8 animals tested, with human cells 
comprising 1.8-12.0% of the marrow.
Conclusions: Lin-UCB contains precursors capable of homing, engraftment, and 
differentiation into ECs in vivo. Injection of these cells decreases neointima formation in 
the vein grafts of SCID mice. These data implicate a potential therapeutic role for UCB 
in vessel injury.
